public_id,VJ_INTERVAL,MMTX_TYPE,MMTX_ISTHISLINEOFT,MMTX_SPECIFY6,MMTX_THERAPY,MMTX_SPECIFY,MMTX_ENTERCLINICAL,MMTX_ONGOING,MMTX_REASONFORTREA,MMTX_SPECIFY4,MMTX_DOSE,MMTX_UNITS,MMTX_SPECIFY2,MMTX_FREQUENCY,MMTX_SPECIFY3,MMTX_ROUTE,MMTX_SPECIFY5,startday,stopday,enr
MMRF_1014,Baseline,First line of therapy,,,Bortezomib,,,,Lack of response,,2,mg,,QD,,IVB,,1,166,1
MMRF_1014,,First line of therapy,,,Bortezomib,,,,Adverse Event or co-morbidity,,2,mg,,QD,,Other,injection,1,57,1
MMRF_1014,,First line of therapy,,,Vincristine,,,,Adverse Event or co-morbidity,,2,mg,,Oth,q28 days,IV,,381,407,1
MMRF_1014,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,daily on Days 1-4 (all cycles) and 9-12 (cycle 1 and 2),PO,,1,819,1
MMRF_1014,,First line of therapy,,,Lenalidomide,,,,Adverse Event or co-morbidity,,25,mg,,QD,,PO,,66,106,1
MMRF_1014,,First line of therapy,,,Thalidomide,,,,Other,plateaued response,100,mg,,Q d,,PO,,186,365,1
MMRF_1014,,First line of therapy,,,Liposomal doxorubicin,,,,Adverse Event or co-morbidity,,75,mg,,Oth,q28 days,IV,,381,407,1
MMRF_1014,,First line of therapy,Induction,,Carfilzomib,,,,Investigator decision for other reasons,,39,mg,,QD,,IV,,449,535,1
MMRF_1014,,First line of therapy,Maintenance,,Thalidomide,,,Checked,,,100,mg,,Q d,,PO,,977,,1
MMRF_1014,,First line of therapy,Other,Plateaued,Cyclophosphamide,,,,Completed regimen,,500,mg,,Oth,Q WEEK,IV,,540,752,1
MMRF_1014,,First line of therapy,Other,High dose chemo pre transplant,Melphalan,,,,Completed regimen,,200,mg,,Oth,unknow,IV,,814,815,1
MMRF_1014,,First line of therapy,Other,Plateaued,Bortezomib,,,,Completed regimen,,2.6,mg,,Q w,,IV,,540,752,1
MMRF_1017,,First line of therapy,,,Dexamethasone,,,,Other,death,40,mg,,QWK,,PO,,1,508,1
MMRF_1017,Baseline,First line of therapy,,,Lenalidomide,,,,Other,death,15,mg,,QD,,PO,,9,508,1
MMRF_1024,,First line of therapy,,,Bortezomib,,,,Adverse Event or co-morbidity,,2,mg,,QD,,IV,,295,582,1
MMRF_1024,,First line of therapy,,,Prednisone,,,,Lack of response,,60,mg,,Oth,daily for 7 days each month,PO,,1,149,1
MMRF_1024,,First line of therapy,,,Dexamethasone,,,,Adverse Event or co-morbidity,,40,mg,,Oth,"QD days 1,2,4,5,8,9,11,12",PO,,295,582,1
MMRF_1024,Baseline,First line of therapy,,,Melphalan,,,,Lack of response,,6,mg,,Oth,daily for 7 days each month; then daily for 5 days each month,PO,,1,149,1
MMRF_1024,,First line of therapy,,,Thalidomide,,,,Lack of response,,100,mg,,Oth,daily,PO,,1,149,1
MMRF_1024,,First line of therapy,Unknown,,Dexamethasone,,,,Adverse Event or co-morbidity,,40,mg,,Q w,,PO,,162,240,1
MMRF_1024,,First line of therapy,Unknown,,Lenalidomide,,,,Adverse Event or co-morbidity,,15,mg,,QD,,PO,,162,240,1
MMRF_1024,,Second Line Therapy (after,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,5,mg,,QD,,PO,,659,1352,1
MMRF_1024,,Second Line Therapy (after,Maintenance,,Lenalidomide,,,Checked,,,2.5,mg,,QD,,PO,,1353,,1
MMRF_1038,,First line of therapy,,,Dexamethasone,,,,Other,death,40,mg,,QWK,,PO,,1,1735,1
MMRF_1038,Baseline,First line of therapy,,,Lenalidomide,,,,Other,death,15,mg,,Oth,daily,PO,,9,1738,1
MMRF_1033,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,40,mg,,QWK,,PO,,1,123,1
MMRF_1033,Baseline,First line of therapy,,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,123,1
MMRF_1007,,First line of therapy,,,Lenalidomide,,,,Adverse Event or co-morbidity,,10,mg,,Oth,"once a day, 3 weeks on, 1 week off",PO,,92,145,1
MMRF_1007,,First line of therapy,,,Dexamethasone,,,,Adverse Event or co-morbidity,,20,mg,,Q w,,PO,,92,145,1
MMRF_1007,Baseline,First line of therapy,,,Melphalan,,,,Adverse Event or co-morbidity,,8,mg,,QD,,PO,,1,85,1
MMRF_1007,,First line of therapy,,,Prednisone,,,,Adverse Event or co-morbidity,,80,mg,,Oth,QD (D1-28),PO,,1,85,1
MMRF_1007,,First line of therapy,,,Thalidomide,,,,Adverse Event or co-morbidity,,50,mg,,QD,,PO,,1,85,1
MMRF_1007,,First line of therapy,,,Bortezomib,,,,Adverse Event or co-morbidity,,2,mg,,Q w,,IV SubQ,,155,208,1
MMRF_1007,,First line of therapy,Unknown,,Dexamethasone,,,,Adverse Event or co-morbidity,,10,mg,,Q w,,PO,,155,208,1
MMRF_1052,,First line of therapy,,,Dexamethasone,,,,Adverse Event or co-morbidity,,20,mg,,QWK,,PO,,1,51,1
MMRF_1052,,First line of therapy,,,Thalidomide,,,,Adverse Event or co-morbidity,,200,mg,,QD,,PO,,119,160,1
MMRF_1052,Baseline,First line of therapy,,,Lenalidomide,,,,Adverse Event or co-morbidity,,15,mg,,Oth,1 tablet daily for 28 days,PO,,1,29,1
MMRF_1052,,First line of therapy,,,Dexamethasone,,,,Adverse Event or co-morbidity,,40,mg,,Oth,"odd cycles: D1-4, 9-12 and 17-20; even cycles: D1-4",PO,,119,162,1
MMRF_1052,,First line of therapy,,,Bortezomib,,,,Completed regimen,,2.8,mg,,QD,,IV SubQ,,174,273,1
MMRF_1082,Baseline,First line of therapy,,,Bortezomib,,,,Investigator decision for other reasons,,1.3,mg/m^,,QD,,IV SubQ,,1,274,1
MMRF_1082,,First line of therapy,,,Dexamethasone,,,,Investigator decision for other reasons,,40,mg,,QWK,,IVB,,1,274,1
MMRF_1082,,First line of therapy,,,Thalidomide,,,,Investigator decision for other reasons,,50,mg,,QD,,PO,,1,274,1
MMRF_1082,,Second Line Therapy (after,,,Lenalidomide,,,,Investigator decision for other reasons,,25,mg,,QD,,PO,,288,326,1
MMRF_1082,,Second Line Therapy (after,,,Dexamethasone,,,,Investigator decision for other reasons,,40,mg,,Oth,"D1, 8,15, 22",PO,,288,326,1
MMRF_1082,,Second Line Therapy (after,,,Bortezomib,,,,Investigator decision for other reasons,,1.3,mg/m^,,QD,,IV SubQ,,288,326,1
MMRF_1082,,Second Line Therapy (after,Unknown,,Melphalan,,,,Completed regimen,,100,mg/m^,,BID,,IV,,371,372,1
MMRF_1082,,Third Line Therapy (followi,Other,salvage,Cyclophosphamide,,,,Completed regimen,,750,mg,,QD,,Other,CIV,661,750,1
MMRF_1082,,Second Line Therapy (after,Maintenance,,Lenalidomide,,,,Completed regimen,,10,mg,,QD,,PO,,500,582,1
MMRF_1082,,Third Line Therapy (followi,Consolidation,,Dexamethasone,,,,Completed regimen,,4,mg,,QD,,IV,,661,750,1
MMRF_1082,,Third Line Therapy (followi,Consolidation,,Other,Cisplatin,,,Completed regimen,,75,mg,,QD,,Other,CIV,661,750,1
MMRF_1082,,Third Line Therapy (followi,Consolidation,,Other,Etoposide,,,Completed regimen,,75,mg,,QD,,Other,CIV,661,750,1
MMRF_1082,,Second Line Therapy (after,Other,New line,Pomalidomide,,,,Disease progression/Relapse,,4,mg,,QD,,PO,,588,680,1
MMRF_1094,Baseline,First line of therapy,,,Bortezomib,,,,Completed regimen,,2,mg,,QD,,IV SubQ,,1,95,1
MMRF_1094,,First line of therapy,,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,95,1
MMRF_1094,,First line of therapy,,,Melphalan,,,,Completed regimen,,154,mg,,Q d,,IV,,142,143,1
MMRF_1094,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,40,mg,,QWK,,PO,,1,95,1
MMRF_1094,,Second Line Therapy (after,Induction,,Other,ACP-196,,,Adverse Event or co-morbidity,,100,mg,,BID,,PO,,1327,1454,1
MMRF_1094,,Second Line Therapy (after,Induction,,Other,Pembrolizumab,,,Adverse Event or co-morbidity,,2,mg/m^,,Oth,Every day 1,IV,,1327,1454,1
MMRF_1094,,Third Line Therapy (followi,Induction,,Daratumumab,,,Checked,,,900,mg,,Oth,"C1-2D1,8,15,22; C3-6D1,15; C7+D1",Other,IVBP,1830,,1
MMRF_1094,,Third Line Therapy (followi,Induction,,Dexamethasone,,,Checked,,,20,mg,,Oth,"D1,8,15,22",IV,,1830,,1
MMRF_1094,,Third Line Therapy (followi,Induction,,Lenalidomide,,,Checked,,,25,mg,,QD,,PO,,1829,,1
MMRF_1093,Baseline,First line of therapy,,,Lenalidomide,,,,Investigator decision for other reasons,,25,mg,,QD,,PO,,1,154,1
MMRF_1093,,First line of therapy,,,Dexamethasone,,,,Investigator decision for other reasons,,40,mg,,Q w,,PO,,1,185,1
MMRF_1129,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,"daily on days 1, 8, 15, 22",PO,,1,211,1
MMRF_1129,Baseline,First line of therapy,,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,211,1
MMRF_1129,,First line of therapy,Maintenance,,Lenalidomide,,,,Other,death,10,mg,,QD,,PO,,256,611,1
MMRF_1130,Baseline,First line of therapy,,,Lenalidomide,,,,Investigator decision for other reasons,,25,mg,,QD,,PO,,1,351,1
MMRF_1130,,First line of therapy,,,Bortezomib,,,,Investigator decision for other reasons,,2.5,mg,,QD,,IV SubQ,,1,351,1
MMRF_1130,,First line of therapy,Maintenance,,Lenalidomide,,,,Investigator decision for other reasons,,25,mg,,QD,,PO,,361,541,1
MMRF_1130,,First line of therapy,,,Dexamethasone,,,,Investigator decision for other reasons,,40,mg,,QWK,,PO,,1,351,1
MMRF_1130,,Second Line Therapy (after,Other,Progression of Myeloma,Lenalidomide,,,,Lack of response,,25,mg,,QD,,PO,,879,1243,1
MMRF_1130,,Second Line Therapy (after,Other,Progressive multiple myeloma,Dexamethasone,,,,Lack of response,,40,mg,,Oth,"QD ( D1, D8, D15 AND D22)",PO,,879,1243,1
MMRF_1130,,Third Line Therapy (followi,Induction,,Pomalidomide,,,Checked,,,4,mg,,Q d,,PO,,1373,,1
MMRF_1137,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,40,mg,,QWK,,PO,,5,178,1
MMRF_1137,Baseline,First line of therapy,,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,195,1
MMRF_1137,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,100,mg/m^,,Q d,,IV,,223,224,1
MMRF_1137,,First line of therapy,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,10,mg,,QD,,PO,,337,501,1
MMRF_1137,,Second Line Therapy (after,Maintenance,,Lenalidomide,,,,Lack of response,,5,mg,,Oth,every other day,PO,,632,675,1
MMRF_1137,,Third Line Therapy (followi,Maintenance,,Lenalidomide,,,,Lack of response,,5,mg,,Q d,,PO,,675,722,1
MMRF_1137,,Third Line Therapy (followi,Unknown,,Bortezomib,,,,Disease progression/Relapse,,1.3,mg/m^,,Oth,"QD ( D1, D4, D8, D11, D21)",IV,,722,764,1
MMRF_1137,,Fourth Line Therapy (follow,Unknown,,Pomalidomide,,,,Disease progression/Relapse,,4,mg,,QD,,PO,,785,1090,1
MMRF_1137,,Fourth Line Therapy (follow,Unknown,,Dexamethasone,,,,Disease progression/Relapse,,20,mg,,Oth,"QD ( D1, d2, D8, D9, D16, D22, D23)",PO,,785,1090,1
MMRF_1137,,Third Line Therapy (followi,Unknown,,Dexamethasone,,,,Disease progression/Relapse,,20,mg,,Oth,"QD ( D1, D4, D8, D11, D21)",PO,,722,764,1
MMRF_1132,Baseline,First line of therapy,,,Lenalidomide,,,,Lack of response,,25,mg,,QD,,PO,,1,92,1
MMRF_1132,,First line of therapy,,,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,Q w,,PO,,5,85,1
MMRF_1132,,First line of therapy,,,Bortezomib,,,,Other,death,2,mg,,QD,,IV,,103,238,1
MMRF_1132,,First line of therapy,,,Dexamethasone,,,,Other,death,40,mg,,QD,,PO,,103,238,1
MMRF_1178,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,"Day 1-4, 9-12",PO,,1,150,1
MMRF_1178,,First line of therapy,,,Melphalan,,,,Completed regimen,,100,mg/m^,,QD,,IV,,130,162,1
MMRF_1178,Baseline,First line of therapy,,,Bortezomib,,,,Other,proceeding with autologous stem cell transplant,2.6,mg,,QD,,IV SubQ,,1,150,1
MMRF_1178,,Second Line Therapy (after,Maintenance,,Lenalidomide,,,Checked,,,25,mg,,QD,,PO,,1870,,1
MMRF_1178,,Second Line Therapy (after,Maintenance,,Carfilzomib,,,Checked,,,59,mg/m^,,QD,,IVB,,1870,,1
MMRF_1178,,Second Line Therapy (after,Maintenance,,Dexamethasone,,,Checked,,,40,mg,,QD,,PO,,1870,,1
MMRF_1193,Baseline,First line of therapy,,,Bortezomib,,,,Completed regimen,,2.6,mg,,QWK,,IV SubQ,,1,144,1
MMRF_1193,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,40,mg,,QWK,,PO,,1,144,1
MMRF_1193,,Second Line Therapy (after,Induction,,Lenalidomide,,,,Other,Partial Response.,25,mg,,QD,,PO,,596,682,1
MMRF_1193,,Second Line Therapy (after,Induction,,Bortezomib,,,,Other,Partial response.,1.3,mg,,Oth,"Day 1, 8, 15",IV SubQ,,596,682,1
MMRF_1193,,Third Line Therapy (followi,Other,Progresive disease,Lenalidomide,,,,Adverse Event or co-morbidity,,25,mg,,QD,,PO,,896,1321,1
MMRF_1193,,Third Line Therapy (followi,Other,Progressive Disease,Dexamethasone,,,,Adverse Event or co-morbidity,,40,mg,,Q w,,PO,,896,1321,1
MMRF_1193,,Fourth Line Therapy (follow,Induction,,Pomalidomide,,,,Disease progression/Relapse,,4,mg,,QD,,PO,,1381,1437,1
MMRF_1193,,Fourth Line Therapy (follow,Induction,,Elotuzumab,,,,Disease progression/Relapse,,647,mg,,Oth,"day 1, 8, 15, 22  (28 day cycle)",IV,,1381,1437,1
MMRF_1193,,Fourth Line Therapy (follow,Induction,,Dexamethasone,,,,Disease progression/Relapse,,8,mg,,Oth,"day 1, 8, 15, 22",IV,,1381,1437,1
MMRF_1193,,Fourth Line Therapy (follow,Induction,,Dexamethasone,,,,Disease progression/Relapse,,4,mg,,Oth,"day 1, 8, 15, 22 of each 28 day cycle",PO,,1379,1437,1
MMRF_1229,,First line of therapy,,,Lenalidomide,,,,Lack of response,,25,mg,,QD,,PO,,1,173,1
MMRF_1229,,First line of therapy,,,Dexamethasone,,,,Lack of response,,40,mg,,Q w,,PO,,1,173,1
MMRF_1229,Baseline,First line of therapy,,,Bortezomib,,,,Disease progression/Relapse,,1.3,mg/m^,,QD,,IV SubQ,,1,172,1
MMRF_1229,,Second Line Therapy (after,Induction,,Liposomal doxorubicin,,,,Disease progression/Relapse,,67,mg,,Oth,every 21 days,IV,,186,270,1
MMRF_1229,,Second Line Therapy (after,Induction,,Carfilzomib,,,,Completed regimen,,27,mg/m^,,QD,,IV,,311,395,1
MMRF_1229,,First line of therapy,Induction,,Bortezomib,,,,Disease progression/Relapse,,1.3,mg/m^,,QD,,IV,,183,277,1
MMRF_1229,,First line of therapy,Consolidation,,Melphalan,,,,Completed regimen,,200,mg,,Q d,,IV,,426,427,1
MMRF_1229,,Third Line Therapy (followi,Induction,,Carfilzomib,,,Checked,,,20,mg/m^,,QD,,IV,,1538,,1
MMRF_1229,,Third Line Therapy (followi,Induction,,Dexamethasone,,,Checked,,,10,mg,,Q d,,PO,,1538,,1
MMRF_1229,,Third Line Therapy (followi,Induction,,Lenalidomide,,,Checked,,,25,mg,,Q d,,PO,,1538,,1
MMRF_1256,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,"days 1-4, 9-12",PO,,1,172,1
MMRF_1256,Baseline,First line of therapy,,,Bortezomib,,,,Completed regimen,,2.5,mg,,QWK,,IV SubQ,,1,172,1
MMRF_1256,,First line of therapy,Induction,,Lenalidomide,,,,Investigator decision for other reasons,,25,mg,,QD,,PO,,206,488,1
MMRF_1256,,First line of therapy,Induction,,Dexamethasone,,,,Investigator decision for other reasons,,40,mg,,Oth,Days 2 and 9,PO,,206,488,1
MMRF_1256,,First line of therapy,Induction,,Bortezomib,,,,Investigator decision for other reasons,,2.5,mg,,Oth,Days 1 and 8,IV SubQ,,206,488,1
MMRF_1256,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,10,mg,,QD,,PO,,506,,1
MMRF_1277,,First line of therapy,,,Lenalidomide,,,,Completed regimen,,10,mg,,QD,,PO,,1,77,1
MMRF_1277,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,20,mg,,QD,,PO,,46,77,1
MMRF_1277,Baseline,First line of therapy,,,Bortezomib,,,,Completed regimen,,2.9,mg,,QD,,IV SubQ,,1,77,1
MMRF_1285,Baseline,First line of therapy,,,Bortezomib,,,,Completed regimen,,1.5,mg/m^,,Q w,,IV SubQ,,1,204,1
MMRF_1285,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,40,mg,,Q w,,PO,,1,204,1
MMRF_1285,,First line of therapy,,,Cyclophosphamide,,,,Completed regimen,,550,mg,,Oth,"Days 1, 8, 15, 22 of each cycle",PO,,1,204,1
MMRF_1285,,First line of therapy,Maintenance,,Bortezomib,,,,Disease progression/Relapse,,2.5,mg,,Oth,Q21days,IV SubQ,,303,877,1
MMRF_1285,,Second Line Therapy (after,Other,After progression,Bortezomib,,,,Investigator decision for other reasons,,2.5,mg,,Oth,"Weekly ( Q D1, D8,D15) 1 week off",IV,,898,1051,1
MMRF_1285,,Second Line Therapy (after,Other,New line due to progression,Lenalidomide,,,,Investigator decision for other reasons,,15,mg,,QD,,PO,,898,1051,1
MMRF_1285,,Second Line Therapy (after,Other,New line due to progression,Dexamethasone,,,,Investigator decision for other reasons,,20,mg,,QWK,,PO,,898,1051,1
MMRF_1285,,Second Line Therapy (after,Maintenance,,Lenalidomide,,,,Disease progression/Relapse,,15,mg,,QD,,PO,,1093,1205,1
MMRF_1285,,Second Line Therapy (after,Unknown,,Lenalidomide,,,Checked,,,15,mg,,QD,,PO,,1280,,1
MMRF_1285,,Third Line Therapy (followi,Induction,,Lenalidomide,,,Checked,,,15,mg,,QD,,PO,,1851,,1
MMRF_1285,,Third Line Therapy (followi,Induction,,Ixazomib,,,Checked,,,4,mg,,QWK,,PO,,1851,,1
MMRF_1285,,Third Line Therapy (followi,Induction,,Dexamethasone,,,Checked,,,40,mg,,Q w,,PO,,1851,,1
MMRF_1359,Baseline,First line of therapy,,,Bortezomib,,,,Other,to proceed with transplant,2.5,mg,,QD,,IV SubQ,,1,116,1
MMRF_1359,,First line of therapy,,,Dexamethasone,,,,Other,to proceed with transplant,40,mg,,Oth,"D1-4, D 9-12",PO,,1,116,1
MMRF_1359,,Second Line Therapy (after,Induction,,Cyclophosphamide,,,,Completed regimen,,500,mg,,Oth,"QD ( D1, D8, D15, D22)",PO,,694,876,1
MMRF_1359,,Second Line Therapy (after,Induction,,Bortezomib,,,,Completed regimen,,3,mg,,Oth,"QD ( D1, D8,D15,D22)",Other,SUB - Q,694,862,1
MMRF_1359,,Second Line Therapy (after,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,QWK,,PO,,694,876,1
MMRF_1359,,First line of therapy,Other,Mobilation prior to harvested aoutologous stem cell tranplant,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,168,169,1
MMRF_1359,,Third Line Therapy (followi,Induction,,Lenalidomide,,,,Disease progression/Relapse,,25,mg,,Q d,,PO,,1123,1162,1
MMRF_1359,,Second Line Therapy (after,Maintenance,,Lenalidomide,,,,Disease progression/Relapse,,25,mg,,QD,,PO,,882,1106,1
MMRF_1359,,Third Line Therapy (followi,Induction,,Carfilzomib,,,,Disease progression/Relapse,,36,mg,,QD,,IVB,,1123,1162,1
MMRF_1359,,Third Line Therapy (followi,Induction,,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,Q d,,PO,,1123,1162,1
MMRF_1395,,First line of therapy,,,Dexamethasone,,,,Adverse Event or co-morbidity,,20,mg,,Oth,"Q 1, 2, 4, 5, 8, 9, 11, 12 of each 21-day cycle",PO,,1,126,1
MMRF_1395,,First line of therapy,,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,126,1
MMRF_1395,Baseline,First line of therapy,,,Bortezomib,,,,Adverse Event or co-morbidity,,2.6,mg,,QD,,IV SubQ,,1,108,1
MMRF_1395,,First line of therapy,Consolidation,,Melphalan,,,,Completed regimen,,100,mg/m^,,Q d,,IV,,189,190,1
MMRF_1395,,Second Line Therapy (after,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,10,mg,,QD,,PO,,1156,1492,1
MMRF_1395,,Second Line Therapy (after,Maintenance,,Lenalidomide,,,Checked,,,5,mg,,QD,,PO,,1493,,1
MMRF_1401,Baseline,First line of therapy,,,Bortezomib,,,,Completed regimen,,2.4,mg,,QD,,IV SubQ,,1,75,1
MMRF_1401,Month 3,First line of therapy,,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,75,1
MMRF_1401,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,40,mg,,QWK,,PO,,1,542,1
MMRF_1401,,Second Line Therapy (after,Consolidation,,Lenalidomide,,,,Lack of response,,15,mg,,Oth,QD,PO,,91,260,1
MMRF_1401,,Second Line Therapy (after,Maintenance,,Lenalidomide,,,,Disease progression/Relapse,,15,mg,,Oth,qd,PO,,261,427,1
MMRF_1401,,Second Line Therapy (after,Induction,,Carfilzomib,,,,Lack of response,,20,mg/m^,,QD,,IV,,91,247,1
MMRF_1401,,Third Line Therapy (followi,Induction,,Carfilzomib,,,,Disease progression/Relapse,,20,mg/m^,,QD,,IV,,430,500,1
MMRF_1401,,Third Line Therapy (followi,Induction,,Pomalidomide,,,,Disease progression/Relapse,,4,mg,,QD,,PO,,430,500,1
MMRF_1410,,First line of therapy,,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,164,1
MMRF_1410,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,40,mg,,Q w,,PO,,1,164,1
MMRF_1410,Baseline,First line of therapy,,,Bortezomib,,,,Completed regimen,,2.5,mg,,QD,,IV SubQ,,1,164,1
MMRF_1410,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,5,mg,,QD,,PO,,245,,1
MMRF_1410,,First line of therapy,Consolidation,,Other,"Randomized MILS trial, J1343 (No MILS arm)",,,Completed regimen,,200,Other,unknown,Q d,,IV,,187,187,1
MMRF_1598,Baseline,First line of therapy,Induction,,Thalidomide,,,,Other,death,100,mg,,Q d,,PO,,1,45,1
MMRF_1598,,First line of therapy,Induction,,Dexamethasone,,,,Other,death,20,mg,,Q w,,PO,,1,45,1
MMRF_1670,Baseline,First line of therapy,Induction,,Bortezomib,,,,Other,Plan for stem cell rescue when in remission,3,mg,,QD,,IV SubQ,,1,81,1
MMRF_1670,,First line of therapy,Induction,,Lenalidomide,,,,Other,Plan for stem cell rescue when in remission.,25,mg,,QD,,PO,,1,74,1
MMRF_1670,,First line of therapy,Induction,,Dexamethasone,,,,Other,Plan for stem cell rescue when in remission.,40,mg,,Oth,once weekly,PO,,1,74,1
MMRF_1670,,Second Line Therapy (after,Other,Due to progression,Carfilzomib,,,,Disease progression/Relapse,,20,mg/m^,,Oth,"D1,D8,D15",IV,,484,612,1
MMRF_1670,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,210,mg,,Oth,QD ON DAYS -2 AND -1 PRE TRANSPLANT,IV,,127,128,1
MMRF_1670,,First line of therapy,Maintenance,,Lenalidomide,,,,Disease progression/Relapse,,10,mg,,Oth,QD,PO,,278,477,1
MMRF_1670,,Third Line Therapy (followi,Induction,,Other,ACP-196,,,Disease progression/Relapse,,100,mg,,BID,,PO,,683,773,1
MMRF_1670,,Third Line Therapy (followi,Induction,,Other,pembrolizumab,,,Disease progression/Relapse,,2,mg/kg,,Oth,day 1,IV,,683,773,1
MMRF_1670,,Fourth Line Therapy (follow,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,1.5,mg/m^,,Oth,"Days 1, 8, 15, 22",IV,,943,1111,1
MMRF_1670,,Fourth Line Therapy (follow,Induction,,Cyclophosphamide,,,,Adverse Event or co-morbidity,,600,mg,,Oth,"Days 1, 8, 15, 22",PO,,943,1111,1
MMRF_1670,,Fifth Line Therapy (followi,Unknown,,Dexamethasone,,,Checked,,,40,mg,,Oth,unknown,PO,,1283,,1
MMRF_1670,,Fifth Line Therapy (followi,Unknown,,Daratumumab,,,,Disease progression/Relapse,,16,mg/m^,,QD,,IV,,1283,1429,1
MMRF_1670,,Fifth Line Therapy (followi,Unknown,,Lenalidomide,,,,Disease progression/Relapse,,25,mg,,QD,,PO,,1283,1429,1
MMRF_1670,,Sixth Line Therapy (followi,Maintenance,,Elotuzumab,,,Checked,,,1100,mg,,QWK,,IV,,1436,,1
MMRF_1670,,Sixth Line Therapy (followi,Maintenance,,Lenalidomide,,,Checked,,,10,mg,,QD,,PO,,1436,,1
MMRF_1670,,Seventh Line of Therapy (fo,Maintenance,,Other,etoposide,,Checked,,,75,mg,,QD,,IV,,1478,,1
MMRF_1670,,Seventh Line of Therapy (fo,Maintenance,,Cyclophosphamide,,,Checked,,,750,mg,,QD,,IV,,1478,,1
MMRF_1670,,Seventh Line of Therapy (fo,Maintenance,,Other,cisplatin,,Checked,,,25,mg,,QD,,IV,,1479,,1
MMRF_1695,,First line of therapy,Induction,,Lenalidomide,,,,Other,"Due to transplant , mobilization",15,mg,,Oth,every other day days 1-14,PO,,1,144,1
MMRF_1695,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Q w,,PO,,1,214,1
MMRF_1695,Baseline,First line of therapy,Induction,,Bortezomib,,,,Other,"Due to transplant , mobilization",2.6,mg,,Oth,"QD (D1, D4, D8, D11)",IV,,1,144,1
MMRF_1695,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,5,mg,,QD,,PO,,471,,1
MMRF_1695,,First line of therapy,Other,Mobilization,Melphalan,,,,Completed regimen,,70,mg/kg,,Q d,,IV,,198,198,1
MMRF_1838,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.5,mg/m^,,Oth,"Days 1, 8, 15, 22",IV SubQ,,78,155,1
MMRF_1838,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,"Days 1-4, 9-12, 17-20",PO,,78,155,1
MMRF_1838,Baseline,First line of therapy,Induction,,Cyclophosphamide,,,,Investigator decision for other reasons,,50,mg,,Oth,"Days 1, 8, 15, 22",PO,,1,71,1
MMRF_1838,,First line of therapy,Other,Not sufficient response to previous treatment.,Lenalidomide,,,,Other,Autologous transplant,25,mg,,QD,,PO,,78,155,1
MMRF_1838,,First line of therapy,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,15,mg,,QD,,PO,,316,615,1
MMRF_1838,,First line of therapy,Other,Pre Transplant treament,Melphalan,,,,Completed regimen,,70,mg/m^,,Q d,,IV,,209,210,1
MMRF_1838,,Second Line Therapy (after,Induction,,Dexamethasone,,,,Other,death,4,mg,,QD,,IV,,630,1005,1
MMRF_1838,,Second Line Therapy (after,Induction,,Carfilzomib,,,,Other,death,48,mg,,QD,,IV,,630,639,1
MMRF_1866,Baseline,First line of therapy,Induction,,Lenalidomide,,,,Patient decision,,25,mg,,QD,,PO,,1,235,1
MMRF_1866,,First line of therapy,Induction,,Dexamethasone,,,,Other,Completed cycle 4,20,mg,,Oth,"QD ( D1,D2,D4,D5,D8,D9,D11,12) OF 21-day cycle",PO,,65,78,1
MMRF_1866,,First line of therapy,Induction,,Dexamethasone,,,,Other,completed cycle 2,20,mg,,Oth,"QD ( D1,D2,D4,D5,D8,D9,D11,12) OF 21-day cycle",PO,,22,33,1
MMRF_1866,,First line of therapy,Induction,,Dexamethasone,,,,Other,completed cycle 5,20,mg,,Oth,"QD ( D1,D2,D4,D5,D8,D9,D11,12) OF 21-day cycle",PO,,85,96,1
MMRF_1866,,First line of therapy,Induction,,Dexamethasone,,,,Other,completed cycle,20,mg,,Oth,"QD(D1, D2,D4,D5,D8,D9,D11) of each 21-day cycle.",PO,,1,13,1
MMRF_1866,,First line of therapy,Maintenance,,Lenalidomide,,,,Patient decision,,10,mg,,QD,,PO,,104,985,1
MMRF_1866,,First line of therapy,Maintenance,,Dexamethasone,,,,Patient decision,,12,mg,,QWK,,PO,,104,985,1
MMRF_1866,,First line of therapy,Induction,,Dexamethasone,,,,Other,completed cycle 3,20,mg,,Oth,"QD ( D1,D2,D4,D5,D8,D9,D11,12) OF 21-day cycle",PO,,43,57,1
MMRF_1866,,First line of therapy,Maintenance,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IVB,,19,94,1
MMRF_1866,,Second Line Therapy (after,Maintenance,,Daratumumab,,,Checked,,,16,mg/kg,,QWK,,IV,,1269,,1
MMRF_1950,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,3,mg,,Oth,"Q D1, 8, 15, 22",IV SubQ,,1,289,1
MMRF_1950,,First line of therapy,Induction,,Cyclophosphamide,,,,Investigator decision for other reasons,,300,mg/m^,,Oth,"Q 1, 8, 15, 22",PO,,1,107,1
MMRF_1950,,First line of therapy,Induction,,Dexamethasone,,,,Investigator decision for other reasons,,40,mg,,QWK,,PO,,1,107,1
MMRF_1950,,First line of therapy,Maintenance,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"QD (D1,D2) Q 2 WEEKS",PO,,114,289,1
MMRF_1950,,Second Line Therapy (after,Maintenance,,Daratumumab,,,Checked,,,1100,mg,,Q w,,IVB,,1138,,1
MMRF_1997,Baseline,First line of therapy,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,40,mg,,QWK,,PO,,7,93,1
MMRF_1997,,First line of therapy,Induction,,Lenalidomide,,,,Patient decision,,10,mg,,QD,,PO,,1,787,1
MMRF_1997,,First line of therapy,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,20,mg,,Q w,,PO,,94,241,1
MMRF_1997,,First line of therapy,Maintenance,,Bortezomib,,,,Disease progression/Relapse,,1.3,mg/m^,,Oth,"day 1, 15",IV,,579,705,1
MMRF_1997,,First line of therapy,Induction,,Bortezomib,,,,Investigator decision for other reasons,,2.2,mg,,Oth,"Days 1, 8, 15, 22",IV,,473,558,1
MMRF_2214,,First line of therapy,Induction,,Cyclophosphamide,,,,Investigator decision for other reasons,,300,mg/m^,,Oth,"Day 1, 8, 15, 22",PO,,1,426,1
MMRF_2214,,First line of therapy,Induction,,Dexamethasone,,,,Investigator decision for other reasons,,4,mg,,QWK,,PO,,1,433,1
MMRF_2214,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,3.1,mg,,Q w,,IV SubQ,,9,36,1
MMRF_2214,,First line of therapy,Maintenance,,Lenalidomide,,,,Investigator decision for other reasons,,10,mg,,Oth,Q3 weeks on and one week off,PO,,44,433,1
MMRF_2230,,First line of therapy,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,2.7,mg,,Oth,"Day 1. 8, 15 and 22",IV,,1,64,1
MMRF_2230,,First line of therapy,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,40,mg,,Oth,"Day 1-4. 9-12, 17-20",PO,,1,124,1
MMRF_2230,Baseline,First line of therapy,Induction,,Cyclophosphamide,,,,Adverse Event or co-morbidity,,500,mg,,Oth,"Days 1, 8, 15 and 22",PO,,1,64,1
MMRF_2258,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Q w,,PO,,1,112,1
MMRF_2258,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,2.2,mg,,QD,,IV,,1,112,1
MMRF_2442,Baseline,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,190,1
MMRF_2442,,First line of therapy,Induction,,Dexamethasone,,,,Investigator decision for other reasons,,20,mg,,Oth,"Day 1-2, 4-5, 8-9, 11-12",PO,,1,36,1
MMRF_2442,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,"Day 1-2, 4-5, 8-9, 11-12",PO,,36,190,1
MMRF_2442,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,2.4,mg,,QD,,IV SubQ,,1,190,1
MMRF_2442,,First line of therapy,Unknown,,Melphalan,,,,Completed regimen,,177,mg,,Q d,,IV,,224,225,1
MMRF_2442,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,10,mg,,QD,,PO,,406,,1
MMRF_2442,,First line of therapy,Induction,,Dexamethasone,,,Checked,,,12,mg,,Oth,"1-2, 4-5, 8-9, 11-12",PO,,1165,,1
MMRF_2456,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,3,mg,,Oth,"day 1, 8, 15, 22",IV SubQ,,5,124,1
MMRF_2456,Baseline,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,600,mg,,Oth,"day 1, 8, 15, 22",PO,,5,89,1
MMRF_2456,,First line of therapy,Induction,,Dexamethasone,,,Checked,,,40,mg,,BID,,PO,,1,,1
MMRF_2456,,First line of therapy,Unknown,,Carfilzomib,,,Checked,,,54,mg,,Oth,"Q WEEKLY D1,D8,D15",IV,,153,,1
MMRF_2456,,First line of therapy,Unknown,,Lenalidomide,,,Checked,,,25,mg,,QD,,PO,,153,,1
MMRF_2456,,Second Line Therapy (after,Induction,,Lenalidomide,,,,Disease progression/Relapse,,10,mg,,QD,,PO,,596,918,1
MMRF_2456,,Third Line Therapy (followi,Maintenance,,Lenalidomide,,,Checked,,,5,mg,,QD,,PO,,918,,1
MMRF_2471,,First line of therapy,Induction,,Dexamethasone,,,Checked,,,40,mg,,Oth,"days 1, 8, 15, 22",PO,,4,,1
MMRF_2471,Baseline,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,231,1
MMRF_2471,,Second Line Therapy (after,Induction,,Carfilzomib,,,Checked,,,50,mg,,QD,,IVB,,1148,,1
MMRF_2471,,Second Line Therapy (after,Induction,,Lenalidomide,,,Checked,,,10,mg,,QD,,PO,,1148,,1
MMRF_2471,,Second Line Therapy (after,Induction,,Dexamethasone,,,Checked,,,40,mg,,Q w,,PO,,1148,,1
MMRF_2471,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,5,mg,,BID,,PO,,232,,1
MMRF_2471,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,154,231,1
MMRF_2471,,Second Line Therapy (after,Induction,,Carfilzomib,,,Checked,,,56,mg/m^,,QD,,IV,,1136,,1
MMRF_2475,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1,2,4,5,8,9,11,12 of each 21 day cycle",PO,,1,222,1
MMRF_2475,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,3,mg,,QD,,IV SubQ,,1,131,1
MMRF_2475,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,222,1
MMRF_2475,,Second Line Therapy (after,Maintenance,,Lenalidomide,,,Checked,,,10,mg,,Q d,,PO,,423,,1
MMRF_2546,,First line of therapy,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,20,mg,,Q w,,PO,,1,136,1
MMRF_2546,Baseline,First line of therapy,Induction,,Lenalidomide,,,,Lack of response,,25,mg,,QD,,PO,,1,117,1
MMRF_2546,,First line of therapy,Unknown,,Bortezomib,,,,Disease progression/Relapse,,2.8,mg,,Oth,"Q 28 D ( D1,8,15)",IV,,197,366,1
MMRF_2579,Baseline,First line of therapy,Induction,,Lenalidomide,,,Checked,,,25,mg,,QD,,PO,,1,,1
MMRF_2579,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,2.5,mg,,QD,,IV SubQ,,1,105,1
MMRF_2579,,First line of therapy,Induction,,Dexamethasone,,,Checked,,,20,mg,,Oth,"QD (D1-2, D4-5, D8-9, D11-12)",PO,,1,,1
MMRF_2579,,First line of therapy,Other,INDUCTION,Melphalan,,,,Completed regimen,,100,mg/m^,,Q d,,IV,,140,141,1
MMRF_1021,,First line of therapy,,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,29,1
MMRF_1021,Baseline,First line of therapy,,,Bortezomib,,,,Other,Toxicity,2,mg,,QD,,IV,,1,29,1
MMRF_1021,,First line of therapy,,,Dexamethasone,,,,Other,toxicity,40,mg,,QD,,PO,,1,29,1
MMRF_1021,,Second Line Therapy (after,Other,evidence of disease progression,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,PO,,630,825,1
MMRF_1021,,Second Line Therapy (after,Other,evidence of disease progresion,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,630,825,1
MMRF_1021,,Second Line Therapy (after,Other,conditioning,Other,fludarabine,,,Completed regimen,,30,mg/m^,,Q d,,IV,,844,847,1
MMRF_1021,,Second Line Therapy (after,Other,conditioning,Other,thymoglobulin,,,Completed regimen,,2,Other,mg/kg,QD,,IV,,847,848,1
MMRF_1021,,Second Line Therapy (after,Other,consolidation,Melphalan,,,,Completed regimen,,140,mg/m^,,Q d,,IV,,847,847,1
MMRF_1021,,Second Line Therapy (after,Other,conditioning,Bortezomib,,,,Completed regimen,,1.6,mg/m^,,QD,,IV SubQ,,845,848,1
MMRF_1021,,First line of therapy,Other,conditioning,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,84,84,1
MMRF_1030,Baseline,First line of therapy,,,Bortezomib,,,,Other,patient went to transplant,1,mg,,QWK,,IV,,1,106,1
MMRF_1030,,First line of therapy,,,Lenalidomide,,,,Other,patient went to transplant,25,mg,,QD,,PO,,1,106,1
MMRF_1030,,First line of therapy,,,Dexamethasone,,,,Other,patient went to transplant,20,mg,,QWK,,IV,,1,106,1
MMRF_1030,,First line of therapy,,,Other,Etoposide,,,Other,patient going to transplant,300,mg,,Q d,,IV,,116,116,1
MMRF_1030,,First line of therapy,,,Cyclophosphamide,,,,Other,patient going to transplant,3,Other,grams,Q d,,IV,,116,116,1
MMRF_1030,,First line of therapy,,,Bortezomib,,,,Completed regimen,,1.6,mg/m^,,Q d,,IV,,281,283,1
MMRF_1030,,First line of therapy,,,Thalidomide,,,,Completed regimen,,1000,mg,,Q d,,PO,,280,283,1
MMRF_1030,,First line of therapy,,,Dexamethasone,,,,Other,patient going to transplant,40,mg,,Q d,,IV,,116,116,1
MMRF_1030,,First line of therapy,,,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,140,140,1
MMRF_1030,,First line of therapy,,,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,282,282,1
MMRF_1030,,Second Line Therapy (after,Unknown,,Carfilzomib,,,,Adverse Event or co-morbidity,,20,mg/m^,,QD,,IV,,1984,2205,1
MMRF_1030,,Second Line Therapy (after,Unknown,,Lenalidomide,,,,Adverse Event or co-morbidity,,25,mg,,QD,,PO,,1984,2205,1
MMRF_1030,,Second Line Therapy (after,Unknown,,Dexamethasone,,,,Adverse Event or co-morbidity,,20,mg,,QD,,IV,,1984,2205,1
MMRF_1030,,Third Line Therapy (followi,Other,salvage,Dexamethasone,,,Checked,,,20,mg,,Q w,,PO,,2373,,1
MMRF_1030,,Third Line Therapy (followi,Other,salvage,Lenalidomide,,,Checked,,,25,mg,,QD,,PO,,2373,,1
MMRF_1030,,Third Line Therapy (followi,Other,salvage,Ixazomib,,,Checked,,,4,mg,,Oth,"Days 1, 8, and 15",PO,,2373,,1
MMRF_1032,Baseline,First line of therapy,,,Bortezomib,,,,Investigator decision for other reasons,,2,mg,,QD,,IV SubQ,,2,52,1
MMRF_1032,,First line of therapy,,,Cyclophosphamide,,,,Investigator decision for other reasons,,1050,mg,,Q w,,IV,,1,39,1
MMRF_1032,,First line of therapy,,,Dexamethasone,,,,Investigator decision for other reasons,,10,mg,,QD,,IV,,1,42,1
MMRF_1032,,Second Line Therapy (after,Unknown,,Lenalidomide,,,,Adverse Event or co-morbidity,,25,mg,,QD,,PO,,439,578,1
MMRF_1032,,Second Line Therapy (after,Unknown,,Dexamethasone,,,,Investigator decision for other reasons,,20,mg,,Q w,,PO,,439,725,1
MMRF_1032,,Second Line Therapy (after,Unknown,,Dexamethasone,,,,Other,died,12,mg,,Q w,,PO,,726,934,1
MMRF_1032,,Second Line Therapy (after,Unknown,,Lenalidomide,,,,Other,died,15,mg,,QD,,PO,,612,934,1
MMRF_1072,Baseline,First line of therapy,,,Lenalidomide,,,,Adverse Event or co-morbidity,,25,mg,,QD,,PO,,1,14,1
MMRF_1072,,First line of therapy,,,Bortezomib,,,,Other,pt going to transplant,2,mg,,QD,,IV SubQ,,1,32,1
MMRF_1072,,First line of therapy,,,Dexamethasone,,,,Other,going to transplant,40,mg,,QD,,PO,,1,32,1
MMRF_1072,,First line of therapy,Other,mobilization,Dexamethasone,,,,Completed regimen,,10,mg,,Q d,,IV,,60,60,1
MMRF_1072,,First line of therapy,Other,conditionig,Melphalan,,,,Completed regimen,,312,mg,,Q d,,IV,,86,86,1
MMRF_1072,,First line of therapy,Other,mobilization,Cyclophosphamide,,,,Completed regimen,,3.1,Other,g,Q d,,PO,,60,60,1
MMRF_1072,,First line of therapy,Other,mobilization,Other,etoposide,,,Completed regimen,,310,mg,,Q d,,IV,,60,60,1
MMRF_1079,Baseline,First line of therapy,Induction,,Bortezomib,,,,Other,move to transplant,1.3,mg/m^,,QD,,IV SubQ,,1,40,1
MMRF_1079,,First line of therapy,Induction,,Dexamethasone,,,,Other,proceed to transplant,40,mg,,QD,,PO,,1,40,1
MMRF_1079,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,2000,mg/m^,,Q d,,IV,,75,75,1
MMRF_1079,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,10,mg,,Q d,,IV,,75,75,1
MMRF_1079,,First line of therapy,Induction,,Other,etoposide,,,Completed regimen,,200,mg/m^,,Q d,,IV,,75,75,1
MMRF_1079,,First line of therapy,Induction,,Lenalidomide,,,,Other,proceed to transplant,25,mg,,QD,,PO,,1,43,1
MMRF_1079,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,99,99,1
MMRF_1079,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,226,226,1
MMRF_1079,,Second Line Therapy (after,Other,second line,Carfilzomib,,,,Disease progression/Relapse,,27,mg/m^,,QD,,IV,,1331,1752,1
MMRF_1079,,Second Line Therapy (after,Other,second line,Lenalidomide,,,,Disease progression/Relapse,,25,mg,,QD,,PO,,1331,1752,1
MMRF_1079,,Second Line Therapy (after,Other,second line,Dexamethasone,,,,Disease progression/Relapse,,20,mg,,QD,,IV,,1331,1752,1
MMRF_1079,,Third Line Therapy (followi,Other,third line,Cyclophosphamide,,,,Disease progression/Relapse,,500,mg/m^,,Oth,"D1, 8",IV,,1597,1752,1
MMRF_1079,,Fifth Line Therapy (followi,Unknown,,Bortezomib,,,,Disease progression/Relapse,,2.4,mg,,Oth,"QD(D1,D5,D15,D19)",IV SubQ,,1999,2074,1
MMRF_1079,,Fifth Line Therapy (followi,Unknown,,Panobinostat,,,,Disease progression/Relapse,,20,mg,,Oth,"QD (D1, D3, D5, D15, D17, D19)",PO,,1999,2074,1
MMRF_1079,,Fifth Line Therapy (followi,Unknown,,Dexamethasone,,,,Disease progression/Relapse,,20,mg,,Oth,on days of velcade,PO,,1999,2074,1
MMRF_1079,,Fourth Line Therapy (follow,Unknown,,Daratumumab,,,,Disease progression/Relapse,,16,mg/kg,,Oth,"Days 1,8,15 & 22 of a 28 days for C1&2/Days a and 15 C3to C6/Days 1 cycle 7",IV,,1887,1971,1
MMRF_1079,,Fourth Line Therapy (follow,Unknown,,Pomalidomide,,,,Disease progression/Relapse,,4,mg,,QD,,PO,,1887,1971,1
MMRF_1079,,Fourth Line Therapy (follow,Unknown,,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,Oth,with each daratumumab infusion,IV,,1887,1971,1
MMRF_1079,,Sixth Line Therapy (followi,Unknown,,Bortezomib,,,,Other,Death,2.5,mg,,QD,,IV SubQ,,2081,2126,1
MMRF_1079,,Sixth Line Therapy (followi,Unknown,,Other,nelfinavir (VIRACEPT),,,Other,Death,625,mg,,Q d,,PO,,2081,2126,1
MMRF_1079,,Sixth Line Therapy (followi,Unknown,,Dexamethasone,,,,Other,Death,20,mg,,QD,,PO,,2081,2126,1
MMRF_1098,Baseline,First line of therapy,,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,89,1
MMRF_1098,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,PO,,1,89,1
MMRF_1098,,First line of therapy,,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,92,1
MMRF_1098,,First line of therapy,,,Dexamethasone,,,,Patient decision,,40,mg,,Q w,,PO,,105,329,1
MMRF_1099,Baseline,First line of therapy,,,Bortezomib,,,,Adverse Event or co-morbidity,,1.3,mg/m^,,QD,,IV SubQ,,1,4,1
MMRF_1099,,First line of therapy,,,Lenalidomide,,,,Adverse Event or co-morbidity,,25,mg,,QD,,PO,,1,136,1
MMRF_1099,,Second Line Therapy (after,,,Pomalidomide,,,,Patient decision,,4,mg,,QD,,PO,,333,588,1
MMRF_1099,,First line of therapy,,,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,QD,,PO,,1,285,1
MMRF_1099,,First line of therapy,Induction,,Lenalidomide,,,,Disease progression/Relapse,,25,mg,,Oth,every other day,PO,,144,285,1
MMRF_1099,,Second Line Therapy (after,Unknown,,Dexamethasone,,,,Patient decision,,40,mg,,Q w,,PO,,333,588,1
MMRF_1139,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,PO,,1,53,1
MMRF_1139,Baseline,First line of therapy,,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,53,1
MMRF_1139,,First line of therapy,,,Lenalidomide,,,,Investigator decision for other reasons,,25,mg,,QD,,PO,,1,35,1
MMRF_1139,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,10,mg,,Q d,,IV,,74,74,1
MMRF_1139,,First line of therapy,,,Other,Etoposide,,,Completed regimen,,200,mg/m^,,Q d,,IV,,74,74,1
MMRF_1139,,First line of therapy,,,Cyclophosphamide,,,,Completed regimen,,2,Other,g/m^2,Q d,,IV,,74,74,1
MMRF_1139,,First line of therapy,Other,conditioning,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,276,276,1
MMRF_1139,,First line of therapy,Other,Conditioning,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,99,99,1
MMRF_1139,,First line of therapy,Other,conditioning,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV,,274,277,1
MMRF_1159,Baseline,First line of therapy,,,Bortezomib,,,,Completed regimen,,3.1,mg,,QD,,IV SubQ,,1,92,1
MMRF_1159,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,10,mg,,Oth,once,IV,,122,122,1
MMRF_1159,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,20,mg,,QD,,PO,,1,92,1
MMRF_1159,,First line of therapy,,,Cyclophosphamide,,,,Completed regimen,,4.7,Other,g,Oth,once,IV,,122,122,1
MMRF_1159,,First line of therapy,,,Melphalan,,,,Completed regimen,,200,mg/m^,,Oth,once,IV,,170,170,1
MMRF_1159,,First line of therapy,,,Other,Etoposide,,,Completed regimen,,200,mg/m^,,Oth,once,IV,,122,122,1
MMRF_1177,,First line of therapy,,,Cyclophosphamide,,,,Other,intolerance to therapy,500,mg/m^,,Oth,"QD (D1, D8)",IV,,1,242,1
MMRF_1177,Baseline,First line of therapy,,,Bortezomib,,,,Investigator decision for other reasons,,1.3,mg/m^,,QD,,IV SubQ,,1,242,1
MMRF_1177,,First line of therapy,,,Dexamethasone,,,,Other,intolerance to therapy,20,mg,,QD,,PO,,1,242,1
MMRF_1177,,Second Line Therapy (after,Other,salvage,Dexamethasone,,,,Other,death,20,mg,,QD,,PO,,711,819,1
MMRF_1177,,Second Line Therapy (after,Other,salvage,Bortezomib,,,,Other,death,1.3,mg/m^,,QD,,IV SubQ,,711,819,1
MMRF_1177,,Second Line Therapy (after,Other,salvage,Cyclophosphamide,,,,Other,death,890,mg,,Oth,"QD (D1, D8)",IV,,711,819,1
MMRF_1208,,First line of therapy,,,Cyclophosphamide,,,,Completed regimen,,500,mg/m^,,Oth,QD 1-8,IV,,1,63,1
MMRF_1208,Baseline,First line of therapy,,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,8,66,1
MMRF_1208,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,PO,,1,63,1
MMRF_1208,,First line of therapy,Other,conditioning,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,170,170,1
MMRF_1208,,Second Line Therapy (after,Other,second line therapy,Bortezomib,,,,Adverse Event or co-morbidity,,1.3,mg/m^,,QD,,IV SubQ,,711,722,1
MMRF_1208,,Second Line Therapy (after,Other,second line therapy,Dexamethasone,,,,Investigator decision for other reasons,,40,mg,,QD,,PO,,711,742,1
MMRF_1208,,Second Line Therapy (after,Other,second line,Lenalidomide,,,,Disease progression/Relapse,,15,mg,,QD,,PO,,732,905,1
MMRF_1208,,Third Line Therapy (followi,Consolidation,,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,Oth,"Days 1, 8, 15",IV,,1074,1114,1
MMRF_1208,,Third Line Therapy (followi,Consolidation,,Carfilzomib,,,,Adverse Event or co-morbidity,,32,mg,,Oth,QD (Day1-Day2; Day15-Day16),IV,,1137,1320,1
MMRF_1208,,Third Line Therapy (followi,Consolidation,,Thalidomide,,,,Disease progression/Relapse,,100,mg,,QD,,PO,,1074,1114,1
MMRF_1208,,Third Line Therapy (followi,Consolidation,,Cyclophosphamide,,,,Disease progression/Relapse,,300,mg/m^,,Oth,Days 1 & 15,IV,,1074,1102,1
MMRF_1208,,Third Line Therapy (followi,Unknown,,Dexamethasone,,,,Adverse Event or co-morbidity,,40,mg,,QD,,IV,,1137,1320,1
MMRF_1194,Baseline,First line of therapy,,,Lenalidomide,,,,Lack of response,,25,mg,,QD,,PO,,1,90,1
MMRF_1194,,First line of therapy,,,Bortezomib,,,,Adverse Event or co-morbidity,,1.3,mg/m^,,QD,,IV SubQ,,91,100,1
MMRF_1194,,First line of therapy,,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,91,136,1
MMRF_1194,,First line of therapy,,,Dexamethasone,,,,Lack of response,,40,mg,,Q w,,PO,,1,90,1
MMRF_1194,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,20,mg,,QD,,IV,,91,136,1
MMRF_1194,,First line of therapy,Other,Mobilization,Cyclophosphamide,,,,Completed regimen,,2000,mg/m^,,QID,,IV,,142,142,1
MMRF_1194,,First line of therapy,Other,Mobilization,Other,Etoposide,,,Completed regimen,,200,mg/m^,,QID,,IV,,142,142,1
MMRF_1194,,First line of therapy,Other,Mobilization,Dexamethasone,,,,Completed regimen,,10,mg,,QID,,IV,,142,142,1
MMRF_1194,,First line of therapy,Other,conditioning,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,181,181,1
MMRF_1205,,First line of therapy,,,Cyclophosphamide,,,,Lack of response,,300,mg/m^,,Oth,"QD (D1, D8)",IV,,1,85,1
MMRF_1205,Baseline,First line of therapy,,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,142,1
MMRF_1205,,First line of therapy,Other,conditioning,Melphalan,,,,Completed regimen,,140,mg/m^,,Q d,,IV,,187,187,1
MMRF_1205,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,20,mg,,QD,,PO,,1,142,1
MMRF_1205,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,114,127,1
MMRF_1205,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,500,mg/m^,,QWK,,IV,,135,135,1
MMRF_1205,,Second Line Therapy (after,Unknown,,Pomalidomide,,,,Adverse Event or co-morbidity,,4,mg,,QD,,PO,,618,666,1
MMRF_1205,,Second Line Therapy (after,Unknown,,Dexamethasone,,,,Adverse Event or co-morbidity,,20,mg,,Q w,,PO,,618,666,1
MMRF_1205,,Second Line Therapy (after,Other,n/a,Pomalidomide,,,,Adverse Event or co-morbidity,,4,mg,,Oth,QOD (D1-21),PO,,667,685,1
MMRF_1205,,Second Line Therapy (after,Other,n/a,Dexamethasone,,,,Adverse Event or co-morbidity,,12,mg,,Q w,,PO,,667,685,1
MMRF_1211,,First line of therapy,,,Dexamethasone,,,,Adverse Event or co-morbidity,,20,mg,,QD,,PO,,1,53,1
MMRF_1211,Baseline,First line of therapy,,,Bortezomib,,,,Adverse Event or co-morbidity,,1.3,mg/m^,,QD,,IV SubQ,,1,53,1
MMRF_1211,,First line of therapy,Induction,,Dexamethasone,,,,Investigator decision for other reasons,,40,mg,,Oth,"QD1, 8, 15",PO,,64,78,1
MMRF_1211,,First line of therapy,Other,conditioning,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,127,127,1
MMRF_1211,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,2000,mg/m^,,Q d,,IV,,101,101,1
MMRF_1211,,First line of therapy,Induction,,Bortezomib,,,,Investigator decision for other reasons,,1.6,mg/m^,,Oth,"QD1, 8, 15",IV SubQ,,64,78,1
MMRF_1211,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Q d,,IV,,101,101,1
MMRF_1211,,First line of therapy,Induction,,Other,etoposide,,,Completed regimen,,200,mg/m^,,Q d,,IV,,101,101,1
MMRF_1221,Baseline,First line of therapy,,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,64,1
MMRF_1221,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,PO,,1,64,1
MMRF_1221,,First line of therapy,,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,64,1
MMRF_1221,,First line of therapy,Other,Moblozation,Cyclophosphamide,,,,Completed regimen,,2000,mg/m^,,Q d,,IV,,96,96,1
MMRF_1221,,First line of therapy,Other,Mobilization,Bortezomib,,,,Completed regimen,,1.6,mg/m^,,Oth,Day 1 and 4,IV,,295,298,1
MMRF_1221,,First line of therapy,Other,Mobilization,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,Day 1 and 4,IV,,295,298,1
MMRF_1221,,First line of therapy,Other,Conditioning,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,297,297,1
MMRF_1221,,First line of therapy,Other,Mobilization,Other,Etoposide,,,Completed regimen,,200,mg/m^,,Q d,,IV,,96,96,1
MMRF_1221,,First line of therapy,Other,Mobilization,Dexamethasone,,,,Completed regimen,,10,mg,,Q d,,IV,,96,96,1
MMRF_1221,,First line of therapy,Induction,,Other,Th1 cell infusion,,,Completed regimen,,0,Other,n/a. infusion,Oth,once,IV,,352,352,1
MMRF_1221,,First line of therapy,Other,conditioning,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,128,128,1
MMRF_1221,,Second Line Therapy (after,Other,reinduction,Lenalidomide,,,,Investigator decision for other reasons,,25,mg,,QD,,PO,,711,760,1
MMRF_1221,,Third Line Therapy (followi,Unknown,,Carfilzomib,,,,Disease progression/Relapse,,27,mg/m^,,QD,,IV,,851,922,1
MMRF_1221,,Third Line Therapy (followi,Unknown,,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,QD,,IV,,852,922,1
MMRF_1221,,Second Line Therapy (after,Other,reinduction,Dexamethasone,,,,Investigator decision for other reasons,,40,mg,,QWK,,PO,,711,760,1
MMRF_1221,,Third Line Therapy (followi,Unknown,,Cyclophosphamide,,,,Disease progression/Relapse,,500,mg/m^,,Oth,D1 and D8,IV,,851,914,1
MMRF_1221,,Fifth Line Therapy (followi,Maintenance,,Dexamethasone,,,,Other,admitted,40,mg,,QD,,PO,,1093,1164,1
MMRF_1221,,Fourth Line Therapy (follow,Unknown,,Carfilzomib,,,,Investigator decision for other reasons,,27,mg/m^,,QD,,IV,,947,1067,1
MMRF_1221,,Fourth Line Therapy (follow,Unknown,,Pomalidomide,,,,Disease progression/Relapse,,4,mg,,QD,,PO,,947,1079,1
MMRF_1221,,Fourth Line Therapy (follow,Unknown,,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,Q w,,PO,,947,1080,1
MMRF_1221,,Fifth Line Therapy (followi,Unknown,,Other,panobinostat,,,Other,admitted,20,mg,,Oth,Three times weekly (Monday-Wednesday-Friday),PO,,1093,1164,1
MMRF_1221,,Fifth Line Therapy (followi,Unknown,,Bortezomib,,,,Other,admitted,1.3,mg/m^,,QD,,IV SubQ,,1093,1164,1
MMRF_1221,,Fifth Line Therapy (followi,Unknown,,Pomalidomide,,,,Other,admission,4,mg,,QD,,PO,,1093,1164,1
MMRF_1230,,First line of therapy,,,Cyclophosphamide,,,,Investigator decision for other reasons,,500,mg/m^,,Oth,QD D1 and D8,IV,,22,102,1
MMRF_1230,Baseline,First line of therapy,,,Bortezomib,,,,Investigator decision for other reasons,,1.3,mg/m^,,QD,,IV SubQ,,1,106,1
MMRF_1230,,First line of therapy,,,Lenalidomide,,,,Investigator decision for other reasons,,25,mg,,QD,,PO,,1,107,1
MMRF_1230,,First line of therapy,,,Dexamethasone,,,,Investigator decision for other reasons,,40,mg,,QD,,PO,,1,106,1
MMRF_1230,,First line of therapy,,,Other,etoposide,,,Completed regimen,,200,mg/m^,,Q d,,IV,,136,136,1
MMRF_1230,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,10,mg,,Q d,,IV,,136,136,1
MMRF_1230,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,8,mg,,Q d,,PO,,169,169,1
MMRF_1230,,First line of therapy,,,Cyclophosphamide,,,,Completed regimen,,2,Other,g/m^2,Q d,,IV,,136,136,1
MMRF_1230,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,12,mg,,Q d,,PO,,168,168,1
MMRF_1230,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,8,mg,,BID,,PO,,170,170,1
MMRF_1230,,First line of therapy,,,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,168,168,1
MMRF_1257,Baseline,First line of therapy,,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,52,1
MMRF_1257,,First line of therapy,,,Cyclophosphamide,,,,Completed regimen,,500,mg/m^,,Oth,QD Day 1-8,IV,,1,29,1
MMRF_1257,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,20,mg,,QD,,IV,,1,52,1
MMRF_1257,,First line of therapy,Other,Conditioning,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,99,99,1
MMRF_1257,,Second Line Therapy (after,Unknown,,Bortezomib,,,,Disease progression/Relapse,,1.3,mg/m^,,QD,,IV SubQ,,905,1214,1
MMRF_1257,,Second Line Therapy (after,Unknown,,Cyclophosphamide,,,,Disease progression/Relapse,,500,mg/m^,,QD,,IV,,905,1207,1
MMRF_1257,,Second Line Therapy (after,Unknown,,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,QD,,PO,,905,1214,1
MMRF_1257,,Third Line Therapy (followi,Unknown,,Lenalidomide,,,,Disease progression/Relapse,,25,mg,,QD,,PO,,1248,1418,1
MMRF_1257,,Third Line Therapy (followi,Unknown,,Ixazomib,,,,Disease progression/Relapse,,4,mg,,Oth,"QD (D1, D8 & D15)",PO,,1248,1418,1
MMRF_1257,,Third Line Therapy (followi,Unknown,,Dexamethasone,,,,Disease progression/Relapse,,20,mg,,Q w,,PO,,1248,1418,1
MMRF_1257,,Fourth Line Therapy (follow,Unknown,,Carfilzomib,,,,Disease progression/Relapse,,27,mg/m^,,QD,,IV,,1428,1443,1
MMRF_1257,,Fourth Line Therapy (follow,Unknown,,Pomalidomide,,,,Disease progression/Relapse,,4,mg,,QD,,PO,,1428,1448,1
MMRF_1257,,Fifth Line Therapy (followi,Unknown,,Daratumumab,,,,Disease progression/Relapse,,16,mg/kg,,Oth,"weekly for weeks 1-8, every other week 9-24, monthly week 25 onwards",IV,,1449,1578,1
MMRF_1257,,Fifth Line Therapy (followi,Unknown,,Dexamethasone,,,,Disease progression/Relapse,,4,mg,,Q w,,PO,,1449,1578,1
MMRF_1257,,Fifth Line Therapy (followi,Unknown,,Thalidomide,,,,Investigator decision for other reasons,,200,mg,,Q d,,PO,,1449,1554,1
MMRF_1257,,Fifth Line Therapy (followi,Unknown,,Prednisone,,,,Disease progression/Relapse,,25,mg,,Oth,Days 1 and 2 following Dara dosing,PO,,1452,1578,1
MMRF_1257,,Fourth Line Therapy (follow,Unknown,,Dexamethasone,,,,Disease progression/Relapse,,20,mg,,QD,,IV,,1428,1443,1
MMRF_1257,,Fifth Line Therapy (followi,Unknown,,Pomalidomide,,,,Disease progression/Relapse,,3,mg,,QD,,PO,,1564,1578,1
MMRF_1257,,Sixth Line Therapy (followi,Unknown,,Carfilzomib,,,,Completed regimen,,56,mg/m^,,Q d,,IV,,1589,1590,1
MMRF_1257,,Seventh Line of Therapy (fo,Unknown,,Other,Pembrolizumab,,,Other,death,100,mg,,Oth,every two weeks,IV,,1617,1666,1
MMRF_1257,,Seventh Line of Therapy (fo,Unknown,,Pomalidomide,,,,Other,death,4,mg,,QD,,PO,,1610,1666,1
MMRF_1257,,Seventh Line of Therapy (fo,Unknown,,Dexamethasone,,,,Other,death,20,mg,,Q w,,PO,,1617,1666,1
MMRF_1257,,Fifth Line Therapy (followi,Other,anti cancer regimen,Cyclophosphamide,,,,Disease progression/Relapse,,300,mg/m^,,Oth,"D 1,8 &15",IV,,1536,1578,1
MMRF_1257,,Sixth Line Therapy (followi,Unknown,,Bendamustine,,,,Completed regimen,,110,mg/m^,,Q d,,IV,,1589,1590,1
MMRF_1257,,Sixth Line Therapy (followi,Unknown,,Dexamethasone,,,,Completed regimen,,40,mg,,Q d,,IV,,1589,1590,1
MMRF_1257,,Third Line Therapy (followi,Unknown,,Lenalidomide,,,,Disease progression/Relapse,,25,mg,,QD,,PO,,1248,1418,1
MMRF_1274,,First line of therapy,,,Cyclophosphamide,,,,Completed regimen,,500,mg/m^,,QD,,IV,,1,50,1
MMRF_1274,Baseline,First line of therapy,,,Bortezomib,,,,Investigator decision for other reasons,,1.3,mg/m^,,QD,,IV SubQ,,1,54,1
MMRF_1274,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,PO,,1,54,1
MMRF_1274,,First line of therapy,,,Other,fludarabine,,,Completed regimen,,30,mg/m^,,Q d,,IV,,288,291,1
MMRF_1274,,First line of therapy,Other,mobilization,Other,etoposide,,,Completed regimen,,200,mg/m^,,Oth,once,IV,,92,92,1
MMRF_1274,,First line of therapy,Other,mobilization,Dexamethasone,,,,Completed regimen,,10,mg,,Oth,once,IV,,92,92,1
MMRF_1274,,First line of therapy,Other,mobilization,Cyclophosphamide,,,,Completed regimen,,2,Other,g/m^2,Oth,once,IV,,92,92,1
MMRF_1274,,First line of therapy,Other,conditioning,Melphalan,,,,Completed regimen,,200,mg/m^,,Oth,once,IV,,117,117,1
MMRF_1274,,First line of therapy,Other,conditioning,Melphalan,,,,Completed regimen,,140,mg/m^,,Q d,,IV,,291,291,1
MMRF_1274,,First line of therapy,Other,mobilization,Bortezomib,,,,Completed regimen,,1.6,mg/m^,,QD,,IV SubQ,,289,292,1
MMRF_1286,,First line of therapy,,,Other,Etoposide,,,Completed regimen,,200,mg/m^,,Oth,once,IV,,74,74,1
MMRF_1286,,First line of therapy,,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,47,1
MMRF_1286,,First line of therapy,,,Cyclophosphamide,,,,Completed regimen,,2,Other,g/m^2,Oth,once,IV,,74,74,1
MMRF_1286,Baseline,First line of therapy,,,Bortezomib,,,,Completed regimen,,2.6,mg,,QD,,IV SubQ,,1,40,1
MMRF_1286,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,20,mg,,QD,,PO,,1,40,1
MMRF_1286,,First line of therapy,Other,Mobilization,Dexamethasone,,,,Completed regimen,,10,mg,,Q d,,IV,,74,74,1
MMRF_1286,,First line of therapy,Other,Conditioning,Melphalan,,,,Completed regimen,,140,mg/m^,,Q d,,IV,,100,100,1
MMRF_1286,,Second Line Therapy (after,Induction,,Lenalidomide,,,,Disease progression/Relapse,,15,mg,,QD,,PO,,268,920,1
MMRF_1286,,Second Line Therapy (after,Unknown,,Dexamethasone,,,,Disease progression/Relapse,,20,mg,,Q w,,PO,,268,1018,1
MMRF_1286,,Fourth Line Therapy (follow,Other,fourth line (velcade pomalidomide dexamethasone),Dexamethasone,,,,Investigator decision for other reasons,,20,mg,,Oth,"QD (D1, 8, 15)",PO,,1032,1101,1
MMRF_1286,,Third Line Therapy (followi,Other,third line,Pomalidomide,,,,Investigator decision for other reasons,,4,mg,,QD,,PO,,941,1107,1
MMRF_1286,,Fourth Line Therapy (follow,Other,fourth line (velcade pomalidomide dexamethasone),Bortezomib,,,,Investigator decision for other reasons,,1.3,mg/m^,,Oth,"QD (D1, 8, 15)",IV SubQ,,1032,1101,1
MMRF_1286,,Fourth Line Therapy (follow,Other,"fourth line (ixazomib, pomalidomide, dexamethasone)",Dexamethasone,,,,Disease progression/Relapse,,20,mg,,Q w,,PO,,1129,1206,1
MMRF_1286,,Fourth Line Therapy (follow,Other,"fourth line (ixazomib, pomalidomide, dexamethasone)",Ixazomib,,,,Disease progression/Relapse,,4,mg,,Oth,"QWk (D1, 8, 15)",PO,,1129,1199,1
MMRF_1286,,Fourth Line Therapy (follow,Other,"fourth line (ixazomib, pom, dex)",Pomalidomide,,,,Disease progression/Relapse,,4,mg,,QD,,PO,,1129,1205,1
MMRF_1286,,Fifth Line Therapy (followi,Other,fifth line,Dexamethasone,,,Checked,,,40,mg,,Q w,,IV,,1227,,1
MMRF_1286,,Fifth Line Therapy (followi,Other,fifth line,Prednisone,,,Checked,,,25,mg,,Oth,every Friday and Saturday after daratumumab administration,PO,,1229,,1
MMRF_1286,,Fifth Line Therapy (followi,Other,fifth line,Daratumumab,,,Checked,,,16,mg/kg,,Q w,,IV,,1227,,1
MMRF_1286,,Fifth Line Therapy (followi,Other,fifth line,Pomalidomide,,,Checked,,,4,mg,,QD,,PO,,1227,,1
MMRF_1286,,Fifth Line Therapy (followi,Other,salvage,Bortezomib,,,Checked,,,1.6,mg/m^,,Oth,"QD (1,8,15)",IV SubQ,,1955,,1
MMRF_1325,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,40,mg,,QWK,,PO,,1,78,1
MMRF_1325,,First line of therapy,,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,39,78,1
MMRF_1325,Baseline,First line of therapy,,,Lenalidomide,,,,Completed regimen,,15,mg,,Q d,,PO,,1,80,1
MMRF_1325,,First line of therapy,Other,Mobilization,Dexamethasone,,,,Completed regimen,,10,mg,,QID,,IV,,123,123,1
MMRF_1325,,First line of therapy,Other,Mobilization,Cyclophosphamide,,,,Completed regimen,,2000,mg/m^,,QID,,IV,,123,123,1
MMRF_1325,,First line of therapy,Other,Mobilization,Other,Etoposide,,,Completed regimen,,200,mg/m^,,QID,,IV,,123,123,1
MMRF_1325,,First line of therapy,Other,conditioning,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,148,148,1
MMRF_1394,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,PO,,1,74,1
MMRF_1394,Baseline,First line of therapy,,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,74,1
MMRF_1394,,First line of therapy,,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,77,1
MMRF_1394,,First line of therapy,Other,mobilization,Cyclophosphamide,,,,Completed regimen,,2,Other,g/m^2,Oth,once,IV,,87,87,1
MMRF_1394,,First line of therapy,Other,mobilization,Dexamethasone,,,,Completed regimen,,10,mg,,Oth,once,IV,,87,87,1
MMRF_1394,,First line of therapy,Other,conditioning,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,112,112,1
MMRF_1394,,First line of therapy,Other,mobilization,Other,etoposide,,,Completed regimen,,200,mg/m^,,Oth,once,IV,,87,87,1
MMRF_1394,,Second Line Therapy (after,Unknown,,Ixazomib,,,,Adverse Event or co-morbidity,,4,mg,,Oth,"QD (D1,8,15)",PO,,1366,1409,1
MMRF_1394,,Second Line Therapy (after,Unknown,,Lenalidomide,,,,Adverse Event or co-morbidity,,25,mg,,QD,,PO,,1366,1409,1
MMRF_1394,,Second Line Therapy (after,Unknown,,Dexamethasone,,,,Adverse Event or co-morbidity,,40,mg,,Q w,,PO,,1366,1409,1
MMRF_1394,,Third Line Therapy (followi,Other,Salvage,Bortezomib,,,Checked,,,1.3,mg/m^,,Oth,"D1, D8, D15",IV,,1821,,1
MMRF_1394,,Third Line Therapy (followi,Other,Salvage,Dexamethasone,,,Checked,,,20,mg,,Oth,day of and day after dara,PO,,1821,,1
MMRF_1394,,Third Line Therapy (followi,Other,Salvage,Daratumumab,,,Checked,,,16,mg/kg,,Oth,"Weekly for weeks 1-8, qow 9-24, monthly 25 onward",IV,,1821,,1
MMRF_1408,Baseline,First line of therapy,,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,96,1
MMRF_1408,,First line of therapy,,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,101,1
MMRF_1408,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,20,mg,,QD,,PO,,1,96,1
MMRF_1408,,First line of therapy,Other,moilization,Dexamethasone,,,,Completed regimen,,10,mg,,Q d,,IV,,121,121,1
MMRF_1408,,First line of therapy,Other,conditioning,Melphalan,,,,Completed regimen,,296,mg,,Q d,,IV,,272,272,1
MMRF_1408,,First line of therapy,Other,mobilization,Other,Etoposide,,,Completed regimen,,290,mg,,Q d,,IV,,121,121,1
MMRF_1408,,First line of therapy,Other,mobilization,Cyclophosphamide,,,,Completed regimen,,2.9,Other,gm,Q d,,IV,,121,121,1
MMRF_1408,,Second Line Therapy (after,Unknown,,Ixazomib,,,,Adverse Event or co-morbidity,,4,mg,,Oth,"QD (D1, D8, D15, D22)",PO,,1624,1722,1
MMRF_1408,,Second Line Therapy (after,Unknown,,Lenalidomide,,,,Adverse Event or co-morbidity,,25,mg,,QD,,PO,,1624,1722,1
MMRF_1408,,Second Line Therapy (after,Unknown,,Dexamethasone,,,,Adverse Event or co-morbidity,,40,mg,,QWK,,PO,,1624,1722,1
MMRF_1408,,Third Line Therapy (followi,Unknown,,Dexamethasone,,,Checked,,,28,mg,,Oth,3-24 hours prior to Elo,IV,,1748,,1
MMRF_1408,,Third Line Therapy (followi,Unknown,,Lenalidomide,,,Checked,,,25,mg,,QD,,PO,,1748,,1
MMRF_1408,,Third Line Therapy (followi,Unknown,,Elotuzumab,,,Checked,,,10,mg/kg,,Oth,"weekly 1-8, qow 9 onward",IV,,1748,,1
MMRF_1413,Baseline,First line of therapy,,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,81,1
MMRF_1413,,First line of therapy,Other,conditioning,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,127,127,1
MMRF_1413,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,500,mg/m^,,Oth,"QD (D1, D8)",IV,,1,78,1
MMRF_1413,,First line of therapy,Other,mobilization,Cyclophosphamide,,,,Completed regimen,,2,Other,g/m^2,Q d,,IV,,101,101,1
MMRF_1413,,First line of therapy,Other,mobilization,Dexamethasone,,,,Completed regimen,,10,mg,,Q d,,PO,,101,101,1
MMRF_1413,,First line of therapy,Other,mobilization,Other,etoposide,,,Completed regimen,,200,mg/m^,,Q d,,IV,,101,101,1
MMRF_1413,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,PO,,1,81,1
MMRF_1413,,Second Line Therapy (after,Unknown,,Elotuzumab,,,Checked,,,10,mg/kg,,Oth,"weekly for weeks 1-8, qow weeks 9 onward",IV,,1591,,1
MMRF_1413,,Second Line Therapy (after,Unknown,,Lenalidomide,,,Checked,,,20,mg,,QD,,PO,,1571,,1
MMRF_1413,,Second Line Therapy (after,Unknown,,Dexamethasone,,,Checked,,,8,mg,,Q w,,PO,,1570,,1
MMRF_1418,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,PO,,1,53,1
MMRF_1418,,First line of therapy,,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,57,1
MMRF_1418,Baseline,First line of therapy,,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,53,1
MMRF_1418,,First line of therapy,Other,Mobilization,Dexamethasone,,,,Completed regimen,,10,mg,,QID,,IV,,80,80,1
MMRF_1418,,First line of therapy,Consolidation,,Melphalan,,,,Completed regimen,,200,mg/m^,,QID,,IV,,108,108,1
MMRF_1418,,First line of therapy,Other,Mobilization,Cyclophosphamide,,,,Completed regimen,,2000,mg/m^,,QID,,IV,,80,80,1
MMRF_1418,,First line of therapy,Other,MObilization,Other,Etoposide,,,Completed regimen,,200,mg/m^,,QID,,IV,,80,80,1
MMRF_1418,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,286,286,1
MMRF_1418,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.6,mg/m^,,Oth,QOD,IV SubQ,,284,286,1
MMRF_1418,,Second Line Therapy (after,Unknown,,Carfilzomib,,,Checked,,,27,mg/m^,,QD,,IV,,1185,,1
MMRF_1418,,Second Line Therapy (after,Unknown,,Lenalidomide,,,Checked,,,25,mg,,QD,,PO,,1185,,1
MMRF_1418,,Second Line Therapy (after,Unknown,,Dexamethasone,,,Checked,,,20,mg,,QD,,IV,,1185,,1
MMRF_1423,Baseline,First line of therapy,,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,28,1
MMRF_1423,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,QD,,PO,,1,28,1
MMRF_1423,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,28,1
MMRF_1423,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,99,99,1
MMRF_1426,,First line of therapy,,,Lenalidomide,,,,Investigator decision for other reasons,,25,mg,,QD,,PO,,1,62,1
MMRF_1426,,First line of therapy,,,Dexamethasone,,,,Investigator decision for other reasons,,20,mg,,QD,,PO,,1,59,1
MMRF_1426,Baseline,First line of therapy,,,Bortezomib,,,,Adverse Event or co-morbidity,,1.3,mg/m^,,QD,,IV SubQ,,1,59,1
MMRF_1426,,First line of therapy,Other,mobilization,Dexamethasone,,,,Completed regimen,,10,mg,,Q d,,PO,,122,122,1
MMRF_1426,,First line of therapy,Other,mobilization,Other,etoposide,,,Completed regimen,,200,mg/m^,,Q d,,IV,,122,122,1
MMRF_1426,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,71,91,1
MMRF_1426,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Q w,,PO,,71,92,1
MMRF_1426,,First line of therapy,Other,conditioning,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,147,147,1
MMRF_1426,,First line of therapy,Other,mobilization,Cyclophosphamide,,,,Completed regimen,,2,Other,g/m^2,Q d,,IV,,122,122,1
MMRF_1433,Baseline,First line of therapy,,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,65,1
MMRF_1433,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,PO,,1,68,1
MMRF_1433,,First line of therapy,,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,68,1
MMRF_1433,,First line of therapy,Other,Mobilization,Other,Etoposide,,,Completed regimen,,200,mg/m^,,Q d,,IV,,95,95,1
MMRF_1433,,First line of therapy,Other,Mobilization,Dexamethasone,,,,Completed regimen,,10,mg,,Q d,,IV,,95,95,1
MMRF_1433,,First line of therapy,Other,mobilization,Cyclophosphamide,,,,Completed regimen,,2,Other,g/m2,Q d,,IV,,95,95,1
MMRF_1433,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,257,257,1
MMRF_1433,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,120,120,1
MMRF_1433,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.6,mg/m^,,Q d,,IV SubQ,,256,256,1
MMRF_1433,,Second Line Therapy (after,Unknown,,Lenalidomide,,,,Adverse Event or co-morbidity,,25,mg,,QD,,PO,,883,1082,1
MMRF_1433,,Second Line Therapy (after,Unknown,,Carfilzomib,,,,Adverse Event or co-morbidity,,70,mg/m^,,Q w,,IV,,883,1082,1
MMRF_1433,,Second Line Therapy (after,Unknown,,Dexamethasone,,,,Adverse Event or co-morbidity,,40,mg,,Q w,,PO,,883,1082,1
MMRF_1433,,Third Line Therapy (followi,Unknown,,Pomalidomide,,,,Disease progression/Relapse,,4,mg,,Oth,QD (D1-21),PO,,1100,1332,1
MMRF_1433,,Third Line Therapy (followi,Unknown,,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,Q w,,IV,,1100,1332,1
MMRF_1433,,Fifth Line Therapy (followi,Unknown,,Other,Idasanutlin,,,Disease progression/Relapse,,200,mg,,Oth,QD (D1-5) of a 28 days cycle,PO,,1523,1607,1
MMRF_1433,,Fifth Line Therapy (followi,Unknown,,Ixazomib,,,,Disease progression/Relapse,,4,mg,,Oth,"QD (D1,8,15) of a28 days cycle",PO,,1523,1607,1
MMRF_1433,,Fifth Line Therapy (followi,Unknown,,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,Oth,"QD (D1,D8,D15,D22) of a 28 days cycle",PO,,1523,1607,1
MMRF_1433,,Fourth Line Therapy (follow,Unknown,,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,Q w,,PO,,1359,1472,1
MMRF_1433,,Fourth Line Therapy (follow,Unknown,,Other,pembrolizumab,,,Disease progression/Relapse,,200,mg,,Oth,Q2W,IV,,1359,1472,1
MMRF_1433,,Fourth Line Therapy (follow,Unknown,,Lenalidomide,,,,Disease progression/Relapse,,25,mg,,Oth,QD 91-21),PO,,1359,1472,1
MMRF_1433,,Sixth Line Therapy (followi,Unknown,,Daratumumab,,,Checked,,,1778,mg,,Oth,"weekly for cycles 1-3, q3 weeks 4-8, monthly 9 onward",IV,,1646,,1
MMRF_1433,,Sixth Line Therapy (followi,Unknown,,Bortezomib,,,Checked,,,1.3,mg/m^,,QD,,IV SubQ,,1646,,1
MMRF_1433,,Sixth Line Therapy (followi,Unknown,,Dexamethasone,,,Checked,,,20,mg,,Oth,"Days 1,2,4,5,8,9,11,12",IV,,1646,,1
MMRF_1434,Baseline,First line of therapy,,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,53,1
MMRF_1434,,First line of therapy,,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,56,1
MMRF_1434,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,PO,,1,53,1
MMRF_1434,,First line of therapy,Other,mobilization,Cyclophosphamide,,,,Completed regimen,,2,Other,g/m^2,Q d,,IV,,88,88,1
MMRF_1434,,First line of therapy,Other,mobilization,Dexamethasone,,,,Completed regimen,,10,mg,,Q d,,IV,,88,88,1
MMRF_1434,,First line of therapy,Other,mobilization,Other,etoposide,,,Completed regimen,,200,mg/m^,,Q d,,IV,,88,88,1
MMRF_1434,,First line of therapy,Other,conditioning,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,113,113,1
MMRF_1434,,Second Line Therapy (after,Unknown,,Lenalidomide,,,Checked,,,25,mg,,QD,,PO,,1677,,1
MMRF_1434,,Second Line Therapy (after,Unknown,,Dexamethasone,,,Checked,,,40,mg,,Q w,,PO,,1677,,1
MMRF_1452,Baseline,First line of therapy,,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,86,1
MMRF_1452,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,PO,,2,86,1
MMRF_1452,,First line of therapy,,,Cyclophosphamide,,,,Completed regimen,,500,mg/m^,,Oth,D1 & D8,IV,,1,83,1
MMRF_1452,,First line of therapy,Other,conditioning,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,133,133,1
MMRF_1452,,First line of therapy,Other,mobilization,Cyclophosphamide,,,,Completed regimen,,2,Other,g/m^2,Q d,,IV,,107,107,1
MMRF_1452,,First line of therapy,Other,mobilization,Dexamethasone,,,,Completed regimen,,10,mg,,Q d,,IV,,107,107,1
MMRF_1452,,First line of therapy,Other,mobilization,Other,etoposide,,,Completed regimen,,200,mg/m^,,Q d,,IV,,107,107,1
MMRF_1452,,Second Line Therapy (after,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,177,272,1
MMRF_1452,,Second Line Therapy (after,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,PO,,177,272,1
MMRF_1452,,Second Line Therapy (after,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,177,272,1
MMRF_1452,,Second Line Therapy (after,Other,consolidation,Other,fludarabine,,,Completed regimen,,49,mg,,Q d,,IV,,288,291,1
MMRF_1452,,Second Line Therapy (after,Other,maintenance,Melphalan,,,,Completed regimen,,140,mg/m^,,Q d,,IV,,291,291,1
MMRF_1452,,Second Line Therapy (after,Other,conditioning,Bortezomib,,,,Completed regimen,,1.6,mg/m^,,Q d,,IV SubQ,,289,292,1
MMRF_1461,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,53,1
MMRF_1461,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,PO,,1,53,1
MMRF_1461,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,56,1
MMRF_1461,,First line of therapy,Consolidation,,Melphalan,,,,Completed regimen,,200,mg/m^,,QID,,IV,,107,107,1
MMRF_1461,,Second Line Therapy (after,Unknown,,Lenalidomide,,,,Disease progression/Relapse,,25,mg,,QD,,PO,,508,815,1
MMRF_1461,,Second Line Therapy (after,Unknown,,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,Q w,,PO,,508,815,1
MMRF_1461,,Third Line Therapy (followi,Unknown,,Pomalidomide,,,,Patient decision,,4,mg,,QD,,PO,,823,831,1
MMRF_1461,,Fourth Line Therapy (follow,Unknown,,Carfilzomib,,,,Disease progression/Relapse,,44,mg,,QD,,IV,,850,865,1
MMRF_1461,,Fifth Line Therapy (followi,Unknown,,Dexamethasone,,,,Disease progression/Relapse,,20,mg,,QD,,PO,,878,962,1
MMRF_1461,,Sixth Line Therapy (followi,Unknown,,Dexamethasone,,,,Adverse Event or co-morbidity,,20,mg,,QD,,PO,,969,1003,1
MMRF_1461,,Third Line Therapy (followi,Unknown,,Dexamethasone,,,,Patient decision,,40,mg,,Q w,,PO,,823,831,1
MMRF_1461,,Fourth Line Therapy (follow,Unknown,,Dexamethasone,,,,Disease progression/Relapse,,20,mg,,QD,,PO,,850,865,1
MMRF_1461,,Fourth Line Therapy (follow,Unknown,,Cyclophosphamide,,,,Disease progression/Relapse,,500,mg/m^,,Oth,QD (D1 and D8),IV,,850,865,1
MMRF_1461,,Fifth Line Therapy (followi,Unknown,,Carfilzomib,,,,Disease progression/Relapse,,27,mg/m^,,QD,,IV,,878,962,1
MMRF_1461,,Sixth Line Therapy (followi,Unknown,,Lenalidomide,,,,Adverse Event or co-morbidity,,15,mg,,QD,,PO,,969,1003,1
MMRF_1461,,Fifth Line Therapy (followi,Unknown,,Panobinostat,,,,Disease progression/Relapse,,20,mg,,Oth,"D1 ,3,5,15,17,19",PO,,878,962,1
MMRF_1461,,Sixth Line Therapy (followi,Unknown,,Carfilzomib,,,,Adverse Event or co-morbidity,,27,mg/m^,,QD,,IV,,969,1003,1
MMRF_1461,,Sixth Line Therapy (followi,Unknown,,Panobinostat,,,,Adverse Event or co-morbidity,,20,mg,,Oth,"D1, 3,5,15,17,19",PO,,969,1003,1
MMRF_1466,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,54,1
MMRF_1466,,First line of therapy,Other,conditioning,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,115,115,1
MMRF_1466,,First line of therapy,Other,conditioning,Bortezomib,,,,Completed regimen,,1.6,mg/m^,,QD,,IV,,113,116,1
MMRF_1466,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,3,57,1
MMRF_1466,,First line of therapy,Other,mobilization,Cyclophosphamide,,,,Completed regimen,,2,Other,g/m^2,Q d,,IV,,88,88,1
MMRF_1466,,First line of therapy,Other,mobilization,Dexamethasone,,,,Completed regimen,,10,mg,,Q d,,IV,,88,88,1
MMRF_1466,,First line of therapy,Other,mobilization,Other,etoposide,,,Completed regimen,,200,mg/m^,,Q d,,IV,,88,88,1
MMRF_1466,,First line of therapy,Other,conditioning,Dexamethasone,,,,Completed regimen,,10,mg,,Q d,,IV,,113,113,1
MMRF_1466,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,PO,,1,54,1
MMRF_1466,,Second Line Therapy (after,Other,not applicable,Lenalidomide,,,,Investigator decision for other reasons,,25,mg,,QD,,PO,,745,942,1
MMRF_1466,,Second Line Therapy (after,Other,not applicable,Dexamethasone,,,,Investigator decision for other reasons,,20,mg,,Q w,,PO,,745,943,1
MMRF_1466,,Third Line Therapy (followi,Other,third line,Carfilzomib,,,Checked,,,36,mg/m^,,QD,,IV,,1327,,1
MMRF_1466,,Third Line Therapy (followi,Other,third line,Dexamethasone,,,Checked,,,20,mg,,QD,,IV,,1327,,1
MMRF_1466,,Third Line Therapy (followi,Other,third line,Lenalidomide,,,Checked,,,15,mg,,QD,,PO,,1327,,1
MMRF_1478,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,73,1
MMRF_1478,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,PO,,1,73,1
MMRF_1478,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,500,mg/m^,,Q d,,IV,,7,7,1
MMRF_1478,,First line of therapy,Other,mobilization,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,91,94,1
MMRF_1478,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,21,76,1
MMRF_1478,,First line of therapy,Other,mobilization,Cyclophosphamide,,,,Completed regimen,,500,mg/m^,,QD,,IV,,91,94,1
MMRF_1478,,First line of therapy,Other,mobilization,Other,cisplatin,,,Completed regimen,,15,mg/m^,,QD,,IV,,91,94,1
MMRF_1478,,First line of therapy,Other,conditioning,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,118,118,1
MMRF_1478,,First line of therapy,Other,mobilization,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,91,94,1
MMRF_1478,,First line of therapy,Other,mobilization,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,PO,,91,94,1
MMRF_1478,,First line of therapy,Other,mobilization,Other,etoposide,,,Completed regimen,,40,mg/m^,,QD,,IV,,91,94,1
MMRF_1478,,First line of therapy,Other,mobilization,Doxorubicin,,,,Completed regimen,,10,mg/m^,,QD,,IV,,91,94,1
MMRF_1478,,First line of therapy,Other,conditioning,Other,fludarabine,,,Completed regimen,,30,mg/m^,,Q d,,IV,,305,308,1
MMRF_1478,,First line of therapy,Other,conditioning,Melphalan,,,,Completed regimen,,140,mg/m^,,Q d,,IV,,675,675,1
MMRF_1485,Baseline,First line of therapy,Induction,,Lenalidomide,,,,Investigator decision for other reasons,,25,mg,,QD,,PO,,1,15,1
MMRF_1485,,First line of therapy,Induction,,Dexamethasone,,,,Investigator decision for other reasons,,40,mg,,Q w,,PO,,1,15,1
MMRF_1497,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,35,119,1
MMRF_1497,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Q w,,PO,,1,22,1
MMRF_1497,Baseline,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,21,1
MMRF_1497,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,PO,,35,119,1
MMRF_1497,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,35,119,1
MMRF_1497,,First line of therapy,Other,debulking/mobilization,Cyclophosphamide,,,,Completed regimen,,2,Other,g/m^2,Q d,,IV,,172,172,1
MMRF_1497,,First line of therapy,Other,conditioning,Melphalan,,,,Completed regimen,,360,mg,,Q d,,IV,,208,208,1
MMRF_1497,,First line of therapy,Other,debulking/mobolization,Other,etoposide,,,Completed regimen,,200,mg/m^,,Q d,,IV,,182,182,1
MMRF_1497,,First line of therapy,Other,debulking/mobilization,Dexamethasone,,,,Completed regimen,,10,mg,,Q d,,IV,,182,182,1
MMRF_1489,,First line of therapy,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,25,mg,,QD,,PO,,1,107,1
MMRF_1489,Baseline,First line of therapy,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,1.3,mg/m^,,QD,,IV SubQ,,1,107,1
MMRF_1489,,First line of therapy,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,40,mg,,QD,,PO,,1,107,1
MMRF_1489,,First line of therapy,Other,mobilization,Other,plerixafor,,,Completed regimen,,18,mg,,Oth,QD first 3 days; QOD week 2,IV SubQ,,334,343,1
MMRF_1489,,First line of therapy,Other,conditioning,Melphalan,,,,Completed regimen,,200,mg/m^,,Oth,once,IV,,357,357,1
MMRF_1491,Baseline,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,"QD (D1, 8, 15, 22)",PO,,1,179,1
MMRF_1491,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,179,1
MMRF_1491,,First line of therapy,Other,mobilization,Cyclophosphamide,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,193,193,1
MMRF_1491,,First line of therapy,Other,mobilization,Dexamethasone,,,,Completed regimen,,10,mg,,Q d,,IV,,193,193,1
MMRF_1491,,First line of therapy,Other,mobilization,Other,etoposide,,,Completed regimen,,360,mg,,Q d,,IV,,193,193,1
MMRF_1491,,Second Line Therapy (after,Other,salvage regimen,Bortezomib,,,,Other,patient deceased,1.3,mg/m^,,QD,,IV SubQ,,390,397,1
MMRF_1491,,Second Line Therapy (after,Other,salvage regimen,Cyclophosphamide,,,,Other,patient deceased,500,mg,,Oth,day 1 and  8,IV,,390,397,1
MMRF_1491,,Second Line Therapy (after,Other,salvage regimen,Dexamethasone,,,,Other,patient deceased,40,mg,,QD,,IV,,390,397,1
MMRF_1491,,First line of therapy,Other,Conditioning,Melphalan,,,,Completed regimen,,200,mg/m^,,Oth,Once,IV,,234,234,1
MMRF_1494,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,34,1
MMRF_1494,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,35,1
MMRF_1494,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,PO,,1,34,1
MMRF_1494,,First line of therapy,Other,mobilization,Cyclophosphamide,,,,Completed regimen,,2000,mg/m^,,Q d,,IV,,65,65,1
MMRF_1494,,First line of therapy,Other,mobilization,Dexamethasone,,,,Completed regimen,,10,mg,,Q d,,IV,,65,65,1
MMRF_1494,,First line of therapy,Other,mobilization,Other,etoposide,,,Completed regimen,,200,mg/m^,,Q d,,IV,,65,65,1
MMRF_1494,,First line of therapy,Other,conditioning,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,90,90,1
MMRF_1494,,First line of therapy,Other,conditioning,Bortezomib,,,,Completed regimen,,1.6,mg/m^,,Oth,Days -4 and -1,IV SubQ,,264,272,1
MMRF_1494,,First line of therapy,Other,consolidation,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,266,266,1
MMRF_1500,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,65,1
MMRF_1500,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,PO,,1,65,1
MMRF_1500,,First line of therapy,Induction,,Lenalidomide,,,,Investigator decision for other reasons,,25,mg,,QD,,PO,,1,46,1
MMRF_1500,,First line of therapy,Other,mobilization,Dexamethasone,,,,Completed regimen,,10,mg,,Q d,,PO,,102,102,1
MMRF_1500,,First line of therapy,Other,mobilization,Other,etoposide,,,Completed regimen,,200,mg/m^,,Q d,,IV,,102,102,1
MMRF_1500,,First line of therapy,Other,conditioning,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,122,122,1
MMRF_1500,,First line of therapy,Other,mobilization,Cyclophosphamide,,,,Completed regimen,,2,Other,g/m^2,Q d,,IV,,102,102,1
MMRF_1500,,First line of therapy,Other,consolidation,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,262,262,1
MMRF_1500,,First line of therapy,Other,consolidation,Dexamethasone,,,,Completed regimen,,10,mg,,Q d,,IV,,260,263,1
MMRF_1500,,First line of therapy,Other,conditioning,Bortezomib,,,,Completed regimen,,1.6,mg/m^,,Oth,Days -4 and -1,IV SubQ,,260,263,1
MMRF_1500,,Second Line Therapy (after,Unknown,,Carfilzomib,,,,Other,patient goin ot ASTC,36,mg/m^,,QD,,IV,,947,1198,1
MMRF_1500,,Second Line Therapy (after,Unknown,,Lenalidomide,,,,Adverse Event or co-morbidity,,25,mg,,QD,,PO,,947,974,1
MMRF_1500,,Second Line Therapy (after,Unknown,,Dexamethasone,,,,Other,patient going to ASCT,20,mg,,QD,,IV,,947,1198,1
MMRF_1500,,Second Line Therapy (after,Other,conditioning,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,1214,1214,1
MMRF_1500,,Second Line Therapy (after,Maintenance,,Other,Nivolumab,,Checked,,,3,mg/kg,,Oth,"Weeks 1,4,7,10,12,14,16,18,22,24,& 26",IV,,1243,,1
MMRF_1500,,Second Line Therapy (after,Maintenance,,Other,ipilimimab,,Checked,,,1,mg/kg,,Oth,"Weeks 1,4,7,10,16 & 22",IV,,1243,,1
MMRF_1500,,Second Line Therapy (after,Consolidation,,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,1214,1214,1
MMRF_1500,,Second Line Therapy (after,Other,Salvage,Prednisone,,,Checked,,,2.5,mg,,Q d,,PO,,1670,,1
MMRF_1500,,Second Line Therapy (after,Other,Salvage,Prednisone,,,,Other,Reduce dosage per sub-investigator,5,mg,,Q d,,PO,,1636,1670,1
MMRF_1523,,First line of therapy,Other,mobolization,Other,Etoposide,,,Completed regimen,,200,mg,,QID,,IV,,79,79,1
MMRF_1523,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,41,1
MMRF_1523,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,44,1
MMRF_1523,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Q w,,PO,,1,41,1
MMRF_1523,,First line of therapy,Other,mobilization,Cyclophosphamide,,,,Completed regimen,,2000,mg/m^,,QID,,IV,,79,79,1
MMRF_1523,,First line of therapy,Other,mobolization,Dexamethasone,,,,Completed regimen,,10,mg,,QID,,IV,,79,79,1
MMRF_1523,,First line of therapy,Other,conditioning,Bortezomib,,,,Completed regimen,,1.6,mg/m^,,Oth,Days -7 and -1 pre-PBSCT,IV SubQ,,250,259,1
MMRF_1523,,First line of therapy,Other,conditioning,Melphalan,,,,Completed regimen,,200,mg/m^,,Oth,Day -2 of PBSCT,IV,,258,258,1
MMRF_1523,,First line of therapy,Other,conditining,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,103,103,1
MMRF_1537,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,52,1
MMRF_1537,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,52,1
MMRF_1537,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,QD,,PO,,1,52,1
MMRF_1565,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,IV,,1,104,1
MMRF_1565,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,20,104,1
MMRF_1565,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,104,1
MMRF_1565,,First line of therapy,Other,mobolization,Cyclophosphamide,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,129,129,1
MMRF_1565,,First line of therapy,Other,mobilization,Other,etoposide,,,Completed regimen,,315,mg,,Q d,,IV,,129,129,1
MMRF_1565,,First line of therapy,Other,mobilization,Dexamethasone,,,,Completed regimen,,10,mg,,Q d,,IV,,129,129,1
MMRF_1565,,First line of therapy,Other,conditioning,Melphalan,,,,Completed regimen,,314,mg,,Q d,,IV,,162,162,1
MMRF_1565,,Second Line Therapy (after,Unknown,,Carfilzomib,,,Checked,,,27,mg/m^,,QD,,IV,,1183,,1
MMRF_1565,,Second Line Therapy (after,Unknown,,Lenalidomide,,,Checked,,,25,mg,,QD,,PO,,1183,,1
MMRF_1565,,Second Line Therapy (after,Unknown,,Dexamethasone,,,Checked,,,20,mg,,QD,,PO,,1183,,1
MMRF_1573,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,111,1
MMRF_1573,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,88,1
MMRF_1573,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,QD,,PO,,1,88,1
MMRF_1573,,First line of therapy,Other,conditioning,Melphalan,,,,Completed regimen,,140,mg/m^,,Q d,,IV,,195,195,1
MMRF_1573,,First line of therapy,Other,conditioning,Bortezomib,,,,Completed regimen,,1.6,mg/m^,,Oth,Days -4 and -1 pre-SCT,IV SubQ,,193,196,1
MMRF_1583,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,53,1
MMRF_1583,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,500,mg/m^,,Oth,"QD1, 8",IV,,1,29,1
MMRF_1583,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,PO,,1,53,1
MMRF_1583,,First line of therapy,Other,mobilization,Other,etoposide,,,Completed regimen,,370,mg,,Q d,,IV,,67,67,1
MMRF_1583,,First line of therapy,Other,mobilization,Cyclophosphamide,,,,Completed regimen,,3.7,Other,g,Q d,,IV,,67,67,1
MMRF_1583,,First line of therapy,Other,conditioning,Melphalan,,,,Completed regimen,,370,mg,,Q d,,IV,,261,261,1
MMRF_1583,,First line of therapy,Other,conditioning,Bortezomib,,,,Completed regimen,,1.6,mg/m^,,Oth,Days -7 to -1,IV SubQ,,259,262,1
MMRF_1583,,First line of therapy,Other,condition,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,262,262,1
MMRF_1583,,First line of therapy,Other,mobolization,Dexamethasone,,,,Completed regimen,,10,mg,,Q d,,IV,,67,67,1
MMRF_1583,,First line of therapy,Other,conditioning,Melphalan,,,,Completed regimen,,364,mg,,Q d,,IV,,119,119,1
MMRF_1625,Baseline,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,500,mg/m^,,Oth,D1 & D8,IV,,1,12,1
MMRF_1625,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,12,1
MMRF_1625,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,PO,,1,12,1
MMRF_1625,,First line of therapy,Other,mobilization,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,29,32,1
MMRF_1625,,First line of therapy,Other,mobilization,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,PO,,29,32,1
MMRF_1625,,First line of therapy,Other,mobilization,Lenalidomide,,,,Completed regimen,,25,mg,,Q d,,PO,,30,34,1
MMRF_1625,,First line of therapy,Other,mobilization,Other,etoposide,,,Completed regimen,,40,mg/m^,,Q d,,IV,,30,34,1
MMRF_1625,,First line of therapy,Other,mobilization,Doxorubicin,,,,Completed regimen,,10,mg/m^,,Q d,,IV,,30,34,1
MMRF_1625,,First line of therapy,Other,mobilization,Cyclophosphamide,,,,Completed regimen,,500,mg/m^,,Q d,,IV,,30,34,1
MMRF_1625,,First line of therapy,Other,mobilization,Other,cisplatin,,,Completed regimen,,15,mg/m^,,Q d,,IV,,30,34,1
MMRF_1625,,First line of therapy,Other,conditioning,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,111,111,1
MMRF_1625,,Second Line Therapy (after,Other,conditioning,Bortezomib,,,,Completed regimen,,1.6,mg/m^,,Oth,"QD D-4, D-1",IV SubQ,,243,246,1
MMRF_1625,,Second Line Therapy (after,Other,conditioning,Melphalan,,,,Completed regimen,,200,mg/m^,,Oth,once,IV,,245,245,1
MMRF_1640,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,32,1
MMRF_1640,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,34,1
MMRF_1640,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,PO,,1,32,1
MMRF_1640,,First line of therapy,Other,conditioning,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,136,136,1
MMRF_1683,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,84,1
MMRF_1683,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,85,1
MMRF_1683,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,PO,,1,84,1
MMRF_1683,,First line of therapy,Other,consolidation,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,135,135,1
MMRF_1683,,Second Line Therapy (after,Other,salvage,Lenalidomide,,,Checked,,,25,mg,,QD,,PO,,1363,,1
MMRF_1683,,Second Line Therapy (after,Other,salvage,Dexamethasone,,,Checked,,,20,mg,,Q w,,IV,,1363,,1
MMRF_1683,,Second Line Therapy (after,Unknown,,Other,Solumedrol,,Checked,,,100,mg,,Oth,prior to each dose of daratumumab,IV,,1220,,1
MMRF_1683,,Second Line Therapy (after,Other,salvage,Daratumumab,,,Checked,,,16,mg/kg,,Q w,,IV,,1363,,1
MMRF_1714,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,50,1
MMRF_1714,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,53,1
MMRF_1714,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,PO,,1,50,1
MMRF_1714,,First line of therapy,Other,mobilization,Other,etoposide,,,Completed regimen,,440,mg,,Q d,,IV,,74,74,1
MMRF_1714,,First line of therapy,Other,conditioning,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,100,100,1
MMRF_1714,,First line of therapy,Other,mobilization,Cyclophosphamide,,,,Completed regimen,,4.4,Other,g,Q d,,IV,,74,74,1
MMRF_1714,,First line of therapy,Other,mobilization,Dexamethasone,,,,Completed regimen,,10,mg,,Q d,,IV,,74,74,1
MMRF_1731,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,500,mg/m^,,Oth,"QD (D1, 8)",IV,,1,9,1
MMRF_1731,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,PO,,1,35,1
MMRF_1731,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,35,1
MMRF_1731,,First line of therapy,Other,mobilization,Dexamethasone,,,,Completed regimen,,10,mg,,Q d,,IV,,59,59,1
MMRF_1731,,First line of therapy,Other,mobilization,Cyclophosphamide,,,,Completed regimen,,3.1,Other,g,Q d,,IV,,59,59,1
MMRF_1731,,First line of therapy,Other,mobilization,Other,etoposide,,,Completed regimen,,310,mg,,Q d,,IV,,69,69,1
MMRF_1731,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Q d,,PO,,24,37,1
MMRF_1731,,First line of therapy,Other,consolidation,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,84,84,1
MMRF_1731,,Second Line Therapy (after,Induction,,Carfilzomib,,,Checked,,,36,mg/m^,,QD,,IV,,755,,1
MMRF_1731,,Second Line Therapy (after,Induction,,Pomalidomide,,,Checked,,,4,mg,,QD,,PO,,755,,1
MMRF_1731,,Second Line Therapy (after,Induction,,Dexamethasone,,,Checked,,,40,mg,,QD,,IV,,755,,1
MMRF_1730,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,PO,,1,33,1
MMRF_1730,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,33,1
MMRF_1730,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,36,1
MMRF_1730,,First line of therapy,Other,mobilization,Other,etoposide,,,Completed regimen,,420,mg,,Q d,,IV,,92,92,1
MMRF_1730,,First line of therapy,Other,mobolization,Cyclophosphamide,,,,Completed regimen,,4.2,Other,g,Q d,,IV,,92,92,1
MMRF_1730,,First line of therapy,Other,conditioning,Melphalan,,,,Completed regimen,,428,mg,,Q d,,IV,,117,117,1
MMRF_1730,,First line of therapy,Other,mobilization,Dexamethasone,,,,Completed regimen,,10,mg,,Q d,,IV,,92,92,1
MMRF_1730,,Second Line Therapy (after,Unknown,,Lenalidomide,,,Checked,,,25,mg,,QD,,PO,,706,,1
MMRF_1730,,Second Line Therapy (after,Unknown,,Dexamethasone,,,Checked,,,40,mg,,QWK,,PO,,705,,1
MMRF_1759,,First line of therapy,Induction,,Cyclophosphamide,,,,Investigator decision for other reasons,,500,mg/m^,,Oth,"QD (D1, 8)",IV,,1,507,1
MMRF_1759,Baseline,First line of therapy,Induction,,Bortezomib,,,,Investigator decision for other reasons,,1.3,mg/m^,,QD,,IV SubQ,,1,507,1
MMRF_1759,,First line of therapy,Induction,,Dexamethasone,,,,Investigator decision for other reasons,,20,mg,,QD,,PO,,1,507,1
MMRF_1759,,First line of therapy,Maintenance,,Bortezomib,,,,Disease progression/Relapse,,2.4,mg,,Oth,every two to three weeks,IV SubQ,,507,714,1
MMRF_1759,,First line of therapy,Maintenance,,Dexamethasone,,,,Disease progression/Relapse,,5,mg,,Oth,every two to three weeks with bortezomib dosing,PO,,507,714,1
MMRF_1759,,Second Line Therapy (after,Unknown,,Lenalidomide,,,Checked,,,0,Other,mg (dose unknown),QD,,PO,,741,,1
MMRF_1759,,Second Line Therapy (after,Unknown,,Carfilzomib,,,Checked,,,37,mg,,QD,,IV,,741,,1
MMRF_1759,,Second Line Therapy (after,Unknown,,Dexamethasone,,,Checked,,,5,mg,,QWK,,PO,,741,,1
MMRF_1758,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,65,1
MMRF_1758,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,QD,,PO,,1,65,1
MMRF_1758,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,500,mg/m^,,Oth,"QD (D1, 8)",IV,,1,62,1
MMRF_1758,,First line of therapy,Other,conditioning,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,111,111,1
MMRF_1758,,Second Line Therapy (after,Unknown,,Carfilzomib,,,Checked,,,44,mg,,QD,,IV,,1300,,1
MMRF_1758,,Second Line Therapy (after,Unknown,,Dexamethasone,,,Checked,,,12,mg,,QD,,IV,,1300,,1
MMRF_1781,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,PO,,1,57,1
MMRF_1781,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,60,1
MMRF_1781,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,57,1
MMRF_1781,,First line of therapy,Other,conditioning,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,106,106,1
MMRF_1781,,First line of therapy,Other,mobilization,Other,mobozil,,,Completed regimen,,12,mg,,Q d,,IV SubQ,,85,87,1
MMRF_1781,,First line of therapy,Other,pre-transplant,Bortezomib,,,,Completed regimen,,1.6,mg/m^,,QD,,IV SubQ,,295,298,1
MMRF_1781,,First line of therapy,Other,pre-transplant,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,297,297,1
MMRF_1787,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,53,1
MMRF_1787,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,PO,,1,53,1
MMRF_1787,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,56,1
MMRF_1787,,First line of therapy,Other,mobilization,Dexamethasone,,,,Completed regimen,,10,mg,,Q d,,IV,,82,82,1
MMRF_1787,,First line of therapy,Other,conditioning,Melphalan,,,,Completed regimen,,412,mg,,Q d,,IV,,106,106,1
MMRF_1787,,First line of therapy,Other,mobilization,Cyclophosphamide,,,,Completed regimen,,4.3,Other,g,Q d,,IV,,82,82,1
MMRF_1787,,First line of therapy,Other,mobilization,Other,etoposide,,,Completed regimen,,430,mg,,Q d,,IV,,82,82,1
MMRF_1802,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,54,1
MMRF_1802,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,PO,,1,54,1
MMRF_1802,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,57,1
MMRF_1802,,First line of therapy,Other,mobilization,Other,etoposide,,,Completed regimen,,360,mg,,Q d,,IV,,85,85,1
MMRF_1802,,First line of therapy,Other,mobilization,Cyclophosphamide,,,,Completed regimen,,3.6,Other,g,Q d,,IV,,85,85,1
MMRF_1802,,First line of therapy,Other,conditioning,Melphalan,,,,Completed regimen,,352,mg,,Q d,,IV,,111,111,1
MMRF_1802,,First line of therapy,Other,mobilization,Dexamethasone,,,,Completed regimen,,10,mg,,Q d,,IV,,85,85,1
MMRF_1802,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.6,mg/m^,,Oth,once,IV,,232,232,1
MMRF_1802,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.6,mg/m^,,Oth,once,IV,,235,235,1
MMRF_1802,,First line of therapy,Other,Conditioning,Melphalan,,,,Completed regimen,,200,mg/m^,,Oth,once,IV,,234,234,1
MMRF_1801,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,84,1
MMRF_1801,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,87,1
MMRF_1801,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,PO,,1,84,1
MMRF_1801,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,127,127,1
MMRF_1801,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,2000,mg/m^,,Q d,,IV,,102,102,1
MMRF_1801,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,10,mg,,Q d,,IV,,102,102,1
MMRF_1801,,First line of therapy,Induction,,Other,etoposide,,,Completed regimen,,200,mg/m^,,Q d,,IV,,102,102,1
MMRF_1801,,First line of therapy,Other,pre-transplant,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,297,297,1
MMRF_1801,,First line of therapy,Other,pre-transplant,Bortezomib,,,,Completed regimen,,1.6,mg/m^,,QD,,IV SubQ,,295,298,1
MMRF_1807,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,82,1
MMRF_1807,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,76,1
MMRF_1807,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,PO,,1,82,1
MMRF_1807,,First line of therapy,Other,conditioning,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,122,122,1
MMRF_1819,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,35,1
MMRF_1819,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,35,1
MMRF_1819,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,PO,,1,766,1
MMRF_1850,Baseline,First line of therapy,Induction,,Bortezomib,,,,Other,move to transplant,1.3,mg/m^,,QD,,IV SubQ,,9,68,1
MMRF_1850,,First line of therapy,Induction,,Dexamethasone,,,,Other,move to transplant,40,mg,,QD,,PO,,9,68,1
MMRF_1850,,First line of therapy,Induction,,Lenalidomide,,,,Other,move to transplant,25,mg,,QD,,PO,,1,71,1
MMRF_1850,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,10,mg,,Q d,,IV,,95,95,1
MMRF_1850,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,121,121,1
MMRF_1850,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,2000,mg/m^,,Q d,,IV,,95,95,1
MMRF_1850,,First line of therapy,Induction,,Other,etoposide,,,Completed regimen,,200,mg/m^,,Q d,,IV,,95,95,1
MMRF_1850,,First line of therapy,Other,mobilization,Bortezomib,,,,Completed regimen,,1.6,mg/m^,,QD,,IV,,274,277,1
MMRF_1850,,First line of therapy,Other,conditioning,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,276,276,1
MMRF_1850,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,10,mg,,QD,,PO,,515,,1
MMRF_1860,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,75,1
MMRF_1860,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,75,1
MMRF_1860,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,PO,,1,75,1
MMRF_1860,,First line of therapy,Other,mobilization,Other,etoposide,,,Completed regimen,,75,mg,,Q d,,IV,,95,98,1
MMRF_1860,,First line of therapy,Other,conditioning,Melphalan,,,,Completed regimen,,428,mg,,Q d,,IV,,123,123,1
MMRF_1860,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,1090,mg,,Q d,,IV,,95,98,1
MMRF_1860,,First line of therapy,Other,mobilization,Other,cisplatin,,,Completed regimen,,25,mg,,Q d,,IV,,95,98,1
MMRF_1860,,First line of therapy,Other,mobilization,Doxorubicin,,,,Completed regimen,,22,mg,,Q d,,IV,,95,98,1
MMRF_1860,,First line of therapy,Other,mobilization,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,Q d,,IV SubQ,,95,95,1
MMRF_1860,,First line of therapy,Other,conditioning,Melphalan,,,,Completed regimen,,438,mg,,Q d,,IV,,256,256,1
MMRF_1860,,First line of therapy,Other,conditioning,Bortezomib,,,,Completed regimen,,3.5,mg,,Oth,D1 to D4,IV SubQ,,254,257,1
MMRF_1865,,First line of therapy,Induction,,Lenalidomide,,,,Lack of response,,25,mg,,QD,,PO,,1,33,1
MMRF_1865,Baseline,First line of therapy,Induction,,Bortezomib,,,,Lack of response,,1.3,mg/m^,,QD,,IV SubQ,,1,30,1
MMRF_1865,,First line of therapy,Induction,,Dexamethasone,,,,Lack of response,,40,mg,,QD,,PO,,1,30,1
MMRF_1865,,First line of therapy,Induction,,Carfilzomib,,,,Other,move to transplant,27,mg/m^,,QD,,IV,,47,118,1
MMRF_1865,,First line of therapy,Induction,,Cyclophosphamide,,,,Other,move to transplant,300,mg/m^,,Oth,"QD1, 8, 15",IV,,47,117,1
MMRF_1865,,First line of therapy,Induction,,Dexamethasone,,,,Other,move to transplant,40,mg,,Oth,"Qweek D1, 8, 15, 22",PO,,47,124,1
MMRF_1865,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,2000,mg/m^,,Q d,,IV,,141,141,1
MMRF_1865,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,10,mg,,Q d,,IV,,141,141,1
MMRF_1865,,First line of therapy,Induction,,Other,etoposide,,,Completed regimen,,200,mg/m^,,Q d,,IV,,141,141,1
MMRF_1865,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,167,167,1
MMRF_1865,,First line of therapy,Induction,,Other,fludarabine,,,Completed regimen,,30,mg/m^,,QD,,IV,,324,326,1
MMRF_1865,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,214,mg,,Oth,once,IV,,327,327,1
MMRF_1865,,First line of therapy,Other,mobilization,Cyclophosphamide,,,,Completed regimen,,465,mg,,Oth,once,IV,,141,141,1
MMRF_1865,,First line of therapy,Other,mobilization,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,once,IV,,141,141,1
MMRF_1865,,First line of therapy,Other,mobilization,Other,Etoposide,,,Completed regimen,,200,mg/m^,,Oth,once,IV,,141,141,1
MMRF_1865,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.6,mg/m^,,Oth,D-4 and -1 transplant,IV,,325,328,1
MMRF_1865,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,10,mg,,Oth,once,IV,,167,167,1
MMRF_1895,,First line of therapy,Induction,,Lenalidomide,,,,Other,moving to transplant,25,mg,,QD,,PO,,1,98,1
MMRF_1895,Baseline,First line of therapy,Induction,,Bortezomib,,,,Other,moving to transplant,1.3,mg/m^,,QD,,IV SubQ,,1,95,1
MMRF_1895,,First line of therapy,Induction,,Dexamethasone,,,,Other,moving to transplant,40,mg,,QD,,PO,,1,95,1
MMRF_1895,,First line of therapy,Induction,,Other,etoposide,,,Completed regimen,,200,mg/m^,,Q d,,IV,,122,122,1
MMRF_1895,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,2000,mg/m^,,Q d,,IV,,122,122,1
MMRF_1895,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,10,mg,,Q d,,IV,,122,122,1
MMRF_1895,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,148,148,1
MMRF_1895,,First line of therapy,Other,mobilization,Bortezomib,,,,Completed regimen,,1.6,mg/m^,,QD,,IV,,287,290,1
MMRF_1895,,First line of therapy,Other,conditioning,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,289,289,1
MMRF_1936,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,57,1
MMRF_1936,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,57,1
MMRF_1936,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,PO,,1,57,1
MMRF_1936,,First line of therapy,Other,mobilization,Other,Cisplatin,,,Completed regimen,,25,mg,,Q d,,IV,,97,99,1
MMRF_1936,,First line of therapy,Other,mobolization,Cyclophosphamide,,,,Completed regimen,,1065,mg,,Q d,,IV,,97,99,1
MMRF_1936,,Second Line Therapy (after,Other,first relapse,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,155,242,1
MMRF_1936,,First line of therapy,Induction,,Other,etoposide,,,Completed regimen,,75,mg,,Q d,,IV,,97,99,1
MMRF_1936,,First line of therapy,Other,mobilization,Doxorubicin,,,,Completed regimen,,20,mg,,Q d,,IV,,97,99,1
MMRF_1936,,Second Line Therapy (after,Other,first relapse,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,PO,,155,242,1
MMRF_1936,,Second Line Therapy (after,Other,fisrt relapse,Pomalidomide,,,,Completed regimen,,4,mg,,Oth,"QD from day 1 - 14, off for 7 days in a 21 day cycle",PO,,155,256,1
MMRF_1936,,Third Line Therapy (followi,Other,first relapse,Carfilzomib,,,,Investigator decision for other reasons,,41,mg,,QD,,IV,,457,457,1
MMRF_1936,,Third Line Therapy (followi,Other,relapse,Cyclophosphamide,,,,Investigator decision for other reasons,,1020,mg,,Oth,days 1 and 8 of 21 days cycle,IV,,457,526,1
MMRF_1936,,Third Line Therapy (followi,Other,relapse,Dexamethasone,,,,Investigator decision for other reasons,,4,mg,,QD,,IV,,457,457,1
MMRF_1936,,Third Line Therapy (followi,Unknown,,Dexamethasone,,,,Lack of response,,40,mg,,QD,,PO,,465,529,1
MMRF_1936,,Second Line Therapy (after,Other,Mobilization,Cyclophosphamide,,,,Completed regimen,,4.2,Other,g,Q d,,IV,,270,270,1
MMRF_1936,,Second Line Therapy (after,Other,mobilization,Dexamethasone,,,,Completed regimen,,10,mg,,Q d,,IV,,270,270,1
MMRF_1936,,Third Line Therapy (followi,Unknown,,Bortezomib,,,,Lack of response,,2.7,mg,,QD,,IV,,465,529,1
MMRF_1936,,Second Line Therapy (after,Other,conditioning,Melphalan,,,,Completed regimen,,426,mg,,Q d,,IV,,294,294,1
MMRF_1936,,Second Line Therapy (after,Other,mobilization,Other,Etoposide,,,Completed regimen,,420,mg,,Q d,,IV,,270,270,1
MMRF_1936,,Third Line Therapy (followi,Unknown,,Pomalidomide,,,,Investigator decision for other reasons,,4,mg,,QD,,PO,,465,524,1
MMRF_1936,,Fourth Line Therapy (follow,Unknown,,Other,Panobinostat,,,Disease progression/Relapse,,20,mg,,Oth,"QD (D1,D3,D5,D8,D10,D12)",PO,,557,568,1
MMRF_1936,,First line of therapy,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,1.3,mg/m^,,Q d,,IV SubQ,,97,97,1
MMRF_1936,,Third Line Therapy (followi,Unknown,,Other,Panibinostat,,,Disease progression/Relapse,,20,mg,,Oth,"QD (D1,3,5,8,10 &12)",PO,,550,556,1
MMRF_1936,,Fifth Line Therapy (followi,Induction,,Other,carmustine,,,Completed regimen,,120,mg,,Q d,,IV,,578,578,1
MMRF_1936,,Fourth Line Therapy (follow,Unknown,,Bortezomib,,,,Disease progression/Relapse,,1.3,mg/m^,,QD,,IV SubQ,,557,568,1
MMRF_1936,,Fourth Line Therapy (follow,Unknown,,Dexamethasone,,,,Disease progression/Relapse,,20,mg,,QD,,IV,,557,568,1
MMRF_1936,,Fifth Line Therapy (followi,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Q d,,IV,,578,578,1
MMRF_1936,,Sixth Line Therapy (followi,Unknown,,Daratumumab,,,,Disease progression/Relapse,,1345,mg,,QD,,IV,,604,625,1
MMRF_1936,,Sixth Line Therapy (followi,Unknown,,Prednisone,,,,Disease progression/Relapse,,20,mg,,Oth,two days after daratumumab,PO,,604,625,1
MMRF_1936,,Fifth Line Therapy (followi,Unknown,,Melphalan,,,,Completed regimen,,120,mg,,Q d,,IV,,578,578,1
MMRF_1941,,First line of therapy,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,40,mg,,QD,,PO,,1,84,1
MMRF_1941,,First line of therapy,Induction,,Lenalidomide,,,,Other,move to transplant,25,mg,,QD,,PO,,1,98,1
MMRF_1941,Baseline,First line of therapy,Induction,,Bortezomib,,,,Other,move to transplant,1.3,mg/m^,,QD,,IV SubQ,,1,95,1
MMRF_1941,,First line of therapy,Induction,,Other,etoposide,,,Completed regimen,,200,mg/m^,,Q d,,IV,,130,130,1
MMRF_1941,,First line of therapy,Induction,,Dexamethasone,,,,Other,move to transplant,12,mg,,QD,,PO,,85,95,1
MMRF_1941,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,2000,mg/m^,,Q d,,IV,,130,130,1
MMRF_1941,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,10,mg,,Q d,,IV,,130,130,1
MMRF_1941,,First line of therapy,Other,conditioning,Melphalan,,,,Completed regimen,,200,mg/m^,,Oth,other,IV,,191,191,1
MMRF_1947,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,53,1
MMRF_1947,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,PO,,1,53,1
MMRF_1947,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,56,1
MMRF_1947,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,105,105,1
MMRF_1947,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,2,Other,g/m^2,Q d,,IV,,80,80,1
MMRF_1947,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,10,mg,,Q d,,PO,,80,80,1
MMRF_1947,,First line of therapy,Induction,,Other,etoposide,,,Completed regimen,,200,mg/m^,,Q d,,IV,,80,80,1
MMRF_1947,,First line of therapy,Other,mobilization,Bortezomib,,,,Completed regimen,,1.6,mg/m^,,QD,,IV,,287,290,1
MMRF_1947,,First line of therapy,Other,conditioning,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,289,289,1
MMRF_1947,,Second Line Therapy (after,Unknown,,Daratumumab,,,Checked,,,16,mg/kg,,Oth,"16 mg/k (weekly 1-8, qow 9-24, monthly 25 onward)",IV,,1218,,1
MMRF_1947,,Second Line Therapy (after,Unknown,,Dexamethasone,,,Checked,,,20,mg,,Oth,each daratumumab dose,PO,,1218,,1
MMRF_1947,,Second Line Therapy (after,Unknown,,Lenalidomide,,,Checked,,,25,mg,,QD,,PO,,1218,,1
MMRF_1951,Baseline,First line of therapy,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,25,mg,,QD,,PO,,1,607,1
MMRF_1951,,First line of therapy,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,20,mg,,QWK,,PO,,1,607,1
MMRF_1951,,Second Line Therapy (after,Unknown,,Bortezomib,,,,Adverse Event or co-morbidity,,1.3,mg/m^,,QD,,IV SubQ,,614,617,1
MMRF_1951,,Third Line Therapy (followi,Unknown,,Ixazomib,,,,Disease progression/Relapse,,4,mg,,Oth,"QD (D1, D8, D15, D20)",PO,,656,918,1
MMRF_1951,,Third Line Therapy (followi,Unknown,,Dexamethasone,,,,Disease progression/Relapse,,20,mg,,Q w,,PO,,656,918,1
MMRF_1951,,Second Line Therapy (after,Unknown,,Dexamethasone,,,,Adverse Event or co-morbidity,,20,mg,,QD,,PO,,614,617,1
MMRF_1951,,Fourth Line Therapy (follow,Unknown,,Lenalidomide,,,,Disease progression/Relapse,,15,mg,,QD,,PO,,930,972,1
MMRF_1951,,Fourth Line Therapy (follow,Unknown,,Dexamethasone,,,,Disease progression/Relapse,,28,mg,,Oth,3-24H prior Elotuzumab dosing,PO,,930,972,1
MMRF_1951,,Fourth Line Therapy (follow,Unknown,,Dexamethasone,,,,Disease progression/Relapse,,8,mg,,Oth,prior to ELO,PO,,899,972,1
MMRF_1951,,Sixth Line Therapy (followi,Unknown,,Daratumumab,,,Checked,,,1131,mg,,Oth,"WEEKLY FOR weeks 1-8, qow weeks 9-25, monthly week 25 onward",IV,,1104,,1
MMRF_1951,,Sixth Line Therapy (followi,Unknown,,Pomalidomide,,,Checked,,,4,mg,,QD,,PO,,1104,,1
MMRF_1951,,Sixth Line Therapy (followi,Unknown,,Prednisone,,,Checked,,,25,mg,,Oth,"days 1,2 following each dara dose",PO,,1107,,1
MMRF_1951,,Sixth Line Therapy (followi,Unknown,,Other,Solumedrol,,Checked,,,100,mg,,Oth,prior to each dose of dara,IV,,1077,,1
MMRF_1951,,Fourth Line Therapy (follow,Unknown,,Elotuzumab,,,,Disease progression/Relapse,,695,mg,,Q w,,IV,,930,972,1
MMRF_1951,,Fifth Line Therapy (followi,Unknown,,Pomalidomide,,,,Disease progression/Relapse,,4,mg,,QD,,PO,,986,1097,1
MMRF_1951,,Fifth Line Therapy (followi,Unknown,,Dexamethasone,,,,Disease progression/Relapse,,20,mg,,Q w,,PO,,986,1097,1
MMRF_1967,Baseline,First line of therapy,Induction,,Lenalidomide,,,Checked,,,25,mg,,QD,,PO,,1,,1
MMRF_1967,,First line of therapy,Induction,,Dexamethasone,,,Checked,,,20,mg,,QD,,PO,,1,,1
MMRF_1967,,First line of therapy,Induction,,Bortezomib,,,Checked,,,1.3,mg/m^,,QD,,IV SubQ,,1,,1
MMRF_1967,,First line of therapy,Other,conditioning,Melphalan,,,,Completed regimen,,200,mg/m^,,Oth,once,IV,,166,166,1
MMRF_1965,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,6,60,1
MMRF_1965,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,57,1
MMRF_1965,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,PO,,1,57,1
MMRF_1965,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,81,84,1
MMRF_1965,,First line of therapy,Induction,,Other,cisplatin,,,Completed regimen,,15,mg/m^,,QD,,IV,,81,84,1
MMRF_1965,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,500,mg/m^,,QD,,IV,,81,84,1
MMRF_1965,,First line of therapy,Induction,,Other,etoposide,,,Completed regimen,,40,mg/m^,,QD,,IV,,81,84,1
MMRF_1965,,First line of therapy,Induction,,Doxorubicin,,,,Completed regimen,,10,mg/m^,,QD,,IV,,81,84,1
MMRF_1965,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,Oth,QD1 & 4,IV SubQ,,81,84,1
MMRF_1965,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,IV,,81,84,1
MMRF_1965,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,111,111,1
MMRF_1965,,First line of therapy,Other,pre-transplant,Melphalan,,,,Completed regimen,,140,mg/m^,,Q d,,IV,,264,264,1
MMRF_1965,,First line of therapy,Other,pre-transplant,Bortezomib,,,,Completed regimen,,1.6,mg/m^,,QD,,IV SubQ,,262,265,1
MMRF_1965,,First line of therapy,Other,pre-transplant,Other,fludarabine,,,Completed regimen,,30,mg/m^,,Oth,"D -5, D -2",IV,,261,264,1
MMRF_1965,,Second Line Therapy (after,Other,second line,Prednisone,,,,Investigator decision for other reasons,,32,mg,,Q d,,PO,,904,910,1
MMRF_1965,,Second Line Therapy (after,Other,second line,Prednisone,,,,Investigator decision for other reasons,,16,mg,,Q d,,PO,,911,924,1
MMRF_1965,,Second Line Therapy (after,Other,second line,Prednisone,,,,Investigator decision for other reasons,,8,mg,,Q d,,PO,,925,945,1
MMRF_1965,,Second Line Therapy (after,Other,second line,Prednisone,,,Checked,,,4,mg,,Oth,"8mg QOD, 4mg QOD",PO,,946,,1
MMRF_1965,,Second Line Therapy (after,Other,second line,Pomalidomide,,,Checked,,,3,mg,,QD,,PO,,946,,1
MMRF_1965,,Second Line Therapy (after,Other,second line,Prednisone,,,,Investigator decision for other reasons,,16,mg,,Oth,"48mg in QAM, 32mg QHS",PO,,855,903,1
MMRF_1965,,Second Line Therapy (after,Other,second line,Pomalidomide,,,,Investigator decision for other reasons,,4,mg,,QD,,PO,,855,938,1
MMRF_1981,Baseline,First line of therapy,Induction,,Bortezomib,,,,Other,Toxicity (neuropathy),1.3,mg/m^,,QD,,IV SubQ,,1,39,1
MMRF_1981,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,15,mg,,QD,,PO,,1,76,1
MMRF_1981,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,PO,,1,76,1
MMRF_1981,,First line of therapy,Other,conditioning,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,126,126,1
MMRF_1981,,First line of therapy,Other,mobilization,Cyclophosphamide,,,,Completed regimen,,4100,mg,,Q d,,IV,,101,101,1
MMRF_1981,,First line of therapy,Other,mobilization,Other,Etoposide,,,Completed regimen,,410,mg,,Q d,,IV,,101,101,1
MMRF_1981,,First line of therapy,Other,mobilization,Dexamethasone,,,,Completed regimen,,10,mg,,Q d,,IV,,101,101,1
MMRF_1981,,Second Line Therapy (after,Unknown,,Ixazomib,,,,Disease progression/Relapse,,4,mg,,Oth,"QD (D 1, 8, 15)",PO,,1022,1418,1
MMRF_1981,,Second Line Therapy (after,Unknown,,Cyclophosphamide,,,,Disease progression/Relapse,,650,mg,,Oth,"QD (D 1, 8, 15)",PO,,1022,1418,1
MMRF_1981,,Second Line Therapy (after,Unknown,,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,Q w,,PO,,1022,1418,1
MMRF_1981,,Third Line Therapy (followi,Other,salvage,Daratumumab,,,Checked,,,16,mg/kg,,Oth,"weeks 1-8, qow 9-24, monthly 25 onward",IV,,1429,,1
MMRF_1981,,Third Line Therapy (followi,Other,salvage,Ixazomib,,,Checked,,,4,mg,,Oth,"days 1,8,15",PO,,1429,,1
MMRF_1981,,Third Line Therapy (followi,Other,salvage,Dexamethasone,,,Checked,,,20,mg,,Oth,the day of and day after dara,PO,,1429,,1
MMRF_1988,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,82,1
MMRF_1988,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,85,1
MMRF_1988,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,QD,,PO,,1,82,1
MMRF_1988,,First line of therapy,Other,conditioning,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,115,115,1
MMRF_2059,Baseline,First line of therapy,Induction,,Bortezomib,,,,Other,move to transplant,1.3,mg/m^,,QD,,IV SubQ,,1,43,1
MMRF_2059,,First line of therapy,Induction,,Dexamethasone,,,,Other,move to transplant,40,mg,,QD,,IV,,1,43,1
MMRF_2059,,First line of therapy,Induction,,Cyclophosphamide,,,,Other,move to transplant,500,mg/m^,,Oth,Day 1 and 8 of 21-day cycle,IV,,1,43,1
MMRF_2059,,First line of therapy,Induction,,Lenalidomide,,,,Other,move to transplant,5,mg,,QD,,PO,,1,46,1
MMRF_2059,,First line of therapy,Induction,,Other,mozobil,,,Completed regimen,,18.6,mg,,Q d,,IV SubQ,,74,76,1
MMRF_2059,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,140,mg/m^,,Q d,,IV,,105,105,1
MMRF_2059,,Second Line Therapy (after,Other,second line,Dexamethasone,,,Checked,,,40,mg,,QD,,IV,,839,,1
MMRF_2059,,Second Line Therapy (after,Other,second line,Carfilzomib,,,Checked,,,27,mg/m^,,QD,,IV,,839,,1
MMRF_2059,,Second Line Therapy (after,Other,second line,Pomalidomide,,,Checked,,,4,mg,,QD,,PO,,839,,1
MMRF_2061,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,44,1
MMRF_2061,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,500,mg/m^,,Oth,Day 1 & 8 of 28 days cycle,IV,,1,44,1
MMRF_2061,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,IV,,1,44,1
MMRF_2061,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,47,1
MMRF_2061,,First line of therapy,Other,conditioning,Melphalan,,,,Completed regimen,,402,mg,,Q d,,IV,,85,85,1
MMRF_2076,Baseline,First line of therapy,Induction,,Bortezomib,,,,Other,toxicity; peripheral neuropathy,1.3,mg,,QD,,IV SubQ,,1,42,1
MMRF_2076,,First line of therapy,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,25,mg,,QD,,PO,,1,42,1
MMRF_2076,,First line of therapy,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,40,mg,,QD,,PO,,1,42,1
MMRF_2076,,First line of therapy,Other,Conditioning,Melphalan,,,,Completed regimen,,200,mg/m^,,Oth,once,IV,,124,124,1
MMRF_2076,,Second Line Therapy (after,Unknown,,Lenalidomide,,,,Other,bone marrow aspirate and biopsy did not show aggressive relapse of disease,15,mg,,QD,,PO,,943,1363,1
MMRF_2076,,Second Line Therapy (after,Unknown,,Daratumumab,,,,Other,bone marrow aspirate and biopsy did not show aggressive relapse of disease,16,mg/kg,,Oth,"D a,8,15 and 22 of a 28d cycle for C1-C2/D 1 & 15 for cycle 3-6/ D1 C7 and",IV,,943,1363,1
MMRF_2076,,Second Line Therapy (after,Unknown,,Dexamethasone,,,,Other,bone marrow aspirate and biopsy did not show aggressive relapse of disease,20,mg,,Oth,with each daratumumab infusion,IV,,943,1363,1
MMRF_2129,Baseline,First line of therapy,Induction,,Bortezomib,,,,Other,move to transplant,1.3,mg/m^,,QD,,IV SubQ,,1,123,1
MMRF_2129,,First line of therapy,Induction,,Lenalidomide,,,,Other,move to transplant,25,mg,,QD,,PO,,1,125,1
MMRF_2129,,First line of therapy,Induction,,Dexamethasone,,,,Other,move to transplant,40,mg,,QD,,PO,,1,123,1
MMRF_2129,,First line of therapy,Induction,,Cyclophosphamide,,,,Other,move to transplant,500,mg/m^,,Oth,"QD1, 8 of each cycle",IV,,49,119,1
MMRF_2129,,First line of therapy,Other,mobilization,Other,etoposide,,,Completed regimen,,330,mg,,Q d,,IV,,151,151,1
MMRF_2129,,First line of therapy,Other,conditioning,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,175,175,1
MMRF_2129,,First line of therapy,Other,mobilization,Cyclophosphamide,,,,Completed regimen,,3.3,Other,g,Q d,,IV,,151,151,1
MMRF_2129,,First line of therapy,Other,mobilization,Dexamethasone,,,,Completed regimen,,10,mg,,Q d,,IV,,151,151,1
MMRF_1755,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,IV,,1,105,1
MMRF_1755,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,105,1
MMRF_1755,,First line of therapy,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,25,mg,,QD,,PO,,1,21,1
MMRF_1755,,First line of therapy,Other,conditioning,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,205,205,1
MMRF_2152,,First line of therapy,Induction,,Dexamethasone,,,Checked,,,40,mg,,QD,,PO,,1,,1
MMRF_2152,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,53,1
MMRF_2152,,First line of therapy,Induction,,Cyclophosphamide,,,Checked,,,500,mg/m^,,Oth,Day 1 and 8,IV,,1,,1
MMRF_2172,,First line of therapy,Induction,,Lenalidomide,,,,Other,move to transplant,25,mg,,QD,,PO,,1,74,1
MMRF_2172,Baseline,First line of therapy,Induction,,Bortezomib,,,,Other,move to transplant,1.3,mg/m^,,QD,,IV SubQ,,1,71,1
MMRF_2172,,First line of therapy,Induction,,Dexamethasone,,,,Other,move to transplant,40,mg,,QD,,PO,,1,71,1
MMRF_2172,,First line of therapy,Other,mobilization,Other,mobozil,,,Completed regimen,,22,mg,,Oth,twice (5/jan/15 and 13/jan/15),IV SubQ,,103,111,1
MMRF_2172,,First line of therapy,Other,conditioning,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,126,126,1
MMRF_2172,,Second Line Therapy (after,Other,second line,Dexamethasone,,,,Other,switch route with carfilzomib addition,40,mg,,QWK,,PO,,349,364,1
MMRF_2172,,Second Line Therapy (after,Other,second line,Dexamethasone,,,,Adverse Event or co-morbidity,,40,mg,,QD,,IV,,365,555,1
MMRF_2172,,Second Line Therapy (after,Other,second line,Carfilzomib,,,,Investigator decision for other reasons,,27,mg/m^,,QD,,IV,,365,461,1
MMRF_2172,,Second Line Therapy (after,Other,second line,Lenalidomide,,,,Investigator decision for other reasons,,25,mg,,QD,,PO,,345,431,1
MMRF_2172,,Second Line Therapy (after,Other,second line,Pomalidomide,,,,Investigator decision for other reasons,,4,mg,,QD,,PO,,446,522,1
MMRF_2172,,Second Line Therapy (after,Other,second line,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,pulse D1-4 then Qwk,PO,,345,348,1
MMRF_2172,,Second Line Therapy (after,Other,second line,Carfilzomib,,,,Investigator decision for other reasons,,60,mg,,QD,,IV,,474,513,1
MMRF_2172,,Second Line Therapy (after,Other,second line,Lenalidomide,,,,Adverse Event or co-morbidity,,25,mg,,QD,,PO,,540,560,1
MMRF_2172,,Second Line Therapy (after,Other,second line,Carfilzomib,,,,Adverse Event or co-morbidity,,36,mg/m^,,QD,,IV,,540,555,1
MMRF_2172,,Second Line Therapy (after,Other,second line,Cyclophosphamide,,,,Adverse Event or co-morbidity,,300,mg/m^,,Oth,"Days 1, 8, 15",IV,,474,554,1
MMRF_2231,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,64,1
MMRF_2231,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,QD,,PO,,1,64,1
MMRF_2231,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,64,1
MMRF_2231,,First line of therapy,Other,mobilization,Other,etoposide,,,Completed regimen,,325,mg,,Q d,,IV,,130,130,1
MMRF_2231,,First line of therapy,Other,mobilization,Dexamethasone,,,,Completed regimen,,10,mg,,Q d,,IV,,130,130,1
MMRF_2231,,First line of therapy,Other,mobilization,Cyclophosphamide,,,,Completed regimen,,3.2,Other,g,Q d,,IV,,130,130,1
MMRF_2231,,First line of therapy,Other,conditioning,Melphalan,,,,Completed regimen,,200,mg,,Q d,,IV,,232,232,1
MMRF_2267,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,QD,,PO,,1,142,1
MMRF_2267,Baseline,First line of therapy,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,1.3,mg/m^,,QD,,IV SubQ,,1,58,1
MMRF_2267,,First line of therapy,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,25,mg,,QD,,PO,,1,23,1
MMRF_2267,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,4,mg,,Oth,"QD(1-2,8-9 & 15-16)",PO,,72,142,1
MMRF_2267,,First line of therapy,Other,conditioning,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,155,155,1
MMRF_2267,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,20,mg/m^,,Oth,"QD(1-2,8-9 & 15-16)",IV,,62,142,1
MMRF_2291,,First line of therapy,Induction,,Lenalidomide,,,Checked,,,25,mg,,QD,,PO,,1,,1
MMRF_2291,,First line of therapy,Induction,,Dexamethasone,,,Checked,,,20,mg,,QD,,PO,,1,,1
MMRF_2291,Baseline,First line of therapy,Induction,,Bortezomib,,,Checked,,,1.3,mg/m^,,QD,,IV SubQ,,1,,1
MMRF_2310,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,53,1
MMRF_2310,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,500,mg/m^,,Oth,"QD1, D8",IV,,1,8,1
MMRF_2310,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,PO,,1,53,1
MMRF_2310,,First line of therapy,Other,conditioning,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,119,119,1
MMRF_2310,,First line of therapy,Other,mobilization,Other,etoposide,,,Completed regimen,,200,mg/m^,,Q d,,IV,,95,95,1
MMRF_2310,,First line of therapy,Other,mobilization,Dexamethasone,,,,Completed regimen,,10,mg,,Q d,,IV,,95,95,1
MMRF_2310,,First line of therapy,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,25,mg,,QD,,PO,,22,43,1
MMRF_2310,,First line of therapy,Other,mobilization,Cyclophosphamide,,,,Completed regimen,,2,Other,g/m2,Q d,,IV,,95,95,1
MMRF_2310,,Second Line Therapy (after,Unknown,,Elotuzumab,,,,Disease progression/Relapse,,10,mg/kg,,Oth,"QD (1,8,15,22)",IV,,605,648,1
MMRF_2310,,Second Line Therapy (after,Unknown,,Dexamethasone,,,,Disease progression/Relapse,,8,mg,,Oth,"QD (1,8,15,22)",IV,,605,648,1
MMRF_2310,,Second Line Therapy (after,Unknown,,Lenalidomide,,,,Disease progression/Relapse,,25,mg,,QD,,PO,,605,655,1
MMRF_2310,,Third Line Therapy (followi,Unknown,,Carfilzomib,,,,Adverse Event or co-morbidity,,27,mg,,QD,,IV,,666,759,1
MMRF_2310,,Third Line Therapy (followi,Unknown,,Pomalidomide,,,,Adverse Event or co-morbidity,,4,mg,,QD,,PO,,666,815,1
MMRF_2310,,Third Line Therapy (followi,Unknown,,Dexamethasone,,,,Adverse Event or co-morbidity,,40,mg,,Oth,"QD (1,8,15,22)",IV,,666,815,1
MMRF_2310,,Fourth Line Therapy (follow,Unknown,,Daratumumab,,,,Adverse Event or co-morbidity,,1384,mg,,QID,,IV,,815,815,1
MMRF_2316,Baseline,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,1080,mg,,QD,,IV,,1,102,1
MMRF_2316,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,71,1
MMRF_2316,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,PO,,1,102,1
MMRF_2330,Baseline,First line of therapy,Induction,,Bortezomib,,,,Other,proceed to transplant,1.3,mg/m^,,QD,,IV SubQ,,1,74,1
MMRF_2330,,First line of therapy,Induction,,Dexamethasone,,,,Other,proceed to transplant,40,mg,,QD,,PO,,1,74,1
MMRF_2330,,First line of therapy,Induction,,Lenalidomide,,,,Other,proceed to transplant,25,mg,,QD,,PO,,1,77,1
MMRF_2330,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,122,122,1
MMRF_2330,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,2000,mg/m^,,Q d,,IV,,88,88,1
MMRF_2330,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,10,mg,,Q d,,IV,,88,88,1
MMRF_2330,,First line of therapy,Induction,,Other,etoposide,,,Completed regimen,,200,mg/m^,,Q d,,IV,,88,88,1
MMRF_2330,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,Q d,,IV,,235,235,1
MMRF_2330,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,234,234,1
MMRF_2330,,Second Line Therapy (after,Unknown,,Lenalidomide,,,,Lack of response,,25,mg,,QD,,PO,,607,683,1
MMRF_2330,,Second Line Therapy (after,Unknown,,Dexamethasone,,,,Lack of response,,40,mg,,Oth,QWk 1 day before elotuzumab,IV,,607,684,1
MMRF_2330,,Second Line Therapy (after,Unknown,,Elotuzumab,,,,Lack of response,,10,mg/kg,,Oth,"D1, 8, 15, 22",IV,,607,677,1
MMRF_2330,,Second Line Therapy (after,Other,second line,Carfilzomib,,,,Completed regimen,,27,mg/m^,,QD,,IV,,694,857,1
MMRF_2330,,Second Line Therapy (after,Other,second line,Lenalidomide,,,,Other,took lenalidomide until pomalidomide delivered,25,mg,,QD,,PO,,694,695,1
MMRF_2330,,Second Line Therapy (after,Other,second line,Dexamethasone,,,,Completed regimen,,20,mg,,QD,,IV,,694,857,1
MMRF_2330,,Second Line Therapy (after,Other,second line,Pomalidomide,,,,Completed regimen,,4,mg,,QD,,PO,,696,857,1
MMRF_2330,,Second Line Therapy (after,Other,conditioning,Melphalan,,,,Completed regimen,,100,mg/m^,,Q d,,IV,,874,874,1
MMRF_2330,,Second Line Therapy (after,Other,conditioning,Other,Fludarabine,,,Completed regimen,,77,mg,,Q d,,IV,,875,875,1
MMRF_2330,,Third Line Therapy (followi,Other,salvage,Other,methylprednisone,,Checked,,,125,mg,,Oth,with dara administration,IV,,1186,,1
MMRF_2330,,Third Line Therapy (followi,Other,salvage,Daratumumab,,,Checked,,,16,mg/kg,,Q w,,IV,,1186,,1
MMRF_2330,,Third Line Therapy (followi,Other,salvage,Pomalidomide,,,Checked,,,4,mg,,QD,,PO,,1186,,1
MMRF_2331,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,64,1
MMRF_2331,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,64,1
MMRF_2331,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,PO,,1,64,1
MMRF_2331,,First line of therapy,Other,consolidation,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,122,122,1
MMRF_2378,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,44,1
MMRF_2378,Baseline,First line of therapy,Induction,,Bortezomib,,,,Investigator decision for other reasons,,2.7,mg,,QD,,IV SubQ,,1,32,1
MMRF_2378,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,PO,,1,25,1
MMRF_2378,,First line of therapy,Other,conditioning,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,86,86,1
MMRF_2407,Baseline,First line of therapy,Induction,,Bortezomib,,,,Other,proceed to transplant,1.3,mg/m^,,QD,,IV SubQ,,1,33,1
MMRF_2407,,First line of therapy,Induction,,Dexamethasone,,,,Other,proceed to transplant,40,mg,,QD,,PO,,1,33,1
MMRF_2407,,First line of therapy,Induction,,Cyclophosphamide,,,,Other,switched to lenalidomide after one cycle,500,mg/m^,,Oth,D1 and D8,IV,,1,8,1
MMRF_2407,,First line of therapy,Induction,,Lenalidomide,,,,Other,proceed to transplant,25,mg,,QD,,PO,,22,36,1
MMRF_2407,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,2000,mg/m^,,Q d,,IV,,64,64,1
MMRF_2407,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,10,mg,,Q d,,IV,,64,64,1
MMRF_2407,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,89,89,1
MMRF_2407,,First line of therapy,Induction,,Other,etoposide,,,Completed regimen,,200,mg/m^,,Q d,,IV,,64,64,1
MMRF_2407,,First line of therapy,Other,conditioning,Bortezomib,,,,Completed regimen,,1.6,mg/m^,,Oth,D-4 and D-1,IV,,207,210,1
MMRF_2407,,First line of therapy,Other,conditioning,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,209,209,1
MMRF_2422,Baseline,First line of therapy,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,1.3,mg/m^,,QD,,IV SubQ,,1,85,1
MMRF_2422,,First line of therapy,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,40,mg,,QD,,PO,,1,85,1
MMRF_2422,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,4200,mg,,Q d,,IV,,237,237,1
MMRF_2422,,First line of therapy,Other,conditioning,Melphalan,,,,Completed regimen,,424,mg,,Q d,,IV,,254,254,1
MMRF_2437,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,53,1
MMRF_2437,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,500,mg/m^,,Oth,QD (D1 and D8),IV,,1,8,1
MMRF_2437,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,57,1
MMRF_2437,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,PO,,1,53,1
MMRF_2437,,First line of therapy,Other,conditioning,Dexamethasone,,,,Completed regimen,,12,mg,,Q d,,PO,,106,106,1
MMRF_2437,,First line of therapy,Other,conditioning,Melphalan,,,,Completed regimen,,278,mg,,Q d,,IV,,106,106,1
MMRF_2489,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,53,1
MMRF_2489,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,PO,,1,53,1
MMRF_2489,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,56,1
MMRF_2489,,First line of therapy,Other,mobilization,Cyclophosphamide,,,,Completed regimen,,4,Other,g,Q d,,IV,,73,73,1
MMRF_2489,,First line of therapy,Other,mobilization,Dexamethasone,,,,Completed regimen,,10,mg,,Q d,,IV,,73,73,1
MMRF_2489,,First line of therapy,Other,conditioning,Melphalan,,,,Completed regimen,,390,mg,,Q d,,IV,,98,98,1
MMRF_2489,,First line of therapy,Other,mobilization,Other,Etoposide,,,Completed regimen,,400,mg,,Q d,,IV,,73,73,1
MMRF_2489,,First line of therapy,Other,Conditioning,Bortezomib,,,,Completed regimen,,1.6,mg/m^,,Oth,Days -4 and -1,IV,,273,276,1
MMRF_2489,,First line of therapy,Other,conditioning,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,275,275,1
MMRF_2499,,First line of therapy,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,25,mg,,QD,,PO,,1,58,1
MMRF_2499,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,PO,,28,115,1
MMRF_2499,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,28,86,1
MMRF_2499,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,1045,mg,,Oth,"QD (D1, D8)",IV,,58,115,1
MMRF_2499,,First line of therapy,Consolidation,,Melphalan,,,,Completed regimen,,412,mg,,Oth,once,IV,,871,871,1
MMRF_2499,,First line of therapy,Consolidation,,Other,etoposide,,,Completed regimen,,420,mg,,Oth,once,IV,,115,115,1
MMRF_2506,Baseline,First line of therapy,Induction,,Lenalidomide,,,,Other,MD temporarily giving patient break from treatment,25,mg,,QD,,PO,,1,369,1
MMRF_2506,,First line of therapy,Induction,,Dexamethasone,,,,Other,MD temporarily giving patient break from treatment,20,mg,,Q w,,PO,,1,370,1
MMRF_2548,Baseline,First line of therapy,Induction,,Cyclophosphamide,,,,Investigator decision for other reasons,,500,mg/m^,,Oth,"QD (D1, D8)",IV,,1,1,1
MMRF_2548,,First line of therapy,Induction,,Bortezomib,,,,Other,proceed to transplant,1.3,mg/m^,,QD,,IV SubQ,,1,54,1
MMRF_2548,,First line of therapy,Induction,,Dexamethasone,,,,Other,proceed to transplant,40,mg,,QD,,PO,,1,54,1
MMRF_2548,,First line of therapy,Induction,,Lenalidomide,,,,Other,proceed to transplant,25,mg,,QD,,PO,,8,57,1
MMRF_2548,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,2000,mg/m^,,Q d,,IV,,79,79,1
MMRF_2548,,First line of therapy,Induction,,Other,etoposide,,,Completed regimen,,200,mg/m^,,Q d,,IV,,79,79,1
MMRF_2548,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,10,mg,,Q d,,IV,,79,79,1
MMRF_2548,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,103,103,1
MMRF_2548,,First line of therapy,Other,conditioning,Other,fludarabine,,,Completed regimen,,30,mg/m^,,Q d,,IV,,247,249,1
MMRF_2548,,First line of therapy,Other,conditioning,Melphalan,,,,Completed regimen,,140,mg/m^,,Q d,,IV,,250,250,1
MMRF_2548,,First line of therapy,Other,conditioning,Bortezomib,,,,Completed regimen,,1.6,mg/m^,,Oth,"QD-4, D-1",IV,,248,251,1
MMRF_2554,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,102,1
MMRF_2554,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,PO,,1,102,1
MMRF_2554,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,102,1
MMRF_2554,,First line of therapy,Other,mobilization,Other,Etoposide,,,Completed regimen,,330,mg,,Q d,,IV,,126,126,1
MMRF_2554,,First line of therapy,Other,mobolization,Cyclophosphamide,,,,Completed regimen,,3.3,Other,g,Q d,,IV,,126,126,1
MMRF_2554,,First line of therapy,Other,mobilization,Dexamethasone,,,,Completed regimen,,10,mg,,Q d,,IV,,126,126,1
MMRF_2554,,First line of therapy,Other,conditioning,Melphalan,,,,Completed regimen,,320,mg,,Q d,,IV,,161,161,1
MMRF_2574,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,54,1
MMRF_2574,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,54,1
MMRF_2574,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,PO,,1,54,1
MMRF_2574,,Second Line Therapy (after,Unknown,,Carfilzomib,,,,Adverse Event or co-morbidity,,40,mg,,Oth,"Days 1,2,8,9,15,16",IV,,445,446,1
MMRF_2574,,Second Line Therapy (after,Unknown,,Dexamethasone,,,,Adverse Event or co-morbidity,,40,mg,,Oth,"1,2,8,9,15,16",IV,,445,446,1
MMRF_2574,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,200,mg/m^,,Oth,once,IV,,89,89,1
MMRF_2593,Baseline,First line of therapy,Induction,,Bortezomib,,,,Other,proceed to transplant,1.3,mg/m^,,QD,,IV SubQ,,1,50,1
MMRF_2593,,First line of therapy,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,25,mg,,QD,,PO,,1,15,1
MMRF_2593,,First line of therapy,Induction,,Dexamethasone,,,,Other,proceed to transplant,40,mg,,QD,,PO,,1,50,1
MMRF_2593,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,2000,mg/m^,,Q d,,IV,,64,64,1
MMRF_2593,,First line of therapy,Induction,,Other,etoposide,,,Completed regimen,,200,mg/m^,,Q d,,IV,,64,64,1
MMRF_2593,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,90,90,1
MMRF_2593,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,10,mg,,Q d,,IV,,64,64,1
MMRF_2596,,First line of therapy,Other,conditioning,Melphalan,,,,Completed regimen,,392,mg,,Q d,,IV,,78,78,1
MMRF_2596,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,32,1
MMRF_2596,,First line of therapy,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,25,mg,,QD,,PO,,1,11,1
MMRF_2596,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,PO,,1,32,1
MMRF_2605,,First line of therapy,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,25,mg,,QD,,PO,,1,37,1
MMRF_2605,Baseline,First line of therapy,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,1.3,mg/m^,,QD,,IV SubQ,,1,37,1
MMRF_2605,,First line of therapy,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,40,mg,,QD,,PO,,1,37,1
MMRF_2605,,First line of therapy,Other,mobilization,Other,Etoposide,,,Completed regimen,,310,mg,,Q d,,IV,,65,65,1
MMRF_2605,,First line of therapy,Other,mobiization,Cyclophosphamide,,,,Completed regimen,,3.1,Other,g,Q d,,IV,,65,65,1
MMRF_2605,,First line of therapy,Other,mobilization,Dexamethasone,,,,Completed regimen,,10,mg,,Q d,,IV,,65,65,1
MMRF_2605,,First line of therapy,Other,conditioning,Melphalan,,,,Completed regimen,,302,mg,,Q d,,IV,,90,90,1
MMRF_2605,,First line of therapy,Other,conditioning,Bortezomib,,,,Completed regimen,,2.5,mg,,Q d,,IV,,257,260,1
MMRF_2605,,First line of therapy,Other,conditioning,Melphalan,,,,Completed regimen,,310,mg,,Q d,,IV,,259,259,1
MMRF_2605,,First line of therapy,Other,conditioning,Dexamethasone,,,,Completed regimen,,10,mg,,Q d,,IV,,257,260,1
MMRF_2605,,Second Line Therapy (after,Unknown,,Carfilzomib,,,,Disease progression/Relapse,,27,mg/m^,,QD,,IV,,603,884,1
MMRF_2605,,Second Line Therapy (after,Unknown,,Lenalidomide,,,,Disease progression/Relapse,,25,mg,,QD,,PO,,603,884,1
MMRF_2605,,Second Line Therapy (after,Unknown,,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,QD,,PO,,603,884,1
MMRF_2605,,Fourth Line Therapy (follow,Other,salvage,Other,idasinutlin,,,Disease progression/Relapse,,200,mg,,Oth,QD (D 1-5),PO,,1016,1020,1
MMRF_2605,,Fourth Line Therapy (follow,Other,salvage,Ixazomib,,,,Disease progression/Relapse,,4,mg,,Oth,"QD (D 1, 8, 15 out of 28 days cycle)",PO,,1016,1030,1
MMRF_2605,,Third Line Therapy (followi,Unknown,,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,Oth,days of and after Daratummumab,PO,,901,971,1
MMRF_2605,,Third Line Therapy (followi,Unknown,,Daratumumab,,,,Disease progression/Relapse,,850,mg,,Oth,"days 1,8,15,22",IV,,901,971,1
MMRF_2605,,Fourth Line Therapy (follow,Other,salvage,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,QWK,,PO,,1016,1030,1
MMRF_2605,,Third Line Therapy (followi,Unknown,,Pomalidomide,,,,Disease progression/Relapse,,4,mg,,QD,,PO,,901,971,1
MMRF_2619,,First line of therapy,Induction,,Dexamethasone,,,,Investigator decision for other reasons,,40,mg,,QD,,PO,,444,457,1
MMRF_2619,,First line of therapy,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,25,mg,,QD,,PO,,444,457,1
MMRF_2619,Baseline,First line of therapy,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,1.3,mg/m^,,QD,,IV SubQ,,444,457,1
MMRF_2619,,First line of therapy,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,1.5,mg/m^,,QD,,IV,,28,35,1
MMRF_2619,,First line of therapy,Other,mobilization,Cyclophosphamide,,,,Completed regimen,,4.6,Other,g,Q d,,IV,,510,510,1
MMRF_2619,,First line of therapy,Other,Mobilization,Other,Etoposide,,,Completed regimen,,4.6,Other,g,Q d,,IV,,510,510,1
MMRF_2619,,First line of therapy,Induction,,Cyclophosphamide,,,,Adverse Event or co-morbidity,,300,mg/m^,,Oth,physician discretion,IV,,1,35,1
MMRF_2619,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,27,mg/m^,,QD,,IV,,472,500,1
MMRF_2619,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,QD,,IV,,472,500,1
MMRF_2619,,First line of therapy,Other,mobilization,Dexamethasone,,,,Completed regimen,,10,mg,,Q d,,IV,,510,510,1
MMRF_2619,,First line of therapy,Other,conditioning,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,536,536,1
MMRF_1222,,First line of therapy,,,Dexamethasone,,,,Lack of response,,20,mg,,Q w,,PO,,1,160,1
MMRF_1222,,Second Line Therapy (after,,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,IV,,170,354,1
MMRF_1222,,Second Line Therapy (after,,,Carfilzomib,,,,Completed regimen,,27,mg/m^,,QD,,IV,,170,354,1
MMRF_1222,Baseline,First line of therapy,,,Bortezomib,,,,Lack of response,,1.3,mg/m^,,QD,,Other,SubQ,1,160,1
MMRF_1222,,Second Line Therapy (after,,,Pomalidomide,,,,Completed regimen,,4,mg,,QD,,PO,,170,359,1
MMRF_1222,,Third Line Therapy (followi,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,1.3,mg/m^,,QWK,,IV SubQ,,513,520,1
MMRF_1222,,Third Line Therapy (followi,Induction,,Bortezomib,,,,Lack of response,,1.3,mg/m^,,Q w,,IV SubQ,,597,611,1
MMRF_1222,,Third Line Therapy (followi,Induction,,Carfilzomib,,,,Other,dose to be escalated per standard treatment regimen,20,mg/m^,,Oth,"QD1, D2",IV,,618,619,1
MMRF_1222,,Third Line Therapy (followi,Consolidation,,Carfilzomib,,,,Other,stopped so patient could receive XRT to orbital plasmacytoma,36,mg/m^,,QD,,IV,,646,660,1
MMRF_1222,,Third Line Therapy (followi,Induction,,Carfilzomib,,,,Other,dose to be escalated per standard treatment regimen,27,mg/m^,,Oth,"QD (D8-9, D15-16)",IV,,625,633,1
MMRF_1222,,Second Line Therapy (after,Consolidation,,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,407,407,1
MMRF_1222,,Third Line Therapy (followi,Consolidation,,Melphalan,,,,Completed regimen,,140,mg/m^,,Q d,,IV,,532,532,1
MMRF_1222,,Third Line Therapy (followi,Induction,,Bendamustine,,,,Adverse Event or co-morbidity,,120,mg/m^,,Oth,unknown,IV,,513,513,1
MMRF_1222,,Third Line Therapy (followi,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,20,mg,,Q w,,IV,,513,520,1
MMRF_1264,,First line of therapy,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,5,mg,,QD,,PO,,45,58,1
MMRF_1264,Baseline,First line of therapy,,,Bortezomib,,,,Lack of response,,1.3,mg/m^,,QD,,IV SubQ,,1,372,1
MMRF_1264,,First line of therapy,,,Dexamethasone,,,,Investigator decision for other reasons,,20,mg,,Q w,,PO,,1,15,1
MMRF_1264,,First line of therapy,,,Melphalan,,,,Investigator decision for other reasons,,2,mg,,Oth,6 tabs daily for 5 days q6 weeks,PO,,86,302,1
MMRF_1264,,Second Line Therapy (after,Induction,,Pomalidomide,,,,Adverse Event or co-morbidity,,3,mg,,QD,,PO,,388,1210,1
MMRF_1264,,Second Line Therapy (after,Induction,,Pomalidomide,,,,Other,dose decreased,3,mg,,QD,,PO,,1239,1550,1
MMRF_1264,,Second Line Therapy (after,Induction,,Pomalidomide,,,,Adverse Event or co-morbidity,,2,mg,,Q d,,PO,,1551,1579,1
MMRF_1547,Baseline,First line of therapy,Induction,,Bortezomib,,,,Other,subject to be worked up for transplant,1.3,mg/m^,,QWK,,IV SubQ,,1,148,1
MMRF_1547,,First line of therapy,Induction,,Dexamethasone,,,,Other,subject to be worked up for transplant,10,mg,,Oth,QD (D1-2),PO,,1,148,1
MMRF_1547,,First line of therapy,Induction,,Cyclophosphamide,,,,Other,subject to be worked up for transplant,300,mg,,QWK,,PO,,1,148,1
MMRF_1547,,First line of therapy,Other,2 days high dose melphalan prior to transplant,Melphalan,,,,Completed regimen,,200,mg/m^,,Oth,"QD -1,-2",IV,,192,193,1
MMRF_1547,,First line of therapy,Maintenance,,Bortezomib,,,,Other,patient started to have difficulties tolerating therapy,1.3,mg/m^,,Oth,"Q (D1, D8)",IV SubQ,,642,865,1
MMRF_1547,,First line of therapy,Maintenance,,Ixazomib,,,,Investigator decision for other reasons,,4,mg,,Q w,,PO,,892,1222,1
MMRF_1570,Baseline,First line of therapy,Induction,,Bortezomib,,,,Patient decision,,2.3,mg,,QD,,Other,SubQ injection,1,29,1
MMRF_1570,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,150,mg,,Oth,day 1 and day 2,PO,,1,110,1
MMRF_1570,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,2.3,mg,,QD,,IV SubQ,,29,110,1
MMRF_1570,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,10,mg,,Oth,day 1 and day 2,PO,,1,110,1
MMRF_1570,,First line of therapy,Other,High dose melphalan given 1 day prior to autologous stem cell transplant,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,155,155,1
MMRF_1570,,First line of therapy,Maintenance,,Bortezomib,,,,Disease progression/Relapse,,1.3,mg/m^,,Oth,Q2W,IV SubQ,,386,546,1
MMRF_1570,,Second Line Therapy (after,Unknown,,Dexamethasone,,,,Patient decision,,10,mg,,Oth,Monday & Tuesday for 3 weeks then 1 week off,PO,,546,546,1
MMRF_1570,,Second Line Therapy (after,Unknown,,Lenalidomide,,,,Patient decision,,15,mg,,QD,,PO,,546,546,1
MMRF_1586,Baseline,First line of therapy,Induction,,Bortezomib,,,,Other,Changed frequency,2.04,mg,,QD,,Other,SubQ,1,128,1
MMRF_1586,,First line of therapy,Induction,,Dexamethasone,,,Checked,,,10,mg,,Oth,"Qd 1-2, 8-9, 22-23, 29-30",PO,,1,,1
MMRF_1586,,First line of therapy,Maintenance,,Bortezomib,,,Checked,,,1.3,mg/m^,,Oth,Q every 2 weeks,IV SubQ,,128,,1
MMRF_2038,,First line of therapy,Induction,,Dexamethasone,,,,Lack of response,,10,mg,,Oth,QD (D1-D2),PO,,1,94,1
MMRF_2038,Baseline,First line of therapy,Induction,,Bortezomib,,,,Lack of response,,2,mg,,Q w,,IV SubQ,,1,92,1
MMRF_2038,,First line of therapy,Induction,,Cyclophosphamide,,,,Investigator decision for other reasons,,300,mg,,QWK,,PO,,1,34,1
MMRF_2038,,First line of therapy,Induction,,Lenalidomide,,,,Lack of response,,5,mg,,Q d,,PO,,35,94,1
MMRF_2038,,First line of therapy,Unknown,,Dexamethasone,,,,Completed regimen,,20,mg,,Q d,,IV,,158,158,1
MMRF_2038,,First line of therapy,Unknown,,Dexamethasone,,,,Completed regimen,,20,mg,,Q d,,IV,,164,164,1
MMRF_2038,,First line of therapy,Unknown,,Dexamethasone,,,,Completed regimen,,20,mg,,Q d,,IV,,168,168,1
MMRF_2038,,First line of therapy,Unknown,,Melphalan,,,,Completed regimen,,50,mg/m^,,Q d,,IV,,158,158,1
MMRF_2038,,First line of therapy,Unknown,,Melphalan,,,,Completed regimen,,50,mg/m^,,Q d,,IV,,164,164,1
MMRF_2038,,First line of therapy,Unknown,,Melphalan,,,,Completed regimen,,75,mg/m^,,Q d,,IV,,168,168,1
MMRF_2038,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,Oth,"Days 1,4,8",IV SubQ,,121,128,1
MMRF_2038,,First line of therapy,Induction,,Thalidomide,,,,Completed regimen,,200,mg,,BID,,PO,,124,127,1
MMRF_2038,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,Days 1-4 and Day 8,PO,,121,128,1
MMRF_2038,,First line of therapy,Induction,,Other,adriamycin,,,Completed regimen,,10,mg/m^,,QD,,IV,,121,124,1
MMRF_2038,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,QD,,IV,,121,124,1
MMRF_2038,,First line of therapy,Induction,,Other,etoposide,,,Completed regimen,,40,mg/m^,,QD,,IV,,121,124,1
MMRF_2038,,First line of therapy,Maintenance,,Lenalidomide,,,,Investigator decision for other reasons,,5,mg,,Q d,,PO,,275,666,1
MMRF_2038,,First line of therapy,Maintenance,,Thalidomide,,,,Adverse Event or co-morbidity,,50,mg,,Q d,,PO,,275,409,1
MMRF_2038,,First line of therapy,Maintenance,,Dexamethasone,,,,Investigator decision for other reasons,,12,mg,,Q w,,PO,,539,632,1
MMRF_2038,,First line of therapy,Maintenance,,Pomalidomide,,,Checked,,,1,mg,,Oth,Every other day for 28 day cycles with no break,PO,,732,,1
MMRF_2038,,First line of therapy,Maintenance,,Pomalidomide,,,,Investigator decision for other reasons,,1,mg,,QD,,PO,,698,719,1
MMRF_2168,Baseline,First line of therapy,Induction,,Bortezomib,,,,Investigator decision for other reasons,,1.3,mg/m^,,QD,,IV SubQ,,1,281,1
MMRF_2168,,First line of therapy,Induction,,Dexamethasone,,,,Investigator decision for other reasons,,10,mg,,Oth,"QD (D1-2, D8-9, D22-23, D29-30)",PO,,1,322,1
MMRF_2168,,First line of therapy,Induction,,Lenalidomide,,,,Investigator decision for other reasons,,15,mg,,QD,,PO,,135,276,1
MMRF_2168,,First line of therapy,Other,conditioning for bone marrow transplant,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,308,308,1
MMRF_2168,,First line of therapy,Other,High-dose priming prior to stem cell collection,Cyclophosphamide,,,,Completed regimen,,3000,mg/m^,,Q d,,IV,,288,288,1
MMRF_2168,,First line of therapy,Consolidation,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,430,542,1
MMRF_2168,,First line of therapy,Consolidation,,Ixazomib,,,,Completed regimen,,4,mg,,Q w,,PO,,430,542,1
MMRF_2168,,First line of therapy,Consolidation,,Dexamethasone,,,,Completed regimen,,20,mg,,Q w,,PO,,430,542,1
MMRF_2168,,First line of therapy,Induction,,Daratumumab,,,,Completed regimen,,16,mg/m^,,Oth,Q2 weeks,IV,,626,891,1
MMRF_2168,,First line of therapy,Induction,,Daratumumab,,,Checked,,,16,mg/m^,,Oth,Q4 weeks,IV,,919,,1
MMRF_2215,Baseline,First line of therapy,Induction,,Bortezomib,,,,Investigator decision for other reasons,,1.3,mg/m^,,QD,,IV SubQ,,1,93,1
MMRF_2215,,First line of therapy,Induction,,Dexamethasone,,,,Investigator decision for other reasons,,10,mg,,Oth,"QD (D1-2, D4-5, D8-9, D11-12)",PO,,1,94,1
MMRF_2215,,First line of therapy,Consolidation,,Melphalan,,,,Completed regimen,,140,mg/m^,,Q d,,IV,,128,128,1
MMRF_2215,,First line of therapy,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,5,mg,,QD,,PO,,242,423,1
MMRF_2215,,First line of therapy,Maintenance,,Lenalidomide,,,,Other,changed dosing frequency,5,mg,,QD,,PO,,428,1090,1
MMRF_2215,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,5,mg,,Q d,,PO,,1098,,1
MMRF_1011,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,Day 1 and Day 8,PO,,67,156,1
MMRF_1011,Baseline,First line of therapy,,,Bortezomib,,,,Other,Grade 2 Neuropathy,2.7,mg,,QD,,IV,,1,74,1
MMRF_1011,,First line of therapy,,,Lenalidomide,,,,Other,Dose change,10,mg,,QD,,PO,,253,451,1
MMRF_1011,,First line of therapy,Maintenance,,Lenalidomide,,,,Other,patient diagnosed with colon cancer,15,mg,,QD,,PO,,452,925,1
MMRF_1011,,First line of therapy,Other,conditioning,Cyclophosphamide,,,,Completed regimen,,3720,mg,,Oth,once,IV,,131,131,1
MMRF_1011,,First line of therapy,Other,Mobilization for bone marrow transplant,Cyclophosphamide,,,,Completed regimen,,3720,mg,,Oth,once,IV,,131,131,1
MMRF_1011,,First line of therapy,Other,Conditioning,Melphalan,,,,Completed regimen,,370,mg,,Oth,once,IV,,153,153,1
MMRF_1011,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,"D1, D2, D3, D4,D9,D10, D11, D12",PO,,1,67,1
MMRF_1011,,Second Line Therapy (after,Induction,,Carfilzomib,,,,Completed regimen,,27,mg/m^,,QD,,IV,,1726,1908,1
MMRF_1011,,Second Line Therapy (after,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,QD,,IV,,1726,1909,1
MMRF_1011,,Second Line Therapy (after,Maintenance,,Pomalidomide,,,Checked,,,1,mg/dL,,Q d,,PO,,1933,,1
MMRF_1034,,First line of therapy,,,Dexamethasone,,,,Other,Doseage and frequency changed,20,mg,,QWK,,PO,,60,110,1
MMRF_1034,,First line of therapy,,,Dexamethasone,,,,Other,doseage changed,10,mg,,QD,,PO,,1,60,1
MMRF_1034,,First line of therapy,,,Dexamethasone,,,,Other,beginning stem cell moblization for autologous stem cell transplant,40,mg,,Oth,"Days 1, 8, 15, 22",PO,,115,249,1
MMRF_1034,,First line of therapy,,,Lenalidomide,,,,Other,Beginning stem cell mobilization for autologous stem cell transplant,25,mg,,QD,,PO,,115,249,1
MMRF_1034,Baseline,First line of therapy,,,Bortezomib,,,,Other,doseage and route changed due to neuropathy,2,mg,,QWK,,IV,,5,60,1
MMRF_1034,,First line of therapy,,,Bortezomib,,,,Other,patient developed hypercalcemia,1,mg/dL,,QWK,,IV SubQ,,60,115,1
MMRF_1034,,First line of therapy,Other,stem cell mobilization,Other,Plerixafor,,,Completed regimen,,24,mg,,Q d,,Other,subq,254,255,1
MMRF_1034,,First line of therapy,Consolidation,,Melphalan,,,,Completed regimen,,300,mg,,Q d,,IV,,258,258,1
MMRF_1029,,First line of therapy,,,Lenalidomide,,,,Investigator decision for other reasons,,25,mg,,QD,,PO,,22,560,1
MMRF_1029,,First line of therapy,,,Dexamethasone,,,,Investigator decision for other reasons,,20,mg,,QD,,PO,,85,530,1
MMRF_1029,Baseline,First line of therapy,,,Bortezomib,,,,Other,Grade 2 peripheral neuropathy and good response,3,mg,,QD,,IV,,1,74,1
MMRF_1029,,First line of therapy,,,Dexamethasone,,,Checked,,,20,mg,,Q w,,PO,,561,,1
MMRF_1029,,First line of therapy,,,Dexamethasone,,,,Investigator decision for other reasons,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23",PO,,1,84,1
MMRF_1029,,First line of therapy,,,Lenalidomide,,,,Adverse Event or co-morbidity,,15,mg,,Q d,,PO,,561,883,1
MMRF_1029,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,15,mg,,QD,,PO,,913,,1
MMRF_1042,Baseline,First line of therapy,,,Bortezomib,,,,Other,Patient's response reached a plateau,2.4,mg,,QWK,,IV SubQ,,1,148,1
MMRF_1042,,First line of therapy,,,Dexamethasone,,,,Other,doseage reduced,40,mg,,QWK,,PO,,1,148,1
MMRF_1042,,Second Line Therapy (after,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,20,mg,,QD,,PO,,581,644,1
MMRF_1042,,Second Line Therapy (after,Induction,,Lenalidomide,,,,Other,lowered dosage,10,mg,,QD,,PO,,581,882,1
MMRF_1042,,Second Line Therapy (after,Induction,,Dexamethasone,,,,Investigator decision for other reasons,,20,mg,,Q w,,PO,,644,700,1
MMRF_1042,,Second Line Therapy (after,Maintenance,,Lenalidomide,,,Checked,,,5,mg,,QD,,PO,,882,,1
MMRF_1042,,Second Line Therapy (after,Induction,,Dexamethasone,,,,Investigator decision for other reasons,,8,mg,,QWK,,PO,,1429,1764,1
MMRF_1039,Baseline,First line of therapy,,,Bortezomib,,,,Completed regimen,,2.6,mg,,QWK,,IV SubQ,,1,105,1
MMRF_1039,,First line of therapy,,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,102,210,1
MMRF_1039,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,"Days 1-4, 9-12",PO,,1,246,1
MMRF_1039,,Second Line Therapy (after,Induction,,Lenalidomide,,,,Investigator decision for other reasons,,25,mg,,QD,,PO,,998,1149,1
MMRF_1039,,Second Line Therapy (after,Induction,,Lenalidomide,,,,Completed regimen,,15,mg,,QD,,PO,,1150,1358,1
MMRF_1039,,Second Line Therapy (after,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Q w,,PO,,1038,1358,1
MMRF_1039,,First line of therapy,Consolidation,,Melphalan,,,,Completed regimen,,385,mg,,Oth,once,IV,,243,243,1
MMRF_1039,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,2,mg,,Q w,,IV SubQ,,210,221,1
MMRF_1039,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,2.5,mg,,Q w,,IV SubQ,,105,210,1
MMRF_1039,,Second Line Therapy (after,Induction,,Dexamethasone,,,Checked,,,20,mg,,Q w,,PO,,1373,,1
MMRF_1039,,Second Line Therapy (after,Induction,,Pomalidomide,,,Checked,,,2,mg,,QD,,PO,,1403,,1
MMRF_1055,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,40,mg,,QWK,,PO,,1,142,1
MMRF_1055,Baseline,First line of therapy,,,Bortezomib,,,,Completed regimen,,2.5,Other,mg,Q w,,IV SubQ,,1,142,1
MMRF_1055,,Second Line Therapy (after,,,Lenalidomide,,,,Adverse Event or co-morbidity,,25,mg,,QD,,PO,,296,392,1
MMRF_1055,,Second Line Therapy (after,,,Lenalidomide,,,,Adverse Event or co-morbidity,,10,mg,,QD,,PO,,414,444,1
MMRF_1055,,First line of therapy,Consolidation,,Melphalan,,,,Completed regimen,,385,mg,,Oth,once,IV,,165,165,1
MMRF_1124,,First line of therapy,,,Bortezomib,,,,Patient decision,,2.1,mg,,QD,,IV,,18,379,1
MMRF_1124,,First line of therapy,,,Dexamethasone,,,,Investigator decision for other reasons,,20,mg,,Oth,Day 1-4 and day 9-12,PO,,15,60,1
MMRF_1124,,First line of therapy,,,Dexamethasone,,,,Patient decision,,20,mg,,Q w,,PO,,60,379,1
MMRF_1124,Baseline,First line of therapy,,,Dexamethasone,,,,Other,discharged from hospital to follow-up care in Oklahoma,20,mg,,Oth,One time dosing,PO,,1,1,1
MMRF_1166,,First line of therapy,,,Lenalidomide,,,,Adverse Event or co-morbidity,,25,mg,,QD,,PO,,1,106,1
MMRF_1166,Baseline,First line of therapy,,,Bortezomib,,,,Adverse Event or co-morbidity,,1.3,mg/m^,,QD,,IV,,1,106,1
MMRF_1166,,First line of therapy,,,Dexamethasone,,,,Adverse Event or co-morbidity,,20,mg,,Oth,"D1-2, D4-5, D8-9, D11-12",PO,,1,106,1
MMRF_1209,Baseline,First line of therapy,,,Bortezomib,,,,Other,Death,2.1,mg,,QD,,IV SubQ,,1,320,1
MMRF_1209,,First line of therapy,,,Cyclophosphamide,,,,Other,Death,750,mg,,Oth,"D1, D8, D11",PO,,1,320,1
MMRF_1209,,First line of therapy,,,Dexamethasone,,,,Other,Death,20,mg,,Oth,"D1, D8, D15",PO,,1,320,1
MMRF_1333,Baseline,First line of therapy,,,Bortezomib,,,,Adverse Event or co-morbidity,,1.3,mg/m^,,Q w,,IV,,1,176,1
MMRF_1333,,First line of therapy,,,Cyclophosphamide,,,,Adverse Event or co-morbidity,,750,mg/m^,,Oth,Q28D (D1),IV,,1,176,1
MMRF_1333,,First line of therapy,,,Dexamethasone,,,,Adverse Event or co-morbidity,,40,mg,,Q w,,IV,,1,176,1
MMRF_1342,,First line of therapy,,,Dexamethasone,,,,Other,Patient was experiencing anxiety,20,mg,,QD,,PO,,1,498,1
MMRF_1342,,First line of therapy,,,Lenalidomide,,,,Patient decision,,15,mg,,QD,,PO,,1,747,1
MMRF_1342,Baseline,First line of therapy,,,Bortezomib,,,,Completed regimen,,2.4,mg,,QD,,IV SubQ,,1,747,1
MMRF_1342,,First line of therapy,Induction,,Dexamethasone,,,,Patient decision,,12,mg,,Oth,twice a week,PO,,498,672,1
MMRF_1342,,First line of therapy,Induction,,Dexamethasone,,,,Other,death,16,mg,,Q w,,PO,,672,778,1
MMRF_1383,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Q w,,PO,,57,135,1
MMRF_1383,Baseline,First line of therapy,,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,Q w,,IV SubQ,,1,135,1
MMRF_1383,,First line of therapy,,,Dexamethasone,,,,Investigator decision for other reasons,,20,mg,,Oth,"Days 1-4, 9-12, 17-20",PO,,1,56,1
MMRF_1383,,First line of therapy,,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Q w,,PO,,1,135,1
MMRF_1383,,First line of therapy,Maintenance,,Bortezomib,,,,Completed regimen,,2.3,mg/m^,,Oth,Q2Weeks,IV SubQ,,276,1009,1
MMRF_1383,,First line of therapy,Consolidation,,Melphalan,,,,Completed regimen,,240,mg,,Oth,once,IV,,167,167,1
MMRF_1550,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Q w,,PO,,1,204,1
MMRF_1550,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,500,mg/m^,,Q w,,PO,,1,142,1
MMRF_1550,Baseline,First line of therapy,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,1.5,mg/m^,,Q w,,IV SubQ,,1,23,1
MMRF_1550,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,0.7,mg/m^,,Q w,,IV SubQ,,58,142,1
MMRF_1550,,First line of therapy,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,1,mg/m^,,Q w,,IV SubQ,,30,51,1
MMRF_1550,,First line of therapy,Maintenance,,Lenalidomide,,,,Disease progression/Relapse,,5,mg/dL,,QD,,PO,,310,708,1
MMRF_1550,,Second Line Therapy (after,Induction,,Carfilzomib,,,,Lack of response,,20,mg/m^,,QD,,IV,,709,827,1
MMRF_1550,,Second Line Therapy (after,Induction,,Daratumumab,,,,Lack of response,,16,mg/kg,,Oth,Q2WK,IV,,838,1232,1
MMRF_1568,Baseline,First line of therapy,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,1.5,mg/m^,,Q w,,IV SubQ,,1,22,1
MMRF_1568,,First line of therapy,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,40,mg,,QD,,PO,,1,22,1
MMRF_1568,,First line of therapy,Induction,,Cyclophosphamide,,,,Adverse Event or co-morbidity,,500,mg/m^,,Q w,,PO,,1,50,1
MMRF_1568,,First line of therapy,Induction,,Cyclophosphamide,,,,Investigator decision for other reasons,,100,mg/m^,,Q w,,PO,,55,113,1
MMRF_1568,,First line of therapy,Induction,,Dexamethasone,,,,Investigator decision for other reasons,,40,mg,,Q w,,PO,,29,113,1
MMRF_1568,,First line of therapy,Induction,,Bortezomib,,,,Investigator decision for other reasons,,1,mg/m^,,Q w,,IV SubQ,,29,113,1
MMRF_1568,,First line of therapy,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,10,mg,,QD,,PO,,285,441,1
MMRF_1568,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,300,mg,,Oth,once,IV,,171,171,1
MMRF_1568,,Second Line Therapy (after,Induction,,Bortezomib,,,Checked,,,2.4,mg/m^,,Oth,"D1, D8",Other,injection,1275,,1
MMRF_1568,,Second Line Therapy (after,Induction,,Daratumumab,,,Checked,,,8,mg/kg,,Oth,"cycle 1 - d1, d2, d8, d15, d22, cycle 2 and beyond - d1, d8, d15, d22",IV,,1275,,1
MMRF_1568,,Second Line Therapy (after,Induction,,Dexamethasone,,,Checked,,,40,mg,,QWK,,PO,,1275,,1
MMRF_1721,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,Q w,,IV SubQ,,1,120,1
MMRF_1721,,First line of therapy,Induction,,Cyclophosphamide,,,,Investigator decision for other reasons,,300,mg/m^,,Q w,,PO,,1,120,1
MMRF_1721,,First line of therapy,Induction,,Dexamethasone,,,,Other,trouble sleeping,40,mg,,Oth,"D1-4. d9-12, d17-20",PO,,1,120,1
MMRF_1721,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Q w,,PO,,57,120,1
MMRF_1834,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,69,1
MMRF_1834,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"D1-2, 4-5, 8-9, 11-12",PO,,1,69,1
MMRF_1834,Baseline,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,69,1
MMRF_1834,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,300,mg,,Oth,once,IV,,145,145,1
MMRF_1834,,First line of therapy,Maintenance,,Dexamethasone,,,,Completed regimen,,4,mg,,Oth,"d1, d8d, d15",PO,,222,940,1
MMRF_1834,,First line of therapy,Maintenance,,Lenalidomide,,,,Completed regimen,,10,mg,,QD,,PO,,222,940,1
MMRF_1970,,First line of therapy,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,40,mg,,Oth,"days 1,8,15,22",PO,,1,148,1
MMRF_1970,Baseline,First line of therapy,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,3.5,mg,,QD,,IV SubQ,,1,176,1
MMRF_2057,Baseline,First line of therapy,Induction,,Lenalidomide,,,Checked,,,10,mg,,QD,,PO,,1,,1
MMRF_2057,,First line of therapy,Induction,,Dexamethasone,,,Checked,,,20,mg,,Oth,"days. 1,8,15,22",PO,,1,,1
MMRF_2454,Baseline,First line of therapy,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,25,mg,,BID,,PO,,1,74,1
MMRF_2454,,First line of therapy,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,40,mg,,Q w,,IV,,1,74,1
MMRF_2480,,First line of therapy,Induction,,Dexamethasone,,,,Other,death,20,mg,,Q w,,PO,,14,141,1
MMRF_2480,Baseline,First line of therapy,Induction,,Lenalidomide,,,,Other,death,25,mg,,QD,,PO,,1,141,1
MMRF_2560,Baseline,First line of therapy,Induction,,Lenalidomide,,,Checked,,,10,mg,,QD,,PO,,1,,1
MMRF_2560,,First line of therapy,Induction,,Bortezomib,,,,Other,dose adjustment,2.6,mg,,QD,,IV SubQ,,1,11,1
MMRF_2560,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"20 Mg daily on D1, D2, D4, D5, D8, D9, D11, D12 and D21.",PO,,1,74,1
MMRF_2560,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,2,mg,,QD,,IV SubQ,,22,74,1
MMRF_1031,Baseline,First line of therapy,,,Bortezomib,,,,Completed regimen,,1,mg,,QD,,IV,,1,61,1
MMRF_1031,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"D1, D4, D11, D18",PO,,1,61,1
MMRF_1031,,First line of therapy,,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,61,1
MMRF_1031,,First line of therapy,,,Other,MAGE vaccine,,,Disease progression/Relapse,,300,Other,mcg,Oth,q3 weeks approximately,IV,,185,1339,1
MMRF_1031,,Second Line Therapy (after,Consolidation,,Lenalidomide,,,,Disease progression/Relapse,,25,mg,,Q d,,PO,,1339,1581,1
MMRF_1031,,Second Line Therapy (after,Consolidation,,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,Q w,,PO,,1339,1581,1
MMRF_1031,,Third Line Therapy (followi,Consolidation,,Dexamethasone,,,,Adverse Event or co-morbidity,,10,mg,,QD,,PO,,1581,1670,1
MMRF_1031,,Third Line Therapy (followi,Consolidation,,Carfilzomib,,,,Adverse Event or co-morbidity,,20,mg/m^,,QD,,IV,,1581,1670,1
MMRF_1018,,First line of therapy,,,Lenalidomide,,,Checked,,,10,mg,,QD,,PO,,218,,1
MMRF_1018,Baseline,First line of therapy,,,Lenalidomide,,,,Completed regimen,,15,mg,,QD,,PO,,1,160,1
MMRF_1018,,First line of therapy,,,Dexamethasone,,,Checked,,,20,mg,,Q w,,PO,,218,,1
MMRF_1018,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,20,mg,,QWK,,PO,,1,160,1
MMRF_1018,,First line of therapy,,,Bortezomib,,,,Adverse Event or co-morbidity,,1.3,mg/m^,,Oth,"D1,8,15",IV SubQ,,44,105,1
MMRF_1041,Baseline,First line of therapy,,,Dexamethasone,,,,Investigator decision for other reasons,,40,mg,,QD,,IV,,1,18,1
MMRF_1041,,First line of therapy,,,Cyclophosphamide,,,,Investigator decision for other reasons,,250,mg/m^,,Oth,"Days 4, 11",IV,,1,18,1
MMRF_1041,,First line of therapy,,,Dexamethasone,,,,Lack of response,,40,mg,,QD,,IV,,18,432,1
MMRF_1041,,First line of therapy,,,Bortezomib,,,,Investigator decision for other reasons,,1.3,mg/m^,,QD,,IVB,,1,18,1
MMRF_1041,,First line of therapy,,,Cyclophosphamide,,,,Completed regimen,,250,mg/m^,,Oth,"Days 1, 8",IV,,18,159,1
MMRF_1041,,First line of therapy,,,Thalidomide,,,,Adverse Event or co-morbidity,,50,mg,,Oth,Days 1 - 28,PO,,18,260,1
MMRF_1041,,First line of therapy,,,Bortezomib,,,,Adverse Event or co-morbidity,,1.3,mg/m^,,QD,,IV SubQ,,18,211,1
MMRF_1041,,First line of therapy,Consolidation,,Lenalidomide,,,,Disease progression/Relapse,,15,mg,,Oth,every other day for 21 days,PO,,260,406,1
MMRF_1041,,Second Line Therapy (after,Consolidation,,Carfilzomib,,,,Disease progression/Relapse,,20,mg/m^,,QD,,IV,,432,953,1
MMRF_1041,,Second Line Therapy (after,Consolidation,,Cyclophosphamide,,,,Disease progression/Relapse,,300,mg/m^,,QD,,IV,,432,953,1
MMRF_1041,,Third Line Therapy (followi,Consolidation,,Pomalidomide,,,,Disease progression/Relapse,,2,mg,,QD,,PO,,981,1084,1
MMRF_1041,,Third Line Therapy (followi,Consolidation,,Cyclophosphamide,,,,Investigator decision for other reasons,,300,mg/m^,,Oth,QD D1 and D15,IV,,1061,1095,1
MMRF_1041,,Third Line Therapy (followi,Consolidation,,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,Q d,,PO,,953,1226,1
MMRF_1016,,First line of therapy,,,Dexamethasone,,,,Investigator decision for other reasons,,40,mg,,Oth,"Days 1, 4, 11, 18",PO,,113,158,1
MMRF_1016,,First line of therapy,,,Lenalidomide,,,,Investigator decision for other reasons,,25,mg,,QD,,PO,,43,113,1
MMRF_1016,,First line of therapy,,,Cyclophosphamide,,,,Investigator decision for other reasons,,250,mg/m^,,Oth,"Days 1, 11",IV,,113,158,1
MMRF_1016,Baseline,First line of therapy,,,Dexamethasone,,,,Investigator decision for other reasons,,40,mg,,Oth,"Days 1, 4, 11, 18",PO,,1,43,1
MMRF_1016,,First line of therapy,,,Bortezomib,,,,Lack of response,,1.3,mg/m^,,Oth,"Days 1, 8, 15",IV SubQ,,234,535,1
MMRF_1016,,First line of therapy,,,Lenalidomide,,,,Lack of response,,25,mg,,QD,,PO,,234,458,1
MMRF_1016,,First line of therapy,,,Bortezomib,,,,Investigator decision for other reasons,,1.3,mg/m^,,Oth,"Days 1, 4, 11, 18",Other,"IVP on Days 1, 4 and SubQ on 11 and 18",1,43,1
MMRF_1016,,First line of therapy,,,Cyclophosphamide,,,,Investigator decision for other reasons,,250,mg/m^,,Oth,"Days 1, 11",IVB,,1,43,1
MMRF_1016,,First line of therapy,,,Bortezomib,,,,Investigator decision for other reasons,,1.3,mg/m^,,Oth,"Days 1, 4, 11, 18",IV SubQ,,43,113,1
MMRF_1016,,First line of therapy,,,Dexamethasone,,,,Investigator decision for other reasons,,40,mg,,Oth,"Days 1, 4, 11, 18",PO,,43,113,1
MMRF_1016,,First line of therapy,,,Bortezomib,,,,Investigator decision for other reasons,,1.3,mg/m^,,Oth,"Days 1, 4, 11, 18",IV SubQ,,113,158,1
MMRF_1016,,First line of therapy,,,Dexamethasone,,,,Adverse Event or co-morbidity,,40,mg,,Oth,"Days 1, 8, 15",PO,,234,673,1
MMRF_1016,,First line of therapy,Consolidation,,Carfilzomib,,,,Adverse Event or co-morbidity,,20,mg/m^,,QD,,IV,,547,673,1
MMRF_1016,,First line of therapy,Consolidation,,Cyclophosphamide,,,,Adverse Event or co-morbidity,,300,mg/m^,,QD,,IV,,547,673,1
MMRF_1054,,First line of therapy,,,Cyclophosphamide,,,,Investigator decision for other reasons,,300,mg/m^,,Oth,"Days 1, 8",IV,,112,162,1
MMRF_1054,,First line of therapy,,,Dexamethasone,,,,Investigator decision for other reasons,,40,mg,,Oth,"Days 1, 4, 11, 18",PO,,112,169,1
MMRF_1054,,First line of therapy,,,Prednisone,,,,Investigator decision for other reasons,,50,mg,,Oth,"3 x per week: M, W, F",PO,,169,568,1
MMRF_1054,Baseline,First line of therapy,,,Dexamethasone,,,,Investigator decision for other reasons,,20,mg,,QWK,,PO,,1,21,1
MMRF_1054,,First line of therapy,,,Prednisone,,,,Investigator decision for other reasons,,50,mg,,Oth,"3 x per week: M, W, F",PO,,29,112,1
MMRF_1054,,First line of therapy,,,Lenalidomide,,,,Investigator decision for other reasons,,15,mg,,QD,,PO,,1,112,1
MMRF_1054,,First line of therapy,,,Bortezomib,,,,Investigator decision for other reasons,,1.3,mg/m^,,Oth,"Days 1, 4, 11, 18",IV SubQ,,112,568,1
MMRF_1054,,First line of therapy,,,Lenalidomide,,,Checked,,,15,mg/dL,,QD,,PO,,167,,1
MMRF_1054,,First line of therapy,Induction,,Prednisone,,,,Completed regimen,,30,mg,,QD,,PO,,568,680,1
MMRF_1049,,First line of therapy,,,Bortezomib,,,,Investigator decision for other reasons,,1.3,mg/m^,,QD,,Other,IVP,22,49,1
MMRF_1049,,First line of therapy,,,Cyclophosphamide,,,,Investigator decision for other reasons,,300,mg/m^,,Oth,"Days 1, 8",IVB,,22,49,1
MMRF_1049,,First line of therapy,,,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,QD,,PO,,176,1079,1
MMRF_1049,Baseline,First line of therapy,,,Bortezomib,,,,Investigator decision for other reasons,,1.3,mg/m^,,QD,,IV SubQ,,1,22,1
MMRF_1049,,First line of therapy,,,Bortezomib,,,,Investigator decision for other reasons,,1.3,mg/m^,,Oth,"Days 1, 4, 11, 18",IV SubQ,,49,176,1
MMRF_1049,,First line of therapy,,,Dexamethasone,,,,Investigator decision for other reasons,,40,mg,,Oth,"Days 1, 4, 11, 18",PO,,49,176,1
MMRF_1049,,First line of therapy,,,Dexamethasone,,,,Investigator decision for other reasons,,40,mg,,QD,,PO,,1,22,1
MMRF_1049,,First line of therapy,,,Dexamethasone,,,,Investigator decision for other reasons,,40,mg,,QD,,PO,,22,49,1
MMRF_1049,,First line of therapy,,,Lenalidomide,,,,Investigator decision for other reasons,,15,mg,,QD,,PO,,49,176,1
MMRF_1049,,First line of therapy,,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,176,697,1
MMRF_1049,,First line of therapy,,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,"Days 1, 8",IV,,176,183,1
MMRF_1049,,First line of therapy,Consolidation,,Lenalidomide,,,,Completed regimen,,15,mg,,QD,,PO,,218,1037,1
MMRF_1049,,Second Line Therapy (after,Consolidation,,Panobinostat,,,,Disease progression/Relapse,,20,mg,,Oth,"QD (1,3,5,15,17)",PO,,1084,1240,1
MMRF_1049,,Second Line Therapy (after,Consolidation,,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,Oth,"QD (1, 8, 15)",PO,,1084,1240,1
MMRF_1049,,Second Line Therapy (after,Consolidation,,Lenalidomide,,,,Disease progression/Relapse,,25,mg,,QD,,PO,,1084,1240,1
MMRF_1049,,Third Line Therapy (followi,Consolidation,,Other,MPDL3280A (ANTI&#8722;PD-L1 ANTIBODY),,,Disease progression/Relapse,,1200,mg,,Oth,D1 of 21 day cycle,IV,,1291,1315,1
MMRF_1049,,Fourth Line Therapy (follow,Consolidation,,Daratumumab,,,,Disease progression/Relapse,,16,mg/kg,,Oth,once week,IV,,1406,2113,1
MMRF_1049,,Fourth Line Therapy (follow,Consolidation,,Dexamethasone,,,,Disease progression/Relapse,,20,mg,,Oth,day after daratumumab,PO,,1392,2113,1
MMRF_1049,,Fourth Line Therapy (follow,Consolidation,,Pomalidomide,,,,Disease progression/Relapse,,4,mg,,QD,,PO,,1392,2113,1
MMRF_1049,,Fifth Line Therapy (followi,Unknown,,Dexamethasone,,,,Disease progression/Relapse,,20,mg,,Q w,,PO,,2113,2141,1
MMRF_1049,,Sixth Line Therapy (followi,Unknown,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,QD,,IV,,2144,2149,1
MMRF_1049,,Sixth Line Therapy (followi,Maintenance,,Other,cisplatin,,,Completed regimen,,7.5,mg/m^,,QD,,IV,,2144,2149,1
MMRF_1049,,Sixth Line Therapy (followi,Unknown,,Other,etoposide,,,Completed regimen,,30,mg/m^,,QD,,IV,,2144,2149,1
MMRF_1049,,Sixth Line Therapy (followi,Unknown,,Dexamethasone,,,,Completed regimen,,20,mg,,QD,,PO,,2144,2147,1
MMRF_1049,,Fifth Line Therapy (followi,Unknown,,Ixazomib,,,,Disease progression/Relapse,,4,mg,,Oth,"Day 1.8,15",PO,,2113,2141,1
MMRF_1049,,Fifth Line Therapy (followi,Unknown,,Lenalidomide,,,,Disease progression/Relapse,,15,mg,,QD,,PO,,2113,2141,1
MMRF_1064,Baseline,First line of therapy,,,Lenalidomide,,,Checked,,,25,mg,,QD,,PO,,1,,1
MMRF_1064,,First line of therapy,,,Bortezomib,,,,Investigator decision for other reasons,,1.3,mg/m^,,QD,,IV,,1,92,1
MMRF_1064,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,20,mg,,QD,,PO,,1,80,1
MMRF_1064,,First line of therapy,Maintenance,,Dexamethasone,,,,Completed regimen,,20,mg,,QWK,,PO,,172,762,1
MMRF_1064,,First line of therapy,Maintenance,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,172,762,1
MMRF_1064,,Second Line Therapy (after,Consolidation,,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,Oth,"day 1, 8, 15",PO,,1511,1543,1
MMRF_1064,,Second Line Therapy (after,Consolidation,,Lenalidomide,,,,Disease progression/Relapse,,25,mg,,Q d,,PO,,1511,1543,1
MMRF_1064,,Second Line Therapy (after,Consolidation,,Ixazomib,,,,Disease progression/Relapse,,4,mg,,Oth,"Days 1, 8, 15",PO,,1511,1543,1
MMRF_1064,,Third Line Therapy (followi,Consolidation,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1543,1602,1
MMRF_1064,,Third Line Therapy (followi,Consolidation,,Carfilzomib,,,,Completed regimen,,20,mg/m^,,Oth,days 1 and 2,IV,,1543,1602,1
MMRF_1064,,Third Line Therapy (followi,Consolidation,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"days 8, 9, 15, 16",IV,,1543,1592,1
MMRF_1064,,Third Line Therapy (followi,Consolidation,,Dexamethasone,,,,Completed regimen,,20,mg,,QD,,PO,,1543,1602,1
MMRF_1064,,Third Line Therapy (followi,Consolidation,,Melphalan,,,,Completed regimen,,200,mg/m^,,Oth,once,IV,,1616,1616,1
MMRF_1071,,First line of therapy,,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,"Days 1, 8",IV,,102,137,1
MMRF_1071,Baseline,First line of therapy,,,Lenalidomide,,,,Investigator decision for other reasons,,25,mg,,QD,,PO,,1,7,1
MMRF_1071,,First line of therapy,,,Dexamethasone,,,,Investigator decision for other reasons,,40,mg,,QD,,PO,,1,65,1
MMRF_1071,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,"Days 1, 8, 15",PO,,102,137,1
MMRF_1071,,First line of therapy,,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,Oth,"Days 1, 8, 15",IV SubQ,,102,137,1
MMRF_1071,,First line of therapy,Induction,,Other,MAGE- A3 vaccine,,,Completed regimen,,300,Other,mcg,Oth,given q3wks then 3 month intervals.,Other,IM,158,197,1
MMRF_1071,,First line of therapy,,,Bortezomib,,,,Investigator decision for other reasons,,1.3,mg/m^,,QD,,IV SubQ,,1,65,1
MMRF_1071,,Second Line Therapy (after,Consolidation,,Dexamethasone,,,,Completed regimen,,40,mg,,QWK,,PO,,973,1728,1
MMRF_1071,,Second Line Therapy (after,Consolidation,,Pomalidomide,,,,Completed regimen,,4,mg,,QD,,PO,,973,1757,1
MMRF_1071,,Second Line Therapy (after,Maintenance,,Pomalidomide,,,Checked,,,2,mg,,QD,,PO,,1757,,1
MMRF_1084,Baseline,First line of therapy,,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QWK,,IV SubQ,,1,93,1
MMRF_1084,,First line of therapy,,,Lenalidomide,,,,Completed regimen,,15,mg,,QD,,PO,,1,93,1
MMRF_1084,,First line of therapy,,,Dexamethasone,,,,Investigator decision for other reasons,,20,mg,,QWK,,PO,,1,93,1
MMRF_1084,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,12,mg,,QWK,,PO,,200,313,1
MMRF_1084,,First line of therapy,,,Lenalidomide,,,,Adverse Event or co-morbidity,,15,mg,,QD,,PO,,200,313,1
MMRF_1084,,Second Line Therapy (after,Consolidation,,Carfilzomib,,,,Disease progression/Relapse,,20,mg/m^,,QD,,IV,,631,996,1
MMRF_1084,,Second Line Therapy (after,Consolidation,,Cyclophosphamide,,,,Disease progression/Relapse,,300,mg/m^,,Oth,"D1,D8",IV,,631,996,1
MMRF_1084,,Second Line Therapy (after,Consolidation,,Dexamethasone,,,,Disease progression/Relapse,,10,mg,,QD,,PO,,631,984,1
MMRF_1084,,Third Line Therapy (followi,Consolidation,,Pomalidomide,,,,Disease progression/Relapse,,2,mg,,Oth,QD  (D1-28),PO,,996,1142,1
MMRF_1084,,Third Line Therapy (followi,Consolidation,,Dexamethasone,,,,Disease progression/Relapse,,10,mg,,QWK,,PO,,996,1142,1
MMRF_1084,,Third Line Therapy (followi,Consolidation,,Bortezomib,,,,Disease progression/Relapse,,1.3,mg/m^,,QWK,,IV SubQ,,1102,1142,1
MMRF_1084,,Fourth Line Therapy (follow,Consolidation,,Doxorubicin,,,,Disease progression/Relapse,,20,mg/m^,,QD,,IV,,1166,1338,1
MMRF_1084,,Fourth Line Therapy (follow,Consolidation,,Cyclophosphamide,,,,Disease progression/Relapse,,400,mg/m^,,QD,,IV,,1166,1338,1
MMRF_1084,,Fifth Line Therapy (followi,Consolidation,,Daratumumab,,,,Disease progression/Relapse,,16,mg/kg,,Q w,,IV,,1363,1648,1
MMRF_1084,,Fifth Line Therapy (followi,Consolidation,,Dexamethasone,,,,Disease progression/Relapse,,20,mg,,Oth,twice weekly,PO,,1363,1648,1
MMRF_1084,,Fourth Line Therapy (follow,Consolidation,,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,Q d,,PO,,1166,1338,1
MMRF_1084,,Fourth Line Therapy (follow,Consolidation,,Other,Cisplatin,,,Disease progression/Relapse,,15,mg/m^,,QD,,IV,,1166,1338,1
MMRF_1084,,Fourth Line Therapy (follow,Consolidation,,Other,Etoposide,,,Disease progression/Relapse,,40,mg/m^,,QD,,IV,,1166,1338,1
MMRF_1100,Baseline,First line of therapy,,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,Oth,"D1,4,11,18",IV,,1,128,1
MMRF_1100,,First line of therapy,,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,D1-28,PO,,1,128,1
MMRF_1100,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"D1,4,11,18",PO,,1,128,1
MMRF_1100,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,20,mg,,Q w,,PO,,128,155,1
MMRF_1100,,First line of therapy,,,Bortezomib,,,,Completed regimen,,2.5,mg,,Oth,day 1 and day 4,IV,,128,155,1
MMRF_1100,,First line of therapy,,,Cyclophosphamide,,,,Completed regimen,,580,mg,,Oth,day 1 and day 4,IV,,128,155,1
MMRF_1100,,First line of therapy,Consolidation,,Lenalidomide,,,,Lack of response,,25,mg,,QD,,PO,,190,974,1
MMRF_1100,,First line of therapy,Consolidation,,Dexamethasone,,,,Lack of response,,20,mg,,Oth,"D1,4,11,18",PO,,190,974,1
MMRF_1100,,First line of therapy,Consolidation,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,Oth,"D1,4,11,18",IV,,190,606,1
MMRF_1100,,Second Line Therapy (after,Consolidation,,Bortezomib,,,,Lack of response,,1.3,mg/m^,,Q w,,IV SubQ,,859,947,1
MMRF_1100,,Second Line Therapy (after,Consolidation,,Melphalan,,,,Completed regimen,,160,mg/m^,,Oth,once,IV,,975,975,1
MMRF_1100,,Third Line Therapy (followi,Consolidation,,Daratumumab,,,Checked,,,16,mg/kg,,Oth,once wkly,IV,,1187,,1
MMRF_1100,,Third Line Therapy (followi,Consolidation,,Pomalidomide,,,,Adverse Event or co-morbidity,,4,mg,,QD,,PO,,1384,1800,1
MMRF_1101,,First line of therapy,,,Cyclophosphamide,,,,Investigator decision for other reasons,,250,mg/m^,,BID,,PO,,1,29,1
MMRF_1101,,First line of therapy,,,Dexamethasone,,,,Adverse Event or co-morbidity,,20,mg,,Oth,"Days 1, 8, 15",PO,,1,422,1
MMRF_1101,,First line of therapy,,,Lenalidomide,,,,Other,PET CT negative,15,mg,,QD,,PO,,50,534,1
MMRF_1101,Baseline,First line of therapy,,,Bortezomib,,,,Investigator decision for other reasons,,1.3,mg/m^,,Oth,"Days 1, 8, 15",IV SubQ,,1,99,1
MMRF_1101,,First line of therapy,Maintenance,,Lenalidomide,,,,Other,CR,10,mg,,QD,,PO,,534,924,1
MMRF_1111,,First line of therapy,,,Cyclophosphamide,,,,Investigator decision for other reasons,,300,mg/m^,,Oth,"Days 1, 5, 8, 12",IV,,1,26,1
MMRF_1111,,First line of therapy,,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,Oth,"Days 1, 4, 8, 15",IV SubQ,,26,285,1
MMRF_1111,,First line of therapy,,,Lenalidomide,,,,Investigator decision for other reasons,,25,mg,,QD,,PO,,26,340,1
MMRF_1111,Baseline,First line of therapy,,,Bortezomib,,,,Investigator decision for other reasons,,1.3,mg/m^,,Oth,"Days 1, 5, 8, 12",IV SubQ,,1,26,1
MMRF_1111,,First line of therapy,,,Lenalidomide,,,,Completed regimen,,15,mg,,QD,,PO,,340,2062,1
MMRF_1111,,First line of therapy,,,Dexamethasone,,,,Investigator decision for other reasons,,40,mg,,Oth,"Days 1, 5, 8, 12",PO,,1,26,1
MMRF_1111,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,"Days 1, 4, 8, 15",PO,,26,448,1
MMRF_1111,,First line of therapy,Consolidation,,Cyclophosphamide,,,,Investigator decision for other reasons,,300,mg/m^,,Oth,"Days 1, 5, 8, 12",IV,,109,124,1
MMRF_1127,,First line of therapy,,,Dexamethasone,,,,Investigator decision for other reasons,,40,mg,,Oth,"Days 1, 8, 15",PO,,2,82,1
MMRF_1127,,First line of therapy,,,Lenalidomide,,,,Investigator decision for other reasons,,25,mg,,QD,,PO,,1,82,1
MMRF_1127,Baseline,First line of therapy,,,Bortezomib,,,,Investigator decision for other reasons,,1.3,mg/m^,,Oth,"Days 1, 8, 15",IV,,1,82,1
MMRF_1127,,First line of therapy,Consolidation,,Melphalan,,,,Completed regimen,,200,mg/m^,,Oth,once,IV,,264,264,1
MMRF_1127,,Second Line Therapy (after,Unknown,,Bortezomib,,,Checked,,,1.3,mg/m^,,Q w,,IV SubQ,,2018,,1
MMRF_1127,,Second Line Therapy (after,Unknown,,Dexamethasone,,,Checked,,,12,mg,,Q w,,IV,,2018,,1
MMRF_1127,,Second Line Therapy (after,Unknown,,Lenalidomide,,,Checked,,,10,mg/dL,,QD,,PO,,2018,,1
MMRF_1151,,First line of therapy,,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,37,1
MMRF_1151,,First line of therapy,,,Dexamethasone,,,,Other,death,40,mg,,QWK,,IV,,71,250,1
MMRF_1151,,First line of therapy,,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,"Days 1, 8",IV,,1,37,1
MMRF_1151,,First line of therapy,,,Bortezomib,,,,Other,Death,1.3,Other,mg/msq,QWK,,IV SubQ,,70,250,1
MMRF_1151,Baseline,First line of therapy,,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,PO,,1,37,1
MMRF_1156,Baseline,First line of therapy,,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,84,1
MMRF_1156,,First line of therapy,,,Dexamethasone,,,,Other,Induction,40,mg,,QD,,PO,,1,204,1
MMRF_1156,,First line of therapy,Induction,,Other,Etoposide,,,Other,induction,30,mg/m^,,QD,,IV,,143,204,1
MMRF_1156,,Second Line Therapy (after,Consolidation,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,315,1358,1
MMRF_1156,,First line of therapy,Induction,,Other,Cisplatin,,,Other,induction,15,mg/m^,,QD,,IV,,143,204,1
MMRF_1156,,Second Line Therapy (after,Consolidation,,Dexamethasone,,,,Completed regimen,,40,mg,,QWK,,PO,,315,1368,1
MMRF_1156,,First line of therapy,,,Bortezomib,,,,Other,Induction,1.3,mg/m^,,QD,,IV SubQ,,1,204,1
MMRF_1156,,First line of therapy,Induction,,Cyclophosphamide,,,,Other,Induction,300,mg,,Oth,"Days 1 , 8,  15",PO,,87,204,1
MMRF_1156,,First line of therapy,Consolidation,,Melphalan,,,,Lack of response,,200,mg/m^,,Oth,once,IV,,211,211,1
MMRF_1156,,Third Line Therapy (followi,Consolidation,,Other,atezolizumab,,,Disease progression/Relapse,,1200,mg,,QWK,,IV,,1746,1893,1
MMRF_1156,,Third Line Therapy (followi,Consolidation,,Lenalidomide,,,,Adverse Event or co-morbidity,,25,mg,,QD,,PO,,1746,1863,1
MMRF_1156,,Fourth Line Therapy (follow,Unknown,,Pomalidomide,,,Checked,,,3,mg,,QD,,PO,,1982,,1
MMRF_1156,,Fourth Line Therapy (follow,Unknown,,Daratumumab,,,Checked,,,20,Other,mg/ML,Oth,every other week,IV,,1955,,1
MMRF_1157,,First line of therapy,,,Bortezomib,,,,Other,SCH,1.3,mg,,QD,,IV SubQ,,1,156,1
MMRF_1157,Baseline,First line of therapy,,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,PO,,1,240,1
MMRF_1157,,First line of therapy,,,Cyclophosphamide,,,,Other,further therapy,300,mg/m^,,Oth,"Days 1, 8",IV,,1,43,1
MMRF_1157,,First line of therapy,Induction,,Lenalidomide,,,,Other,increased dose,15,mg,,QD,,PO,,43,71,1
MMRF_1157,,First line of therapy,Induction,,Lenalidomide,,,,Other,induction,25,mg,,QD,,PO,,71,222,1
MMRF_1157,,First line of therapy,Maintenance,,Lenalidomide,,,,Disease progression/Relapse,,10,mg,,QD,,PO,,326,442,1
MMRF_1157,,First line of therapy,Induction,,Lenalidomide,,,,Disease progression/Relapse,,25,mg,,QD,,PO,,415,556,1
MMRF_1157,,First line of therapy,Consolidation,,Dexamethasone,,,,Disease progression/Relapse,,20,mg,,QD,,PO,,415,527,1
MMRF_1157,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,140,mg/m^,,Oth,Once,IV,,240,240,1
MMRF_1157,,Second Line Therapy (after,Consolidation,,Carfilzomib,,,,Disease progression/Relapse,,56,mg/m^,,QD,,IV,,682,921,1
MMRF_1157,,Second Line Therapy (after,Consolidation,,Other,Ibrutinib,,,Disease progression/Relapse,,140,mg,,Q d,,PO,,598,682,1
MMRF_1157,,Second Line Therapy (after,Consolidation,,Carfilzomib,,,,Disease progression/Relapse,,33,mg,,QD,,IV,,591,682,1
MMRF_1157,,Second Line Therapy (after,Consolidation,,Dexamethasone,,,,Disease progression/Relapse,,8,mg,,QD,,PO,,682,921,1
MMRF_1157,,Third Line Therapy (followi,Consolidation,,Pomalidomide,,,,Adverse Event or co-morbidity,,4,mg,,QD,,PO,,960,969,1
MMRF_1157,,Third Line Therapy (followi,Consolidation,,Daratumumab,,,,Disease progression/Relapse,,16,mg/kg,,Oth,"D1, 18,15, 22",IV,,960,1578,1
MMRF_1157,,Third Line Therapy (followi,Consolidation,,Pomalidomide,,,,Disease progression/Relapse,,3,mg,,QD,,PO,,990,1578,1
MMRF_1157,,Fourth Line Therapy (follow,Consolidation,,Dexamethasone,,,,Disease progression/Relapse,,20,mg,,Oth,"d1,3,8,10,15,17,22,24",PO,,1626,1836,1
MMRF_1157,,Fourth Line Therapy (follow,Consolidation,,Other,selinexor,,,Disease progression/Relapse,,80,mg,,Oth,"days 1, 3, 8, 10, 15, 17, 22 and 24",PO,,1626,1836,1
MMRF_1157,,Sixth Line Therapy (followi,Unknown,,Daratumumab,,,,Disease progression/Relapse,,16,mg/kg,,Oth,once weekly,IV,,1944,2097,1
MMRF_1157,,Sixth Line Therapy (followi,Unknown,,Dexamethasone,,,Checked,,,20,mg,,Oth,once weekly,IV,,1944,,1
MMRF_1157,,Sixth Line Therapy (followi,Unknown,,Carfilzomib,,,,Disease progression/Relapse,,27,mg/m^,,Oth,once weekly,IV,,1944,2097,1
MMRF_1157,,Seventh Line of Therapy (fo,Unknown,,Other,GPCR5D,,Checked,,,1.5,Other,ug/kg,Oth,Day 1 and Day 15 on 28 day cycle,IV,,2130,,1
MMRF_1157,,Fifth Line Therapy (followi,Unknown,,Other,tas4464,,,Disease progression/Relapse,,40,mg/m^,,Oth,twice weekly,IV,,1870,1927,1
MMRF_1179,,First line of therapy,,,Dexamethasone,,,,Disease progression/Relapse,,20,mg,,Q w,,PO,,1,1024,1
MMRF_1179,,First line of therapy,Consolidation,,Cyclophosphamide,,,,Investigator decision for other reasons,,400,mg,,Oth,"QWK (Day 1, 8, 15)",PO,,687,715,1
MMRF_1179,Baseline,First line of therapy,,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,Q w,,IV SubQ,,1,269,1
MMRF_1179,,First line of therapy,,,Lenalidomide,,,,Disease progression/Relapse,,10,mg,,QD,,PO,,1,715,1
MMRF_1179,,Second Line Therapy (after,Consolidation,,Carfilzomib,,,,Disease progression/Relapse,,27,mg/m^,,QD,,IV,,715,799,1
MMRF_1179,,Second Line Therapy (after,Consolidation,,Carfilzomib,,,,Disease progression/Relapse,,36,mg/m^,,Oth,"QD (1-2, 8-9)",IV,,799,1024,1
MMRF_1179,,Second Line Therapy (after,Consolidation,,Thalidomide,,,,Completed regimen,,50,mg,,QD,,PO,,843,1024,1
MMRF_1179,,Third Line Therapy (followi,Consolidation,,Daratumumab,,,,Disease progression/Relapse,,16,mg/kg,,Q w,,IV,,1087,1709,1
MMRF_1179,,Fourth Line Therapy (follow,Consolidation,,Pomalidomide,,,,Disease progression/Relapse,,2,mg,,QD,,PO,,1356,1693,1
MMRF_1179,,Fifth Line Therapy (followi,Unknown,,Other,venetoclax,,Checked,,,100,mg,,Q d,,PO,,1732,,1
MMRF_1179,,Fifth Line Therapy (followi,Unknown,,Ixazomib,,,Checked,,,3,mg,,Q w,,PO,,1767,,1
MMRF_1212,,First line of therapy,,,Dexamethasone,,,,Investigator decision for other reasons,,20,mg,,Oth,QD (1-28),PO,,1,176,1
MMRF_1212,Baseline,First line of therapy,,,Bortezomib,,,,Investigator decision for other reasons,,1.3,mg/m^,,QD,,IV SubQ,,1,233,1
MMRF_1212,,First line of therapy,,,Cyclophosphamide,,,,Investigator decision for other reasons,,300,mg/m^,,Oth,"D1,D8",IV,,1,148,1
MMRF_1212,,First line of therapy,Consolidation,,Cyclophosphamide,,,,Other,lost to follow up,50,mg,,BID,,PO,,148,947,1
MMRF_1212,,First line of therapy,Consolidation,,Prednisone,,,Checked,,,50,mg,,Oth,3 x week,PO,,176,,1
MMRF_1212,,First line of therapy,Consolidation,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,Oth,Every other week,IV SubQ,,233,657,1
MMRF_1212,,First line of therapy,,,Lenalidomide,,,,Adverse Event or co-morbidity,,15,mg,,QD,,PO,,120,127,1
MMRF_1212,,First line of therapy,,,Thalidomide,,,Checked,,,50,mg,,QD,,PO,,176,,1
MMRF_1223,,First line of therapy,,,Dexamethasone,,,,Adverse Event or co-morbidity,,4,mg,,QD,,PO,,1,508,1
MMRF_1223,,First line of therapy,,,Thalidomide,,,,Other,further therapy,200,mg,,Q d,,PO,,7,95,1
MMRF_1223,Baseline,First line of therapy,,,Bortezomib,,,,Adverse Event or co-morbidity,,1.3,mg/m^,,QD,,IV,,7,254,1
MMRF_1223,,First line of therapy,,,Cyclophosphamide,,,,Other,further therapy,300,mg/m^,,Oth,"Days 1, 8",IV SubQ,,7,95,1
MMRF_1223,,First line of therapy,Consolidation,,Lenalidomide,,,,Completed regimen,,15,mg,,QD,,PO,,95,606,1
MMRF_1223,,Second Line Therapy (after,Consolidation,,Melphalan,,,,Completed regimen,,200,mg/m^,,Oth,One time only,IV,,606,606,1
MMRF_1223,,Second Line Therapy (after,Consolidation,,Carfilzomib,,,,Lack of response,,27,mg/m^,,QD,,IV,,742,839,1
MMRF_1223,,Third Line Therapy (followi,Consolidation,,Daratumumab,,,,Disease progression/Relapse,,16,mg/kg,,QWK,,IV,,942,1453,1
MMRF_1223,,Third Line Therapy (followi,Consolidation,,Dexamethasone,,,,Disease progression/Relapse,,20,mg,,Oth,"Days 1, 2, 4, 5, 8, 9, 15",IV,,942,1453,1
MMRF_1223,,Fourth Line Therapy (follow,Consolidation,,Dexamethasone,,,Checked,,,8,mg,,Q w,,PO,,1481,,1
MMRF_1223,,Fourth Line Therapy (follow,Consolidation,,Daratumumab,,,Checked,,,16,Other,mg/kg,Oth,twice monthly,IV,,1509,,1
MMRF_1223,,Fourth Line Therapy (follow,Consolidation,,Pomalidomide,,,Checked,,,4,mg,,QD,,PO,,1476,,1
MMRF_1223,,Fourth Line Therapy (follow,Consolidation,,Carfilzomib,,,Checked,,,27,mg/m^,,QD,,IV,,1593,,1
MMRF_1224,,First line of therapy,,,Cyclophosphamide,,,,Other,SCH,300,mg/m^,,Oth,"Days 1, 8, 15",PO,,1,203,1
MMRF_1224,Baseline,First line of therapy,,,Bortezomib,,,,Other,SCH,1.3,mg/m^,,QD,,IV SubQ,,1,203,1
MMRF_1224,,First line of therapy,,,Dexamethasone,,,,Other,SCH,20,mg,,QD,,PO,,1,203,1
MMRF_1224,,First line of therapy,Consolidation,,Lenalidomide,,,,Completed regimen,,15,mg,,QD,,PO,,226,1040,1
MMRF_1224,,First line of therapy,Consolidation,,Dexamethasone,,,,Completed regimen,,20,mg,,Q w,,PO,,226,1040,1
MMRF_1224,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,200,mg/m^,,Oth,once,IV,,1057,1057,1
MMRF_1224,,Second Line Therapy (after,Consolidation,,Elotuzumab,,,,Disease progression/Relapse,,10,mg/m^,,Q w,,IV,,1178,1492,1
MMRF_1224,,Second Line Therapy (after,Consolidation,,Lenalidomide,,,,Disease progression/Relapse,,25,mg,,QD,,PO,,1178,1492,1
MMRF_1224,,Second Line Therapy (after,Consolidation,,Dexamethasone,,,,Disease progression/Relapse,,20,mg,,Q w,,PO,,1178,1492,1
MMRF_1224,,Third Line Therapy (followi,Consolidation,,Pomalidomide,,,Checked,,,4,mg,,QD,,PO,,1550,,1
MMRF_1224,,Third Line Therapy (followi,Consolidation,,Dexamethasone,,,Checked,,,40,mg,,Q w,,PO,,1525,,1
MMRF_1224,,Third Line Therapy (followi,Consolidation,,Cyclophosphamide,,,,Investigator decision for other reasons,,50,mg,,BID,,PO,,1525,1893,1
MMRF_1231,,First line of therapy,,,Dexamethasone,,,,Other,death,20,mg,,QD,,PO,,1,85,1
MMRF_1231,Baseline,First line of therapy,,,Cyclophosphamide,,,,Other,death,300,mg/m^,,QD,,IV,,8,85,1
MMRF_1231,,First line of therapy,,,Bortezomib,,,,Other,death,1.3,mg/m^,,QD,,IV SubQ,,1,85,1
MMRF_1232,Baseline,First line of therapy,,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,86,1
MMRF_1232,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,PO,,1,86,1
MMRF_1232,,First line of therapy,Induction,,Other,recMAGE vaccine,,,Completed regimen,,300,Other,mcg,Oth,"21, 10, 31,52,73, 94, 180, 194, 270, 284, 360, 374 days post transplant",Other,IM,109,417,1
MMRF_1232,,First line of therapy,Maintenance,,Lenalidomide,,,,Investigator decision for other reasons,,10,mg,,QD,,PO,,522,560,1
MMRF_1232,,First line of therapy,Unknown,,Dexamethasone,,,,Investigator decision for other reasons,,40,mg,,QD,,PO,,560,707,1
MMRF_1232,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,QD,,IV,,33,101,1
MMRF_1232,,First line of therapy,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,25,mg,,QD,,PO,,560,655,1
MMRF_1232,,Second Line Therapy (after,Induction,,Lenalidomide,,,,Investigator decision for other reasons,,15,mg,,QD,,PO,,655,707,1
MMRF_1232,,Fourth Line Therapy (follow,Consolidation,,Dexamethasone,,,,Disease progression/Relapse,,20,mg,,QD,,PO,,852,951,1
MMRF_1232,,Fourth Line Therapy (follow,Consolidation,,Pomalidomide,,,,Disease progression/Relapse,,3,mg,,QD,,PO,,847,951,1
MMRF_1232,,Third Line Therapy (followi,Consolidation,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,783,847,1
MMRF_1232,,Third Line Therapy (followi,Consolidation,,Dexamethasone,,,,Completed regimen,,40,mg,,Q d,,PO,,783,847,1
MMRF_1232,,Third Line Therapy (followi,Consolidation,,Other,Cisplatin,,,Completed regimen,,17,mg,,QD,,IV,,783,847,1
MMRF_1232,,Third Line Therapy (followi,Consolidation,,Cyclophosphamide,,,,Completed regimen,,336,mg,,QD,,IV,,783,847,1
MMRF_1232,,Third Line Therapy (followi,Consolidation,,Other,Etoposide,,,Completed regimen,,34,mg,,QD,,IV,,783,847,1
MMRF_1232,,Fourth Line Therapy (follow,Consolidation,,Carfilzomib,,,,Disease progression/Relapse,,20,mg/m^,,QD,,IV,,852,951,1
MMRF_1244,Baseline,First line of therapy,,,Bortezomib,,,,Other,unknown,1.3,mg/m^,,QD,,IV SubQ,,1,158,1
MMRF_1244,,First line of therapy,,,Dexamethasone,,,,Other,unknown,40,mg,,QD,,PO,,1,158,1
MMRF_1244,,First line of therapy,,,Cyclophosphamide,,,,Other,unknown,300,mg/m^,,Oth,"Days 1, 8",IV SubQ,,1,158,1
MMRF_1252,Baseline,First line of therapy,,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,45,1
MMRF_1252,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,PO,,1,45,1
MMRF_1252,,First line of therapy,,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,"Days 1, 8",IV,,1,45,1
MMRF_1252,,First line of therapy,,,Dexamethasone,,,,Disease progression/Relapse,,20,mg,,QD,,PO,,45,333,1
MMRF_1252,,First line of therapy,,,Bortezomib,,,,Disease progression/Relapse,,1.3,mg/m^,,QD,,IV SubQ,,45,333,1
MMRF_1252,,First line of therapy,,,Lenalidomide,,,,Disease progression/Relapse,,25,mg,,QD,,PO,,45,333,1
MMRF_1252,,Second Line Therapy (after,Consolidation,,Pomalidomide,,,,Disease progression/Relapse,,4,mg,,QD,,PO,,338,366,1
MMRF_1252,,Second Line Therapy (after,Consolidation,,Dexamethasone,,,,Disease progression/Relapse,,20,mg,,QWK,,PO,,338,366,1
MMRF_1266,,First line of therapy,,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,Oth,"QD (D1, D4, D11, D18)",IV SubQ,,1,1314,1
MMRF_1266,Baseline,First line of therapy,,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,1632,1
MMRF_1266,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"QD (D1, D4, D11, D18)",PO,,1,408,1
MMRF_1266,,First line of therapy,Maintenance,,Ixazomib,,,,Completed regimen,,4,mg,,Q w,,PO,,1314,1437,1
MMRF_1267,Baseline,First line of therapy,,,Bortezomib,,,,Disease progression/Relapse,,1.3,mg/m^,,QD,,IV SubQ,,1,183,1
MMRF_1267,,First line of therapy,,,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,QD,,PO,,1,183,1
MMRF_1267,,First line of therapy,,,Lenalidomide,,,,Disease progression/Relapse,,25,mg,,QD,,PO,,2,183,1
MMRF_1267,,Second Line Therapy (after,Consolidation,,Lenalidomide,,,,Disease progression/Relapse,,4,mg,,QD,,PO,,191,224,1
MMRF_1267,,Second Line Therapy (after,Consolidation,,Carfilzomib,,,,Disease progression/Relapse,,20,mg/m^,,QD,,IV,,191,224,1
MMRF_1267,,Second Line Therapy (after,Consolidation,,Melphalan,,,,Completed regimen,,540,mg,,Oth,once,IV,,234,234,1
MMRF_1267,,Second Line Therapy (after,Consolidation,,Melphalan,,,,Completed regimen,,272,mg,,Oth,once,IV,,368,368,1
MMRF_1267,,Second Line Therapy (after,Consolidation,,Dexamethasone,,,,Disease progression/Relapse,,20,mg,,QD,,PO,,191,224,1
MMRF_1267,,Second Line Therapy (after,Maintenance,,Bortezomib,,,,Disease progression/Relapse,,1.3,mg/m^,,QD,,IV,,472,665,1
MMRF_1267,,Second Line Therapy (after,Consolidation,,Lenalidomide,,,,Completed regimen,,15,mg,,QD,,PO,,472,563,1
MMRF_1267,,Second Line Therapy (after,Maintenance,,Dexamethasone,,,,Disease progression/Relapse,,20,mg,,QD,,PO,,472,1066,1
MMRF_1267,,Fifth Line Therapy (followi,Consolidation,,Other,Nivolumab,,,Disease progression/Relapse,,6,mg/kg,,Q w,,IV,,1010,1016,1
MMRF_1267,,Sixth Line Therapy (followi,Consolidation,,Daratumumab,,,,Disease progression/Relapse,,16,mg/kg,,Oth,"D1, D8, D15, D22",IV,,1036,1066,1
MMRF_1267,,Fourth Line Therapy (follow,Consolidation,,BCNU,,,,Disease progression/Relapse,,300,mg/m^,,Oth,once,IV,,945,963,1
MMRF_1267,,Fourth Line Therapy (follow,Consolidation,,Melphalan,,,,Completed regimen,,100,mg/m^,,Oth,once,IV,,960,960,1
MMRF_1267,,Seventh Line of Therapy (fo,Consolidation,,Bortezomib,,,,Disease progression/Relapse,,1,mg/m^,,Oth,"D1,4,7,10,13,16,19,22,25,28",IV,,1066,1094,1
MMRF_1267,,Seventh Line of Therapy (fo,Consolidation,,Thalidomide,,,,Disease progression/Relapse,,100,mg,,Q d,,PO,,1066,1094,1
MMRF_1267,,Seventh Line of Therapy (fo,Consolidation,,Dexamethasone,,,,Disease progression/Relapse,,12,mg,,Oth,"D1-4, 7-10, 13-16, 19-22, 25-28",PO,,1066,1094,1
MMRF_1267,,Seventh Line of Therapy (fo,Consolidation,,Doxorubicin,,,,Disease progression/Relapse,,1,mg/m^,,Q d,,IV,,1066,1094,1
MMRF_1267,,Seventh Line of Therapy (fo,Consolidation,,Other,Cisplatin,,,Disease progression/Relapse,,1,mg/m^,,Q d,,IV,,1066,1094,1
MMRF_1267,,Seventh Line of Therapy (fo,Consolidation,,Bortezomib,,,,Disease progression/Relapse,,0.07,mg,,Q d,,IV,,1066,1094,1
MMRF_1267,,Fifth Line Therapy (followi,Consolidation,,Pomalidomide,,,,Disease progression/Relapse,,2,mg,,QD,,PO,,985,1016,1
MMRF_1267,,Third Line Therapy (followi,Consolidation,,Bendamustine,,,,Completed regimen,,90,mg/m^,,Oth,once,IV,,901,901,1
MMRF_1267,,Third Line Therapy (followi,Consolidation,,Pomalidomide,,,,Disease progression/Relapse,,2,mg,,QD,,PO,,901,924,1
MMRF_1267,,Third Line Therapy (followi,Consolidation,,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,Q d,,PO,,901,945,1
MMRF_1275,Baseline,First line of therapy,,,Bortezomib,,,,Lack of response,,1.3,mg/m^,,QD,,IV SubQ,,1,11,1
MMRF_1275,,First line of therapy,,,Dexamethasone,,,,Lack of response,,40,mg,,QD,,PO,,1,11,1
MMRF_1275,,First line of therapy,,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,19,380,1
MMRF_1275,,First line of therapy,,,Cyclophosphamide,,,,Lack of response,,300,mg/m^,,Oth,"Days 1, 8",IV,,1,8,1
MMRF_1275,,First line of therapy,,,Carfilzomib,,,,Completed regimen,,20,mg/m^,,QD,,IV,,19,391,1
MMRF_1275,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,8,mg,,QD,,PO,,19,380,1
MMRF_1275,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,200,mg/m^,,Oth,once,IV,,401,401,1
MMRF_1275,,Third Line Therapy (followi,Consolidation,,Bortezomib,,,,Disease progression/Relapse,,1.3,mg/m^,,QD,,IV,,663,695,1
MMRF_1275,,Second Line Therapy (after,Consolidation,,Carfilzomib,,,,Disease progression/Relapse,,56,mg/m^,,QD,,IV,,638,663,1
MMRF_1275,,Fourth Line Therapy (follow,Consolidation,,Other,Cisplatin,,,Completed regimen,,67,mg,,QD,,IV,,663,666,1
MMRF_1275,,Third Line Therapy (followi,Consolidation,,Bortezomib,,,,Disease progression/Relapse,,1.3,mg/m^,,QD,,IV SubQ,,695,733,1
MMRF_1275,,Second Line Therapy (after,Consolidation,,Bortezomib,,,,Disease progression/Relapse,,3,mg,,Q w,,IV SubQ,,557,620,1
MMRF_1275,,Third Line Therapy (followi,Consolidation,,Cyclophosphamide,,,,Completed regimen,,2688,mg,,QD,,IV,,663,667,1
MMRF_1275,,Third Line Therapy (followi,Consolidation,,Doxorubicin,,,,Completed regimen,,30,mg/m^,,Oth,Once,IV,,663,663,1
MMRF_1275,,Third Line Therapy (followi,Induction,,Bendamustine,,,,Disease progression/Relapse,,90,mg/m^,,QD,,IV,,695,733,1
MMRF_1275,,Second Line Therapy (after,Consolidation,,Pomalidomide,,,,Disease progression/Relapse,,4,mg,,QD,,PO,,557,663,1
MMRF_1275,,Second Line Therapy (after,Consolidation,,Dexamethasone,,,,Disease progression/Relapse,,20,mg,,QWK,,PO,,610,663,1
MMRF_1275,,Third Line Therapy (followi,Consolidation,,Other,Etoposide,,,Completed regimen,,270,mg,,QD,,IV,,663,667,1
MMRF_1275,,Second Line Therapy (after,Consolidation,,Dexamethasone,,,,Disease progression/Relapse,,20,mg,,QWK,,PO,,557,610,1
MMRF_1275,,Third Line Therapy (followi,Consolidation,,Melphalan,,,,Disease progression/Relapse,,200,mg/m^,,Oth,once,IV,,792,848,1
MMRF_1280,Baseline,First line of therapy,,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,351,1
MMRF_1280,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,4,mg,,QD,,PO,,1,351,1
MMRF_1280,,First line of therapy,,,Cyclophosphamide,,,,Investigator decision for other reasons,,580,mg/dL,,QD,,IV,,4,37,1
MMRF_1280,,First line of therapy,,,Lenalidomide,,,,Completed regimen,,15,mg,,QD,,PO,,37,351,1
MMRF_1280,,First line of therapy,Consolidation,,Prednisone,,,,Completed regimen,,60,mg,,Q d,,PO,,401,429,1
MMRF_1280,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,200,mg/m^,,Oth,once,IV,,350,350,1
MMRF_1280,,First line of therapy,Maintenance,,Bortezomib,,,,Adverse Event or co-morbidity,,1.3,mg/m^,,Q w,,IV,,589,645,1
MMRF_1280,,Second Line Therapy (after,Consolidation,,Cyclophosphamide,,,,Lack of response,,300,mg/m^,,Oth,3 of 4 weeks,IV,,997,1193,1
MMRF_1280,,Second Line Therapy (after,Consolidation,,Dexamethasone,,,,Lack of response,,20,mg,,Oth,3 of 4 weeks,PO,,997,1193,1
MMRF_1280,,Second Line Therapy (after,Consolidation,,Bortezomib,,,,Lack of response,,1.3,mg/m^,,Q w,,IV SubQ,,1024,1193,1
MMRF_1280,,Third Line Therapy (followi,Induction,,Daratumumab,,,,Completed regimen,,16,mg/kg,,QWK,,IV,,1235,1900,1
MMRF_1280,,Second Line Therapy (after,Consolidation,,Thalidomide,,,,Patient decision,,50,mg,,Q d,,PO,,1130,1130,1
MMRF_1280,,Fourth Line Therapy (follow,Consolidation,,Bortezomib,,,Checked,,,1.3,mg/m^,,Oth,every 2 weeks,IV SubQ,,1522,,1
MMRF_1308,Baseline,First line of therapy,,,Bortezomib,,,,Disease progression/Relapse,,1.3,mg/m^,,QD,,IV SubQ,,1,232,1
MMRF_1308,,First line of therapy,,,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,QD,,PO,,1,232,1
MMRF_1308,,First line of therapy,,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,"Days 1, 8, 15",IV,,1,138,1
MMRF_1308,,First line of therapy,Consolidation,,Lenalidomide,,,,Investigator decision for other reasons,,25,mg,,QD,,PO,,26,102,1
MMRF_1308,,Second Line Therapy (after,Consolidation,,Pomalidomide,,,,Disease progression/Relapse,,4,mg,,QD,,PO,,283,563,1
MMRF_1308,,Second Line Therapy (after,Consolidation,,Cyclophosphamide,,,,Disease progression/Relapse,,50,mg,,QD,,PO,,354,563,1
MMRF_1308,,Second Line Therapy (after,Consolidation,,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,Oth,"D1, D8, D15",PO,,283,563,1
MMRF_1308,,Third Line Therapy (followi,Consolidation,,Lenalidomide,,,Checked,,,25,mg,,QD,,PO,,563,,1
MMRF_1308,,Third Line Therapy (followi,Consolidation,,Dexamethasone,,,Checked,,,40,mg,,Q w,,PO,,563,,1
MMRF_1308,,Third Line Therapy (followi,Consolidation,,Panobinostat,,,,Disease progression/Relapse,,20,mg,,QWK,,PO,,563,1670,1
MMRF_1307,Baseline,First line of therapy,,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,1142,1
MMRF_1307,,First line of therapy,,,Lenalidomide,,,Checked,,,10,mg,,QD,,PO,,11,,1
MMRF_1307,,First line of therapy,,,Dexamethasone,,,Checked,,,40,mg,,Oth,"D1,8,15,22",PO,,11,,1
MMRF_1307,,First line of therapy,Induction,,Ixazomib,,,Checked,,,4,mg,,Oth,every other week,PO,,1142,,1
MMRF_1314,,First line of therapy,,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,"D1, D8",IV,,1,15,1
MMRF_1314,Baseline,First line of therapy,,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,PO,,1,1428,1
MMRF_1314,,First line of therapy,,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,1428,1
MMRF_1314,,First line of therapy,,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,15,1428,1
MMRF_1311,,First line of therapy,,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,252,1
MMRF_1311,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,20,mg,,QD,,PO,,1,242,1
MMRF_1311,Baseline,First line of therapy,,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,242,1
MMRF_1311,,First line of therapy,Other,conditioning,Melphalan,,,,Completed regimen,,450,mg,,Q d,,IV,,281,281,1
MMRF_1311,,First line of therapy,Other,conditioning,Melphalan,,,,Completed regimen,,446,mg,,Q d,,IV,,443,443,1
MMRF_1311,,First line of therapy,Other,conditioning,Bortezomib,,,,Completed regimen,,3.6,mg,,Q d,,IV SubQ,,441,441,1
MMRF_1324,,First line of therapy,,,Lenalidomide,,,,Adverse Event or co-morbidity,,15,mg,,QD,,PO,,4,424,1
MMRF_1324,,First line of therapy,,,Cyclophosphamide,,,,Other,Induction,300,mg/m^,,Oth,once,PO,,1,3,1
MMRF_1324,Baseline,First line of therapy,,,Bortezomib,,,,Disease progression/Relapse,,1.3,mg/m^,,QD,,IV SubQ,,1,607,1
MMRF_1324,,First line of therapy,,,Cyclophosphamide,,,,Other,SCH,300,mg/m^,,Q w,,IV,,92,124,1
MMRF_1324,,First line of therapy,,,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,QD,,PO,,1,334,1
MMRF_1324,,First line of therapy,Maintenance,,Prednisone,,,,Disease progression/Relapse,,50,mg,,Oth,once,PO,,323,607,1
MMRF_1324,,First line of therapy,Consolidation,,Melphalan,,,,Completed regimen,,200,mg/m^,,Oth,once,IV,,774,774,1
MMRF_1324,,First line of therapy,Other,ASCT,Melphalan,,,,Completed regimen,,200,mg/m^,,Oth,once,IV,,775,775,1
MMRF_1324,,First line of therapy,Maintenance,,Lenalidomide,,,,Investigator decision for other reasons,,15,mg,,QD,,PO,,880,1446,1
MMRF_1324,,Second Line Therapy (after,Maintenance,,Carfilzomib,,,,Completed regimen,,27,mg/m^,,Oth,QOW,IV,,953,1310,1
MMRF_1324,,Second Line Therapy (after,Consolidation,,Carfilzomib,,,,Adverse Event or co-morbidity,,1.3,mg/m^,,Q w,,IV,,623,680,1
MMRF_1324,,Second Line Therapy (after,Consolidation,,Cyclophosphamide,,,,Completed regimen,,50,mg,,Q w,,PO,,623,730,1
MMRF_1324,,Second Line Therapy (after,Consolidation,,Dexamethasone,,,,Completed regimen,,10,mg,,Q w,,PO,,623,1310,1
MMRF_1324,,Second Line Therapy (after,Consolidation,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,Q w,,IV SubQ,,680,730,1
MMRF_1324,,Second Line Therapy (after,Unknown,,Carfilzomib,,,Checked,,,56,mg/m^,,Oth,QOW,IV,,1310,,1
MMRF_1324,,Second Line Therapy (after,Unknown,,Dexamethasone,,,Checked,,,8,mg,,Q w,,IV,,1310,,1
MMRF_1345,,First line of therapy,Induction,,Cyclophosphamide,,,,Investigator decision for other reasons,,300,mg/m^,,Oth,"D1,8",IV,,95,218,1
MMRF_1345,,First line of therapy,,,Lenalidomide,,,,Investigator decision for other reasons,,25,mg,,QD,,PO,,9,73,1
MMRF_1345,,First line of therapy,,,Dexamethasone,,,,Investigator decision for other reasons,,40,mg,,QWK,,PO,,1,218,1
MMRF_1345,Baseline,First line of therapy,,,Bortezomib,,,,Investigator decision for other reasons,,1.3,mg/m^,,QD,,IV SubQ,,1,218,1
MMRF_1345,,First line of therapy,Consolidation,,Melphalan,,,,Completed regimen,,200,mg/m^,,Oth,once,IV,,219,219,1
MMRF_1345,,Second Line Therapy (after,Consolidation,,Cyclophosphamide,,,,Completed regimen,,250,mg/m^,,Q w,,IV,,911,1086,1
MMRF_1345,,Second Line Therapy (after,Consolidation,,Dexamethasone,,,,Disease progression/Relapse,,20,mg,,Q w,,PO,,911,1598,1
MMRF_1345,,Second Line Therapy (after,Consolidation,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,Q w,,IV,,911,1086,1
MMRF_1345,,Second Line Therapy (after,Maintenance,,Pomalidomide,,,,Disease progression/Relapse,,4,mg,,QD,,PO,,1086,1598,1
MMRF_1345,,Fourth Line Therapy (follow,Unknown,,Dexamethasone,,,Checked,,,20,mg,,QD,,PO,,1774,,1
MMRF_1345,,Fourth Line Therapy (follow,Unknown,,Carfilzomib,,,Checked,,,27,mg/m^,,QD,,IV,,1774,,1
MMRF_1345,,Fourth Line Therapy (follow,Unknown,,Pomalidomide,,,Checked,,,3,mg,,QD,,PO,,1774,,1
MMRF_1345,,Third Line Therapy (followi,Other,salvage,Daratumumab,,,,Disease progression/Relapse,,16,mg/kg,,Q w,,IV,,1674,1751,1
MMRF_1345,,Third Line Therapy (followi,Other,salvage,Lenalidomide,,,,Disease progression/Relapse,,10,mg,,QD,,PO,,1674,1751,1
MMRF_1345,,Third Line Therapy (followi,Other,salvage,Dexamethasone,,,,Disease progression/Relapse,,20,mg,,Q w,,PO,,1674,1751,1
MMRF_1352,,First line of therapy,,,Lenalidomide,,,,Completed regimen,,25,mg/dL,,QD,,PO,,1,190,1
MMRF_1352,Baseline,First line of therapy,,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,Oth,weekly x 4 weeks,IV SubQ,,1,218,1
MMRF_1352,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,weekly x 4 weeks,PO,,1,233,1
MMRF_1352,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,200,mg/m^,,Oth,once,IV,,267,267,1
MMRF_1352,,First line of therapy,Consolidation,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,D1 and 8,IV,,190,218,1
MMRF_1352,,First line of therapy,Maintenance,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,374,1102,1
MMRF_1352,,First line of therapy,Consolidation,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,3 weeks on and 1 week off,PO,,374,1102,1
MMRF_1352,,First line of therapy,Maintenance,,Lenalidomide,,,,Completed regimen,,10,mg,,QD,,PO,,1102,1515,1
MMRF_1352,,First line of therapy,Maintenance,,Dexamethasone,,,,Completed regimen,,8,mg,,QD,,PO,,1102,1515,1
MMRF_1354,,First line of therapy,,,Dexamethasone,,,,Investigator decision for other reasons,,40,mg,,QD,,PO,,1,142,1
MMRF_1354,,First line of therapy,Induction,,Lenalidomide,,,,Disease progression/Relapse,,15,mg,,QD,,PO,,22,389,1
MMRF_1354,Baseline,First line of therapy,,,Bortezomib,,,,Adverse Event or co-morbidity,,1.3,mg/m^,,QD,,IV SubQ,,1,67,1
MMRF_1354,,First line of therapy,,,Cyclophosphamide,,,,Other,further therapy,520,mg,,QD,,IV,,1,22,1
MMRF_1354,,Second Line Therapy (after,Induction,,Prednisone,,,,Lack of response,,10,mg,,Oth,3 times a week,PO,,391,1175,1
MMRF_1354,,Second Line Therapy (after,Induction,,Elotuzumab,,,Checked,,,10,mg/kg,,Oth,day 1 and 15 of 21 day cycle,IV,,1089,,1
MMRF_1354,,Second Line Therapy (after,Consolidation,,Prednisone,,,Checked,,,100,mg,,Oth,"day 1, 8, 15",PO,,1175,,1
MMRF_1354,,Second Line Therapy (after,Consolidation,,Lenalidomide,,,Checked,,,15,mg,,QD,,PO,,1175,,1
MMRF_1089,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,"Days 1, 8, 15",PO,,1,547,1
MMRF_1089,Baseline,First line of therapy,,,Bortezomib,,,,Completed regimen,,1.3,mg,,QD,,IV SubQ,,1,547,1
MMRF_1089,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,10,mg,,QD,,PO,,547,,1
MMRF_1387,,First line of therapy,,,Dexamethasone,,,Checked,,,40,mg,,Oth,"Days 1, 8, 15",PO,,1,,1
MMRF_1387,Baseline,First line of therapy,,,Bortezomib,,,Checked,,,1.3,mg,,QD,,IV SubQ,,1,,1
MMRF_1387,,First line of therapy,,,Cyclophosphamide,,,Checked,,,300,mg/m^,,Oth,"D1, D8",IV,,1,,1
MMRF_1389,,First line of therapy,,,Bortezomib,,,,Completed regimen,,1.3,mg,,QWK,,IV SubQ,,1,78,1
MMRF_1389,Baseline,First line of therapy,,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,78,1
MMRF_1389,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,"Days 1, 8, 15",PO,,1,78,1
MMRF_1389,,First line of therapy,Consolidation,,Melphalan,,,,Completed regimen,,200,mg/m^,,Oth,once,IV,,183,183,1
MMRF_1391,Baseline,First line of therapy,,,Bortezomib,,,,Other,Pt moving to Florida.,1.3,mg/m^,,QD,,Other,IVP,1,148,1
MMRF_1391,,First line of therapy,,,Lenalidomide,,,,Other,Patient moving to Florida,25,mg,,QD,,PO,,1,148,1
MMRF_1391,,First line of therapy,,,Dexamethasone,,,,Other,Patient moving to Florida,20,mg,,Oth,"Days 1,2,4,5,8,9,11,12",PO,,1,148,1
MMRF_1391,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,320,mg/dL,,Oth,once,IV,,161,161,1
MMRF_1391,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,10,mg/dL,,QD,,PO,,1026,,1
MMRF_1446,Baseline,First line of therapy,,,Bortezomib,,,,Lack of response,,1.3,mg/m^,,QD,,IV SubQ,,1,99,1
MMRF_1446,,First line of therapy,,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,"D4,11",IV,,1,11,1
MMRF_1446,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,PO,,1,346,1
MMRF_1446,,First line of therapy,Consolidation,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,"D1,D8",IV,,163,190,1
MMRF_1446,,First line of therapy,Consolidation,,Carfilzomib,,,,Completed regimen,,20,mg/m^,,QD,,IV,,106,346,1
MMRF_1446,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,200,mg/m^,,Oth,Once,IV,,345,345,1
MMRF_1446,,First line of therapy,Induction,,Lenalidomide,,,,Disease progression/Relapse,,25,mg,,QD,,PO,,239,346,1
MMRF_1446,,Second Line Therapy (after,Induction,,Pomalidomide,,,,Investigator decision for other reasons,,4,mg,,QD,,PO,,805,1682,1
MMRF_1446,,First line of therapy,Induction,,Thalidomide,,,,Disease progression/Relapse,,50,mg,,Q w,,PO,,190,239,1
MMRF_1446,,First line of therapy,Consolidation,,Lenalidomide,,,,Disease progression/Relapse,,25,mg,,QD,,PO,,106,162,1
MMRF_1446,,Second Line Therapy (after,Consolidation,,Dexamethasone,,,,Adverse Event or co-morbidity,,40,mg,,Q w,,PO,,805,1682,1
MMRF_1446,,Second Line Therapy (after,Consolidation,,Other,ACY-1215,,,Adverse Event or co-morbidity,,160,mg,,QD,,PO,,805,1682,1
MMRF_1450,Baseline,First line of therapy,,,Bortezomib,,,,Other,Death,1.3,mg/m^,,QD,,IV SubQ,,1,16,1
MMRF_1450,,First line of therapy,,,Dexamethasone,,,,Other,Death,20,mg,,QD,,PO,,1,16,1
MMRF_1455,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,10,mg,,Q w,,PO,,1,82,1
MMRF_1455,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,82,1
MMRF_1455,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,Q w,,IV SubQ,,1,82,1
MMRF_1455,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,10,mg,,QD,,PO,,252,,1
MMRF_1455,,First line of therapy,Maintenance,,Dexamethasone,,,Checked,,,10,mg,,Oth,"D1,8,15",PO,,247,,1
MMRF_1455,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,200,mg/m^,,Oth,once,IV,,146,146,1
MMRF_1454,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,40,mg,,Q w,,PO,,1,159,1
MMRF_1454,,First line of therapy,,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,Q w,,IV SubQ,,1,159,1
MMRF_1454,Baseline,First line of therapy,,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,159,1
MMRF_1454,,First line of therapy,Consolidation,,Melphalan,,,,Completed regimen,,200,mg/m^,,Oth,once,IV,,160,160,1
MMRF_1454,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1,mg/m^,,Q w,,IV SubQ,,337,524,1
MMRF_1474,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,389,1030,1
MMRF_1474,Baseline,First line of therapy,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,1.3,mg/m^,,QD,,IV SubQ,,1,8,1
MMRF_1474,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,IV,,1,947,1
MMRF_1474,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,300,mg,,Oth,once,IV,,205,205,1
MMRF_1474,,First line of therapy,Maintenance,,Lenalidomide,,,,Disease progression/Relapse,,10,mg,,QD,,PO,,389,1030,1
MMRF_1474,,First line of therapy,Maintenance,,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,Q w,,PO,,526,942,1
MMRF_1474,,Second Line Therapy (after,Consolidation,,Other,atezolizumab,,,Patient decision,,840,mg,,Oth,"D12,D16 of Cycle 1 and D1,D15 of cycles thereafter",IV,,1188,1457,1
MMRF_1474,,Second Line Therapy (after,Consolidation,,Daratumumab,,,,Patient decision,,16,mg/kg,,Oth,"D1,8,15,22",IV,,1187,1457,1
MMRF_1474,,Third Line Therapy (followi,Unknown,,Carfilzomib,,,Checked,,,20,mg/m^,,QD,,IV,,1697,,1
MMRF_1474,,Third Line Therapy (followi,Unknown,,Pomalidomide,,,Checked,,,3,mg,,QD,,PO,,1691,,1
MMRF_1474,,Third Line Therapy (followi,Unknown,,Dexamethasone,,,Checked,,,20,mg,,QD,,IV,,1697,,1
MMRF_1479,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,5,190,1
MMRF_1479,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,twice weekly,PO,,1,151,1
MMRF_1479,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,Q w,,IV SubQ,,1,190,1
MMRF_1479,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,200,mg/m^,,Oth,once,IV,,204,204,1
MMRF_1479,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,QD,,PO,,314,647,1
MMRF_1479,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,15,mg,,QD,,PO,,314,1166,1
MMRF_1479,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV,,314,363,1
MMRF_1479,,Second Line Therapy (after,Consolidation,,Ixazomib,,,,Disease progression/Relapse,,4,mg,,Q w,,PO,,1185,1254,1
MMRF_1479,,Second Line Therapy (after,Consolidation,,Lenalidomide,,,,Patient decision,,15,mg,,QD,,PO,,1185,1254,1
MMRF_1479,,Second Line Therapy (after,Consolidation,,Dexamethasone,,,,Disease progression/Relapse,,8,mg,,Q w,,PO,,1185,1254,1
MMRF_1479,,Third Line Therapy (followi,Consolidation,,Daratumumab,,,Checked,,,16,mg/kg,,Q w,,IV,,1275,,1
MMRF_1479,,Third Line Therapy (followi,Unknown,,Pomalidomide,,,,Completed regimen,,4,mg,,QD,,PO,,1275,1613,1
MMRF_1479,,Third Line Therapy (followi,Consolidation,,Dexamethasone,,,Checked,,,20,mg,,QD,,IV,,1275,,1
MMRF_1479,,Third Line Therapy (followi,Consolidation,,Carfilzomib,,,Checked,,,20,mg/m^,,QD,,IV,,1275,,1
MMRF_1479,,Third Line Therapy (followi,Consolidation,,Other,trametinib,,,Completed regimen,,2,mg,,TID,,PO,,1272,1612,1
MMRF_1479,,Third Line Therapy (followi,Unknown,,Pomalidomide,,,Checked,,,2,mg,,QD,,PO,,1613,,1
MMRF_1502,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,IV,,1,47,1
MMRF_1502,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,47,1
MMRF_1502,,Second Line Therapy (after,Consolidation,,Lenalidomide,,,,Disease progression/Relapse,,25,mg,,QD,,PO,,812,1182,1
MMRF_1502,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,"D1,8",IV,,1,47,1
MMRF_1502,,Second Line Therapy (after,Consolidation,,Dexamethasone,,,,Disease progression/Relapse,,28,mg,,Oth,"D1, D8, D15, D22",PO,,812,1143,1
MMRF_1502,,First line of therapy,Consolidation,,Melphalan,,,,Completed regimen,,200,mg/m^,,Oth,once,IV,,218,218,1
MMRF_1502,,First line of therapy,Maintenance,,Bortezomib,,,,Disease progression/Relapse,,1.3,mg/m^,,QWK,,IV,,368,764,1
MMRF_1502,,Second Line Therapy (after,Consolidation,,Elotuzumab,,,,Completed regimen,,631,mg,,Oth,"D1, D8, D15, D22",IV,,829,898,1
MMRF_1502,,Third Line Therapy (followi,Consolidation,,Daratumumab,,,,Disease progression/Relapse,,16,mg/dL,,Q w,,IV,,1130,1311,1
MMRF_1502,,Third Line Therapy (followi,Consolidation,,Dexamethasone,,,,Disease progression/Relapse,,20,mg,,Q w,,PO,,1130,1311,1
MMRF_1502,,Third Line Therapy (followi,Consolidation,,Pomalidomide,,,,Disease progression/Relapse,,4,mg,,QD,,PO,,1130,1311,1
MMRF_1502,,Fourth Line Therapy (follow,Consolidation,,Other,trametinib,,,,,2,mg,,QD,,PO,,1403,1403,1
MMRF_1502,,Fourth Line Therapy (follow,Consolidation,,Daratumumab,,,,,,,,,Q w,,IV,,1346,1403,1
MMRF_1502,,Fourth Line Therapy (follow,Consolidation,,Pomalidomide,,,,,,4,mg,,QD,,PO,,1346,1403,1
MMRF_1502,,Fourth Line Therapy (follow,Consolidation,,Carfilzomib,,,,Disease progression/Relapse,,20,mg/m^,,Oth,unk,IV,,1346,1394,1
MMRF_1502,,Fourth Line Therapy (follow,Consolidation,,Dexamethasone,,,,,,16,mg,,Q w,,PO,,1346,1403,1
MMRF_1510,,First line of therapy,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,40,mg,,QD,,PO,,1,281,1
MMRF_1510,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,726,1
MMRF_1510,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,240,1
MMRF_1510,,First line of therapy,Maintenance,,Lenalidomide,,,,Patient decision,,10,mg,,QD,,PO,,726,1447,1
MMRF_1510,,First line of therapy,Maintenance,,Dexamethasone,,,,Completed regimen,,12,mg,,Q w,,PO,,245,281,1
MMRF_1510,,Second Line Therapy (after,Consolidation,,Carfilzomib,,,,Completed regimen,,20,mg/m^,,QD,,IV,,1470,1671,1
MMRF_1510,,Second Line Therapy (after,Consolidation,,Cyclophosphamide,,,,Disease progression/Relapse,,300,mg/m^,,Oth,"Day 1,8",IV,,1481,1516,1
MMRF_1510,,Second Line Therapy (after,Consolidation,,Dexamethasone,,,,Completed regimen,,10,mg,,QD,,PO,,1470,1671,1
MMRF_1513,Baseline,First line of therapy,Induction,,Lenalidomide,,,,Disease progression/Relapse,,25,mg,,QD,,PO,,1,889,1
MMRF_1513,,First line of therapy,Induction,,Bortezomib,,,,Disease progression/Relapse,,2.73,mg,,QD,,IV,,1,889,1
MMRF_1513,,First line of therapy,Induction,,Dexamethasone,,,,Disease progression/Relapse,,20,mg,,Oth,"days 1, 2, 4, 5, 8, 9, 11 and 12 every 21 day cycle",PO,,1,889,1
MMRF_1513,,Second Line Therapy (after,Consolidation,,Melphalan,,,,Completed regimen,,200,mg/m^,,Oth,once,IV,,904,905,1
MMRF_1513,,Second Line Therapy (after,Maintenance,,Ixazomib,,,,Disease progression/Relapse,,3,mg,,Oth,once a week,PO,,1022,1620,1
MMRF_1513,,Third Line Therapy (followi,Consolidation,,Daratumumab,,,,Disease progression/Relapse,,16,mg/kg,,QWK,,IV,,1646,1717,1
MMRF_1513,,Fourth Line Therapy (follow,Consolidation,,Other,Etoposide,,Checked,,,120,mg/m^,,QD,,IV,,1722,,1
MMRF_1513,,Fourth Line Therapy (follow,Consolidation,,Dexamethasone,,,Checked,,,4,mg,,Oth,"Take 5 tablets by mouth once a week. For 3 weeks, one week break",PO,,1722,,1
MMRF_1513,,Fourth Line Therapy (follow,Consolidation,,Cyclophosphamide,,,Checked,,,1200,mg/m^,,QD,,IV,,1722,,1
MMRF_1513,,Fourth Line Therapy (follow,Consolidation,,Other,Cisplatin,,Checked,,,30,mg/m^,,QD,,IV,,1722,,1
MMRF_1513,,Third Line Therapy (followi,Consolidation,,Other,atezolizumab,,,Disease progression/Relapse,,840,mg,,QWK,,IV,,1646,1717,1
MMRF_1516,Baseline,First line of therapy,Induction,,Lenalidomide,,,Checked,,,10,mg,,QD,,PO,,1,,1
MMRF_1516,,First line of therapy,Induction,,Prednisone,,,Checked,,,30,mg,,Oth,"TIW (mon,wed,fri)",PO,,1,,1
MMRF_1622,Baseline,First line of therapy,Induction,,Bortezomib,,,,Lack of response,,1.3,mg/m^,,QD,,IV,,1,638,1
MMRF_1622,,First line of therapy,Induction,,Dexamethasone,,,,Lack of response,,40,mg,,QD,,PO,,1,638,1
MMRF_1622,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,10,mg/m^,,Oth,"D1,8",IV,,1,18,1
MMRF_1622,,First line of therapy,Induction,,Lenalidomide,,,,Lack of response,,25,mg,,QD,,PO,,18,638,1
MMRF_1622,,First line of therapy,Consolidation,,Melphalan,,,,Completed regimen,,200,mg/m^,,Oth,once,IV,,306,306,1
MMRF_1622,,First line of therapy,Induction,,Pomalidomide,,,Checked,,,4,mg,,QD,,PO,,638,,1
MMRF_1622,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Q w,,PO,,638,990,1
MMRF_1628,Baseline,First line of therapy,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,25,mg,,QD,,PO,,1,404,1
MMRF_1628,,First line of therapy,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,40,mg,,QWK,,PO,,1,404,1
MMRF_1628,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,20,mg/m^,,QD,,IV,,430,1027,1
MMRF_1628,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,15,mg,,QD,,PO,,430,1027,1
MMRF_1628,,First line of therapy,Induction,,Prednisone,,,,Completed regimen,,50,mg,,Oth,BIW,PO,,430,641,1
MMRF_1628,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,200,mg/m^,,Oth,once,IV,,1158,1158,1
MMRF_1628,,Second Line Therapy (after,Unknown,,Carfilzomib,,,Checked,,,20,mg/m^,,QD,,IV,,1550,,1
MMRF_1628,,Second Line Therapy (after,Unknown,,Pomalidomide,,,Checked,,,3,mg,,QD,,PO,,1550,,1
MMRF_1628,,Second Line Therapy (after,Unknown,,Daratumumab,,,Checked,,,16,mg/kg,,Q w,,IV,,1550,,1
MMRF_1628,,Second Line Therapy (after,Unknown,,Dexamethasone,,,Checked,,,4,mg,,QD,,PO,,1550,,1
MMRF_1628,,Second Line Therapy (after,Unknown,,Other,mekinist,,Checked,,,2,mg,,Oth,days Monday/thursday x 4/4 weeks,PO,,1550,,1
MMRF_1634,Baseline,First line of therapy,Induction,,Bortezomib,,,,Other,death,1.3,mg/m^,,QD,,IV,,1,16,1
MMRF_1634,,First line of therapy,Induction,,Lenalidomide,,,,Other,death,25,mg,,QD,,PO,,1,16,1
MMRF_1634,,First line of therapy,Induction,,Dexamethasone,,,,Other,death,40,mg,,QD,,PO,,1,16,1
MMRF_1637,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV,,1,206,1
MMRF_1637,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,209,1
MMRF_1637,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,PO,,1,209,1
MMRF_1637,,First line of therapy,Other,transplant,Melphalan,,,,Completed regimen,,422,mg,,Oth,Once,IV,,206,206,1
MMRF_1637,,First line of therapy,Consolidation,,Lenalidomide,,,,Disease progression/Relapse,,25,mg,,QD,,PO,,337,596,1
MMRF_1637,,First line of therapy,Maintenance,,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,Oth,"D1, D8, D15",PO,,337,596,1
MMRF_1637,,First line of therapy,Consolidation,,Bortezomib,,,,Disease progression/Relapse,,1.3,mg/m^,,Oth,"D1, 8, 15",IV SubQ,,337,460,1
MMRF_1637,,Second Line Therapy (after,Consolidation,,Dexamethasone,,,,Patient decision,,40,mg,,Q w,,PO,,597,621,1
MMRF_1637,,Second Line Therapy (after,Consolidation,,Pomalidomide,,,,Patient decision,,4,mg,,QD,,PO,,597,621,1
MMRF_1637,,Second Line Therapy (after,Consolidation,,Pomalidomide,,,,Disease progression/Relapse,,2,mg,,QD,,PO,,662,719,1
MMRF_1637,,Second Line Therapy (after,Consolidation,,Dexamethasone,,,,Disease progression/Relapse,,20,mg,,Oth,weekly x 3 weeks on/1 week off,PO,,662,719,1
MMRF_1637,,Third Line Therapy (followi,Consolidation,,Dexamethasone,,,,Disease progression/Relapse,,20,mg,,Oth,weekly x 3 weeks on/1 week off,PO,,721,1073,1
MMRF_1637,,Second Line Therapy (after,Consolidation,,Cyclophosphamide,,,,Disease progression/Relapse,,300,mg,,Oth,weekly x 3 weeks on/1 week off,PO,,662,719,1
MMRF_1637,,Third Line Therapy (followi,Consolidation,,Carfilzomib,,,,Investigator decision for other reasons,,20,mg/m^,,Q w,,IV,,721,838,1
MMRF_1637,,Third Line Therapy (followi,Consolidation,,Carfilzomib,,,,Disease progression/Relapse,,36,mg/m^,,QD,,IV,,838,901,1
MMRF_1637,,Third Line Therapy (followi,Consolidation,,Carfilzomib,,,,Disease progression/Relapse,,70,mg/m^,,Q w,,IV,,906,1073,1
MMRF_1637,,Third Line Therapy (followi,Consolidation,,Pomalidomide,,,,Disease progression/Relapse,,2,mg,,QD,,PO,,964,1073,1
MMRF_1637,,Fourth Line Therapy (follow,Consolidation,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,4 days,IV,,1073,1073,1
MMRF_1637,,Fourth Line Therapy (follow,Consolidation,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,4 days,PO,,1073,1073,1
MMRF_1637,,Fourth Line Therapy (follow,Consolidation,,Other,cisplatin,,,Completed regimen,,10,mg/m^,,Oth,4 days,IV,,1073,1073,1
MMRF_1637,,Fourth Line Therapy (follow,Consolidation,,Other,etoposide,,,Completed regimen,,30,mg/m^,,Oth,4 days,IV,,1073,1073,1
MMRF_1637,,Fifth Line Therapy (followi,Consolidation,,Pomalidomide,,,,Completed regimen,,2,mg,,QD,,PO,,1272,1510,1
MMRF_1637,,Fifth Line Therapy (followi,Consolidation,,Panobinostat,,,,Disease progression/Relapse,,20,mg,,Oth,"Days 1, 3, 5, 8, 10, 12 of 21 day cycle",PO,,1272,1510,1
MMRF_1637,,Fifth Line Therapy (followi,Consolidation,,Daratumumab,,,,Disease progression/Relapse,,16,mg/kg,,Q w,,IV,,1272,1510,1
MMRF_1637,,Sixth Line Therapy (followi,Other,salvage,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,PO,,1510,1513,1
MMRF_1637,,Sixth Line Therapy (followi,Other,salvage,Other,etoposide,,,Completed regimen,,30,mg/m^,,QD,,IV,,1510,1513,1
MMRF_1637,,Sixth Line Therapy (followi,Other,salvage,Other,cisplatin,,,Completed regimen,,7.5,mg/m^,,QD,,IV,,1510,1513,1
MMRF_1637,,Sixth Line Therapy (followi,Other,salvage,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,QD,,IV,,1510,1513,1
MMRF_1637,,Sixth Line Therapy (followi,Other,salvage,Other,adriamycin,,,Completed regimen,,10,mg/m^,,QD,,IV,,1510,1513,1
MMRF_1637,,First line of therapy,Consolidation,,Panobinostat,,,,Adverse Event or co-morbidity,,20,mg,,Oth,"days 1, 3, 5, 8, 10, 12",PO,,1289,1346,1
MMRF_1637,,Fifth Line Therapy (followi,Consolidation,,Carfilzomib,,,,Disease progression/Relapse,,20,mg/m^,,QD,,IV,,1433,1510,1
MMRF_1637,,Fifth Line Therapy (followi,Consolidation,,Other,venetoclax,,,Disease progression/Relapse,,400,mg,,Oth,Day 1-28,PO,,1433,1510,1
MMRF_1643,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,359,1
MMRF_1643,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,PO,,1,479,1
MMRF_1643,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,632,1
MMRF_1648,Baseline,First line of therapy,Induction,,Bortezomib,,,Checked,,,1.3,mg/m^,,QD,,IV,,1,,1
MMRF_1648,,First line of therapy,Induction,,Lenalidomide,,,Checked,,,25,mg,,QD,,PO,,1,,1
MMRF_1648,,First line of therapy,Induction,,Dexamethasone,,,Checked,,,20,mg,,Oth,"Days 1,2,4,5,8,9,11 and 12",PO,,1,,1
MMRF_1665,,First line of therapy,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,15,mg,,QD,,PO,,22,121,1
MMRF_1665,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,309,1
MMRF_1665,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,QD,,PO,,1,309,1
MMRF_1665,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,D1 and D8,PO,,1,22,1
MMRF_1665,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,200,mg/m^,,Oth,Once,IV,,309,309,1
MMRF_1665,,First line of therapy,Induction,,Lenalidomide,,,,Other,decreasing renal function,5,mg,,Oth,MWF 3 wks on 1 wk off,PO,,432,831,1
MMRF_1665,,First line of therapy,Induction,,Prednisone,,,,Investigator decision for other reasons,,50,mg,,Oth,MWF QW,PO,,432,831,1
MMRF_1665,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,Oth,Every other week,IV SubQ,,436,932,1
MMRF_1665,,First line of therapy,Maintenance,,Ixazomib,,,Checked,,,3,mg,,Oth,once a week,PO,,936,,1
MMRF_1677,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,218,1
MMRF_1677,,First line of therapy,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,25,mg,,QD,,PO,,7,26,1
MMRF_1677,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,QWK,,PO,,2,218,1
MMRF_1677,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,15,mg,,QD,,PO,,38,218,1
MMRF_1677,,First line of therapy,Consolidation,,Lenalidomide,,,Checked,,,25,mg,,QD,,PO,,218,,1
MMRF_1677,,First line of therapy,Consolidation,,Dexamethasone,,,Checked,,,10,mg,,QD,,PO,,218,,1
MMRF_1677,,First line of therapy,Consolidation,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,QD,,IV SubQ,,218,574,1
MMRF_1677,,First line of therapy,Induction,,Liposomal doxorubicin,,,,Completed regimen,,200,mg/m^,,Oth,once,IV,,300,300,1
MMRF_1677,,First line of therapy,Consolidation,,Melphalan,,,,Completed regimen,,200,mg/m^,,Oth,once,IV,,300,300,1
MMRF_1686,,First line of therapy,Induction,,Dexamethasone,,,Checked,,,40,mg,,QWK,,PO,,1,,1
MMRF_1686,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,300,mg,,QWK,,PO,,1,214,1
MMRF_1686,Baseline,First line of therapy,Induction,,Bortezomib,,,Checked,,,1.3,mg/m^,,QD,,IV SubQ,,1,,1
MMRF_1686,,First line of therapy,Consolidation,,Melphalan,,,,Completed regimen,,200,mg/m^,,Oth,once,IV,,224,224,1
MMRF_1710,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,QWK,,PO,,1,235,1
MMRF_1710,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,300,mg,,QWK,,PO,,1,235,1
MMRF_1710,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,235,1
MMRF_1710,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,25,mg,,QD,,PO,,580,,1
MMRF_1710,,First line of therapy,Maintenance,,Dexamethasone,,,Checked,,,20,mg,,QWK,,PO,,618,,1
MMRF_1710,,First line of therapy,Maintenance,,Bortezomib,,,Checked,,,1.3,mg/m^,,QWK,,IV SubQ,,253,,1
MMRF_1698,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,60,1
MMRF_1698,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1,2,4,5,8,9,11,12",PO,,1,54,1
MMRF_1698,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,54,1
MMRF_1698,,First line of therapy,Consolidation,,Melphalan,,,,Completed regimen,,200,mg/m^,,Oth,once,IV,,127,127,1
MMRF_1698,,First line of therapy,Consolidation,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,204,270,1
MMRF_1698,,First line of therapy,Consolidation,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV,,204,270,1
MMRF_1698,,First line of therapy,Consolidation,,Dexamethasone,,,,Completed regimen,,10,mg,,QD,,PO,,204,270,1
MMRF_1698,,First line of therapy,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,10,mg,,QD,,PO,,268,900,1
MMRF_1746,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,153,1
MMRF_1746,Baseline,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,22,153,1
MMRF_1746,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,PO,,1,153,1
MMRF_1746,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,10,mg,,QD,,PO,,274,,1
MMRF_1746,,First line of therapy,Consolidation,,Melphalan,,,,Completed regimen,,200,mg/m^,,Oth,once,IV,,160,160,1
MMRF_1744,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,Day 1 and Day 4,IV,,1,321,1
MMRF_1744,Baseline,First line of therapy,Induction,,Bortezomib,,,,Disease progression/Relapse,,1.3,mg/m^,,QD,,IV SubQ,,1,874,1
MMRF_1744,,First line of therapy,Induction,,Dexamethasone,,,,Disease progression/Relapse,,20,mg,,QD,,PO,,1,854,1
MMRF_1744,,First line of therapy,Induction,,Doxorubicin,,,,Completed regimen,,30,mg/m^,,Oth,Day 4,IV,,43,64,1
MMRF_1744,,First line of therapy,Induction,,Thalidomide,,,,Adverse Event or co-morbidity,,100,mg,,Oth,D1-28,PO,,30,37,1
MMRF_1744,,Second Line Therapy (after,Consolidation,,Dexamethasone,,,,Disease progression/Relapse,,8,mg,,Q w,,PO,,885,947,1
MMRF_1744,,First line of therapy,Induction,,Lenalidomide,,,,Disease progression/Relapse,,10,mg,,Oth,MWF,PO,,120,854,1
MMRF_1744,,First line of therapy,Induction,,Elotuzumab,,,,Disease progression/Relapse,,10,mg/m^,,QWK,,IV,,727,867,1
MMRF_1744,,Second Line Therapy (after,Consolidation,,Daratumumab,,,,Disease progression/Relapse,,16,mg/kg,,QD,,IV,,884,1128,1
MMRF_1744,,Second Line Therapy (after,Consolidation,,Pomalidomide,,,,Disease progression/Relapse,,2,mg,,QD,,PO,,875,1156,1
MMRF_1744,,Third Line Therapy (followi,Consolidation,,Daratumumab,,,,Disease progression/Relapse,,16,mg/kg,,Oth,monthly,IV,,1161,1525,1
MMRF_1744,,Second Line Therapy (after,Consolidation,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,Q w,,IV,,1075,1155,1
MMRF_1744,,Second Line Therapy (after,Consolidation,,Other,Nelfinavir,,,Disease progression/Relapse,,625,mg,,Oth,BID for 14 days,PO,,1075,1155,1
MMRF_1744,,Third Line Therapy (followi,Consolidation,,Carfilzomib,,,,Disease progression/Relapse,,20,mg/m^,,QD,,IV,,1161,1532,1
MMRF_1744,,Third Line Therapy (followi,Unknown,,Other,venetoclax,,,Disease progression/Relapse,,400,mg,,Oth,QD,PO,,1155,1433,1
MMRF_1744,,Fourth Line Therapy (follow,Unknown,,Carfilzomib,,,,Completed regimen,,100,mg/m^,,Oth,QD,IV,,1550,1550,1
MMRF_1744,,Fourth Line Therapy (follow,Unknown,,Melphalan,,,,Completed regimen,,100,mg/m^,,Oth,QD,IV,,1551,1551,1
MMRF_1768,Baseline,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,148,1
MMRF_1768,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,PO,,1,148,1
MMRF_1768,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,148,1
MMRF_1768,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,200,mg/m^,,Oth,Once,IV,,148,148,1
MMRF_1808,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,65,1
MMRF_1808,,First line of therapy,Induction,,Cyclophosphamide,,,,Investigator decision for other reasons,,300,mg/m^,,Oth,Day 1 and Day 8,IV,,1,15,1
MMRF_1808,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,IV,,1,175,1
MMRF_1808,,First line of therapy,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,25,mg,,QD,,PO,,33,71,1
MMRF_1808,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,20,mg/m^,,QD,,IV,,79,175,1
MMRF_1808,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,QWK,,IV,,79,175,1
MMRF_1808,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,200,mg/m^,,Oth,once,IV,,174,174,1
MMRF_1808,,First line of therapy,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,10,mg,,QD,,PO,,267,396,1
MMRF_1808,,First line of therapy,Induction,,Prednisone,,,,Completed regimen,,30,mg,,Oth,TIW,PO,,267,367,1
MMRF_1808,,First line of therapy,Consolidation,,Carfilzomib,,,,Completed regimen,,56,mg/m^,,QWK,,IV,,367,501,1
MMRF_1808,,First line of therapy,Consolidation,,Dexamethasone,,,,Completed regimen,,20,mg,,QWK,,PO,,367,501,1
MMRF_1830,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,862,1
MMRF_1830,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,QD,,PO,,1,1317,1
MMRF_1830,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,Day 1 and Day 8,IV,,1,79,1
MMRF_1830,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,15,mg,,QD,,PO,,123,1317,1
MMRF_1830,,First line of therapy,Induction,,Ixazomib,,,,Completed regimen,,4,mg,,QD,,PO,,863,1317,1
MMRF_1830,,First line of therapy,Maintenance,,Dexamethasone,,,Checked,,,8,mg,,Oth,QOW,PO,,1317,,1
MMRF_1830,,First line of therapy,Maintenance,,Ixazomib,,,Checked,,,3,mg,,Oth,QOW,PO,,1317,,1
MMRF_1830,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,10,mg,,QD,,PO,,1317,,1
MMRF_1859,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,Q w,,IV SubQ,,1,161,1
MMRF_1859,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Q w,,PO,,1,161,1
MMRF_1859,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,15,mg,,QD,,PO,,1,161,1
MMRF_1859,,First line of therapy,Induction,,Bortezomib,,,Checked,,,1.3,mg/m^,,QD,,IV SubQ,,234,,1
MMRF_1859,,First line of therapy,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,10,mg,,QD,,PO,,262,945,1
MMRF_1859,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,QW 3wk on 1wk off,IV,,234,262,1
MMRF_1871,,First line of therapy,Induction,,Dexamethasone,,,Checked,,,4,mg,,Q d,,PO,,3,,1
MMRF_1871,,First line of therapy,Induction,,Cyclophosphamide,,,Checked,,,300,mg/m^,,Oth,"Day 1, 8, 15",IV,,1,,1
MMRF_1871,Baseline,First line of therapy,Induction,,Bortezomib,,,Checked,,,1.3,mg/m^,,QD,,IV SubQ,,1,,1
MMRF_1871,,First line of therapy,Consolidation,,Melphalan,,,,Completed regimen,,200,mg/m^,,Oth,once,IV,,166,166,1
MMRF_1921,,First line of therapy,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,25,mg,,Q d,,PO,,1,34,1
MMRF_1921,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,419,1
MMRF_1921,,First line of therapy,Induction,,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,QD,,PO,,1,720,1
MMRF_1921,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,QD (D1 and D8),IV,,34,207,1
MMRF_1921,,First line of therapy,Consolidation,,Melphalan,,,,Completed regimen,,200,mg/m^,,Oth,once,IV,,221,221,1
MMRF_1921,,First line of therapy,Maintenance,,Bortezomib,,,,Disease progression/Relapse,,1.3,mg/m^,,Oth,"D1, D15",IV SubQ,,419,720,1
MMRF_1921,,First line of therapy,Induction,,Ixazomib,,,,Disease progression/Relapse,,3,mg,,Q w,,PO,,724,1307,1
MMRF_1921,,Second Line Therapy (after,Unknown,,Other,Isatuximab,,Checked,,,5,mg/kg,,QD,,IV,,1342,,1
MMRF_1921,,Second Line Therapy (after,Unknown,,Dexamethasone,,,Checked,,,20,mg,,QD,,IV,,1342,,1
MMRF_1921,,Second Line Therapy (after,Unknown,,Carfilzomib,,,Checked,,,20,mg/m^,,QD,,IV,,1342,,1
MMRF_1963,,First line of therapy,Induction,,Dexamethasone,,,Checked,,,40,mg,,Q w,,PO,,1,,1
MMRF_1963,Baseline,First line of therapy,Induction,,Bortezomib,,,Checked,,,1.3,mg/m^,,Q w,,IV SubQ,,1,,1
MMRF_1963,,First line of therapy,Induction,,Lenalidomide,,,Checked,,,25,mg,,QD,,PO,,1,,1
MMRF_1992,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,430,mg,,Oth,"D 1, 8, 15",IV,,2,19,1
MMRF_1992,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,2,113,1
MMRF_1992,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,"D1,2,3,5,6",PO,,1,111,1
MMRF_1992,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,19,113,1
MMRF_1992,,Second Line Therapy (after,Consolidation,,Lenalidomide,,,,Disease progression/Relapse,,25,mg,,QD,,PO,,467,659,1
MMRF_1992,,Second Line Therapy (after,Consolidation,,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,Oth,"D1,8,15",PO,,467,653,1
MMRF_1992,,Second Line Therapy (after,Consolidation,,Panobinostat,,,,Disease progression/Relapse,,20,mg,,Oth,"days 1, 3, 5, 15, 17, 19.",PO,,467,655,1
MMRF_1992,,First line of therapy,Consolidation,,Melphalan,,,,Completed regimen,,200,mg/m^,,Oth,once,IV,,166,166,1
MMRF_1992,,Third Line Therapy (followi,Consolidation,,Elotuzumab,,,,Investigator decision for other reasons,,10,mg/m^,,Oth,"D1,8,15,22",IV,,701,786,1
MMRF_1992,,Third Line Therapy (followi,Consolidation,,Pomalidomide,,,,Investigator decision for other reasons,,4,mg,,QD,,PO,,701,786,1
MMRF_1992,,Fourth Line Therapy (follow,Consolidation,,Daratumumab,,,,Disease progression/Relapse,,1800,mg,,Oth,"D1,8,15,22",IV SubQ,,811,961,1
MMRF_1992,,Third Line Therapy (followi,Consolidation,,Dexamethasone,,,,Investigator decision for other reasons,,8,mg,,Oth,"D1,8,15,22",IV,,701,786,1
MMRF_1992,,Fourth Line Therapy (follow,Consolidation,,Daratumumab,,,Checked,,,16,mg/kg,,Q w,,IV,,975,,1
MMRF_1992,,Fourth Line Therapy (follow,Consolidation,,Pomalidomide,,,Checked,,,4,mg,,QD,,PO,,975,,1
MMRF_1998,Baseline,First line of therapy,Induction,,Bortezomib,,,,Other,death,1.3,mg/m^,,QD,,IV SubQ,,1,292,1
MMRF_1998,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Q w,,PO,,1,121,1
MMRF_1998,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,QD D1 and D8,IV,,1,85,1
MMRF_1998,,First line of therapy,Maintenance,,Dexamethasone,,,,Completed regimen,,8,mg,,Q w,,PO,,162,252,1
MMRF_1998,,First line of therapy,Maintenance,,Lenalidomide,,,,Completed regimen,,25,mg,,Q d,,PO,,162,252,1
MMRF_2000,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,93,1
MMRF_2000,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,"D1, D8",IV,,1,8,1
MMRF_2000,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,QD,,PO,,1,93,1
MMRF_2000,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,200,mg/m^,,Oth,once,IV,,126,126,1
MMRF_2000,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,18,93,1
MMRF_2000,,First line of therapy,Induction,,Lenalidomide,,,Checked,,,10,mg,,QD,,PO,,287,,1
MMRF_2000,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Q w,,PO,,287,638,1
MMRF_2000,,First line of therapy,Maintenance,,Dexamethasone,,,Checked,,,12,mg,,Q w,,PO,,638,,1
MMRF_2000,,First line of therapy,Consolidation,,Elotuzumab,,,Checked,,,10,mg/kg,,Q w,,IV,,1178,,1
MMRF_2002,,First line of therapy,Induction,,Dexamethasone,,,Checked,,,20,mg,,QD,,PO,,1,,1
MMRF_2002,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,450,1
MMRF_2002,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,"D1, D8",IV,,1,80,1
MMRF_2002,,First line of therapy,Induction,,Lenalidomide,,,Checked,,,15,mg,,Oth,"WD (D1, 4, 11, and 18)",PO,,80,,1
MMRF_2018,,First line of therapy,Induction,,Dexamethasone,,,,Investigator decision for other reasons,,40,mg,,QD,,PO,,1,29,1
MMRF_2018,Baseline,First line of therapy,Induction,,Bortezomib,,,,Investigator decision for other reasons,,1.3,mg/m^,,QD,,IV SubQ,,1,29,1
MMRF_2018,,First line of therapy,Induction,,Lenalidomide,,,,Investigator decision for other reasons,,25,mg,,QD,,PO,,1,29,1
MMRF_2018,,First line of therapy,Induction,,Bortezomib,,,,Investigator decision for other reasons,,1.3,mg/m^,,Oth,"once a week. X 3  Out of 4 weeks,",IV SubQ,,29,126,1
MMRF_2018,,First line of therapy,Induction,,Thalidomide,,,,Completed regimen,,100,mg,,Q d,,PO,,29,211,1
MMRF_2018,,First line of therapy,Induction,,Cyclophosphamide,,,,Lack of response,,300,mg/m^,,Oth,D1 and D8,IV,,29,126,1
MMRF_2018,,First line of therapy,Induction,,Carfilzomib,,,Checked,,,20,mg/m^,,QD,,IV,,126,,1
MMRF_2018,,First line of therapy,Induction,,Dexamethasone,,,Checked,,,40,mg,,Oth,weekly x 3 weeks,PO,,80,,1
MMRF_2081,Baseline,First line of therapy,Induction,,Carfilzomib,,,Checked,,,20,mg/m^,,QD,,IV,,1,,1
MMRF_2081,,First line of therapy,Induction,,Dexamethasone,,,Checked,,,20,mg,,QD,,PO,,1,,1
MMRF_2081,,First line of therapy,Induction,,Lenalidomide,,,Checked,,,25,mg,,QD,,PO,,8,,1
MMRF_2081,,First line of therapy,Consolidation,,Melphalan,,,,Completed regimen,,180,mg/m^,,Oth,once,IV,,179,179,1
MMRF_2082,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,Q w,,IV SubQ,,1,284,1
MMRF_2082,,First line of therapy,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,25,mg,,QD,,PO,,1,284,1
MMRF_2082,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Q w,,PO,,1,284,1
MMRF_2082,,First line of therapy,Consolidation,,Melphalan,,,,Completed regimen,,200,mg/m^,,Oth,once,IV,,508,508,1
MMRF_2082,,Second Line Therapy (after,Consolidation,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,Q w,,IV SubQ,,437,498,1
MMRF_2082,,Second Line Therapy (after,Consolidation,,Dexamethasone,,,,Completed regimen,,40,mg,,Q w,,PO,,437,498,1
MMRF_2082,,Second Line Therapy (after,Consolidation,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,437,498,1
MMRF_2107,Baseline,First line of therapy,Induction,,Bortezomib,,,Checked,,,1.3,mg/m^,,Q w,,IV SubQ,,1,,1
MMRF_2107,,First line of therapy,Induction,,Lenalidomide,,,Checked,,,25,mg,,QD,,PO,,1,,1
MMRF_2107,,First line of therapy,Induction,,Dexamethasone,,,Checked,,,40,mg,,Q w,,PO,,1,,1
MMRF_2144,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,68,1
MMRF_2144,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,QD,,PO,,1,68,1
MMRF_2144,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,Days 1 and 8 of every 21 day cycle,IV,,1,68,1
MMRF_2144,,First line of therapy,Induction,,Lenalidomide,,,Checked,,,10,mg,,QD,,PO,,253,,1
MMRF_2176,Baseline,First line of therapy,Induction,,Bortezomib,,,Checked,,,1.3,mg/m^,,Q w,,IV SubQ,,1,,1
MMRF_2176,,First line of therapy,Induction,,Dexamethasone,,,Checked,,,40,mg,,Q w,,PO,,1,,1
MMRF_2176,,First line of therapy,Induction,,Lenalidomide,,,Checked,,,25,mg,,QD,,PO,,1,,1
MMRF_2180,Baseline,First line of therapy,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,15,mg,,QD,,PO,,1,102,1
MMRF_2180,,First line of therapy,Induction,,Dexamethasone,,,,Lack of response,,10,mg,,Q w,,PO,,1,176,1
MMRF_2180,,First line of therapy,Induction,,Bortezomib,,,,Lack of response,,1.3,mg/m^,,Q w,,IV SubQ,,1,176,1
MMRF_2180,,First line of therapy,Induction,,Cyclophosphamide,,,,Lack of response,,50,mg,,Q w,,PO,,102,176,1
MMRF_2180,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,5,mg,,Oth,TIW,PO,,176,380,1
MMRF_2180,,First line of therapy,Induction,,Prednisone,,,,Completed regimen,,30,mg,,Oth,TIW,PO,,176,380,1
MMRF_2180,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,20,mg/m^,,QD,,IV,,176,380,1
MMRF_2180,,First line of therapy,Consolidation,,Daratumumab,,,Checked,,,16,mg/kg,,Oth,QOW,IV,,1033,,1
MMRF_2180,,First line of therapy,Consolidation,,Dexamethasone,,,Checked,,,4,mg,,Oth,2 days post Dara infusion,PO,,1033,,1
MMRF_2199,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,Q w,,IV SubQ,,1,237,1
MMRF_2199,,First line of therapy,Induction,,Dexamethasone,,,Checked,,,20,mg,,Q w,,PO,,1,,1
MMRF_2199,,First line of therapy,Induction,,Lenalidomide,,,Checked,,,15,mg,,QD,,PO,,13,,1
MMRF_2207,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,122,1
MMRF_2207,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,Q w,,IV SubQ,,1,122,1
MMRF_2207,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Q w,,PO,,1,122,1
MMRF_2207,,First line of therapy,Consolidation,,Melphalan,,,,Completed regimen,,200,mg/m^,,Oth,once,IV,,172,172,1
MMRF_2207,,First line of therapy,Consolidation,,Dexamethasone,,,Checked,,,20,mg,,Q w,,PO,,323,,1
MMRF_2207,,First line of therapy,Consolidation,,Lenalidomide,,,Checked,,,15,mg,,QD,,PO,,323,,1
MMRF_2207,,First line of therapy,Consolidation,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Q w,,IV,,323,802,1
MMRF_2207,,First line of therapy,Consolidation,,Ixazomib,,,Checked,,,3,mg,,Q w,,PO,,802,,1
MMRF_2240,Baseline,First line of therapy,Induction,,Bortezomib,,,,Lack of response,,1.3,mg/m^,,Oth,"D1, D8, D15",IV SubQ,,1,90,1
MMRF_2240,,First line of therapy,Induction,,Cyclophosphamide,,,,Lack of response,,300,mg/m^,,Oth,D1 and D8,PO,,1,68,1
MMRF_2240,,First line of therapy,Induction,,Dexamethasone,,,,Disease progression/Relapse,,20,mg,,QWK,,PO,,1,91,1
MMRF_2240,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,27,mg/m^,,QD,,IV,,202,672,1
MMRF_2240,,First line of therapy,Consolidation,,Dexamethasone,,,,Lack of response,,20,mg,,Oth,weekly x 3 weeks on/1 week off,PO,,91,202,1
MMRF_2240,,First line of therapy,Consolidation,,Lenalidomide,,,,Lack of response,,25,mg,,QD,,PO,,91,202,1
MMRF_2240,,First line of therapy,Consolidation,,Bortezomib,,,,Lack of response,,1.3,mg/m^,,Oth,weekly x 3 weeks on/1 week off,IV SubQ,,91,202,1
MMRF_2240,,First line of therapy,Consolidation,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,202,672,1
MMRF_2240,,First line of therapy,Consolidation,,Dexamethasone,,,,Completed regimen,,10,mg,,QD,,PO,,202,672,1
MMRF_2240,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,200,mg/m^,,Oth,once,IV,,733,733,1
MMRF_2240,,Second Line Therapy (after,Consolidation,,Daratumumab,,,Checked,,,16,mg/m^,,Oth,once weekly,IV,,849,,1
MMRF_2240,,Second Line Therapy (after,Consolidation,,Dexamethasone,,,Checked,,,12,mg,,Oth,D1 and D2 after Dara infusion,PO,,849,,1
MMRF_2240,,Second Line Therapy (after,Consolidation,,Pomalidomide,,,Checked,,,2,mg,,QD,,PO,,846,,1
MMRF_2289,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV,,1,239,1
MMRF_2289,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,D1-D14,PO,,1,239,1
MMRF_2289,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"D1, D2, D4, D5, D8, D9, D10, D11",PO,,1,239,1
MMRF_2289,,Second Line Therapy (after,Consolidation,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,QD,,IV,,359,431,1
MMRF_2289,,Second Line Therapy (after,Consolidation,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,359,431,1
MMRF_2289,,Second Line Therapy (after,Consolidation,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,PO,,359,431,1
MMRF_2289,,Second Line Therapy (after,Consolidation,,Melphalan,,,,Completed regimen,,200,mg/m^,,Oth,once,IV,,442,442,1
MMRF_2289,,First line of therapy,Maintenance,,Lenalidomide,,,,Disease progression/Relapse,,10,mg,,QD,,PO,,239,358,1
MMRF_2289,,Second Line Therapy (after,Maintenance,,Ixazomib,,,Checked,,,4,mg,,Q w,,PO,,550,,1
MMRF_2341,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,Q w,,IV SubQ,,1,85,1
MMRF_2341,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,85,1
MMRF_2341,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Q w,,PO,,1,85,1
MMRF_2344,Baseline,First line of therapy,Induction,,Bortezomib,,,,Lack of response,,1.3,mg/m^,,QD,,IV SubQ,,1,85,1
MMRF_2344,,First line of therapy,Induction,,Dexamethasone,,,Checked,,,40,mg,,QD,,PO,,1,,1
MMRF_2344,,First line of therapy,Induction,,Cyclophosphamide,,,,Lack of response,,300,mg,,Oth,"D1, D8",IV,,1,22,1
MMRF_2344,,Second Line Therapy (after,Consolidation,,Bortezomib,,,,Lack of response,,1.3,mg/m^,,Q w,,IV SubQ,,219,328,1
MMRF_2344,,First line of therapy,Induction,,Lenalidomide,,,,Disease progression/Relapse,,25,mg,,QD,,PO,,22,175,1
MMRF_2344,,Second Line Therapy (after,Unknown,,Pomalidomide,,,,Completed regimen,,4,mg,,QD,,PO,,338,568,1
MMRF_2344,,First line of therapy,Consolidation,,Cyclophosphamide,,,,Lack of response,,300,mg/m^,,Q w,,IV,,106,267,1
MMRF_2344,,Second Line Therapy (after,Consolidation,,Cyclophosphamide,,,,Disease progression/Relapse,,250,mg/m^,,Q w,,IV SubQ,,279,328,1
MMRF_2344,,Second Line Therapy (after,Consolidation,,Lenalidomide,,,,Disease progression/Relapse,,15,mg,,Q d,,PO,,279,328,1
MMRF_2344,,Second Line Therapy (after,Unknown,,Daratumumab,,,,Completed regimen,,16,mg/kg,,QD,,IV,,338,568,1
MMRF_2344,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,200,mg/m^,,Oth,once,IV,,572,572,1
MMRF_2353,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,Oth,"Day 1, 8 , 15",IV SubQ,,1,127,1
MMRF_2353,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,"day 1, 8, 15",PO,,1,127,1
MMRF_2353,,First line of therapy,Induction,,Lenalidomide,,,,Lack of response,,25,mg,,QD,,PO,,1,288,1
MMRF_2353,,First line of therapy,Consolidation,,Melphalan,,,,Completed regimen,,200,mg/m^,,Oth,once,IV,,443,443,1
MMRF_2353,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,500,mg,,Oth,weekly,PO,,176,394,1
MMRF_2353,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,176,394,1
MMRF_2353,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,weekly,PO,,176,394,1
MMRF_2366,,First line of therapy,Induction,,Dexamethasone,,,,Disease progression/Relapse,,20,mg,,Oth,"D 1, 8, 15",PO,,1,42,1
MMRF_2366,,First line of therapy,Induction,,Cyclophosphamide,,,,Disease progression/Relapse,,250,mg/m^,,Oth,"D 1, 8 15",IV,,1,42,1
MMRF_2366,Baseline,First line of therapy,Induction,,Bortezomib,,,,Disease progression/Relapse,,1.3,mg/m^,,Oth,"D 1, 8, 15",IV SubQ,,1,42,1
MMRF_2366,,Second Line Therapy (after,Consolidation,,Bortezomib,,,,Disease progression/Relapse,,1.32,mg/m^,,Oth,"D 1,8,15",IV SubQ,,80,261,1
MMRF_2366,,Second Line Therapy (after,Consolidation,,Dexamethasone,,,,Disease progression/Relapse,,20,mg,,Oth,"Day 1,8,15",PO,,80,261,1
MMRF_2366,,Second Line Therapy (after,Consolidation,,Lenalidomide,,,,Adverse Event or co-morbidity,,15,mg,,QD,,PO,,80,164,1
MMRF_2366,,Third Line Therapy (followi,Consolidation,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"D1, 8, 15",PO,,324,387,1
MMRF_2366,,Third Line Therapy (followi,Consolidation,,Dexamethasone,,,,Completed regimen,,4,mg,,Oth,"D2, 9, 16",PO,,324,387,1
MMRF_2366,,Second Line Therapy (after,Unknown,,Bendamustine,,,,Disease progression/Relapse,,70,mg/m^,,Oth,"days 1, 4",IV,,261,287,1
MMRF_2366,,Third Line Therapy (followi,Consolidation,,Dexamethasone,,,Checked,,,4,mg,,QD,,PO,,387,,1
MMRF_2366,,Second Line Therapy (after,Consolidation,,Bortezomib,,,,Disease progression/Relapse,,1.3,mg/m^,,Oth,"day 1, 4",IV,,261,287,1
MMRF_2366,,Second Line Therapy (after,Consolidation,,Dexamethasone,,,,Disease progression/Relapse,,20,mg,,Oth,"day 1, 4",PO,,261,287,1
MMRF_2366,,Third Line Therapy (followi,Consolidation,,Carfilzomib,,,Checked,,,20,mg/m^,,QD,,IV,,324,,1
MMRF_2373,,First line of therapy,Induction,,Lenalidomide,,,,Disease progression/Relapse,,25,mg,,QD,,PO,,1,146,1
MMRF_2373,,First line of therapy,Induction,,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,Oth,"D 1, 4, 11 , 18",PO,,1,146,1
MMRF_2373,Baseline,First line of therapy,Induction,,Bortezomib,,,,Disease progression/Relapse,,1.3,mg/m^,,Oth,"D 1, 4 , 11, 18",IV SubQ,,1,146,1
MMRF_2373,,Second Line Therapy (after,Consolidation,,Lenalidomide,,,,Disease progression/Relapse,,15,mg,,QD,,PO,,274,515,1
MMRF_2373,,Second Line Therapy (after,Consolidation,,Carfilzomib,,,,Disease progression/Relapse,,20,mg/m^,,QD,,IV,,274,351,1
MMRF_2373,,Second Line Therapy (after,Consolidation,,Dexamethasone,,,,Disease progression/Relapse,,20,mg,,QD,,PO,,274,515,1
MMRF_2373,,Second Line Therapy (after,Consolidation,,Carfilzomib,,,,Disease progression/Relapse,,36,mg/m^,,QD,,IV,,361,515,1
MMRF_2404,Baseline,First line of therapy,Induction,,Bortezomib,,,,Disease progression/Relapse,,1.3,mg/m^,,Oth,weekly x 3 weeks on / 1 week off,IV SubQ,,1,29,1
MMRF_2404,,First line of therapy,Induction,,Cyclophosphamide,,,,Disease progression/Relapse,,300,mg/m^,,Oth,"days 1 ,8",IV,,1,29,1
MMRF_2404,,First line of therapy,Induction,,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,Oth,weekly x 3 weeks on / 1 week off,PO,,1,29,1
MMRF_2404,,First line of therapy,Consolidation,,Melphalan,,,,Completed regimen,,200,mg/m^,,Oth,once,IV,,103,103,1
MMRF_2404,,First line of therapy,Consolidation,,Cyclophosphamide,,,,Disease progression/Relapse,,400,mg/m^,,QD,,PO,,33,202,1
MMRF_2404,,First line of therapy,Consolidation,,Other,Cisplatin,,,Disease progression/Relapse,,15,mg/m^,,QD,,IV,,33,202,1
MMRF_2404,,Second Line Therapy (after,Consolidation,,Carfilzomib,,,,Disease progression/Relapse,,27,mg/m^,,Q d,,IV,,207,245,1
MMRF_2404,,First line of therapy,Consolidation,,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,Q d,,IV,,33,202,1
MMRF_2404,,First line of therapy,Consolidation,,Other,Etoposide,,,Disease progression/Relapse,,40,mg/m^,,Q d,,IV,,33,202,1
MMRF_2404,,Second Line Therapy (after,Consolidation,,Lenalidomide,,,,Disease progression/Relapse,,25,mg,,Q d,,PO,,207,245,1
MMRF_2404,,Second Line Therapy (after,Consolidation,,Dexamethasone,,,,Disease progression/Relapse,,10,mg,,Q d,,PO,,207,245,1
MMRF_2410,Baseline,First line of therapy,Induction,,Bortezomib,,,Checked,,,1.3,mg/m^,,QD,,IV SubQ,,1,,1
MMRF_2410,,First line of therapy,Induction,,Lenalidomide,,,Checked,,,25,mg,,QD,,PO,,1,,1
MMRF_2410,,First line of therapy,Induction,,Dexamethasone,,,,Investigator decision for other reasons,,40,mg,,QD,,PO,,1,64,1
MMRF_2410,,First line of therapy,Induction,,Dexamethasone,,,Checked,,,20,mg,,QD,,PO,,75,,1
MMRF_2445,Baseline,First line of therapy,Consolidation,,Bortezomib,,,,Completed regimen,,2.75,mg,,Oth,2x a week,IV SubQ,,1,361,1
MMRF_2445,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,QD,,PO,,1,479,1
MMRF_2445,,First line of therapy,Induction,,Lenalidomide,,,,Disease progression/Relapse,,25,mg,,QD,,PO,,116,479,1
MMRF_2445,,Third Line Therapy (followi,Consolidation,,Dexamethasone,,,,Completed regimen,,20,mg,,QD,,PO,,779,782,1
MMRF_2445,,Second Line Therapy (after,Consolidation,,Lenalidomide,,,,Disease progression/Relapse,,20,mg,,QD,,PO,,592,691,1
MMRF_2445,,Second Line Therapy (after,Consolidation,,Elotuzumab,,,,Disease progression/Relapse,,10,mg/kg,,Q w,,IV,,585,704,1
MMRF_2445,,Third Line Therapy (followi,Consolidation,,Other,cisplatin,,,Completed regimen,,7.5,mg/m^,,QD,,IV,,779,782,1
MMRF_2445,,Third Line Therapy (followi,Consolidation,,Cyclophosphamide,,,,Completed regimen,,250,mg/m^,,QD,,IV,,779,782,1
MMRF_2445,,Third Line Therapy (followi,Consolidation,,Other,etoposide,,,Completed regimen,,20,mg/m^,,QD,,IV,,779,782,1
MMRF_2445,,Third Line Therapy (followi,Consolidation,,Daratumumab,,,Checked,,,16,mg/kg,,Oth,QOW,IV,,802,,1
MMRF_2457,Baseline,First line of therapy,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,1.3,mg/m^,,Oth,"weekly X3, 3 weekd on 1/week off",IV SubQ,,1,9,1
MMRF_2457,,First line of therapy,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,20,mg,,Oth,"weekly X 3, 3 weeks on/1 week off",PO,,1,40,1
MMRF_2457,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,331,1
MMRF_2457,,First line of therapy,Induction,,Cyclophosphamide,,,,Disease progression/Relapse,,1.5,mg/m^,,Q w,,PO,,40,331,1
MMRF_2457,,First line of therapy,Induction,,Prednisone,,,,Completed regimen,,10,mg,,Oth,three times week,PO,,40,162,1
MMRF_2457,,First line of therapy,Consolidation,,Dexamethasone,,,,Completed regimen,,20,mg,,Q w,,PO,,162,198,1
MMRF_2457,,Second Line Therapy (after,Consolidation,,Melphalan,,,,Completed regimen,,200,mg/m^,,Oth,once,IV,,369,369,1
MMRF_2457,,First line of therapy,Consolidation,,Prednisone,,,,Disease progression/Relapse,,10,mg,,Oth,three times week,PO,,223,331,1
MMRF_2457,,Second Line Therapy (after,Consolidation,,Elotuzumab,,,,Disease progression/Relapse,,10,mg/m^,,Oth,"Days 1, 8, 15, 22",IV,,587,699,1
MMRF_2457,,Second Line Therapy (after,Consolidation,,Pomalidomide,,,,Disease progression/Relapse,,4,mg/dL,,QD,,PO,,587,699,1
MMRF_2457,,Second Line Therapy (after,Consolidation,,Dexamethasone,,,,Disease progression/Relapse,,28,mg,,Oth,"Days 1, 8, 15, 22",PO,,587,699,1
MMRF_2457,,Third Line Therapy (followi,Consolidation,,Daratumumab,,,,Disease progression/Relapse,,1800,mg,,Q w,,IV SubQ,,734,805,1
MMRF_2457,,Fourth Line Therapy (follow,Consolidation,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,q24H,PO,,825,828,1
MMRF_2457,,Fourth Line Therapy (follow,Consolidation,,Cyclophosphamide,,,,Completed regimen,,10,mg/m^,,Oth,q24H,IV,,825,828,1
MMRF_2457,,Fourth Line Therapy (follow,Consolidation,,Other,cisplatin,,,Completed regimen,,10,mg/m^,,Oth,q24H,IV,,825,828,1
MMRF_2457,,Fourth Line Therapy (follow,Consolidation,,Other,etoposide,,,Completed regimen,,30,mg/m^,,Oth,q24H,IV,,825,828,1
MMRF_2457,,Fourth Line Therapy (follow,Consolidation,,Daratumumab,,,,Disease progression/Relapse,,16,mg/kg,,Q w,,IV,,881,916,1
MMRF_2457,,Fourth Line Therapy (follow,Consolidation,,Pomalidomide,,,,Disease progression/Relapse,,4,mg,,QD,,PO,,881,893,1
MMRF_2457,,Fourth Line Therapy (follow,Consolidation,,Panobinostat,,,,Disease progression/Relapse,,15,mg,,Oth,every other day.,PO,,905,929,1
MMRF_2457,,Seventh Line of Therapy (fo,Unknown,,Dexamethasone,,,,Disease progression/Relapse,,8,mg,,QD,,IV,,1051,1058,1
MMRF_2457,,Seventh Line of Therapy (fo,Unknown,,Carfilzomib,,,,Completed regimen,,20,mg/m^,,QD,,IV,,1051,1058,1
MMRF_2457,,Seventh Line of Therapy (fo,Unknown,,Pomalidomide,,,,Disease progression/Relapse,,2,mg,,QD,,PO,,1051,1058,1
MMRF_2469,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,QD,,IV,,1,235,1
MMRF_2469,Baseline,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,8,235,1
MMRF_2469,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,235,1
MMRF_2469,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,200,mg/m^,,Oth,once,IV,,396,396,1
MMRF_2469,,First line of therapy,Consolidation,,Elotuzumab,,,,Completed regimen,,20,mg/m^,,Oth,day 1 of every 28 day cycle,IV,,401,708,1
MMRF_2469,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,10,mg,,QD,,PO,,736,,1
MMRF_2472,,First line of therapy,Induction,,Cyclophosphamide,,,,Lack of response,,500,mg,,Q w,,PO,,1,1,1
MMRF_2472,,First line of therapy,Induction,,Dexamethasone,,,Checked,,,40,mg,,QWK,,PO,,1,,1
MMRF_2472,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QWK,,IV SubQ,,1,1086,1
MMRF_2472,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,36,283,1
MMRF_2472,,First line of therapy,Induction,,Lenalidomide,,,Checked,,,15,mg,,QD,,PO,,283,,1
MMRF_2498,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,106,1
MMRF_2498,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,PO,,1,111,1
MMRF_2498,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,111,1
MMRF_2498,,First line of therapy,Consolidation,,Melphalan,,,,Completed regimen,,200,mg/m^,,Oth,once,IV,,173,173,1
MMRF_2498,,First line of therapy,Maintenance,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,Oth,twice monthly,IV SubQ,,288,343,1
MMRF_2498,,First line of therapy,Maintenance,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,twice monthly,PO,,288,343,1
MMRF_2498,,First line of therapy,Maintenance,,Ixazomib,,,Checked,,,4,mg,,QD,,PO,,338,,1
MMRF_2538,,First line of therapy,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,25,mg,,QD,,PO,,1,77,1
MMRF_2538,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,PO,,1,99,1
MMRF_2538,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,Oth,"D1,8,15,22",IV SubQ,,1,727,1
MMRF_2538,,First line of therapy,Induction,,Prednisone,,,,Completed regimen,,30,mg,,Oth,"Q Monday, Wed, Friday",PO,,162,727,1
MMRF_2538,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,"q 3 weeks on, 1 week off",IV,,92,99,1
MMRF_2538,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,10,mg,,QD,,PO,,162,727,1
MMRF_2538,,First line of therapy,Induction,,Elotuzumab,,,,Disease progression/Relapse,,10,mg/kg,,Q w,,IV,,727,977,1
MMRF_2538,,First line of therapy,Induction,,Prednisone,,,,Disease progression/Relapse,,10,mg,,Oth,MWF,PO,,727,977,1
MMRF_2538,,First line of therapy,Induction,,Lenalidomide,,,,Disease progression/Relapse,,10,mg,,QD,,PO,,727,977,1
MMRF_2538,,Second Line Therapy (after,Maintenance,,Bortezomib,,,Checked,,,1.3,mg/m^,,Oth,"D1,8, 15, 22",IV,,1075,,1
MMRF_2538,,Second Line Therapy (after,Unknown,,Daratumumab,,,Checked,,,16,mg/m^,,Oth,"D1,8,15,22",IV,,1075,,1
MMRF_2550,,First line of therapy,Induction,,Dexamethasone,,,Checked,,,20,mg,,QD,,PO,,1,,1
MMRF_2550,,First line of therapy,Induction,,Lenalidomide,,,Checked,,,25,mg,,QD,,PO,,1,,1
MMRF_2550,Baseline,First line of therapy,Induction,,Bortezomib,,,Checked,,,1.3,mg/m^,,QD,,IV SubQ,,1,,1
MMRF_2564,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Q w,,PO,,1,414,1
MMRF_2564,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Q w,,PO,,1,71,1
MMRF_2564,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,Q w,,IV SubQ,,1,71,1
MMRF_2564,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,200,mg/m^,,Oth,once,IV,,118,118,1
MMRF_2577,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,Q w,,IV SubQ,,1,191,1
MMRF_2577,,First line of therapy,Induction,,Cyclophosphamide,,,,Investigator decision for other reasons,,200,mg/m^,,Q w,,IV,,1,171,1
MMRF_2577,,First line of therapy,Induction,,Dexamethasone,,,Checked,,,40,mg,,Q w,,PO,,1,,1
MMRF_2577,,First line of therapy,Induction,,Lenalidomide,,,Checked,,,15,mg,,QD,,PO,,171,,1
MMRF_2577,,First line of therapy,Induction,,Ixazomib,,,Checked,,,4,mg,,Oth,"D1,8,15",PO,,185,,1
MMRF_2577,,First line of therapy,Induction,,Daratumumab,,,Checked,,,16,mg/m^,,Q w,,IV,,470,,1
MMRF_2614,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,Q w,,IV SubQ,,1,180,1
MMRF_2614,,First line of therapy,Induction,,Lenalidomide,,,Checked,,,25,mg,,QD,,PO,,1,,1
MMRF_2614,,First line of therapy,Induction,,Dexamethasone,,,Checked,,,40,mg,,Q w,,PO,,1,,1
MMRF_2614,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,200,mg/m^,,Oth,once,IV,,181,181,1
MMRF_1037,,First line of therapy,,,Dexamethasone,,,,Patient decision,,40,mg,,QD,,PO,,1,88,1
MMRF_1037,Baseline,First line of therapy,,,Lenalidomide,,,,Patient decision,,25,mg,,QD,,PO,,15,88,1
MMRF_1088,Baseline,First line of therapy,,,Bortezomib,,,,Adverse Event or co-morbidity,,2.7,mg,,QD,,IVB,,3,87,1
MMRF_1088,,First line of therapy,,,Dexamethasone,,,,Adverse Event or co-morbidity,,40,mg,,QD,,PO,,1,13,1
MMRF_1088,,First line of therapy,,,Lenalidomide,,,,Adverse Event or co-morbidity,,25,mg,,QD,,PO,,124,126,1
MMRF_1088,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg,,QD,,IV,,109,118,1
MMRF_1102,Baseline,First line of therapy,,,Thalidomide,,,,Patient decision,,200,mg,,Q d,,PO,,28,34,1
MMRF_1102,,First line of therapy,,,Dexamethasone,,,,Adverse Event or co-morbidity,,20,mg,,Q w,,PO,,1,13,1
MMRF_1128,Baseline,First line of therapy,,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IVB,,1,116,1
MMRF_1128,,First line of therapy,,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,Day 1 & 8,IV,,1,40,1
MMRF_1128,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,4,mg,,Oth,"Day 1-2, 4-5, 8-9, 11-12",PO,,1,117,1
MMRF_1128,,First line of therapy,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,10,mg,,QD,,PO,,313,537,1
MMRF_1128,,First line of therapy,Induction,,Thalidomide,,,,Completed regimen,,100,mg,,Q d,,PO,,62,147,1
MMRF_1128,,First line of therapy,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,5,mg,,QD,,PO,,537,634,1
MMRF_1128,,First line of therapy,Maintenance,,Lenalidomide,,,,Patient decision,,5,mg,,Oth,QOD D1-21,PO,,634,1118,1
MMRF_1128,,First line of therapy,Consolidation,,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,214,215,1
MMRF_1475,Baseline,First line of therapy,Induction,,Lenalidomide,,,Checked,,,25,mg,,QD,,PO,,1,,1
MMRF_1735,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/dL,,QD,,IV SubQ,,1,74,1
MMRF_1735,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Q w,,PO,,1,85,1
MMRF_1735,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,85,1
MMRF_1735,,First line of therapy,Maintenance,,Lenalidomide,,,,Disease progression/Relapse,,10,mg,,QD,,PO,,241,507,1
MMRF_1735,,First line of therapy,Maintenance,,Lenalidomide,,,,Investigator decision for other reasons,,5,mg,,QD,,PO,,176,241,1
MMRF_1735,,Second Line Therapy (after,Unknown,,Pomalidomide,,,,Investigator decision for other reasons,,4,mg,,QD,,PO,,516,1011,1
MMRF_1735,,Second Line Therapy (after,Unknown,,Dexamethasone,,,,Adverse Event or co-morbidity,,40,mg,,Q w,,PO,,516,718,1
MMRF_1735,,First line of therapy,Consolidation,,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,106,107,1
MMRF_1735,,Second Line Therapy (after,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,20,mg,,QWK,,PO,,718,764,1
MMRF_1061,,First line of therapy,,,Dexamethasone,,,,Other,Autologous bone marrow transplant,20,mg,,Oth,"Days 1,2, 4,5, 8, 9, 11, 12",PO,,1,74,1
MMRF_1061,Baseline,First line of therapy,,,Bortezomib,,,,Other,Autologous bone marrow transplant,1.3,mg/m^,,QD,,IV SubQ,,1,74,1
MMRF_1061,,First line of therapy,,,Lenalidomide,,,,Other,Autologous Bone marrow transplant,25,mg,,QD,,PO,,15,74,1
MMRF_1061,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,240,mg,,Q d,,IV,,118,118,1
MMRF_1061,,Second Line Therapy (after,Induction,,Carfilzomib,,,Checked,,,43,mg,,Oth,every other week,IV,,2061,,1
MMRF_1068,Baseline,First line of therapy,,,Bortezomib,,,,Completed regimen,,2.7,mg,,QD,,IV SubQ,,1,78,1
MMRF_1068,,First line of therapy,,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,64,1
MMRF_1068,,First line of therapy,,,Lenalidomide,,,,Completed regimen,,15,mg,,QD,,PO,,239,407,1
MMRF_1068,,First line of therapy,,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QWK,,IV SubQ,,239,407,1
MMRF_1068,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,4,mg,,QD,,PO,,239,407,1
MMRF_1068,,Second Line Therapy (after,Induction,,Carfilzomib,,,,Disease progression/Relapse,,20,mg/m^,,QWK,,IV,,477,535,1
MMRF_1068,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,4,mg,,Oth,Days 1 - 7,PO,,1,78,1
MMRF_1068,,First line of therapy,Other,Melphalan,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,127,127,1
MMRF_1065,,First line of therapy,,,Lenalidomide,,,Checked,,,25,mg,,QD,,PO,,71,,1
MMRF_1065,Baseline,First line of therapy,,,Bortezomib,,,,Completed regimen,,2.1,mg,,QD,,IV SubQ,,1,81,1
MMRF_1065,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,4,mg,,Oth,"Days 1,2,3,4,5",PO,,1,214,1
MMRF_1065,,First line of therapy,Other,Malphalan,Melphalan,,,,Completed regimen,,100,mg/m^,,Q d,,IV,,124,125,1
MMRF_1368,Baseline,First line of therapy,,,Bortezomib,,,,Completed regimen,,2.7,mg,,QD,,IV SubQ,,1,282,1
MMRF_1368,,First line of therapy,,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,282,1
MMRF_1368,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,4,mg,,Oth,"Days 1,2,3,4,5",PO,,1,282,1
MMRF_1368,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,10,mg,,Oth,Days 1 - 28,PO,,299,,1
MMRF_1368,,First line of therapy,Other,Transplant,Other,Mozobil,,,Completed regimen,,26,mg,,Q d,,IV SubQ,,148,150,1
MMRF_1180,,First line of therapy,,,Cyclophosphamide,,,,Completed regimen,,50,mg,,Q d,,PO,,7,539,1
MMRF_1180,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,40,mg,,Q d,,PO,,1,125,1
MMRF_1180,Baseline,First line of therapy,,,Bortezomib,,,,Completed regimen,,2.3,mg,,Oth,"D1, D8, D22",IV,,7,112,1
MMRF_1180,,First line of therapy,Other,Transplant,Other,Melphalan,,,Completed regimen,,50,mg,,Q d,,IV,,194,194,1
MMRF_1180,,First line of therapy,Other,Transplant,Other,Alkeran,,,Completed regimen,,215,mg,,Q d,,IV,,194,194,1
MMRF_1188,,First line of therapy,,,Bendamustine,,,,Completed regimen,,156,mg,,Oth,"D1, D2",IV,,1,234,1
MMRF_1188,,First line of therapy,,,Dexamethasone,,,Checked,,,20,mg,,QD,,PO,,1,,1
MMRF_1188,Baseline,First line of therapy,,,Bortezomib,,,,Completed regimen,,2.54,mg,,QD,,IV,,1,800,1
MMRF_1188,,First line of therapy,Induction,,Elotuzumab,,,,Adverse Event or co-morbidity,,778,mg,,Oth,Unknown,IV,,1198,1331,1
MMRF_1188,,Second Line Therapy (after,Induction,,Lenalidomide,,,,Investigator decision for other reasons,,5,mg,,QD,,PO,,1303,1352,1
MMRF_1188,,Second Line Therapy (after,Induction,,Ixazomib,,,,Adverse Event or co-morbidity,,3,mg,,Oth,"Days 1, 8, 15, and 28/cycle",PO,,1479,1647,1
MMRF_1213,Baseline,First line of therapy,,,Lenalidomide,,,,Investigator decision for other reasons,,15,mg,,QD,,PO,,1,1638,1
MMRF_1213,,First line of therapy,,,Bortezomib,,,,Disease progression/Relapse,,2.9,mg,,Oth,"Days 1, 4, 8, 22",Other,Subcutaneous,34,217,1
MMRF_1213,,First line of therapy,Unknown,,Dexamethasone,,,,Other,death,4,mg,,Oth,"Days 1,2,3,4,5",PO,,224,1694,1
MMRF_1213,,First line of therapy,Unknown,,Pomalidomide,,,,Adverse Event or co-morbidity,,2,mg,,QD,,PO,,210,1251,1
MMRF_1213,,Second Line Therapy (after,Induction,,Carfilzomib,,,,Adverse Event or co-morbidity,,85,mg,,Q d,,IV,,1055,1384,1
MMRF_1213,,Second Line Therapy (after,Induction,,Elotuzumab,,,,Other,lack of insurance,993,mg,,QWK,,IV,,1271,1450,1
MMRF_1213,,Third Line Therapy (followi,Induction,,Daratumumab,,,,Other,death,1364,mg,,QWK,,IV,,1462,1694,1
MMRF_1268,Baseline,First line of therapy,,,Bortezomib,,,,Adverse Event or co-morbidity,,2.7,mg,,QD,,IV,,1,100,1
MMRF_1268,,First line of therapy,,,Other,Bendamustine,,,Adverse Event or co-morbidity,,167,mg,,Oth,Days 1 & 2,IV,,1,87,1
MMRF_1268,,First line of therapy,,,Dexamethasone,,,,Adverse Event or co-morbidity,,12,mg,,Oth,"Days 1, 2, 8, 15",IV,,1,100,1
MMRF_1331,,First line of therapy,,,Lenalidomide,,,,Lack of response,,10,mg,,QD,,PO,,1,99,1
MMRF_1331,Baseline,First line of therapy,,,Bortezomib,,,,Lack of response,,2.8,mg,,QD,,Other,Subcutaneous,1,99,1
MMRF_1331,,First line of therapy,,,Dexamethasone,,,,Lack of response,,20,mg,,Oth,"Days 1, 2, 4, 5, 8, 9, 11, and 12",PO,,1,99,1
MMRF_1331,,First line of therapy,Other,"Second Line of Treatment, Prior to Relapse",Lenalidomide,,,Checked,,,10,mg,,QD,,PO,,102,,1
MMRF_1331,,First line of therapy,Other,"Second Line of Treatment, Prior to relapse",Dexamethasone,,,Checked,,,4,mg,,Oth,Daily 1-10,PO,,102,,1
MMRF_1487,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,2.4,mg,,QD,,IV SubQ,,1,970,1
MMRF_1487,,First line of therapy,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,15,mg,,QD,,PO,,1,60,1
MMRF_1487,,First line of therapy,Other,Transplant,Melphalan,,,,Completed regimen,,170,mg,,Q d,,IV,,184,185,1
MMRF_1487,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,4,mg,,Oth,"Days 1,2,4,5, 8,9,11,12",PO,,1,136,1
MMRF_1541,Baseline,First line of therapy,Induction,,Carfilzomib,,,,Disease progression/Relapse,,36,mg/m^,,Oth,"C1-C8: D1, D2, D8, D9, D15, D16, D22",IV,,1,204,1
MMRF_1541,,,,,,,,,,,,,,,,,,,,1
MMRF_1541,,First line of therapy,Induction,,Lenalidomide,,,,Disease progression/Relapse,,25,mg,,QD,,PO,,1,204,1
MMRF_1541,,First line of therapy,Induction,,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,Oth,"Day 1, 8, 15, & 22",IV,,1,204,1
MMRF_1541,,Second Line Therapy (after,Consolidation,,Pomalidomide,,,,Disease progression/Relapse,,3,mg,,QD,,PO,,379,561,1
MMRF_1541,,Third Line Therapy (followi,Maintenance,,Other,KPT-330,,,Disease progression/Relapse,,40,mg,,QD,,PO,,561,645,1
MMRF_1541,,Fourth Line Therapy (follow,Maintenance,,Carfilzomib,,,,Completed regimen,,61,mg,,Q d,,IV,,676,860,1
MMRF_1541,,Fifth Line Therapy (followi,Maintenance,,Dexamethasone,,,Checked,,,40,mg,,QWK,,PO,,889,,1
MMRF_1541,,Fifth Line Therapy (followi,Maintenance,,Daratumumab,,,,Disease progression/Relapse,,1700,mg,,Q d,,IV,,902,1308,1
MMRF_1541,,Sixth Line Therapy (followi,Induction,,Daratumumab,,,,Completed regimen,,20,Other,mg/mL,QWK,,IV,,1295,1469,1
MMRF_1541,,Sixth Line Therapy (followi,Induction,,Lenalidomide,,,Checked,,,25,mg,,QD,,PO,,1309,,1
MMRF_1603,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,400,mg,,QD,,IV,,1,280,1
MMRF_1603,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,280,1
MMRF_1603,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,"D1, D8, D15",IV,,1,280,1
MMRF_1603,,First line of therapy,Maintenance,,Lenalidomide,,,,Investigator decision for other reasons,,10,mg,,QD,,PO,,280,403,1
MMRF_1603,,First line of therapy,Maintenance,,Bortezomib,,,,Investigator decision for other reasons,,2.4,mg,,Q d,,IV SubQ,,731,819,1
MMRF_1603,,Second Line Therapy (after,Maintenance,,Dexamethasone,,,Checked,,,4,mg,,Q w,,PO,,731,,1
MMRF_1664,Baseline,First line of therapy,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,25,mg,,QD,,PO,,1,940,1
MMRF_1664,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,"Days 1, 8, 15, 22",PO,,17,676,1
MMRF_1664,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,76,mg,,QD,,IV,,17,676,1
MMRF_1664,,First line of therapy,Other,Transplant,Melphalan,,,,Completed regimen,,100,mg/m^,,Q d,,IV,,174,175,1
MMRF_1664,,First line of therapy,Induction,,Lenalidomide,,,Checked,,,5,mg,,QD,,PO,,941,,1
MMRF_1719,Baseline,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,10,197,1
MMRF_1719,,First line of therapy,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,2.4,mg,,QD,,IV SubQ,,10,51,1
MMRF_1719,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,4,mg,,Oth,"Days 1,2,4,5, 8,9,11,12",PO,,1,197,1
MMRF_1719,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,200,mg/m^,,QD,,IV,,199,203,1
MMRF_1719,,First line of therapy,Maintenance,,Dexamethasone,,,,Adverse Event or co-morbidity,,4,mg,,Q w,,PO,,218,310,1
MMRF_1719,,First line of therapy,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,25,mg,,QD,,PO,,218,310,1
MMRF_1719,,First line of therapy,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,10,mg,,QD,,PO,,310,419,1
MMRF_1815,,First line of therapy,Induction,,Lenalidomide,,,,Patient decision,,25,mg,,QD,,PO,,1,117,1
MMRF_1815,Baseline,First line of therapy,Induction,,Dexamethasone,,,,Patient decision,,4,mg,,Oth,Days 1-5,PO,,1,117,1
MMRF_1880,,First line of therapy,Induction,,Lenalidomide,,,,Investigator decision for other reasons,,25,mg,,QD,,PO,,1,142,1
MMRF_1880,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,4,mg,,Oth,"Days 1,2,3,4,5",PO,,1,142,1
MMRF_1880,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,2.5,mg,,QD,,IV,,1,142,1
MMRF_1880,,First line of therapy,Other,Transplant,Melphalan,,,,Completed regimen,,170,mg,,Q d,,IV,,188,189,1
MMRF_1949,Baseline,First line of therapy,Induction,,Carfilzomib,,,,Investigator decision for other reasons,,68,mg,,QD,,IV,,1,667,1
MMRF_1949,,First line of therapy,Induction,,Lenalidomide,,,,Investigator decision for other reasons,,5,mg,,QD,,PO,,1,400,1
MMRF_1949,,First line of therapy,Induction,,Dexamethasone,,,Checked,,,4,mg,,Oth,Days 1-5,PO,,1,,1
MMRF_1949,,First line of therapy,Other,Transplant,Melphalan,,,,Completed regimen,,140,mg/m^,,Q d,,IV,,184,184,1
MMRF_1949,,Second Line Therapy (after,Induction,,Elotuzumab,,,,Disease progression/Relapse,,814,mg,,QD,,IV,,708,1369,1
MMRF_1949,,Second Line Therapy (after,Induction,,Pomalidomide,,,,Disease progression/Relapse,,4,mg,,QD,,PO,,708,1369,1
MMRF_1949,,Third Line Therapy (followi,Maintenance,,Daratumumab,,,Checked,,,1357,mg,,Oth,"C1-C2 (D1, D8, D15, D22), C3-ongoing (D1, D15)",IV,,1374,,1
MMRF_2216,,First line of therapy,Induction,,Lenalidomide,,,,Disease progression/Relapse,,15,mg,,QD,,PO,,12,385,1
MMRF_2216,Baseline,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,4,mg,,Oth,"Days 1, 8, 15, 22",PO,,1,77,1
MMRF_2429,,First line of therapy,Induction,,Lenalidomide,,,Checked,,,40,mg/dL,,Oth,"days 1,8,15",PO,,1,,1
MMRF_2429,Baseline,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,43,mg,,QD,,IV,,1,253,1
MMRF_2429,,First line of therapy,Induction,,Dexamethasone,,,Checked,,,40,mg,,Oth,"D 1,8,15, 22",IV SubQ,,1,,1
MMRF_2429,,First line of therapy,Induction,,Carfilzomib,,,,Investigator decision for other reasons,,77,mg,,Oth,"D 8-9, 15-16",IV SubQ,,1,625,1
MMRF_2539,,First line of therapy,Induction,,Dexamethasone,,,Checked,,,4,mg,,Oth,Days 1-10,PO,,1,,1
MMRF_2539,,First line of therapy,Induction,,Lenalidomide,,,Checked,,,25,mg,,QD,,PO,,1,,1
MMRF_2539,Baseline,First line of therapy,Induction,,Bortezomib,,,Checked,,,2.4,mg,,QD,,IV SubQ,,1,,1
MMRF_2562,Baseline,First line of therapy,Induction,,Bortezomib,,,,Disease progression/Relapse,,1.3,mg/m^,,QD,,IV SubQ,,1,137,1
MMRF_2562,,First line of therapy,Induction,,Dexamethasone,,,,Disease progression/Relapse,,4,mg,,Oth,Days 1-10,PO,,1,137,1
MMRF_2562,,First line of therapy,Induction,,Lenalidomide,,,,Disease progression/Relapse,,25,mg,,QD,,PO,,1,137,1
MMRF_2562,,Second Line Therapy (after,Induction,,Dexamethasone,,,,Other,Patient received ASCT,20,mg,,QWK,,IV,,298,396,1
MMRF_2562,,Second Line Therapy (after,Induction,,Carfilzomib,,,,Other,Patient received ASCT,56,mg/m^,,Q w,,IV,,199,396,1
MMRF_2562,,Third Line Therapy (followi,Unknown,,Pomalidomide,,,,Disease progression/Relapse,,4,mg,,QD,,PO,,704,1004,1
MMRF_2562,,Second Line Therapy (after,Unknown,,Dexamethasone,,,,Other,Patient underwent ASCT,40,mg,,QWK,,PO,,199,297,1
MMRF_2562,,Second Line Therapy (after,Unknown,,Lenalidomide,,,,Investigator decision for other reasons,,25,mg,,QD,,PO,,199,255,1
MMRF_2562,,Second Line Therapy (after,Maintenance,,Ixazomib,,,,Disease progression/Relapse,,3,mg,,Oth,"QD (D1, D8, D15)",PO,,585,661,1
MMRF_2562,,Third Line Therapy (followi,Unknown,,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,Oth,Q28D,PO,,704,1004,1
MMRF_2562,,Fourth Line Therapy (follow,Unknown,,Dexamethasone,,,Checked,,,20,mg,,Q w,,PO,,1038,,1
MMRF_2562,,Fourth Line Therapy (follow,Unknown,,Daratumumab,,,Checked,,,1432,mg,,Q w,,IV,,1039,,1
MMRF_2562,,Fourth Line Therapy (follow,Unknown,,Pomalidomide,,,Checked,,,3,mg/dL,,QD,,PO,,1038,,1
MMRF_1020,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,"QD (D1-4, D9-11)",PO,,1,61,1
MMRF_1020,Baseline,First line of therapy,,,Bortezomib,,,,Completed regimen,,2.5,mg,,QD,,IV SubQ,,6,91,1
MMRF_1020,,First line of therapy,,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,61,1
MMRF_1020,,Second Line Therapy (after,Induction,,Lenalidomide,,,,Disease progression/Relapse,,25,mg,,QD,,PO,,827,1360,1
MMRF_1020,,Second Line Therapy (after,Induction,,Bortezomib,,,,Disease progression/Relapse,,1.3,mg/m^,,QD,,IV,,827,1360,1
MMRF_1020,,Second Line Therapy (after,Induction,,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,Oth,"QD (D1-4, D9-11)",PO,,827,1360,1
MMRF_1020,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,200,mg,,Q d,,IV,,132,133,1
MMRF_1020,,Second Line Therapy (after,Induction,,Melphalan,,,,Completed regimen,,200,mg,,Q d,,IV,,987,988,1
MMRF_1020,,Third Line Therapy (followi,Induction,,Cyclophosphamide,,,,Investigator decision for other reasons,,300,mg/m^,,Oth,"D1, D8, D15",IV,,1370,1623,1
MMRF_1020,,Third Line Therapy (followi,Induction,,Dexamethasone,,,Checked,,,40,mg,,QWK,,PO,,1370,,1
MMRF_1020,,Third Line Therapy (followi,Induction,,Carfilzomib,,,,Investigator decision for other reasons,,27,mg/m^,,QD,,IV,,1370,1623,1
MMRF_1020,,Fourth Line Therapy (follow,Induction,,Daratumumab,,,Checked,,,16,mg,,QWK,,IV,,1638,,1
MMRF_1045,Baseline,First line of therapy,,,Lenalidomide,,,,Other,Continue at a reduced dose due to bad taste/decreased appetite,15,mg,,QD,,PO,,1,127,1
MMRF_1045,,First line of therapy,,,Lenalidomide,,,,Adverse Event or co-morbidity,,10,mg,,QD,,PO,,130,322,1
MMRF_1045,,First line of therapy,,,Dexamethasone,,,,Adverse Event or co-morbidity,,20,mg,,Q w,,PO,,1,229,1
MMRF_1044,,First line of therapy,,,Lenalidomide,,,,Adverse Event or co-morbidity,,25,mg,,QD,,PO,,1,78,1
MMRF_1044,Baseline,First line of therapy,,,Bortezomib,,,,Adverse Event or co-morbidity,,1.3,mg/m^,,QD,,IV SubQ,,1,155,1
MMRF_1044,,First line of therapy,,,Dexamethasone,,,,Adverse Event or co-morbidity,,40,mg,,Q w,,PO,,1,29,1
MMRF_1044,,First line of therapy,,,Lenalidomide,,,,Adverse Event or co-morbidity,,10,mg,,QD,,PO,,127,183,1
MMRF_1044,,First line of therapy,,,Lenalidomide,,,Checked,,,5,mg,,Oth,QD (D1-12),PO,,183,,1
MMRF_1044,,First line of therapy,,,Dexamethasone,,,,Investigator decision for other reasons,,24,mg,,Q w,,PO,,29,541,1
MMRF_1044,,First line of therapy,,,Lenalidomide,,,,Adverse Event or co-morbidity,,15,mg,,QD,,PO,,78,127,1
MMRF_1044,,First line of therapy,,,Bortezomib,,,,Completed regimen,,1,mg/m^,,Oth,"Day 1, 8, 15",IV SubQ,,183,1688,1
MMRF_1044,,First line of therapy,,,Bortezomib,,,,Adverse Event or co-morbidity,,1.3,mg/m^,,Oth,"Day 1, 8, 15",IV SubQ,,155,183,1
MMRF_1044,,First line of therapy,Maintenance,,Dexamethasone,,,,Completed regimen,,12,mg,,QWK,,PO,,568,1688,1
MMRF_1046,,First line of therapy,,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,QD (D1-14),PO,,5,105,1
MMRF_1046,,First line of therapy,,,Dexamethasone,,,,Other,Decreased dose,20,mg,,Oth,"QD (D1-2, 4-5, 8-9, 11-12)",PO,,1,82,1
MMRF_1046,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,10,mg,,Oth,"QD (D1-2, 4-5, 8-9, 11-12)",PO,,92,103,1
MMRF_1046,,First line of therapy,,,Bortezomib,,,,Adverse Event or co-morbidity,,1.3,mg/m^,,QD,,IV SubQ,,218,267,1
MMRF_1046,Baseline,First line of therapy,,,Bortezomib,,,,Other,Route switched from IV to SubQ,2.3,mg,,QD,,IV,,1,32,1
MMRF_1046,,First line of therapy,,,Bortezomib,,,,Completed regimen,,2.3,mg,,QD,,IV SubQ,,43,102,1
MMRF_1046,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"QD (D1, 2, 4, 5, 8, 9, 11, 12)",PO,,218,306,1
MMRF_1046,,First line of therapy,,,Lenalidomide,,,,Completed regimen,,15,mg,,QD,,PO,,267,308,1
MMRF_1046,,First line of therapy,,,Bortezomib,,,,Completed regimen,,1,mg/m^,,QD,,IV SubQ,,267,305,1
MMRF_1046,,First line of therapy,,,Lenalidomide,,,,Adverse Event or co-morbidity,,25,mg,,QD,,PO,,218,267,1
MMRF_1046,,First line of therapy,,,Lenalidomide,,,Checked,,,10,mg,,QD,,PO,,323,,1
MMRF_1046,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,170,mg,,Q d,,IV,,134,135,1
MMRF_1059,,First line of therapy,,,Dexamethasone,,,,Other,Dose Reduced,20,mg,,Oth,"QD (D1-2, 4-5, 8-9. 11-12)",PO,,1,115,1
MMRF_1059,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,10,mg,,Oth,"QD (D1-2, 4-5, 8-9, 11-12)",PO,,116,176,1
MMRF_1059,Baseline,First line of therapy,,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV,,1,175,1
MMRF_1059,,First line of therapy,,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,287,390,1
MMRF_1059,,First line of therapy,,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,74,181,1
MMRF_1059,,First line of therapy,,,Lenalidomide,,,,Lack of response,,15,mg,,QD,,PO,,390,1236,1
MMRF_1059,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,160,mg,,Q d,,IV,,934,935,1
MMRF_1059,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,25,mg,,QD,,PO,,1243,,1
MMRF_1059,,Second Line Therapy (after,Maintenance,,Dexamethasone,,,Checked,,,20,mg,,QWK,,PO,,1827,,1
MMRF_1074,,First line of therapy,,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,98,1
MMRF_1074,,First line of therapy,,,Bortezomib,,,,Completed regimen,,1,mg/m^,,QD,,IV SubQ,,22,95,1
MMRF_1074,Baseline,First line of therapy,,,Bortezomib,,,,Other,dose modified,1,mg/m^,,QD,,IV,,1,8,1
MMRF_1074,,First line of therapy,,,Bortezomib,,,,Other,Dose modified,0.7,mg/m^,,QD,,IV SubQ,,8,11,1
MMRF_1074,,First line of therapy,,,Dexamethasone,,,,Investigator decision for other reasons,,20,mg,,Oth,"QD (1-2, 4-5, 8-9, 11-12)",PO,,1,54,1
MMRF_1074,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,10,mg,,Oth,"QD (D 1-2, 4-5, 8-9, 11-12)",PO,,64,96,1
MMRF_1074,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"QD (D1, D2, D4, D5, D8, D9, D11, D12)",PO,,204,294,1
MMRF_1074,,First line of therapy,,,Bortezomib,,,,Completed regimen,,1,mg/m^,,QD,,IV SubQ,,225,294,1
MMRF_1074,,Second Line Therapy (after,,,Cyclophosphamide,,,,Disease progression/Relapse,,300,mg/m^,,Oth,once,IV,,330,386,1
MMRF_1074,,First line of therapy,,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,204,319,1
MMRF_1074,,Second Line Therapy (after,,,Dexamethasone,,,,Lack of response,,40,mg,,Q w,,PO,,414,414,1
MMRF_1074,,First line of therapy,,,Bortezomib,,,,Adverse Event or co-morbidity,,1.3,mg/m^,,QD,,IV SubQ,,204,225,1
MMRF_1074,,First line of therapy,,,Bortezomib,,,,Disease progression/Relapse,,1,mg/m^,,QD,,IV SubQ,,294,319,1
MMRF_1074,,First line of therapy,,,Lenalidomide,,,,Disease progression/Relapse,,25,mg,,QD,,PO,,294,319,1
MMRF_1074,,Second Line Therapy (after,,,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,Q w,,PO,,319,414,1
MMRF_1074,,Second Line Therapy (after,,,Carfilzomib,,,,Disease progression/Relapse,,27,mg/m^,,QD,,IV,,330,415,1
MMRF_1074,,First line of therapy,,,Dexamethasone,,,,Disease progression/Relapse,,10,mg,,Oth,"QD (D1, D2, D4, D5, D8, D9, D11, D12)",PO,,294,319,1
MMRF_1074,,Second Line Therapy (after,,,Carfilzomib,,,,Lack of response,,27,mg/m^,,QD,,IV,,414,415,1
MMRF_1074,,Second Line Therapy (after,Unknown,,Other,Methotrexate,,,Patient decision,,15,mg,,Oth,x2,Other,intrathecal,414,417,1
MMRF_1074,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,150,mg,,Q d,,IV,,126,127,1
MMRF_1150,,First line of therapy,,,Dexamethasone,,,Checked,,,20,mg,,QD,,PO,,1,,1
MMRF_1150,,First line of therapy,,,Lenalidomide,,,Checked,,,25,mg,,QD,,PO,,1,,1
MMRF_1150,Baseline,First line of therapy,,,Bortezomib,,,Checked,,,2.6,mg,,Q w,,IV SubQ,,8,,1
MMRF_1181,,First line of therapy,,,Dexamethasone,,,,Other,Patient died,40,mg,,Oth,"Days 1, 2,3,4,8,9, 10, 11",PO,,1,39,1
MMRF_1181,Baseline,First line of therapy,,,Bortezomib,,,,Other,Patient died,1.3,mg/m^,,QD,,IV SubQ,,1,39,1
MMRF_1181,,First line of therapy,,,Lenalidomide,,,,Other,Death,15,mg,,QD,,PO,,22,39,1
MMRF_1242,Baseline,First line of therapy,,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,QWK,,PO,,1,72,1
MMRF_1242,,First line of therapy,,,Bortezomib,,,,Disease progression/Relapse,,1.3,mg/m^,,QWK,,IV SubQ,,1,190,1
MMRF_1242,,First line of therapy,,,Lenalidomide,,,,Completed regimen,,15,mg,,QD,,PO,,141,190,1
MMRF_1242,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,40,mg,,QWK,,PO,,1,190,1
MMRF_1242,,First line of therapy,Consolidation,,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,QD,,PO,,386,540,1
MMRF_1242,,First line of therapy,Consolidation,,Bortezomib,,,,Disease progression/Relapse,,1.3,mg/m^,,Oth,"QD (D1, D8, D15)",IV SubQ,,386,540,1
MMRF_1242,,First line of therapy,Consolidation,,Lenalidomide,,,,Disease progression/Relapse,,25,mg,,QD,,PO,,386,540,1
MMRF_1242,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,100,mg,,Q d,,IV,,232,233,1
MMRF_1242,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,150,mg,,Q d,,IV,,302,303,1
MMRF_1258,,First line of therapy,,,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,Q w,,PO,,11,268,1
MMRF_1258,Baseline,First line of therapy,,,Lenalidomide,,,,Disease progression/Relapse,,15,mg,,QD,,PO,,1,246,1
MMRF_1281,Baseline,First line of therapy,,,Bortezomib,,,,Disease progression/Relapse,,1.9,mg,,QD,,IV,,1,153,1
MMRF_1281,,First line of therapy,,,Dexamethasone,,,,Disease progression/Relapse,,20,mg,,Oth,"QD (D1, D2, D4, D5, D8, D9, D11)",IV,,1,153,1
MMRF_1281,,First line of therapy,,,Cyclophosphamide,,,,Disease progression/Relapse,,560,mg,,QWK,,IV,,1,153,1
MMRF_1318,Baseline,First line of therapy,,,Lenalidomide,,,,Adverse Event or co-morbidity,,25,mg,,QD,,PO,,1,204,1
MMRF_1318,,First line of therapy,,,Dexamethasone,,,,Adverse Event or co-morbidity,,20,mg,,QD,,PO,,85,155,1
MMRF_1318,,First line of therapy,,,Dexamethasone,,,,Investigator decision for other reasons,,20,mg,,Q w,,PO,,1,29,1
MMRF_1318,,First line of therapy,,,Bortezomib,,,,Lack of response,,1.3,mg/m^,,Q w,,IV SubQ,,29,113,1
MMRF_1318,,First line of therapy,,,Dexamethasone,,,,Investigator decision for other reasons,,40,mg,,Q w,,PO,,29,85,1
MMRF_1318,,First line of therapy,,,Bortezomib,,,,Investigator decision for other reasons,,1.3,mg/m^,,QD,,IV SubQ,,113,368,1
MMRF_1318,,First line of therapy,Consolidation,,Dexamethasone,,,Checked,,,20,mg,,QD,,PO,,162,,1
MMRF_1318,,First line of therapy,Consolidation,,Bortezomib,,,Checked,,,1.3,mg/m^,,Oth,"D1, D8, D15",IV,,379,,1
MMRF_1318,,First line of therapy,Consolidation,,Lenalidomide,,,Checked,,,10,mg,,QD,,PO,,211,,1
MMRF_1355,Baseline,First line of therapy,,,Elotuzumab,,,,Investigator decision for other reasons,,20,mg/kg,,Q w,,IV,,1,1282,1
MMRF_1355,,First line of therapy,,,Lenalidomide,,,,Investigator decision for other reasons,,25,mg,,QD,,PO,,1,1282,1
MMRF_1355,,First line of therapy,,,Dexamethasone,,,,Investigator decision for other reasons,,8,mg,,Q w,,PO,,1,1282,1
MMRF_1358,,First line of therapy,,,Dexamethasone,,,,Investigator decision for other reasons,,20,mg,,Q w,,PO,,1,194,1
MMRF_1358,Baseline,First line of therapy,,,Lenalidomide,,,,Patient decision,,25,mg,,QD,,PO,,1,121,1
MMRF_1358,,First line of therapy,Induction,,Bortezomib,,,,Lack of response,,1.6,mg/m^,,Oth,"QD (D1, D8, D15, D22)",IV,,194,313,1
MMRF_1358,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,QD,,PO,,194,327,1
MMRF_1358,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,10,mg,,QD,,PO,,327,,1
MMRF_1361,,First line of therapy,,,Carfilzomib,,,,Completed regimen,,27,mg/m^,,QD,,IV,,68,154,1
MMRF_1361,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,40,mg,,Q w,,PO,,68,160,1
MMRF_1361,,First line of therapy,,,Bortezomib,,,,Investigator decision for other reasons,,1.3,mg/m^,,QD,,IV SubQ,,47,68,1
MMRF_1361,,First line of therapy,,,Dexamethasone,,,,Investigator decision for other reasons,,20,mg,,Oth,"QD (D1, D2, D4, D5, D8, D9, D11, D12)",PO,,1,68,1
MMRF_1361,Baseline,First line of therapy,,,Bortezomib,,,,Other,Switched from IV to SubQ,1.3,mg/m^,,QD,,IV,,1,47,1
MMRF_1361,,First line of therapy,,,Cyclophosphamide,,,,Investigator decision for other reasons,,300,mg/m^,,Q w,,IV,,22,68,1
MMRF_1361,,First line of therapy,,,Lenalidomide,,,,Investigator decision for other reasons,,15,mg,,QD,,PO,,68,138,1
MMRF_1361,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Q w,,IV,,117,153,1
MMRF_1392,Baseline,First line of therapy,,,Carfilzomib,,,,Other,Stem cell collection,27,mg/m^,,QD,,IV,,1,139,1
MMRF_1392,,First line of therapy,,,Dexamethasone,,,,Other,stem cell collection,40,mg,,QD,,PO,,1,139,1
MMRF_1392,,First line of therapy,,,Lenalidomide,,,,Other,stem cell collection,25,mg,,QD,,PO,,1,139,1
MMRF_1392,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,QD,,IV,,168,463,1
MMRF_1392,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,168,463,1
MMRF_1392,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"QD (1, 8, 15, 22)",PO,,168,463,1
MMRF_1392,,First line of therapy,Consolidation,,Lenalidomide,,,,Adverse Event or co-morbidity,,25,mg,,QD,,PO,,595,769,1
MMRF_1392,,First line of therapy,Consolidation,,Dexamethasone,,,,Adverse Event or co-morbidity,,20,mg,,QWK,,PO,,595,763,1
MMRF_1392,,First line of therapy,Consolidation,,Carfilzomib,,,,Adverse Event or co-morbidity,,27,mg/m^,,Oth,"QD D1-2, D15-16)",IV,,595,764,1
MMRF_1392,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,240,mg,,Q d,,IV,,504,505,1
MMRF_1393,Baseline,First line of therapy,,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,QD,,IV,,1,323,1
MMRF_1393,,First line of therapy,,,Dexamethasone,,,,Investigator decision for other reasons,,20,mg,,Oth,"QD (1,2, 8,9, 15,16, 22,23)",PO,,1,490,1
MMRF_1393,,First line of therapy,,,Lenalidomide,,,,Investigator decision for other reasons,,25,mg,,QD,,PO,,1,1209,1
MMRF_1393,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,200,mg,,Q d,,IV,,131,132,1
MMRF_1393,,First line of therapy,Maintenance,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"QD (1, 8, 15, 22)",PO,,490,590,1
MMRF_1393,,First line of therapy,Maintenance,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"QD (D1-2, D15-16)",IV,,323,590,1
MMRF_1393,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,15,mg,,QD,,PO,,1210,,1
MMRF_1420,,First line of therapy,,,Dexamethasone,,,,Investigator decision for other reasons,,20,mg,,Oth,"QD (D1, D2, D4, D5, D8, D9, D11, D12)",PO,,1,1205,1
MMRF_1420,Baseline,First line of therapy,,,Bortezomib,,,,Adverse Event or co-morbidity,,1.3,mg/m^,,QD,,IV SubQ,,1,67,1
MMRF_1420,,First line of therapy,,,Cyclophosphamide,,,,Adverse Event or co-morbidity,,300,mg/m^,,Q w,,IV,,1,64,1
MMRF_1420,,First line of therapy,Induction,,Carfilzomib,,,,Adverse Event or co-morbidity,,20,mg/m^,,QD,,IV,,99,134,1
MMRF_1420,,First line of therapy,Induction,,Lenalidomide,,,,Investigator decision for other reasons,,5,mg,,QD,,PO,,274,1205,1
MMRF_1520,Baseline,First line of therapy,Induction,,Carfilzomib,,,,Adverse Event or co-morbidity,,36,mg/m^,,QD,,IV,,1,71,1
MMRF_1520,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,106,1
MMRF_1520,,First line of therapy,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,40,mg,,QWK,,PO,,1,57,1
MMRF_1520,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,200,mg,,Q d,,IV,,148,149,1
MMRF_1520,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,27,mg/m^,,QD,,IV,,71,106,1
MMRF_1520,,First line of therapy,Consolidation,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,QD,,IV,,225,442,1
MMRF_1520,,First line of therapy,Consolidation,,Lenalidomide,,,,Completed regimen,,20,mg,,QD,,PO,,414,442,1
MMRF_1520,,First line of therapy,Consolidation,,Lenalidomide,,,,Adverse Event or co-morbidity,,25,mg,,QD,,PO,,225,414,1
MMRF_1520,,First line of therapy,Maintenance,,Lenalidomide,,,,Investigator decision for other reasons,,20,mg,,QD,,PO,,442,980,1
MMRF_1520,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"QD (1, 8, 15, 22)",PO,,57,106,1
MMRF_1520,,First line of therapy,Consolidation,,Dexamethasone,,,,Adverse Event or co-morbidity,,20,mg,,Oth,"QD (1, 8, 15, 22)",PO,,225,281,1
MMRF_1520,,First line of therapy,Consolidation,,Dexamethasone,,,,Completed regimen,,12,mg,,Oth,"QD (1, 8, 15, 22)",PO,,281,442,1
MMRF_1520,,First line of therapy,Maintenance,,Dexamethasone,,,,Completed regimen,,12,mg,,Oth,"QD (1, 8, 15, 22)",PO,,442,607,1
MMRF_1520,,First line of therapy,Maintenance,,Carfilzomib,,,,Completed regimen,,27,mg/m^,,Oth,"QD (D1-2, D15-16)",IV,,442,607,1
MMRF_1520,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,15,mg,,QD,,PO,,1204,,1
MMRF_1540,,First line of therapy,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,1.3,mg/m^,,QD,,IV,,1,518,1
MMRF_1540,,First line of therapy,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,20,mg,,QD,,PO,,1,518,1
MMRF_1540,Baseline,First line of therapy,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,25,mg,,QD,,PO,,1,518,1
MMRF_1576,Baseline,First line of therapy,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,1.3,mg/m^,,QD,,IV SubQ,,1,21,1
MMRF_1576,,First line of therapy,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,40,mg,,QWK,,PO,,1,21,1
MMRF_1621,Baseline,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,QD,,IV,,1,106,1
MMRF_1621,,First line of therapy,Induction,,Lenalidomide,,,Checked,,,10,mg,,QD,,PO,,1,,1
MMRF_1621,,First line of therapy,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,40,mg,,Oth,"QD (1, 8, 15, 22)",PO,,1,225,1
MMRF_1621,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,230,mg,,Q d,,IV,,137,138,1
MMRF_1621,,First line of therapy,Consolidation,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"QD (1, 8, 15, 22)",PO,,225,645,1
MMRF_1621,,First line of therapy,Consolidation,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,QD,,IV,,225,365,1
MMRF_1621,,First line of therapy,Maintenance,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"QD (D1-2, D15-16)",IV,,365,645,1
MMRF_1630,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,QD,,IV,,21,133,1
MMRF_1630,Baseline,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,"QD(D1, D8, D15, D22)",PO,,1,133,1
MMRF_1630,,First line of therapy,Induction,,Lenalidomide,,,,Investigator decision for other reasons,,25,mg,,QD,,PO,,21,867,1
MMRF_1630,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,200,mg,,Q d,,IV,,171,172,1
MMRF_1630,,First line of therapy,Consolidation,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,QD,,IV,,252,371,1
MMRF_1630,,First line of therapy,Maintenance,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"QD (D1-2, D15-16)",IV,,371,658,1
MMRF_1630,,First line of therapy,Consolidation,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"QD (1, 8, 15, 22)",PO,,252,658,1
MMRF_1630,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,10,mg,,QD,,PO,,867,,1
MMRF_1652,Baseline,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,QD,,IV,,1,100,1
MMRF_1652,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,"QD(D1, D8, D15, D22)",PO,,1,100,1
MMRF_1652,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,100,1
MMRF_1652,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,200,mg,,Q d,,IV,,139,140,1
MMRF_1652,,First line of therapy,Consolidation,,Lenalidomide,,,Checked,,,15,mg,,QD,,PO,,246,,1
MMRF_1652,,First line of therapy,Consolidation,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,QD,,IV,,246,632,1
MMRF_1652,,First line of therapy,Consolidation,,Dexamethasone,,,,Completed regimen,,20,mg,,QWK,,PO,,246,632,1
MMRF_1690,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,"QD (D1, D8, D15, D22)",PO,,1,107,1
MMRF_1690,Baseline,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,QD,,IV,,1,107,1
MMRF_1690,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,107,1
MMRF_1690,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,180,mg,,Q d,,IV,,138,139,1
MMRF_1690,,First line of therapy,Maintenance,,Dexamethasone,,,,Adverse Event or co-morbidity,,4,mg,,Oth,"QD (D2, D16)",PO,,457,569,1
MMRF_1690,,First line of therapy,Maintenance,,Dexamethasone,,,,Adverse Event or co-morbidity,,14,mg,,Oth,"QD (D8, D22)",PO,,457,569,1
MMRF_1690,,First line of therapy,Consolidation,,Carfilzomib,,,,Completed regimen,,27,mg/m^,,QD,,IV,,226,345,1
MMRF_1690,,First line of therapy,Maintenance,,Carfilzomib,,,,Completed regimen,,27,mg/m^,,Oth,"QD (D1-2, D15-16)",IV,,345,625,1
MMRF_1690,,First line of therapy,Consolidation,,Lenalidomide,,,,Adverse Event or co-morbidity,,15,mg,,QD,,PO,,226,254,1
MMRF_1690,,First line of therapy,Consolidation,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,254,345,1
MMRF_1690,,First line of therapy,Maintenance,,Lenalidomide,,,,Investigator decision for other reasons,,25,mg,,QD,,PO,,345,653,1
MMRF_1690,,First line of therapy,Maintenance,,Lenalidomide,,,,Investigator decision for other reasons,,25,mg,,Oth,"QD (1-21: 2D on, 1D off)",PO,,653,734,1
MMRF_1690,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,15,mg,,QD,,PO,,734,,1
MMRF_1690,,First line of therapy,Consolidation,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,QD (D22),PO,,226,345,1
MMRF_1690,,First line of therapy,Maintenance,,Dexamethasone,,,,Adverse Event or co-morbidity,,10,mg,,QD,,PO,,345,401,1
MMRF_1690,,First line of therapy,Maintenance,,Dexamethasone,,,,Adverse Event or co-morbidity,,20,mg,,Oth,QD (D22),PO,,345,401,1
MMRF_1690,,First line of therapy,Maintenance,,Dexamethasone,,,,Completed regimen,,8,mg,,Oth,"QD (D1, D15)",PO,,569,625,1
MMRF_1690,,First line of therapy,Maintenance,,Dexamethasone,,,,Completed regimen,,4,mg,,Oth,"QD (D2, D16)",PO,,569,625,1
MMRF_1690,,First line of therapy,Maintenance,,Dexamethasone,,,,Completed regimen,,12,mg,,Oth,"QD (D8, D22)",PO,,569,625,1
MMRF_1690,,First line of therapy,Consolidation,,Dexamethasone,,,,Completed regimen,,10,mg,,QD,,PO,,226,345,1
MMRF_1690,,First line of therapy,Maintenance,,Dexamethasone,,,,Adverse Event or co-morbidity,,10,mg,,Oth,"QD (D1, D15)",PO,,401,569,1
MMRF_1690,,First line of therapy,Maintenance,,Dexamethasone,,,,Adverse Event or co-morbidity,,6,mg,,Oth,"QD (D2, D16)",PO,,401,457,1
MMRF_1690,,First line of therapy,Maintenance,,Dexamethasone,,,,Adverse Event or co-morbidity,,16,mg,,Oth,"QD (D8, D22)",PO,,401,457,1
MMRF_1749,Baseline,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,27,mg/m^,,QD,,IV,,1,106,1
MMRF_1749,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,106,1
MMRF_1749,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,QWK,,Other,IV or PO,1,106,1
MMRF_1749,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,195,mg,,Q d,,IV,,144,145,1
MMRF_1749,,First line of therapy,Consolidation,,Lenalidomide,,,,Other,dose escalation,15,mg,,QD,,PO,,596,617,1
MMRF_1749,,First line of therapy,Consolidation,,Lenalidomide,,,Checked,,,25,mg,,QD,,PO,,259,,1
MMRF_1749,,First line of therapy,Consolidation,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,QD,,IV,,231,953,1
MMRF_1749,,First line of therapy,Consolidation,,Dexamethasone,,,Checked,,,12,mg,,Q w,,PO,,231,,1
MMRF_1773,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,191,1
MMRF_1773,,First line of therapy,Induction,,Lenalidomide,,,Checked,,,10,mg,,QD,,PO,,1,,1
MMRF_1773,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"QD (1,2, 4,5, 8,9, 11,12)",PO,,1,722,1
MMRF_1773,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,225,mg,,Q d,,IV,,116,117,1
MMRF_1773,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,230,mg,,Q d,,IV,,217,218,1
MMRF_1773,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,27,mg/m^,,QD,,IV,,303,710,1
MMRF_1797,Baseline,First line of therapy,Induction,,Carfilzomib,,,,Adverse Event or co-morbidity,,36,mg/m^,,QD,,IV,,1,567,1
MMRF_1797,,First line of therapy,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,40,mg,,Q w,,PO,,1,567,1
MMRF_1797,,First line of therapy,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,25,mg,,QD,,PO,,1,567,1
MMRF_1797,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,200,mg,,Q d,,IV,,225,226,1
MMRF_1822,,First line of therapy,Induction,,Lenalidomide,,,,Patient decision,,25,mg,,QD,,PO,,1,135,1
MMRF_1822,,First line of therapy,Induction,,Dexamethasone,,,,Patient decision,,40,mg,,Q w,,PO,,1,136,1
MMRF_1822,Baseline,First line of therapy,Induction,,Carfilzomib,,,,Patient decision,,36,mg/m^,,QD,,IV,,1,130,1
MMRF_1822,,First line of therapy,Induction,,Dexamethasone,,,,Patient decision,,40,mg,,QD,,PO,,185,284,1
MMRF_1822,,First line of therapy,Induction,,Bortezomib,,,,Patient decision,,1.3,mg/m^,,Oth,"QD (D1, D18, D15, D22)",IV SubQ,,185,284,1
MMRF_1822,,First line of therapy,Induction,,Lenalidomide,,,,Patient decision,,25,mg,,QD,,PO,,185,284,1
MMRF_1822,,Second Line Therapy (after,Induction,,Ixazomib,,,,Other,INSURANCE REASONS,4,mg,,Oth,ONCE WEEK FOR 3WKS 4TH WK OFF,PO,,746,962,1
MMRF_1822,,Third Line Therapy (followi,Induction,,Dexamethasone,,,Checked,,,4,mg,,Oth,"QD (D1, D8, D15, D22)",PO,,962,,1
MMRF_2005,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Q w,,PO,,1,112,1
MMRF_2005,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,112,1
MMRF_2005,Baseline,First line of therapy,Induction,,Carfilzomib,,,,Adverse Event or co-morbidity,,36,mg/m^,,QD,,IV,,1,29,1
MMRF_2005,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,200,mg,,Q d,,IV,,148,149,1
MMRF_2005,,First line of therapy,Induction,,Carfilzomib,,,,Investigator decision for other reasons,,27,mg,,QD,,IV,,29,64,1
MMRF_2005,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg,,QD,,IV,,64,113,1
MMRF_2005,,First line of therapy,Consolidation,,Dexamethasone,,,,Completed regimen,,20,mg,,Q w,,PO,,239,639,1
MMRF_2005,,First line of therapy,Consolidation,,Lenalidomide,,,,Other,dose escalation,15,mg,,QD,,PO,,239,260,1
MMRF_2005,,First line of therapy,Consolidation,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,QD,,IV,,239,626,1
MMRF_2005,,First line of therapy,Consolidation,,Lenalidomide,,,Checked,,,25,mg,,QD,,PO,,267,,1
MMRF_2021,Baseline,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,21,mg/m^,,QD,,IV,,1,105,1
MMRF_2021,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,"QD (D1, D8, D22, D22)",PO,,1,105,1
MMRF_2021,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,105,1
MMRF_2021,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,220,mg,,Q d,,IV,,144,145,1
MMRF_2021,,First line of therapy,Consolidation,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,252,336,1
MMRF_2021,,First line of therapy,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,25,mg,,QD,,PO,,336,354,1
MMRF_2021,,First line of therapy,Consolidation,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"QD (1, 8, 15, 22)",PO,,224,336,1
MMRF_2021,,First line of therapy,Maintenance,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"QD (1, 8, 15, 22)",PO,,336,687,1
MMRF_2021,,First line of therapy,Consolidation,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,QD,,IV,,224,336,1
MMRF_2021,,First line of therapy,Consolidation,,Lenalidomide,,,,Investigator decision for other reasons,,15,mg,,QD,,PO,,224,252,1
MMRF_2021,,First line of therapy,Maintenance,,Carfilzomib,,,,Adverse Event or co-morbidity,,36,mg/m^,,Oth,"QD (D1-2, D15-16)",IV,,336,449,1
MMRF_2021,,First line of therapy,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,20,mg,,QD,,PO,,364,434,1
MMRF_2021,,First line of therapy,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,20,mg,,Oth,"QD (1-21: 3D on, 1D off)",PO,,434,450,1
MMRF_2021,,First line of therapy,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,15,mg,,QD,,PO,,462,504,1
MMRF_2021,,First line of therapy,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,10,mg,,QD,,PO,,504,505,1
MMRF_2021,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,15,mg,,QD,,PO,,529,,1
MMRF_2056,,First line of therapy,Induction,,Lenalidomide,,,Checked,,,25,mg,,QD,,PO,,1,,1
MMRF_2056,Baseline,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,QD,,IV,,1,106,1
MMRF_2056,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,"QD (D1, D8, D15, D22)",PO,,1,106,1
MMRF_2056,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,175,mg,,Q d,,IV,,141,142,1
MMRF_2056,,First line of therapy,Consolidation,,Dexamethasone,,,Checked,,,20,mg,,Oth,"QD (1, 8, 15, 22)",PO,,232,,1
MMRF_2056,,First line of therapy,Consolidation,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,QD,,IV,,232,359,1
MMRF_2056,,First line of therapy,Maintenance,,Carfilzomib,,,Checked,,,36,mg/m^,,Oth,"QD (D1-2, D15-16)",IV,,359,,1
MMRF_2091,,First line of therapy,Induction,,Lenalidomide,,,,Disease progression/Relapse,,15,mg,,QD,,PO,,1,1080,1
MMRF_2091,Baseline,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/dL,,QD,,IV,,1,617,1
MMRF_2091,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,"QD (D1, D8, D15, D22)",PO,,1,617,1
MMRF_2091,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,230,mg,,Q d,,IV,,141,142,1
MMRF_2091,,Second Line Therapy (after,Induction,,Carfilzomib,,,Checked,,,27,mg/m^,,QD,,IV,,1149,,1
MMRF_2091,,Second Line Therapy (after,Induction,,Pomalidomide,,,Checked,,,4,mg,,QD,,PO,,1149,,1
MMRF_2091,,Second Line Therapy (after,Induction,,Dexamethasone,,,Checked,,,20,mg,,QD,,PO,,1149,,1
MMRF_2091,,Second Line Therapy (after,Induction,,Daratumumab,,,Checked,,,16,mg/kg,,Oth,"split 1+2, 8, 15, 22",IV,,1149,,1
MMRF_2098,,First line of therapy,Induction,,Lenalidomide,,,,Investigator decision for other reasons,,20,mg,,QD,,PO,,1,216,1
MMRF_2098,Baseline,First line of therapy,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,20,mg,,Oth,QD (D1-5; D8-12; D15-19),PO,,1,216,1
MMRF_2122,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV,,1,264,1
MMRF_2122,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,264,1
MMRF_2122,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"QD (D1-2, D4-5, D8-9, D11-12)",PO,,1,264,1
MMRF_2122,,Second Line Therapy (after,Induction,,Dexamethasone,,,Checked,,,4,mg,,Q w,,PO,,615,,1
MMRF_2122,,Second Line Therapy (after,Induction,,Lenalidomide,,,Checked,,,25,mg,,QD,,PO,,609,,1
MMRF_2122,,Second Line Therapy (after,Induction,,Ixazomib,,,Checked,,,4,mg,,Oth,"QD (D1, D8, D15)",PO,,602,,1
MMRF_2238,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV,,27,118,1
MMRF_2238,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,QWK,,PO,,1,118,1
MMRF_2238,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,QD,,IV,,27,118,1
MMRF_2238,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,5,mg,,Q d,,PO,,230,,1
MMRF_2238,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,245,mg,,Q d,,IV,,140,141,1
MMRF_2570,Baseline,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,QD,,IV,,1,101,1
MMRF_2570,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,106,1
MMRF_2570,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,QWK,,PO,,1,107,1
MMRF_2570,,First line of therapy,Consolidation,,Dexamethasone,,,,Investigator decision for other reasons,,40,mg,,Oth,"QD (1, 8, 15, 22)",PO,,225,253,1
MMRF_2570,,First line of therapy,Consolidation,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"QD (1, 8, 15, 22)",PO,,253,625,1
MMRF_2570,,First line of therapy,Consolidation,,Lenalidomide,,,,Completed regimen,,20,mg,,QD,,PO,,225,623,1
MMRF_2570,,First line of therapy,Consolidation,,Carfilzomib,,,,Completed regimen,,27,mg/m^,,Oth,"QD (D1-2, D15-16)",IV,,225,618,1
MMRF_2570,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,150,mg,,Q d,,IV,,145,146,1
MMRF_2570,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,20,mg,,QD,,PO,,631,,1
MMRF_1085,Baseline,First line of therapy,,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV,,1,211,1
MMRF_1085,,First line of therapy,,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,217,1
MMRF_1085,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"D1, D2, D4, D5, D8, D9, D11, and D12",PO,,1,212,1
MMRF_1085,,Second Line Therapy (after,Induction,,Pomalidomide,,,,Disease progression/Relapse,,4,mg,,QD,,PO,,449,841,1
MMRF_1085,,First line of therapy,,,Lenalidomide,,,,Adverse Event or co-morbidity,,10,mg,,Q d,,PO,,225,308,1
MMRF_1085,,First line of therapy,Induction,,Lenalidomide,,,,Disease progression/Relapse,,5,mg,,QD,,PO,,316,413,1
MMRF_1085,,Second Line Therapy (after,Induction,,Carfilzomib,,,,Disease progression/Relapse,,20,mg/m^,,QD,,IV,,449,841,1
MMRF_1085,,Second Line Therapy (after,Induction,,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,QWK,,PO,,449,841,1
MMRF_1085,,Second Line Therapy (after,Unknown,,Melphalan,,,,Completed regimen,,140,mg/m^,,Oth,Single dose in preparation for stem cell transplant,IV,,870,870,1
MMRF_1085,,Third Line Therapy (followi,Consolidation,,Bendamustine,,,,Disease progression/Relapse,,201,mg,,Oth,Days 1 & 2,IV,,1105,1162,1
MMRF_1085,,Fourth Line Therapy (follow,Consolidation,,Dexamethasone,,,,Other,Difficulty tolerating therapy,20,mg,,Oth,twice per week,PO,,1182,1217,1
MMRF_1085,,Fourth Line Therapy (follow,Consolidation,,Other,Selinexor,,,Adverse Event or co-morbidity,,80,mg,,Oth,twice per week,PO,,1182,1217,1
MMRF_1085,,Third Line Therapy (followi,Consolidation,,Bortezomib,,,,Disease progression/Relapse,,1.4,mg,,Oth,Days 1 & 8,IV,,1105,1162,1
MMRF_1233,Baseline,First line of therapy,,,Cyclophosphamide,,,,Other,patient non-compliant,500,mg/m^,,Q w,,IV,,2,128,1
MMRF_1233,,First line of therapy,,,Bortezomib,,,,Investigator decision for other reasons,,1.5,mg/m^,,Q w,,IV SubQ,,1,319,1
MMRF_1233,,First line of therapy,,,Dexamethasone,,,,Patient decision,,40,mg,,Q w,,PO,,1,266,1
MMRF_1233,,First line of therapy,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,15,mg,,Oth,every other day,PO,,477,589,1
MMRF_1233,,Second Line Therapy (after,Consolidation,,Pomalidomide,,,Checked,,,2,mg,,QD,,PO,,589,,1
MMRF_1233,,First line of therapy,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,20,mg,,QWK,,PO,,477,575,1
MMRF_1327,,First line of therapy,,,Bortezomib,,,Checked,,,1.5,mg/m^,,Q w,,IV,,1,,1
MMRF_1327,,First line of therapy,,,Dexamethasone,,,Checked,,,40,mg,,Q w,,PO,,1,,1
MMRF_1327,Baseline,First line of therapy,,,Cyclophosphamide,,,Checked,,,300,mg/m^,,Q w,,PO,,1,,1
MMRF_1700,Baseline,First line of therapy,Induction,,Lenalidomide,,,,Other,toxicity - bone and joint arthralgia,15,mg,,QD,,PO,,1,14,1
MMRF_1700,,First line of therapy,Induction,,Dexamethasone,,,,Lack of response,,20,mg,,QWK,,PO,,1,481,1
MMRF_1700,,First line of therapy,Induction,,Bortezomib,,,,Disease progression/Relapse,,2.6,mg,,Q w,,IV SubQ,,19,432,1
MMRF_1700,,First line of therapy,Induction,,Cyclophosphamide,,,,Investigator decision for other reasons,,300,mg/m^,,Q w,,IV,,47,194,1
MMRF_1700,,First line of therapy,Induction,,Lenalidomide,,,,Disease progression/Relapse,,5,mg/dL,,QD,,PO,,194,432,1
MMRF_1700,,Second Line Therapy (after,Induction,,Carfilzomib,,,,Lack of response,,20,mg/m^,,QD,,IV,,439,481,1
MMRF_1700,,Third Line Therapy (followi,Induction,,Pomalidomide,,,,Adverse Event or co-morbidity,,2,mg,,Q d,,PO,,481,559,1
MMRF_1739,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.5,mg/m^,,QWK,,Other,SQ,1,253,1
MMRF_1739,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,QWK,,PO,,1,253,1
MMRF_1739,,First line of therapy,Induction,,Cyclophosphamide,,,,Lack of response,,350,mg/m^,,QWK,,IV,,1,155,1
MMRF_1739,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,15,mg,,QD,,PO,,171,256,1
MMRF_1739,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,10,mg,,Q d,,PO,,525,,1
MMRF_1739,,First line of therapy,Maintenance,,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,Q w,,PO,,734,1100,1
MMRF_1739,,First line of therapy,Maintenance,,Lenalidomide,,,,Disease progression/Relapse,,25,mg,,QD,,PO,,734,1100,1
MMRF_1739,,Second Line Therapy (after,Other,Salvage,Daratumumab,,,,Disease progression/Relapse,,44,Other,mL,Q w,,IV,,1101,1195,1
MMRF_1739,,Third Line Therapy (followi,Other,Salvage,Pomalidomide,,,Checked,,,4,mg,,QD,,PO,,1193,,1
MMRF_1739,,Third Line Therapy (followi,Other,Salvage,Carfilzomib,,,Checked,,,27,mg/m^,,QD,,IV,,1193,,1
MMRF_1739,,Third Line Therapy (followi,Other,Salvage,Dexamethasone,,,Checked,,,20,mg,,QD,,PO,,1193,,1
MMRF_1774,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV,,1,211,1
MMRF_1774,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"D1, 2, 4, 5, 8, 9, 11, and 12",PO,,1,212,1
MMRF_1774,Baseline,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,214,1
MMRF_1774,,First line of therapy,Maintenance,,Lenalidomide,,,,Completed regimen,,10,mg,,QD,,PO,,213,305,1
MMRF_1774,,First line of therapy,Maintenance,,Lenalidomide,,,,Disease progression/Relapse,,15,mg,,QD,,PO,,306,954,1
MMRF_1774,,Second Line Therapy (after,Other,Salvage,Melphalan,,,,Other,Given in preoaration for transplant,140,mg/m^,,Oth,One time,IVB,,1013,1013,1
MMRF_1774,,Second Line Therapy (after,Other,Salvage,Bortezomib,,,,Disease progression/Relapse,,1.3,mg,,Q w,,IV,,986,1435,1
MMRF_1774,,Second Line Therapy (after,Other,Salvage,Dexamethasone,,,,Disease progression/Relapse,,20,mg,,Q w,,PO,,986,1435,1
MMRF_1774,,Third Line Therapy (followi,Induction,,Dexamethasone,,,Checked,,,20,mg,,QD,,PO,,1461,,1
MMRF_1774,,Third Line Therapy (followi,Consolidation,,Pomalidomide,,,Checked,,,20,mg,,Q d,,PO,,1461,,1
MMRF_1814,Baseline,First line of therapy,Induction,,Cyclophosphamide,,,,Patient decision,,552,mg,,QWK,,IV,,1,113,1
MMRF_1814,,First line of therapy,Induction,,Bortezomib,,,,Patient decision,,1.5,mg/m^,,QWK,,Other,SQ,1,113,1
MMRF_1814,,First line of therapy,Induction,,Dexamethasone,,,,Patient decision,,20,mg,,QWK,,PO,,1,113,1
MMRF_1823,Baseline,First line of therapy,Induction,,Bortezomib,,,,Other,proceeding to autologous stem cell transplant,1.3,mg/m^,,QWK,,Other,SQ,1,141,1
MMRF_1823,,First line of therapy,Induction,,Lenalidomide,,,,Other,proceeding to autologous stem cell transplant,25,mg,,QD,,PO,,1,141,1
MMRF_1823,,First line of therapy,Induction,,Dexamethasone,,,,Other,proceeding to autologous stem cell transplant,40,mg,,QWK,,PO,,1,141,1
MMRF_1823,,First line of therapy,Maintenance,,Lenalidomide,,,,Disease progression/Relapse,,10,mg,,Q d,,PO,,293,743,1
MMRF_1823,,Second Line Therapy (after,Other,Salvage,Lenalidomide,,,,Disease progression/Relapse,,25,mg,,QD,,PO,,714,887,1
MMRF_1823,,Second Line Therapy (after,Other,Salvage,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,Q w,,PO,,714,887,1
MMRF_1823,,Third Line Therapy (followi,Other,Salvage,Carfilzomib,,,,Disease progression/Relapse,,27,mg/m^,,QD,,IVB,,888,1280,1
MMRF_1823,,Third Line Therapy (followi,Other,Salvage,Dexamethasone,,,,Other,Dose reduction per protocol requirement,40,mg,,QWK,,PO,,888,994,1
MMRF_1823,,Third Line Therapy (followi,Other,Salvage,Pomalidomide,,,,Disease progression/Relapse,,4,mg,,QD,,PO,,888,1345,1
MMRF_1823,,Third Line Therapy (followi,Other,Salvage,Dexamethasone,,,,Disease progression/Relapse,,20,mg,,QWK,,PO,,1001,1280,1
MMRF_1823,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,200,mg/m^,,Oth,Once,IV,,196,196,1
MMRF_1832,Baseline,First line of therapy,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,1.3,mg/m^,,QD,,Other,SubQ,1,117,1
MMRF_1832,,First line of therapy,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,40,mg,,QD,,PO,,1,117,1
MMRF_1832,,First line of therapy,Maintenance,,Bortezomib,,,,Lack of response,,1.3,mg/m^,,Oth,Every other week,IV SubQ,,141,210,1
MMRF_1832,,First line of therapy,Maintenance,,Dexamethasone,,,,Lack of response,,40,mg,,Oth,every other week,PO,,141,210,1
MMRF_1832,,First line of therapy,Maintenance,,Bortezomib,,,,Other,Death,1.3,mg/m^,,Q w,,IV SubQ,,211,1188,1
MMRF_1832,,First line of therapy,Maintenance,,Dexamethasone,,,,Other,Death,40,mg,,Q w,,PO,,211,1188,1
MMRF_1841,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,113,1
MMRF_1841,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"D1, 2, 4, 5, 8, 9, 11, 12",PO,,1,162,1
MMRF_1841,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV,,1,162,1
MMRF_1841,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,10,mg,,Q d,,PO,,288,,1
MMRF_1841,,First line of therapy,Maintenance,,Bortezomib,,,Checked,,,2.2,mg/m^,,Q w,,IV SubQ,,439,,1
MMRF_2080,Baseline,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,212,1
MMRF_2080,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV,,1,212,1
MMRF_2080,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"D 1, 2, 4, 5, 8, 9, 11, 12",PO,,1,212,1
MMRF_2080,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,10,mg,,Q d,,PO,,212,,1
MMRF_2104,,First line of therapy,Induction,,Lenalidomide,,,Checked,,,25,mg,,QD,,PO,,1,,1
MMRF_2104,,First line of therapy,Induction,,Dexamethasone,,,Checked,,,20,mg,,Oth,"D 1, 2, 4, 5, 8, 9, 11, 12",PO,,1,,1
MMRF_2104,Baseline,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,43,mg,,QD,,IV,,1,269,1
MMRF_2104,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,10,mg,,QD,,PO,,302,,1
MMRF_2190,,First line of therapy,Induction,,Dexamethasone,,,,Disease progression/Relapse,,20,mg,,Oth,"days 1, 2, 4, 5, 8, 9, 11, and 12",PO,,1,1295,1
MMRF_2190,Baseline,First line of therapy,Induction,,Bortezomib,,,Checked,,,1.3,mg/m^,,QD,,IV,,1,,1
MMRF_2190,,First line of therapy,Induction,,Lenalidomide,,,,Disease progression/Relapse,,25,mg,,QD,,PO,,1,1295,1
MMRF_2190,,Second Line Therapy (after,Consolidation,,Daratumumab,,,Checked,,,1042,mg,,Q w,,IV,,1305,,1
MMRF_2190,,Second Line Therapy (after,Consolidation,,Lenalidomide,,,Checked,,,25,mg,,QD,,PO,,1305,,1
MMRF_2190,,Second Line Therapy (after,Consolidation,,Dexamethasone,,,Checked,,,20,mg,,QD,,PO,,1305,,1
MMRF_2250,Baseline,First line of therapy,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,1.3,mg/m^,,QD,,IV,,1,106,1
MMRF_2250,,First line of therapy,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,25,mg,,QD,,PO,,1,106,1
MMRF_2250,,First line of therapy,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,20,mg,,Oth,"D 1, 2, 4, 5, 8, 9, 11, 12",PO,,1,106,1
MMRF_2250,,First line of therapy,Maintenance,,Lenalidomide,,,,Disease progression/Relapse,,10,mg,,QD,,PO,,106,1066,1
MMRF_2250,,Second Line Therapy (after,Consolidation,,Daratumumab,,,Checked,,,923,mg,,Q w,,IV,,1072,,1
MMRF_2250,,Second Line Therapy (after,Consolidation,,Dexamethasone,,,Checked,,,20,mg,,Q w,,PO,,1072,,1
MMRF_2250,,Second Line Therapy (after,Consolidation,,Lenalidomide,,,Checked,,,10,mg,,QD,,PO,,1072,,1
MMRF_2333,,First line of therapy,Maintenance,,Dexamethasone,,,Checked,,,20,mg,,QWK,,PO,,1,,1
MMRF_2333,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,10,mg,,QD,,PO,,1,,1
MMRF_2333,Baseline,First line of therapy,Maintenance,,Bortezomib,,,,Completed regimen,,2.2,mg,,QWK,,Other,Subcutaneous,1,176,1
MMRF_2333,,First line of therapy,Maintenance,,Bortezomib,,,Checked,,,1.3,mg/m^,,Oth,Every other week,IV SubQ,,176,,1
MMRF_2511,Baseline,First line of therapy,Induction,,Bortezomib,,,Checked,,,1.3,mg/m^,,QD,,IV,,1,,1
MMRF_2511,,First line of therapy,Induction,,Lenalidomide,,,Checked,,,10,mg,,QD,,PO,,1,,1
MMRF_2511,,First line of therapy,Induction,,Dexamethasone,,,Checked,,,20,mg,,Oth,"days 1, 2, 4, 5, 8, 9, 11, and 12",PO,,1,,1
MMRF_2511,,First line of therapy,Consolidation,,Melphalan,,,,Completed regimen,,140,mg/m^,,Oth,One time dose,IV,,391,391,1
MMRF_1056,Baseline,First line of therapy,,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,69,1
MMRF_1056,,First line of therapy,,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,69,1
MMRF_1056,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,day of and day after bortezomib,PO,,1,69,1
MMRF_1056,,First line of therapy,,,Lenalidomide,,,,Investigator decision for other reasons,,10,mg,,QD,,PO,,215,446,1
MMRF_1056,,First line of therapy,Maintenance,,Bortezomib,,,,Disease progression/Relapse,,1.3,mg/m^,,Oth,Twice monthly,IV,,446,635,1
MMRF_1056,,Second Line Therapy (after,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,2.5,mg,,QD,,IV SubQ,,635,691,1
MMRF_1056,,Second Line Therapy (after,Induction,,Dexamethasone,,,,Lack of response,,20,mg,,Oth,Day of and day After Bortezomib,PO,,653,1396,1
MMRF_1056,,Second Line Therapy (after,Induction,,Bortezomib,,,,Disease progression/Relapse,,1.9,mg,,QD,,IV SubQ,,698,1142,1
MMRF_1056,,Third Line Therapy (followi,Consolidation,,Cyclophosphamide,,,,Disease progression/Relapse,,10,mg/kg,,Q w,,PO,,1063,1142,1
MMRF_1056,,Fourth Line Therapy (follow,Consolidation,,Other,Oprozomib,,,Lack of response,,180,mg,,QD,,PO,,1170,1237,1
MMRF_1056,,Fourth Line Therapy (follow,Consolidation,,Lenalidomide,,,,Lack of response,,25,mg,,QD,,PO,,1269,1396,1
MMRF_1056,,Fourth Line Therapy (follow,Consolidation,,Other,SAR650984,,,Lack of response,,10,mg/kg,,Q w,,IV,,1269,1396,1
MMRF_1056,,Fourth Line Therapy (follow,Other,Salvage,Pomalidomide,,,,Disease progression/Relapse,,2,mg,,QD,,PO,,1397,1766,1
MMRF_1056,,Fourth Line Therapy (follow,Other,Salvage,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,QWK,,PO,,1397,1766,1
MMRF_1056,,Fourth Line Therapy (follow,Other,Salvage,Other,Biaxin,,,Disease progression/Relapse,,500,mg,,Q d,,PO,,1397,1766,1
MMRF_1056,,Fifth Line Therapy (followi,Other,salvage,Carfilzomib,,,,Lack of response,,27,mg/m^,,QD,,IV,,1780,1912,1
MMRF_1056,,Fifth Line Therapy (followi,Other,salvage,Cyclophosphamide,,,,Lack of response,,150,mg/m^,,Oth,"QD (D1, D8, D15)",PO,,1843,1912,1
MMRF_1056,,Fifth Line Therapy (followi,Other,salvage,Dexamethasone,,,Checked,,,20,mg,,QWK,,PO,,1929,,1
MMRF_1056,,Fifth Line Therapy (followi,Other,salvage,Pomalidomide,,,Checked,,,2,mg,,QD,,PO,,1929,,1
MMRF_1056,,Fifth Line Therapy (followi,Other,salvage,Daratumumab,,,Checked,,,16,mg/kg,,Oth,"QW(C1-2), Q2W(C3-6), Q4W(C7+)",IV,,1929,,1
MMRF_1056,,Fifth Line Therapy (followi,Other,salvage,Cyclophosphamide,,,,Other,dose reduction to improve blood counts,300,mg/m^,,Oth,"QD (D1, D8, D15)",IV,,1780,1842,1
MMRF_1056,,Fifth Line Therapy (followi,Other,salvage,Dexamethasone,,,,Lack of response,,20,mg,,Q w,,PO,,1780,1912,1
MMRF_1048,Baseline,First line of therapy,,,Bortezomib,,,,Completed regimen,,2.2,mg/m^,,QD,,IV,,1,81,1
MMRF_1048,,First line of therapy,,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,81,1
MMRF_1048,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,PO,,1,81,1
MMRF_1048,,First line of therapy,Maintenance,,Bortezomib,,,,Completed regimen,,1,mg/kg,,QWK,,IV SubQ,,192,953,1
MMRF_1048,,First line of therapy,Maintenance,,Lenalidomide,,,,Completed regimen,,5,mg,,Q d,,PO,,192,953,1
MMRF_1048,,First line of therapy,Consolidation,,Melphalan,,,,Completed regimen,,200,mg/m^,,Oth,Days -3 -2,IV,,81,82,1
MMRF_1048,,Second Line Therapy (after,Other,salvage,Elotuzumab,,,Checked,,,10,mg/kg,,Oth,"weekly(C1-2), Q 2 weeks(C3+)",IV,,1832,,1
MMRF_1048,,Second Line Therapy (after,Other,salvage,Dexamethasone,,,Checked,,,40,mg,,Q w,,PO,,1832,,1
MMRF_1048,,Second Line Therapy (after,Other,salvage,Lenalidomide,,,Checked,,,25,mg,,QD,,PO,,1832,,1
MMRF_1057,Baseline,First line of therapy,,,Bortezomib,,,,Other,Moved to SCT,1.3,mg/m^,,QD,,IV SubQ,,1,103,1
MMRF_1057,,First line of therapy,,,Lenalidomide,,,,Other,Moved to Auto SCT,25,mg,,QD,,PO,,22,103,1
MMRF_1057,,First line of therapy,Maintenance,,Lenalidomide,,,,Completed regimen,,10,mg,,Q d,,PO,,233,954,1
MMRF_1057,,First line of therapy,,,Dexamethasone,,,,Other,Moved to Auto SCT,40,mg,,QD,,PO,,1,103,1
MMRF_1057,,First line of therapy,Consolidation,,Melphalan,,,,Completed regimen,,200,mg/m^,,Oth,Days -3 -2,IV,,132,133,1
MMRF_1060,,First line of therapy,,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,54,138,1
MMRF_1060,Baseline,First line of therapy,,,Vincristine,,,,Lack of response,,0.1,mg/dL,,QD,,IV,,1,54,1
MMRF_1060,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,PO,,1,138,1
MMRF_1060,,First line of therapy,,,Cyclophosphamide,,,,Completed regimen,,1000,mg,,Oth,once monthly,IV,,1,138,1
MMRF_1060,,First line of therapy,Maintenance,,Dexamethasone,,,,Adverse Event or co-morbidity,,40,mg,,QWK,,PO,,285,716,1
MMRF_1060,,First line of therapy,Maintenance,,Lenalidomide,,,,Investigator decision for other reasons,,10,mg,,QD,,PO,,285,425,1
MMRF_1060,,First line of therapy,Maintenance,,Bortezomib,,,,Adverse Event or co-morbidity,,1,mg/m^,,QD,,IV SubQ,,285,716,1
MMRF_1060,,First line of therapy,Maintenance,,Lenalidomide,,,,Completed regimen,,5,mg,,QD,,PO,,534,898,1
MMRF_1060,,Second Line Therapy (after,Other,salvage,Dexamethasone,,,,Other,peripheral neuropathy,20,mg,,QD,,PO,,1990,2088,1
MMRF_1060,,Second Line Therapy (after,Other,salvage,Ixazomib,,,,Other,peripheral neuropathy,4,mg,,Oth,"QD (days 1, 8, 15)",PO,,1990,2088,1
MMRF_1070,,First line of therapy,,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,93,1
MMRF_1070,Baseline,First line of therapy,,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,93,1
MMRF_1070,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,PO,,1,93,1
MMRF_1070,,First line of therapy,,,Bortezomib,,,Checked,,,1.3,mg/m^,,Oth,Every 2 weeks---maintenance therapy,IV,,208,,1
MMRF_1086,,First line of therapy,,,Lenalidomide,,,,Other,Moved to Auto SCT,25,mg,,QD,,PO,,1,142,1
MMRF_1086,,First line of therapy,,,Dexamethasone,,,,Other,Moved to auto SCT,40,mg,,Q w,,PO,,1,142,1
MMRF_1086,Baseline,First line of therapy,,,Bortezomib,,,,Other,Moved to Auto SCT,1.3,mg/m^,,QD,,IV SubQ,,1,142,1
MMRF_1086,,First line of therapy,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,10,mg,,Q d,,PO,,23,114,1
MMRF_1086,,First line of therapy,Maintenance,,Lenalidomide,,,,Other,traumatic Right leg fracture- non-MM,10,mg,,Q d,,PO,,257,358,1
MMRF_1086,,Second Line Therapy (after,Other,salvage,Ixazomib,,,,Adverse Event or co-morbidity,,4,mg,,Oth,"QD (D1, D8, D15)",PO,,1900,1942,1
MMRF_1086,,Second Line Therapy (after,Other,salvage,Dexamethasone,,,Checked,,,40,mg,,Q w,,PO,,1900,,1
MMRF_1086,,Second Line Therapy (after,Other,salvage,Bortezomib,,,Checked,,,1.3,mg/m^,,Oth,Q 2 weeks,IV SubQ,,1956,,1
MMRF_1097,Baseline,First line of therapy,,,Bortezomib,,,,Investigator decision for other reasons,,1.3,mg/m^,,QD,,IV,,1,85,1
MMRF_1097,,First line of therapy,,,Dexamethasone,,,,Investigator decision for other reasons,,40,mg,,Q w,,PO,,1,85,1
MMRF_1097,,First line of therapy,,,Lenalidomide,,,,Investigator decision for other reasons,,25,mg,,QD,,PO,,1,85,1
MMRF_1097,,Second Line Therapy (after,Other,salvage,Bortezomib,,,,Other,doctor decision,1.3,mg/m^,,Q w,,IV,,1196,1492,1
MMRF_1097,,Second Line Therapy (after,Other,salvage,Dexamethasone,,,,Other,doctor decision,20,mg,,Oth,"QD (D1-2, D4-5, D8-9, D11-12)",PO,,1196,1492,1
MMRF_1110,,First line of therapy,,,Dexamethasone,,,,Other,Moved to Auto SCT,40,mg,,Q w,,PO,,1,71,1
MMRF_1110,Baseline,First line of therapy,,,Bortezomib,,,,Other,moved to Auto SCT,3.5,mg,,QD,,IV,,1,71,1
MMRF_1110,,First line of therapy,,,Lenalidomide,,,,Other,Moved to Auto SCT,25,mg,,QD,,PO,,1,71,1
MMRF_1110,,First line of therapy,Maintenance,,Lenalidomide,,,,Other,Hospitalization for Pneumonia,5,mg,,Q d,,PO,,371,671,1
MMRF_1110,,First line of therapy,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,10,mg,,Q d,,PO,,204,344,1
MMRF_1110,,First line of therapy,Maintenance,,Lenalidomide,,,,Investigator decision for other reasons,,5,mg,,QD,,PO,,712,876,1
MMRF_1110,,Second Line Therapy (after,Other,salvage,Dexamethasone,,,,Completed regimen,,40,mg,,Q w,,PO,,1331,1496,1
MMRF_1110,,Second Line Therapy (after,Other,salvage,Carfilzomib,,,,Completed regimen,,36,mg/m^,,QD,,IV,,1331,1496,1
MMRF_1110,,Second Line Therapy (after,Other,salvage,Cyclophosphamide,,,,Other,poor tolerance,300,mg/m^,,Oth,"QD: D1, D8, D15",PO,,1331,1387,1
MMRF_1110,,Second Line Therapy (after,Other,Transplant,Melphalan,,,,Completed regimen,,250,mg,,Oth,day -2,IV,,1501,1501,1
MMRF_1110,,Second Line Therapy (after,Maintenance,,Pomalidomide,,,,Disease progression/Relapse,,2,mg,,Q d,,PO,,1635,1822,1
MMRF_1110,,Third Line Therapy (followi,Other,salvage,Ixazomib,,,,Disease progression/Relapse,,4,mg,,Oth,"days 1, 8, 15 of 28d cycle",PO,,1846,1895,1
MMRF_1110,,Third Line Therapy (followi,Other,salvage,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,QWK,,PO,,1846,1895,1
MMRF_1110,,Fourth Line Therapy (follow,Other,salvage,Dexamethasone,,,Checked,,,40,mg,,QWK,,PO,,1909,,1
MMRF_1110,,Fourth Line Therapy (follow,Other,salvage,Daratumumab,,,Checked,,,16,mg/kg,,Oth,weekly(c1-c2); Q 2 weeks(c3-c6); monthly(c7+),IV,,1909,,1
MMRF_1110,,Fourth Line Therapy (follow,Other,salvage,Pomalidomide,,,Checked,,,2,mg,,QD,,PO,,1909,,1
MMRF_1119,,First line of therapy,,,Lenalidomide,,,,Other,Moved to Auto SCT,25,mg,,QD,,PO,,22,70,1
MMRF_1119,Baseline,First line of therapy,,,Bortezomib,,,,Other,Moved to Auto SCT,1.3,mg/m^,,QD,,IV SubQ,,1,67,1
MMRF_1119,,First line of therapy,,,Dexamethasone,,,,Other,Moved to auto SCT,20,mg,,Oth,Day of and Day after Bortezomib,PO,,1,68,1
MMRF_1119,,First line of therapy,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,10,mg,,Q d,,PO,,207,225,1
MMRF_1119,,First line of therapy,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,10,mg,,Q d,,PO,,379,683,1
MMRF_1119,,First line of therapy,Maintenance,,Lenalidomide,,,,Completed regimen,,5,mg,,Q d,,PO,,683,960,1
MMRF_1119,,First line of therapy,Maintenance,,Lenalidomide,,,,Other,Dose increased,5,mg,,Q d,,PO,,225,379,1
MMRF_1119,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,5,mg,,Q d,,PO,,960,,1
MMRF_1138,,First line of therapy,,,Thalidomide,,,,Other,Moved to SCT,0,Other,dose unknown,Oth,unknown,PO,,1,60,1
MMRF_1138,Baseline,First line of therapy,,,Bortezomib,,,,Other,MOved to SCT,1.3,mg/m^,,QD,,IV SubQ,,1,60,1
MMRF_1138,,First line of therapy,,,Dexamethasone,,,,Other,moved to SCT,40,mg,,QWK,,PO,,1,60,1
MMRF_1138,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,5,mg,,Q d,,PO,,258,,1
MMRF_1141,,First line of therapy,,,Dexamethasone,,,,Adverse Event or co-morbidity,,40,mg,,QD,,PO,,1,175,1
MMRF_1141,Baseline,First line of therapy,,,Bortezomib,,,,Adverse Event or co-morbidity,,1.3,mg/m^,,QD,,IV SubQ,,1,175,1
MMRF_1141,,First line of therapy,,,Lenalidomide,,,,Adverse Event or co-morbidity,,25,mg,,QD,,PO,,1,48,1
MMRF_1142,,First line of therapy,,,Bortezomib,,,,Other,Moved to SCT,1.3,mg/m^,,QD,,IV SubQ,,1,63,1
MMRF_1142,Baseline,First line of therapy,,,Lenalidomide,,,,Other,Moved to SCT,25,mg,,QD,,PO,,1,63,1
MMRF_1142,,First line of therapy,,,Dexamethasone,,,,Other,Moved to SCT,20,mg,,Oth,Day of and Day After Bortezomib,PO,,1,63,1
MMRF_1142,,First line of therapy,Maintenance,,Lenalidomide,,,,Disease progression/Relapse,,10,mg,,Q d,,PO,,216,948,1
MMRF_1142,,First line of therapy,Other,Transplant,Melphalan,,,,Completed regimen,,185,mg,,Oth,"Days -3, -2",IV,,103,104,1
MMRF_1142,,First line of therapy,Other,Transplant,Dexamethasone,,,,Completed regimen,,10,mg,,Oth,"Days -3, -2, -1",IV,,103,105,1
MMRF_1143,Baseline,First line of therapy,,,Dexamethasone,,,,Completed regimen,,40,mg,,Q w,,PO,,1,187,1
MMRF_1143,,First line of therapy,,,Lenalidomide,,,,Completed regimen,,15,mg,,QD,,PO,,1,187,1
MMRF_1143,,Second Line Therapy (after,Consolidation,,Lenalidomide,,,,Completed regimen,,15,mg,,QD,,PO,,997,1090,1
MMRF_1143,,Second Line Therapy (after,Consolidation,,Bortezomib,,,,Completed regimen,,1,mg/m^,,QD,,IV SubQ,,997,1090,1
MMRF_1143,,Second Line Therapy (after,Consolidation,,Dexamethasone,,,,Completed regimen,,20,mg,,QD,,PO,,997,1090,1
MMRF_1143,,Third Line Therapy (followi,Maintenance,,Lenalidomide,,,,Completed regimen,,10,mg,,Q d,,PO,,1202,1652,1
MMRF_1155,Baseline,First line of therapy,,,Bortezomib,,,,Other,moved to SCT,1.3,mg/m^,,QD,,IV SubQ,,1,67,1
MMRF_1155,,First line of therapy,,,Dexamethasone,,,,Other,moved to SCT,40,mg,,QD,,PO,,1,67,1
MMRF_1155,,First line of therapy,,,Lenalidomide,,,,Other,Toxicity,25,mg,,QD,,PO,,1,596,1
MMRF_1155,,Second Line Therapy (after,Other,salvage,Carfilzomib,,,,Completed regimen,,36,mg/m^,,QD,,IV,,1473,1586,1
MMRF_1155,,Second Line Therapy (after,Other,salvage,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,"QD: (D1, D8, D15)",PO,,1473,1586,1
MMRF_1155,,Second Line Therapy (after,Other,salvage,Dexamethasone,,,,Completed regimen,,40,mg,,Q w,,PO,,1473,1586,1
MMRF_1155,,Second Line Therapy (after,Other,Transplant,Melphalan,,,,Completed regimen,,375,mg,,Oth,day -2,IV,,1591,1591,1
MMRF_1155,,Second Line Therapy (after,Maintenance,,Ixazomib,,,,Other,dose reduction due to fatigue,4,mg,,Oth,"days 1, 8, 15 of 28d cycle",PO,,1771,1829,1
MMRF_1155,,Second Line Therapy (after,Maintenance,,Ixazomib,,,,Other,dose reduction due to fatigue,3,mg,,Oth,"days 1, 8, 15 of 28d cycle",PO,,1830,1872,1
MMRF_1155,,Second Line Therapy (after,Maintenance,,Ixazomib,,,Checked,,,2.3,mg,,Oth,"days 1, 8, 15 of 28d cycle",PO,,1873,,1
MMRF_1160,Baseline,First line of therapy,,,Bortezomib,,,Checked,,,1.3,mg/m^,,QD,,IV,,1,,1
MMRF_1173,Baseline,First line of therapy,,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,126,1
MMRF_1173,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,20,mg,,QD,,PO,,1,126,1
MMRF_1173,,First line of therapy,,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,126,1
MMRF_1173,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,10,mg,,QD,,PO,,248,,1
MMRF_1195,Baseline,First line of therapy,,,Bortezomib,,,Checked,,,1.3,mg/m^,,QD,,IV SubQ,,1,,1
MMRF_1195,,First line of therapy,,,Dexamethasone,,,Checked,,,20,mg,,QD,,PO,,1,,1
MMRF_1195,,First line of therapy,,,Lenalidomide,,,Checked,,,25,mg,,Oth,QD 1-14,PO,,1,,1
MMRF_1195,,First line of therapy,Other,Transplant,Melphalan,,,,Completed regimen,,185,mg,,Oth,"Days -3, -2",IV,,106,107,1
MMRF_1195,,First line of therapy,Other,Transplant,Dexamethasone,,,,Completed regimen,,10,mg,,Oth,"Days -3, -2, -1",IV,,106,108,1
MMRF_1219,Baseline,First line of therapy,,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,95,1
MMRF_1219,,First line of therapy,,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,95,1
MMRF_1219,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,25,mg,,QD,,PO,,1,95,1
MMRF_1219,,Second Line Therapy (after,Induction,,Carfilzomib,,,,Disease progression/Relapse,,72,mg/m^,,QD,,IV,,278,1307,1
MMRF_1219,,Second Line Therapy (after,Induction,,Doxorubicin,,,,Disease progression/Relapse,,30,mg/m^,,Oth,Day 8,IV,,278,1307,1
MMRF_1219,,Third Line Therapy (followi,Induction,,Pomalidomide,,,Checked,,,3,mg,,QD,,PO,,1433,,1
MMRF_1219,,Third Line Therapy (followi,Induction,,Dexamethasone,,,Checked,,,40,mg,,Q w,,PO,,1377,,1
MMRF_1219,,Third Line Therapy (followi,Induction,,Elotuzumab,,,,Completed regimen,,10,mg/kg,,Q w,,IV,,1377,1433,1
MMRF_1219,,Third Line Therapy (followi,Induction,,Pomalidomide,,,,Other,dose reduction due to dizziness,4,mg,,QD,,PO,,1377,1433,1
MMRF_1219,,Third Line Therapy (followi,Induction,,Elotuzumab,,,,Completed regimen,,10,mg/kg,,Oth,"D1, D15",IV,,1433,1545,1
MMRF_1219,,Third Line Therapy (followi,Induction,,Elotuzumab,,,Checked,,,20,mg/kg,,Oth,D1,IV,,1545,,1
MMRF_1225,,First line of therapy,,,Dexamethasone,,,,Other,moved to SCT,40,mg,,QD,,PO,,1,132,1
MMRF_1225,,First line of therapy,,,Lenalidomide,,,,Other,moved to SCT,25,mg,,QD,,PO,,1,132,1
MMRF_1225,Baseline,First line of therapy,,,Bortezomib,,,,Other,moved to SCT,1.3,mg/m^,,QD,,IV SubQ,,1,132,1
MMRF_1225,,First line of therapy,Consolidation,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,"Days 1, 8, and 15",PO,,267,344,1
MMRF_1225,,First line of therapy,Consolidation,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV,,267,341,1
MMRF_1225,,First line of therapy,Consolidation,,Lenalidomide,,,,Completed regimen,,15,mg,,QD,,PO,,267,344,1
MMRF_1225,,First line of therapy,Maintenance,,Bortezomib,,,,Patient decision,,1.3,mg/m^,,Oth,Twice a month,IV SubQ,,431,960,1
MMRF_1225,,First line of therapy,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,10,mg,,Q d,,PO,,358,394,1
MMRF_1225,,First line of therapy,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,5,mg,,Q d,,PO,,410,431,1
MMRF_1225,,Second Line Therapy (after,Other,salvage,Dexamethasone,,,,Completed regimen,,20,mg,,Q w,,PO,,1422,1513,1
MMRF_1225,,Second Line Therapy (after,Other,salvage,Dexamethasone,,,,Other,dose reduction,40,mg,,Q w,,PO,,1373,1422,1
MMRF_1225,,Third Line Therapy (followi,Other,salvage,Ixazomib,,,Checked,,,4,mg,,Oth,"days 1, 8, 15",PO,,1669,,1
MMRF_1225,,Third Line Therapy (followi,Other,salvage,Dexamethasone,,,Checked,,,20,mg,,QD,,PO,,1669,,1
MMRF_1226,,First line of therapy,,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,4,68,1
MMRF_1226,Baseline,First line of therapy,,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,68,1
MMRF_1226,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,20,mg,,QD,,PO,,1,68,1
MMRF_1226,,First line of therapy,Maintenance,,Bortezomib,,,,Other,doctor decision,2.2,mg,,Oth,Q2W,IV SubQ,,218,1212,1
MMRF_1226,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,5,mg,,QD,,PO,,736,,1
MMRF_1226,,First line of therapy,Maintenance,,Dexamethasone,,,,Patient decision,,40,mg,,Q w,,PO,,1219,1377,1
MMRF_1226,,First line of therapy,Maintenance,,Ixazomib,,,Checked,,,4,mg,,Oth,"QD: days 1, 8, 15",PO,,1219,,1
MMRF_1226,,First line of therapy,Other,transplant,Melphalan,,,,Completed regimen,,160,mg,,Oth,"days -3, -2",IV,,96,97,1
MMRF_1234,Baseline,First line of therapy,,,Bortezomib,,,Checked,,,1.3,mg/m^,,QD,,IV SubQ,,1,,1
MMRF_1234,,First line of therapy,,,Dexamethasone,,,Checked,,,40,mg,,QD,,PO,,1,,1
MMRF_1234,,First line of therapy,,,Lenalidomide,,,Checked,,,25,mg,,QD,,PO,,1,,1
MMRF_1234,,First line of therapy,Other,Transplant,Dexamethasone,,,,Completed regimen,,10,mg,,Oth,"Days -3, -2, -1",IV,,80,82,1
MMRF_1234,,First line of therapy,Other,Transplant,Melphalan,,,,Completed regimen,,215,mg,,Oth,"Days -3, -2",IV,,80,81,1
MMRF_1234,,First line of therapy,Other,Transplant,Dexamethasone,,,,Completed regimen,,10,mg,,Oth,"Days -3, -2, -1",IV,,204,206,1
MMRF_1234,,First line of therapy,Other,Transplant,Melphalan,,,,Completed regimen,,210,mg,,Oth,"Days -3, -2",IV,,204,205,1
MMRF_1269,,First line of therapy,,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,103,1
MMRF_1269,Baseline,First line of therapy,,,Bortezomib,,,,Completed regimen,,3,mg/m^,,QD,,IV SubQ,,1,103,1
MMRF_1269,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,20,mg,,QD,,PO,,1,103,1
MMRF_1269,,First line of therapy,Maintenance,,Lenalidomide,,,,Disease progression/Relapse,,10,mg,,QD,,PO,,236,1462,1
MMRF_1269,,Second Line Therapy (after,Other,salvage,Carfilzomib,,,,Disease progression/Relapse,,27,mg/m^,,QD,,IV,,1475,1538,1
MMRF_1269,,Second Line Therapy (after,Other,salvage,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,Q w,,Other,"IV weeks with Carfilzomib, PO off-week",1475,1538,1
MMRF_1269,,Third Line Therapy (followi,Other,salvage,Pomalidomide,,,,Other,death,2,mg,,QD,,PO,,1544,1590,1
MMRF_1269,,Third Line Therapy (followi,Other,salvage,Dexamethasone,,,,Other,death,4,mg,,Oth,"days 1, 2 after daratumumab",PO,,1544,1590,1
MMRF_1269,,Third Line Therapy (followi,Other,salvage,Daratumumab,,,,Other,death,16,mg/kg,,Q w,,IV,,1544,1590,1
MMRF_1269,,First line of therapy,Other,Pre-Transplant,Melphalan,,,,Completed regimen,,205,mg,,Oth,"days -3, -2",IV,,135,136,1
MMRF_1270,,First line of therapy,,,Lenalidomide,,,Checked,,,25,mg,,QD,,PO,,1,,1
MMRF_1270,Baseline,First line of therapy,,,Bortezomib,,,Checked,,,1.3,mg/m^,,QD,,IV SubQ,,1,,1
MMRF_1270,,First line of therapy,,,Dexamethasone,,,Checked,,,40,mg,,QD,,PO,,1,,1
MMRF_1289,,First line of therapy,,,Dexamethasone,,,,Other,Moved to Auto SCT,20,mg,,Oth,Day of and Day after Bortezomib,PO,,1,49,1
MMRF_1289,Baseline,First line of therapy,,,Bortezomib,,,,Other,Moved to Auto SCT,1.3,mg/m^,,QD,,IV SubQ,,1,49,1
MMRF_1289,,First line of therapy,,,Lenalidomide,,,,Other,moved to Auto SCT,25,mg,,QD,,PO,,1,49,1
MMRF_1289,,First line of therapy,Maintenance,,Lenalidomide,,,,Disease progression/Relapse,,10,mg,,Q d,,PO,,219,295,1
MMRF_1289,,First line of therapy,Maintenance,,Bortezomib,,,,Disease progression/Relapse,,1.3,mg/m^,,Oth,Twice a month,IV SubQ,,219,295,1
MMRF_1289,,First line of therapy,Induction,,Cyclophosphamide,,,,Disease progression/Relapse,,300,mg/m^,,Q w,,PO,,330,393,1
MMRF_1289,,First line of therapy,Induction,,Carfilzomib,,,,Disease progression/Relapse,,36,mg/m^,,QD,,IV,,330,393,1
MMRF_1289,,First line of therapy,Induction,,Dexamethasone,,,,Disease progression/Relapse,,20,mg,,QWK,,PO,,330,393,1
MMRF_1289,,Second Line Therapy (after,Induction,,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,Oth,Daily Days 1-4,PO,,393,417,1
MMRF_1289,,Second Line Therapy (after,Induction,,Cyclophosphamide,,,,Disease progression/Relapse,,400,mg/m^,,Oth,Daily Days 1-4,IV,,393,417,1
MMRF_1289,,Second Line Therapy (after,Induction,,Other,Etoposide,,,Patient decision,,40,mg/m^,,Oth,Daily Days 1-4,IV,,393,417,1
MMRF_1289,,Second Line Therapy (after,Induction,,Other,Cisplatin,,,Disease progression/Relapse,,10,mg/m^,,Oth,Daily Days 1-4,IV,,393,417,1
MMRF_1289,,Third Line Therapy (followi,Unknown,,Melphalan,,,,Other,Patient went on Hospice,8,mg/m^,,QD,,PO,,465,477,1
MMRF_1289,,Third Line Therapy (followi,Unknown,,Cyclophosphamide,,,,Other,Patient went on Hospice,400,mg/m^,,QD,,IV,,465,477,1
MMRF_1289,,Third Line Therapy (followi,Unknown,,Vincristine,,,,Other,Patient went on Hospice,1.2,mg/m^,,QID,,IV,,465,477,1
MMRF_1289,,Third Line Therapy (followi,Unknown,,BCNU,,,,Other,Patient went on Hospice,20,mg/m^,,QID,,IV,,465,477,1
MMRF_1289,,Third Line Therapy (followi,Unknown,,Prednisone,,,,Other,Patient went on Hospice,40,mg/m^,,QD,,PO,,465,477,1
MMRF_1289,,First line of therapy,Other,transplant,Melphalan,,,,Completed regimen,,190,mg,,Oth,"days -3, -2",IV,,88,89,1
MMRF_1356,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,PO,,1,260,1
MMRF_1356,,First line of therapy,,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,260,1
MMRF_1356,Baseline,First line of therapy,,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,260,1
MMRF_1356,,First line of therapy,Maintenance,,Lenalidomide,,,,Disease progression/Relapse,,10,mg,,Q d,,PO,,260,464,1
MMRF_1356,,Second Line Therapy (after,Maintenance,,Bortezomib,,,,Disease progression/Relapse,,1.3,mg/m^,,Oth,every 2 weeks,IV SubQ,,659,1002,1
MMRF_1356,,Second Line Therapy (after,Other,salvage,Elotuzumab,,,,Adverse Event or co-morbidity,,10,mg/kg,,Q w,,IV,,1018,1298,1
MMRF_1356,,Second Line Therapy (after,Other,salvage,Dexamethasone,,,,Adverse Event or co-morbidity,,40,mg,,Q w,,PO,,1018,1298,1
MMRF_1356,,Second Line Therapy (after,Other,salvage,Lenalidomide,,,,Adverse Event or co-morbidity,,25,mg,,QD,,PO,,1018,1298,1
MMRF_1356,,Third Line Therapy (followi,Other,salvage,Lenalidomide,,,,Adverse Event or co-morbidity,,25,mg,,Q w,,PO,,1424,1501,1
MMRF_1356,,Third Line Therapy (followi,Other,salvage,Dexamethasone,,,,Adverse Event or co-morbidity,,50,mg,,Q w,,Other,10 mg IV; 40 mg PO,1424,1501,1
MMRF_1356,,Third Line Therapy (followi,Other,salvage,Carfilzomib,,,,Adverse Event or co-morbidity,,57,mg,,QD,,IV,,1424,1501,1
MMRF_1356,,Third Line Therapy (followi,Other,salvage,Daratumumab,,,,Disease progression/Relapse,,16,mg/kg,,Oth,weekly(C1-2); Q 2 weeks(C3-6); monthly(C7+),IV,,1515,1675,1
MMRF_1356,,Second Line Therapy (after,Other,transplant,Melphalan,,,,Completed regimen,,125,mg,,Oth,"days -3, -2",IV,,548,549,1
MMRF_1356,,Third Line Therapy (followi,Other,salvage,Dexamethasone,,,,Disease progression/Relapse,,20,mg,,Q w,,IV,,1515,1675,1
MMRF_1373,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,20,mg,,QD,,PO,,1,71,1
MMRF_1373,,First line of therapy,,,Lenalidomide,,,,Adverse Event or co-morbidity,,25,mg,,QD,,PO,,1,18,1
MMRF_1373,Baseline,First line of therapy,,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IVB,,1,71,1
MMRF_1373,,First line of therapy,Other,transplant,Melphalan,,,,Completed regimen,,155,mg,,Oth,"days -3, -2",IV,,124,125,1
MMRF_1373,,First line of therapy,Maintenance,,Lenalidomide,,,,Other,dose reduction due to neutropenia,10,mg,,Q d,,PO,,227,328,1
MMRF_1373,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,5,mg,,Q d,,PO,,328,,1
MMRF_1390,Baseline,First line of therapy,,,Bortezomib,,,,Lack of response,,1.3,mg/m^,,QD,,IV SubQ,,1,47,1
MMRF_1390,,First line of therapy,,,Dexamethasone,,,,Investigator decision for other reasons,,40,mg,,QD,,PO,,1,26,1
MMRF_1441,,First line of therapy,,,Lenalidomide,,,Checked,,,15,mg,,QD,,PO,,1,,1
MMRF_1441,Baseline,First line of therapy,,,Bortezomib,,,Checked,,,2.16,mg,,QD,,IV,,1,,1
MMRF_1441,,First line of therapy,,,Dexamethasone,,,Checked,,,10,mg,,QD,,PO,,1,,1
MMRF_1445,,First line of therapy,,,Bortezomib,,,,Adverse Event or co-morbidity,,2.08,mg,,QD,,IV SubQ,,1,86,1
MMRF_1445,,First line of therapy,,,Dexamethasone,,,,Adverse Event or co-morbidity,,40,mg,,Q w,,PO,,1,86,1
MMRF_1445,Baseline,First line of therapy,,,Lenalidomide,,,,Adverse Event or co-morbidity,,25,mg,,QD,,PO,,1,37,1
MMRF_1445,,First line of therapy,Induction,,Dexamethasone,,,Checked,,,4,mg,,Q w,,PO,,133,,1
MMRF_1445,,First line of therapy,Induction,,Bortezomib,,,Checked,,,2.08,mg,,QD,,IV,,133,,1
MMRF_1496,Baseline,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Q w,,PO,,1,121,1
MMRF_1496,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,2.6,mg/m^,,QD,,IV SubQ,,5,60,1
MMRF_1496,,Second Line Therapy (after,Consolidation,,Pomalidomide,,,,Completed regimen,,4,mg,,QD,,PO,,383,423,1
MMRF_1496,,First line of therapy,Consolidation,,Bortezomib,,,,Investigator decision for other reasons,,1.3,mg/m^,,QD,,IV SubQ,,320,342,1
MMRF_1496,,First line of therapy,Consolidation,,Cyclophosphamide,,,,Completed regimen,,50,mg,,QWK,,PO,,320,370,1
MMRF_1496,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,10,mg,,QD,,PO,,47,121,1
MMRF_1496,,First line of therapy,Maintenance,,Lenalidomide,,,,Disease progression/Relapse,,10,mg,,Q d,,PO,,226,293,1
MMRF_1496,,First line of therapy,Consolidation,,Dexamethasone,,,,Completed regimen,,4,mg,,Q d,,PO,,289,453,1
MMRF_1496,,Second Line Therapy (after,Consolidation,,Carfilzomib,,,,Completed regimen,,20,mg/m^,,QD,,IV,,342,423,1
MMRF_1496,,First line of therapy,Other,transplant,Melphalan,,,,Completed regimen,,180,mg,,Oth,"days -3, -2",IV,,121,122,1
MMRF_1496,,Second Line Therapy (after,Other,transplant,Cyclophosphamide,,,,Completed regimen,,4200,mg,,Oth,"days -3, -2",IV,,423,424,1
MMRF_1511,,First line of therapy,Induction,,Dexamethasone,,,,Other,MOved to SCT,40,mg,,Q w,,PO,,1,63,1
MMRF_1511,,First line of therapy,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,25,mg,,QD,,PO,,1,8,1
MMRF_1511,Baseline,First line of therapy,Induction,,Bortezomib,,,,Other,Moved to SCT,2.4,mg,,QD,,IV SubQ,,1,63,1
MMRF_1511,,First line of therapy,Maintenance,,Bortezomib,,,,Other,increasing neuropathy,1,mg/m^,,Oth,Twice a month,IV SubQ,,192,777,1
MMRF_1511,,First line of therapy,Maintenance,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"QD: days 1, 2, 15, 16",IV,,777,973,1
MMRF_1511,,Third Line Therapy (followi,Other,salvage,Daratumumab,,,,Patient decision,,16,mg/kg,,QWK,,IV,,1518,1600,1
MMRF_1511,,Second Line Therapy (after,Other,salvage,Ixazomib,,,,Disease progression/Relapse,,4,mg,,Q w,,PO,,1215,1496,1
MMRF_1511,,Second Line Therapy (after,Other,salvage,Dexamethasone,,,,Disease progression/Relapse,,2,mg,,Q w,,PO,,1215,1496,1
MMRF_1511,,Third Line Therapy (followi,Other,salvage,Dexamethasone,,,Checked,,,2,mg,,QWK,,PO,,1518,,1
MMRF_1511,,Third Line Therapy (followi,Other,salvage,Pomalidomide,,,Checked,,,2,mg,,Oth,Q 2 days (days 1-21 of 28d),PO,,1518,,1
MMRF_1584,Baseline,First line of therapy,Induction,,Lenalidomide,,,Checked,,,25,mg,,QD,,PO,,32,,1
MMRF_1584,,First line of therapy,Induction,,Bortezomib,,,Checked,,,2.2,mg,,QD,,IV,,32,,1
MMRF_1584,,First line of therapy,Induction,,Dexamethasone,,,Checked,,,40,mg,,Q w,,PO,,32,,1
MMRF_1584,,First line of therapy,Induction,,Dexamethasone,,,,Other,chnaged dose,4,mg,,Q d,,PO,,11,32,1
MMRF_1584,,First line of therapy,Induction,,Dexamethasone,,,,Other,Changed dose,16,mg,,Q d,,PO,,1,11,1
MMRF_1624,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,2.9,mg,,QD,,IV,,1,142,1
MMRF_1624,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,142,1
MMRF_1624,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,QD,,PO,,1,142,1
MMRF_1624,,First line of therapy,Maintenance,,Lenalidomide,,,,Disease progression/Relapse,,10,mg,,Q d,,PO,,292,1440,1
MMRF_1624,,Second Line Therapy (after,Other,salvage,Daratumumab,,,,Disease progression/Relapse,,16,mg/kg,,Oth,QW(C1-2); Q2W(C3-6),IV,,1449,1582,1
MMRF_1624,,Second Line Therapy (after,Other,salvage,Dexamethasone,,,,Adverse Event or co-morbidity,,40,mg,,Q w,,PO,,1449,1469,1
MMRF_1624,,Second Line Therapy (after,Other,salvage,Pomalidomide,,,,Adverse Event or co-morbidity,,4,mg/dL,,Q d,,PO,,1449,1469,1
MMRF_1667,Baseline,First line of therapy,Induction,,Dexamethasone,,,,Other,Moved to SCT,20,mg,,Oth,Day of and Day After Velcade,PO,,1,107,1
MMRF_1667,,First line of therapy,Induction,,Bortezomib,,,,Other,Moved to SCT,1.3,mg/m^,,Q w,,IV SubQ,,1,106,1
MMRF_1667,,First line of therapy,Induction,,Cyclophosphamide,,,,Other,Moved to SCT,300,mg/m^,,Q w,,PO,,1,106,1
MMRF_1667,,First line of therapy,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,10,mg,,Q d,,PO,,259,474,1
MMRF_1667,,First line of therapy,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,5,mg,,Q d,,PO,,475,536,1
MMRF_1668,Baseline,First line of therapy,Induction,,Cyclophosphamide,,,,Disease progression/Relapse,,650,mg,,QD,,IV,,8,142,1
MMRF_1668,,First line of therapy,Induction,,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,Q w,,PO,,2,142,1
MMRF_1668,,First line of therapy,Induction,,Bortezomib,,,,Disease progression/Relapse,,3.2,mg,,Q w,,IV,,1,142,1
MMRF_1668,,Second Line Therapy (after,Induction,,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,QWK,,IV,,143,202,1
MMRF_1668,,Second Line Therapy (after,Induction,,Lenalidomide,,,,Disease progression/Relapse,,10,mg,,QD,,PO,,142,202,1
MMRF_1668,,Second Line Therapy (after,Induction,,Carfilzomib,,,,Disease progression/Relapse,,20,mg/m^,,QD,,IV,,142,202,1
MMRF_1668,,Third Line Therapy (followi,Consolidation,,Carfilzomib,,,,Completed regimen,,27,mg/m^,,QD,,IV,,209,251,1
MMRF_1668,,Third Line Therapy (followi,Consolidation,,Pomalidomide,,,,Completed regimen,,4,mg,,QD,,PO,,209,251,1
MMRF_1668,,Third Line Therapy (followi,Consolidation,,Dexamethasone,,,,Completed regimen,,20,mg,,QWK,,PO,,209,251,1
MMRF_1760,,First line of therapy,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,15,mg,,QD,,PO,,1,134,1
MMRF_1760,Baseline,First line of therapy,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,40,mg,,Q w,,PO,,22,134,1
MMRF_1760,,First line of therapy,Induction,,Melphalan,,,,Disease progression/Relapse,,16,mg,,QD,,PO,,135,197,1
MMRF_1760,,First line of therapy,Induction,,Prednisone,,,,Disease progression/Relapse,,100,mg,,QD,,PO,,135,197,1
MMRF_1760,,Second Line Therapy (after,Other,salvage,Bortezomib,,,,Adverse Event or co-morbidity,,1,mg/m^,,Q w,,IV SubQ,,211,848,1
MMRF_1760,,Second Line Therapy (after,Other,salvage,Dexamethasone,,,,Other,doctor decision,20,mg,,Q w,,PO,,211,673,1
MMRF_1760,,Third Line Therapy (followi,Other,salvage,Pomalidomide,,,,Other,frequency change due to peripheral neuropathy,2,mg,,QD,,PO,,953,1057,1
MMRF_1760,,Third Line Therapy (followi,Other,salvage,Dexamethasone,,,,Adverse Event or co-morbidity,,20,mg,,Q w,,PO,,953,1113,1
MMRF_1760,,Third Line Therapy (followi,Other,salvage,Pomalidomide,,,,Adverse Event or co-morbidity,,2,mg,,Oth,Q 2 days (days 1-21),PO,,1058,1113,1
MMRF_1760,,Fourth Line Therapy (follow,Other,salvage,Daratumumab,,,Checked,,,16,mg/kg,,Oth,weekly(C1-2); Q 2 weeks(C3-6); monthy (C7+),IV,,1211,,1
MMRF_1760,,Fourth Line Therapy (follow,Other,salvage,Dexamethasone,,,Checked,,,8,mg,,Oth,weekly(C1-2); Q 2 weeks(C3-6); monthy (C7+),PO,,1211,,1
MMRF_1783,,First line of therapy,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,3.71,mg,,QD,,IV,,1,11,1
MMRF_1783,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Q w,,PO,,1,156,1
MMRF_1783,Baseline,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,156,1
MMRF_1783,,First line of therapy,Induction,,Lenalidomide,,,,Disease progression/Relapse,,10,mg,,Q d,,PO,,192,380,1
MMRF_1783,,Second Line Therapy (after,Unknown,,Carfilzomib,,,,Completed regimen,,20,mg/m^,,QD,,IV,,380,481,1
MMRF_1783,,Second Line Therapy (after,Unknown,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,QWK,,PO,,380,481,1
MMRF_1783,,Second Line Therapy (after,Unknown,,Dexamethasone,,,,Completed regimen,,40,mg,,QWK,,PO,,380,481,1
MMRF_1783,,First line of therapy,Induction,,Bortezomib,,,,Disease progression/Relapse,,1.3,mg/m^,,Q w,,IV SubQ,,192,380,1
MMRF_1783,,Second Line Therapy (after,Maintenance,,Pomalidomide,,,,Other,Death,2,mg,,QD,,PO,,632,718,1
MMRF_1783,,Second Line Therapy (after,Other,transplant,Melphalan,,,,Completed regimen,,470,mg,,Oth,day -2,IV,,493,493,1
MMRF_1784,Baseline,First line of therapy,Induction,,Dexamethasone,,,,Other,Moved to SCT,40,mg,,Oth,Day of and after bortezoib,PO,,1,75,1
MMRF_1784,,First line of therapy,Induction,,Bortezomib,,,,Other,Moved to auto SCT,2.7,mg,,QD,,IV SubQ,,1,74,1
MMRF_1784,,First line of therapy,Induction,,Lenalidomide,,,,Other,Moved to SCT,25,mg,,QD,,PO,,22,77,1
MMRF_1784,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,10,mg,,QD,,PO,,204,,1
MMRF_1839,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,102,1
MMRF_1839,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,7,102,1
MMRF_1839,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,QWK,,PO,,1,102,1
MMRF_1839,,First line of therapy,Maintenance,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,Oth,twice a month,IV,,240,898,1
MMRF_1839,,First line of therapy,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,5,mg,,QD,,PO,,240,1123,1
MMRF_1851,,First line of therapy,Induction,,Bortezomib,,,,Other,Patient went on hospice,1.3,mg/m^,,QD,,IV SubQ,,12,25,1
MMRF_1851,,First line of therapy,Induction,,Lenalidomide,,,,Other,Patient went on hospice,20,mg,,QD,,PO,,13,25,1
MMRF_1851,Baseline,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Q d,,PO,,1,4,1
MMRF_1851,,First line of therapy,Induction,,Dexamethasone,,,,Other,Patient went on hospice,20,mg,,Oth,Day of and day after bortezomib,PO,,12,25,1
MMRF_1876,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,QWK,,PO,,1,85,1
MMRF_1876,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,"QD 1-4, 9-12, 17-20 of 28",PO,,1,85,1
MMRF_1876,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,85,1
MMRF_1876,,Second Line Therapy (after,Other,salvage,Dexamethasone,,,,Lack of response,,20,mg,,QD,,PO,,490,564,1
MMRF_1876,,Second Line Therapy (after,Other,salvage,Bortezomib,,,,Lack of response,,1,mg/m^,,QD,,IV,,490,564,1
MMRF_1876,,Second Line Therapy (after,Other,salvage,Cyclophosphamide,,,,Lack of response,,150,mg/m^,,Oth,BID (D1-5),PO,,490,564,1
MMRF_1876,,First line of therapy,Maintenance,,Lenalidomide,,,,Disease progression/Relapse,,10,mg,,Q d,,PO,,239,490,1
MMRF_1889,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,QWK,,PO,,1,106,1
MMRF_1889,Baseline,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,38,mg,,QD,,IV,,1,106,1
MMRF_1889,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,106,1
MMRF_1889,,First line of therapy,Maintenance,,Lenalidomide,,,,Disease progression/Relapse,,25,mg,,Q d,,PO,,266,421,1
MMRF_1889,,Second Line Therapy (after,Other,Salvage,Bortezomib,,,,Disease progression/Relapse,,1.5,mg/m^,,QWK,,IV SubQ,,421,519,1
MMRF_1889,,Second Line Therapy (after,Other,Salvage,Cyclophosphamide,,,,Disease progression/Relapse,,300,mg/m^,,QWK,,PO,,421,519,1
MMRF_1889,,Second Line Therapy (after,Other,Salvage,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,Q d,,PO,,421,519,1
MMRF_1889,,Third Line Therapy (followi,Other,salvage,Bendamustine,,,,Disease progression/Relapse,,80,mg/m^,,Oth,"D1, D2",IVB,,557,638,1
MMRF_1889,,Third Line Therapy (followi,Other,salvage,Carfilzomib,,,,Lack of response,,27,mg/m^,,QD,,IV,,519,554,1
MMRF_1889,,Third Line Therapy (followi,Other,salvage,Thalidomide,,,,Lack of response,,200,mg,,Q d,,PO,,519,554,1
MMRF_1889,,Fourth Line Therapy (follow,Other,salvage,Pomalidomide,,,,Other,dose reduction due to adverse event,4,mg,,QD,,PO,,659,687,1
MMRF_1889,,Fourth Line Therapy (follow,Other,salvage,Dexamethasone,,,,Adverse Event or co-morbidity,,20,mg,,Q w,,PO,,659,800,1
MMRF_1889,,Third Line Therapy (followi,Other,salvage,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,Q w,,PO,,519,638,1
MMRF_1889,,Fourth Line Therapy (follow,Other,salvage,Daratumumab,,,,Adverse Event or co-morbidity,,60,mg/kg,,Q w,,IV,,659,800,1
MMRF_1889,,First line of therapy,Other,Transplant,Melphalan,,,,Completed regimen,,160,mg,,Oth,"Days -3, -2",IV,,139,140,1
MMRF_1889,,Fourth Line Therapy (follow,Other,salvage,Pomalidomide,,,,Adverse Event or co-morbidity,,2,mg,,QD,,PO,,687,800,1
MMRF_1891,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,103,1
MMRF_1891,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,103,1
MMRF_1891,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,Day of and day after bortezomib,PO,,1,103,1
MMRF_1891,,First line of therapy,Maintenance,,Lenalidomide,,,,Disease progression/Relapse,,10,mg,,Q d,,PO,,204,599,1
MMRF_1891,,Second Line Therapy (after,Other,salvage,Other,ABBV-838,,,Other,neuropathy,0.6,mg/kg,,Oth,Q 21 days,IV,,645,1037,1
MMRF_1891,,Second Line Therapy (after,Other,salvage,Elotuzumab,,,Checked,,,10,mg/kg,,Oth,weekly(C1-2); Q 2 weeks(C3+),IV,,1058,,1
MMRF_1891,,Second Line Therapy (after,Other,salvage,Lenalidomide,,,Checked,,,25,mg,,QD,,PO,,1058,,1
MMRF_1891,,Second Line Therapy (after,Other,salvage,Dexamethasone,,,Checked,,,28,mg,,Q w,,PO,,1058,,1
MMRF_1893,Baseline,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,4,73,1
MMRF_1893,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,4,73,1
MMRF_1893,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,Day of and day after bortezomib,PO,,4,73,1
MMRF_1893,,First line of therapy,Induction,,Dexamethasone,,,,Other,Switched regimen,40,mg,,Q d,,PO,,1,3,1
MMRF_1893,,First line of therapy,Maintenance,,Lenalidomide,,,,Other,patient forgetfullness and inability/reluctance to meet deductible,20,mg,,Q d,,PO,,232,802,1
MMRF_1900,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,Oth,"Day 1, Day 8 & Day 15, of 28",IV SubQ,,1,253,1
MMRF_1900,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,15,mg,,QD,,PO,,1,253,1
MMRF_1900,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Day 1, Day 8 & Day 15, of 28",PO,,1,253,1
MMRF_1900,,First line of therapy,Maintenance,,Lenalidomide,,,,Investigator decision for other reasons,,5,mg,,Q d,,PO,,253,344,1
MMRF_1900,,Second Line Therapy (after,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,5,mg,,QD,,PO,,405,539,1
MMRF_1900,,Second Line Therapy (after,Maintenance,,Dexamethasone,,,,Adverse Event or co-morbidity,,20,mg,,Oth,Twice weekly,PO,,405,539,1
MMRF_1900,,Second Line Therapy (after,Maintenance,,Lenalidomide,,,,Other,doctor decision,5,mg,,QD,,PO,,614,708,1
MMRF_1900,,Second Line Therapy (after,Maintenance,,Dexamethasone,,,,Other,doctor decision,20,mg,,Oth,b.i. weekly,PO,,614,708,1
MMRF_1900,,Third Line Therapy (followi,Other,salvage,Dexamethasone,,,,Other,death,4,mg,,Oth,3x weekly,PO,,925,1282,1
MMRF_1900,,Third Line Therapy (followi,Other,salvage,Lenalidomide,,,,Other,death,5,mg,,QD,,PO,,925,1282,1
MMRF_1911,Baseline,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,20,mg/m^,,QD,,IV,,1,91,1
MMRF_1911,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,91,1
MMRF_1911,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,QWK,,PO,,1,91,1
MMRF_1911,,First line of therapy,Consolidation,,Carfilzomib,,,,Completed regimen,,20,mg/m^,,QD,,IV,,213,317,1
MMRF_1911,,First line of therapy,Consolidation,,Dexamethasone,,,,Completed regimen,,40,mg,,Q w,,PO,,213,317,1
MMRF_1911,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,10,mg,,Q d,,PO,,360,,1
MMRF_1911,,First line of therapy,Consolidation,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,213,317,1
MMRF_1953,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Q w,,PO,,1,65,1
MMRF_1953,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,65,1
MMRF_1953,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,65,1
MMRF_1953,,First line of therapy,Maintenance,,Lenalidomide,,,,Other,Doctor decision,10,mg,,Q d,,PO,,248,640,1
MMRF_1953,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,10,mg,,QD,,PO,,752,,1
MMRF_1953,,First line of therapy,Other,transplant,Melphalan,,,,Completed regimen,,175,mg,,Q d,,IV,,124,125,1
MMRF_1955,Baseline,First line of therapy,Induction,,Dexamethasone,,,,Other,Switched to weekly Dex,40,mg,,Q d,,IV,,1,4,1
MMRF_1955,,First line of therapy,Induction,,Dexamethasone,,,,Investigator decision for other reasons,,20,mg,,Oth,Day of and Day after Bortezomib,PO,,10,162,1
MMRF_1955,,First line of therapy,Induction,,Bortezomib,,,,Investigator decision for other reasons,,1.3,mg/m^,,QD,,IV SubQ,,3,162,1
MMRF_1974,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,96,1
MMRF_1974,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,Days 1 and 8,IV,,4,96,1
MMRF_1974,,First line of therapy,Induction,,Dexamethasone,,,,Other,changed frequency,40,mg,,Oth,"Days 1-4, 9-12, 17-20",PO,,1,22,1
MMRF_1974,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,Day of and day after bortezomib,PO,,23,96,1
MMRF_1974,,Second Line Therapy (after,Other,Salvage,Pomalidomide,,,,Disease progression/Relapse,,4,mg,,QD,,PO,,371,398,1
MMRF_1974,,Second Line Therapy (after,Other,salvage,Bendamustine,,,,Disease progression/Relapse,,75,mg/m^,,QD,,IV,,408,419,1
MMRF_1974,,Second Line Therapy (after,Other,salvage,Cyclophosphamide,,,,Investigator decision for other reasons,,400,mg/m^,,Oth,continuous infusion days 1-4,IV,,429,545,1
MMRF_1974,,Second Line Therapy (after,Other,salvage,Other,Cisplatin (Platinol),,,Investigator decision for other reasons,,15,mg/m^,,Oth,continuous infusion days 1-4,IV,,429,545,1
MMRF_1974,,Second Line Therapy (after,Other,salvage,Other,Clarithromycin (Biaxin),,,Disease progression/Relapse,,250,mg,,BID,,PO,,371,398,1
MMRF_1974,,Second Line Therapy (after,Other,salvage,Prednisone,,,,Disease progression/Relapse,,50,mg,,QD,,PO,,408,419,1
MMRF_1974,,Second Line Therapy (after,Other,salvage,Other,Etoposide (Vepesid),,,Investigator decision for other reasons,,40,mg/m^,,Oth,continuous infusion days 1-4,IV,,429,545,1
MMRF_1974,,First line of therapy,Maintenance,,Lenalidomide,,,,Disease progression/Relapse,,25,mg,,QD,,PO,,188,363,1
MMRF_1974,,Second Line Therapy (after,Other,salvage,Dexamethasone,,,,Investigator decision for other reasons,,40,mg,,QD,,PO,,429,545,1
MMRF_1974,,First line of therapy,Maintenance,,Carfilzomib,,,,Disease progression/Relapse,,20,mg/m^,,QD,,IV,,188,363,1
MMRF_1974,,First line of therapy,Maintenance,,Dexamethasone,,,,Disease progression/Relapse,,10,mg,,QD,,PO,,188,363,1
MMRF_1974,,Second Line Therapy (after,Other,Salvage,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,Oth,"Days 1,8,15,22",PO,,371,398,1
MMRF_1974,,Second Line Therapy (after,Other,Salvage,Dexamethasone,,,,Investigator decision for other reasons,,40,mg,,Q w,,PO,,573,636,1
MMRF_1974,,Third Line Therapy (followi,Other,Salvage,Other,Etoposide (Vepesid),,,Disease progression/Relapse,,40,mg/m^,,Oth,continuous infusion days 1-4,IV,,721,842,1
MMRF_1974,,Third Line Therapy (followi,Other,Salvage,Other,Cisplatin (Platinol),,,Disease progression/Relapse,,15,mg/m^,,Oth,continuous infusion days 1-4,IV,,721,842,1
MMRF_1974,,Second Line Therapy (after,Other,Salvage,Daratumumab,,,,Disease progression/Relapse,,16,mg/kg,,Q w,,IV,,573,713,1
MMRF_1974,,Second Line Therapy (after,Other,Salvage,Pomalidomide,,,,Investigator decision for other reasons,,2.5,mg,,Q d,,PO,,573,636,1
MMRF_1974,,Second Line Therapy (after,Other,Salvage,Pomalidomide,,,,Disease progression/Relapse,,2,mg,,QD,,PO,,671,713,1
MMRF_1974,,Third Line Therapy (followi,Other,Salvage,Cyclophosphamide,,,,Disease progression/Relapse,,400,mg/m^,,Oth,continuous infusion days 1-4,IV,,721,842,1
MMRF_1974,,Third Line Therapy (followi,Other,Salvage,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,QD,,PO,,721,842,1
MMRF_1974,,Fourth Line Therapy (follow,Other,salvage,Other,nivolumab,,,Other,death,3,mg/kg,,Oth,"QD (D1, D15)",IV,,863,892,1
MMRF_1974,,Fourth Line Therapy (follow,Other,salvage,Pomalidomide,,,,Other,death,2,mg,,QD,,PO,,863,892,1
MMRF_1974,,Fourth Line Therapy (follow,Other,salvage,Dexamethasone,,,,Other,death,40,mg,,Oth,"QD (D8, D22)",PO,,863,892,1
MMRF_1974,,First line of therapy,Other,Transplant,Melphalan,,,,Completed regimen,,185,mg,,Oth,"Days -3, -2",IV,,103,104,1
MMRF_1982,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,91,1
MMRF_1982,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,91,1
MMRF_1982,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,Day of and Day after Velcade,PO,,1,91,1
MMRF_1982,,First line of therapy,Maintenance,,Dexamethasone,,,,Completed regimen,,4,mg,,Q d,,PO,,91,165,1
MMRF_1986,,First line of therapy,Induction,,Dexamethasone,,,,Other,discontinued due to grade 2 transaminitis,40,mg,,Q w,,PO,,6,398,1
MMRF_1986,,First line of therapy,Induction,,Lenalidomide,,,,Other,discontinued due to grade 2 transaminitis,25,mg,,QD,,PO,,13,398,1
MMRF_1986,Baseline,First line of therapy,Induction,,Dexamethasone,,,,Other,switched to PO dex,40,mg,,Q d,,IV,,1,2,1
MMRF_1986,,First line of therapy,Induction,,Dexamethasone,,,,Other,switched to weekly Dex,40,mg,,Q d,,PO,,3,4,1
MMRF_1986,,First line of therapy,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,1.3,mg/m^,,QD,,IV SubQ,,6,125,1
MMRF_1999,Baseline,First line of therapy,Induction,,Dexamethasone,,,,Other,Switched to weekly,40,mg,,Q d,,PO,,1,4,1
MMRF_1999,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.9,mg,,QD,,IV SubQ,,14,56,1
MMRF_1999,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,10,56,1
MMRF_1999,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Q w,,PO,,10,56,1
MMRF_1999,,First line of therapy,Other,Transplant,Melphalan,,,,Completed regimen,,145,mg,,Oth,"days -3, -2",IV,,118,119,1
MMRF_2014,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,93,1
MMRF_2014,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,93,1
MMRF_2014,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Q w,,PO,,1,93,1
MMRF_2014,,First line of therapy,Maintenance,,Lenalidomide,,,,Disease progression/Relapse,,10,mg,,Q d,,PO,,212,1010,1
MMRF_2014,,First line of therapy,Maintenance,,Prednisone,,,,Completed regimen,,40,mg,,Q d,,PO,,458,711,1
MMRF_2014,,Second Line Therapy (after,Other,salvage,Elotuzumab,,,Checked,,,10,mg/kg,,Q w,,IV,,1066,,1
MMRF_2014,,Second Line Therapy (after,Other,salvage,Lenalidomide,,,Checked,,,15,mg,,QD,,PO,,1066,,1
MMRF_2014,,Second Line Therapy (after,Other,salvage,Dexamethasone,,,Checked,,,28,mg,,Q w,,PO,,1066,,1
MMRF_2043,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,81,1
MMRF_2043,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,81,1
MMRF_2043,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Q w,,PO,,1,81,1
MMRF_2043,,First line of therapy,Maintenance,,Lenalidomide,,,,Patient decision,,10,mg,,Q d,,PO,,202,254,1
MMRF_2063,,First line of therapy,Induction,,Cyclophosphamide,,,,Other,patient expired,450,mg,,Q w,,PO,,1,46,1
MMRF_2063,Baseline,First line of therapy,Induction,,Bortezomib,,,,Other,patient expired,1.3,mg/m^,,QD,,IV SubQ,,1,46,1
MMRF_2101,Baseline,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,4,mg,,QWK,,PO,,1,89,1
MMRF_2101,,First line of therapy,Induction,,Lenalidomide,,,,Investigator decision for other reasons,,10,mg,,QD,,PO,,20,62,1
MMRF_2101,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,89,1
MMRF_2101,,First line of therapy,Maintenance,,Lenalidomide,,,,Other,dose reduction,10,mg,,Q d,,PO,,224,567,1
MMRF_2101,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,5,mg,,Q d,,PO,,567,,1
MMRF_2124,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,2.2,mg,,Q w,,IV,,1,20,1
MMRF_2124,Baseline,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Q w,,PO,,1,20,1
MMRF_2124,,First line of therapy,Consolidation,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,280,679,1
MMRF_2124,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,20,mg/m^,,QD,,IV,,21,159,1
MMRF_2124,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,10,mg,,QD,,PO,,21,159,1
MMRF_2124,,First line of therapy,Consolidation,,Dexamethasone,,,,Completed regimen,,10,mg,,QD,,PO,,280,679,1
MMRF_2124,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,21,159,1
MMRF_2124,,First line of therapy,Consolidation,,Carfilzomib,,,,Completed regimen,,20,mg/m^,,QD,,IV,,280,679,1
MMRF_2124,,First line of therapy,Maintenance,,Lenalidomide,,,,Other,dose reduction due to grade 2 neutropenia,5,mg,,Q d,,PO,,679,762,1
MMRF_2124,,First line of therapy,Maintenance,,Lenalidomide,,,,Disease progression/Relapse,,2.5,mg,,Q d,,PO,,763,1218,1
MMRF_2124,,Second Line Therapy (after,Induction,,Elotuzumab,,,Checked,,,10,mg/kg,,Q w,,IV,,1258,,1
MMRF_2124,,Second Line Therapy (after,Induction,,Pomalidomide,,,Checked,,,4,mg,,QD,,PO,,1258,,1
MMRF_2124,,Second Line Therapy (after,Induction,,Dexamethasone,,,Checked,,,40,mg,,Q w,,PO,,1258,,1
MMRF_2198,Baseline,First line of therapy,Induction,,Lenalidomide,,,,Investigator decision for other reasons,,25,mg,,QD,,PO,,1,29,1
MMRF_2198,,First line of therapy,Induction,,Dexamethasone,,,,Other,Toxicity,20,mg,,QD,,PO,,1,99,1
MMRF_2198,,First line of therapy,Induction,,Bortezomib,,,,Other,Toxicity,1.3,mg/m^,,QD,,IV SubQ,,1,99,1
MMRF_2198,,First line of therapy,Induction,,Cyclophosphamide,,,,Other,Toxicity,50,mg,,Q d,,PO,,29,99,1
MMRF_2198,,Second Line Therapy (after,Consolidation,,Carfilzomib,,,,Completed regimen,,20,mg/m^,,QD,,IV,,141,225,1
MMRF_2198,,Second Line Therapy (after,Consolidation,,Dexamethasone,,,,Completed regimen,,10,mg,,Q d,,PO,,141,225,1
MMRF_2198,,Second Line Therapy (after,Maintenance,,Bortezomib,,,,Other,Fatigue,1.3,mg/m^,,Oth,every other week,IV SubQ,,365,743,1
MMRF_2198,,Second Line Therapy (after,Maintenance,,Ixazomib,,,,Disease progression/Relapse,,4,mg,,Oth,"QD (D1, D8, D15)",PO,,743,897,1
MMRF_2198,,Third Line Therapy (followi,Other,salvage,Dexamethasone,,,,Disease progression/Relapse,,20,mg,,QWK,,PO,,943,1170,1
MMRF_2198,,Third Line Therapy (followi,Other,salvage,Daratumumab,,,,Disease progression/Relapse,,16,mg/kg,,Oth,"weekly(C1-2), Q 2weeks(C3-6), monthly(C7+)",IV,,943,1170,1
MMRF_2198,,Third Line Therapy (followi,Other,salvage,Other,Durvalumab,,,Disease progression/Relapse,,1500,mg,,Oth,day 1 (28d cycle),IV,,943,1170,1
MMRF_2198,,Fourth Line Therapy (follow,Other,salvage,Carfilzomib,,,Checked,,,27,mg/m^,,QD,,IV,,1188,,1
MMRF_2198,,Fourth Line Therapy (follow,Other,salvage,Pomalidomide,,,,Other,dose reduction,4,mg,,QD,,PO,,1188,1274,1
MMRF_2198,,Fourth Line Therapy (follow,Other,salvage,Dexamethasone,,,Checked,,,20,mg,,QD,,PO,,1188,,1
MMRF_2198,,Fourth Line Therapy (follow,Other,Salvage,Pomalidomide,,,Checked,,,2,mg,,QD,,PO,,1275,,1
MMRF_2226,Baseline,First line of therapy,Induction,,Bortezomib,,,Checked,,,1,mg,,QD,,IV SubQ,,1,,1
MMRF_2226,,First line of therapy,Induction,,Lenalidomide,,,Checked,,,15,mg,,QD,,PO,,1,,1
MMRF_2226,,First line of therapy,Induction,,Dexamethasone,,,Checked,,,20,mg,,QD,,PO,,1,,1
MMRF_2270,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,2.9,mg,,QD,,IV SubQ,,1,99,1
MMRF_2270,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,99,1
MMRF_2270,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,QD,,PO,,1,99,1
MMRF_2270,,First line of therapy,Consolidation,,Melphalan,,,,Completed regimen,,200,mg/m^,,Oth,"Days -3, -2",IV,,110,111,1
MMRF_2270,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,10,mg,,Q d,,PO,,226,,1
MMRF_2271,Baseline,First line of therapy,Induction,,Bortezomib,,,,Investigator decision for other reasons,,1,mg/m^,,QD,,IV SubQ,,1,154,1
MMRF_2271,,First line of therapy,Induction,,Dexamethasone,,,,Investigator decision for other reasons,,12,mg,,QD,,PO,,1,154,1
MMRF_2272,Baseline,First line of therapy,Induction,,Bortezomib,,,,Disease progression/Relapse,,1.3,mg/m^,,QD,,IV SubQ,,1,17,1
MMRF_2272,,First line of therapy,Induction,,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,QD,,PO,,1,17,1
MMRF_2449,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,74,1
MMRF_2449,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,10,mg/kg,,Q w,,PO,,1,74,1
MMRF_2449,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Q d,,PO,,1,74,1
MMRF_2449,,First line of therapy,Other,pre-ASCT,Melphalan,,,,Completed regimen,,315,mg,,Q d,,IVB,,114,114,1
MMRF_2449,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,5,mg,,Q d,,PO,,215,,1
MMRF_2449,,First line of therapy,Maintenance,,Bortezomib,,,Checked,,,1.3,mg/m^,,Oth,every 2 weeks,IV SubQ,,215,,1
MMRF_2446,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Q w,,PO,,1,93,1
MMRF_2446,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.5,mg/m^,,QD,,IV SubQ,,1,93,1
MMRF_2446,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,PO,,1,93,1
MMRF_2446,,First line of therapy,Maintenance,,Bortezomib,,,Checked,,,1.6,mg/m^,,Oth,twice a month,IV,,232,,1
MMRF_2446,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,10,mg,,QD,,PO,,260,,1
MMRF_2514,,First line of therapy,Induction,,Lenalidomide,,,,Investigator decision for other reasons,,15,mg,,QD,,PO,,1,23,1
MMRF_2514,,First line of therapy,Induction,,Dexamethasone,,,,Investigator decision for other reasons,,20,mg,,QD,,PO,,1,24,1
MMRF_2514,Baseline,First line of therapy,Induction,,Bortezomib,,,,Investigator decision for other reasons,,1,mg,,QD,,IV SubQ,,1,23,1
MMRF_2514,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV,,105,210,1
MMRF_2514,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Q w,,PO,,105,210,1
MMRF_2514,,First line of therapy,Maintenance,,Dexamethasone,,,,Completed regimen,,20,mg,,Q w,,PO,,287,389,1
MMRF_2514,,First line of therapy,Maintenance,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,Oth,"D1, D8, D15",IV SubQ,,287,389,1
MMRF_2514,,First line of therapy,Induction,,Lenalidomide,,,,Investigator decision for other reasons,,10,mg,,QD,,PO,,105,196,1
MMRF_2514,,First line of therapy,Other,Transplant,Melphalan,,,,Completed regimen,,330,mg,,Oth,day -2,IV,,418,418,1
MMRF_2514,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,10,mg,,Q d,,PO,,555,,1
MMRF_2531,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,10,mg,,QD,,PO,,1,85,1
MMRF_2531,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,4,mg,,QD,,PO,,1,85,1
MMRF_2531,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,85,1
MMRF_2531,,First line of therapy,Maintenance,,Lenalidomide,,,,Disease progression/Relapse,,10,mg,,Q d,,PO,,239,413,1
MMRF_2531,,Second Line Therapy (after,Other,salvage,Carfilzomib,,,,Disease progression/Relapse,,20,mg/m^,,QD,,IV,,423,480,1
MMRF_2531,,Second Line Therapy (after,Other,salvage,Cyclophosphamide,,,,Disease progression/Relapse,,300,mg/m^,,Oth,"QD (D1, D8, D15)",IV,,423,480,1
MMRF_2531,,Second Line Therapy (after,Other,salvage,Dexamethasone,,,,Disease progression/Relapse,,20,mg,,QD,,PO,,423,480,1
MMRF_2531,,Third Line Therapy (followi,Other,salvage,Pomalidomide,,,,Adverse Event or co-morbidity,,2,mg,,QD,,PO,,484,505,1
MMRF_2531,,Third Line Therapy (followi,Other,salvage,Daratumumab,,,,Other,death,16,mg/kg,,Q w,,IV,,484,546,1
MMRF_2531,,Third Line Therapy (followi,Other,salvage,Dexamethasone,,,,Other,death,4,mg,,Oth,"QD: D1, D2 after daratumumab infusion",PO,,484,546,1
MMRF_2531,,First line of therapy,Other,Transplant,Melphalan,,,,Completed regimen,,298,mg,,Oth,day -2,IV,,119,119,1
MMRF_2541,Baseline,First line of therapy,Induction,,Bortezomib,,,,Lack of response,,1.3,mg/m^,,QD,,IV SubQ,,1,93,1
MMRF_2541,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,QWK,,PO,,1,158,1
MMRF_2541,,First line of therapy,Induction,,Cyclophosphamide,,,,Lack of response,,500,mg/m^,,QWK,,IV,,1,93,1
MMRF_2541,,First line of therapy,Other,salvage,Carfilzomib,,,,Completed regimen,,36,mg/m^,,QD,,IV,,106,158,1
MMRF_2541,,First line of therapy,Other,salvage,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,106,158,1
MMRF_2541,,First line of therapy,Maintenance,,Ixazomib,,,,Completed regimen,,3,mg,,Oth,"QD: D1, D8, D15",PO,,273,385,1
MMRF_2541,,First line of therapy,Maintenance,,Lenalidomide,,,,Disease progression/Relapse,,10,mg,,QD,,PO,,273,561,1
MMRF_2541,,First line of therapy,Maintenance,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,"QD: D1, D8, D15",PO,,273,385,1
MMRF_2541,,Second Line Therapy (after,Other,salvage,Daratumumab,,,,Lack of response,,16,mg/kg,,Q w,,IV,,571,662,1
MMRF_2541,,Second Line Therapy (after,Other,salvage,Pomalidomide,,,,Other,dose/frequency change,4,mg,,Oth,Q 2 days,PO,,571,620,1
MMRF_2541,,Second Line Therapy (after,Other,salvage,Dexamethasone,,,,Lack of response,,4,mg,,Oth,"day 1, 2 after daratumumab infusion",PO,,571,662,1
MMRF_2541,,Third Line Therapy (followi,Other,salvage,Prednisone,,,,Disease progression/Relapse,,50,mg,,QD,,PO,,819,834,1
MMRF_2541,,Fourth Line Therapy (follow,Other,salvage,Bortezomib,,,,Disease progression/Relapse,,1.3,mg/m^,,QD,,IV SubQ,,847,903,1
MMRF_2541,,Second Line Therapy (after,Other,salvage,Carfilzomib,,,,Disease progression/Relapse,,36,mg/m^,,Oth,"QD (D1, D8, D15)",IV,,701,760,1
MMRF_2541,,Second Line Therapy (after,Other,salvage,Carfilzomib,,,,Other,frequency change due to shortness of breath,36,mg,,QD,,IV,,666,701,1
MMRF_2541,,Second Line Therapy (after,Other,salvage,Dexamethasone,,,,Disease progression/Relapse,,20,mg,,QD,,IV,,666,760,1
MMRF_2541,,Third Line Therapy (followi,Other,salvage,Other,Viracept,,,Adverse Event or co-morbidity,,2500,mg,,Oth,BID (D1-14),PO,,792,803,1
MMRF_2541,,Third Line Therapy (followi,Other,salvage,Bendamustine,,,,Disease progression/Relapse,,70,mg/m^,,Oth,QD (D 1-2),IV,,819,834,1
MMRF_2541,,Third Line Therapy (followi,Other,salvage,Bortezomib,,,,Adverse Event or co-morbidity,,1.3,mg/m^,,QD,,IV SubQ,,792,803,1
MMRF_2541,,Third Line Therapy (followi,Other,salvage,Dexamethasone,,,,Adverse Event or co-morbidity,,20,mg,,QD,,PO,,792,803,1
MMRF_2541,,Second Line Therapy (after,Other,salvage,Pomalidomide,,,,Adverse Event or co-morbidity,,2,mg,,QD,,PO,,621,701,1
MMRF_2541,,Fourth Line Therapy (follow,Other,salvage,Daratumumab,,,,Disease progression/Relapse,,16,mg/kg,,QWK,,IV,,847,903,1
MMRF_2541,,Fourth Line Therapy (follow,Other,salvage,Dexamethasone,,,,Disease progression/Relapse,,20,mg,,QWK,,PO,,847,903,1
MMRF_2541,,Seventh Line of Therapy (fo,Other,Salvage,Bortezomib,,,,Disease progression/Relapse,,1.3,mg/m^,,Oth,"days 1,4,15,18",IV SubQ,,1043,1064,1
MMRF_2541,,Seventh Line of Therapy (fo,Other,Salvage,Panobinostat,,,,Disease progression/Relapse,,20,mg,,Oth,"M, W, F: Q 2 weeks",PO,,1043,1064,1
MMRF_2541,,Fifth Line Therapy (followi,Other,salvage,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,QD,,IV,,926,953,1
MMRF_2541,,Fifth Line Therapy (followi,Other,salvage,Cyclophosphamide,,,,Disease progression/Relapse,,400,mg/m^,,QD,,IV,,926,953,1
MMRF_2541,,Fifth Line Therapy (followi,Other,salvage,Other,Etoposide,,,Disease progression/Relapse,,40,mg/m^,,QD,,IV,,926,953,1
MMRF_2541,,Fifth Line Therapy (followi,Other,salvage,Other,Cisplatin,,,Disease progression/Relapse,,10,mg/m^,,QD,,IV,,926,953,1
MMRF_2541,,Sixth Line Therapy (followi,Other,salvage,Vincristine,,,,Disease progression/Relapse,,1.28,mg,,Oth,day 1,IV,,968,1029,1
MMRF_2541,,Seventh Line of Therapy (fo,Other,Salvage,Dexamethasone,,,,Disease progression/Relapse,,20,mg,,Oth,"days 1,2,4,5,15,16,18,19",PO,,1043,1064,1
MMRF_2541,,Eighth Line of Therapy (fol,Other,Salvage,Cyclophosphamide,,,Checked,,,2100,mg,,Oth,day 1,IV,,1068,,1
MMRF_2541,,Sixth Line Therapy (followi,Other,salvage,Prednisone,,,,Disease progression/Relapse,,10,mg,,Oth,"5 times a day for days 1-7, taper by 10 mg for days 8-11",PO,,968,1029,1
MMRF_2541,,Sixth Line Therapy (followi,Other,salvage,Cyclophosphamide,,,,Disease progression/Relapse,,425,mg,,Oth,day 1,IV,,968,1029,1
MMRF_2541,,Sixth Line Therapy (followi,Other,salvage,BCNU,,,,Disease progression/Relapse,,16,mg,,Oth,day 1,IV,,968,1029,1
MMRF_2541,,Sixth Line Therapy (followi,Other,salvage,Melphalan,,,,Disease progression/Relapse,,2,mg,,QD,,PO,,968,1029,1
MMRF_2592,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,PO,,1,125,1
MMRF_2592,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QWK,,IV SubQ,,1,125,1
MMRF_2592,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,QWK,,IV,,1,125,1
MMRF_2592,,First line of therapy,Consolidation,,Ixazomib,,,,Completed regimen,,4,mg,,Oth,"QD: D1, D8, D15",PO,,282,394,1
MMRF_2592,,First line of therapy,Consolidation,,Lenalidomide,,,,Completed regimen,,15,mg,,QD,,PO,,282,394,1
MMRF_2592,,First line of therapy,Consolidation,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,"QD: D1, D8, D15",PO,,282,394,1
MMRF_2592,,First line of therapy,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,10,mg,,Q d,,PO,,415,468,1
MMRF_2592,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,5,mg,,Q d,,PO,,482,,1
MMRF_2611,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,105,1
MMRF_2611,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,105,1
MMRF_2611,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,PO,,1,105,1
MMRF_2611,,First line of therapy,Maintenance,,Ixazomib,,,,Completed regimen,,4,mg,,Q w,,PO,,246,358,1
MMRF_2611,,First line of therapy,Maintenance,,Lenalidomide,,,,Completed regimen,,15,mg,,QD,,PO,,246,358,1
MMRF_2611,,First line of therapy,Maintenance,,Dexamethasone,,,,Completed regimen,,40,mg,,Q w,,PO,,246,358,1
MMRF_2611,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,10,mg,,Q d,,PO,,379,,1
MMRF_2621,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,133,1
MMRF_2621,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,133,1
MMRF_2621,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,QWK,,PO,,1,133,1
MMRF_1013,Baseline,First line of therapy,,,Lenalidomide,,,,Adverse Event or co-morbidity,,25,mg/m^,,QD,,PO,,1,47,1
MMRF_1013,,First line of therapy,,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV,,1,96,1
MMRF_1013,,First line of therapy,,,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,135,136,1
MMRF_1013,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,20,mg,,QD,,PO,,1,96,1
MMRF_1013,,First line of therapy,,,Lenalidomide,,,,Disease progression/Relapse,,5,mg,,QD,,PO,,212,1865,1
MMRF_1013,,Third Line Therapy (followi,Unknown,,Elotuzumab,,,,Disease progression/Relapse,,10,mg/kg,,Oth,"QD(D1,D8,D15,D22)",IV,,1896,1957,1
MMRF_1013,,Fourth Line Therapy (follow,Unknown,,Dexamethasone,,,,Disease progression/Relapse,,20,mg,,Q w,,PO,,2038,2079,1
MMRF_1013,,Fourth Line Therapy (follow,Unknown,,Daratumumab,,,,Disease progression/Relapse,,16,mg/m^,,Q w,,IV,,2038,2088,1
MMRF_1013,,Fourth Line Therapy (follow,Unknown,,Other,Cisplatin,,,Completed regimen,,8,mg,,QD,,IVB,,1986,1989,1
MMRF_1013,,Fourth Line Therapy (follow,Unknown,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,PO,,1986,1989,1
MMRF_1013,,Fourth Line Therapy (follow,Unknown,,Other,Etoposide,,,Completed regimen,,46,mg,,QD,,IVB,,1986,1989,1
MMRF_1013,,Fourth Line Therapy (follow,Unknown,,Bortezomib,,,,Completed regimen,,2,mg,,Oth,"QD(D1,D4)",IV SubQ,,1986,1989,1
MMRF_1013,,Fourth Line Therapy (follow,Unknown,,Cyclophosphamide,,,,Completed regimen,,620,mg,,QD,,IVB,,1986,1989,1
MMRF_1013,,Second Line Therapy (after,Unknown,,Ixazomib,,,,Disease progression/Relapse,,3,mg,,Oth,"QD(D1,D8,D15)",PO,,1655,1865,1
MMRF_1013,,Second Line Therapy (after,Unknown,,Dexamethasone,,,,Disease progression/Relapse,,20,mg,,QWK,,PO,,1657,1865,1
MMRF_1013,,Third Line Therapy (followi,Unknown,,Lenalidomide,,,,Disease progression/Relapse,,15,mg,,QD,,PO,,1896,1957,1
MMRF_1013,,Third Line Therapy (followi,Unknown,,Dexamethasone,,,,Disease progression/Relapse,,28,mg,,Oth,"QD(D1,D8,D15,D22)",PO,,1896,1957,1
MMRF_1013,,Fifth Line Therapy (followi,Unknown,,Melphalan,,,,Completed regimen,,50,mg/m^,,Q d,,IV,,2126,2126,1
MMRF_1013,,Fifth Line Therapy (followi,Unknown,,Bortezomib,,,,Adverse Event or co-morbidity,,2,mg,,Q d,,Other,subcutan injection,2098,2098,1
MMRF_1013,,Fifth Line Therapy (followi,Unknown,,Dexamethasone,,,,Adverse Event or co-morbidity,,40,mg,,Q d,,PO,,2098,2100,1
MMRF_1013,,Fifth Line Therapy (followi,Unknown,,Other,Etoposide,,,Adverse Event or co-morbidity,,30,mg,,Q d,,IVB,,2098,2100,1
MMRF_1013,,Fifth Line Therapy (followi,Unknown,,Cyclophosphamide,,,,Adverse Event or co-morbidity,,460,mg,,Q d,,IVB,,2098,2100,1
MMRF_1013,,Fifth Line Therapy (followi,Unknown,,Other,cisplatin,,,Adverse Event or co-morbidity,,8,mg,,Q d,,IVB,,2098,2100,1
MMRF_1073,Baseline,First line of therapy,,,Lenalidomide,,,,Completed regimen,,25,mg/m^,,QD,,PO,,1,92,1
MMRF_1073,,First line of therapy,,,Bortezomib,,,,Completed regimen,,1.9,mg/m^,,QD,,IV SubQ,,1,92,1
MMRF_1073,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,20,mg,,QD,,PO,,1,92,1
MMRF_1073,,First line of therapy,,,Melphalan,,,,Completed regimen,,200,mg/m^,,Oth,1x,IV,,139,139,1
MMRF_1073,,First line of therapy,,,Lenalidomide,,,Checked,,,10,mg/dL,,QD,,PO,,265,,1
MMRF_1076,Baseline,First line of therapy,,,Lenalidomide,,,,Completed regimen,,25,mg/m^,,QD,,PO,,1,77,1
MMRF_1076,,First line of therapy,,,Bortezomib,,,,Completed regimen,,2.1,mg/m^,,QD,,IV SubQ,,1,75,1
MMRF_1076,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,12,mg,,QD,,PO,,1,77,1
MMRF_1076,,First line of therapy,Maintenance,,Lenalidomide,,,,Disease progression/Relapse,,15,mg,,QD,,PO,,434,884,1
MMRF_1076,,Second Line Therapy (after,Maintenance,,Dexamethasone,,,,Disease progression/Relapse,,8,mg,,Oth,Q twice a week,PO,,479,884,1
MMRF_1076,,First line of therapy,Maintenance,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,77,108,1
MMRF_1076,,Third Line Therapy (followi,Unknown,,Dexamethasone,,,,Adverse Event or co-morbidity,,8,mg,,Oth,Every other day,PO,,927,1022,1
MMRF_1076,,Third Line Therapy (followi,Unknown,,Other,Cytoxan,,,Adverse Event or co-morbidity,,500,mg,,Q w,,PO,,927,1030,1
MMRF_1095,Baseline,First line of therapy,,,Lenalidomide,,,,Completed regimen,,25,mg/m^,,QD,,PO,,1,85,1
MMRF_1095,,First line of therapy,,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV,,1,85,1
MMRF_1095,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,20,mg,,QD,,PO,,1,85,1
MMRF_1095,,First line of therapy,,,Melphalan,,,,Completed regimen,,140,mg/m^,,Oth,1x,IV,,286,286,1
MMRF_1095,,First line of therapy,,,Dexamethasone,,,,Other,"Planned for 2 cycles, Stem cell mobilization, then continue 2 more cycles",20,mg,,QD,,PO,,113,142,1
MMRF_1095,,First line of therapy,,,Lenalidomide,,,,Other,"Planned for 2 cycles, Stem cell mobilization, then continue 2 more cycles",25,mg,,QD,,PO,,113,142,1
MMRF_1095,,First line of therapy,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,10,mg,,QD,,PO,,449,478,1
MMRF_1095,,First line of therapy,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,5,mg,,QD,,PO,,479,899,1
MMRF_1092,Baseline,First line of therapy,,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,83,1
MMRF_1092,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,40,mg,,Q w,,PO,,1,83,1
MMRF_1092,,First line of therapy,,,Bortezomib,,,,Completed regimen,,1.3,mg,,QD,,IV SubQ,,1,83,1
MMRF_1092,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"1, 8",PO,,96,161,1
MMRF_1092,,First line of therapy,,,Lenalidomide,,,,Completed regimen,,15,mg,,QD,,PO,,96,161,1
MMRF_1092,,First line of therapy,,,Bortezomib,,,,Completed regimen,,1,mg/m^,,Oth,"1, 8",IV SubQ,,96,161,1
MMRF_1092,,First line of therapy,Maintenance,,Lenalidomide,,,,Disease progression/Relapse,,15,mg,,QD,,PO,,191,1539,1
MMRF_1092,,First line of therapy,Maintenance,,Dexamethasone,,,,Disease progression/Relapse,,20,mg,,Q w,,PO,,191,1539,1
MMRF_1092,,Second Line Therapy (after,Unknown,,Melphalan,,,,Completed regimen,,140,mg/m^,,Oth,Once,IV,,1549,1549,1
MMRF_1092,,Second Line Therapy (after,Maintenance,,Ixazomib,,,Checked,,,3,mg,,Oth,"QD(D1,D8,D15)",PO,,1683,,1
MMRF_1092,,Second Line Therapy (after,Maintenance,,Dexamethasone,,,Checked,,,20,mg,,Q w,,PO,,1683,,1
MMRF_1115,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,"D1, D8, D15 of 21 day cycle",PO,,1,85,1
MMRF_1115,Baseline,First line of therapy,,,Bortezomib,,,,Completed regimen,,2.5,mg/m^,,Oth,"D1, D8, D15",IV SubQ,,1,85,1
MMRF_1115,,First line of therapy,,,Melphalan,,,,Completed regimen,,200,mg/m^,,Oth,1x,IV,,119,119,1
MMRF_1115,,First line of therapy,,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,85,1
MMRF_1134,Baseline,First line of therapy,,,Bortezomib,,,,Completed regimen,,2.5,mg,,QD,,IV SubQ,,1,56,1
MMRF_1134,,First line of therapy,,,Lenalidomide,,,,Completed regimen,,25,mg/m^,,QD,,PO,,1,56,1
MMRF_1134,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,20,mg,,QD,,PO,,1,56,1
MMRF_1134,,First line of therapy,,,Melphalan,,,,Completed regimen,,200,mg/m^,,Oth,1x,IV,,134,134,1
MMRF_1134,,First line of therapy,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,10,mg,,QD,,PO,,531,757,1
MMRF_1134,,First line of therapy,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,10,mg,,QD,,PO,,972,1047,1
MMRF_1134,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,5,mg,,QD,,PO,,1047,,1
MMRF_1153,Baseline,First line of therapy,,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,102,1
MMRF_1153,,First line of therapy,,,Bortezomib,,,,Investigator decision for other reasons,,1.3,mg,,QD,,IV SubQ,,1,102,1
MMRF_1153,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,20,mg,,QD,,PO,,1,102,1
MMRF_1153,,First line of therapy,,,Melphalan,,,,Completed regimen,,200,mg,,Oth,1x,IV,,183,183,1
MMRF_1153,,First line of therapy,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,10,mg,,QD,,PO,,339,875,1
MMRF_1153,,First line of therapy,Maintenance,,Bortezomib,,,,Disease progression/Relapse,,1.3,mg/m^,,Oth,"QD(Q1,Q15,Q29,Q430",IV SubQ,,974,1240,1
MMRF_1153,,Second Line Therapy (after,Unknown,,Ixazomib,,,,Disease progression/Relapse,,4,mg,,Q w,,PO,,1317,1380,1
MMRF_1153,,Second Line Therapy (after,Unknown,,Lenalidomide,,,,Disease progression/Relapse,,10,mg,,QD,,PO,,1317,1362,1
MMRF_1153,,Second Line Therapy (after,Unknown,,Dexamethasone,,,,Disease progression/Relapse,,20,mg,,Q w,,PO,,1317,1362,1
MMRF_1153,,Third Line Therapy (followi,Unknown,,Daratumumab,,,Checked,,,16,mg/kg,,Oth,"QD(D1,D8,D15,D22)",IV,,1389,,1
MMRF_1153,,Third Line Therapy (followi,Unknown,,Lenalidomide,,,Checked,,,15,mg,,QD,,PO,,1389,,1
MMRF_1153,,Third Line Therapy (followi,Unknown,,Prednisone,,,Checked,,,20,mg,,Oth,two doses post Dara infusion,PO,,1389,,1
MMRF_1168,Baseline,First line of therapy,,,Lenalidomide,,,,Completed regimen,,25,mg/dL,,QD,,PO,,1,156,1
MMRF_1168,,First line of therapy,,,Bortezomib,,,,Completed regimen,,2.3,mg/m^,,QD,,IV SubQ,,1,156,1
MMRF_1168,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,20,mg,,Q w,,PO,,1,156,1
MMRF_1168,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,10,mg,,QD,,PO,,187,,1
MMRF_1171,Baseline,First line of therapy,,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,89,1
MMRF_1171,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,20,mg,,Q w,,PO,,1,89,1
MMRF_1171,,First line of therapy,,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,89,1
MMRF_1171,,First line of therapy,,,Melphalan,,,,Completed regimen,,200,mg/m^,,Oth,1x,IV,,155,155,1
MMRF_1171,,First line of therapy,Induction,,Lenalidomide,,,Checked,,,10,mg,,Q d,,PO,,245,,1
MMRF_1185,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,20,mg,,Q w,,PO,,1,81,1
MMRF_1185,Baseline,First line of therapy,,,Lenalidomide,,,,Completed regimen,,10,mg,,QD,,PO,,1,81,1
MMRF_1185,,First line of therapy,,,Bortezomib,,,,Completed regimen,,1.3,mg,,Q w,,IV,,1,81,1
MMRF_1185,,First line of therapy,,,Lenalidomide,,,,Adverse Event or co-morbidity,,5,mg,,QD,,PO,,256,1211,1
MMRF_1185,,First line of therapy,,,Melphalan,,,,Completed regimen,,200,mg/m^,,Oth,1x,IV,,117,117,1
MMRF_1196,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,4,mg,,Oth,"1,2,4,5,8,9,11,12",PO,,1,259,1
MMRF_1196,,First line of therapy,,,Bortezomib,,,,Completed regimen,,1.3,mg,,QD,,IV,,1,259,1
MMRF_1196,,Second Line Therapy (after,Consolidation,,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,327,327,1
MMRF_1196,Baseline,First line of therapy,,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,259,1
MMRF_1196,,Second Line Therapy (after,Maintenance,,Lenalidomide,,,,Disease progression/Relapse,,10,mg,,QD,,PO,,370,616,1
MMRF_1196,,Third Line Therapy (followi,Induction,,Pomalidomide,,,,Disease progression/Relapse,,2,mg,,QD,,PO,,617,660,1
MMRF_1196,,Third Line Therapy (followi,Induction,,Carfilzomib,,,,Disease progression/Relapse,,40,mg,,QD,,IV,,617,660,1
MMRF_1196,,Third Line Therapy (followi,Induction,,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,QD,,IV,,617,660,1
MMRF_1196,,Third Line Therapy (followi,Other,Salvage Cycle 2,Other,Cisplatin,,,Completed regimen,,10,mg,,Oth,"QD(D4,D5)",IVB,,740,745,1
MMRF_1196,,Third Line Therapy (followi,Other,Salvage Cycle 1,Cyclophosphamide,,,,Completed regimen,,820,mg,,QD,,IVB,,702,705,1
MMRF_1196,,Third Line Therapy (followi,Other,Salvage cycle 1,Other,Etoposide,,,Completed regimen,,40,mg,,QD,,IVB,,702,705,1
MMRF_1196,,Third Line Therapy (followi,Other,Salvage Cycle 1,Other,Cisplatin,,,Completed regimen,,10,mg,,QD,,IVB,,702,705,1
MMRF_1196,,Third Line Therapy (followi,Other,Salvage Cycle 1,Bortezomib,,,,Completed regimen,,2.7,mg,,Oth,"QD(D1,D4)",IV SubQ,,702,706,1
MMRF_1196,,Third Line Therapy (followi,Other,Salvage,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,PO,,702,705,1
MMRF_1196,,Third Line Therapy (followi,Other,Salvage Cycle 2,Bortezomib,,,,Completed regimen,,2.6,mg,,Oth,"QD(D1,D4)",IV SubQ,,740,745,1
MMRF_1196,,Third Line Therapy (followi,Other,Salvage Cycle 2,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,"QD(D4,D5)",PO,,740,745,1
MMRF_1196,,Third Line Therapy (followi,Other,Salvage Cycle 2,Cyclophosphamide,,,,Completed regimen,,800,mg,,Oth,"QD(D4,D5)",IVB,,740,745,1
MMRF_1196,,Third Line Therapy (followi,Other,Salgave Cycle2,Other,Etoposide,,,Completed regimen,,40,mg,,Oth,"QD(D4,D5)",IVB,,740,745,1
MMRF_1235,Baseline,First line of therapy,,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,72,1
MMRF_1235,,First line of therapy,,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,72,1
MMRF_1235,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"1-2, 4-5, 8-9, 11-12",PO,,1,72,1
MMRF_1235,,First line of therapy,,,Melphalan,,,,Completed regimen,,200,mg/m^,,Oth,1x,IV,,105,105,1
MMRF_1235,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,10,mg,,QD,,PO,,254,,1
MMRF_1251,,First line of therapy,,,Melphalan,,,,Completed regimen,,200,mg/m^,,Oth,1x,IV,,112,112,1
MMRF_1251,Baseline,First line of therapy,,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,85,1
MMRF_1251,,First line of therapy,,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,85,1
MMRF_1251,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,20,mg,,QD,,PO,,1,85,1
MMRF_1251,,First line of therapy,Consolidation,,Bortezomib,,,,Completed regimen,,2.9,mg,,QD,,IV,,183,213,1
MMRF_1251,,First line of therapy,Consolidation,,Lenalidomide,,,,Completed regimen,,5,mg,,QD,,PO,,183,213,1
MMRF_1251,,First line of therapy,Maintenance,,Bortezomib,,,,Disease progression/Relapse,,2.9,mg,,Oth,Q week for 3 weeks on a 28 day cycle,IV SubQ,,232,1142,1
MMRF_1251,,First line of therapy,Consolidation,,Dexamethasone,,,,Completed regimen,,10,mg,,QD,,PO,,183,213,1
MMRF_1251,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,10,mg,,QD,,PO,,834,,1
MMRF_1251,,First line of therapy,Maintenance,,Bortezomib,,,,Disease progression/Relapse,,1.3,mg/m^,,QD,,IV,,288,1142,1
MMRF_1251,,Second Line Therapy (after,Unknown,,Ixazomib,,,Checked,,,4,mg,,Oth,"QD(D1,D8D15)",PO,,1156,,1
MMRF_1290,,First line of therapy,,,Lenalidomide,,,,Completed regimen,,10,mg,,QD,,PO,,3,86,1
MMRF_1290,,First line of therapy,,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,7,86,1
MMRF_1290,Baseline,First line of therapy,,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,2x a wk (Saturdays and Sundays),PO,,1,86,1
MMRF_1290,,First line of therapy,,,Melphalan,,,,Completed regimen,,200,mg/m^,,Oth,1x,IV,,130,130,1
MMRF_1290,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,10,mg,,QD,,Other,"PO (month and year for start date are correct, the exact day is unknown)",206,,1
MMRF_1284,,First line of therapy,,,Lenalidomide,,,,Other,"Planned for 3 cycles, VDCEP, then stem cell mobilization",25,mg,,QD,,PO,,1,43,1
MMRF_1284,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,PO,,71,74,1
MMRF_1284,,First line of therapy,,,Cyclophosphamide,,,,Completed regimen,,760,mg,,QD,,IV,,71,74,1
MMRF_1284,,First line of therapy,,,Bortezomib,,,,Completed regimen,,2.5,mg,,Oth,"Q72h, 2 doses",IV SubQ,,71,74,1
MMRF_1284,,First line of therapy,,,Other,Cisplatin,,,Completed regimen,,19,mg,,QD,,IV,,71,74,1
MMRF_1284,Baseline,First line of therapy,,,Bortezomib,,,,Other,"Planned for 3 cycles, VDCEP, then stem cell mobilization",2.4,mg,,QD,,IV SubQ,,1,43,1
MMRF_1284,,First line of therapy,,,Dexamethasone,,,,Other,"Planned for 3 cycles, VDCEP, then stem cell mobilization",20,mg,,Oth,"1,2,4,5,8,9,11,12",PO,,1,43,1
MMRF_1284,,First line of therapy,,,Other,Etoposide,,,Completed regimen,,76,mg,,QD,,IV,,71,74,1
MMRF_1284,,Second Line Therapy (after,Consolidation,,Pomalidomide,,,Checked,,,2,mg,,QD,,PO,,240,,1
MMRF_1284,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,200,mg,,Q d,,IVB,,107,107,1
MMRF_1304,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"1,2,4,5,8,9,11,12",PO,,1,78,1
MMRF_1304,Baseline,First line of therapy,,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,78,1
MMRF_1304,,First line of therapy,,,Bortezomib,,,,Completed regimen,,2.7,mg,,Q w,,IV SubQ,,1,78,1
MMRF_1304,,First line of therapy,,,Melphalan,,,,Completed regimen,,200,mg,,Oth,1x,IV,,122,122,1
MMRF_1304,,First line of therapy,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,10,mg,,QD,,PO,,288,401,1
MMRF_1304,,First line of therapy,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,10,mg,,QD,,PO,,429,1038,1
MMRF_1304,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,5,mg,,QD,,PO,,1038,,1
MMRF_1323,,First line of therapy,Induction,,Melphalan,,,,Other,Given for ASCT,150,mg/kg,,Oth,For ASCT Collection,IV,,117,117,1
MMRF_1323,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,QD,,PO,,1,77,1
MMRF_1323,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,2.5,mg,,QD,,IV SubQ,,1,77,1
MMRF_1323,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,20,77,1
MMRF_1323,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,10,mg,,QD,,PO,,230,,1
MMRF_1328,Baseline,First line of therapy,,,Lenalidomide,,,,Completed regimen,,25,mg/dL,,QD,,PO,,1,215,1
MMRF_1328,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"1,2,4,5,8,9,11,12",PO,,1,215,1
MMRF_1328,,First line of therapy,,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,215,1
MMRF_1328,,First line of therapy,Maintenance,,Lenalidomide,,,,Disease progression/Relapse,,10,mg,,Oth,unknown,PO,,216,544,1
MMRF_1328,,Second Line Therapy (after,Maintenance,,Carfilzomib,,,,Completed regimen,,40,mg,,Oth,"QD, day 1 and 2 of cycle 1",IV,,684,685,1
MMRF_1328,,Second Line Therapy (after,Consolidation,,Carfilzomib,,,,Completed regimen,,53,mg,,QD,,IV,,713,728,1
MMRF_1328,,Second Line Therapy (after,Unknown,,Pomalidomide,,,,Disease progression/Relapse,,2,mg,,QD,,PO,,684,838,1
MMRF_1328,,Second Line Therapy (after,Consolidation,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,"QD(D1,D8,D15)",PO,,684,699,1
MMRF_1328,,Second Line Therapy (after,Maintenance,,Carfilzomib,,,,Completed regimen,,54,mg,,Oth,"QD days 8,9,15,16 of cycle 1",IV,,691,699,1
MMRF_1328,,Second Line Therapy (after,Maintenance,,Carfilzomib,,,,Disease progression/Relapse,,56,mg/m^,,Oth,"QD(D1,D8,D15)",IV,,768,838,1
MMRF_1328,,Second Line Therapy (after,Maintenance,,Dexamethasone,,,,Disease progression/Relapse,,20,mg,,Oth,"QD(D1,D8,D15)",PO,,741,838,1
MMRF_1328,,Third Line Therapy (followi,Other,Cycle 1,Bortezomib,,,,Completed regimen,,2,mg,,Oth,Q72Hr,IV SubQ,,856,859,1
MMRF_1328,,Third Line Therapy (followi,Other,Cycle 1,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,PO,,856,859,1
MMRF_1328,,Third Line Therapy (followi,Other,Cycle 1,Cyclophosphamide,,,,Completed regimen,,800,mg,,QD,,IVB,,856,859,1
MMRF_1328,,Third Line Therapy (followi,Other,Cycle 1,Other,Cisplatin,,,Completed regimen,,20,mg,,QD,,IVB,,856,859,1
MMRF_1328,,Third Line Therapy (followi,Other,cycle 1,Other,Etoposide,,,Completed regimen,,80,mg,,QD,,IVB,,856,859,1
MMRF_1328,,Third Line Therapy (followi,Unknown,,Thalidomide,,,,Completed regimen,,100,mg,,Q d,,PO,,862,897,1
MMRF_1328,,Third Line Therapy (followi,Other,Cycle 2,Bortezomib,,,,Completed regimen,,2.7,mg,,Oth,Qd(every 72 hrs),IV SubQ,,881,885,1
MMRF_1328,,Third Line Therapy (followi,Other,Cycle 2,Other,Cisplatin,,,Completed regimen,,21,mg,,QD,,IVB,,881,885,1
MMRF_1328,,Third Line Therapy (followi,Other,Cycle 2 VDCEP,Cyclophosphamide,,,,Completed regimen,,830,mg,,QD,,IVB,,881,885,1
MMRF_1328,,Third Line Therapy (followi,Other,Cycle 2 VDCEP,Other,Etoposide,,,Completed regimen,,83,mg,,QD,,IVB,,881,885,1
MMRF_1328,,Second Line Therapy (after,Consolidation,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"QD(D1,D8,D15)",PO,,713,728,1
MMRF_1328,,Second Line Therapy (after,Maintenance,,Carfilzomib,,,,Completed regimen,,56,mg/m^,,Oth,"QD(D1,D7,D14)",IV,,376,754,1
MMRF_1328,,Third Line Therapy (followi,Other,Cycle 2 VDCEP,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,PO,,880,885,1
MMRF_1328,,Second Line Therapy (after,Induction,,Melphalan,,,,Completed regimen,,400,mg,,Q d,,IVB,,593,593,1
MMRF_1328,,Third Line Therapy (followi,Unknown,,Dexamethasone,,,,Disease progression/Relapse,,4,mg,,Oth,Once a week on Monday,PO,,916,974,1
MMRF_1328,,Third Line Therapy (followi,Maintenance,,Pomalidomide,,,,Disease progression/Relapse,,4,mg,,QD,,PO,,916,974,1
MMRF_1328,,Fourth Line Therapy (follow,Unknown,,Cyclophosphamide,,,,Completed regimen,,40,mg,,Oth,"QD(D1,D2,D3,D5)",PO,,996,1001,1
MMRF_1328,,Fourth Line Therapy (follow,Unknown,,Bortezomib,,,,Completed regimen,,2.7,mg,,Oth,"Q(D1,D5)",IV SubQ,,996,1001,1
MMRF_1328,,Fourth Line Therapy (follow,Unknown,,Other,Cisplatin,,,Completed regimen,,21,mg,,Oth,"QD(D1,D3,D4,D5)",Other,IVPB,996,1001,1
MMRF_1328,,Fourth Line Therapy (follow,Unknown,,Cyclophosphamide,,,,Completed regimen,,824,mg,,Oth,"QD(D1,D3,D4,D5)",Other,IVPB,996,1001,1
MMRF_1328,,Fourth Line Therapy (follow,Unknown,,Other,Etoposide,,,Completed regimen,,82,mg,,Oth,"QD(D1,D3,D4,D5)",Other,IVPB,996,1001,1
MMRF_1328,,Third Line Therapy (followi,Unknown,,Dexamethasone,,,,Disease progression/Relapse,,4,mg,,Q w,,PO,,1038,1252,1
MMRF_1328,,Fourth Line Therapy (follow,Unknown,,Daratumumab,,,,Disease progression/Relapse,,16,mg/kg,,Oth,"QD(D1,D8,D15,D22)",IV,,1038,1252,1
MMRF_1328,,Third Line Therapy (followi,Unknown,,Pomalidomide,,,,Disease progression/Relapse,,4,mg,,QD,,PO,,1038,1252,1
MMRF_1328,,Fifth Line Therapy (followi,Unknown,,Other,Nivolumab,,,Disease progression/Relapse,,3,mg/kg,,Oth,"Qd(D1,D15))",IV,,1182,1252,1
MMRF_1328,,Sixth Line Therapy (followi,Unknown,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,PO,,1268,1271,1
MMRF_1328,,Sixth Line Therapy (followi,Unknown,,Bortezomib,,,,Completed regimen,,2.7,mg,,Oth,"QD(D1,D5)",IV SubQ,,1268,1272,1
MMRF_1328,,Sixth Line Therapy (followi,Unknown,,Other,Cisplatin,,,Completed regimen,,21,mg,,Oth,"QD(D1,D2,D3,D5)",IV,,1268,1272,1
MMRF_1328,,Sixth Line Therapy (followi,Unknown,,Cyclophosphamide,,,,Completed regimen,,830,mg,,Oth,"QD(D1,D2,D3,D5)",IV,,1268,1272,1
MMRF_1328,,Sixth Line Therapy (followi,Unknown,,Other,Etoposide,,,Completed regimen,,83,mg,,Oth,"QD(D1,D2,D3,D5)",IV,,1268,1272,1
MMRF_1328,,Eighth Line of Therapy (fol,Unknown,,Cyclophosphamide,,,,Disease progression/Relapse,,300,mg,,QWK,,PO,,1441,1455,1
MMRF_1328,,Sixth Line Therapy (followi,Unknown,,Carfilzomib,,,,Completed regimen,,41,mg/m^,,Oth,D1,IV,,1334,1334,1
MMRF_1328,,Sixth Line Therapy (followi,Unknown,,Carfilzomib,,,,Completed regimen,,56,mg/m^,,Oth,"QD(D8,D15)",IV,,1336,1343,1
MMRF_1328,,Sixth Line Therapy (followi,Unknown,,Dexamethasone,,,,Disease progression/Relapse,,20,mg,,Oth,"QD(D1,D8,D15)",PO,,1334,1371,1
MMRF_1328,,Sixth Line Therapy (followi,Unknown,,Cyclophosphamide,,,,Disease progression/Relapse,,300,mg,,Oth,"QD(D1,D8,D15)",IV,,1334,1371,1
MMRF_1328,,Sixth Line Therapy (followi,Unknown,,Pomalidomide,,,,Disease progression/Relapse,,2,mg,,QD,,PO,,1334,1371,1
MMRF_1328,,Sixth Line Therapy (followi,Unknown,,Carfilzomib,,,,Disease progression/Relapse,,56,mg/m^,,Oth,"QD(D1,D8,D15)",IV,,1357,1371,1
MMRF_1328,,Sixth Line Therapy (followi,Unknown,,Panobinostat,,,,Disease progression/Relapse,,20,mg,,Oth,QD(Tues/Thurs/Sat weeks 1 and 3),PO,,1357,1367,1
MMRF_1328,,Seventh Line of Therapy (fo,Unknown,,Dexamethasone,,,,Disease progression/Relapse,,28,mg,,Oth,"QD(D1,D8,D15,D22) during C1&C2, QD(D1,D15) during C3 and beyond",PO,,1406,1449,1
MMRF_1328,,Sixth Line Therapy (followi,Unknown,,Other,Etoposide,,,Completed regimen,,82,mg,,QD,,IVB,,1293,1296,1
MMRF_1328,,Sixth Line Therapy (followi,Unknown,,Cyclophosphamide,,,,Completed regimen,,825,mg,,QD,,IVB,,1293,1296,1
MMRF_1328,,Seventh Line of Therapy (fo,Unknown,,Bortezomib,,,,Completed regimen,,2.7,mg,,Oth,Q72hr,IV SubQ,,1385,1389,1
MMRF_1328,,Seventh Line of Therapy (fo,Unknown,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,PO,,1385,1389,1
MMRF_1328,,Seventh Line of Therapy (fo,Unknown,,Cyclophosphamide,,,,Completed regimen,,820,mg,,QD,,IVB,,1385,1389,1
MMRF_1328,,Seventh Line of Therapy (fo,Unknown,,Other,Cisplatin,,,Completed regimen,,20,mg,,QD,,IVB,,1385,1389,1
MMRF_1328,,Seventh Line of Therapy (fo,Unknown,,Other,Etoposide,,,Completed regimen,,82,mg,,QD,,IVB,,1385,1389,1
MMRF_1328,,Seventh Line of Therapy (fo,Unknown,,Other,Nivolumab,,,Disease progression/Relapse,,3,mg/kg,,Oth,"QD(D1,D15)",IV,,1406,1448,1
MMRF_1328,,Seventh Line of Therapy (fo,Unknown,,Elotuzumab,,,,Disease progression/Relapse,,10,mg/kg,,Oth,"QD(D1,D8,D15,D22)",IV,,1406,1455,1
MMRF_1328,,Seventh Line of Therapy (fo,Unknown,,Pomalidomide,,,,Disease progression/Relapse,,2,mg,,QD,,PO,,1406,1449,1
MMRF_1328,,Sixth Line Therapy (followi,Unknown,,Bortezomib,,,,Completed regimen,,2.7,mg,,Oth,D1 & D4,IV SubQ,,1293,1296,1
MMRF_1328,,Sixth Line Therapy (followi,Unknown,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,PO,,1293,1296,1
MMRF_1328,,Sixth Line Therapy (followi,Unknown,,Other,Cisplatin,,,Completed regimen,,21,mg,,QD,,IVB,,1293,1296,1
MMRF_1374,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,UNK,PO,,1,23,1
MMRF_1374,,First line of therapy,,,Other,Etoposide,,,Completed regimen,,82,mg,,Oth,unk,IV,,1,23,1
MMRF_1374,Baseline,First line of therapy,,,Bortezomib,,,,Completed regimen,,2.7,mg,,Oth,UNK,IV,,1,23,1
MMRF_1374,,First line of therapy,,,Cyclophosphamide,,,,Completed regimen,,825,mg,,Oth,unk,IV,,1,23,1
MMRF_1374,,First line of therapy,,,Other,Cisplatin,,,Completed regimen,,21,mg,,Oth,unk,IV,,1,23,1
MMRF_1374,,First line of therapy,Maintenance,,Lenalidomide,,,,Disease progression/Relapse,,10,mg,,QD,,PO,,319,340,1
MMRF_1374,,First line of therapy,Maintenance,,Dexamethasone,,,,Adverse Event or co-morbidity,,40,mg,,Oth,"QD: Day 1, 8, 15",PO,,144,183,1
MMRF_1374,,First line of therapy,Maintenance,,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,Oth,"QD 1,8,15",PO,,319,340,1
MMRF_1374,,First line of therapy,Maintenance,,Bortezomib,,,,Disease progression/Relapse,,1.6,mg/m^,,Oth,"QD 1,8,15",IV SubQ,,319,340,1
MMRF_1374,,First line of therapy,Maintenance,,Bortezomib,,,,Adverse Event or co-morbidity,,1.6,mg/m^,,Oth,"QD: day 1, 8, 15",IV SubQ,,144,183,1
MMRF_1374,,First line of therapy,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,10,mg,,QD,,PO,,144,183,1
MMRF_1374,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,58,58,1
MMRF_1415,Baseline,First line of therapy,,,Lenalidomide,,,,Completed regimen,,15,mg,,QD,,PO,,1,84,1
MMRF_1415,,First line of therapy,,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,84,1
MMRF_1415,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,20,mg,,QD,,PO,,1,84,1
MMRF_1415,,First line of therapy,Maintenance,,Lenalidomide,,,,Lack of response,,10,mg,,Oth,QD on a 28 day cycle,PO,,220,310,1
MMRF_1415,,First line of therapy,Maintenance,,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,Q w,,PO,,320,371,1
MMRF_1415,,Second Line Therapy (after,Other,salvage therapy,Cyclophosphamide,,,,Completed regimen,,0,Other,unknown,Oth,unknown,Other,unknown,378,381,1
MMRF_1415,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,200,mg/m^,,Oth,QD,IV,,115,115,1
MMRF_1415,,First line of therapy,Maintenance,,Lenalidomide,,,,Disease progression/Relapse,,25,mg,,Oth,QD on 28 day cycle,PO,,310,371,1
MMRF_1415,,Second Line Therapy (after,Other,salvage therapy,Other,etoposide,,,Completed regimen,,0,Other,unknown,Oth,unknown,Other,unknown,378,381,1
MMRF_1415,,Second Line Therapy (after,Other,salvage,Other,cisplatin,,,Completed regimen,,0,Other,unknown,Oth,unknown,Other,unknown,378,381,1
MMRF_1415,,Second Line Therapy (after,Other,salvage therapy,Other,prednisone,,,Completed regimen,,0,Other,unknown,Oth,unknown,Other,unknown,378,381,1
MMRF_1415,,Second Line Therapy (after,Other,salvage therapy,Bortezomib,,,,Completed regimen,,0,Other,unknown,Oth,unknown,Other,unknown,378,381,1
MMRF_1415,,Second Line Therapy (after,Induction,,Carfilzomib,,,,Lack of response,,58,mg,,Oth,unknown,IV,,402,463,1
MMRF_1415,,Second Line Therapy (after,Unknown,,Pomalidomide,,,,Lack of response,,4,mg,,Oth,unknown,PO,,402,463,1
MMRF_1415,,Second Line Therapy (after,Unknown,,Dexamethasone,,,,Lack of response,,20,mg,,Oth,unknown,PO,,402,463,1
MMRF_1415,,First line of therapy,Maintenance,,Bortezomib,,,,Disease progression/Relapse,,3,mg,,Oth,unknown,IV SubQ,,310,371,1
MMRF_1430,,First line of therapy,,,Dexamethasone,,,,Other,dose reduction,40,mg,,QD,,PO,,1,3,1
MMRF_1430,Baseline,First line of therapy,,,Bortezomib,,,,Completed regimen,,2.8,mg,,QD,,IV SubQ,,1,119,1
MMRF_1430,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,QD,,PO,,4,119,1
MMRF_1430,,First line of therapy,Induction,,Thalidomide,,,,Completed regimen,,100,mg,,Oth,unknown,PO,,42,119,1
MMRF_1430,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,140,mg/m^,,Q d,,IV,,192,192,1
MMRF_1430,,First line of therapy,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,5,mg,,QD,,PO,,316,665,1
MMRF_1430,,Second Line Therapy (after,Unknown,,Daratumumab,,,Checked,,,16,mg/kg,,Oth,"QD(D1,D8,D15,D22)",IV,,1453,,1
MMRF_1430,,Second Line Therapy (after,Unknown,,Bortezomib,,,Checked,,,1.6,mg/m^,,Oth,"QD(D1,D8,D15)",IV SubQ,,1453,,1
MMRF_1430,,Second Line Therapy (after,Unknown,,Dexamethasone,,,Checked,,,20,mg,,Oth,"QD(D2,D9,D16)",PO,,1453,,1
MMRF_1430,,Third Line Therapy (followi,Unknown,,Pomalidomide,,,Checked,,,3,mg,,QD,,PO,,1533,,1
MMRF_1447,Baseline,First line of therapy,,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,81,1
MMRF_1447,,First line of therapy,,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,81,1
MMRF_1447,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"1,2,4,5,8,9,11,12",PO,,1,81,1
MMRF_1447,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,200,mg/m^,,Oth,unknown,Other,unknown,125,125,1
MMRF_1447,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,10,mg,,QD,,PO,,259,,1
MMRF_1506,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,2.2,mg/m^,,QD,,IV SubQ,,1,77,1
MMRF_1506,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,QD,,PO,,1,77,1
MMRF_1506,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,77,1
MMRF_1506,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,200,mg,,Q d,,IVB,,105,105,1
MMRF_1522,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,"QD (D1, D3, D6, D9)",PO,,1,105,1
MMRF_1522,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"QD D1, D2, D6, D7",PO,,1,105,1
MMRF_1522,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,2.3,mg,,Oth,"QD (D1, D3, D6, D9)",IV SubQ,,1,105,1
MMRF_1522,,First line of therapy,Maintenance,,Bortezomib,,,,Disease progression/Relapse,,1.3,mg/m^,,Oth,"QD 1,8,15",IV,,205,1291,1
MMRF_1522,,First line of therapy,Maintenance,,Lenalidomide,,,,Disease progression/Relapse,,10,mg,,QD,,PO,,205,1291,1
MMRF_1522,,First line of therapy,Maintenance,,Dexamethasone,,,,Disease progression/Relapse,,20,mg,,Oth,"QD days 1,2,8,9,15,16",PO,,205,1291,1
MMRF_1522,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,200,mg,,Q d,,IV,,113,113,1
MMRF_1522,,Second Line Therapy (after,Unknown,,Pomalidomide,,,,Disease progression/Relapse,,4,mg,,QD,,PO,,1322,1565,1
MMRF_1522,,Second Line Therapy (after,Unknown,,Ixazomib,,,,Disease progression/Relapse,,4,mg,,Oth,"QD(D1,D8,D15)",PO,,1322,1565,1
MMRF_1522,,Third Line Therapy (followi,Unknown,,Pomalidomide,,,Checked,,,2,mg,,QD,,PO,,1597,,1
MMRF_1522,,Third Line Therapy (followi,Unknown,,Daratumumab,,,Checked,,,16,mg/kg,,Oth,1x every 2 weeks,IV,,1597,,1
MMRF_1522,,Third Line Therapy (followi,Unknown,,Dexamethasone,,,Checked,,,16,mg,,Q w,,PO,,1597,,1
MMRF_1534,Baseline,First line of therapy,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,15,mg,,Oth,QOD for 14 days,PO,,1,15,1
MMRF_1534,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,"QD days 1,8,15",PO,,1,76,1
MMRF_1534,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,2.6,mg,,QD,,IV SubQ,,1,76,1
MMRF_1534,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,10,mg,,QD,,PO,,15,76,1
MMRF_1534,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,10,mg,,QD,,PO,,107,138,1
MMRF_1534,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,"QD 1,8,15,21",PO,,107,138,1
MMRF_1534,,First line of therapy,Consolidation,,Melphalan,,,,Completed regimen,,200,mg/m^,,Oth,unknown,Other,unknown,161,163,1
MMRF_1534,,First line of therapy,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,10,mg,,QD,,PO,,238,928,1
MMRF_1534,,First line of therapy,Maintenance,,Lenalidomide,,,,Disease progression/Relapse,,5,mg,,QD,,PO,,947,1101,1
MMRF_1534,,Second Line Therapy (after,Unknown,,Other,Venetoclax,,,Disease progression/Relapse,,800,mg,,QD,,PO,,1122,1290,1
MMRF_1534,,Second Line Therapy (after,Unknown,,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,Oth,"QD(D1,D81,D15)",PO,,1122,1290,1
MMRF_1534,,Third Line Therapy (followi,Unknown,,Daratumumab,,,,Disease progression/Relapse,,1800,mg,,Oth,"QD(D1,D2,D3,D4,D8,D15,D22)",Other,Subcutaneous,1331,1485,1
MMRF_1534,,Fourth Line Therapy (follow,Unknown,,Dexamethasone,,,Checked,,,40,mg,,Oth,Night before dara infusion,PO,,1526,,1
MMRF_1534,,Fourth Line Therapy (follow,Unknown,,Daratumumab,,,Checked,,,16,mg/kg,,Oth,"WeeklyX8weeks,every 2weeksx8 weeks,then monthly",IV,,1526,,1
MMRF_1534,,Fourth Line Therapy (follow,Unknown,,Pomalidomide,,,Checked,,,4,mg,,QD,,PO,,1526,,1
MMRF_1539,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"QD D1,D2,D4,D5,D8,D9, D11,D12",PO,,1,175,1
MMRF_1539,Baseline,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,45,175,1
MMRF_1539,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.9,mg,,QD,,IV SubQ,,1,175,1
MMRF_1539,,First line of therapy,Maintenance,,Lenalidomide,,,,Disease progression/Relapse,,10,mg,,QD,,PO,,327,1181,1
MMRF_1539,,First line of therapy,Maintenance,,Bortezomib,,,,Disease progression/Relapse,,1.3,mg/m^,,Q w,,IV SubQ,,605,878,1
MMRF_1539,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,140,mg,,Q d,,IV,,227,227,1
MMRF_1539,,Second Line Therapy (after,Unknown,,Ixazomib,,,,Disease progression/Relapse,,4,mg,,Oth,"QD(D1,8,15)",PO,,878,1181,1
MMRF_1539,,Second Line Therapy (after,Unknown,,Dexamethasone,,,,Disease progression/Relapse,,20,mg,,Oth,"QD(D1,8,15)",PO,,878,1181,1
MMRF_1539,,Third Line Therapy (followi,Unknown,,Pomalidomide,,,,Disease progression/Relapse,,4,mg,,QD,,PO,,1181,1361,1
MMRF_1539,,Third Line Therapy (followi,Unknown,,Daratumumab,,,,Disease progression/Relapse,,16,mg/kg,,QWK,,IV,,1181,1361,1
MMRF_1539,,Fourth Line Therapy (follow,Unknown,,Other,Venetoclex,,Checked,,,400,mg,,QD,,PO,,1398,,1
MMRF_1539,,Fourth Line Therapy (follow,Unknown,,Dexamethasone,,,Checked,,,20,mg,,Q w,,PO,,1398,,1
MMRF_1543,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,4,mg,,Oth,"QD 1,8,15,22",PO,,1,109,1
MMRF_1543,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,2,mg,,Oth,"QD 1,8,15,22",IV,,1,109,1
MMRF_1543,Baseline,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,109,1
MMRF_1543,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,200,mg,,Q d,,IV,,143,143,1
MMRF_1546,,First line of therapy,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,2.2,mg,,QD,,IV SubQ,,1,84,1
MMRF_1546,,First line of therapy,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,25,mg,,QD,,PO,,1,84,1
MMRF_1546,Baseline,First line of therapy,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,20,mg,,QD,,PO,,1,84,1
MMRF_1546,,First line of therapy,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,10,mg,,QWK,,PO,,140,596,1
MMRF_1546,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,140,237,1
MMRF_1546,,First line of therapy,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,20,mg,,QD,,PO,,238,386,1
MMRF_1546,,First line of therapy,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,10,mg,,QD,,PO,,414,534,1
MMRF_1546,,First line of therapy,Induction,,Dexamethasone,,,,Other,To allow optimal muscle strengthening,8,mg,,Q w,,PO,,596,680,1
MMRF_1546,,First line of therapy,Induction,,Lenalidomide,,,Checked,,,5,mg,,QD,,PO,,534,,1
MMRF_1546,,First line of therapy,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,15,mg,,QD,,PO,,386,414,1
MMRF_1572,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,2.7,mg,,QD,,IV SubQ,,1,124,1
MMRF_1572,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,124,1
MMRF_1572,Baseline,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Q D1, D2, D4, D5, D8, D9, D11, D12",PO,,1,124,1
MMRF_1572,,First line of therapy,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,10,mg,,QD,,PO,,268,270,1
MMRF_1572,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,200,mg,,Q d,,IVB,,149,149,1
MMRF_1595,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,Oth,"QD (D1,D8,D15)",IV,,1,107,1
MMRF_1595,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,15,mg,,QD,,PO,,1,107,1
MMRF_1595,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"QD 1,8,15,22",PO,,1,107,1
MMRF_1595,,First line of therapy,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,10,mg,,QD,,PO,,107,162,1
MMRF_1595,,First line of therapy,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,10,mg,,QD,,PO,,179,227,1
MMRF_1602,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,2.6,Other,unknown,QWK,,IV,,1,83,1
MMRF_1602,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,QWK,,PO,,1,83,1
MMRF_1602,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,83,1
MMRF_1602,,First line of therapy,Consolidation,,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,116,116,1
MMRF_1602,,First line of therapy,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,10,mg,,QD,,PO,,265,704,1
MMRF_1602,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,10,mg,,QD,,PO,,1041,,1
MMRF_1656,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,4,mg,,Oth,"QD 1,2,4,5,8,9,11,12",PO,,1,79,1
MMRF_1656,,First line of therapy,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,25,mg,,QD,,PO,,1,22,1
MMRF_1656,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,2.3,mg,,QD,,IV,,1,79,1
MMRF_1656,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,QOD Days 1-14,PO,,22,79,1
MMRF_1656,,First line of therapy,Other,mobilization,Cyclophosphamide,,,,Completed regimen,,3,Other,g/m2,Oth,unknown,IV,,99,110,1
MMRF_1656,,First line of therapy,Other,conditioning,Melphalan,,,,Completed regimen,,140,mg/m^,,Oth,unknown,IV,,131,133,1
MMRF_1656,,First line of therapy,Consolidation,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV,,229,260,1
MMRF_1656,,First line of therapy,Consolidation,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,"days 1,8,15,22",PO,,229,260,1
MMRF_1656,,First line of therapy,Consolidation,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,229,260,1
MMRF_1656,,Second Line Therapy (after,Unknown,,Bortezomib,,,,Disease progression/Relapse,,1.3,mg/m^,,QD,,IV SubQ,,444,505,1
MMRF_1656,,Third Line Therapy (followi,Unknown,,Bortezomib,,,,Completed regimen,,2.1,mg,,Oth,"QD(D1,D4)",IV SubQ,,512,515,1
MMRF_1656,,Third Line Therapy (followi,Unknown,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,PO,,512,515,1
MMRF_1656,,Third Line Therapy (followi,Unknown,,Cyclophosphamide,,,,Completed regimen,,660,mg,,Oth,"QD(D1,D4)",Other,IVPB,512,515,1
MMRF_1656,,Third Line Therapy (followi,Unknown,,Other,Cisplatin,,,Completed regimen,,16.5,mg,,Oth,"QD(D1,D4)",Other,IVPB,512,515,1
MMRF_1656,,Second Line Therapy (after,Unknown,,Lenalidomide,,,,Disease progression/Relapse,,25,mg,,QD,,PO,,444,505,1
MMRF_1656,,Second Line Therapy (after,Unknown,,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,Oth,"QD(D1,D8,D15,D22)",PO,,444,505,1
MMRF_1656,,Third Line Therapy (followi,Unknown,,Other,Etoposide,,,Completed regimen,,66,mg,,Oth,"QD(D1,D4)",Other,IVPB,512,515,1
MMRF_1674,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,2.1,mg,,Oth,"QD 1,3,7,10",IV SubQ,,1,104,1
MMRF_1674,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,104,1
MMRF_1674,,First line of therapy,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,20,mg,,Oth,"QD 1,3,7,10",PO,,1,63,1
MMRF_1674,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,10,mg,,Oth,"QD 2,5,9,12",PO,,64,104,1
MMRF_1674,,First line of therapy,Maintenance,,Bortezomib,,,,Other,MRD negative,1.3,mg/m^,,Oth,"QD 1,8,15",IV SubQ,,235,912,1
MMRF_1674,,First line of therapy,Consolidation,,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,138,138,1
MMRF_1694,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"QD 1,2,4,5,8,9,11,12",PO,,1,108,1
MMRF_1694,Baseline,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,20,mg,,QD,,PO,,1,108,1
MMRF_1694,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV,,1,108,1
MMRF_1694,,First line of therapy,Consolidation,,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,168,168,1
MMRF_1694,,First line of therapy,Maintenance,,Lenalidomide,,,,Disease progression/Relapse,,5,mg,,QD,,PO,,394,935,1
MMRF_1694,,Second Line Therapy (after,Unknown,,Ixazomib,,,Checked,,,4,mg,,Oth,"QD(D1,D8,D15) every 28 days",PO,,931,,1
MMRF_1694,,Second Line Therapy (after,Unknown,,Lenalidomide,,,Checked,,,25,mg,,QD,,PO,,931,,1
MMRF_1694,,Second Line Therapy (after,Unknown,,Dexamethasone,,,Checked,,,20,mg,,QWK,,PO,,931,,1
MMRF_1711,,First line of therapy,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,20,mg,,Oth,"QD 1,2,4,5,8,9,11,12",PO,,1,11,1
MMRF_1711,,First line of therapy,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,25,mg,,QD,,PO,,1,11,1
MMRF_1711,Baseline,First line of therapy,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,2.8,mg,,QD,,IV SubQ,,1,11,1
MMRF_1711,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,15,mg,,QD,,PO,,29,109,1
MMRF_1711,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV,,29,109,1
MMRF_1711,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"QD 1,2,4,5,8,9,11,12",PO,,29,109,1
MMRF_1711,,First line of therapy,Consolidation,,Melphalan,,,,Completed regimen,,200,mg,,Q d,,Other,unknown,122,122,1
MMRF_1711,,First line of therapy,Maintenance,,Lenalidomide,,,,Disease progression/Relapse,,10,mg,,QD,,PO,,240,1017,1
MMRF_1711,,Second Line Therapy (after,Unknown,,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,Q w,,PO,,1020,1080,1
MMRF_1711,,Second Line Therapy (after,Unknown,,Lenalidomide,,,,Disease progression/Relapse,,25,mg,,QD,,PO,,1020,1080,1
MMRF_1711,,Third Line Therapy (followi,Unknown,,Daratumumab,,,,Disease progression/Relapse,,16,mg/kg,,Oth,"QD(D1,D8,D15,D22)",IV,,1095,1150,1
MMRF_1711,,Third Line Therapy (followi,Unknown,,Pomalidomide,,,,Disease progression/Relapse,,4,mg,,QD,,PO,,1095,1150,1
MMRF_1711,,Third Line Therapy (followi,Unknown,,Dexamethasone,,,,Disease progression/Relapse,,20,mg,,Oth,"QD(D1,D8,D15,D22)",PO,,1095,1150,1
MMRF_1711,,Second Line Therapy (after,Unknown,,Ixazomib,,,,Disease progression/Relapse,,4,mg,,Oth,"QD(D1,D8,D15,D22)",PO,,1020,1080,1
MMRF_1711,,Third Line Therapy (followi,Unknown,,Prednisone,,,Checked,,,60,mg,,Oth,"QD(D2,D9,D16)",PO,,1304,,1
MMRF_1711,,Fourth Line Therapy (follow,Unknown,,Dexamethasone,,,Checked,,,40,mg,,Oth,D22,PO,,1157,,1
MMRF_1711,,Fourth Line Therapy (follow,Unknown,,Cyclophosphamide,,,,Completed regimen,,600,mg,,Oth,"QD(D1,D8,D15)",PO,,1157,1290,1
MMRF_1711,,Fourth Line Therapy (follow,Unknown,,Carfilzomib,,,Checked,,,41,mg,,Oth,"QD(D1,D2)",IV,,1157,,1
MMRF_1711,,Fourth Line Therapy (follow,Unknown,,Carfilzomib,,,Checked,,,56,mg,,Oth,"QD(D8,D9,D15,D16)",IV,,1157,,1
MMRF_1713,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Q w,,PO,,1,126,1
MMRF_1713,Baseline,First line of therapy,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,1.3,mg/m^,,QD,,IV,,1,83,1
MMRF_1713,,First line of therapy,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,15,mg,,Oth,QD 1-14 on 21 day cycle,PO,,21,28,1
MMRF_1713,,First line of therapy,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,10,mg,,QD,,PO,,281,350,1
MMRF_1713,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,Oth,Q weekly (4 on and 2 off),IV,,84,126,1
MMRF_1713,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,200,mg,,Q d,,IV,,170,170,1
MMRF_1713,,First line of therapy,Maintenance,,Lenalidomide,,,,Patient decision,,5,mg,,QD,,PO,,350,448,1
MMRF_1713,,Second Line Therapy (after,Unknown,,Lenalidomide,,,,Investigator decision for other reasons,,5,mg,,QD,,PO,,1053,1148,1
MMRF_1713,,Second Line Therapy (after,Unknown,,Lenalidomide,,,Checked,,,5,mg,,QD,,PO,,1233,,1
MMRF_1713,,Second Line Therapy (after,Unknown,,Lenalidomide,,,,Adverse Event or co-morbidity,,10,mg,,QD,,PO,,1148,1233,1
MMRF_1722,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,71,1
MMRF_1722,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,QWK,,PO,,1,71,1
MMRF_1722,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV,,1,71,1
MMRF_1722,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,140,mg/m^,,Q d,,IV,,139,139,1
MMRF_1722,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,10,mg,,QD,,PO,,408,,1
MMRF_1736,Baseline,First line of therapy,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,1.3,mg/m^,,QD,,IV,,1,34,1
MMRF_1736,,First line of therapy,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,10,mg,,QD,,PO,,1,34,1
MMRF_1736,,First line of therapy,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,20,mg,,Oth,day after each dose of velcade,PO,,1,34,1
MMRF_1736,,Second Line Therapy (after,Unknown,,Daratumumab,,,Checked,,,16,mg/kg,,Oth,"QD(D1,D8,D15,D22)",IV,,1219,,1
MMRF_1736,,Second Line Therapy (after,Unknown,,Dexamethasone,,,Checked,,,4,mg,,Oth,4mg two days after Dara infusion,PO,,1219,,1
MMRF_1817,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,93,1
MMRF_1817,,First line of therapy,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,20,mg,,Oth,"Days 1,2,4,5,8,9,11,12",PO,,1,25,1
MMRF_1817,Baseline,First line of therapy,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,1.3,mg/m^,,QD,,IV,,1,92,1
MMRF_1817,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,12,mg,,Oth,"QD 1,2",PO,,26,29,1
MMRF_1817,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,16,mg,,Oth,"QD 1,2,4,5,8,9,11,12",PO,,30,93,1
MMRF_1817,,First line of therapy,Maintenance,,Lenalidomide,,,,Patient decision,,10,mg,,QD,,PO,,401,432,1
MMRF_1817,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,200,mg,,Q d,,IVB,,169,169,1
MMRF_1817,,First line of therapy,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,5,mg,,QD,,PO,,550,774,1
MMRF_1817,,First line of therapy,Maintenance,,Lenalidomide,,,,Disease progression/Relapse,,5,mg,,QD,,PO,,947,1251,1
MMRF_1817,,Second Line Therapy (after,Unknown,,Other,Venetaclex,,Checked,,,400,mg,,Q d,,PO,,1293,,1
MMRF_1837,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,76,1
MMRF_1837,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"QD 1,2,4,5,8,9,11,12",PO,,1,76,1
MMRF_1837,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,2.29,mg,,QD,,IV,,1,76,1
MMRF_1837,,First line of therapy,Other,conditioning,Melphalan,,,,Completed regimen,,200,mg/m^,,Oth,unknown,Other,unknown,123,124,1
MMRF_1837,,First line of therapy,Maintenance,,Lenalidomide,,,,Disease progression/Relapse,,10,mg,,QD,,PO,,216,1248,1
MMRF_1837,,First line of therapy,Maintenance,,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,Oth,"QD(D1,D8,D15)",PO,,216,1248,1
MMRF_1837,,First line of therapy,Maintenance,,Bortezomib,,,,Patient decision,,1.3,mg/m^,,Oth,"QD (D1,D8,D15)",IV SubQ,,216,700,1
MMRF_1837,,First line of therapy,Maintenance,,Ixazomib,,,,Adverse Event or co-morbidity,,4,mg,,Oth,"QD(D1,D8,D15)",PO,,693,776,1
MMRF_1837,,First line of therapy,Maintenance,,Ixazomib,,,,Disease progression/Relapse,,3,mg,,Q w,,PO,,776,1248,1
MMRF_1837,,Second Line Therapy (after,Unknown,,Dexamethasone,,,Checked,,,20,mg,,Q w,,PO,,1267,,1
MMRF_1837,,Second Line Therapy (after,Unknown,,Other,Venetoclex,,,Adverse Event or co-morbidity,,800,mg,,Q d,,PO,,1267,1323,1
MMRF_1837,,Second Line Therapy (after,Unknown,,Other,Venetaclex,,Checked,,,400,mg,,Q d,,PO,,1323,,1
MMRF_1854,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,85,1
MMRF_1854,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,QD,,PO,,1,85,1
MMRF_1854,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,2.5,mg,,QD,,IV SubQ,,1,85,1
MMRF_1854,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,15,mg,,QD,,PO,,208,,1
MMRF_1854,,First line of therapy,Maintenance,,Bortezomib,,,Checked,,,1.3,mg/m^,,Oth,"QD (D1,D8,D15)",IV SubQ,,208,,1
MMRF_1854,,First line of therapy,Maintenance,,Dexamethasone,,,Checked,,,20,mg,,Oth,"QD (D1,D2,D8,D9,D15,D16)",PO,,208,,1
MMRF_1854,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,118,118,1
MMRF_1906,Baseline,First line of therapy,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,1.3,mg/m^,,QD,,IV SubQ,,8,167,1
MMRF_1906,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"QD days 1,2,4,5,8,9,11,12",PO,,8,206,1
MMRF_1906,,First line of therapy,Induction,,Cyclophosphamide,,,,Investigator decision for other reasons,,300,mg,,Oth,"QD days 1,8 of 28 day cycle",PO,,1,28,1
MMRF_1906,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,500,mg,,Oth,Days 15 and 22 of 28 day cycle,PO,,28,206,1
MMRF_1906,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1,mg/m^,,QD,,IV SubQ,,168,206,1
MMRF_1906,,First line of therapy,Induction,,Other,Cytoxan,,,Completed regimen,,500,mg,,Oth,"QD (D1,D8)",PO,,63,206,1
MMRF_1906,,First line of therapy,Maintenance,,Lenalidomide,,,,Disease progression/Relapse,,15,mg,,QD,,PO,,238,313,1
MMRF_1906,,Second Line Therapy (after,Unknown,,Pomalidomide,,,,Disease progression/Relapse,,4,mg,,QD,,PO,,344,772,1
MMRF_1906,,Second Line Therapy (after,Unknown,,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,Q w,,PO,,344,772,1
MMRF_1906,,Second Line Therapy (after,Unknown,,Carfilzomib,,,,Completed regimen,,20,mg/m^,,Oth,"QD(D1,D2)",IV SubQ,,421,422,1
MMRF_1906,,Second Line Therapy (after,Unknown,,Carfilzomib,,,,Disease progression/Relapse,,27,mg/m^,,Oth,"QD(D8,D9,D15,D16)",IV SubQ,,421,772,1
MMRF_1906,,Third Line Therapy (followi,Unknown,,Dexamethasone,,,,Completed regimen,,8,mg,,Oth,"QD(D15,22)",PO,,792,813,1
MMRF_1906,,Third Line Therapy (followi,Unknown,,Lenalidomide,,,,Adverse Event or co-morbidity,,10,mg,,QD,,PO,,792,876,1
MMRF_1906,,Third Line Therapy (followi,Unknown,,Daratumumab,,,,Adverse Event or co-morbidity,,16,mg/kg,,Oth,"QD(D1,8,15,22)",IV,,792,876,1
MMRF_1906,,Third Line Therapy (followi,Unknown,,Dexamethasone,,,Checked,,,8,mg,,Oth,"QD(D1,D8,D15,D22)",PO,,820,,1
MMRF_1940,,First line of therapy,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,25,mg,,QD,,PO,,1,18,1
MMRF_1940,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,2.7,mg,,QD,,IV SubQ,,1,81,1
MMRF_1940,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"QD 2,5,9,12",PO,,1,81,1
MMRF_1940,,First line of therapy,Maintenance,,Bortezomib,,,Checked,,,1.3,mg/m^,,Oth,"QD(D1,D15,D29,D43)",IV SubQ,,291,,1
MMRF_1940,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,200,mg,,Q d,,IV,,160,160,1
MMRF_1957,Baseline,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,144,1
MMRF_1957,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Q w,,PO,,1,144,1
MMRF_1957,,First line of therapy,Maintenance,,Lenalidomide,,,,Disease progression/Relapse,,10,mg,,QD,,PO,,308,1077,1
MMRF_1957,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,270,mg,,Q d,,IV,,194,194,1
MMRF_1957,,Second Line Therapy (after,Unknown,,Other,Venetoclex,,Checked,,,800,mg,,Oth,QD(D1-D28),PO,,1222,,1
MMRF_2001,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,103,1
MMRF_2001,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"QD 1,2,4,5,8,9,11,12",PO,,1,103,1
MMRF_2001,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV,,1,103,1
MMRF_2001,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,169,169,1
MMRF_2001,,First line of therapy,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,10,mg,,QD,,PO,,404,549,1
MMRF_2090,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,95,1
MMRF_2090,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,14,95,1
MMRF_2090,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"QD 1,2,4,5,8,9,11,12",PO,,1,95,1
MMRF_2090,,First line of therapy,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,10,mg,,QD,,PO,,263,477,1
MMRF_2090,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,139,139,1
MMRF_2090,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,5,mg,,QD,,PO,,513,,1
MMRF_2111,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV,,1,73,1
MMRF_2111,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,73,1
MMRF_2111,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,QWK,,PO,,1,73,1
MMRF_2111,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,10,mg,,QD,,PO,,327,,1
MMRF_2111,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,200,mg,,Q d,,IVB,,153,153,1
MMRF_2128,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,106,1
MMRF_2128,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,QD 1-14 of 21 days,PO,,1,106,1
MMRF_2128,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"QD 1,2,4,5,8,9,11,12",PO,,1,106,1
MMRF_2128,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,140,mg/m^,,Q d,,IV,,161,161,1
MMRF_2128,,First line of therapy,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,10,mg,,QD,,PO,,323,343,1
MMRF_2137,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"QD 1,8,15,22",PO,,1,107,1
MMRF_2137,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,Oth,"QD 1,4,8,11,15,18",IV,,1,107,1
MMRF_2137,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,107,1
MMRF_2137,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,112,112,1
MMRF_2137,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,10,mg,,QD,,PO,,467,,1
MMRF_2140,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV,,1,90,1
MMRF_2140,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,90,1
MMRF_2140,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,"QD 1,8,15",PO,,1,90,1
MMRF_2140,,First line of therapy,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,10,mg,,QD,,PO,,272,357,1
MMRF_2140,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,5,mg,,QD,,PO,,357,,1
MMRF_2211,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,74,1
MMRF_2211,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,"Days 1,2,4,5,8,9,11,12",PO,,1,36,1
MMRF_2211,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"QD(D1,D2,D4,D5,D8,D9,D11,D12)",PO,,43,74,1
MMRF_2211,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,43,74,1
MMRF_2211,,First line of therapy,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,10,mg,,QD,,PO,,249,384,1
MMRF_2211,,First line of therapy,Other,ASCT,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,120,120,1
MMRF_2211,,First line of therapy,Maintenance,,Lenalidomide,,,,Disease progression/Relapse,,5,mg,,QD,,PO,,396,1054,1
MMRF_2211,,Second Line Therapy (after,Unknown,,Pomalidomide,,,Checked,,,4,mg,,QD,,PO,,1075,,1
MMRF_2211,,Second Line Therapy (after,Unknown,,Prednisone,,,Checked,,,20,mg,,Oth,"Daily x 2 on QD(D2,D9,D16,D23)",PO,,1075,,1
MMRF_2211,,Second Line Therapy (after,Unknown,,Daratumumab,,,Checked,,,16,mg/kg,,Oth,"QD(D1,D8,D15,D22)",IV,,1075,,1
MMRF_2209,Baseline,First line of therapy,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,1.3,mg/m^,,QD,,IV SubQ,,1,8,1
MMRF_2209,,First line of therapy,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,25,mg,,QD,,PO,,1,8,1
MMRF_2209,,First line of therapy,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,20,mg,,Oth,"QD 1,2,4,5,8,9,11,12",PO,,1,8,1
MMRF_2209,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,20,mg/m^,,Oth,"Q wk X3 (Days 1,2,8,9,15,16) with 12 say rest Q 28 days X",IV,,22,125,1
MMRF_2209,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,"QD 1,8,15,22",PO,,22,125,1
MMRF_2209,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,140,mg/m^,,Q d,,IVB,,173,173,1
MMRF_2239,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"QD1 2,4,5,8,9,11,12",PO,,1,74,1
MMRF_2239,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1,mg/m^,,QD,,IV SubQ,,43,74,1
MMRF_2239,Baseline,First line of therapy,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,1.3,mg/m^,,QD,,IV SubQ,,1,32,1
MMRF_2239,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,74,1
MMRF_2239,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,140,mg,,Q d,,IVB,,126,126,1
MMRF_2239,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,10,mg,,QD,,PO,,236,,1
MMRF_2284,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,94,1
MMRF_2284,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"QD 1,2,4,5,8,9,11,12",PO,,1,64,1
MMRF_2284,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,74,1
MMRF_2284,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,200,mg,,Q d,,IV,,132,132,1
MMRF_2284,,First line of therapy,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,10,mg,,QD,,PO,,226,771,1
MMRF_2397,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"QD(1,2,4,5,8,9,11,12)",PO,,1,53,1
MMRF_2397,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,2.6,mg,,QD,,IV SubQ,,1,53,1
MMRF_2397,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,53,1
MMRF_2397,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,400,mg,,Q d,,IVB,,99,99,1
MMRF_2397,,First line of therapy,Consolidation,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,183,218,1
MMRF_2397,,First line of therapy,Consolidation,,Dexamethasone,,,,Completed regimen,,10,mg,,QD,,PO,,183,218,1
MMRF_2397,,First line of therapy,Consolidation,,Lenalidomide,,,,Completed regimen,,15,mg,,QD,,PO,,183,218,1
MMRF_2397,,First line of therapy,Maintenance,,Ixazomib,,,,Adverse Event or co-morbidity,,4,mg,,Oth,"QD(D1,D8,D15)",PO,,343,876,1
MMRF_2397,,First line of therapy,Maintenance,,Bortezomib,,,,Investigator decision for other reasons,,1.3,mg/m^,,Oth,"QD(D1,D8,D15)",IV SubQ,,284,343,1
MMRF_2397,,First line of therapy,Maintenance,,Ixazomib,,,Checked,,,3,mg,,Oth,"QD(D1,D8,D15)",PO,,876,,1
MMRF_2383,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,2.6,mg,,QD,,IV SubQ,,1,74,1
MMRF_2383,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,"QD(d1,d8,d15)",PO,,1,74,1
MMRF_2383,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,74,1
MMRF_2383,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IVB,,126,126,1
MMRF_2383,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,10,mg,,QD,,PO,,235,,1
MMRF_2388,Baseline,First line of therapy,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,15,mg,,QD,,PO,,1,85,1
MMRF_2388,,First line of therapy,Induction,,Bortezomib,,,,Disease progression/Relapse,,1.3,mg/m^,,Oth,"QD (D1,8,15)",IV SubQ,,1,616,1
MMRF_2388,,First line of therapy,Induction,,Dexamethasone,,,Checked,,,20,mg,,Oth,"QD(D1,D8,D15)",PO,,1,,1
MMRF_2388,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,5,mg,,QD,,PO,,150,175,1
MMRF_2388,,First line of therapy,Induction,,Lenalidomide,,,,Disease progression/Relapse,,20,mg,,QD,,PO,,175,616,1
MMRF_2388,,Second Line Therapy (after,Unknown,,Lenalidomide,,,Checked,,,10,mg,,Oth,"QD(D1-D7),(D15-D21)",PO,,633,,1
MMRF_2388,,Second Line Therapy (after,Unknown,,Daratumumab,,,Checked,,,16,mg/kg,,Oth,"QD(D1,D8,D15,D22)",IV,,633,,1
MMRF_2411,Baseline,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,74,1
MMRF_2411,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,QD,,PO,,1,74,1
MMRF_2411,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,2.6,mg,,QD,,IV SubQ,,1,74,1
MMRF_2411,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IVB,,129,129,1
MMRF_2411,,First line of therapy,Maintenance,,Lenalidomide,,,,Disease progression/Relapse,,10,mg,,QD,,PO,,244,914,1
MMRF_2411,,Second Line Therapy (after,Unknown,,Daratumumab,,,,Disease progression/Relapse,,16,mg/kg,,Oth,"QD(D1,D8,D15,D22)",IV,,926,1023,1
MMRF_2411,,Second Line Therapy (after,Unknown,,Pomalidomide,,,,Disease progression/Relapse,,4,mg,,QD,,PO,,926,1023,1
MMRF_2411,,Second Line Therapy (after,Unknown,,Prednisone,,,,Disease progression/Relapse,,20,mg,,Oth,daily x 2 days beginning the day after each Dara infusion,PO,,928,1023,1
MMRF_2411,,Third Line Therapy (followi,Unknown,,Dexamethasone,,,Checked,,,20,mg,,Q w,,PO,,1058,,1
MMRF_2411,,Third Line Therapy (followi,Unknown,,Carfilzomib,,,Checked,,,56,mg/m^,,QD,,IV,,1058,,1
MMRF_2411,,Third Line Therapy (followi,Unknown,,Cyclophosphamide,,,Checked,,,600,mg,,Oth,"QD(D1,D8,D15)",PO,,1058,,1
MMRF_2459,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,82,1
MMRF_2459,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,82,1
MMRF_2459,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"QD(D1,D2,D4,D5,D8,D9,D11,D12)",PO,,1,82,1
MMRF_2459,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,136,136,1
MMRF_2459,,First line of therapy,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,10,mg,,QD,,PO,,224,606,1
MMRF_2459,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,10,mg,,QD,,PO,,606,,1
MMRF_2516,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,PO,,1,4,1
MMRF_2516,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"QD 2,5,9,12",PO,,22,74,1
MMRF_2516,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,22,74,1
MMRF_2516,,First line of therapy,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,25,mg,,QD,,PO,,22,77,1
MMRF_2516,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,3,9,1
MMRF_2516,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,140,mg/m^,,Q d,,IV,,119,119,1
MMRF_2516,,First line of therapy,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,15,mg,,QD,,PO,,245,259,1
MMRF_2532,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"QD(D1,D2,D4,D5,D8,D9,D11,D12)",PO,,1,81,1
MMRF_2532,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,0.7,mg/m^,,QD,,IV,,71,81,1
MMRF_2532,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,15,mg,,QD,,PO,,1,81,1
MMRF_2532,Baseline,First line of therapy,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,1.3,mg/m^,,QD,,IV SubQ,,1,71,1
MMRF_2532,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,140,mg/m^,,Q d,,IV,,133,133,1
MMRF_2532,,First line of therapy,Maintenance,,Lenalidomide,,,,Patient decision,,10,mg,,QD,,PO,,239,605,1
MMRF_2559,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,QD,,PO,,1,74,1
MMRF_2559,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,74,1
MMRF_2559,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,74,1
MMRF_2559,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,200,mg/m^,,QID,,IVB,,131,131,1
MMRF_2559,,First line of therapy,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,15,mg,,QD,,PO,,275,410,1
MMRF_2559,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,15,mg,,QD,,PO,,410,,1
MMRF_1121,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"D1,2,4,5,8,9,11,12",PO,,1,74,1
MMRF_1121,Baseline,First line of therapy,,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,74,1
MMRF_1121,,First line of therapy,,,Bortezomib,,,,Completed regimen,,2,mg,,QD,,IV SubQ,,1,74,1
MMRF_1121,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,200,Other,mg/m2,Q d,,IV,,494,494,1
MMRF_1121,,First line of therapy,Maintenance,,Lenalidomide,,,,Other,dose reduced due to peripheral neuropathy,10,mg,,QD,,PO,,345,375,1
MMRF_1121,,First line of therapy,Maintenance,,Lenalidomide,,,,Other,Going on vacation to China,5,mg,,QD,,PO,,375,464,1
MMRF_1121,,First line of therapy,Maintenance,,Lenalidomide,,,,Other,lost insurance for one month,5,mg,,QD,,PO,,541,653,1
MMRF_1121,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,5,mg,,QD,,PO,,653,,1
MMRF_1149,,First line of therapy,,,Lenalidomide,,,,Other,referred for bone marrow transplant,25,Other,MG,QD,,PO,,1,85,1
MMRF_1149,,First line of therapy,,,Dexamethasone,,,,Other,referred for bone marrow transplant,20,mg,,Oth,"D1,2,4,5,8,9,11,12",PO,,1,85,1
MMRF_1149,Baseline,First line of therapy,,,Bortezomib,,,,Other,Referred for bone marrow transplant,1.3,mg/m^,,QD,,IV SubQ,,1,74,1
MMRF_1149,,Second Line Therapy (after,,,Melphalan,,,,Completed regimen,,200,mg/m^,,Oth,Total dose,IV,,158,204,1
MMRF_1149,,Second Line Therapy (after,Maintenance,,Lenalidomide,,,,Disease progression/Relapse,,10,mg,,Oth,daily days 1 - 21 of a 28 day cycle,PO,,330,457,1
MMRF_1149,,Third Line Therapy (followi,Unknown,,Dexamethasone,,,,Disease progression/Relapse,,4,mg,,Oth,"Day 2,9,16 of each 28 day cycle",IV,,458,563,1
MMRF_1149,,Third Line Therapy (followi,Unknown,,Carfilzomib,,,,Disease progression/Relapse,,20,mg/m^,,QD,,IV,,458,564,1
MMRF_1149,,Third Line Therapy (followi,Unknown,,Pomalidomide,,,,Disease progression/Relapse,,2,mg,,QD,,PO,,458,564,1
MMRF_1149,,Third Line Therapy (followi,Unknown,,Dexamethasone,,,,Disease progression/Relapse,,20,mg,,Oth,"D 1,8, 15, 21",PO,,458,564,1
MMRF_1149,,Third Line Therapy (followi,Unknown,,Other,Cisplatin,,,Completed regimen,,20,mg,,Oth,QD for 4 days (off for 24 days),IV,,564,595,1
MMRF_1149,,Fourth Line Therapy (follow,Other,salvage,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,Q w,,PO,,701,760,1
MMRF_1149,,Fourth Line Therapy (follow,Other,salvage,Other,vorinostat,,,Disease progression/Relapse,,400,mg,,QD,,PO,,701,730,1
MMRF_1149,,Third Line Therapy (followi,Unknown,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,QD for four days (off for 24 days),PO,,564,595,1
MMRF_1149,,Third Line Therapy (followi,Unknown,,Cyclophosphamide,,,,Completed regimen,,800,mg,,Oth,QD for four days (off for 24 days),IV,,564,595,1
MMRF_1149,,Third Line Therapy (followi,Unknown,,Other,etoposide,,,Completed regimen,,80,mg,,Oth,QD for 4 days (off for 24 days),IV,,564,595,1
MMRF_1149,,Fourth Line Therapy (follow,Other,salvage,Cyclophosphamide,,,,Disease progression/Relapse,,600,mg,,Oth,"QD 1,8,15,22",PO,,701,760,1
MMRF_1149,,Fourth Line Therapy (follow,Other,salvage,Thalidomide,,,,Disease progression/Relapse,,50,mg,,Oth,QD 1-28,PO,,701,760,1
MMRF_1149,,Third Line Therapy (followi,Unknown,,Bortezomib,,,,Completed regimen,,2.6,mg,,Oth,QD for four days (off for 24 days),IV SubQ,,564,595,1
MMRF_1149,,Third Line Therapy (followi,Other,salvage,Bortezomib,,,,Disease progression/Relapse,,1.6,mg/m^,,Oth,"QD 1,8,15",IV SubQ,,620,645,1
MMRF_1149,,Third Line Therapy (followi,Maintenance,,Lenalidomide,,,,Disease progression/Relapse,,10,mg,,QD,,PO,,620,645,1
MMRF_1149,,Third Line Therapy (followi,Other,salvage,Dexamethasone,,,,Disease progression/Relapse,,20,mg,,Q w,,PO,,620,645,1
MMRF_1149,,Fourth Line Therapy (follow,Other,salvage,Bortezomib,,,,Disease progression/Relapse,,2.6,mg,,QD,,IV SubQ,,701,760,1
MMRF_1149,,Sixth Line Therapy (followi,Unknown,,Bortezomib,,,,Completed regimen,,2.6,mg,,Oth,QD 1 and 4,IV SubQ,,772,776,1
MMRF_1149,,Sixth Line Therapy (followi,Unknown,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"QD 1,2,4,5",PO,,772,776,1
MMRF_1149,,Sixth Line Therapy (followi,Unknown,,Doxorubicin,,,,Completed regimen,,20,mg,,Oth,"QD 1,2,3,4",IV,,772,776,1
MMRF_1149,,Sixth Line Therapy (followi,Unknown,,Other,Cisplatin,,,Completed regimen,,20,mg,,Oth,"QD 1,2,3,4",IV,,772,776,1
MMRF_1149,,Sixth Line Therapy (followi,Unknown,,Cyclophosphamide,,,,Completed regimen,,800,mg,,Oth,"QD 1,2,3,4",IV,,772,776,1
MMRF_1149,,Sixth Line Therapy (followi,Unknown,,Other,Etoposide,,,Completed regimen,,80,mg,,Oth,"QD 1,2,3,4",IV,,772,776,1
MMRF_1149,,Sixth Line Therapy (followi,Unknown,,Thalidomide,,,,Completed regimen,,50,mg,,Oth,"QD 1,2,3,4",PO,,772,776,1
MMRF_1149,,Eighth Line of Therapy (fol,Unknown,,Dexamethasone,,,,Completed regimen,,40,mg,,Q d,,PO,,844,845,1
MMRF_1149,,Eighth Line of Therapy (fol,Unknown,,Carfilzomib,,,,Completed regimen,,20,mg/m^,,Oth,"QD(D1,D2)",IV,,844,846,1
MMRF_1149,,Seventh Line of Therapy (fo,Unknown,,Lenalidomide,,,,Disease progression/Relapse,,15,mg,,QD,,PO,,809,837,1
MMRF_1149,,Eighth Line of Therapy (fol,Unknown,,Carfilzomib,,,,Adverse Event or co-morbidity,,27,mg/m^,,Oth,"QD(D8,D9,D15,D16)",IV,,851,852,1
MMRF_1149,,Seventh Line of Therapy (fo,Unknown,,Dexamethasone,,,,Disease progression/Relapse,,28,mg,,QD,,PO,,809,837,1
MMRF_1149,,Seventh Line of Therapy (fo,Unknown,,Other,Elotuzumab,,,Disease progression/Relapse,,795,mg,,Oth,"QD(D1,D8,D15,D22)",IV,,809,837,1
MMRF_1149,,Seventh Line of Therapy (fo,Unknown,,Bortezomib,,,,Disease progression/Relapse,,1.3,mg/m^,,QD,,IV,,809,837,1
MMRF_1149,,Eighth Line of Therapy (fol,Unknown,,Cyclophosphamide,,,,Adverse Event or co-morbidity,,300,mg/m^,,Oth,"QD(D1,D8,D15)",IV,,844,852,1
MMRF_1080,Baseline,First line of therapy,,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,Oth,D1 Q21 Days,IV,,1,144,1
MMRF_1080,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,40,mg,,QWK,,PO,,1,144,1
MMRF_1080,,First line of therapy,,,Lenalidomide,,,Checked,,,10,mg,,Q d,,PO,,295,,1
MMRF_1080,,First line of therapy,,,Lenalidomide,,,,Completed regimen,,25,mg/dL,,Oth,D1 & D8 Q21 Days,IV,,1,144,1
MMRF_1198,Baseline,First line of therapy,,,Bortezomib,,,,Adverse Event or co-morbidity,,1.3,mg/m^,,QD,,IV SubQ,,1,309,1
MMRF_1198,,First line of therapy,,,Dexamethasone,,,,Adverse Event or co-morbidity,,20,mg,,QD,,PO,,1,309,1
MMRF_1198,,First line of therapy,,,Lenalidomide,,,,Adverse Event or co-morbidity,,25,mg/dL,,Oth,D1 Q21 Days,IV,,1,309,1
MMRF_1198,,First line of therapy,Maintenance,,Lenalidomide,,,,Investigator decision for other reasons,,10,mg,,Q d,,PO,,316,434,1
MMRF_1198,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,10,mg,,Oth,QAD,PO,,434,,1
MMRF_1255,Baseline,First line of therapy,,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,4,179,1
MMRF_1255,,First line of therapy,,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,Oth,Q21 Days,IV,,1,179,1
MMRF_1255,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,20,mg,,QD,,PO,,1,179,1
MMRF_1255,,First line of therapy,Induction,,Lenalidomide,,,Checked,,,10,mg,,Q d,,PO,,179,,1
MMRF_1339,,First line of therapy,,,Dexamethasone,,,,Adverse Event or co-morbidity,,20,mg,,QD,,PO,,1,24,1
MMRF_1339,Baseline,First line of therapy,,,Bortezomib,,,,Adverse Event or co-morbidity,,1.3,mg/m^,,QD,,IV,,1,24,1
MMRF_1236,,First line of therapy,,,Dexamethasone,,,,Investigator decision for other reasons,,20,mg,,QD,,PO,,1,190,1
MMRF_1236,Baseline,First line of therapy,,,Bortezomib,,,,Investigator decision for other reasons,,1.3,mg/m^,,QD,,IV SubQ,,1,190,1
MMRF_1236,,First line of therapy,,,Lenalidomide,,,,Investigator decision for other reasons,,25,mg,,QD,,PO,,1,190,1
MMRF_1236,,First line of therapy,Maintenance,,Pomalidomide,,,,Investigator decision for other reasons,,2,mg,,QD,,PO,,313,342,1
MMRF_1236,,First line of therapy,Maintenance,,Pomalidomide,,,,Disease progression/Relapse,,2,mg,,QD,,PO,,343,1397,1
MMRF_1236,,First line of therapy,Maintenance,,Dexamethasone,,,,Adverse Event or co-morbidity,,20,mg,,Oth,"days 1,2,8,9,15,16 of 21 day cycle",PO,,1028,1069,1
MMRF_1236,,First line of therapy,Maintenance,,Dexamethasone,,,,Lack of response,,20,mg,,Q w,,PO,,1069,1173,1
MMRF_1236,,First line of therapy,Maintenance,,Dexamethasone,,,,Disease progression/Relapse,,20,mg,,Oth,"days 1,4,8,11,15,19",PO,,1174,1397,1
MMRF_1236,,Second Line Therapy (after,Consolidation,,Daratumumab,,,,Disease progression/Relapse,,16,mg/kg,,Oth,"weekly x8, bi-weekly to 6 months,then monthly",IV,,1407,1673,1
MMRF_1236,,Second Line Therapy (after,Consolidation,,Pomalidomide,,,,Disease progression/Relapse,,4,mg,,QD,,PO,,1407,1700,1
MMRF_1236,,Third Line Therapy (followi,Maintenance,,Dexamethasone,,,Checked,,,20,mg,,Oth,"d1 to d2, d8",PO,,1701,,1
MMRF_1236,,Third Line Therapy (followi,Induction,,Carfilzomib,,,,Investigator decision for other reasons,,20,mg/m^,,Oth,d1 to d2,IV,,1701,1735,1
MMRF_1236,,Third Line Therapy (followi,Maintenance,,Carfilzomib,,,Checked,,,27,mg/m^,,Oth,"d8 to d9, d1",IV,,1701,,1
MMRF_1236,,Third Line Therapy (followi,Maintenance,,Cyclophosphamide,,,Checked,,,300,mg/m^,,Oth,"Day 1, 8, 15",PO,,1792,,1
MMRF_1918,,First line of therapy,Induction,,Dexamethasone,,,,Other,referred for autologous transplant,40,mg,,QD,,PO,,1,270,1
MMRF_1918,Baseline,First line of therapy,Induction,,Bortezomib,,,,Other,referred for autologous transplant,25,mg,,QD,,IV SubQ,,1,270,1
MMRF_1918,,First line of therapy,Induction,,Lenalidomide,,,,Other,referred for autologous transplant,25,mg,,QD,,PO,,1,273,1
MMRF_1918,,First line of therapy,Other,stem cell mobilization,Cyclophosphamide,,,,Completed regimen,,573,mg,,Q w,,IV,,92,99,1
MMRF_1918,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,286,287,1
MMRF_1918,,First line of therapy,Consolidation,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,days 1-21 of 28 day cycle,PO,,456,631,1
MMRF_1918,,First line of therapy,Consolidation,,Carfilzomib,,,,Investigator decision for other reasons,,20,mg/m^,,Oth,"days 1,2,8,9,15,16 of 28 day cycle",IV,,456,471,1
MMRF_1918,,First line of therapy,Consolidation,,Carfilzomib,,,,Investigator decision for other reasons,,27,mg/m^,,Oth,"days 1,2, 8,9,15,16 of 21 day cycle",IV,,484,527,1
MMRF_1918,,First line of therapy,Consolidation,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"days 1,2,8,9,15,16 of 21 day cycle",IV,,547,625,1
MMRF_1918,,First line of therapy,Consolidation,,Lenalidomide,,,,Completed regimen,,15,mg,,QD,,PO,,659,992,1
MMRF_1918,,First line of therapy,Consolidation,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,"days 1,8,15 of 28 day cycle",PO,,659,992,1
MMRF_1918,,First line of therapy,Consolidation,,Ixazomib,,,,Completed regimen,,4,mg,,Oth,"days 1,8,15  of 28 day cycle",PO,,659,992,1
MMRF_1918,,First line of therapy,Maintenance,,Dexamethasone,,,Checked,,,28,mg,,Oth,"d1, d8, d22",PO,,1060,,1
MMRF_1918,,First line of therapy,Maintenance,,Elotuzumab,,,Checked,,,10,mg/kg,,Oth,weeklyx9 weeks then every 2 weeks,IV,,1060,,1
MMRF_1918,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,25,mg,,QD,,PO,,1060,,1
MMRF_1918,,First line of therapy,Maintenance,,Dexamethasone,,,Checked,,,8,mg,,Oth,d1,IV,,1060,,1
MMRF_2329,Baseline,First line of therapy,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,1.3,mg/m^,,QD,,IV SubQ,,1,176,1
MMRF_2329,,First line of therapy,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,25,mg,,QD,,PO,,1,155,1
MMRF_2329,,First line of therapy,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,20,mg,,QD,,PO,,1,176,1
MMRF_2329,,First line of therapy,Maintenance,,Lenalidomide,,,,Other,dose escalation,5,mg,,Q d,,PO,,358,501,1
MMRF_2329,,First line of therapy,Maintenance,,Lenalidomide,,,,Other,whipple procedure and complications; dose held; pancreatic cancer treatment,10,mg,,Q d,,PO,,502,724,1
MMRF_2329,,Second Line Therapy (after,Induction,,Dexamethasone,,,Checked,,,20,mg,,Oth,"d2, d 9, d 16, d 23",PO,,1172,,1
MMRF_2329,,Second Line Therapy (after,Induction,,Lenalidomide,,,Checked,,,10,mg,,QD,,PO,,1172,,1
MMRF_2329,,First line of therapy,Maintenance,,Lenalidomide,,,,Disease progression/Relapse,,10,mg,,QD,,PO,,1016,1171,1
MMRF_2329,,Second Line Therapy (after,Induction,,Daratumumab,,,Checked,,,16,mg/m^,,Oth,"D1, D8, D15, D22",IV,,1172,,1
MMRF_2329,,Second Line Therapy (after,Induction,,Dexamethasone,,,Checked,,,20,mg,,Oth,"day 1, day 8, day 15, day 22",IV,,1172,,1
MMRF_1067,Baseline,First line of therapy,,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,112,1
MMRF_1067,,First line of therapy,,,Cyclophosphamide,,,,Completed regimen,,4380,mg,,Oth,Once,IV,,148,148,1
MMRF_1067,,First line of therapy,,,Melphalan,,,,Completed regimen,,250,mg,,Oth,Once,IV,,161,161,1
MMRF_1067,,First line of therapy,,,Cyclophosphamide,,,,Investigator decision for other reasons,,300,mg/m^,,Q w,,IV,,1,15,1
MMRF_1067,,First line of therapy,,,Dexamethasone,,,,Adverse Event or co-morbidity,,40,mg,,Oth,"Days 1, 2, 4, 5, 8, 9, 11, 12",PO,,1,12,1
MMRF_1067,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,12,mg,,Oth,Once,PO,,148,148,1
MMRF_1067,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,20,mg,,Q w,,PO,,53,113,1
MMRF_1067,,First line of therapy,,,Lenalidomide,,,,Completed regimen,,15,mg,,QD,,PO,,348,417,1
MMRF_1067,,First line of therapy,,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,Other,Subcutaneous,348,421,1
MMRF_1067,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1,2,4,5,8,9,11,12",PO,,348,419,1
MMRF_1067,,First line of therapy,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,10,mg,,QD,,PO,,545,718,1
MMRF_1067,,First line of therapy,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,5,mg,,QD,,PO,,718,865,1
MMRF_1067,,Second Line Therapy (after,Induction,,Daratumumab,,,Checked,,,1216,mg,,Q w,,IV,,1294,,1
MMRF_1067,,Second Line Therapy (after,Maintenance,,Bortezomib,,,Checked,,,1.3,mg/m^,,QD,,IV,,1427,,1
MMRF_1067,,Second Line Therapy (after,Maintenance,,Dexamethasone,,,Checked,,,40,mg,,Q w,,PO,,1369,,1
MMRF_1131,,First line of therapy,,,Dexamethasone,,,,Adverse Event or co-morbidity,,20,mg,,Oth,"8, 9, 11 and 12",PO,,8,12,1
MMRF_1131,,First line of therapy,,,Prednisone,,,,Completed regimen,,20,mg,,Oth,"1, 2, 4, 5, 8, 9, 11, 12",PO,,22,269,1
MMRF_1131,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,"1, 2, 4, 5",PO,,1,57,1
MMRF_1131,Baseline,First line of therapy,,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,Other,Subcutaneously,1,256,1
MMRF_1131,,First line of therapy,,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,22,345,1
MMRF_1131,,First line of therapy,,,Bortezomib,,,,Adverse Event or co-morbidity,,1,mg/m^,,Q w,,Other,Subcutaneous,100,114,1
MMRF_1131,,First line of therapy,,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,Oth,"DQ (D1, D7, D14)",Other,Subcutaneous,186,256,1
MMRF_1131,,First line of therapy,,,Lenalidomide,,,,Adverse Event or co-morbidity,,25,mg,,QD,,PO,,100,175,1
MMRF_1131,,First line of therapy,,,Lenalidomide,,,,Completed regimen,,15,mg,,QD,,PO,,179,269,1
MMRF_1131,,Second Line Therapy (after,Induction,,Prednisone,,,,Patient decision,,50,mg,,Q w,,PO,,312,333,1
MMRF_1131,,Second Line Therapy (after,Induction,,Pomalidomide,,,,Patient decision,,4,mg,,QD,,PO,,312,333,1
MMRF_1245,Baseline,First line of therapy,,,Bortezomib,,,,Completed regimen,,1.5,mg/m^,,Oth,"QD (D1, D8, D15, D22)",Other,Subcutaneous,1,239,1
MMRF_1245,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"QD ( D1, D8, D15, D22)",PO,,1,239,1
MMRF_1245,,First line of therapy,Maintenance,,Bortezomib,,,,Other,moved to Ohio,1.5,mg/m^,,Oth,once every 2 weeks,Other,Subcutaneous,250,295,1
MMRF_1412,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,40,mg,,Q w,,PO,,1,99,1
MMRF_1412,Baseline,First line of therapy,,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,Other,Subcutaneous,1,96,1
MMRF_1412,,First line of therapy,,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,99,1
MMRF_1412,,First line of therapy,Other,conditioning regimen,Melphalan,,,,Completed regimen,,410,mg,,Oth,once,IV,,147,147,1
MMRF_1412,,First line of therapy,Other,mobilization,Cyclophosphamide,,,,Completed regimen,,5176,mg,,Oth,once,IV,,134,134,1
MMRF_1412,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,5,mg,,QD,,PO,,323,,1
MMRF_1412,,First line of therapy,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,10,mg,,QD,,PO,,294,323,1
MMRF_1680,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.5,mg/m^,,Oth,"D1, D8, D15",Other,Subcutaneous,1,104,1
MMRF_1680,,First line of therapy,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,25,mg,,QD,,PO,,1,27,1
MMRF_1680,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Q w,,PO,,1,132,1
MMRF_1680,,First line of therapy,Other,conditioning regimen,Melphalan,,,,Completed regimen,,505,mg,,Oth,once,IV,,145,145,1
MMRF_1680,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,15,mg,,QD,,PO,,28,132,1
MMRF_1680,,First line of therapy,Other,mobilization,Cyclophosphamide,,,,Completed regimen,,6250,mg,,Oth,once,IV,,133,133,1
MMRF_2119,Baseline,First line of therapy,Induction,,Lenalidomide,,,,Other,strigent complete response,10,mg,,QD,,PO,,1,165,1
MMRF_2119,,First line of therapy,Induction,,Bortezomib,,,,Other,Strigent Complete Response,1.5,mg/m^,,Oth,"Day 1, 8, 15",Other,subcutane,1,165,1
MMRF_2119,,First line of therapy,Induction,,Dexamethasone,,,,Other,Strigent Complete Response,40,mg,,Oth,"Day 1, 8, 15, 22",PO,,1,165,1
MMRF_2119,,First line of therapy,Unknown,,Lenalidomide,,,,Investigator decision for other reasons,,10,mg,,QD,,PO,,191,530,1
MMRF_2119,,First line of therapy,Unknown,,Dexamethasone,,,,Investigator decision for other reasons,,20,mg,,Oth,Q Monday and Tuesday,PO,,191,530,1
MMRF_2119,,Second Line Therapy (after,Maintenance,,Ixazomib,,,,Disease progression/Relapse,,4,mg,,QD,,PO,,533,654,1
MMRF_2119,,Second Line Therapy (after,Unknown,,Dexamethasone,,,,Disease progression/Relapse,,20,mg,,QD,,PO,,533,652,1
MMRF_2119,,First line of therapy,Unknown,,Bortezomib,,,,Investigator decision for other reasons,,1.5,mg/m^,,QD,,IV,,422,530,1
MMRF_2119,,First line of therapy,Unknown,,Lenalidomide,,,,Investigator decision for other reasons,,10,mg,,QD,,PO,,422,530,1
MMRF_2119,,Third Line Therapy (followi,Unknown,,Cyclophosphamide,,,,Investigator decision for other reasons,,50,mg,,QD,,PO,,653,716,1
MMRF_2119,,Third Line Therapy (followi,Unknown,,Pomalidomide,,,,Investigator decision for other reasons,,4,mg,,QD,,PO,,736,785,1
MMRF_2119,,Third Line Therapy (followi,Unknown,,Dexamethasone,,,,Investigator decision for other reasons,,20,mg,,QD,,PO,,736,770,1
MMRF_2119,,Third Line Therapy (followi,Unknown,,Bortezomib,,,,Investigator decision for other reasons,,1.3,mg/m^,,QD,,IV,,653,716,1
MMRF_2119,,Third Line Therapy (followi,Unknown,,Dexamethasone,,,,Investigator decision for other reasons,,20,mg,,QD,,PO,,653,716,1
MMRF_2119,,Third Line Therapy (followi,Unknown,,Dexamethasone,,,,Completed regimen,,20,mg,,QD,,PO,,771,925,1
MMRF_2119,,Third Line Therapy (followi,Unknown,,Carfilzomib,,,,Completed regimen,,20,mg/m^,,QD,,IV,,771,857,1
MMRF_2213,,First line of therapy,Induction,,Dexamethasone,,,Checked,,,40,mg,,Q w,,PO,,1,,1
MMRF_2213,Baseline,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,"Days 1, 8, 15, 22",IV,,1,99,1
MMRF_2213,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.5,mg/m^,,Oth,"Days 1, 8, 15, 22",Other,Subcutaneous,1,99,1
MMRF_2213,,First line of therapy,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,5,mg,,Q d,,PO,,312,356,1
MMRF_2213,,First line of therapy,Induction,,Bortezomib,,,Checked,,,1.78,mg,,Oth,QOW,IV,,356,,1
MMRF_2476,,First line of therapy,Induction,,Lenalidomide,,,Checked,,,10,mg,,QD,,PO,,29,,1
MMRF_2476,Baseline,First line of therapy,Induction,,Dexamethasone,,,Checked,,,10,mg,,Oth,Q Wednesday and Thursday with breakfast,PO,,1,,1
MMRF_2549,Baseline,First line of therapy,Unknown,,Dexamethasone,,,,Lack of response,,20,mg,,Q d,,PO,,1,6,1
MMRF_2549,,First line of therapy,Unknown,,Dexamethasone,,,Checked,,,40,mg,,Oth,twice a week,PO,,39,,1
MMRF_2549,,First line of therapy,Unknown,,Bortezomib,,,Checked,,,3.08,mg,,Oth,bi-weekly,IV SubQ,,40,,1
MMRF_2549,,First line of therapy,Unknown,,Dexamethasone,,,,Lack of response,,40,mg,,Q w,,PO,,7,39,1
MMRF_1309,Baseline,First line of therapy,,,Lenalidomide,,,,Adverse Event or co-morbidity,,10,mg,,Q d,,PO,,1,3,1
MMRF_1309,,First line of therapy,,,Bortezomib,,,,Adverse Event or co-morbidity,,2.6,mg,,QWK,,IV SubQ,,34,97,1
MMRF_1309,,Second Line Therapy (after,Maintenance,,Bortezomib,,,Checked,,,2.5,mg,,Q w,,IV SubQ,,1663,,1
MMRF_1431,Baseline,First line of therapy,,,Lenalidomide,,,,Adverse Event or co-morbidity,,25,mg,,Q d,,PO,,1,1230,1
MMRF_1431,,First line of therapy,,,Dexamethasone,,,,Adverse Event or co-morbidity,,40,mg,,QD,,PO,,1,1230,1
MMRF_1431,,First line of therapy,Maintenance,,Bortezomib,,,,Adverse Event or co-morbidity,,2.6,mg,,Q w,,IV SubQ,,33,837,1
MMRF_2308,,First line of therapy,Induction,,Dexamethasone,,,Checked,,,20,mg,,QWK,,PO,,1,,1
MMRF_2308,Baseline,First line of therapy,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,25,mg,,QD,,PO,,1,12,1
MMRF_2308,,First line of therapy,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,25,mg,,Oth,QOD,PO,,13,42,1
MMRF_2308,,First line of therapy,Induction,,Lenalidomide,,,Checked,,,5,mg,,QD,,PO,,94,,1
MMRF_2308,,First line of therapy,Maintenance,,Bortezomib,,,Checked,,,1.8,mg,,Q w,,IV SubQ,,127,,1
MMRF_1077,Baseline,First line of therapy,,,Bortezomib,,,,Other,Cycle ended,1.3,mg/m^,,QD,,IVB,,1,11,1
MMRF_1077,,First line of therapy,,,Lenalidomide,,,,Other,Cycle ended,10,Other,mg,Oth,Daily,PO,,22,31,1
MMRF_1077,,First line of therapy,,,Dexamethasone,,,,Other,Cycle ended,40,mg,,QD,,PO,,1,11,1
MMRF_1077,,First line of therapy,,,Bortezomib,,,,Other,Cycle ended,1.3,mg/m^,,QD,,IVB,,43,71,1
MMRF_1077,,First line of therapy,,,Bortezomib,,,,Other,Cycle ended,1.3,mg/m^,,QD,,IVB,,22,32,1
MMRF_1077,,First line of therapy,,,Dexamethasone,,,,Other,Cycle ended,40,mg,,QD,,PO,,43,71,1
MMRF_1077,,First line of therapy,,,Lenalidomide,,,,Lack of response,,10,Other,mg,QD,,PO,,43,1903,1
MMRF_1077,,First line of therapy,,,Dexamethasone,,,,Other,Cycle ended,40,mg,,QD,,PO,,22,32,1
MMRF_1077,,First line of therapy,,,Cyclophosphamide,,,,Completed regimen,,3510,mg,,Q d,,IV,,205,205,1
MMRF_1077,,First line of therapy,Consolidation,,Bortezomib,,,,Completed regimen,,3,mg,,Q w,,IV SubQ,,245,259,1
MMRF_1077,,First line of therapy,Maintenance,,Dexamethasone,,,Checked,,,4,mg,,BID,,PO,,1429,,1
MMRF_1078,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"D1-2, D4-5, D8-9, D11-12",PO,,1,75,1
MMRF_1078,,First line of therapy,,,Lenalidomide,,,,Completed regimen,,25,Other,mg,QD,,PO,,1,77,1
MMRF_1078,Baseline,First line of therapy,,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,74,1
MMRF_1078,,First line of therapy,,,Melphalan,,,,Completed regimen,,406,mg,,Q d,,IV,,174,174,1
MMRF_1105,,First line of therapy,,,Lenalidomide,,,,Completed regimen,,25,Other,mg,QD,,PO,,1,295,1
MMRF_1105,Baseline,First line of therapy,,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,302,1
MMRF_1105,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,40,mg,,Q w,,PO,,1,339,1
MMRF_1105,,First line of therapy,,,Cyclophosphamide,,,,Completed regimen,,875,mg,,Oth,"Days 1, 8",IV,,169,302,1
MMRF_1105,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,10,mg,,Oth,everyday/no breaks,PO,,618,,1
MMRF_1136,Baseline,First line of therapy,,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV,,1,85,1
MMRF_1136,,First line of therapy,,,Dexamethasone,,,,Investigator decision for other reasons,,20,mg,,Oth,"D1-4, D8-11",PO,,1,23,1
MMRF_1136,,First line of therapy,,,Lenalidomide,,,,Completed regimen,,10,Other,mg,QD,,PO,,1,77,1
MMRF_1136,,First line of therapy,,,Dexamethasone,,,,Investigator decision for other reasons,,20,mg,,QD,,PO,,23,64,1
MMRF_1136,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,PO,,96,100,1
MMRF_1136,,First line of therapy,,,Other,Etoposide,,,Completed regimen,,60,mg,,QD,,IV,,127,131,1
MMRF_1136,,First line of therapy,,,Melphalan,,,,Completed regimen,,284,mg,,Q d,,IV,,205,205,1
MMRF_1136,,First line of therapy,Induction,,Carfilzomib,,,,Disease progression/Relapse,,15,mg/m^,,Q w,,IV,,309,309,1
MMRF_1136,,Second Line Therapy (after,,,Cyclophosphamide,,,,Disease progression/Relapse,,50,mg,,Q d,,PO,,366,372,1
MMRF_1136,,First line of therapy,,,Other,Cisplatin,,,Completed regimen,,10,mg,,QD,,IV,,96,100,1
MMRF_1136,,First line of therapy,,,Cyclophosphamide,,,,Completed regimen,,414,mg,,QD,,IV,,96,100,1
MMRF_1136,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,20,mg,,QD,,PO,,85,95,1
MMRF_1136,,First line of therapy,,,Other,Etoposide,,,Completed regimen,,41,mg,,QD,,IV,,96,100,1
MMRF_1136,,First line of therapy,,,Other,Cisplatin,,,Completed regimen,,8,mg,,QD,,IV,,127,131,1
MMRF_1136,,First line of therapy,,,Cyclophosphamide,,,,Completed regimen,,610,mg,,QD,,IV,,127,131,1
MMRF_1136,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,IV,,127,130,1
MMRF_1136,,First line of therapy,Induction,,Pomalidomide,,,,Disease progression/Relapse,,1,mg,,Q d,,PO,,342,360,1
MMRF_1136,,First line of therapy,,,Dexamethasone,,,,Investigator decision for other reasons,,20,mg,,Oth,"D1-4, D8-11",PO,,64,85,1
MMRF_1136,,First line of therapy,,,Cyclophosphamide,,,,Completed regimen,,6120,mg,,Q d,,IV,,170,170,1
MMRF_1136,,First line of therapy,Induction,,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,QD,,PO,,342,360,1
MMRF_1148,Baseline,First line of therapy,,,Bortezomib,,,,Other,Patient died,1.3,mg/m^,,QD,,IVB,,1,270,1
MMRF_1148,,First line of therapy,,,Dexamethasone,,,,Other,patient died,40,mg,,Q w,,PO,,6,270,1
MMRF_1148,,Second Line Therapy (after,Induction,,Carfilzomib,,,,Other,patient died,20,mg/m^,,QD,,IV,,227,270,1
MMRF_1148,,First line of therapy,,,Lenalidomide,,,,Lack of response,,10,Other,mg,QD,,PO,,6,227,1
MMRF_1189,Baseline,First line of therapy,,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IVB,,1,11,1
MMRF_1189,,Second Line Therapy (after,,,Lenalidomide,,,,Adverse Event or co-morbidity,,15,mg,,QD,,PO,,697,1271,1
MMRF_1189,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"QD (D8, D11)",PO,,8,11,1
MMRF_1189,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,PO,,1,4,1
MMRF_1214,,First line of therapy,,,Lenalidomide,,,,Lack of response,,5,mg,,Oth,"QD (D1, D3, D5, D8, D10, D12)",PO,,11,18,1
MMRF_1214,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"QD (D1-4, D9-12, D17-20)",PO,,39,162,1
MMRF_1214,Baseline,First line of therapy,,,Bortezomib,,,,Lack of response,,1.3,mg/m^,,QD,,IV SubQ,,1,151,1
MMRF_1214,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,4,mg,,QD,,IV,,39,303,1
MMRF_1214,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,530,mg,,Oth,Day 1,PO,,39,301,1
MMRF_1335,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"D1,2,4,5,8,9,11,12",PO,,1,352,1
MMRF_1335,Baseline,First line of therapy,,,Bortezomib,,,,Investigator decision for other reasons,,1.3,mg/m^,,QD,,IV,,1,81,1
MMRF_1335,,First line of therapy,,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,22,71,1
MMRF_1335,,Second Line Therapy (after,Induction,,Cyclophosphamide,,,,Completed regimen,,3420,mg,,Oth,Once,IV,,354,354,1
MMRF_1335,,Second Line Therapy (after,Maintenance,,Cyclophosphamide,,,,Completed regimen,,3740,mg,,Q d,,IV,,781,1311,1
MMRF_1335,,Second Line Therapy (after,Maintenance,,Cyclophosphamide,,,,Other,done in attempt to prolong patient survival,3740,mg,,Q d,,IV,,1311,1311,1
MMRF_1402,,First line of therapy,,,Lenalidomide,,,,Completed regimen,,25,mg,,Q d,,PO,,1,246,1
MMRF_1402,Baseline,First line of therapy,,,Dexamethasone,,,,Completed regimen,,40,mg,,Q d,,PO,,1,247,1
MMRF_1402,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,2.2,mg,,QD,,IV SubQ,,143,243,1
MMRF_1402,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,1.5,mg/m^,,Oth,Once,Other,Unknown,282,282,1
MMRF_1560,,First line of therapy,Induction,,Lenalidomide,,,,Patient decision,,25,mg,,QD,,PO,,1,5,1
MMRF_1560,Baseline,First line of therapy,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,3.1,mg,,QD,,IV,,1,25,1
MMRF_1560,,First line of therapy,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,40,mg,,QD,,PO,,1,22,1
MMRF_1560,,First line of therapy,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,25,mg,,QD,,PO,,3,5,1
MMRF_1560,,First line of therapy,Other,Re-induction,Dexamethasone,,,,Completed regimen,,20,mg,,QD,,PO,,186,264,1
MMRF_1560,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,20,mg/m^,,QD,,IV,,44,87,1
MMRF_1560,,First line of therapy,Other,Mobilization,Cyclophosphamide,,,,Completed regimen,,3000,mg/m^,,Oth,Once,Other,Unknown,291,291,1
MMRF_1560,,First line of therapy,Consolidation,,Melphalan,,,,Completed regimen,,200,mg/m^,,Oth,Once,IV,,325,325,1
MMRF_1560,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,QD,,PO,,22,87,1
MMRF_1579,,First line of therapy,Induction,,Dexamethasone,,,,Other,Unknown,20,mg,,Q w,,PO,,17,731,1
MMRF_1579,Baseline,First line of therapy,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,10,mg,,QD,,PO,,17,60,1
MMRF_1579,,First line of therapy,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,10,mg,,Q d,,PO,,1,105,1
MMRF_1579,,First line of therapy,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,5,mg,,Oth,QOD (1-21),PO,,105,123,1
MMRF_1613,,First line of therapy,Induction,,Dexamethasone,,,Checked,,,20,mg,,QD,,PO,,1,,1
MMRF_1613,Baseline,First line of therapy,Induction,,Bortezomib,,,,Other,"Risk for relapse.Does not want transplant, pursuing maintenance- Rev only.",2.86,mg,,QD,,IVB,,1,115,1
MMRF_1613,,Second Line Therapy (after,Maintenance,,Lenalidomide,,,Checked,,,10,mg,,QD,,PO,,466,,1
MMRF_1613,,First line of therapy,Unknown,,Lenalidomide,,,,Lack of response,,5,Other,"this started as 5mg/d ,increased to 10mg/d 2.9.15, inc to 15mg/d on 9.24.15",Oth,21/28d,PO,,393,796,1
MMRF_1613,,Fourth Line Therapy (follow,Unknown,,Elotuzumab,,,,Patient decision,,800,mg,,Oth,every 2 weeks,IV,,1258,1279,1
MMRF_1613,,Second Line Therapy (after,Unknown,,Dexamethasone,,,,Patient decision,,40,Other,"4.2. 10mgwkly, 9.24: 20mg wkly, 10.06.2017: 4mg bid,",Q w,,PO,,489,1279,1
MMRF_1613,,Third Line Therapy (followi,Unknown,,Daratumumab,,,,Patient decision,,1500,mg,,Oth,q wk except when held,IV,,796,1251,1
MMRF_1761,Baseline,First line of therapy,Induction,,Bortezomib,,,,Investigator decision for other reasons,,2.9,mg,,QD,,IV SubQ,,1,990,1
MMRF_1761,,First line of therapy,Unknown,,Lenalidomide,,,,Investigator decision for other reasons,,15,mg,,QID,,PO,,231,568,1
MMRF_1761,,First line of therapy,Maintenance,,Dexamethasone,,,,Investigator decision for other reasons,,20,mg,,BID,,IV,,231,260,1
MMRF_1890,Baseline,First line of therapy,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,2.4,mg,,QD,,IV,,1,100,1
MMRF_1890,,Second Line Therapy (after,Unknown,,Other,RT,,,Lack of response,,150,Other,cGy,Q d,,Other,radiation to liver,129,133,1
MMRF_1890,,Second Line Therapy (after,Unknown,,Dexamethasone,,,,Lack of response,,40,mg,,Oth,every day except for a break from 8.24-8.27.2014,PO,,119,133,1
MMRF_1890,,Second Line Therapy (after,Unknown,,Cyclophosphamide,,,,Completed regimen,,5880,mg,,Oth,once,IV,,121,121,1
MMRF_1890,,Second Line Therapy (after,Unknown,,Other,Mesna,,,Completed regimen,,1176,mg,,BID,,IV,,121,122,1
MMRF_2183,Baseline,First line of therapy,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,1.3,mg,,QD,,IV,,2,103,1
MMRF_2183,,First line of therapy,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,20,mg,,Q d,,PO,,1,103,1
MMRF_2183,,First line of therapy,Induction,,Lenalidomide,,,,Patient decision,,5,mg,,Oth,21/28d,PO,,121,336,1
MMRF_2246,Baseline,First line of therapy,Induction,,Lenalidomide,,,,Other,unknown,25,mg,,Q d,,PO,,23,219,1
MMRF_2246,,First line of therapy,Induction,,Dexamethasone,,,,Other,unknown,40,mg,,Q w,,PO,,1,158,1
MMRF_2477,Baseline,First line of therapy,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,40,mg,,Q d,,PO,,1,71,1
MMRF_2477,,First line of therapy,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,2.4,mg,,QD,,IV SubQ,,8,71,1
MMRF_2477,,First line of therapy,Unknown,,Lenalidomide,,,,Adverse Event or co-morbidity,,25,mg,,Q d,,PO,,40,57,1
MMRF_2477,,Second Line Therapy (after,Induction,,Ixazomib,,,,Adverse Event or co-morbidity,,3,mg,,Oth,"D1, 8, 15 of 28 d cycle",PO,,382,485,1
MMRF_1163,Baseline,First line of therapy,,,Bortezomib,,,,Disease progression/Relapse,,2.6,mg,,QD,,IV SubQ,,3,136,1
MMRF_1163,,First line of therapy,,,Lenalidomide,,,,Disease progression/Relapse,,25,mg,,Oth,qd x 14 days every 21 days,PO,,1,136,1
MMRF_1163,,First line of therapy,,,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,QWK,,PO,,3,136,1
MMRF_1163,,Second Line Therapy (after,,,Carfilzomib,,,Checked,,,40,mg,,QD,,IV,,150,,1
MMRF_1182,Baseline,First line of therapy,,,Bortezomib,,,,Other,Change in dosage,2.4,mg,,QD,,IV,,1,11,1
MMRF_1182,,First line of therapy,,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,234,1
MMRF_1182,,First line of therapy,,,Bortezomib,,,,Completed regimen,,2.5,mg,,QD,,IV,,25,234,1
MMRF_1182,,First line of therapy,Maintenance,,Lenalidomide,,,,Investigator decision for other reasons,,10,mg,,Q d,,PO,,264,433,1
MMRF_1182,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"QD (d1,d2, d4, d5, d8, d9, d11, d12",PO,,1,234,1
MMRF_1182,,First line of therapy,Maintenance,,Lenalidomide,,,,Patient decision,,5,mg,,Q d,,PO,,433,644,1
MMRF_1186,Baseline,First line of therapy,,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,234,1
MMRF_1186,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,"QD (d1-4, 9-12, 17-20)",PO,,1,215,1
MMRF_1186,,First line of therapy,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,10,mg,,Q d,,PO,,312,979,1
MMRF_1186,,Second Line Therapy (after,Unknown,,Lenalidomide,,,,Other,Patient death,10,mg,,Q d,,PO,,1264,1850,1
MMRF_1201,Baseline,First line of therapy,,,Bortezomib,,,,Other,Investigator change in frequency,2,mg/m^,,QD,,IV SubQ,,1,63,1
MMRF_1201,,First line of therapy,,,Lenalidomide,,,,Other,Investigator change in frequency,25,mg,,QD,,PO,,1,63,1
MMRF_1201,,First line of therapy,,,Bortezomib,,,,Completed regimen,,2,mg,,Q w,,IV SubQ,,71,148,1
MMRF_1201,,First line of therapy,,,Dexamethasone,,,,Other,Investigator changed dosage,40,mg,,QD,,PO,,1,31,1
MMRF_1201,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,20,mg,,Q w,,PO,,71,196,1
MMRF_1201,,First line of therapy,,,Dexamethasone,,,,Other,Investigator change in frequency,20,mg,,QD,,PO,,50,54,1
MMRF_1201,,First line of therapy,,,Lenalidomide,,,,Other,"dosage changed, subject on maintenance rev",25,mg,,QD,,PO,,71,148,1
MMRF_1201,,First line of therapy,Maintenance,,Lenalidomide,,,,Completed regimen,,10,mg,,Q d,,PO,,436,513,1
MMRF_1201,,Second Line Therapy (after,Maintenance,,Lenalidomide,,,,Disease progression/Relapse,,10,mg,,Q d,,PO,,643,789,1
MMRF_1201,,Second Line Therapy (after,Other,Salvage,Bortezomib,,,,Lack of response,,2.1,mg,,Q w,,IV SubQ,,790,923,1
MMRF_1201,,Second Line Therapy (after,Other,Salvage,Dexamethasone,,,,Lack of response,,40,mg,,Q w,,PO,,790,923,1
MMRF_1201,,Second Line Therapy (after,Other,Salvage,Cyclophosphamide,,,,Lack of response,,450,mg,,Q w,,PO,,790,923,1
MMRF_1201,,Third Line Therapy (followi,Induction,,Other,CB-5083,,,Lack of response,,200,mg,,QD,,PO,,1007,1034,1
MMRF_1201,,Fourth Line Therapy (follow,Consolidation,,Carfilzomib,,,,Disease progression/Relapse,,59,mg,,QD,,IV,,1034,1356,1
MMRF_1201,,Fourth Line Therapy (follow,Consolidation,,Lenalidomide,,,,Disease progression/Relapse,,15,mg,,QD,,PO,,1430,1729,1
MMRF_1201,,Fourth Line Therapy (follow,Consolidation,,Panobinostat,,,,Disease progression/Relapse,,20,mg,,Oth,"Days 1, 3, 5, 8, 10, 12, 15, 17, 19",PO,,1034,1356,1
MMRF_1201,,Fourth Line Therapy (follow,Consolidation,,Other,CC-90002,,,Lack of response,,116,mg,,Oth,"D 1, 15",IV,,1392,1422,1
MMRF_1201,,Fourth Line Therapy (follow,Consolidation,,Daratumumab,,,,Disease progression/Relapse,,16,mg/kg,,Q w,,IV,,1430,1728,1
MMRF_1201,,Fifth Line Therapy (followi,Unknown,,Bortezomib,,,,Lack of response,,1.3,mg/m^,,Q w,,IV SubQ,,1731,1773,1
MMRF_1201,,Fifth Line Therapy (followi,Unknown,,Dexamethasone,,,,Lack of response,,20,mg,,Q w,,PO,,1731,1773,1
MMRF_1201,,Fifth Line Therapy (followi,Unknown,,Other,Venetoclax,,,Lack of response,,600,mg,,Q d,,PO,,1731,1773,1
MMRF_1201,,Sixth Line Therapy (followi,Unknown,,Pomalidomide,,,Checked,,,2,mg,,QD,,PO,,1783,,1
MMRF_1201,,Sixth Line Therapy (followi,Unknown,,Cyclophosphamide,,,Checked,,,400,mg,,Oth,D 1-2,PO,,1783,,1
MMRF_1201,,Sixth Line Therapy (followi,Unknown,,Dexamethasone,,,Checked,,,20,mg,,Oth,"D 1, 8, 15, 22",PO,,1783,,1
MMRF_1202,Baseline,First line of therapy,,,Dexamethasone,,,,Completed regimen,,40,mg,,Q w,,PO,,1,484,1
MMRF_1202,,First line of therapy,,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,484,1
MMRF_1202,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.5,mg/m^,,Q w,,IV SubQ,,152,484,1
MMRF_1202,,Third Line Therapy (followi,Consolidation,,Carfilzomib,,,,Lack of response,,60,mg,,QD,,IV,,872,890,1
MMRF_1202,,Third Line Therapy (followi,Induction,,Dexamethasone,,,,Lack of response,,20,mg,,QD,,PO,,872,890,1
MMRF_1202,,Second Line Therapy (after,Induction,,Bortezomib,,,,Investigator decision for other reasons,,1.3,mg/m^,,Q w,,IV SubQ,,697,810,1
MMRF_1202,,Second Line Therapy (after,Induction,,Lenalidomide,,,,Investigator decision for other reasons,,25,mg,,QD,,PO,,697,810,1
MMRF_1202,,Second Line Therapy (after,Induction,,Dexamethasone,,,,Investigator decision for other reasons,,20,mg,,Oth,Twice Weekly,PO,,697,810,1
MMRF_1202,,First line of therapy,Other,ASCT,Melphalan,,,,Completed regimen,,0,Other,unk,Oth,unk,Other,unk,312,312,1
MMRF_1210,,First line of therapy,,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,123,1
MMRF_1210,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,PO,,1,246,1
MMRF_1210,Baseline,First line of therapy,,,Bortezomib,,,,Completed regimen,,2.9,mg,,Q w,,IV SubQ,,1,156,1
MMRF_1210,,First line of therapy,Maintenance,,Bortezomib,,,,Completed regimen,,2.9,mg,,QWK,,IV,,171,292,1
MMRF_1210,,Second Line Therapy (after,Consolidation,,Lenalidomide,,,,Completed regimen,,10,mg,,QD,,PO,,1324,1681,1
MMRF_1210,,Second Line Therapy (after,Consolidation,,Carfilzomib,,,,Completed regimen,,20,mg/m^,,QD,,IV,,1503,1681,1
MMRF_1293,,First line of therapy,,,Lenalidomide,,,,Other,Investigator changed dosage,25,mg,,QD,,PO,,1,21,1
MMRF_1293,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,40,mg,,Q w,,PO,,1,432,1
MMRF_1293,Baseline,First line of therapy,,,Bortezomib,,,,Completed regimen,,3,mg,,Q w,,IV SubQ,,1,432,1
MMRF_1293,,First line of therapy,,,Lenalidomide,,,,Completed regimen,,15,mg,,QD,,PO,,32,432,1
MMRF_1293,,Second Line Therapy (after,Induction,,Lenalidomide,,,,Lack of response,,10,mg,,QID,,PO,,916,1163,1
MMRF_1293,,Second Line Therapy (after,Induction,,Dexamethasone,,,,Lack of response,,12,mg,,Q w,,PO,,916,1163,1
MMRF_1293,,Third Line Therapy (followi,Induction,,Lenalidomide,,,Checked,,,25,mg,,QD,,PO,,1320,,1
MMRF_1293,,Third Line Therapy (followi,Induction,,Other,Atezolizumab,,Checked,,,1200,mg,,Oth,Once every 3 weeks,IV,,1320,,1
MMRF_1320,Baseline,First line of therapy,,,Bortezomib,,,,Completed regimen,,2.6,mg,,Q w,,IV,,2,336,1
MMRF_1320,,First line of therapy,,,Cyclophosphamide,,,,Completed regimen,,700,mg,,QD,,IV,,2,336,1
MMRF_1320,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,"D1-3, 8-11, 15-18",PO,,1,336,1
MMRF_1320,,First line of therapy,Induction,,Bortezomib,,,,Disease progression/Relapse,,3,mg,,Oth,Every other week,IV,,337,1073,1
MMRF_1320,,First line of therapy,Induction,,Lenalidomide,,,,Disease progression/Relapse,,15,mg,,QD,,PO,,337,1073,1
MMRF_1320,,Second Line Therapy (after,Induction,,Cyclophosphamide,,,Checked,,,300,mg/m^,,Oth,"Weekly, 3 out of  4 weeks",IV,,1139,,1
MMRF_1320,,Second Line Therapy (after,Induction,,Dexamethasone,,,Checked,,,10,mg,,QD,,IV,,1139,,1
MMRF_1320,,Second Line Therapy (after,Induction,,Carfilzomib,,,Checked,,,27,mg,,QD,,IV,,1139,,1
MMRF_1300,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,20,mg,,QD,,PO,,1,154,1
MMRF_1300,Baseline,First line of therapy,,,Lenalidomide,,,,Completed regimen,,15,mg,,QD,,PO,,1,154,1
MMRF_1300,,First line of therapy,,,Other,Bioxin (BiRD Regimen for a few month then RVD only),,,Completed regimen,,500,mg,,QID,,PO,,1,154,1
MMRF_1300,,First line of therapy,Induction,,Bortezomib,,,,Disease progression/Relapse,,1.3,mg/m^,,Oth,SQ wk,IV,,207,490,1
MMRF_1300,,First line of therapy,Maintenance,,Bortezomib,,,,Lack of response,,1.3,mg/m^,,Oth,SQ wk,IV,,154,207,1
MMRF_1300,,First line of therapy,Induction,,Dexamethasone,,,,Disease progression/Relapse,,20,mg,,Oth,SQ wk,PO,,207,490,1
MMRF_1300,,Second Line Therapy (after,Consolidation,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,Oth,every 7 (seven) days. 3 out of 4 weeks,IV SubQ,,490,727,1
MMRF_1300,,Second Line Therapy (after,Consolidation,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,490,727,1
MMRF_1300,,Second Line Therapy (after,Consolidation,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,every 7 (seven) days. 3 out of 4 weeks,PO,,490,727,1
MMRF_1300,,Third Line Therapy (followi,Induction,,Lenalidomide,,,,Lack of response,,15,mg,,QD,,PO,,910,1479,1
MMRF_1300,,Third Line Therapy (followi,Induction,,Bortezomib,,,,Lack of response,,1.3,mg/m^,,Oth,"QD (D1, 8 & 15)",IV SubQ,,910,1479,1
MMRF_1300,,Third Line Therapy (followi,Induction,,Dexamethasone,,,,Lack of response,,20,mg,,Oth,"QD (D1, 8 & 15)",PO,,910,1479,1
MMRF_1300,,Fourth Line Therapy (follow,Unknown,,Daratumumab,,,Checked,,,16,mg/kg,,Q w,,IV,,1484,,1
MMRF_1300,,Fourth Line Therapy (follow,Unknown,,Bortezomib,,,Checked,,,1.3,mg/m^,,Q w,,IV SubQ,,1492,,1
MMRF_1300,,Fourth Line Therapy (follow,Unknown,,Dexamethasone,,,Checked,,,20,mg,,Q w,,PO,,1484,,1
MMRF_1338,,First line of therapy,,,Lenalidomide,,,,Other,"Allergic reaction, rash changed to QOD instead",25,mg,,QD,,PO,,15,22,1
MMRF_1338,Baseline,First line of therapy,,,Dexamethasone,,,,Other,MD order,40,mg,,Q d,,PO,,1,4,1
MMRF_1338,,First line of therapy,,,Dexamethasone,,,,Other,MD order,40,mg,,Q d,,PO,,9,12,1
MMRF_1338,,First line of therapy,,,Lenalidomide,,,,Disease progression/Relapse,,25,mg,,Oth,QOD no break 14/28 days,PO,,22,852,1
MMRF_1338,,First line of therapy,,,Bortezomib,,,,Disease progression/Relapse,,1.3,mg,,Q w,,IV SubQ,,15,852,1
MMRF_1338,,First line of therapy,,,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,Q w,,PO,,15,852,1
MMRF_1375,Baseline,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,BID,,PO,,1,181,1
MMRF_1375,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Q d,,PO,,41,181,1
MMRF_1375,Month 3,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,2.8,mg/kg,,Q w,,IV SubQ,,21,181,1
MMRF_1375,,First line of therapy,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,10,mg,,Q d,,PO,,360,1583,1
MMRF_1490,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.6,mg/m^,,QWK,,IV SubQ,,1,325,1
MMRF_1490,,First line of therapy,Induction,,Dexamethasone,,,,Investigator decision for other reasons,,40,mg,,Q w,,PO,,1,7,1
MMRF_1490,Baseline,First line of therapy,Induction,,Lenalidomide,,,,Disease progression/Relapse,,25,mg,,QD,,PO,,1,483,1
MMRF_1490,,First line of therapy,Induction,,Dexamethasone,,,Checked,,,40,mg,,Q w,,PO,,15,,1
MMRF_1490,,Second Line Therapy (after,Induction,,Pomalidomide,,,Checked,,,4,mg,,QD,,PO,,514,,1
MMRF_1518,,First line of therapy,Induction,,Bortezomib,,,Checked,,,2.7,mg/m^,,QD,,IV SubQ,,1,,1
MMRF_1518,Baseline,First line of therapy,Induction,,Lenalidomide,,,,Disease progression/Relapse,,25,mg,,QD,,PO,,1,74,1
MMRF_1518,,First line of therapy,Induction,,Dexamethasone,,,,Other,Dose change,20,mg,,Oth,"D1,2, 4,5, 8,9, 11,12",PO,,1,98,1
MMRF_1518,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,730,mg,,Q d,,IV,,98,135,1
MMRF_1518,,Second Line Therapy (after,Consolidation,,Carfilzomib,,,,Other,Patient Death,20,mg,,Oth,QD 1 and 2 and then 27mg /m2,IV SubQ,,221,240,1
MMRF_1518,,First line of therapy,Induction,,Dexamethasone,,,,Other,Change in dose,40,mg,,Q d,,PO,,98,135,1
MMRF_1518,,First line of therapy,Consolidation,,Melphalan,,,,Completed regimen,,340,mg,,Q d,,IV,,155,158,1
MMRF_1518,,First line of therapy,Induction,,Doxorubicin,,,,Completed regimen,,20,mg,,Q d,,IV,,98,135,1
MMRF_1518,,Second Line Therapy (after,Consolidation,,Pomalidomide,,,,Other,Patient Death,4,mg,,QD,,PO,,221,240,1
MMRF_1518,,Second Line Therapy (after,Induction,,Dexamethasone,,,,Other,Patient Death,20,mg,,Oth,On days of Carfilzomib,PO,,221,240,1
MMRF_1772,,First line of therapy,Induction,,Bortezomib,,,,Disease progression/Relapse,,2.6,mg,,QD,,IV SubQ,,1,65,1
MMRF_1772,,First line of therapy,Induction,,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,Q w,,PO,,1,1157,1
MMRF_1772,Baseline,First line of therapy,Induction,,Lenalidomide,,,,Disease progression/Relapse,,25,mg,,Q d,,PO,,1,65,1
MMRF_1772,,First line of therapy,Induction,,Carfilzomib,,,,Disease progression/Relapse,,43,mg,,QD,,IV,,73,1157,1
MMRF_1772,,First line of therapy,Induction,,Cyclophosphamide,,,,Disease progression/Relapse,,650,mg,,Q d,,PO,,73,1157,1
MMRF_1772,,Second Line Therapy (after,Induction,,Ixazomib,,,Checked,,,4,mg,,Q w,,PO,,1256,,1
MMRF_1772,,Second Line Therapy (after,Induction,,Pomalidomide,,,Checked,,,2,mg,,QD,,PO,,1256,,1
MMRF_1772,,Second Line Therapy (after,Induction,,Dexamethasone,,,Checked,,,20,mg,,Q w,,PO,,1256,,1
MMRF_1952,Baseline,First line of therapy,Induction,,Bortezomib,,,,Patient decision,,2.7,mg/m^,,Q w,,IV SubQ,,1,309,1
MMRF_1952,,First line of therapy,Induction,,Cyclophosphamide,,,,Patient decision,,540,mg,,Q w,,IV SubQ,,1,309,1
MMRF_1952,,First line of therapy,Induction,,Dexamethasone,,,,Patient decision,,40,mg,,Q w,,PO,,1,309,1
MMRF_1952,,First line of therapy,Consolidation,,Lenalidomide,,,Checked,,,25,mg,,Oth,Every other day,PO,,320,,1
MMRF_1952,,First line of therapy,Consolidation,,Dexamethasone,,,Checked,,,8,mg,,Oth,"D 1, 7, 14",PO,,320,,1
MMRF_1983,Baseline,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,297,1
MMRF_1983,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Q w,,PO,,1,297,1
MMRF_1983,,Second Line Therapy (after,Unknown,,Daratumumab,,,Checked,,,16,mg/kg,,Oth,"weekly x8, then Q 2 weeks x8, then Q 4 weeks",IV,,1230,,1
MMRF_1983,,Second Line Therapy (after,Unknown,,Dexamethasone,,,Checked,,,20,mg,,Q w,,PO,,1230,,1
MMRF_1983,,Second Line Therapy (after,Unknown,,Lenalidomide,,,Checked,,,25,mg,,Oth,"Daily, days 1-21/28",PO,,1230,,1
MMRF_1991,Baseline,First line of therapy,Induction,,Lenalidomide,,,,Investigator decision for other reasons,,25,mg,,QD,,PO,,1,20,1
MMRF_1991,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,2.6,mg/m^,,QD,,IV,,1,9,1
MMRF_1991,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,PO,,1,9,1
MMRF_1991,,Second Line Therapy (after,Induction,,Pomalidomide,,,,Disease progression/Relapse,,2,mg,,QD,,PO,,516,822,1
MMRF_1991,,Second Line Therapy (after,Induction,,Carfilzomib,,,,Disease progression/Relapse,,20,mg/m^,,QD,,IV SubQ,,516,822,1
MMRF_1991,,Second Line Therapy (after,Induction,,Dexamethasone,,,,Disease progression/Relapse,,20,mg,,QD,,PO,,516,822,1
MMRF_1991,,Third Line Therapy (followi,Consolidation,,Daratumumab,,,Checked,,,16,mg/kg,,Q w,,IV,,876,,1
MMRF_1991,,Third Line Therapy (followi,Consolidation,,Cyclophosphamide,,,,Completed regimen,,350,mg/m^,,Oth,D 1-4,IV,,828,871,1
MMRF_1991,,Third Line Therapy (followi,Consolidation,,Other,Mesna,,,Disease progression/Relapse,,700,mg/m^,,QD,,IV,,828,871,1
MMRF_1991,,Third Line Therapy (followi,Consolidation,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,"D 1-4, 15-18",PO,,828,871,1
MMRF_1991,,Third Line Therapy (followi,Consolidation,,Carfilzomib,,,,Completed regimen,,27,mg/m^,,QD,,IV,,828,871,1
MMRF_1991,,Third Line Therapy (followi,Consolidation,,Pomalidomide,,,Checked,,,4,mg,,Q d,,PO,,876,,1
MMRF_2097,,First line of therapy,Induction,,Dexamethasone,,,Checked,,,20,mg,,QD,,PO,,7,,1
MMRF_2097,Baseline,First line of therapy,Induction,,Cyclophosphamide,,,,Lack of response,,600,mg,,Q w,,PO,,1,162,1
MMRF_2097,,First line of therapy,Induction,,Bortezomib,,,,Investigator decision for other reasons,,2.6,mg,,Q w,,IV SubQ,,7,311,1
MMRF_2097,,First line of therapy,Induction,,Lenalidomide,,,Checked,,,15,mg,,QD,,PO,,162,,1
MMRF_2097,,First line of therapy,Consolidation,,Melphalan,,,,Completed regimen,,200,mg/m^,,Oth,once,IV,,1360,1360,1
MMRF_2367,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,800,mg,,Oth,Weekly 3 out of 4 weeks,PO,,1,246,1
MMRF_2367,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,Weekly 3 out of 4 weeks,PO,,1,581,1
MMRF_2367,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,3,mg,,Oth,Weekly 3 out of 4 weeks,IV SubQ,,1,612,1
MMRF_2367,,Second Line Therapy (after,Induction,,Daratumumab,,,Checked,,,8,mg/kg,,Q w,,IV,,1109,,1
MMRF_2367,,Second Line Therapy (after,Induction,,Carfilzomib,,,Checked,,,20,mg/m^,,QD,,IV,,1109,,1
MMRF_2412,Baseline,First line of therapy,Induction,,Bortezomib,,,,Patient decision,,1.3,mg/m^,,Oth,Twice per week,IV SubQ,,1,130,1
MMRF_2412,,First line of therapy,Induction,,Cyclophosphamide,,,,Patient decision,,400,mg,,Q w,,PO,,1,130,1
MMRF_2412,,First line of therapy,Induction,,Dexamethasone,,,,Patient decision,,40,mg,,QD,,PO,,1,130,1
MMRF_2412,,Second Line Therapy (after,Unknown,,Other,Turmeric,,,Patient decision,,8,Other,gms,QID,,PO,,164,1004,1
MMRF_2412,,Second Line Therapy (after,Unknown,,Daratumumab,,,Checked,,,16,mg/kg,,Q w,,IV,,727,,1
MMRF_2433,,First line of therapy,Induction,,Dexamethasone,,,Checked,,,40,mg,,Q w,,PO,,1,,1
MMRF_2433,Baseline,First line of therapy,Induction,,Bortezomib,,,Checked,,,2.9,mg,,Q w,,IV SubQ,,1,,1
MMRF_2433,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,760,mg,,Q w,,IV,,1,153,1
MMRF_2433,,First line of therapy,Other,Autologous HCT,Melphalan,,,,Completed regimen,,200,mg/m^,,Oth,Once,IV,,248,248,1
MMRF_2458,,First line of therapy,Induction,,Dexamethasone,,,Checked,,,20,mg,,QD,,PO,,1,,1
MMRF_2458,,First line of therapy,Induction,,Bortezomib,,,Checked,,,1.5,mg/m^,,Oth,"D 1, 8, 15",IV SubQ,,1,,1
MMRF_2458,Baseline,First line of therapy,Induction,,Lenalidomide,,,Checked,,,25,mg,,QD,,PO,,1,,1
MMRF_1112,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,40,mg,,Q w,,PO,,1,190,1
MMRF_1112,Baseline,First line of therapy,,,Lenalidomide,,,,Completed regimen,,15,mg,,QD,,PO,,2,190,1
MMRF_1112,,First line of therapy,,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,Q w,,IV SubQ,,1,190,1
MMRF_1112,,First line of therapy,Maintenance,,Dexamethasone,,,Checked,,,20,mg,,Q w,,PO,,489,,1
MMRF_1112,,First line of therapy,Maintenance,,Lenalidomide,,,,Completed regimen,,10,mg,,QD,,PO,,489,685,1
MMRF_1112,,Second Line Therapy (after,Other,rel/refr,Other,Pembrolizumab,,,Disease progression/Relapse,,2,mg/kg,,Oth,Q3wk,IV,,1316,1358,1
MMRF_1112,,Third Line Therapy (followi,Other,rel/refr,Carfilzomib,,,Checked,,,92,mg,,Q w,,IV,,1385,,1
MMRF_1112,,Second Line Therapy (after,Other,rel/refr,Other,ACP-196,,,Disease progression/Relapse,,100,mg,,BID,,PO,,1316,1379,1
MMRF_1152,Baseline,First line of therapy,,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,Oth,"Day 1, 8, 15",IV SubQ,,1,192,1
MMRF_1152,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,"Day 1, 8, 15, 22",PO,,1,192,1
MMRF_1152,,First line of therapy,,,Lenalidomide,,,,Completed regimen,,15,mg,,QD,,PO,,108,192,1
MMRF_1152,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,15,mg,,QD,,PO,,304,,1
MMRF_1283,Baseline,First line of therapy,,,Lenalidomide,,,Checked,,,10,mg,,QD,,PO,,1,,1
MMRF_1283,,First line of therapy,Induction,,Dexamethasone,,,Checked,,,4,mg,,Q d,,PO,,1,,1
MMRF_1360,Baseline,First line of therapy,,,Lenalidomide,,,,Completed regimen,,15,mg,,QD,,PO,,1,389,1
MMRF_1360,,First line of therapy,Induction,,Bortezomib,,,,Other,"completed this piece, on maintenance dex/lenolidamide",1.3,mg/m^,,Q w,,IV SubQ,,1,176,1
MMRF_1360,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Q w,,PO,,1,399,1
MMRF_1484,Baseline,First line of therapy,Induction,,Bortezomib,,,Checked,,,1.3,mg,,Q w,,IV,,1,,1
MMRF_1484,,First line of therapy,Induction,,Dexamethasone,,,Checked,,,40,mg,,Q w,,PO,,1,,1
MMRF_1601,,First line of therapy,Induction,,Dexamethasone,,,,Investigator decision for other reasons,,40,mg,,Q w,,PO,,1,16,1
MMRF_1601,Baseline,First line of therapy,Induction,,Bortezomib,,,,Investigator decision for other reasons,,1.9,mg,,Q w,,IV SubQ,,1,16,1
MMRF_1641,Baseline,First line of therapy,Induction,,Bortezomib,,,,Disease progression/Relapse,,2.2,mg,,Oth,"D1, D8, D15 Q28D",IV SubQ,,1,146,1
MMRF_1641,,First line of therapy,Unknown,,Cyclophosphamide,,,,Completed regimen,,500,mg,,Oth,D1 D8 Q4wk cycle,IV,,34,145,1
MMRF_1641,,Third Line Therapy (followi,Unknown,,Carfilzomib,,,,Completed regimen,,70,mg/m^,,Oth,"D1,8,15 Q28D",IV,,211,470,1
MMRF_1641,,First line of therapy,Unknown,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,"D1,8, 15 Q28D",PO,,20,506,1
MMRF_2083,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,Q w,,IV SubQ,,1,321,1
MMRF_2083,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,15,mg,,QD,,PO,,1,321,1
MMRF_2083,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Q w,,PO,,1,321,1
MMRF_2083,,First line of therapy,Other,rel/ref,Carfilzomib,,,,Disease progression/Relapse,,105,mg,,Oth,"D1, D8, D15 - Q4W",IV,,476,630,1
MMRF_2083,,First line of therapy,Other,rel/refr,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,Oth,"D1, D8, D15, D22 - Q4Wk",PO,,476,630,1
MMRF_2083,,Third Line Therapy (followi,Other,rel/ref,Other,Methylprednisolone,,,Adverse Event or co-morbidity,,100,mg,,Oth,every other week,IV,,659,667,1
MMRF_2083,,Fourth Line Therapy (follow,Other,rel/ref,Other,Etoposide,,,Disease progression/Relapse,,82,mg,,QD,,IV,,682,722,1
MMRF_2083,,Fourth Line Therapy (follow,Other,rel/ref,Other,Cisplatin,,,Disease progression/Relapse,,20,mg,,QD,,IV,,682,722,1
MMRF_2083,,Fifth Line Therapy (followi,Other,rel/ref,Dexamethasone,,,,Patient decision,,20,mg,,Q w,,PO,,804,869,1
MMRF_2083,,Fifth Line Therapy (followi,Other,rel/ref,Elotuzumab,,,,Patient decision,,900,mg,,Oth,"QD (D1, D8, D15, D22)",IV,,804,869,1
MMRF_2083,,Third Line Therapy (followi,Other,rel/ref,Daratumumab,,,,Adverse Event or co-morbidity,,1600,mg,,Oth,Every 2 weeks,IV,,659,667,1
MMRF_2083,,Fourth Line Therapy (follow,Other,rel/ref,Doxorubicin,,,,Disease progression/Relapse,,82,mg,,QD,,IV,,682,722,1
MMRF_2083,,Fourth Line Therapy (follow,Other,rel/ref,Dexamethasone,,,,Adverse Event or co-morbidity,,40,mg,,QD,,PO,,682,683,1
MMRF_2083,,Fourth Line Therapy (follow,Other,rel/ref,Cyclophosphamide,,,,Disease progression/Relapse,,820,mg,,QD,,IV,,682,722,1
MMRF_2400,,First line of therapy,Induction,,Bortezomib,,,,Other,not specified if continuing as part of regimen at this time,1.3,mg/m^,,Q d,,IV SubQ,,14,14,1
MMRF_2400,Baseline,First line of therapy,Induction,,Lenalidomide,,,Checked,,,25,mg,,QD,,PO,,1,,1
MMRF_2400,,First line of therapy,Induction,,Dexamethasone,,,Checked,,,10,mg,,QWK,,PO,,1,,1
MMRF_2473,Baseline,First line of therapy,Induction,,Lenalidomide,,,Checked,,,15,mg,,QD,,PO,,1,,1
MMRF_2473,,First line of therapy,Induction,,Dexamethasone,,,Checked,,,10,mg,,Q d,,PO,,1,,1
MMRF_1310,Baseline,First line of therapy,,,Cyclophosphamide,,,,Completed regimen,,300,mg,,QWK,,IV,,1,148,1
MMRF_1310,,First line of therapy,,,Lenalidomide,,,,Other,decreased dose,25,mg,,QD,,PO,,1,182,1
MMRF_1310,,First line of therapy,,,Bortezomib,,,,Completed regimen,,1.5,mg/m^,,QWK,,IV,,1,148,1
MMRF_1310,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,20,mg,,QWK,,IV,,1,148,1
MMRF_1310,,First line of therapy,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,10,mg,,Q d,,PO,,183,211,1
MMRF_1310,,First line of therapy,Maintenance,,Lenalidomide,,,,Disease progression/Relapse,,5,mg,,Q d,,PO,,225,1751,1
MMRF_1407,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"D1-2, 4-5, 8-9 and 11-12",PO,,1,78,1
MMRF_1407,Baseline,First line of therapy,,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,78,1
MMRF_1407,,First line of therapy,,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,7,78,1
MMRF_1407,,First line of therapy,Consolidation,,Dexamethasone,,,,Completed regimen,,20,mg,,QWK,,PO,,201,271,1
MMRF_1407,,First line of therapy,Consolidation,,Bortezomib,,,,Completed regimen,,2.8,mg,,QWK,,IV SubQ,,201,271,1
MMRF_1407,,First line of therapy,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,10,mg,,Q d,,PO,,286,1021,1
MMRF_1407,,First line of therapy,Consolidation,,Lenalidomide,,,,Completed regimen,,10,mg,,QD,,PO,,201,277,1
MMRF_1424,,First line of therapy,,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,109,1
MMRF_1424,Baseline,First line of therapy,,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,95,1
MMRF_1424,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,20,mg,,QD,,PO,,1,95,1
MMRF_1424,,First line of therapy,Maintenance,,Bortezomib,,,,Completed regimen,,1.5,mg/m^,,Q w,,IV SubQ,,150,192,1
MMRF_1424,,First line of therapy,Maintenance,,Dexamethasone,,,,Completed regimen,,20,mg,,Q w,,PO,,150,192,1
MMRF_1424,,First line of therapy,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,10,mg,,Q d,,PO,,361,473,1
MMRF_1424,,First line of therapy,Other,MOBILIZATION,Cyclophosphamide,,,,Completed regimen,,3000,mg/m^,,Q d,,IV,,214,214,1
MMRF_1424,,First line of therapy,Other,CONIDITIONING,Melphalan,,,,Completed regimen,,100,mg/m^,,Q d,,IV,,247,248,1
MMRF_1424,,First line of therapy,Maintenance,,Lenalidomide,,,,Other,dose changed from 10mg qod to 5mg qd,10,mg,,Oth,every other day,PO,,586,676,1
MMRF_1424,,First line of therapy,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,5,mg,,Q d,,PO,,677,926,1
MMRF_1424,,First line of therapy,Maintenance,,Bortezomib,,,,Disease progression/Relapse,,1.3,mg/m^,,Q w,,IV SubQ,,981,1278,1
MMRF_1424,,Third Line Therapy (followi,Unknown,,Daratumumab,,,,Disease progression/Relapse,,16,mg/kg,,Oth,"D1, D8, D15 & D22 Q 28 Days x 7 Cycles",Other,IVPB,1516,1600,1
MMRF_1424,,Third Line Therapy (followi,Unknown,,Dexamethasone,,,,Disease progression/Relapse,,20,mg,,Oth,"D1, D8, D15 & D22 Q 28 Days",PO,,1516,1600,1
MMRF_1424,,Second Line Therapy (after,Consolidation,,Pomalidomide,,,,Disease progression/Relapse,,3,mg,,QD,,PO,,1376,1495,1
MMRF_1424,,Second Line Therapy (after,Consolidation,,Carfilzomib,,,,Disease progression/Relapse,,27,mg/m^,,QD,,IV,,1376,1377,1
MMRF_1424,,Second Line Therapy (after,Consolidation,,Carfilzomib,,,,Disease progression/Relapse,,56,mg/m^,,Q w,,IV,,1383,1495,1
MMRF_1424,,Fourth Line Therapy (follow,Other,Treatment until disease progression,Pomalidomide,,,Checked,,,3,mg,,QD,,PO,,1614,,1
MMRF_1424,,Fourth Line Therapy (follow,Other,Treatment until disease progression,Elotuzumab,,,Checked,,,800,mg,,QWK,,IVB,,1614,,1
MMRF_1424,,Fourth Line Therapy (follow,Other,Treatment until disease progression,Dexamethasone,,,Checked,,,28,mg,,QWK,,PO,,1614,,1
MMRF_1424,,Fourth Line Therapy (follow,Other,Treatment until disease progression,Dexamethasone,,,Checked,,,8,mg,,QWK,,IVB,,1614,,1
MMRF_1424,,Third Line Therapy (followi,Unknown,,Pomalidomide,,,,Disease progression/Relapse,,3,mg,,QD,,PO,,1516,1600,1
MMRF_1424,,Third Line Therapy (followi,Unknown,,Dexamethasone,,,,Other,Additional steroid to prevent infusion reaction. No longer required.,20,mg,,Oth,"D1, D8, D15 & D22 Q Cycle",IV,,1516,1517,1
MMRF_1556,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.5,mg/m^,,Q w,,IV,,1,113,1
MMRF_1556,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,300,mg,,Q w,,IV,,1,113,1
MMRF_1556,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Q w,,IV,,1,113,1
MMRF_1556,,Second Line Therapy (after,Consolidation,,Dexamethasone,,,,Lack of response,,20,mg,,Oth,WKLY,IV,,1212,1335,1
MMRF_1556,,Second Line Therapy (after,Consolidation,,Cyclophosphamide,,,,Lack of response,,300,mg/m^,,Oth,"D1, D8 & D15 Q28",IVB,,1212,1335,1
MMRF_1556,,Second Line Therapy (after,Consolidation,,Bortezomib,,,,Lack of response,,1.5,mg/m^,,Q w,,IV SubQ,,1212,1337,1
MMRF_1617,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.5,mg/m^,,Q w,,IV SubQ,,1,101,1
MMRF_1617,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,2,108,1
MMRF_1617,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Q w,,PO,,2,101,1
MMRF_1617,,First line of therapy,Other,conditioning,Melphalan,,,,Completed regimen,,120,mg,,Q d,,IV,,146,147,1
MMRF_1617,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,10,mg,,Q d,,PO,,251,,1
MMRF_1723,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,Q w,,IV SubQ,,1,267,1
MMRF_1723,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Q w,,PO,,1,267,1
MMRF_1723,,First line of therapy,Induction,,Lenalidomide,,,,Investigator decision for other reasons,,25,mg,,QD,,PO,,1,121,1
MMRF_1723,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,500,mg,,QWK,,PO,,128,267,1
MMRF_1723,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,10,mg,,Q d,,PO,,272,,1
MMRF_1723,,First line of therapy,Maintenance,,Dexamethasone,,,Checked,,,20,mg,,Oth,"D1, 8, 15 Q28days",PO,,272,,1
MMRF_1984,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,84,1
MMRF_1984,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.5,mg/m^,,QWK,,IV SubQ,,1,84,1
MMRF_1984,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,QWK,,PO,,1,84,1
MMRF_1984,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,10,mg,,Q d,,PO,,257,,1
MMRF_1107,,First line of therapy,,,Bortezomib,,,,Adverse Event or co-morbidity,,1.3,mg/m^,,Q w,,IV,,1,15,1
MMRF_1107,,First line of therapy,,,Bortezomib,,,,Adverse Event or co-morbidity,,1,mg/m^,,Q w,,IV,,15,93,1
MMRF_1107,Baseline,First line of therapy,,,Dexamethasone,,,,Adverse Event or co-morbidity,,12,mg,,QD,,IV,,1,94,1
MMRF_1227,Baseline,First line of therapy,,,Bortezomib,,,,Investigator decision for other reasons,,1.3,mg/m^,,Q w,,IV,,1,127,1
MMRF_1227,,First line of therapy,,,Dexamethasone,,,,Investigator decision for other reasons,,20,mg,,QD,,PO,,207,413,1
MMRF_1227,,First line of therapy,,,Pomalidomide,,,,Investigator decision for other reasons,,4,mg,,Q d,,PO,,207,257,1
MMRF_1227,,First line of therapy,,,Dexamethasone,,,,Disease progression/Relapse,,12,mg,,Oth,twice a week,IV,,65,206,1
MMRF_1227,,First line of therapy,,,Dexamethasone,,,,Other,change in frequency,12,mg,,Q w,,IV,,1,64,1
MMRF_1227,,First line of therapy,,,Lenalidomide,,,,Disease progression/Relapse,,25,mg,,Oth,"3 weeks on, 1 week off",PO,,73,206,1
MMRF_1227,,First line of therapy,Unknown,,Pomalidomide,,,,Patient decision,,2,mg,,Q d,,PO,,258,413,1
MMRF_1271,Baseline,First line of therapy,,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,269,1
MMRF_1271,,First line of therapy,,,Prednisone,,,,Other,Blood sugar become quite high (Side Effect),100,mg,,Q d,,PO,,1,12,1
MMRF_1271,,First line of therapy,,,Melphalan,,,,Adverse Event or co-morbidity,,18,mg,,Q d,,PO,,1,22,1
MMRF_1271,,First line of therapy,Maintenance,,Cyclophosphamide,,,,Investigator decision for other reasons,,500,mg,,Oth,Q3 wks,IV,,383,450,1
MMRF_1271,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,500,mg,,QWK,,IV,,39,269,1
MMRF_1271,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,QWK,,PO,,12,306,1
MMRF_1271,,First line of therapy,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,5,mg,,Oth,QOD,PO,,292,354,1
MMRF_1271,,First line of therapy,Maintenance,,Bortezomib,,,,Completed regimen,,2.5,mg,,Oth,Q 3 weks,IV,,383,1058,1
MMRF_1271,,First line of therapy,Maintenance,,Cyclophosphamide,,,,Investigator decision for other reasons,,1450,mg,,Oth,Q3 wks,IV,,471,542,1
MMRF_1271,,First line of therapy,Maintenance,,Cyclophosphamide,,,,Other,lowering dose to avoid long term problems w bone marrow on alkalating agent,1200,mg,,Oth,Q3 wks,IV,,569,980,1
MMRF_1271,,First line of therapy,Maintenance,,Cyclophosphamide,,,,Completed regimen,,500,mg,,Oth,Q 6weeks,IV,,981,1058,1
MMRF_1271,,First line of therapy,Maintenance,,Prednisone,,,,Adverse Event or co-morbidity,,50,mg,,Oth,days 1-2,PO,,1142,1204,1
MMRF_1271,,First line of therapy,Maintenance,,Melphalan,,,,Adverse Event or co-morbidity,,8,mg,,QD,,PO,,1142,1206,1
MMRF_1271,,First line of therapy,Induction,,Daratumumab,,,Checked,,,1270,mg,,QWK,,IV,,1262,,1
MMRF_1440,Baseline,First line of therapy,,,Bortezomib,,,,Completed regimen,,2.2,mg,,QD,,IV SubQ,,1,149,1
MMRF_1440,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,149,1
MMRF_1440,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,10,mg,,Oth,Q21days  -off 7days q28days,PO,,192,,1
MMRF_1440,,Second Line Therapy (after,Maintenance,,Bortezomib,,,,Completed regimen,,2.2,mg,,Q w,,IVB,,568,799,1
MMRF_1440,,Second Line Therapy (after,Induction,,Dexamethasone,,,,Completed regimen,,10,mg,,Q w,,IVB,,568,680,1
MMRF_1440,,Second Line Therapy (after,Maintenance,,Dexamethasone,,,Checked,,,12,mg,,Q w,,PO,,708,,1
MMRF_1687,Baseline,First line of therapy,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,15,mg,,Q d,,PO,,1,114,1
MMRF_1687,,First line of therapy,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,20,mg,,QWK,,PO,,1,114,1
MMRF_1687,,First line of therapy,Induction,,Bortezomib,,,,Other,pt became to ill,2.1,mg,,QD,,IV,,146,177,1
MMRF_1929,Baseline,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,450,mg,,Oth,"DAy 1, 8, 15 and 22",PO,,1,85,1
MMRF_1929,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,2.2,mg,,Oth,"Days 1,8,15 and 22",IV SubQ,,1,85,1
MMRF_1929,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,"Days 1-4, 9-12 and 17-20",PO,,1,85,1
MMRF_1929,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,5,mg,,QD,,PO,,238,,1
MMRF_2132,Baseline,First line of therapy,Induction,,Bortezomib,,,,Other,pt in rehab,2.7,mg,,QD,,IV SubQ,,1,134,1
MMRF_2132,,First line of therapy,Induction,,Dexamethasone,,,,Other,pt in rehab,40,mg,,Oth,"1-4,9-12",PO,,1,134,1
MMRF_2455,,First line of therapy,Induction,,Lenalidomide,,,,Investigator decision for other reasons,,25,mg,,QD,,PO,,1,255,1
MMRF_2455,,First line of therapy,Induction,,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,QD,,PO,,1,255,1
MMRF_2455,Baseline,First line of therapy,Induction,,Bortezomib,,,,Other,death,2.6,mg,,QD,,IV SubQ,,1,257,1
MMRF_1388,Baseline,First line of therapy,,,Bortezomib,,,,Patient decision,,2.1,mg,,QD,,Other,Sub - Q,1,383,1
MMRF_2598,,First line of therapy,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,15,mg,,QD,,PO,,10,42,1
MMRF_2598,Baseline,First line of therapy,Induction,,Dexamethasone,,,Checked,,,40,mg,,Q w,,PO,,1,,1
MMRF_2598,,First line of therapy,Induction,,Lenalidomide,,,Checked,,,5,mg,,QD,,PO,,100,,1
MMRF_1170,,First line of therapy,,,Dexamethasone,,,,Patient decision,,40,mg,,BID,,PO,,1,161,1
MMRF_1170,Baseline,First line of therapy,,,Bortezomib,,,,Patient decision,,2.6,mg,,QD,,IV,,1,169,1
MMRF_1346,Baseline,First line of therapy,,,Bortezomib,,,,Adverse Event or co-morbidity,,1.9,mg,,QD,,IV SubQ,,1,62,1
MMRF_1439,Baseline,First line of therapy,,,Bortezomib,,,,Other,patient did not show to the clinic. lost to follow up,2.6,mg,,QD,,IV,,1,51,1
MMRF_1108,Baseline,First line of therapy,,,Lenalidomide,,,,Adverse Event or co-morbidity,,25,Other,mg,QD,,PO,,4,40,1
MMRF_1108,,First line of therapy,,,Dexamethasone,,,,Investigator decision for other reasons,,40,mg,,Oth,"D1,D8,D15,D22",PO,,1,44,1
MMRF_1108,,First line of therapy,,,Dexamethasone,,,,Other,partial response,10,mg,,Oth,"Day 1, and D 15",IV,,4,40,1
MMRF_1108,,First line of therapy,,,Bortezomib,,,,Other,partial response,1.6,mg,,Oth,"D1, and D8",IV SubQ,,40,194,1
MMRF_1108,,First line of therapy,,,Lenalidomide,,,,Adverse Event or co-morbidity,,10,mg,,QD,,PO,,4,40,1
MMRF_1108,,Second Line Therapy (after,Other,post induction,Bortezomib,,,,Other,biochemical progression,2.2,mg,,Oth,"D1, D8 and D21",Other,sub Q,1048,1174,1
MMRF_1108,,Second Line Therapy (after,Other,post induction,Dexamethasone,,,,Other,biochemical progression,20,mg,,Oth,"D1, D8 every 21 days",IV,,1048,1174,1
MMRF_1108,,Second Line Therapy (after,Other,post induction,Bortezomib,,,,Adverse Event or co-morbidity,,2.2,mg,,Oth,"every 21 days C1, D15",Other,sub-Q,1188,1314,1
MMRF_1108,,Second Line Therapy (after,Other,post induction,Dexamethasone,,,,Adverse Event or co-morbidity,,20,mg,,Oth,"every 21 days D1 , D15",IV,,1188,1314,1
MMRF_1108,,Second Line Therapy (after,Other,post induction,Bortezomib,,,,Other,switched to a higher dose,1.6,mg,,Oth,"C1, D8",Other,Sub-Q,306,1034,1
MMRF_1108,,Second Line Therapy (after,Other,post induction,Dexamethasone,,,,Other,switched to a higher dose,10,mg,,Oth,"D1, D15 every 21 days",IV,,306,1034,1
MMRF_1108,,Third Line Therapy (followi,Other,progressive disease,Ixazomib,,,,Other,until next treatment,3,mg,,Oth,every one PO every Wednesday for 3 weeks,PO,,1433,1433,1
MMRF_1108,,Third Line Therapy (followi,Other,post induction,Dexamethasone,,,,Other,until next treatment,12,mg,,Oth,once a week with oral chemo,PO,,1433,1433,1
MMRF_1108,,Second Line Therapy (after,Other,post induction,Pomalidomide,,,,Investigator decision for other reasons,,2,mg,,Oth,Days 21 and 28,PO,,1083,1230,1
MMRF_1113,Baseline,First line of therapy,,,Lenalidomide,,,,Disease progression/Relapse,,25,Other,mg,QD,,PO,,1,94,1
MMRF_1113,,First line of therapy,,,Bortezomib,,,,Disease progression/Relapse,,2.3,Other,mg,Oth,D1 and D8 onof 21 D cycle,IV SubQ,,1,94,1
MMRF_1113,,First line of therapy,Maintenance,,Bortezomib,,,,Investigator decision for other reasons,,2.2,mg,,Oth,days 1 and 15,IV SubQ,,437,591,1
MMRF_1113,,First line of therapy,,,Dexamethasone,,,,Disease progression/Relapse,,20,mg,,Q w,,IV,,1,94,1
MMRF_1113,,First line of therapy,Unknown,,Carfilzomib,,,,Investigator decision for other reasons,,35,mg,,Oth,weekly 2 days a week,IV,,107,114,1
MMRF_1113,,Second Line Therapy (after,Maintenance,,Bortezomib,,,,Lack of response,,1.4,mg,,QD,,IV SubQ,,990,1130,1
MMRF_1113,,Second Line Therapy (after,Maintenance,,Thalidomide,,,,Adverse Event or co-morbidity,,100,mg,,Q d,,PO,,842,870,1
MMRF_1113,,Second Line Therapy (after,Maintenance,,Thalidomide,,,,Investigator decision for other reasons,,200,mg,,BID,,PO,,119,162,1
MMRF_1113,,Second Line Therapy (after,Maintenance,,Thalidomide,,,,Investigator decision for other reasons,,100,mg,,Q d,,PO,,59,119,1
MMRF_1113,,Second Line Therapy (after,Maintenance,,Thalidomide,,,,Adverse Event or co-morbidity,,200,mg,,Oth,Every Other Day,PO,,167,245,1
MMRF_1113,,Second Line Therapy (after,Maintenance,,Thalidomide,,,,Adverse Event or co-morbidity,,100,mg,,Q d,,PO,,404,434,1
MMRF_1113,,Second Line Therapy (after,Maintenance,,Thalidomide,,,,Adverse Event or co-morbidity,,50,mg,,Q d,,PO,,434,814,1
MMRF_1164,Baseline,First line of therapy,,,Lenalidomide,,,,Lack of response,,25,mg,,Q d,,PO,,1,280,1
MMRF_1164,,First line of therapy,,,Dexamethasone,,,,Other,Death,40,mg,,Q w,,PO,,1,372,1
MMRF_1164,,First line of therapy,Maintenance,,Bortezomib,,,,Other,Death,24,mg,,QWK,,IV,,280,372,1
MMRF_1169,Baseline,First line of therapy,,,Lenalidomide,,,,Adverse Event or co-morbidity,,25,mg,,QD,,PO,,1,121,1
MMRF_1169,,First line of therapy,,,Bortezomib,,,,Other,disease progression,2.1,mg,,Oth,every 21 days,IV SubQ,,121,139,1
MMRF_1169,,First line of therapy,,,Dexamethasone,,,,Other,disease progression,40,mg,,QD,,PO,,1,139,1
MMRF_1312,,First line of therapy,,,Dexamethasone,,,,Other,preperation for transplant,40,mg,,Oth,"Day 1, 8, 15, and 22",PO,,1,150,1
MMRF_1312,,First line of therapy,,,Lenalidomide,,,,Other,preparation for transplant,25,mg,,QD,,PO,,1,150,1
MMRF_1312,Baseline,First line of therapy,,,Bortezomib,,,,Other,preparation for transplant,2.8,mg,,QD,,IV SubQ,,1,150,1
MMRF_1312,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,10,mg,,Q d,,PO,,341,,1
MMRF_1796,Baseline,First line of therapy,Induction,,Lenalidomide,,,,Investigator decision for other reasons,,25,mg,,Q d,,PO,,1,63,1
MMRF_1796,,First line of therapy,Induction,,Dexamethasone,,,,Investigator decision for other reasons,,10,mg,,QWK,,PO,,1,63,1
MMRF_1796,,First line of therapy,Unknown,,Bortezomib,,,,Adverse Event or co-morbidity,,2.1,mg,,QD,,IV,,66,1161,1
MMRF_1796,,First line of therapy,Unknown,,Dexamethasone,,,Checked,,,40,mg,,Q w,,PO,,66,,1
MMRF_2186,Baseline,First line of therapy,Induction,,Bortezomib,,,Checked,,,3.3,mg,,QD,,IV SubQ,,1,,1
MMRF_2186,,First line of therapy,Induction,,Dexamethasone,,,Checked,,,20,mg,,QD,,PO,,2,,1
MMRF_2186,,First line of therapy,Induction,,Lenalidomide,,,Checked,,,10,mg,,QID,,PO,,41,,1
MMRF_2545,,First line of therapy,Induction,,Bortezomib,,,Checked,,,1.3,mg/m^,,QD,,IV SubQ,,1,,1
MMRF_2545,Baseline,First line of therapy,Induction,,Dexamethasone,,,Checked,,,10,mg,,QD,,IV,,1,,1
MMRF_1239,Baseline,First line of therapy,,,Lenalidomide,,,,Investigator decision for other reasons,,25,mg,,QD,,PO,,1,742,1
MMRF_1239,,First line of therapy,,,Dexamethasone,,,,Adverse Event or co-morbidity,,40,mg,,QWK,,PO,,12,176,1
MMRF_1436,,First line of therapy,,,Dexamethasone,,,Checked,,,40,mg,,Q d,,PO,,1,,1
MMRF_1436,Baseline,First line of therapy,,,Lenalidomide,,,,Investigator decision for other reasons,,25,mg,,Q d,,PO,,1,323,1
MMRF_1436,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,10,mg,,QD,,PO,,323,,1
MMRF_2595,Baseline,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,92,1
MMRF_2595,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,20 MG by mouth on day of and day after velcade therapy,PO,,1,92,1
MMRF_2595,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,75,1
MMRF_2595,,First line of therapy,Maintenance,,Bortezomib,,,,Disease progression/Relapse,,1.3,mg/m^,,Oth,every other week,Other,SQ,260,344,1
MMRF_2595,,Second Line Therapy (after,Induction,,Dexamethasone,,,Checked,,,40,mg,,Q w,,PO,,505,,1
MMRF_2595,,Second Line Therapy (after,Induction,,Lenalidomide,,,Checked,,,25,mg,,QD,,PO,,498,,1
MMRF_2595,,Second Line Therapy (after,Maintenance,,Pomalidomide,,,,Adverse Event or co-morbidity,,4,mg,,QD,,PO,,360,451,1
MMRF_2595,,Second Line Therapy (after,Induction,,Daratumumab,,,,Adverse Event or co-morbidity,,16,mg/kg,,Oth,QW(for weeks 1-8); Q2W(for weeks 9-24); Q4W(there after until Progression),IV,,501,788,1
MMRF_1273,Baseline,First line of therapy,,,Bortezomib,,,,Other,death,2.9,mg,,Q w,,Other,SQ,1,113,1
MMRF_1273,,First line of therapy,,,Cyclophosphamide,,,,Other,death,600,mg,,Q w,,PO,,1,113,1
MMRF_1109,,First line of therapy,,,Bortezomib,,,,Other,Death,2.6,mg,,QD,,IV,,1,117,1
MMRF_1109,Baseline,First line of therapy,,,Dexamethasone,,,,Other,Death,8,mg,,Oth,"8mg PO, once a week on monday, before treatment",PO,,1,117,1
MMRF_1117,Baseline,First line of therapy,,,Bortezomib,,,,Adverse Event or co-morbidity,,1.3,mg/m^,,QD,,IV,,1,74,1
MMRF_1117,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,"day 1,2,4,5,8,9,11,12",PO,,1,106,1
MMRF_1117,,First line of therapy,,,Lenalidomide,,,,Lack of response,,5,mg,,QD,,PO,,321,340,1
MMRF_1117,,Second Line Therapy (after,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,15,mg,,QD,,PO,,395,736,1
MMRF_1117,,First line of therapy,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,1.1,mg/m^,,QD,,IV SubQ,,85,95,1
MMRF_1117,,Second Line Therapy (after,Induction,,Lenalidomide,,,,Other,per MD kappa light chains continue to show increase slowly,10,mg,,QD,,PO,,341,394,1
MMRF_1117,,Third Line Therapy (followi,Maintenance,,Lenalidomide,,,,Disease progression/Relapse,,15,mg,,QD,,PO,,737,924,1
MMRF_1117,,Fourth Line Therapy (follow,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,925,1193,1
MMRF_1117,,Fifth Line Therapy (followi,Induction,,Pomalidomide,,,,Investigator decision for other reasons,,4,mg,,Oth,21 days on 7 days off,PO,,1062,1312,1
MMRF_1146,Baseline,First line of therapy,,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,167,1
MMRF_1146,,First line of therapy,,,Melphalan,,,,Other,preparative regimen for transplant,214,mg,,Q d,,IV,,198,199,1
MMRF_1146,,First line of therapy,Maintenance,,Lenalidomide,,,,Disease progression/Relapse,,10,mg,,Q d,,PO,,319,1194,1
MMRF_1146,,Second Line Therapy (after,Induction,,Bortezomib,,,Checked,,,3.3,mg,,Q w,,IV SubQ,,1201,,1
MMRF_1146,,First line of therapy,,,Dexamethasone,,,,Investigator decision for other reasons,,4,mg,,Oth,10 tabs a week,PO,,9,184,1
MMRF_1184,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,"days 1,8,15,22",PO,,1,199,1
MMRF_1184,Baseline,First line of therapy,,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,161,1
MMRF_1184,,First line of therapy,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,10,mg,,Q d,,PO,,295,546,1
MMRF_1184,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,5,mg,,Q d,,PO,,547,,1
MMRF_1250,Baseline,First line of therapy,,,Lenalidomide,,,,Investigator decision for other reasons,,25,mg,,QD,,PO,,1,33,1
MMRF_1250,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,"Days 1,8,15 & 22",PO,,1,298,1
MMRF_1250,,First line of therapy,,,Lenalidomide,,,,Completed regimen,,15,mg,,QD,,PO,,33,298,1
MMRF_1250,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,10,mg,,Q d,,PO,,337,,1
MMRF_1261,Baseline,First line of therapy,,,Cyclophosphamide,,,,Completed regimen,,300,mg,,Q w,,PO,,1,106,1
MMRF_1261,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,PO,,1,202,1
MMRF_1261,,First line of therapy,,,Bortezomib,,,,Completed regimen,,1.5,mg/m^,,Q w,,IV SubQ,,1,232,1
MMRF_1261,,First line of therapy,Maintenance,,Bortezomib,,,,Disease progression/Relapse,,2.5,mg,,Oth,Q14days,IV SubQ,,364,615,1
MMRF_1261,,First line of therapy,Maintenance,,Lenalidomide,,,,Disease progression/Relapse,,10,mg,,QD,,PO,,351,615,1
MMRF_1261,,Second Line Therapy (after,Induction,,Carfilzomib,,,,Disease progression/Relapse,,33,mg,,Oth,"Days 1, 8, 15",IV,,638,757,1
MMRF_1261,,Third Line Therapy (followi,Induction,,Other,investigational product,,,Disease progression/Relapse,,45,mg,,BID,,PO,,793,909,1
MMRF_1261,,Fourth Line Therapy (follow,Induction,,Pomalidomide,,,,Disease progression/Relapse,,4,mg,,Q d,,PO,,932,1060,1
MMRF_1261,,Fourth Line Therapy (follow,Induction,,Dexamethasone,,,,Disease progression/Relapse,,20,mg,,Oth,"Days 1-2, 8-9, 15-16, 22-23",PO,,932,1060,1
MMRF_1261,,Fourth Line Therapy (follow,Induction,,Other,Investigational Product,,,Disease progression/Relapse,,1,Other,tablet,Oth,"Days 1-2, 8-9, 15-16, 22-23",PO,,932,1060,1
MMRF_1261,,Fifth Line Therapy (followi,Induction,,Other,Investigational Product,,,Disease progression/Relapse,,110,mg,,Oth,Q21D,IV,,1077,1098,1
MMRF_1261,,Fifth Line Therapy (followi,Induction,,Other,Investigational Product,,,Disease progression/Relapse,,100,mg,,BID,,PO,,1077,1098,1
MMRF_1260,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,"days 1-4,9-12,17-20 on cycles 1 &2",PO,,1,106,1
MMRF_1260,,First line of therapy,,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,"days 1,8,15,22",PO,,1,106,1
MMRF_1260,Baseline,First line of therapy,,,Bortezomib,,,,Completed regimen,,2.5,mg,,Q w,,IV,,1,106,1
MMRF_1260,,First line of therapy,Maintenance,,Bortezomib,,,,Disease progression/Relapse,,2.5,mg,,Oth,Q2weeks,Other,sub-Q,142,1038,1
MMRF_1260,,First line of therapy,Maintenance,,Dexamethasone,,,,Investigator decision for other reasons,,40,mg,,Oth,"Days 1, 8, 15, 22",PO,,142,226,1
MMRF_1295,Baseline,First line of therapy,,,Bortezomib,,,,Investigator decision for other reasons,,1.3,mg/m^,,Q w,,IV SubQ,,2,381,1
MMRF_1295,,First line of therapy,,,Cyclophosphamide,,,,Investigator decision for other reasons,,500,mg,,Oth,"Day 1, Day 8, Day 15 and Day 22",PO,,37,282,1
MMRF_1295,,First line of therapy,,,Dexamethasone,,,,Investigator decision for other reasons,,20,mg,,QD,,PO,,1,282,1
MMRF_1295,,First line of therapy,Induction,,Bortezomib,,,,Investigator decision for other reasons,,1.5,mg/m^,,QWK,,IV SubQ,,23,262,1
MMRF_1295,,First line of therapy,Maintenance,,Dexamethasone,,,Checked,,,20,mg,,Oth,every monday,PO,,418,,1
MMRF_1295,,First line of therapy,Maintenance,,Lenalidomide,,,,Other,unknown at this time,10,mg,,QD,,PO,,418,1376,1
MMRF_1344,Baseline,First line of therapy,,,Bortezomib,,,,Other,dose changed due to grade 1 neuropathy,1.5,mg/m^,,QWK,,IV SubQ,,1,100,1
MMRF_1344,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,40,mg,,QWK,,PO,,1,106,1
MMRF_1344,,First line of therapy,,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,QWK,,PO,,1,106,1
MMRF_1344,,First line of therapy,Other,Mobilization for Stem Cell Transplant,Melphalan,,,,Completed regimen,,200,mg/m^,,Oth,once,IV,,169,169,1
MMRF_1344,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1,mg/m^,,QWK,,IV SubQ,,106,106,1
MMRF_1344,,First line of therapy,Maintenance,,Dexamethasone,,,Checked,,,20,mg,,QWK,,PO,,361,,1
MMRF_1344,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,10,mg,,Q d,,PO,,361,,1
MMRF_1453,,First line of therapy,,,Bortezomib,,,,Completed regimen,,1.5,mg/m^,,Q w,,IV SubQ,,1,106,1
MMRF_1453,Baseline,First line of therapy,,,Cyclophosphamide,,,,Completed regimen,,700,mg,,Oth,"Days 1,8,15,22",PO,,1,106,1
MMRF_1453,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,"days 1-4, 9-12, 17-20",PO,,1,106,1
MMRF_1453,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,10,mg,,Q d,,PO,,236,,1
MMRF_1538,Baseline,First line of therapy,Induction,,Bortezomib,,,,Other,review of bone marrow biopsy showed no evidence of disease,3.1,mg,,QD,,IV SubQ,,1,944,1
MMRF_1538,,First line of therapy,Induction,,Lenalidomide,,,Checked,,,25,mg,,QD,,PO,,1,,1
MMRF_1538,,First line of therapy,Induction,,Dexamethasone,,,Checked,,,20,mg,,Oth,"QD (D1, D2, D4, D5, D8, D9, D11, D12)",PO,,1,,1
MMRF_1588,,First line of therapy,Induction,,Bortezomib,,,,Other,Prep for bone marrow transplant,3.5,mg,,Q w,,IV SubQ,,1,161,1
MMRF_1588,,First line of therapy,Induction,,Dexamethasone,,,,Other,Prep for bone marrow transplant,40,mg,,Oth,"QD (D1-4, D9-12, D17-20)",PO,,1,161,1
MMRF_1588,Baseline,First line of therapy,Induction,,Cyclophosphamide,,,,Other,Prep for bone marrow transplant,700,mg,,Oth,"QD (D1, D8, D15, D22)",PO,,1,161,1
MMRF_1588,,First line of therapy,Other,transplant,Melphalan,,,,Completed regimen,,200,mg/m^,,Oth,once,IV,,205,205,1
MMRF_1596,Baseline,First line of therapy,Induction,,Lenalidomide,,,,Disease progression/Relapse,,25,mg,,QD,,PO,,1,186,1
MMRF_1596,,First line of therapy,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,1.5,mg/m^,,QWK,,IV SubQ,,1,8,1
MMRF_1596,,First line of therapy,Induction,,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,QWK,,PO,,1,186,1
MMRF_1596,,First line of therapy,Induction,,Bortezomib,,,,Disease progression/Relapse,,1.3,mg/m^,,QWK,,IV SubQ,,15,186,1
MMRF_1596,,Third Line Therapy (followi,Induction,,Other,Etoposide,,,Lack of response,,40,mg/m^,,QD,,IV,,284,310,1
MMRF_1596,,Second Line Therapy (after,Induction,,Cyclophosphamide,,,,Disease progression/Relapse,,400,mg,,QWK,,PO,,200,249,1
MMRF_1596,,Third Line Therapy (followi,Induction,,Doxorubicin,,,,Lack of response,,9,mg/m^,,QD,,IV,,284,310,1
MMRF_1596,,Fourth Line Therapy (follow,Induction,,Carfilzomib,,,,Completed regimen,,20,mg/m^,,QD,,IV,,327,343,1
MMRF_1596,,Fourth Line Therapy (follow,Induction,,Carfilzomib,,,,Adverse Event or co-morbidity,,27,mg/m^,,QD,,IV,,356,364,1
MMRF_1596,,Fourth Line Therapy (follow,Induction,,Pomalidomide,,,,Adverse Event or co-morbidity,,4,mg,,QD,,PO,,327,364,1
MMRF_1596,,Fourth Line Therapy (follow,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,20,mg,,QD,,IV,,327,364,1
MMRF_1596,,Second Line Therapy (after,Induction,,Bortezomib,,,,Disease progression/Relapse,,1.5,mg/m^,,QWK,,IV SubQ,,200,249,1
MMRF_1596,,Second Line Therapy (after,Induction,,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,QWK,,PO,,200,249,1
MMRF_1596,,Third Line Therapy (followi,Induction,,Other,Cisplatin,,,Lack of response,,10,mg/m^,,QD,,IV,,284,310,1
MMRF_1596,,Third Line Therapy (followi,Induction,,Cyclophosphamide,,,,Lack of response,,1000,mg,,QD,,IV,,284,310,1
MMRF_1596,,Third Line Therapy (followi,Induction,,Dexamethasone,,,,Lack of response,,40,mg,,QD,,PO,,284,310,1
MMRF_1740,Baseline,First line of therapy,Induction,,Lenalidomide,,,Checked,,,25,mg,,Q d,,PO,,1,,1
MMRF_1740,,First line of therapy,Induction,,Dexamethasone,,,Checked,,,12,mg,,QWK,,PO,,9,,1
MMRF_1740,,Second Line Therapy (after,Unknown,,Bortezomib,,,Checked,,,1.3,mg/m^,,QD,,IV SubQ,,715,,1
MMRF_1794,,First line of therapy,Induction,,Bortezomib,,,Checked,,,1.5,mg/m^,,QWK,,IV SubQ,,1,,1
MMRF_1794,Baseline,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,240,mg/m^,,QWK,,PO,,1,239,1
MMRF_1794,,First line of therapy,Induction,,Dexamethasone,,,Checked,,,40,mg,,QWK,,PO,,1,,1
MMRF_1932,Baseline,First line of therapy,Induction,,Lenalidomide,,,,Other,prep for bone marrow transplant,25,mg,,QD,,PO,,1,164,1
MMRF_1932,,First line of therapy,Induction,,Dexamethasone,,,,Other,prep for bone marrow transplant,10,mg,,Oth,"Days 1,8,15 and 22",PO,,1,164,1
MMRF_1932,,First line of therapy,Other,preparation,Melphalan,,,,Other,stem cell,200,mg/m^,,Oth,once,IV,,184,184,1
MMRF_1932,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,10,mg,,Q d,,PO,,325,,1
MMRF_1980,Baseline,First line of therapy,Induction,,Lenalidomide,,,Checked,,,25,mg,,QD,,PO,,1,,1
MMRF_1980,,First line of therapy,Induction,,Dexamethasone,,,Checked,,,10,mg,,Oth,"D1, 8, 15, 22",PO,,1,,1
MMRF_2173,Baseline,First line of therapy,Induction,,Dexamethasone,,,Checked,,,40,mg,,QD,,PO,,1,,1
MMRF_2173,,First line of therapy,Induction,,Bortezomib,,,,Other,due to toxicity,2,mg,,Oth,"D1, 8, 15 , 22",IV,,15,762,1
MMRF_2173,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,400,mg,,Oth,"Days 1, 8, 15, 22",PO,,15,380,1
MMRF_2220,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Q w,,PO,,1,106,1
MMRF_2220,,First line of therapy,Induction,,Dexamethasone,,,Checked,,,40,mg,,Oth,"D1-4, 9-12, 17-20",PO,,1,,1
MMRF_2220,Baseline,First line of therapy,Induction,,Bortezomib,,,Checked,,,2.8,mg,,Oth,"D1, 8, 15, 22",Other,SubQ,1,,1
MMRF_2587,Baseline,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,5000,mg,,Oth,"days 1, 8, 15, 22",PO,,1,104,1
MMRF_2587,,First line of therapy,Induction,,Dexamethasone,,,Checked,,,40,mg,,Oth,"1-4, 9-12, 17-20",PO,,1,,1
MMRF_2587,,First line of therapy,Induction,,Bortezomib,,,Checked,,,2.5,mg,,Oth,"days 1, 8, 15, 22",Other,sub Q,1,,1
MMRF_2587,,First line of therapy,Other,High Dose followed by stem cell transplant,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,134,138,1
MMRF_1216,Baseline,First line of therapy,,,Bortezomib,,,,Completed regimen,,1.7,mg,,QD,,IV SubQ,,1,116,1
MMRF_1216,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,PO,,43,1023,1
MMRF_1216,,First line of therapy,,,Dexamethasone,,,,Other,different frequency,40,mg,,Oth,day 1-4 then days 9-12,PO,,1,33,1
MMRF_1216,,First line of therapy,,,Bortezomib,,,,Disease progression/Relapse,,2.3,mg,,Oth,"D1,8,15 and 22 q42days",IV SubQ,,141,1023,1
MMRF_1216,,Third Line Therapy (followi,Induction,,Carfilzomib,,,,Disease progression/Relapse,,20,mg/m^,,QD,,IV,,1207,1345,1
MMRF_1216,,Third Line Therapy (followi,Induction,,Dexamethasone,,,,Disease progression/Relapse,,4,mg,,QD,,IV,,1207,1345,1
MMRF_1216,,Second Line Therapy (after,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,25,mg,,Q d,,PO,,1024,1108,1
MMRF_1216,,Second Line Therapy (after,Induction,,Dexamethasone,,,,Completed regimen,,4,mg,,Q d,,PO,,1024,1108,1
MMRF_1228,,First line of therapy,,,Doxorubicin,,,,Disease progression/Relapse,,70,mg,,Oth,q3 weeks,IV,,1,1366,1
MMRF_1228,Baseline,First line of therapy,,,Bortezomib,,,,Disease progression/Relapse,,3,mg,,QD,,IV,,1,1366,1
MMRF_1228,,Second Line Therapy (after,Induction,,Daratumumab,,,,Disease progression/Relapse,,16,mg/m^,,Q w,,IV,,1218,1366,1
MMRF_1228,,First line of therapy,Induction,,Dexamethasone,,,,Disease progression/Relapse,,20,mg,,Q w,,PO,,103,1366,1
MMRF_1228,,First line of therapy,Induction,,Cyclophosphamide,,,,Lack of response,,300,mg/m^,,QD,,IV,,916,1098,1
MMRF_1296,Baseline,First line of therapy,,,Lenalidomide,,,,Adverse Event or co-morbidity,,25,mg,,QD,,PO,,1,197,1
MMRF_1296,,First line of therapy,,,Dexamethasone,,,,Adverse Event or co-morbidity,,40,mg,,Q w,,PO,,1,256,1
MMRF_1296,,First line of therapy,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,15,mg,,QD,,PO,,198,256,1
MMRF_1364,Baseline,First line of therapy,,,Lenalidomide,,,,Lack of response,,25,mg,,Q d,,PO,,1,83,1
MMRF_1364,,First line of therapy,Unknown,,Dexamethasone,,,Checked,,,40,mg,,Q w,,PO,,1,,1
MMRF_1364,,First line of therapy,Induction,,Bortezomib,,,Checked,,,2.8,mg,,Q w,,IV,,1,,1
MMRF_1364,,First line of therapy,Other,mobilization for transplant,Cyclophosphamide,,,Checked,,,4,Other,g/m^2,Q w,,IV,,172,,1
MMRF_1531,Baseline,First line of therapy,Unknown,,Bortezomib,,,,Other,Death,1.5,mg/m^,,QWK,,IV SubQ,,1,520,1
MMRF_1531,,First line of therapy,Unknown,,Dexamethasone,,,,Other,death,40,mg,,Q w,,PO,,1,520,1
MMRF_1531,,First line of therapy,Unknown,,Cyclophosphamide,,,,Other,death,300,mg/m^,,Q w,,PO,,1,520,1
MMRF_1659,Baseline,First line of therapy,Induction,,Bortezomib,,,,Disease progression/Relapse,,2.6,mg,,QD,,IV,,21,323,1
MMRF_1659,,First line of therapy,Induction,,Lenalidomide,,,,Disease progression/Relapse,,25,mg,,Q d,,PO,,7,323,1
MMRF_1659,,First line of therapy,Induction,,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,QWK,,PO,,1,323,1
MMRF_1659,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,42,mg,,Oth,"D1-4, 8 , 9, 15, 16",IVB,,420,463,1
MMRF_1659,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,10,mg,,Oth,"D1-4, 8 , 9, 15, 16",PO,,420,589,1
MMRF_1659,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,4,mg,,Oth,"D1-4, 8 , 9, 15, 16",IV,,420,589,1
MMRF_1659,,Second Line Therapy (after,Induction,,Melphalan,,,Checked,,,200,mg,,QD,,IV,,679,,1
MMRF_1659,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,200,mg,,Q d,,IV,,505,506,1
MMRF_1659,,First line of therapy,Induction,,Carfilzomib,,,,Disease progression/Relapse,,41,mg,,QD,,IV,,331,416,1
MMRF_1691,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,3.3,mg,,QD,,IV,,1,78,1
MMRF_1691,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,300,mg,,Q w,,PO,,1,147,1
MMRF_1691,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Q w,,PO,,1,487,1
MMRF_1691,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,300,mg,,Q d,,IV,,600,600,1
MMRF_1691,,First line of therapy,Induction,,Lenalidomide,,,Checked,,,25,mg,,Q d,,PO,,118,,1
MMRF_1803,,First line of therapy,Induction,,Dexamethasone,,,Checked,,,40,mg,,Q w,,PO,,1,,1
MMRF_1803,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,600,mg,,Q d,,PO,,1,182,1
MMRF_1803,Baseline,First line of therapy,Induction,,Bortezomib,,,Checked,,,3,mg,,QD,,IV SubQ,,1,,1
MMRF_1810,,First line of therapy,Induction,,Dexamethasone,,,,Investigator decision for other reasons,,40,mg,,Q d,,PO,,1,8,1
MMRF_1810,Baseline,First line of therapy,Induction,,Lenalidomide,,,,Disease progression/Relapse,,25,mg,,Q d,,PO,,1,994,1
MMRF_1810,,First line of therapy,Induction,,Bortezomib,,,,Disease progression/Relapse,,2.7,mg,,QD,,IV SubQ,,23,999,1
MMRF_1810,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,191,mg,,Q d,,IV,,159,160,1
MMRF_1810,,First line of therapy,Induction,,Dexamethasone,,,,Investigator decision for other reasons,,20,mg,,Oth,"D1, 2, 4, 5, 8, 9, 11, 12",PO,,20,196,1
MMRF_1810,,Second Line Therapy (after,Induction,,Dexamethasone,,,Checked,,,4,mg,,Oth,"D1, D8, D15, D22",PO,,1090,,1
MMRF_1810,,Second Line Therapy (after,Induction,,Lenalidomide,,,Checked,,,10,mg,,QD,,PO,,1090,,1
MMRF_1810,,First line of therapy,Induction,,Dexamethasone,,,,Investigator decision for other reasons,,4,mg,,Oth,Once every other week,PO,,261,642,1
MMRF_1810,,Second Line Therapy (after,Induction,,Elotuzumab,,,Checked,,,10,mg/kg,,QWK,,IV,,1090,,1
MMRF_1810,,Second Line Therapy (after,Induction,,Dexamethasone,,,Checked,,,8,mg,,Oth,D1-8-15-22,IV,,1090,,1
MMRF_1810,,First line of therapy,Induction,,Dexamethasone,,,,Investigator decision for other reasons,,4,mg,,Q w,,PO,,936,1055,1
MMRF_1810,,Third Line Therapy (followi,Induction,,Bortezomib,,,Checked,,,2.6,mg,,Oth,"D1, D15",IV SubQ,,1258,,1
MMRF_1831,Baseline,First line of therapy,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,2.8,mg,,QD,,IV,,1,80,1
MMRF_1831,,First line of therapy,Induction,,Liposomal doxorubicin,,,,Adverse Event or co-morbidity,,64,mg,,Oth,every 3 weeks,IV,,2,80,1
MMRF_1831,,First line of therapy,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,40,mg,,QD,,IV,,1,80,1
MMRF_1831,,First line of therapy,Induction,,Dexamethasone,,,Checked,,,40,mg,,QD,,IV,,114,,1
MMRF_1831,,First line of therapy,Induction,,Bortezomib,,,Checked,,,2.6,mg,,QD,,IV SubQ,,204,,1
MMRF_1917,Baseline,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Q d,,PO,,1,315,1
MMRF_1917,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Q d,,PO,,1,315,1
MMRF_1917,,Second Line Therapy (after,Induction,,Lenalidomide,,,Checked,,,25,mg,,Q d,,PO,,715,,1
MMRF_1917,,First line of therapy,Maintenance,,Lenalidomide,,,,Completed regimen,,15,mg,,Q d,,PO,,329,389,1
MMRF_1917,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,20,mg/m^,,Oth,"D1,2,8,9,15,16",IV,,16,303,1
MMRF_1917,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,93,mg,,QD,,IV,,44,142,1
MMRF_2290,Baseline,First line of therapy,Induction,,Dexamethasone,,,,Other,Death,20,mg,,Q d,,PO,,1,139,1
MMRF_2290,,First line of therapy,Induction,,Lenalidomide,,,,Other,Death,25,mg,,Q d,,PO,,14,139,1
MMRF_2461,Baseline,First line of therapy,Induction,,Bortezomib,,,,Disease progression/Relapse,,1.7,mg,,Q w,,IV SubQ,,1,491,1
MMRF_2461,,First line of therapy,Induction,,Dexamethasone,,,,Disease progression/Relapse,,4,mg,,QD,,PO,,1,504,1
MMRF_2461,,Second Line Therapy (after,Induction,,Ixazomib,,,,Patient decision,,3,mg,,Q w,,PO,,505,767,1
MMRF_2461,,Second Line Therapy (after,Induction,,Lenalidomide,,,,Patient decision,,10,mg,,Q d,,PO,,505,767,1
MMRF_2461,,Second Line Therapy (after,Induction,,Dexamethasone,,,,Patient decision,,20,mg,,Q w,,PO,,505,767,1
MMRF_1254,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,PO,,1,211,1
MMRF_1254,Baseline,First line of therapy,,,Bortezomib,,,,Disease progression/Relapse,,2.4,mg,,Oth,"D1, 8, 15, 22",IV,,1,267,1
MMRF_1254,,Second Line Therapy (after,Consolidation,,Lenalidomide,,,,Adverse Event or co-morbidity,,15,mg,,QD,,PO,,283,967,1
MMRF_1254,,Third Line Therapy (followi,Induction,,Pomalidomide,,,,Adverse Event or co-morbidity,,3,mg,,Q d,,PO,,1386,1451,1
MMRF_1254,,Third Line Therapy (followi,Maintenance,,Pomalidomide,,,,Patient decision,,2,mg,,Q d,,PO,,1451,1719,1
MMRF_1348,,First line of therapy,,,Dexamethasone,,,Checked,,,40,mg,,QD,,PO,,1,,1
MMRF_1348,Baseline,First line of therapy,,,Bortezomib,,,Checked,,,3.4,mg,,Oth,"Days 1,8, 15 & 22",IV SubQ,,1,,1
MMRF_1371,Baseline,First line of therapy,,,Bortezomib,,,,Lack of response,,1.3,mg/m^,,QWK,,IV,,1,57,1
MMRF_1371,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QWK,,PO,,71,250,1
MMRF_1371,,First line of therapy,Consolidation,,Cyclophosphamide,,,,Completed regimen,,1500,mg,,Oth,once,IV,,264,264,1
MMRF_1371,,First line of therapy,Maintenance,,Lenalidomide,,,,Other,changed dose,10,mg,,Q d,,PO,,404,819,1
MMRF_1371,,First line of therapy,Maintenance,,Lenalidomide,,,,Other,change dose,10,mg,,Oth,QD (D1-5),PO,,819,911,1
MMRF_1371,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,10,mg,,QD,,PO,,911,,1
MMRF_1371,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,QD,,IVB,,1,264,1
MMRF_1377,Baseline,First line of therapy,,,Cyclophosphamide,,,,Completed regimen,,500,mg,,QWK,,PO,,1,143,1
MMRF_1377,,First line of therapy,,,Bortezomib,,,,Completed regimen,,3.5,mg,,QWK,,Other,SQ,1,134,1
MMRF_1377,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,40,mg,,QWK,,PO,,1,143,1
MMRF_1377,,First line of therapy,Other,autologous blood stem cell mobilization,Cyclophosphamide,,,,Completed regimen,,3000,mg,,Oth,once,IV,,165,165,1
MMRF_1377,,Second Line Therapy (after,Induction,,Lenalidomide,,,,Other,changing dose,10,mg,,Q d,,PO,,753,984,1
MMRF_1377,,Second Line Therapy (after,Induction,,Dexamethasone,,,,Other,changed dose,20,mg,,Q w,,PO,,753,1026,1
MMRF_1377,,Second Line Therapy (after,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,15,mg,,Oth,QOD days 1-21,PO,,984,1257,1
MMRF_1377,,Second Line Therapy (after,Maintenance,,Lenalidomide,,,Checked,,,5,mg,,QD,,PO,,1267,,1
MMRF_1703,Baseline,First line of therapy,Induction,,Cyclophosphamide,,,,Lack of response,,500,mg,,Q w,,PO,,1,164,1
MMRF_1703,,First line of therapy,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,3.1,mg,,Q w,,IV SubQ,,1,164,1
MMRF_1703,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Q w,,PO,,1,563,1
MMRF_1703,,First line of therapy,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,20,mg,,QD,,PO,,164,1318,1
MMRF_1703,,Second Line Therapy (after,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,1.7,mg,,Q w,,IV SubQ,,612,773,1
MMRF_1703,,Second Line Therapy (after,Maintenance,,Dexamethasone,,,,Adverse Event or co-morbidity,,4,mg,,Oth,take 10 tablets per week (40mg per wk),PO,,606,1318,1
MMRF_1703,,First line of therapy,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,2.7,mg,,Q w,,IV SubQ,,164,185,1
MMRF_1703,,First line of therapy,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,2.1,mg,,Q w,,IV SubQ,,185,598,1
MMRF_2166,,First line of therapy,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,15,mg,,QD,,PO,,17,28,1
MMRF_2166,Baseline,First line of therapy,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,4,mg,,TID,,PO,,1,12,1
MMRF_2324,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,Q w,,IV SubQ,,1,98,1
MMRF_2324,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,20,mg,,QD,,PO,,1,126,1
MMRF_2324,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Q w,,PO,,1,126,1
MMRF_2324,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,10,mg,,QD,,PO,,275,,1
MMRF_2326,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,15,mg,,QD,,PO,,2,106,1
MMRF_2326,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Q w,,PO,,2,203,1
MMRF_2326,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,Q w,,IV SubQ,,1,99,1
MMRF_2326,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,10,mg,,QD,,PO,,281,,1
MMRF_1090,,First line of therapy,,,Cyclophosphamide,,,,Adverse Event or co-morbidity,,250,mg/m^,,Oth,DAy 1 and Day 8 q 35 days,IV,,1,73,1
MMRF_1090,,First line of therapy,,,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,QWK,,IV,,134,432,1
MMRF_1090,Baseline,First line of therapy,,,Bortezomib,,,,Adverse Event or co-morbidity,,2.4,Other,mg,QD,,IV SubQ,,1,94,1
MMRF_1090,,First line of therapy,,,Thalidomide,,,,Investigator decision for other reasons,,100,Other,mg,Q d,,PO,,1,127,1
MMRF_1090,,First line of therapy,Maintenance,,Bortezomib,,,,Disease progression/Relapse,,1.3,mg,,QWK,,IV SubQ,,134,432,1
MMRF_1090,,Second Line Therapy (after,Maintenance,,Bendamustine,,,,Other,Patient Deceased,90,mg,,Oth,(D1& 2 q 28 d),IV,,435,681,1
MMRF_1090,,Second Line Therapy (after,Maintenance,,Other,Rituxan,,,Other,patient deceased,375,mg,,Oth,D1,IV,,435,681,1
MMRF_1122,,First line of therapy,,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,d1-14 q 21 d,PO,,64,123,1
MMRF_1122,Baseline,First line of therapy,,,Bortezomib,,,,Completed regimen,,2.63,mg,,QD,,IV SubQ,,1,123,1
MMRF_1122,,First line of therapy,Maintenance,,Dexamethasone,,,,Completed regimen,,4,mg,,TID,,PO,,1,123,1
MMRF_1122,,Third Line Therapy (followi,Other,new treatment for disease progression,Bortezomib,,,,Other,Patient died,2.67,mg,,QD,,IV SubQ,,666,697,1
MMRF_1122,,Second Line Therapy (after,Maintenance,,Lenalidomide,,,,Other,Patient to receive transplant,25,mg,,Q d,,PO,,176,229,1
MMRF_1122,,Third Line Therapy (followi,Other,new treatment for disease progression,Dexamethasone,,,,Other,patient died,20,mg,,Q w,,PO,,666,697,1
MMRF_1386,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,45,mg/m^,,QD,,IV,,8,176,1
MMRF_1386,Baseline,First line of therapy,,,Carfilzomib,,,,Other,"Per protocol, 20 mg/m^2 only for C1D1 and C1D2",20,mg/m^,,Oth,"QD (C1D1, C1D2)",IV,,1,2,1
MMRF_1386,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"QD (D1-2, D8-9, D15-16, D22-23)",PO,,1,176,1
MMRF_1386,,First line of therapy,Induction,,Lenalidomide,,,,Other,Per protofcol procedures,25,mg,,QD,,PO,,177,232,1
MMRF_1386,,First line of therapy,Induction,,Dexamethasone,,,,Other,Protocol procedures,40,mg,,Oth,"QD (D1, 8, 15, 22)",PO,,177,232,1
MMRF_1386,,First line of therapy,Induction,,Other,Clarithromycin,,,Other,Protocol procedures,500,mg,,BID,,PO,,177,232,1
MMRF_1386,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,10,mg,,QD,,PO,,232,,1
MMRF_1403,Baseline,First line of therapy,,,Carfilzomib,,,,Other,"Per protocol, 20 mg/m^2 only for C1D1 and C1D2",20,mg/m^,,Oth,"QD (C1D1, C1D2)",IV,,1,2,1
MMRF_1403,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"QD (D1-2, D8-9, D15-16, D22-23)",PO,,1,175,1
MMRF_1403,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,45,mg/m^,,QD,,IV,,8,175,1
MMRF_1403,,First line of therapy,Induction,,Other,Clarithromycin,,,Other,Protocol procedures,500,mg,,BID,,PO,,176,231,1
MMRF_1403,,First line of therapy,Induction,,Lenalidomide,,,,Other,Protocol procedures,25,mg,,QD,,PO,,176,231,1
MMRF_1403,,First line of therapy,Induction,,Dexamethasone,,,,Other,Protocol procedures,40,mg,,Oth,"QD (D1, 8, 15, 22)",PO,,176,231,1
MMRF_1403,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,10,mg,,QD,,PO,,232,925,1
MMRF_1403,,Second Line Therapy (after,Other,Lenalidomide,Lenalidomide,,,,Adverse Event or co-morbidity,,15,mg,,QD,,PO,,932,1516,1
MMRF_1403,,Third Line Therapy (followi,Induction,,Ixazomib,,,Checked,,,4,mg,,Q w,,PO,,1534,,1
MMRF_1403,,Second Line Therapy (after,Induction,,Melphalan,,,,Adverse Event or co-morbidity,,0,Other,n/a,Oth,n/a,Other,n/a,944,1485,1
MMRF_1458,Baseline,First line of therapy,,,Carfilzomib,,,,Other,"Per protocol, 20 mg/m^2 only for C1D1 and C1D2",20,mg/m^,,Oth,"QD (C1D1, C1D2)",IV,,1,2,1
MMRF_1458,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"QD (D1-2, D8-9, D15-16, D22-23)",PO,,1,130,1
MMRF_1458,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,45,mg/m^,,QD,,IV,,8,130,1
MMRF_1458,,First line of therapy,Unknown,,Lenalidomide,,,,Adverse Event or co-morbidity,,15,mg,,QD,,PO,,233,540,1
MMRF_1458,,First line of therapy,Unknown,,Dexamethasone,,,,Disease progression/Relapse,,20,mg,,Q w,,PO,,233,641,1
MMRF_1458,,Second Line Therapy (after,Induction,,Lenalidomide,,,Checked,,,5,mg,,Q w,,PO,,1342,,1
MMRF_1458,,Second Line Therapy (after,Induction,,Ixazomib,,,Checked,,,4,mg,,Q w,,PO,,1342,,1
MMRF_1462,,First line of therapy,Induction,,Carfilzomib,,,,Other,Protocol procedures,45,mg/m^,,QD,,IV,,8,120,1
MMRF_1462,Baseline,First line of therapy,Induction,,Carfilzomib,,,,Other,"Per protocol, 20 mg/m^2 only for C1D1 and C1D2",20,mg/m^,,Oth,"QD (C1D1, C1D2)",IV,,1,2,1
MMRF_1462,,First line of therapy,Induction,,Dexamethasone,,,,Other,Protocol procedures,20,mg,,Oth,"QD (D1-2, D8-9, D15-16, D22-23)",PO,,1,120,1
MMRF_1462,,First line of therapy,Induction,,Lenalidomide,,,,Disease progression/Relapse,,10,mg,,QD,,PO,,178,632,1
MMRF_1462,,First line of therapy,Induction,,Dexamethasone,,,,Other,Protocol procedures,40,mg,,Oth,"QD (D1, D8, D15, D22)",PO,,121,177,1
MMRF_1462,,First line of therapy,Induction,,Other,Clarithromycin,,,Other,Protocol procedures,500,mg,,BID,,PO,,121,177,1
MMRF_1462,,First line of therapy,Induction,,Lenalidomide,,,,Other,Protocol procedures,25,mg,,QD,,PO,,121,177,1
MMRF_1462,,Second Line Therapy (after,Induction,,Bortezomib,,,,Disease progression/Relapse,,1.3,mg/m^,,QD,,IV SubQ,,646,822,1
MMRF_1462,,Second Line Therapy (after,Induction,,Dexamethasone,,,,Disease progression/Relapse,,20,mg,,Oth,"QD (D1-2, D4-5, D8-9, D11-12)",PO,,646,822,1
MMRF_1462,,Third Line Therapy (followi,Unknown,,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,Oth,"days 1, 8, 15, 22",PO,,890,912,1
MMRF_1462,,Third Line Therapy (followi,Unknown,,Other,ACY-241,,,Investigator decision for other reasons,,180,mg,,QD,,PO,,890,910,1
MMRF_1462,,Third Line Therapy (followi,Unknown,,Pomalidomide,,,,Disease progression/Relapse,,4,mg,,QD,,PO,,900,912,1
MMRF_1462,,Third Line Therapy (followi,Unknown,,Dexamethasone,,,Checked,,,20,mg,,Q d,,PO,,912,,1
MMRF_1462,,Third Line Therapy (followi,Unknown,,Pomalidomide,,,Checked,,,4,mg,,Q d,,PO,,912,,1
MMRF_1462,,Third Line Therapy (followi,Unknown,,Carfilzomib,,,Checked,,,46,mg,,QD,,IV,,912,,1
MMRF_1493,Baseline,First line of therapy,Induction,,Carfilzomib,,,,Other,This dose is only for C1D1 and C1D2,20,mg/m^,,Oth,"QD (C1D1, C1D2)",IV,,1,2,1
MMRF_1493,,First line of therapy,Induction,,Dexamethasone,,,,Patient decision,,20,mg,,Oth,"QD (D1-2, D8-9, D15-16, D22-23)",PO,,1,37,1
MMRF_1493,,First line of therapy,Induction,,Carfilzomib,,,,Patient decision,,56,mg/m^,,QD,,IV,,8,37,1
MMRF_1493,,First line of therapy,Induction,,Cyclophosphamide,,,,Investigator decision for other reasons,,500,mg,,Q w,,IV,,50,162,1
MMRF_1493,,First line of therapy,Induction,,Dexamethasone,,,,Investigator decision for other reasons,,40,mg,,Q w,,PO,,50,162,1
MMRF_1493,,First line of therapy,Induction,,Bortezomib,,,,Investigator decision for other reasons,,2.6,mg,,Q w,,IV SubQ,,50,162,1
MMRF_1493,,First line of therapy,Induction,,Lenalidomide,,,Checked,,,10,mg,,QD,,PO,,163,,1
MMRF_1608,,First line of therapy,Induction,,Carfilzomib,,,,Investigator decision for other reasons,,115,mg/m^,,QD,,IV,,3,56,1
MMRF_1608,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"QD (D1-2, D8-9, D15-16, D22-23)",PO,,1,398,1
MMRF_1608,Baseline,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,20,mg/m^,,Oth,"QD (D1, D2)",IV,,1,2,1
MMRF_1608,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,93,mg,,QD,,IV,,56,398,1
MMRF_1608,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,399,539,1
MMRF_1608,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Q w,,PO,,399,539,1
MMRF_1608,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,500,mg,,BID,,PO,,399,539,1
MMRF_1608,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,10,mg,,QD,,PO,,540,,1
MMRF_1662,,First line of therapy,Induction,,Lenalidomide,,,,Investigator decision for other reasons,,25,mg,,QD,,PO,,1,398,1
MMRF_1662,,First line of therapy,Induction,,Dexamethasone,,,,Investigator decision for other reasons,,40,mg,,Q w,,PO,,1,98,1
MMRF_1662,Baseline,First line of therapy,Induction,,Other,Clarithromycin,,,Investigator decision for other reasons,,500,mg,,BID,,PO,,1,98,1
MMRF_1662,,First line of therapy,Induction,,Dexamethasone,,,,Investigator decision for other reasons,,20,mg,,Q w,,PO,,99,192,1
MMRF_1662,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,15,mg,,QD,,PO,,399,,1
MMRF_1689,Baseline,First line of therapy,Induction,,Bortezomib,,,,Investigator decision for other reasons,,2.6,mg,,QWK,,IV,,1,44,1
MMRF_1689,,First line of therapy,Induction,,Cyclophosphamide,,,,Investigator decision for other reasons,,500,mg,,QD,,IV,,1,1,1
MMRF_1689,,First line of therapy,Induction,,Cyclophosphamide,,,,Investigator decision for other reasons,,300,mg,,QWK,,PO,,7,28,1
MMRF_1689,,First line of therapy,Induction,,Dexamethasone,,,,Investigator decision for other reasons,,20,mg,,QWK,,PO,,1,28,1
MMRF_1689,,First line of therapy,Maintenance,,Bortezomib,,,,Adverse Event or co-morbidity,,2.7,mg,,Q w,,Other,SC,45,129,1
MMRF_1689,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,4,mg,,QWK,,PO,,45,715,1
MMRF_1689,,First line of therapy,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,5,mg,,Q d,,PO,,177,230,1
MMRF_1689,,Second Line Therapy (after,Induction,,Daratumumab,,,Checked,,,10,mg,,Q w,,IV,,1213,,1
MMRF_1718,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"QD (D1-2, D8-9, D15-16, D22-23)",PO,,1,183,1
MMRF_1718,Baseline,First line of therapy,Induction,,Carfilzomib,,,,Other,Change of dose as part of regimen,20,mg/m^,,Q d,,IV,,1,2,1
MMRF_1718,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,56,mg/m^,,QD,,IV,,3,183,1
MMRF_1718,,First line of therapy,Consolidation,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,205,288,1
MMRF_1718,,First line of therapy,Consolidation,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,"QD (D1, D8, D15, D22)",PO,,205,288,1
MMRF_1718,,First line of therapy,Consolidation,,Other,Clarithromycin,,,Completed regimen,,250,mg,,BID,,PO,,261,288,1
MMRF_1718,,First line of therapy,Consolidation,,Other,Clarithromycin,,,Adverse Event or co-morbidity,,500,mg,,BID,,PO,,205,260,1
MMRF_1718,,First line of therapy,Maintenance,,Lenalidomide,,,,Disease progression/Relapse,,10,mg,,QD,,PO,,289,410,1
MMRF_1718,,Second Line Therapy (after,Induction,,Cyclophosphamide,,,,Other,patient went to transplant,500,mg,,Oth,"QD (D1, D8)",PO,,418,449,1
MMRF_1718,,Second Line Therapy (after,Induction,,Bortezomib,,,,Other,patient went to transplant,2.7,mg,,QD,,IV SubQ,,418,449,1
MMRF_1718,,Second Line Therapy (after,Induction,,Dexamethasone,,,,Other,patient went to transplant,20,mg,,QD,,PO,,418,449,1
MMRF_1733,Baseline,First line of therapy,Induction,,Carfilzomib,,,,Other,Change of dose as part of regimen,20,mg/m^,,Q d,,IV,,1,2,1
MMRF_1733,,First line of therapy,Induction,,Other,Clarithromycin,,,Completed regimen,,250,mg,,BID,,PO,,37,336,1
MMRF_1733,,First line of therapy,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,25,mg,,QD,,PO,,37,119,1
MMRF_1733,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Q w,,PO,,37,336,1
MMRF_1733,,First line of therapy,Induction,,Carfilzomib,,,,Adverse Event or co-morbidity,,56,mg/m^,,QD,,IV,,3,19,1
MMRF_1733,,First line of therapy,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,20,mg,,Oth,"QD (D1-2, D8-9, D15-16, D22-23)",PO,,1,19,1
MMRF_1733,,First line of therapy,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,10,mg,,QD,,PO,,337,420,1
MMRF_1733,,First line of therapy,Consolidation,,Lenalidomide,,,,Completed regimen,,15,mg,,QD,,PO,,120,336,1
MMRF_1775,,First line of therapy,Induction,,Carfilzomib,,,,Adverse Event or co-morbidity,,45,mg/m^,,QD,,IV,,29,56,1
MMRF_1775,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,QD,,IV,,57,168,1
MMRF_1775,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,12,mg,,Oth,"QD (D1-2, D8-9, D15-16, D22-23)",PO,,85,168,1
MMRF_1775,,First line of therapy,Induction,,Carfilzomib,,,,Adverse Event or co-morbidity,,56,mg/m^,,QD,,IV,,3,28,1
MMRF_1775,Baseline,First line of therapy,Induction,,Carfilzomib,,,,Investigator decision for other reasons,,20,mg/m^,,Q d,,IV,,1,2,1
MMRF_1775,,First line of therapy,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,20,mg,,Oth,"QD (D1-2, D8-9, D15-16, D22-23)",PO,,1,84,1
MMRF_1775,,First line of therapy,Consolidation,,Dexamethasone,,,,Completed regimen,,24,mg,,Oth,"QD (D1, D8, D15, D22)",PO,,184,267,1
MMRF_1775,,First line of therapy,Consolidation,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,184,267,1
MMRF_1775,,First line of therapy,Consolidation,,Other,Clarithromycin,,,Adverse Event or co-morbidity,,500,mg,,BID,,PO,,184,231,1
MMRF_1775,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,10,mg,,QD,,PO,,268,,1
MMRF_1795,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"QD (D1-2, D8-9, D22-23, D29-30)",IV,,9,390,1
MMRF_1795,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,4,mg,,Oth,"QD (D8-9, D22-23, D29-30)",PO,,9,390,1
MMRF_1795,,First line of therapy,Induction,,Melphalan,,,,Adverse Event or co-morbidity,,7,mg/m^,,QD,,PO,,1,1,1
MMRF_1795,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,5,mg/m^,,QD,,PO,,2,392,1
MMRF_1795,,First line of therapy,Induction,,Prednisone,,,,Completed regimen,,100,mg,,QD,,PO,,1,390,1
MMRF_1795,Baseline,First line of therapy,Induction,,Carfilzomib,,,,Other,Change of dose as part of regimen,20,mg/m^,,Q d,,IV,,1,2,1
MMRF_1795,,Second Line Therapy (after,Induction,,Elotuzumab,,,Checked,,,689,mg,,QD,,IV,,1307,,1
MMRF_1825,Baseline,First line of therapy,Induction,,Carfilzomib,,,,Other,Change of dose as part of regimen,20,mg/m^,,Q d,,IV,,1,2,1
MMRF_1825,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"QD (D1-2, D8-9, D15-16, D22-23)",PO,,1,196,1
MMRF_1825,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,45,mg/m^,,QD,,IV,,8,196,1
MMRF_1825,,First line of therapy,Consolidation,,Other,Clarithromycin,,,Completed regimen,,500,mg,,BID,,PO,,197,287,1
MMRF_1825,,First line of therapy,Maintenance,,Lenalidomide,,,,Disease progression/Relapse,,10,mg,,QD,,PO,,1,927,1
MMRF_1825,,First line of therapy,Consolidation,,Dexamethasone,,,,Completed regimen,,40,mg,,Q w,,PO,,197,287,1
MMRF_1825,,First line of therapy,Consolidation,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,197,257,1
MMRF_1825,,Second Line Therapy (after,Consolidation,,Dexamethasone,,,,Patient decision,,4,mg,,Oth,"7tabs 3-24 hours prior D1,8,15,22 & in C1&C2 & D1 & D1&D15 in C3 and beyond",PO,,889,1088,1
MMRF_1825,,Second Line Therapy (after,Consolidation,,Elotuzumab,,,,Patient decision,,10,mg/kg,,QWK,,IV,,889,1088,1
MMRF_1825,,Second Line Therapy (after,Consolidation,,Lenalidomide,,,,Patient decision,,25,mg,,Q d,,PO,,889,1081,1
MMRF_1825,,Third Line Therapy (followi,Consolidation,,Melphalan,,,Checked,,,100,mg/m^,,Oth,Day -2 and -1,IV,,1074,,1
MMRF_1825,,Third Line Therapy (followi,Maintenance,,Lenalidomide,,,Checked,,,25,mg,,QD,,PO,,1074,,1
MMRF_1835,Baseline,First line of therapy,Induction,,Carfilzomib,,,,Other,Change of dose as part of regimen,20,mg/m^,,Q d,,IV,,1,2,1
MMRF_1835,,First line of therapy,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,20,mg,,Oth,"QD (D1-2, D8-9, D15-16, D22-23)",PO,,1,204,1
MMRF_1835,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,56,mg/m^,,QD,,IV,,9,282,1
MMRF_1835,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,10,mg,,QD,,PO,,373,,1
MMRF_1835,,First line of therapy,Consolidation,,Dexamethasone,,,,Adverse Event or co-morbidity,,24,mg,,Q w,,PO,,289,305,1
MMRF_1835,,First line of therapy,Consolidation,,Cyclophosphamide,,,,Adverse Event or co-morbidity,,500,mg,,BID,,PO,,289,305,1
MMRF_1835,,First line of therapy,Consolidation,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,289,372,1
MMRF_1835,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,12,mg,,Oth,"QD (D1-2, D8-9, D15-16, D22-23)",PO,,205,282,1
MMRF_1855,Baseline,First line of therapy,Induction,,Carfilzomib,,,,Other,Change of dose as part of regimen,20,mg/m^,,Q d,,IV,,1,2,1
MMRF_1855,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,56,mg/m^,,QD,,IV,,8,183,1
MMRF_1855,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"QD (D1-2, D8-9, D15-16, D22-23)",PO,,1,183,1
MMRF_1855,,First line of therapy,Consolidation,,Other,Clarithromycin,,,Completed regimen,,500,mg,,BID,,PO,,184,239,1
MMRF_1855,,First line of therapy,Consolidation,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,"QD (D1-2, D8-9, D15-16, D22-23)",PO,,184,239,1
MMRF_1855,,First line of therapy,Consolidation,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,184,239,1
MMRF_1855,,First line of therapy,Maintenance,,Lenalidomide,,,,Other,Patient moving away,10,mg,,QD,,PO,,240,882,1
MMRF_1935,Baseline,First line of therapy,Induction,,Carfilzomib,,,,Disease progression/Relapse,,20,mg,,QD,,IV,,1,611,1
MMRF_1935,,First line of therapy,Induction,,Lenalidomide,,,,Disease progression/Relapse,,25,mg,,QD,,PO,,1,611,1
MMRF_1935,,First line of therapy,Induction,,Dexamethasone,,,,Disease progression/Relapse,,20,mg,,QD,,PO,,1,611,1
MMRF_1935,,Second Line Therapy (after,Induction,,Elotuzumab,,,,Completed regimen,,10,mg/kg,,Oth,weekly x 3 weeks on/1 week off,IV,,632,1343,1
MMRF_1935,,Second Line Therapy (after,Consolidation,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,632,1328,1
MMRF_1935,,Second Line Therapy (after,Consolidation,,Dexamethasone,,,,Completed regimen,,8,mg,,Oth,weekly x 3 weeks on/1 week off,PO,,632,1328,1
MMRF_1935,,Second Line Therapy (after,Consolidation,,Bortezomib,,,Checked,,,1.3,mg/m^,,Q w,,IV,,804,,1
MMRF_1935,,Third Line Therapy (followi,Unknown,,Other,atezolizumab,,Checked,,,840,mg/dL,,Oth,q2weeks,IV,,1378,,1
MMRF_1935,,Third Line Therapy (followi,Unknown,,Pomalidomide,,,Checked,,,4,mg,,QD,,PO,,1378,,1
MMRF_1935,,Third Line Therapy (followi,Unknown,,Daratumumab,,,Checked,,,16,mg/kg,,Q w,,IV,,1378,,1
MMRF_1985,Baseline,First line of therapy,Induction,,Carfilzomib,,,,Investigator decision for other reasons,,20,mg/m^,,Q d,,IV,,1,2,1
MMRF_1985,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,56,mg/m^,,QD,,IV,,3,175,1
MMRF_1985,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"QD (D1-2, D8-9, D15-16, D22-23)",PO,,1,175,1
MMRF_1985,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,10,mg,,QD,,PO,,253,,1
MMRF_1985,,First line of therapy,Consolidation,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,198,252,1
MMRF_1985,,First line of therapy,Consolidation,,Dexamethasone,,,,Completed regimen,,40,mg,,Q w,,PO,,198,252,1
MMRF_1985,,First line of therapy,Consolidation,,Other,Clarithromycin,,,Completed regimen,,500,mg,,BID,,PO,,198,252,1
MMRF_2072,Baseline,First line of therapy,Induction,,Carfilzomib,,,,Investigator decision for other reasons,,20,mg/m^,,QD,,IV,,1,15,1
MMRF_2072,,First line of therapy,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,20,mg,,Oth,"D1-2, 8-9, 15-16, 22-23",PO,,1,37,1
MMRF_2072,,First line of therapy,Induction,,Carfilzomib,,,,Adverse Event or co-morbidity,,56,mg/dL,,QD,,IV,,16,36,1
MMRF_2072,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,45,mg/dL,,QD,,IV,,57,140,1
MMRF_2072,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,12,mg,,Oth,"QD (D1-2, D8-9, D15-16, D22-23)",PO,,57,140,1
MMRF_2072,,First line of therapy,Consolidation,,Dexamethasone,,,,Completed regimen,,24,mg,,Q w,,PO,,141,197,1
MMRF_2072,,First line of therapy,Consolidation,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,50,197,1
MMRF_2072,,First line of therapy,Consolidation,,Other,Clarithromycin,,,Completed regimen,,500,mg,,BID,,PO,,50,197,1
MMRF_2072,,First line of therapy,Maintenance,,Lenalidomide,,,,Disease progression/Relapse,,10,mg,,QD,,PO,,198,1025,1
MMRF_2072,,Second Line Therapy (after,Induction,,Daratumumab,,,Checked,,,860,mg,,Q w,,IV,,1073,,1
MMRF_2095,Baseline,First line of therapy,Induction,,Bortezomib,,,,Disease progression/Relapse,,2.2,mg,,Oth,"D1, 4, 8, 11, 22, 25, 29, 32",IV,,1,519,1
MMRF_2095,,First line of therapy,Induction,,Melphalan,,,,Disease progression/Relapse,,12,mg,,QD,,PO,,1,519,1
MMRF_2095,,First line of therapy,Induction,,Prednisone,,,,Disease progression/Relapse,,100,mg,,QD,,PO,,1,519,1
MMRF_2095,,Second Line Therapy (after,Induction,,Ixazomib,,,,Adverse Event or co-morbidity,,3,mg,,QID,,PO,,877,1079,1
MMRF_2095,,Second Line Therapy (after,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,10,mg,,QD,,PO,,877,1079,1
MMRF_2095,,Second Line Therapy (after,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,16,mg,,QD,,PO,,877,1079,1
MMRF_2159,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"D1-2, 8-9, 15-16, 22-23",PO,,1,90,1
MMRF_2159,Baseline,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,56,mg/m^,,QD,,IV,,1,72,1
MMRF_2159,,First line of therapy,Consolidation,,Lenalidomide,,,,Patient decision,,25,mg,,QD,,PO,,91,455,1
MMRF_2159,,First line of therapy,Consolidation,,Other,Clarithromycin,,,Patient decision,,500,mg,,BID,,PO,,91,455,1
MMRF_2159,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,20,mg/dL,,QD,,IV,,1,2,1
MMRF_2159,,First line of therapy,Consolidation,,Dexamethasone,,,,Adverse Event or co-morbidity,,40,mg,,Q w,,PO,,91,120,1
MMRF_2159,,First line of therapy,Consolidation,,Dexamethasone,,,,Patient decision,,20,mg,,Q w,,PO,,121,455,1
MMRF_2159,,Second Line Therapy (after,Other,Conditioning,Melphalan,,,,Completed regimen,,100,Other,mg/m2,BID,,IV,,1138,1151,1
MMRF_2237,Baseline,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,56,mg/m^,,QD,,IV,,1,120,1
MMRF_2237,,First line of therapy,Induction,,Dexamethasone,,,Checked,,,20,mg,,Oth,"QD (D1-2, D8-9, D15-16, D22-23)",PO,,1,,1
MMRF_2237,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,25,mg,,QD,,PO,,120,,1
MMRF_2236,Baseline,First line of therapy,Induction,,Carfilzomib,,,Checked,,,56,mg/m^,,QD,,IV,,1,,1
MMRF_2236,,First line of therapy,Induction,,Dexamethasone,,,Checked,,,20,mg,,Oth,"QD (D1-2, D8-9, D15-16, D22-23)",PO,,1,,1
MMRF_2244,Baseline,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,56,mg/m^,,QD,,IV,,1,100,1
MMRF_2244,,First line of therapy,Induction,,Dexamethasone,,,,Disease progression/Relapse,,20,mg,,Oth,"QD (D1-2, D8-9, D15-16, D22-23)",PO,,1,715,1
MMRF_2244,,Second Line Therapy (after,Maintenance,,Dexamethasone,,,Checked,,,40,mg,,QD,,PO,,786,,1
MMRF_2244,,Second Line Therapy (after,Maintenance,,Lenalidomide,,,Checked,,,25,mg,,QD,,PO,,786,,1
MMRF_2281,Baseline,First line of therapy,Induction,,Carfilzomib,,,,Disease progression/Relapse,,56,mg/m^,,QD,,IV,,1,877,1
MMRF_2281,,First line of therapy,Induction,,Dexamethasone,,,,Disease progression/Relapse,,20,mg,,Oth,"QD (D1-2, D8-9, D15-16, D22-23)",PO,,1,877,1
MMRF_2281,,Second Line Therapy (after,Induction,,Lenalidomide,,,,Lack of response,,25,mg,,Oth,QD (D1-21),PO,,905,1052,1
MMRF_2281,,Second Line Therapy (after,Induction,,Dexamethasone,,,,Lack of response,,20,mg,,Q w,,PO,,905,1052,1
MMRF_2281,,Third Line Therapy (followi,Induction,,Daratumumab,,,,Disease progression/Relapse,,1450,mg,,QWK,,IV,,1054,1129,1
MMRF_2281,,Fourth Line Therapy (follow,Induction,,Carfilzomib,,,Checked,,,57,mg,,QD,,IV,,1144,,1
MMRF_2292,,First line of therapy,Induction,,Cyclophosphamide,,,,Adverse Event or co-morbidity,,500,mg,,Oth,"QD (D1, D8)",IV,,1,105,1
MMRF_2292,,First line of therapy,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,20,mg,,QD,,PO,,1,105,1
MMRF_2292,Baseline,First line of therapy,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,1.3,mg/m^,,QD,,IV,,1,105,1
MMRF_2292,,Third Line Therapy (followi,Induction,,Bortezomib,,,Checked,,,2.6,mg,,QWK,,IV SubQ,,955,,1
MMRF_2292,,Third Line Therapy (followi,Induction,,Daratumumab,,,Checked,,,800,mg,,Q w,,IV,,941,,1
MMRF_2292,,Second Line Therapy (after,Induction,,Ixazomib,,,,Investigator decision for other reasons,,4,mg,,QWK,,PO,,407,832,1
MMRF_2292,,Second Line Therapy (after,Induction,,Ixazomib,,,,Investigator decision for other reasons,,4,mg,,Q w,,PO,,766,969,1
MMRF_2325,Baseline,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,56,mg/m^,,QD,,IV,,1,212,1
MMRF_2325,,First line of therapy,Induction,,Dexamethasone,,,Checked,,,20,mg,,Oth,"QD (D1-2, 8-9, 15-16, 22-23)",PO,,1,,1
MMRF_2363,Baseline,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,20,mg/dL,,QD,,IV,,1,2,1
MMRF_2363,,First line of therapy,Induction,,Carfilzomib,,,,Patient decision,,56,mg/dL,,QD,,IV,,3,217,1
MMRF_2363,,First line of therapy,Induction,,Dexamethasone,,,,Patient decision,,20,mg,,Oth,"QD (D1-2, D8-9, D15-16, D22-23)",PO,,1,217,1
MMRF_2363,,Second Line Therapy (after,Induction,,Cyclophosphamide,,,,Lack of response,,500,mg,,Q w,,IV,,231,364,1
MMRF_2363,,Second Line Therapy (after,Induction,,Dexamethasone,,,,Lack of response,,20,mg,,QD,,PO,,231,364,1
MMRF_2363,,Third Line Therapy (followi,Induction,,Pomalidomide,,,Checked,,,4,mg,,Q d,,PO,,891,,1
MMRF_2363,,Second Line Therapy (after,Maintenance,,Ixazomib,,,,Disease progression/Relapse,,4,mg,,Q w,,PO,,619,829,1
MMRF_2363,,Second Line Therapy (after,Induction,,Bortezomib,,,,Lack of response,,2.3,mg,,Q w,,IV SubQ,,231,364,1
MMRF_2363,,Second Line Therapy (after,Consolidation,,Melphalan,,,,Completed regimen,,200,mg/m^,,Oth,once,PO,,386,386,1
MMRF_2363,,Third Line Therapy (followi,Induction,,Daratumumab,,,Checked,,,1038,mg,,Oth,Q Month,IV,,878,,1
MMRF_2363,,Third Line Therapy (followi,Induction,,Carfilzomib,,,Checked,,,47,mg,,Q w,,IV,,883,,1
MMRF_2394,Baseline,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,20,mg/dL,,QD,,IV,,1,2,1
MMRF_2394,,First line of therapy,Induction,,Dexamethasone,,,,Disease progression/Relapse,,20,mg,,Oth,"QD (D1-2, D8-9, D15-16, D22-23)",PO,,1,582,1
MMRF_2394,,First line of therapy,Induction,,Carfilzomib,,,,Disease progression/Relapse,,56,mg/m^,,QD,,IV,,3,440,1
MMRF_2394,,Second Line Therapy (after,Maintenance,,Melphalan,,,,Disease progression/Relapse,,20,mg,,Oth,QD month,IV,,582,839,1
MMRF_2394,,Second Line Therapy (after,Maintenance,,Carfilzomib,,,,Disease progression/Relapse,,52.1,mg,,Oth,once a week every other week,IV,,582,839,1
MMRF_2394,,Second Line Therapy (after,Maintenance,,Dexamethasone,,,,Disease progression/Relapse,,20,mg,,Oth,"QD (D1, D2, D8, D9, D15, D16, D22, D23)",PO,,582,839,1
MMRF_2394,,Third Line Therapy (followi,Induction,,Other,nivolumab,,Checked,,,240,mg,,Oth,QD (D1 and D15),PO,,860,,1
MMRF_2394,,Third Line Therapy (followi,Induction,,Pomalidomide,,,Checked,,,4,mg,,QD,,PO,,860,,1
MMRF_2394,,Third Line Therapy (followi,Induction,,Dexamethasone,,,Checked,,,40,mg,,Oth,"QD (D1, D8, D15, and D22)",PO,,860,,1
MMRF_2399,Baseline,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,20,mg/dL,,QD,,IV,,1,2,1
MMRF_2399,,First line of therapy,Induction,,Carfilzomib,,,Checked,,,56,mg/dL,,QD,,IV,,3,,1
MMRF_2399,,First line of therapy,Induction,,Dexamethasone,,,Checked,,,20,mg,,Oth,"QD (D1-2, D8-9, D15-16, D22-23)",PO,,1,,1
MMRF_2453,,First line of therapy,Induction,,Bortezomib,,,,Disease progression/Relapse,,1.3,mg/m^,,QD,,IV SubQ,,1,301,1
MMRF_2453,Baseline,First line of therapy,Induction,,Cyclophosphamide,,,,Investigator decision for other reasons,,500,mg,,Oth,"QD (D1, D8)",PO,,1,273,1
MMRF_2453,,First line of therapy,Induction,,Dexamethasone,,,,Disease progression/Relapse,,20,mg,,QD,,PO,,1,301,1
MMRF_2453,,First line of therapy,Consolidation,,Melphalan,,,,Completed regimen,,200,mg/m^,,Oth,Day -2 and Day-1,IV,,310,312,1
MMRF_2453,,Second Line Therapy (after,Maintenance,,Ixazomib,,,Checked,,,4,mg,,Oth,"QD D1, 8, 15 and 28",PO,,481,,1
MMRF_2503,Baseline,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,20,mg/m^,,Oth,C1 D1-2,IV,,1,2,1
MMRF_2503,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,56,mg/m^,,QD,,IV,,3,141,1
MMRF_2503,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"QD (D1-2, D8-9, D15-16, D22-23)",PO,,1,232,1
MMRF_2503,,First line of therapy,Maintenance,,Lenalidomide,,,,Disease progression/Relapse,,10,mg,,Oth,QD (D1-21),PO,,274,869,1
MMRF_2503,,Second Line Therapy (after,Induction,,Other,CC-122 (Pleiotropic Pathway Modifier ml-122),,Checked,,,4,mg,,Oth,"QD (1-5, 8-12, 15-19, and 22-26)",PO,,883,,1
MMRF_2503,,Second Line Therapy (after,Induction,,Dexamethasone,,,Checked,,,40,mg,,Q w,,PO,,883,,1
MMRF_2522,Baseline,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,20,mg/m^,,QD,,IV,,1,2,1
MMRF_2522,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,56,mg/m^,,QD,,IV,,3,92,1
MMRF_2522,,First line of therapy,Induction,,Dexamethasone,,,Checked,,,20,mg,,Oth,"QD (D1,2,8,9,15,16,22,23)",PO,,1,,1
MMRF_2522,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,25,mg,,QD,,PO,,92,,1
MMRF_2524,Baseline,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,20,mg/m^,,QD,,IV,,1,2,1
MMRF_2524,,First line of therapy,Induction,,Carfilzomib,,,Checked,,,56,mg/m^,,QD,,IV,,3,,1
MMRF_2524,,First line of therapy,Induction,,Dexamethasone,,,Checked,,,20,mg,,Oth,"QD (D1,2,8,9,15,16,22,23)",PO,,1,,1
MMRF_2599,Baseline,First line of therapy,Other,Car/dex to plateau followd by bioxin/rev/dex to plateau followed by rev maintenance,Carfilzomib,,,,Completed regimen,,31,mg,,QD,,IV,,1,85,1
MMRF_2599,,First line of therapy,Other,Car/dex to plateau followd by bioxin/rev/dex to plateau followed by rev maintenance,Dexamethasone,,,,Adverse Event or co-morbidity,,20,mg,,Oth,"1, 8, 15, 22",PO,,1,100,1
MMRF_2599,,First line of therapy,Other,Car/dex to plateau followd by bioxin/rev/dex to plateau followed by rev maintenance,Other,biaxin,,,Disease progression/Relapse,,500,mg,,BID,,PO,,114,793,1
MMRF_2599,,First line of therapy,Other,Car/dex to plateau followd by bioxin/rev/dex to plateau followed by rev maintenance,Lenalidomide,,,,Disease progression/Relapse,,25,mg,,QD,,PO,,114,814,1
MMRF_2599,,Second Line Therapy (after,Induction,,Dexamethasone,,,Checked,,,40,mg,,Oth,Q D1 D8 D15 D22,PO,,828,,1
MMRF_2599,,Second Line Therapy (after,Induction,,Other,Celgene CC-122 -pleiotropic pathway,,Checked,,,4,mg,,Oth,"Q D1-5, 8-12, 15-19, and 22-26",PO,,828,,1
MMRF_1120,Baseline,First line of therapy,,,Bortezomib,,,,Completed regimen,,1.6,mg/m^,,Q w,,IV,,1,21,1
MMRF_1120,,First line of therapy,,,Bortezomib,,,,Completed regimen,,1.6,mg/m^,,Q w,,IV SubQ,,35,203,1
MMRF_1120,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Day of and day after each dose of Velcade. Day 1,2,8,9,15,16, 22, 23",PO,,1,237,1
MMRF_1120,,First line of therapy,,,Lenalidomide,,,,Completed regimen,,25,mg,,Q d,,PO,,16,237,1
MMRF_1120,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,10,mg,,Q d,,PO,,473,,1
MMRF_1120,,First line of therapy,Other,Conditioning regimen,Melphalan,,,,Completed regimen,,100,mg/m^,,Oth,Daily on days -2 and -1 from ASCT,IV,,356,357,1
MMRF_1120,,First line of therapy,Other,Conditioning regimen,Melphalan,,,,Completed regimen,,100,mg/m^,,Oth,Daily on days -2 and -1 from ASCT,IV,,237,238,1
MMRF_1140,Baseline,First line of therapy,,,Bortezomib,,,,Other,"Local velcade reaction, <grade 3 rxn",1.6,mg/m^,,Q w,,IV SubQ,,1,8,1
MMRF_1140,,First line of therapy,,,Bortezomib,,,,Completed regimen,,3,mg/m^,,Q w,,IV SubQ,,15,162,1
MMRF_1140,,First line of therapy,,,Lenalidomide,,,,Completed regimen,,25,Other,mg,Q d,,PO,,2,23,1
MMRF_1140,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Taken day of and day after each dose of Velcade. Day 1, 2, 8, 9, 15, 16, 22",PO,,1,330,1
MMRF_1140,,First line of therapy,,,Bortezomib,,,,Completed regimen,,2.5,mg/m^,,Q w,,IV SubQ,,169,204,1
MMRF_1140,,First line of therapy,Maintenance,,Bortezomib,,,Checked,,,1.3,mg/m^,,Oth,every other week,IV SubQ,,451,,1
MMRF_1167,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,10,mg,,Q d,,PO,,12,13,1
MMRF_1167,,First line of therapy,,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,Q w,,IV SubQ,,12,22,1
MMRF_1167,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,10,mg,,Q d,,PO,,2,5,1
MMRF_1167,,First line of therapy,,,Bortezomib,,,,Completed regimen,,2.75,mg,,Oth,q week for three weeks then hold for two weeks,IV SubQ,,43,293,1
MMRF_1167,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,10,mg,,Q d,,PO,,9,10,1
MMRF_1167,,First line of therapy,,,Dexamethasone,,,,Disease progression/Relapse,,10,mg,,Oth,Q week for three weeks then hold for two weeks,PO,,43,630,1
MMRF_1167,Baseline,First line of therapy,,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,once,PO,,1,2,1
MMRF_1167,,First line of therapy,,,Bortezomib,,,,Disease progression/Relapse,,1.5,mg/m^,,Oth,q2weeks,IV SubQ,,293,630,1
MMRF_1167,,Second Line Therapy (after,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,15,mg,,Q d,,PO,,630,819,1
MMRF_1167,,Second Line Therapy (after,Maintenance,,Dexamethasone,,,,Adverse Event or co-morbidity,,20,mg,,Q w,,PO,,630,834,1
MMRF_1167,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,10,mg,,Q d,,PO,,15,16,1
MMRF_1167,,Second Line Therapy (after,Maintenance,,Lenalidomide,,,,Other,"High risk complications of warfarin on terminal, second malignancy",10,mg,,Q d,,PO,,834,946,1
MMRF_1336,Baseline,First line of therapy,,,Melphalan,,,,Investigator decision for other reasons,,15,mg,,QD,,PO,,1,30,1
MMRF_1336,,First line of therapy,,,Bortezomib,,,,Investigator decision for other reasons,,1.3,mg/m^,,Oth,"D1, 8, 15, 22",IV SubQ,,6,30,1
MMRF_1336,,First line of therapy,,,Prednisone,,,,Investigator decision for other reasons,,100,mg,,QD,,PO,,1,30,1
MMRF_1336,,First line of therapy,,,Dexamethasone,,,,Lack of response,,40,mg,,Oth,"day 1, 8, 15 and 22",PO,,30,275,1
MMRF_1336,,First line of therapy,,,Cyclophosphamide,,,,Lack of response,,300,mg/m^,,Oth,"days 1, 8, 15, and 22",PO,,37,268,1
MMRF_1336,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,15,mg,,QD,,PO,,275,359,1
MMRF_1336,,First line of therapy,Maintenance,,Bortezomib,,,,Other,Patient could no longer afford treatment,1.3,mg/m^,,Oth,Every other week,IV SubQ,,616,933,1
MMRF_1336,,First line of therapy,Induction,,Bortezomib,,,,Lack of response,,1.3,mg/m^,,Oth,"D1, 8, 15, 22",IV SubQ,,44,268,1
MMRF_1336,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,QD,,PO,,289,360,1
MMRF_1336,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.5,mg/m^,,Oth,"D1, 8, 15",IV SubQ,,275,359,1
MMRF_1587,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,D1-4 and D8-11,PO,,1,167,1
MMRF_1587,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,2.75,mg,,Oth,"D1, D4, D8, D11",IV SubQ,,1,167,1
MMRF_1587,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,"D1, D8, D15",IV,,1,167,1
MMRF_1587,,First line of therapy,Maintenance,,Bortezomib,,,,Disease progression/Relapse,,1.5,mg/m^,,Oth,"D1, D8, D15, D22",IV,,190,234,1
MMRF_1587,,First line of therapy,Maintenance,,Dexamethasone,,,,Disease progression/Relapse,,20,mg,,Oth,"D1, D2",PO,,190,234,1
MMRF_1587,,Second Line Therapy (after,Induction,,Dexamethasone,,,,Investigator decision for other reasons,,40,mg,,Oth,"D1-4, D8-11",PO,,234,298,1
MMRF_1587,,Second Line Therapy (after,Induction,,Bortezomib,,,,Investigator decision for other reasons,,2.8,mg,,QD,,IV SubQ,,238,298,1
MMRF_1587,,Second Line Therapy (after,Induction,,Cyclophosphamide,,,,Investigator decision for other reasons,,600,mg,,Q w,,PO,,234,298,1
MMRF_1587,,Second Line Therapy (after,Maintenance,,Bortezomib,,,,Lack of response,,1.5,mg,,Q w,,IV SubQ,,309,672,1
MMRF_1587,,Second Line Therapy (after,Maintenance,,Lenalidomide,,,,Lack of response,,10,mg,,QD,,PO,,309,550,1
MMRF_1587,,Second Line Therapy (after,Maintenance,,Dexamethasone,,,,Lack of response,,40,mg,,Q w,,PO,,309,550,1
MMRF_1857,,First line of therapy,Induction,,Bortezomib,,,,Lack of response,,1.5,mg/m^,,Q w,,IV SubQ,,2,114,1
MMRF_1857,,First line of therapy,Induction,,Dexamethasone,,,,Lack of response,,40,mg,,QWK,,PO,,1,114,1
MMRF_1857,Baseline,First line of therapy,Induction,,Cyclophosphamide,,,,Lack of response,,450,mg,,Q w,,PO,,1,114,1
MMRF_1857,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,10,mg,,Q d,,PO,,377,,1
MMRF_1857,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Q w,,PO,,124,206,1
MMRF_1857,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,15,mg,,Q d,,PO,,124,206,1
MMRF_1857,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,2,mg,,Oth,"Per EMR, frequency not known; patient not seen at OHSU",IV SubQ,,124,219,1
MMRF_2297,,First line of therapy,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,20,mg,,Oth,"D1-2, 4-5, 8-9, 11-12",PO,,1,48,1
MMRF_2297,Baseline,First line of therapy,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,1.3,mg/m^,,QD,,IV,,1,24,1
MMRF_2297,,First line of therapy,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,25,mg,,QD,,PO,,1,48,1
MMRF_2297,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.5,mg/m^,,Oth,"D1, 8, 15, 22",IV SubQ,,76,198,1
MMRF_2297,,First line of therapy,Maintenance,,Bortezomib,,,,Adverse Event or co-morbidity,,1.3,mg/m^,,Oth,"D1, D15",IV SubQ,,406,717,1
MMRF_2297,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Q w,,PO,,76,198,1
MMRF_2297,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,15,mg,,QD,,PO,,76,198,1
MMRF_2297,,First line of therapy,Other,Conditioning regimen,Melphalan,,,,Completed regimen,,100,mg/m^,,Oth,Days -2 and -1,IV,,274,275,1
MMRF_2297,,First line of therapy,Maintenance,,Bortezomib,,,,Adverse Event or co-morbidity,,2,mg,,Oth,D1 and D15,IV,,717,1234,1
MMRF_2297,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,10,mg,,QD,,PO,,1233,,1
MMRF_2302,Baseline,First line of therapy,Induction,,Lenalidomide,,,,Investigator decision for other reasons,,15,mg,,QD,,PO,,1,264,1
MMRF_2302,,First line of therapy,Induction,,Dexamethasone,,,,Investigator decision for other reasons,,40,mg,,QWK,,PO,,1,264,1
MMRF_2302,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,10,mg,,Q d,,PO,,376,,1
MMRF_2302,,First line of therapy,Unknown,,Bortezomib,,,,Investigator decision for other reasons,,1.3,mg/m^,,Oth,"D1, 8, 15, 22",IV SubQ,,283,325,1
MMRF_2302,,First line of therapy,Unknown,,Dexamethasone,,,,Investigator decision for other reasons,,20,mg,,Oth,"D1, 8,15, 22",PO,,283,325,1
MMRF_2302,,First line of therapy,Unknown,,Lenalidomide,,,,Investigator decision for other reasons,,15,mg,,QD,,PO,,283,325,1
MMRF_2352,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV,,1,139,1
MMRF_2352,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,600,mg,,QWK,,PO,,1,139,1
MMRF_2352,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,"Days 1, 2, 4, 5, 8, 9, 11, 12, 15, 16",PO,,3,139,1
MMRF_2352,,First line of therapy,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,10,mg,,Q d,,PO,,307,882,1
MMRF_2352,,First line of therapy,Other,Conditioning regimen,Melphalan,,,,Completed regimen,,190,mg,,Oth,Day -2 and -1 to ASCT,IV,,149,150,1
MMRF_2352,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,5,mg,,Oth,D1-D28 of a 28 day cycle,PO,,883,,1
MMRF_2464,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV,,1,49,1
MMRF_2464,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1-2, 4-5, 8-9, 11-12",PO,,1,49,1
MMRF_2464,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,49,1
MMRF_2464,,First line of therapy,Other,Conditioning regimen,Melphalan,,,,Completed regimen,,100,mg/m^,,Oth,Day -2 and -1,IV,,119,120,1
MMRF_2464,,First line of therapy,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,10,mg,,Q d,,PO,,252,1129,1
MMRF_2464,,First line of therapy,Unknown,,Cyclophosphamide,,,,Completed regimen,,1900,mg,,Oth,Q 3hrs x3,IV,,95,96,1
MMRF_2464,,First line of therapy,Consolidation,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,210,241,1
MMRF_2464,,First line of therapy,Consolidation,,Dexamethasone,,,,Completed regimen,,10,mg,,Oth,"D1, 2, 4, 5, 8, 9, 11 and 12",PO,,210,232,1
MMRF_2464,,First line of therapy,Consolidation,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,210,232,1
MMRF_2464,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,5,mg,,Q d,,PO,,1157,,1
MMRF_2217,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,2.7,mg,,QD,,IV SubQ,,1,11,1
MMRF_2217,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,500,mg,,Oth,Day 1 and 8,PO,,1,8,1
MMRF_2217,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,"Days 1-4, day 8 and day 11",PO,,1,11,1
MMRF_2217,,First line of therapy,Induction,,Cyclophosphamide,,,,Other,dose increased,600,mg,,QWK,,PO,,21,254,1
MMRF_2217,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,QWK,,PO,,21,373,1
MMRF_2217,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,2.7,mg,,Q w,,IV SubQ,,21,373,1
MMRF_2217,,First line of therapy,Maintenance,,Bortezomib,,,,Disease progression/Relapse,,1.3,mg/m^,,Oth,day 1 and day 15,IV SubQ,,373,718,1
MMRF_2217,,First line of therapy,Maintenance,,Dexamethasone,,,,Disease progression/Relapse,,4,mg,,Oth,"4 mg on days 1, 2, 15, 16 of 28-day cycle",PO,,373,736,1
MMRF_2217,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,650,mg,,Q w,,PO,,254,373,1
MMRF_2217,,Second Line Therapy (after,Induction,,Other,Nivolumab,,Checked,,,240,mg,,Oth,"C1D15, C2-6 D1, D15",IV,,997,,1
MMRF_2217,,Second Line Therapy (after,Induction,,Daratumumab,,,Checked,,,16,mg/kg,,Oth,"C1 D1,15,22. C2 D1,16,22. C3-6 D1,15",IV,,997,,1
MMRF_2217,,Second Line Therapy (after,Induction,,Dexamethasone,,,Checked,,,4,mg,,Oth,"C1,C2 D2,3,9,10,16,17,23,24",PO,,997,,1
MMRF_1629,,First line of therapy,Induction,,Cyclophosphamide,,,,Other,Moved to SCT,300,mg/m^,,Q w,,PO,,1,189,1
MMRF_1629,,First line of therapy,Induction,,Dexamethasone,,,,Other,moved to SCT,50,mg,,Q w,,PO,,1,189,1
MMRF_1629,Baseline,First line of therapy,Induction,,Bortezomib,,,,Other,Moved to SCT,1.5,mg/m^,,Q w,,IV SubQ,,1,189,1
MMRF_1629,,First line of therapy,Maintenance,,Bortezomib,,,Checked,,,2.8,mg,,QD,,IV SubQ,,350,,1
MMRF_1629,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,10,mg,,Q d,,PO,,350,,1
MMRF_1380,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,20,mg,,QWK,,PO,,1,386,1
MMRF_1380,,First line of therapy,,,Lenalidomide,,,,Disease progression/Relapse,,25,mg,,QD,,PO,,1,166,1
MMRF_1380,Baseline,First line of therapy,,,Bortezomib,,,,Disease progression/Relapse,,2.6,mg,,QWK,,IV SubQ,,1,166,1
MMRF_1380,,First line of therapy,Other,Intensification of  induction therapy,Cyclophosphamide,,,,Disease progression/Relapse,,950,mg,,Q w,,IV,,106,166,1
MMRF_1380,,First line of therapy,Consolidation,,Carfilzomib,,,,Completed regimen,,27,mg,,QD,,IV,,166,387,1
MMRF_1380,,First line of therapy,Consolidation,,Pomalidomide,,,Checked,,,4,mg,,QD,,PO,,178,,1
MMRF_1432,Baseline,First line of therapy,,,Dexamethasone,,,,Other,patient died,20,mg,,Q w,,PO,,1,400,1
MMRF_1432,,First line of therapy,,,Bortezomib,,,,Adverse Event or co-morbidity,,2.3,mg,,QWK,,IV SubQ,,1,48,1
MMRF_1432,,First line of therapy,,,Lenalidomide,,,,Lack of response,,25,mg,,QD,,PO,,1,337,1
MMRF_1432,,First line of therapy,Other,replacement of velcade,Cyclophosphamide,,,,Investigator decision for other reasons,,1200,mg,,Oth,Qmonth,IV,,89,194,1
MMRF_1432,,Second Line Therapy (after,Unknown,,Pomalidomide,,,,Patient decision,,4,mg,,QD,,PO,,337,393,1
MMRF_1432,,Second Line Therapy (after,Unknown,,Melphalan,,,,Patient decision,,8,mg,,QD,,PO,,348,393,1
MMRF_1460,Baseline,First line of therapy,Induction,,Bortezomib,,,,Other,treatment discontinued due to progression of dementia,2.7,mg,,QD,,IV SubQ,,1,258,1
MMRF_1460,,First line of therapy,Induction,,Dexamethasone,,,,Investigator decision for other reasons,,20,mg,,Q w,,PO,,1,166,1
MMRF_1542,,First line of therapy,Induction,,Bortezomib,,,,Investigator decision for other reasons,,1.3,mg/m^,,Q w,,IV SubQ,,5,43,1
MMRF_1542,,First line of therapy,Induction,,Dexamethasone,,,,Patient decision,,20,mg,,Q w,,PO,,5,101,1
MMRF_1542,Baseline,First line of therapy,Induction,,Lenalidomide,,,,Patient decision,,15,mg,,QD,,PO,,1,128,1
MMRF_1542,,Second Line Therapy (after,Induction,,Pomalidomide,,,,Other,Death,4,mg,,QD,,PO,,803,1137,1
MMRF_1542,,First line of therapy,Induction,,Bortezomib,,,,Other,Death,1.3,mg/m^,,Oth,Qevery 4 weeks,IV SubQ,,155,1137,1
MMRF_1542,,Second Line Therapy (after,Induction,,Cyclophosphamide,,,,Other,Death,1,Other,gram,Oth,Q every 4 weeks,IV,,520,1137,1
MMRF_1542,,First line of therapy,Induction,,Lenalidomide,,,,Investigator decision for other reasons,,25,mg,,QD,,PO,,262,437,1
MMRF_1646,Baseline,First line of therapy,Induction,,Bortezomib,,,,Patient decision,,2.6,mg,,QD,,IV SubQ,,1,15,1
MMRF_1646,,First line of therapy,Induction,,Dexamethasone,,,,Patient decision,,20,mg,,Q w,,PO,,1,23,1
MMRF_1647,Baseline,First line of therapy,Induction,,Bortezomib,,,,Investigator decision for other reasons,,2.6,mg,,QD,,IV SubQ,,1,204,1
MMRF_1647,,First line of therapy,Induction,,Dexamethasone,,,,Patient decision,,20,mg,,Q w,,PO,,1,36,1
MMRF_1647,,First line of therapy,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,5,mg,,QD,,PO,,206,239,1
MMRF_1647,,First line of therapy,Maintenance,,Bortezomib,,,,Patient decision,,2.3,mg,,QD,,IV SubQ,,344,766,1
MMRF_1647,,First line of therapy,Maintenance,,Dexamethasone,,,,Patient decision,,20,mg,,QD,,PO,,344,766,1
MMRF_1778,,First line of therapy,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,20,mg,,Q w,,PO,,1,1,1
MMRF_1778,Baseline,First line of therapy,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,2.5,mg,,Q w,,IV SubQ,,1,1,1
MMRF_2058,Baseline,First line of therapy,Induction,,Lenalidomide,,,,Other,Dose reduced for maintenance,25,mg,,QD,,PO,,1,191,1
MMRF_2058,,First line of therapy,Induction,,Dexamethasone,,,,Other,Patient reached VGPR,40,mg,,Q w,,PO,,1,191,1
MMRF_2058,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,10,mg,,QD,,PO,,191,,1
MMRF_2079,Baseline,First line of therapy,Induction,,Bortezomib,,,Checked,,,2,mg,,QD,,IV SubQ,,1,,1
MMRF_2079,,First line of therapy,Induction,,Dexamethasone,,,Checked,,,40,mg,,Q w,,PO,,1,,1
MMRF_2079,,First line of therapy,Induction,,Lenalidomide,,,,Other,Rash,25,mg,,QD,,PO,,2,26,1
MMRF_2079,,First line of therapy,Induction,,Cyclophosphamide,,,Checked,,,500,mg,,Q w,,PO,,65,,1
MMRF_2143,Baseline,First line of therapy,Induction,,Dexamethasone,,,,Other,Hospital admission,20,mg,,Q w,,PO,,1,1,1
MMRF_2143,,First line of therapy,Induction,,Lenalidomide,,,,Other,Death,25,mg,,QD,,PO,,42,841,1
MMRF_2143,,First line of therapy,Induction,,Dexamethasone,,,,Other,Discontinued by pharmacist,20,mg,,Q w,,PO,,42,118,1
MMRF_2204,Baseline,First line of therapy,Induction,,Dexamethasone,,,,Patient decision,,20,mg,,QWK,,PO,,1,109,1
MMRF_2204,,First line of therapy,Induction,,Lenalidomide,,,,Patient decision,,25,mg,,QD,,PO,,1,147,1
MMRF_2204,,Second Line Therapy (after,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,2.6,mg,,Q w,,IV SubQ,,232,359,1
MMRF_2204,,Second Line Therapy (after,Induction,,Cyclophosphamide,,,,Disease progression/Relapse,,300,mg,,Q w,,PO,,375,394,1
MMRF_2204,,Second Line Therapy (after,Induction,,Dexamethasone,,,,Disease progression/Relapse,,20,mg,,Q w,,PO,,235,394,1
MMRF_2362,Baseline,First line of therapy,Induction,,Bortezomib,,,Checked,,,2.5,mg,,QD,,IV SubQ,,1,,1
MMRF_2362,,First line of therapy,Induction,,Dexamethasone,,,Checked,,,20,mg,,QD,,PO,,1,,1
MMRF_2487,Baseline,First line of therapy,Induction,,Bortezomib,,,Checked,,,2.7,mg,,QD,,IV SubQ,,1,,1
MMRF_2487,,First line of therapy,Induction,,Dexamethasone,,,Checked,,,20,mg,,Q w,,PO,,1,,1
MMRF_2487,,First line of therapy,Consolidation,,Melphalan,,,,Completed regimen,,100,mg/m^,,Oth,qd 1-2,IV,,258,259,1
MMRF_2581,Baseline,First line of therapy,Induction,,Bortezomib,,,,Investigator decision for other reasons,,2.1,mg,,QD,,IV SubQ,,1,83,1
MMRF_2581,,First line of therapy,Induction,,Dexamethasone,,,,Investigator decision for other reasons,,40,mg,,Q w,,PO,,1,83,1
MMRF_1504,Baseline,First line of therapy,Induction,,Dexamethasone,,,,Investigator decision for other reasons,,40,mg,,QD,,PO,,1,84,1
MMRF_1504,,First line of therapy,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,2.4,mg,,QD,,IV SubQ,,1,84,1
MMRF_1504,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,11,158,1
MMRF_1504,,First line of therapy,Maintenance,,Bortezomib,,,,Completed regimen,,2.4,mg,,Oth,Day 1 and Day 8 of each cycle,Other,SubQ,84,152,1
MMRF_1504,,First line of therapy,Maintenance,,Dexamethasone,,,,Patient decision,,20,mg,,Oth,"Days 1, 8 and 15",PO,,84,309,1
MMRF_1504,,First line of therapy,Maintenance,,Lenalidomide,,,,Patient decision,,15,mg,,QD,,PO,,179,262,1
MMRF_1504,,First line of therapy,Maintenance,,Lenalidomide,,,,Patient decision,,15,mg,,QD,,PO,,309,675,1
MMRF_1504,,Second Line Therapy (after,Induction,,Lenalidomide,,,,Disease progression/Relapse,,15,mg,,QD,,PO,,1082,1345,1
MMRF_1504,,Second Line Therapy (after,Induction,,Dexamethasone,,,Checked,,,20,mg,,Q w,,PO,,1082,,1
MMRF_1504,,Third Line Therapy (followi,Induction,,Bortezomib,,,Checked,,,1.3,mg/m^,,Oth,"Day 1, 8 and 15",IV SubQ,,1345,,1
MMRF_2055,,First line of therapy,Induction,,Lenalidomide,,,,Investigator decision for other reasons,,15,mg,,Oth,Every other day,PO,,1,283,1
MMRF_2055,Baseline,First line of therapy,Induction,,Dexamethasone,,,,Other,Hyperglycemia,40,mg,,QWK,,PO,,1,178,1
MMRF_2055,,Second Line Therapy (after,Induction,,Lenalidomide,,,Checked,,,15,mg,,Oth,Every other day; take every other day for 21 days every 28 day cycle,PO,,811,,1
MMRF_2055,,Second Line Therapy (after,Induction,,Bortezomib,,,Checked,,,1.3,mg/dL,,Oth,"Day 1, 8, 15 and 22",IV SubQ,,906,,1
MMRF_2055,,Second Line Therapy (after,Induction,,Dexamethasone,,,Checked,,,28,mg,,Oth,"Day 1, 8, 15 and 22",PO,,906,,1
MMRF_2253,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,"Days 1, 8 and 15",PO,,1,157,1
MMRF_2253,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,2.6,mg,,Oth,"days 1, 5 , 8 & 11",IV SubQ,,1,157,1
MMRF_2253,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,157,1
MMRF_2253,,First line of therapy,Other,Stem Cell Transplant,Melphalan,,,,Completed regimen,,401,mg,,Oth,"Daily x 1, Day (-2)",IV,,164,164,1
MMRF_2253,,First line of therapy,Other,Stem Cell Transplant,Dexamethasone,,,,Completed regimen,,8,mg,,Oth,"Daily Days (-1, 0)",IV,,165,166,1
MMRF_2253,,First line of therapy,Other,Stem Call Transplant,Dexamethasone,,,,Completed regimen,,12,mg,,Oth,Day (-2),IV,,164,164,1
MMRF_2253,,First line of therapy,Maintenance,,Lenalidomide,,,,Investigator decision for other reasons,,15,mg,,QD,,PO,,260,495,1
MMRF_2253,,First line of therapy,Induction,,Bortezomib,,,,Disease progression/Relapse,,2.7,mg,,Q w,,IV SubQ,,514,710,1
MMRF_2253,,First line of therapy,Induction,,Lenalidomide,,,,Disease progression/Relapse,,10,mg,,QD,,PO,,514,716,1
MMRF_2253,,Second Line Therapy (after,Induction,,Pomalidomide,,,,Other,death,4,mg,,Q d,,PO,,719,744,1
MMRF_2253,,Second Line Therapy (after,Induction,,Carfilzomib,,,,Other,death,42,mg,,Oth,X1 on day 1 to 2,IV,,716,744,1
MMRF_1349,,First line of therapy,,,Dexamethasone,,,,Adverse Event or co-morbidity,,40,mg,,Q w,,PO,,1,512,1
MMRF_1349,Baseline,First line of therapy,,,Bortezomib,,,,Adverse Event or co-morbidity,,1.3,mg/m^,,QD,,IV SubQ,,1,508,1
MMRF_1332,,First line of therapy,,,Lenalidomide,,,,Completed regimen,,25,mg,,Q d,,PO,,10,167,1
MMRF_1332,Baseline,First line of therapy,,,Bortezomib,,,,Completed regimen,,2.6,mg,,QD,,IV SubQ,,1,167,1
MMRF_1332,,First line of therapy,,,Dexamethasone,,,,Completed regimen,,40,mg,,Q w,,PO,,1,167,1
MMRF_1332,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,10,mg,,QD,,PO,,310,,1
MMRF_1365,,First line of therapy,,,Dexamethasone,,,,Other,dose prescribed changed transfer to new provider,40,mg,,Q w,,PO,,1,30,1
MMRF_1365,,First line of therapy,,,Cyclophosphamide,,,,Other,dose changed,460,mg,,Q w,,IV,,8,20,1
MMRF_1365,Baseline,First line of therapy,,,Bortezomib,,,,Other,dose change,2,mg,,QD,,IV SubQ,,1,1,1
MMRF_1365,,First line of therapy,Induction,,Cyclophosphamide,,,Checked,,,300,mg/m^,,QWK,,IV,,67,,1
MMRF_1365,,First line of therapy,Induction,,Bortezomib,,,,Other,dose change,2.3,mg,,Oth,once,IV SubQ,,8,8,1
MMRF_1365,,First line of therapy,Induction,,Bortezomib,,,,Other,dose change,2.45,mg,,Oth,once,IV SubQ,,22,22,1
MMRF_1365,,First line of therapy,Induction,,Bortezomib,,,,Other,dose change,1,mg,,Oth,once,IV SubQ,,30,30,1
MMRF_1365,,First line of therapy,Induction,,Bortezomib,,,Checked,,,1,mg/m^,,QWK,,IV SubQ,,60,,1
MMRF_1365,,First line of therapy,Induction,,Cyclophosphamide,,,,Other,dose changed,470,mg,,QWK,,IV,,22,30,1
MMRF_1425,Baseline,First line of therapy,,,Dexamethasone,,,,Investigator decision for other reasons,,40,mg,,QWK,,PO,,1,22,1
MMRF_1425,,First line of therapy,,,Bortezomib,,,,Investigator decision for other reasons,,2.7,mg,,QD,,IV SubQ,,1,11,1
MMRF_1425,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Q w,,PO,,22,227,1
MMRF_1425,,First line of therapy,Maintenance,,Dexamethasone,,,,Other,death,20,mg,,Oth,every 2 weeks,PO,,237,1260,1
MMRF_1425,,First line of therapy,Induction,,Bortezomib,,,,Investigator decision for other reasons,,2.6,mg,,Q w,,IV SubQ,,22,108,1
MMRF_1425,,First line of therapy,Induction,,Bortezomib,,,,Investigator decision for other reasons,,1.3,mg/m^,,Q w,,IV SubQ,,115,227,1
MMRF_1425,,First line of therapy,Maintenance,,Bortezomib,,,,Other,peripheral neuropathy,1.3,mg/m^,,Oth,every 2 week,IV SubQ,,227,1107,1
MMRF_1451,Baseline,First line of therapy,,,Bortezomib,,,,Other,death,1.3,mg/m^,,QD,,IV SubQ,,1,154,1
MMRF_1451,,First line of therapy,,,Dexamethasone,,,,Other,death,20,mg,,QWK,,PO,,1,154,1
MMRF_1451,,First line of therapy,Induction,,Lenalidomide,,,,Other,death,10,mg,,Q d,,PO,,147,154,1
MMRF_1501,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Q w,,IV,,1,314,1
MMRF_1501,Baseline,First line of therapy,Induction,,Bortezomib,,,,Lack of response,,2.5,mg,,Q w,,IV SubQ,,1,375,1
MMRF_1501,,Second Line Therapy (after,Unknown,,Pomalidomide,,,,Lack of response,,4,mg,,Q d,,PO,,375,504,1
MMRF_1501,,First line of therapy,Induction,,Lenalidomide,,,,Lack of response,,25,mg,,Q d,,PO,,224,671,1
MMRF_1501,,Third Line Therapy (followi,Induction,,Carfilzomib,,,,Lack of response,,42,mg,,QWK,,IV,,504,734,1
MMRF_1501,,Third Line Therapy (followi,Induction,,Dexamethasone,,,,Lack of response,,4,mg,,BID,,PO,,448,606,1
MMRF_1501,,First line of therapy,Induction,,Lenalidomide,,,,Investigator decision for other reasons,,10,mg,,QWK,,PO,,84,224,1
MMRF_1501,,Fourth Line Therapy (follow,Maintenance,,Dexamethasone,,,,Completed regimen,,4,mg,,Oth,"Take 1 Tab by mouth every 6 hours. 2 daily for 4 days, then 1 daily x 4 da",PO,,606,622,1
MMRF_1501,,Fourth Line Therapy (follow,Maintenance,,Dexamethasone,,,,Lack of response,,4,mg,,Oth,take 40 mg per week,PO,,622,874,1
MMRF_1525,Baseline,First line of therapy,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,1.3,mg/m^,,Oth,"D1, D8, D15",IV SubQ,,1,237,1
MMRF_1525,,First line of therapy,Induction,,Dexamethasone,,,,Lack of response,,20,mg,,Oth,"D1, 8, 15",PO,,1,1568,1
MMRF_1525,,First line of therapy,Induction,,Lenalidomide,,,,Investigator decision for other reasons,,25,mg,,QD,,PO,,27,208,1
MMRF_1525,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,208,273,1
MMRF_1525,,First line of therapy,Maintenance,,Lenalidomide,,,,Disease progression/Relapse,,10,mg,,Q d,,PO,,889,1421,1
MMRF_1525,,Second Line Therapy (after,Induction,,Lenalidomide,,,,Lack of response,,25,mg,,QD,,PO,,1421,1568,1
MMRF_1525,,Second Line Therapy (after,Induction,,Ixazomib,,,,Lack of response,,4,mg,,QWK,,PO,,1421,1568,1
MMRF_1525,,Third Line Therapy (followi,Other,new therapy after a lack of respose to second line therapy,Carfilzomib,,,Checked,,,35.4,mg,,Oth,D1 - D2,IV,,1589,,1
MMRF_1519,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,QWK,,PO,,1,195,1
MMRF_1519,Baseline,First line of therapy,Induction,,Bortezomib,,,,Other,change from one time dosing to weekly dosing and to weight based dose,3.1,mg,,Oth,one time order Aug 10 and 15,IV SubQ,,1,6,1
MMRF_1519,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,10,mg,,QD,,PO,,81,391,1
MMRF_1519,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,Q w,,IV SubQ,,13,195,1
MMRF_1519,,Second Line Therapy (after,Maintenance,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,Oth,every 2 weeks,IV SubQ,,265,307,1
MMRF_1519,,Second Line Therapy (after,Maintenance,,Dexamethasone,,,,Other,Patient death,20,mg,,Q w,,PO,,269,647,1
MMRF_1627,,First line of therapy,Induction,,Dexamethasone,,,,Investigator decision for other reasons,,20,mg,,QD,,PO,,1,13,1
MMRF_1627,Baseline,First line of therapy,Induction,,Bortezomib,,,,Investigator decision for other reasons,,1.3,mg/m^,,QD,,IV SubQ,,1,13,1
MMRF_1627,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,103,165,1
MMRF_1627,,First line of therapy,Maintenance,,Lenalidomide,,,,Investigator decision for other reasons,,10,mg,,QD,,PO,,172,251,1
MMRF_1627,,First line of therapy,Induction,,Dexamethasone,,,,Investigator decision for other reasons,,20,mg,,Q w,,PO,,27,97,1
MMRF_1627,,First line of therapy,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,1.3,mg/m^,,Q w,,IV SubQ,,27,90,1
MMRF_1627,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Q w,,PO,,131,160,1
MMRF_1627,,Second Line Therapy (after,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,5,mg,,Q d,,PO,,644,742,1
MMRF_1627,,Third Line Therapy (followi,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,10,mg,,Q d,,PO,,1325,1472,1
MMRF_1627,,Fourth Line Therapy (follow,Maintenance,,Bortezomib,,,,Other,patient deceased after this last date of treatment,1.3,mg/m^,,Oth,once very other week,IV SubQ,,1526,1568,1
MMRF_1633,,First line of therapy,Induction,,Dexamethasone,,,Checked,,,40,mg,,QD,,PO,,1,,1
MMRF_1633,Baseline,First line of therapy,Induction,,Bortezomib,,,Checked,,,1.3,mg/m^,,QD,,IV SubQ,,1,,1
MMRF_1639,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,QD,,PO,,1,105,1
MMRF_1639,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,105,1
MMRF_1639,,First line of therapy,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,10,mg,,Q d,,PO,,140,575,1
MMRF_1639,,Second Line Therapy (after,Maintenance,,Pomalidomide,,,,Completed regimen,,1,mg,,Q d,,PO,,520,679,1
MMRF_1639,,First line of therapy,Induction,,Lenalidomide,,,,Lack of response,,5,mg,,Q d,,PO,,210,521,1
MMRF_1639,,Second Line Therapy (after,Induction,,Carfilzomib,,,,Lack of response,,34.2,mg,,QD,,IV,,657,679,1
MMRF_1639,,Second Line Therapy (after,Induction,,Dexamethasone,,,,Completed regimen,,4,mg,,Oth,once,IV,,657,657,1
MMRF_1645,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.5,mg/m^,,Oth,every other week,IV SubQ,,1,117,1
MMRF_1645,,First line of therapy,Consolidation,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,every other week,PO,,1,117,1
MMRF_1645,,First line of therapy,Consolidation,,Lenalidomide,,,,Other,stem cell transplant,5,mg,,Oth,M-W-F for 3 weeks and one week off,PO,,180,439,1
MMRF_1645,,First line of therapy,Induction,,Dexamethasone,,,,Investigator decision for other reasons,,40,mg,,Q w,,PO,,180,370,1
MMRF_1645,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,600,mg,,Oth,every other week,PO,,1,117,1
MMRF_1645,,First line of therapy,Other,SCT,Melphalan,,,,Completed regimen,,140,Other,mg/m2,Q d,,IV,,440,440,1
MMRF_1645,,First line of therapy,Maintenance,,Lenalidomide,,,,Completed regimen,,2.5,mg,,Q d,,PO,,943,1639,1
MMRF_1645,,First line of therapy,Maintenance,,Lenalidomide,,,,Other,stem cell transplant surgeon wanted to increase dose,5,mg,,Oth,"3 times per week - Monday, Wednesday, and Friday",PO,,540,943,1
MMRF_1651,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,"day 8, 15, 22",IV,,8,120,1
MMRF_1651,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,"day 1, 8, 15, 22",PO,,1,120,1
MMRF_1651,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.6,mg/m^,,Oth,"day 1, 8, 15, 22",IV SubQ,,1,120,1
MMRF_1651,,First line of therapy,Consolidation,,Dexamethasone,,,,Completed regimen,,20,mg,,QWK,,PO,,120,633,1
MMRF_1651,,First line of therapy,Consolidation,,Lenalidomide,,,,Other,patient responding to treatment,25,mg,,QD,,PO,,120,358,1
MMRF_1651,,First line of therapy,Maintenance,,Lenalidomide,,,,Completed regimen,,15,mg,,Q d,,PO,,358,379,1
MMRF_1650,Baseline,First line of therapy,Induction,,Bortezomib,,,,Investigator decision for other reasons,,1.3,mg/m^,,Q w,,IV SubQ,,1,32,1
MMRF_1650,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Q w,,PO,,1,36,1
MMRF_1650,,First line of therapy,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,10,mg,,QD,,PO,,106,316,1
MMRF_1650,,First line of therapy,Maintenance,,Lenalidomide,,,,Disease progression/Relapse,,5,mg,,Oth,"By Mouth every Mon, Wed, and Friday then one week off.",PO,,316,486,1
MMRF_1650,,Second Line Therapy (after,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,10,mg,,QD,,PO,,486,659,1
MMRF_1650,,Second Line Therapy (after,Induction,,Pomalidomide,,,,Other,hospice,2,mg,,Q d,,PO,,652,997,1
MMRF_1650,,Second Line Therapy (after,Induction,,Dexamethasone,,,,Other,hospice,20,mg,,Q w,,PO,,666,997,1
MMRF_1672,Baseline,First line of therapy,Induction,,Bortezomib,,,,Investigator decision for other reasons,,2.5,mg,,QWK,,IV SubQ,,1,99,1
MMRF_1672,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.7,mg,,Q w,,IV SubQ,,106,120,1
MMRF_1672,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,500,mg,,Q w,,PO,,1,120,1
MMRF_1672,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Q w,,PO,,1,120,1
MMRF_1672,,First line of therapy,Maintenance,,Lenalidomide,,,,Other,due to thrombocytopenia,25,mg,,Q d,,PO,,154,536,1
MMRF_1672,,First line of therapy,Induction,,Lenalidomide,,,Checked,,,10,mg,,Q d,,PO,,536,,1
MMRF_1693,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,2,166,1
MMRF_1693,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,QWK,,PO,,1,166,1
MMRF_1693,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,145,166,1
MMRF_1693,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,5,mg,,QD,,PO,,532,,1
MMRF_1780,Baseline,First line of therapy,Induction,,Bortezomib,,,,Disease progression/Relapse,,1.3,mg/m^,,QD,,IV SubQ,,1,182,1
MMRF_1780,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,QD,,PO,,1,259,1
MMRF_1780,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,182,259,1
MMRF_1780,,First line of therapy,Maintenance,,Lenalidomide,,,,Completed regimen,,10,mg,,Q d,,PO,,259,287,1
MMRF_1780,,Second Line Therapy (after,Induction,,Lenalidomide,,,,Completed regimen,,15,mg,,Q d,,PO,,552,629,1
MMRF_1780,,Second Line Therapy (after,Induction,,Bortezomib,,,,Disease progression/Relapse,,3.26,mg,,Q w,,IV,,559,615,1
MMRF_1780,,First line of therapy,Induction,,Lenalidomide,,,,Disease progression/Relapse,,5,mg,,Q d,,PO,,287,629,1
MMRF_1780,,Third Line Therapy (followi,Consolidation,,Carfilzomib,,,,Completed regimen,,41,mg,,QD,,IV,,629,644,1
MMRF_1780,,Third Line Therapy (followi,Consolidation,,Bortezomib,,,,Completed regimen,,3.42,mg,,Q w,,IV SubQ,,673,680,1
MMRF_1780,,Third Line Therapy (followi,Consolidation,,Cyclophosphamide,,,,Completed regimen,,700,mg,,Q w,,PO,,673,687,1
MMRF_1897,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Q w,,PO,,25,61,1
MMRF_1897,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV,,1,26,1
MMRF_1922,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,169,1
MMRF_1922,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Q w,,PO,,1,271,1
MMRF_1922,,First line of therapy,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,10,mg,,Q d,,PO,,341,1323,1
MMRF_1945,Baseline,First line of therapy,Induction,,Bortezomib,,,Checked,,,1.3,mg/m^,,QD,,IV SubQ,,1,,1
MMRF_1945,,First line of therapy,Induction,,Dexamethasone,,,Checked,,,40,mg,,QD,,PO,,1,,1
MMRF_1994,Baseline,First line of therapy,Induction,,Bortezomib,,,,Other,Lack of Response and Hospice,1.96,mg,,Oth,"QD (D1, D8, D15, D22)",IV SubQ,,1,272,1
MMRF_1994,,First line of therapy,Induction,,Dexamethasone,,,,Other,Lack of Response and Hospice,4,mg,,Q w,,PO,,1,249,1
MMRF_1994,,First line of therapy,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,10,mg,,QD,,PO,,148,207,1
MMRF_2160,,First line of therapy,Induction,,Dexamethasone,,,,Disease progression/Relapse,,20,mg,,Q w,,PO,,1,79,1
MMRF_2160,Baseline,First line of therapy,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,2.72,mg/m^,,Q w,,IV SubQ,,1,11,1
MMRF_2160,,First line of therapy,Induction,,Lenalidomide,,,,Patient decision,,5,mg,,QD,,PO,,60,71,1
MMRF_2478,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,2.81,mg,,QWK,,IV,,6,167,1
MMRF_2478,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,550,mg,,Q w,,PO,,1,601,1
MMRF_2478,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Q w,,PO,,1,167,1
MMRF_2478,,Second Line Therapy (after,Maintenance,,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,Q w,,PO,,174,855,1
MMRF_2478,,Second Line Therapy (after,Maintenance,,Bortezomib,,,,Adverse Event or co-morbidity,,2.81,mg,,Q w,,IV,,174,319,1
MMRF_2478,,Third Line Therapy (followi,Induction,,Daratumumab,,,,Patient decision,,1324,mg,,Q d,,IV,,848,848,1
MMRF_2478,,Third Line Therapy (followi,Induction,,Pomalidomide,,,,Investigator decision for other reasons,,1,mg,,Oth,"Tuesdays, Thursday, and Saturday days 1 - 21",PO,,847,910,1
MMRF_2478,,Third Line Therapy (followi,Induction,,Pomalidomide,,,,Investigator decision for other reasons,,2,mg,,Oth,"Tuesdays, Thursday, and Saturday days 1 - 21",PO,,910,938,1
MMRF_2505,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Q w,,PO,,1,443,1
MMRF_2505,Baseline,First line of therapy,Induction,,Lenalidomide,,,,Investigator decision for other reasons,,15,mg,,Q w,,PO,,2,22,1
MMRF_2505,,First line of therapy,Induction,,Bortezomib,,,,Disease progression/Relapse,,2.6,mg,,Oth,every 21 days,IV SubQ,,74,808,1
MMRF_2505,,Second Line Therapy (after,Induction,,Carfilzomib,,,,Adverse Event or co-morbidity,,41,mg,,QD,,IV,,850,865,1
MMRF_2505,,Second Line Therapy (after,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,20,mg,,Q w,,PO,,850,857,1
MMRF_2504,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,2.17,mg,,QD,,IV SubQ,,3,164,1
MMRF_2504,,First line of therapy,Induction,,Lenalidomide,,,,Other,Did not tolerate due to pruritus of the scalp,15,mg,,Q d,,PO,,1,80,1
MMRF_2504,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,4,mg,,Q w,,PO,,23,185,1
MMRF_2504,,First line of therapy,Induction,,Cyclophosphamide,,,,Adverse Event or co-morbidity,,525,mg,,QWK,,IV,,102,118,1
MMRF_2504,,First line of therapy,Induction,,Cyclophosphamide,,,,Adverse Event or co-morbidity,,516,mg,,Q w,,IV,,54,68,1
MMRF_2523,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,2.5,mg,,QWK,,IV,,1,297,1
MMRF_2523,,First line of therapy,Induction,,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,Q w,,IV,,1,661,1
MMRF_2523,,First line of therapy,Induction,,Lenalidomide,,,,Disease progression/Relapse,,5,mg,,Q d,,PO,,24,641,1
MMRF_2589,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,2.65,mg,,QD,,IV,,1,131,1
MMRF_2589,,First line of therapy,Induction,,Dexamethasone,,,,Other,prepare for bloodess transplant,4,mg,,Q d,,PO,,2,327,1
MMRF_2589,,First line of therapy,Induction,,Lenalidomide,,,,Other,prepare for transplant,25,mg,,Q d,,PO,,8,327,1
MMRF_2589,,First line of therapy,Other,high dose chemotherapy for bloodless transplant,Melphalan,,,,Completed regimen,,140,mg/m^,,Oth,once,IV,,374,374,1
MMRF_2589,,First line of therapy,Maintenance,,Lenalidomide,,,,Other,pneumonia,10,mg,,Q d,,PO,,519,712,1
MMRF_2589,,Second Line Therapy (after,Maintenance,,Lenalidomide,,,,Other,patient deceased,5,mg,,Q d,,PO,,766,911,1
MMRF_1607,,First line of therapy,Induction,,Lenalidomide,,,Checked,,,15,mg,,QD,,PO,,1,,1
MMRF_1607,,First line of therapy,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,40,mg,,Q w,,PO,,1,113,1
MMRF_1607,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,2.58,mg,,QD,,IV,,1,203,1
MMRF_1607,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,2.2,mg,,Oth,"Days 1, 8, 15",IV SubQ,,141,190,1
MMRF_1607,,First line of therapy,Induction,,Dexamethasone,,,,Other,preparing for stem cell transplant,8,mg,,Q w,,PO,,113,190,1
MMRF_1605,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,Oth,"Days 1, 8, 15",IV SubQ,,1,176,1
MMRF_1605,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,176,1
MMRF_1605,,First line of therapy,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,40,mg,,Oth,Days 1-4 and days 9-11,PO,,1,113,1
MMRF_1605,,First line of therapy,Induction,,Bortezomib,,,,Lack of response,,1.3,mg/m^,,QD,,IV SubQ,,383,453,1
MMRF_1605,,First line of therapy,Consolidation,,Carfilzomib,,,Checked,,,20,mg/m^,,Oth,"days 1, 8, 15 followed by 14 days rest",IV,,523,,1
MMRF_1605,,First line of therapy,Maintenance,,Lenalidomide,,,,Investigator decision for other reasons,,25,mg,,Oth,days 1-14 followed by days 15-27 rest,PO,,383,525,1
MMRF_1605,,First line of therapy,Consolidation,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 8, 15 followed by 14 days rest",PO,,114,176,1
MMRF_1605,,First line of therapy,Maintenance,,Dexamethasone,,,,Adverse Event or co-morbidity,,20,mg,,Q w,,PO,,383,494,1
MMRF_1605,,First line of therapy,Maintenance,,Dexamethasone,,,,Completed regimen,,12,mg,,Q d,,PO,,495,525,1
MMRF_1605,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,25,mg,,Oth,25 mg po daily x 21 day followed by 7 days off,PO,,579,,1
MMRF_1605,,First line of therapy,Maintenance,,Dexamethasone,,,Checked,,,20,mg,,Q w,,PO,,579,,1
MMRF_1939,,First line of therapy,Induction,,Lenalidomide,,,,Patient decision,,15,mg,,QD,,PO,,1,295,1
MMRF_1939,Baseline,First line of therapy,Induction,,Bortezomib,,,,Patient decision,,1.3,mg/m^,,Oth,weekly x 3 weeks,IV,,1,295,1
MMRF_1939,,First line of therapy,Induction,,Dexamethasone,,,,Patient decision,,40,mg,,Oth,Weekly x 3 weeks when receiving velcade,PO,,1,295,1
MMRF_2035,Baseline,First line of therapy,Induction,,Bortezomib,,,Checked,,,2.6,mg,,QD,,IV SubQ,,1,,1
MMRF_2035,,First line of therapy,Induction,,Dexamethasone,,,Checked,,,40,mg,,QD,,PO,,1,,1
MMRF_2493,,First line of therapy,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,1.3,mg/m^,,Oth,weekly x 3 followed by 1 week rest,IV SubQ,,36,258,1
MMRF_2493,,First line of therapy,Induction,,Dexamethasone,,,Checked,,,40,mg,,Q w,,PO,,36,,1
MMRF_2493,Baseline,First line of therapy,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,25,mg,,QD,,PO,,6,16,1
MMRF_2493,,First line of therapy,Induction,,Dexamethasone,,,,Investigator decision for other reasons,,40,mg,,QWK,,PO,,1,16,1
MMRF_2493,,First line of therapy,Maintenance,,Daratumumab,,,Checked,,,16,mg/m^,,Oth,q 4 weeks,IV,,587,,1
MMRF_2493,,First line of therapy,Maintenance,,Ixazomib,,,,Lack of response,,4,mg,,Q w,,PO,,482,573,1
MMRF_1470,Baseline,First line of therapy,,,Lenalidomide,,,,Adverse Event or co-morbidity,,25,mg,,QD,,PO,,5,59,1
MMRF_1470,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,10,mg,,QD,,PO,,60,199,1
MMRF_1470,,First line of therapy,Induction,,Dexamethasone,,,,Patient decision,,40,mg,,Q w,,PO,,1,27,1
MMRF_1470,,First line of therapy,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,5,mg,,QD,,PO,,200,611,1
MMRF_1470,,First line of therapy,Maintenance,,Dexamethasone,,,,Completed regimen,,40,mg,,Q w,,PO,,185,213,1
MMRF_1470,,First line of therapy,Maintenance,,Dexamethasone,,,,Adverse Event or co-morbidity,,40,mg,,Q w,,PO,,291,607,1
MMRF_1820,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,2.2,mg,,QD,,Other,SQ,1,106,1
MMRF_1820,Baseline,First line of therapy,Induction,,Lenalidomide,,,,Investigator decision for other reasons,,10,mg,,QD,,PO,,22,29,1
MMRF_1820,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"D 1,2,4,5,8,9,11,12 q 21 days",PO,,1,106,1
MMRF_1820,,First line of therapy,Induction,,Lenalidomide,,,,Investigator decision for other reasons,,15,mg,,QD,,PO,,64,77,1
MMRF_1820,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,85,106,1
MMRF_1820,,First line of therapy,Induction,,Lenalidomide,,,,Investigator decision for other reasons,,10,mg,,QD,,PO,,43,57,1
MMRF_1820,,First line of therapy,Other,stem cell mobilization,Cyclophosphamide,,,,Completed regimen,,5160,mg,,Oth,once,IV,,138,138,1
MMRF_1820,,First line of therapy,Other,conditioning regimen for transplant,Carfilzomib,,,,Completed regimen,,34.4,mg,,QD,,IV,,164,179,1
MMRF_2115,,First line of therapy,Induction,,Cyclophosphamide,,,,Other,patient died of non disease related causes,650,mg,,Q w,,PO,,1,21,1
MMRF_2115,,First line of therapy,Induction,,Dexamethasone,,,,Other,patient died of non disease related causes,40,mg,,Q w,,PO,,1,21,1
MMRF_2115,Baseline,First line of therapy,Induction,,Bortezomib,,,,Other,patient died of non disease related causes,1.5,mg/m^,,Q w,,IV SubQ,,1,21,1
MMRF_2269,Baseline,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,119,1
MMRF_2269,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"D1,2,4,5,8,9,11,12 q 21 days",PO,,1,117,1
MMRF_2269,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,116,1
MMRF_2269,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,10,mg,,Oth,Day 1-21 every 28 days,PO,,134,,1
MMRF_2026,Baseline,First line of therapy,Induction,,Bortezomib,,,,Other,Patient's neuropathy- Grade 2,1.3,mg/m^,,QD,,IV,,1,147,1
MMRF_2026,,First line of therapy,Induction,,Dexamethasone,,,,Patient decision,,40,mg,,QWK,,PO,,1,938,1
MMRF_2026,,First line of therapy,Induction,,Cyclophosphamide,,,,Other,Patient's Neuropathy,750,mg,,QWK,,PO,,1,147,1
MMRF_2026,,First line of therapy,Maintenance,,Lenalidomide,,,,Disease progression/Relapse,,25,mg,,QD,,PO,,155,917,1
MMRF_2026,,Second Line Therapy (after,Unknown,,Pomalidomide,,,,Patient decision,,4,mg,,QD,,PO,,918,938,1
MMRF_2436,,First line of therapy,Induction,,Bortezomib,,,,Investigator decision for other reasons,,1.5,mg/m^,,Q w,,IV SubQ,,34,215,1
MMRF_2436,Baseline,First line of therapy,Induction,,Bortezomib,,,,Other,dose change to 1.5 mg/m^2,1.3,mg/m^,,Q w,,IV SubQ,,1,27,1
MMRF_2436,,First line of therapy,Induction,,Cyclophosphamide,,,,Other,"dose change from 500 to 550 mg D1, D8, D15 and D22",500,mg,,Q w,,PO,,27,54,1
MMRF_2436,,First line of therapy,Induction,,Dexamethasone,,,,Investigator decision for other reasons,,40,mg,,Q w,,PO,,1,215,1
MMRF_2436,,First line of therapy,Induction,,Cyclophosphamide,,,,Investigator decision for other reasons,,550,mg,,Oth,"D1, D8, D15, D22",PO,,54,215,1
MMRF_2436,,First line of therapy,Other,"Pt very frail, travel difficulty, need to have him on a regimen that he would have a restored qol",Lenalidomide,,,Checked,,,5,mg,,QD,,PO,,259,,1
MMRF_1486,Baseline,First line of therapy,Induction,,Bortezomib,,,,Investigator decision for other reasons,,1.3,mg/m^,,Oth,"D1, D8, D15, off Day 22",IV SubQ,,1,316,1
MMRF_1486,,First line of therapy,Induction,,Dexamethasone,,,,Other,patient deceased,20,mg,,Q w,,PO,,1,437,1
MMRF_1486,,First line of therapy,Induction,,Cyclophosphamide,,,,Investigator decision for other reasons,,600,mg,,Q w,,IV,,113,316,1
MMRF_1486,,First line of therapy,Induction,,Bortezomib,,,,Other,patient deceased,1.3,mg/m^,,Oth,"Q week (D1, D8, D15, off Day 22)",IV SubQ,,317,437,1
MMRF_1486,,First line of therapy,Induction,,Cyclophosphamide,,,,Other,patient deceased,600,mg,,Oth,"Q week (D1, D8, D15, off Day 22)",IV,,317,437,1
MMRF_1671,,First line of therapy,Induction,,Dexamethasone,,,,Investigator decision for other reasons,,20,mg,,Q w,,PO,,1,394,1
MMRF_1671,,First line of therapy,Induction,,Cyclophosphamide,,,,Investigator decision for other reasons,,550,mg,,Q w,,IV,,1,394,1
MMRF_1671,Baseline,First line of therapy,Induction,,Bortezomib,,,,Investigator decision for other reasons,,2.4,mg,,Q w,,IV SubQ,,1,394,1
MMRF_1671,,Second Line Therapy (after,Induction,,Lenalidomide,,,,Investigator decision for other reasons,,15,mg,,Q d,,PO,,141,407,1
MMRF_1671,,First line of therapy,Induction,,Cyclophosphamide,,,,Investigator decision for other reasons,,530,mg,,Oth,"D1, D8, D15",IV,,449,547,1
MMRF_1671,,First line of therapy,Induction,,Dexamethasone,,,,Investigator decision for other reasons,,40,mg,,Q w,,PO,,449,547,1
MMRF_1671,,First line of therapy,Induction,,Bortezomib,,,,Investigator decision for other reasons,,2.3,mg,,Oth,"D1, D8. D15",IV SubQ,,449,547,1
MMRF_1671,,Second Line Therapy (after,Consolidation,,Lenalidomide,,,,Completed regimen,,15,mg,,Q d,,PO,,449,547,1
MMRF_1671,,Second Line Therapy (after,Maintenance,,Lenalidomide,,,,Completed regimen,,15,mg,,Q d,,PO,,548,903,1
MMRF_1671,,Third Line Therapy (followi,Maintenance,,Carfilzomib,,,,Other,dose of Carfilzomib increased at beginning of next cycle,20,mg/m^,,QD,,IV,,877,903,1
MMRF_1671,,Third Line Therapy (followi,Consolidation,,Dexamethasone,,,,Adverse Event or co-morbidity,,40,mg,,QWK,,PO,,877,1227,1
MMRF_1671,,Third Line Therapy (followi,Consolidation,,Pomalidomide,,,,Adverse Event or co-morbidity,,2,mg,,Q d,,PO,,904,1227,1
MMRF_1671,,Third Line Therapy (followi,Consolidation,,Carfilzomib,,,,Other,dose of Carfilzomib increased at beginning of next cycle,27,mg/m^,,QD,,IV,,904,1050,1
MMRF_1671,,Third Line Therapy (followi,Consolidation,,Carfilzomib,,,,Other,dose of Carfilzomib increased at beginning of next cycle,36,mg/m^,,QD,,IV,,1072,1128,1
MMRF_1671,,Third Line Therapy (followi,Consolidation,,Carfilzomib,,,,Other,dose of Carfilzomib increased at beginning of next cycle,30,mg/m^,,QD,,IV,,1051,1071,1
MMRF_1671,,Fourth Line Therapy (follow,Consolidation,,Carfilzomib,,,,Adverse Event or co-morbidity,,52,mg/m^,,QD,,IV,,1128,1227,1
MMRF_1671,,Fourth Line Therapy (follow,Consolidation,,Cyclophosphamide,,,,Adverse Event or co-morbidity,,300,mg/m^,,Oth,"QD (D1, D8, D15)",IV,,1156,1227,1
MMRF_1671,,Fourth Line Therapy (follow,Consolidation,,Carfilzomib,,,,Disease progression/Relapse,,56,mg/m^,,Oth,"QD (D1, D8, D15)",IV,,1303,1507,1
MMRF_1671,,Fourth Line Therapy (follow,Consolidation,,Cyclophosphamide,,,,Disease progression/Relapse,,100,mg/m^,,Oth,"QD (D1, D8, D15)",IV,,1303,1507,1
MMRF_1671,,Fourth Line Therapy (follow,Consolidation,,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,Q w,,PO,,1303,1507,1
MMRF_1671,,Fourth Line Therapy (follow,Consolidation,,Pomalidomide,,,,Disease progression/Relapse,,2,mg,,QD,,PO,,1303,1507,1
MMRF_1671,,Fifth Line Therapy (followi,Unknown,,Pomalidomide,,,Checked,,,4,mg,,QD,,PO,,1527,,1
MMRF_1671,,Fifth Line Therapy (followi,Unknown,,Dexamethasone,,,Checked,,,40,mg,,Q w,,IV,,1527,,1
MMRF_1671,,Fifth Line Therapy (followi,Unknown,,Daratumumab,,,Checked,,,16,mg/kg,,Q w,,IV,,1527,,1
MMRF_1720,,First line of therapy,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,8,mg,,QD,,PO,,4,38,1
MMRF_1720,Baseline,First line of therapy,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,1.9,mg,,QD,,IV SubQ,,1,38,1
MMRF_1720,,First line of therapy,Induction,,Dexamethasone,,,,Other,Given as one time dose since patient did not have oral available,8,mg,,Oth,IV one time only,IV,,1,1,1
MMRF_1912,,First line of therapy,Induction,,Dexamethasone,,,,Investigator decision for other reasons,,20,mg,,QD,,IV,,1,127,1
MMRF_1912,,First line of therapy,Induction,,Cyclophosphamide,,,,Investigator decision for other reasons,,610,mg,,Q w,,IV,,1,127,1
MMRF_1912,Baseline,First line of therapy,Induction,,Bortezomib,,,,Investigator decision for other reasons,,2.8,mg,,QD,,IV SubQ,,1,127,1
MMRF_1912,,First line of therapy,Induction,,Cyclophosphamide,,,,Disease progression/Relapse,,630,mg,,Oth,"D1, D8, D15",IV,,128,204,1
MMRF_1912,,Second Line Therapy (after,Consolidation,,Carfilzomib,,,,Disease progression/Relapse,,60,mg,,QD,,IV,,211,341,1
MMRF_1912,,First line of therapy,Induction,,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,QWK,,PO,,128,204,1
MMRF_1912,,Second Line Therapy (after,Consolidation,,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,Oth,"D1, D8, D15",PO,,211,341,1
MMRF_1912,,Second Line Therapy (after,Consolidation,,Cyclophosphamide,,,,Disease progression/Relapse,,640,mg,,Oth,"D1, D8, D15",IV,,211,341,1
MMRF_1912,,First line of therapy,Induction,,Bortezomib,,,,Disease progression/Relapse,,2.7,mg,,Oth,"D1, D8, D15",IV SubQ,,128,204,1
MMRF_1505,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Q d,,PO,,1,15,1
MMRF_1505,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,1204,mg,,Oth,day 8 starting cycle 2 onwards,IV,,36,127,1
MMRF_1505,Baseline,First line of therapy,Induction,,Bortezomib,,,Checked,,,3.6,mg/dL,,QD,,IV SubQ,,1,,1
MMRF_1782,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,2.4,mg,,Oth,weekly x3 weeks/month,IV SubQ,,1,113,1
MMRF_1782,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,weekly x3 weeks/month with Velcade,PO,,1,113,1
MMRF_1782,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,113,1
MMRF_1782,,Second Line Therapy (after,Maintenance,,Lenalidomide,,,,Disease progression/Relapse,,25,mg,,Q w,,PO,,574,727,1
MMRF_1782,,Second Line Therapy (after,Maintenance,,Dexamethasone,,,,Disease progression/Relapse,,20,mg,,Q w,,PO,,727,835,1
MMRF_1944,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,300,mg,,Q w,,IV,,4,19,1
MMRF_1944,Baseline,First line of therapy,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,1.4,mg,,Q w,,IV,,4,84,1
MMRF_1944,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Q w,,PO,,1,49,1
MMRF_1944,,First line of therapy,Consolidation,,Cyclophosphamide,,,,Completed regimen,,695,mg,,Oth,One dose,IV,,33,40,1
MMRF_1944,,First line of therapy,Other,Dose reduced,Dexamethasone,,,,Other,Death,4,mg,,TID,,PO,,67,84,1
MMRF_2203,,First line of therapy,Induction,,Dexamethasone,,,Checked,,,20,mg,,Q w,,PO,,1,,1
MMRF_2203,,First line of therapy,Induction,,Cyclophosphamide,,,Checked,,,500,mg/m^,,QWK,,IV SubQ,,1,,1
MMRF_2203,Baseline,First line of therapy,Induction,,Bortezomib,,,Checked,,,1.5,mg/m^,,Q w,,IV SubQ,,1,,1
MMRF_1533,,First line of therapy,Induction,,Other,Methylprednisolone,,Checked,,,8,mg,,Oth,every other day,PO,,1,,1
MMRF_1533,,First line of therapy,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,3.7,mg,,Q w,,Other,subcutaneous,1,398,1
MMRF_1533,,First line of therapy,Induction,,Bortezomib,,,,Disease progression/Relapse,,3,mg,,Oth,every 2 weeks,Other,subcutaneous,399,567,1
MMRF_1533,,Second Line Therapy (after,Maintenance,,Pomalidomide,,,Checked,,,4,mg,,Q d,,PO,,581,,1
MMRF_1580,Baseline,First line of therapy,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,3.3,mg,,QWK,,Other,subcutaneous,1,70,1
MMRF_1580,,First line of therapy,Induction,,Prednisone,,,,Adverse Event or co-morbidity,,40,mg,,Oth,every 48 hours,PO,,1,8,1
MMRF_1580,,First line of therapy,Maintenance,,Bortezomib,,,Checked,,,3.3,mg,,Q w,,Other,subcutaneous,81,,1
MMRF_2113,Baseline,First line of therapy,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,10,mg,,Q d,,PO,,1,116,1
MMRF_2113,,First line of therapy,Induction,,Other,Methylprednisolone,,Checked,,,40,mg,,Oth,every other day,PO,,1,,1
MMRF_2113,,First line of therapy,Induction,,Bortezomib,,,Checked,,,31,mg,,Q w,,Other,subcutaneous,123,,1
MMRF_1499,Baseline,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,25,1
MMRF_1499,,First line of therapy,Induction,,Dexamethasone,,,,Investigator decision for other reasons,,28,mg,,Oth,"D1, D15",PO,,1,363,1
MMRF_1499,,First line of therapy,Induction,,Dexamethasone,,,,Investigator decision for other reasons,,40,mg,,Oth,"It is taken on D8, D22 non-elotuzumab treatment days",PO,,56,363,1
MMRF_1499,,First line of therapy,Induction,,Elotuzumab,,,,Investigator decision for other reasons,,10,mg/kg,,Oth,"It is taken on D1, D8, D15, D22",IV,,1,507,1
MMRF_1499,,First line of therapy,Induction,,Lenalidomide,,,,Investigator decision for other reasons,,25,mg,,Oth,It is taken from D1 to D21,PO,,85,624,1
MMRF_1499,,First line of therapy,Induction,,Lenalidomide,,,,Disease progression/Relapse,,15,mg,,Oth,q2 days for 21 days.,PO,,624,1232,1
MMRF_1499,,First line of therapy,Induction,,Elotuzumab,,,,Disease progression/Relapse,,20,mg/kg,,Oth,Daily for 1 day,IV,,516,1232,1
MMRF_1499,,First line of therapy,Induction,,Dexamethasone,,,,Investigator decision for other reasons,,12,mg,,Oth,Take it on Day 1 and Day 15,PO,,364,447,1
MMRF_1499,,First line of therapy,Induction,,Dexamethasone,,,,Investigator decision for other reasons,,20,mg,,Oth,Take on Day 8 and Day 22 on non-elotuzumab days.,PO,,364,447,1
MMRF_1499,,First line of therapy,Induction,,Dexamethasone,,,,Disease progression/Relapse,,12,mg,,Oth,"Take on Day 8, 15 and 22.",PO,,448,1232,1
MMRF_1499,,Second Line Therapy (after,Induction,,Pomalidomide,,,,Disease progression/Relapse,,4,mg,,Oth,Daily for 21 days every cycle.,PO,,1254,1308,1
MMRF_1499,,Second Line Therapy (after,Induction,,Daratumumab,,,,Disease progression/Relapse,,16,mg/kg,,Oth,Day 1 of each cycle,IV,,1254,1308,1
MMRF_1499,,Second Line Therapy (after,Induction,,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,Oth,q1 week for 4 weeks in each cycle,PO,,1254,1308,1
MMRF_1499,,Third Line Therapy (followi,Induction,,Cyclophosphamide,,,,Other,dose change,300,mg/m^,,Oth,Q1 week for 3 weeks.,PO,,1309,1309,1
MMRF_1499,,Third Line Therapy (followi,Induction,,Bortezomib,,,Checked,,,1.5,mg/m^,,Oth,"1 day per week, every 3 weeks ( one cycle)",IV,,1309,,1
MMRF_1499,,Third Line Therapy (followi,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,Q 1 week for 4 weeks,PO,,1309,1336,1
MMRF_1499,,Third Line Therapy (followi,Induction,,Cyclophosphamide,,,Checked,,,263.15,mg/m^,,Oth,q1 week for 3 weeks,PO,,1393,,1
MMRF_1499,,Third Line Therapy (followi,Maintenance,,Dexamethasone,,,Checked,,,20,mg,,Oth,q 1 week for 3 weeks,PO,,1337,,1
MMRF_1512,Baseline,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,425,mg/m^,,Q w,,PO,,1,84,1
MMRF_1512,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,3680,mg,,Oth,at 2500mg/m^2 for 1 day,IV,,119,119,1
MMRF_1512,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,2.2,mg,,Oth,"This is 4th cycle, it is given on D1, D8, D15, D22",IV,,85,158,1
MMRF_1512,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,12,mg,,Oth,"This is 4th cycle, it is taken once a week for four weeks.",PO,,119,125,1
MMRF_1512,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.5,mg/m^,,QWK,,IV,,1,84,1
MMRF_1512,,First line of therapy,Induction,,Dexamethasone,,,,Investigator decision for other reasons,,40,mg,,QWK,,PO,,1,22,1
MMRF_1512,,First line of therapy,Maintenance,,Lenalidomide,,,,Investigator decision for other reasons,,10,mg,,Oth,daily for 21 days,PO,,344,943,1
MMRF_1512,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,Oth,On day 1 and 7 for 1 week.,IV,,155,162,1
MMRF_1512,,Second Line Therapy (after,Maintenance,,Cyclophosphamide,,,Checked,,,425,mg,,Oth,q1 week for 4 weeks,PO,,1541,,1
MMRF_1512,,Second Line Therapy (after,Maintenance,,Bortezomib,,,Checked,,,2.2,mg,,Q d,,IV SubQ,,1546,,1
MMRF_1512,,Second Line Therapy (after,Maintenance,,Dexamethasone,,,Checked,,,20,mg,,Oth,q1 week for 4 weeks each cycle,PO,,1541,,1
MMRF_1577,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,once a week for 4 weeks,PO,,1,233,1
MMRF_1577,Baseline,First line of therapy,Induction,,Bortezomib,,,,Investigator decision for other reasons,,3,mg,,Oth,twice a week for 14 days,IV SubQ,,1,128,1
MMRF_1577,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,700,mg,,Oth,once a week for 3 weeks,PO,,1,149,1
MMRF_1577,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.5,mg/m^,,Oth,Once a week for 14 days,IV,,128,152,1
MMRF_1577,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Daily for 14 days,PO,,86,233,1
MMRF_1577,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,4640,mg,,Oth,Daily for 1 day,IV,,172,172,1
MMRF_1577,,First line of therapy,Consolidation,,Bortezomib,,,,Completed regimen,,1.5,mg/m^,,Oth,daily for 21 days,IV,,340,382,1
MMRF_1577,,First line of therapy,Consolidation,,Dexamethasone,,,,Investigator decision for other reasons,,20,mg,,Oth,q 1 week for 3 weeks,PO,,340,539,1
MMRF_1577,,First line of therapy,Consolidation,,Lenalidomide,,,,Completed regimen,,15,mg,,Oth,daily for 21 days,PO,,340,382,1
MMRF_1577,,First line of therapy,Maintenance,,Lenalidomide,,,,Disease progression/Relapse,,15,mg,,Oth,daily for 21 days,PO,,396,1061,1
MMRF_1577,,First line of therapy,Maintenance,,Dexamethasone,,,,Investigator decision for other reasons,,16,mg,,Q d,,PO,,535,562,1
MMRF_1577,,First line of therapy,Maintenance,,Dexamethasone,,,,Investigator decision for other reasons,,8,mg,,Oth,q 1 week for 4 weeks,PO,,563,589,1
MMRF_1577,,Second Line Therapy (after,Induction,,Bortezomib,,,,Disease progression/Relapse,,1.3,mg/m^,,Oth,q1 week for 4 weeks,IV,,1081,1494,1
MMRF_1577,,Second Line Therapy (after,Induction,,Other,Selinexor (KPT-330),,,Investigator decision for other reasons,,100,mg,,Oth,q 1 week for 5 weeks,PO,,1081,1227,1
MMRF_1577,,Second Line Therapy (after,Induction,,Dexamethasone,,,,Other,Poor tolerance,40,mg,,Oth,q 1 week for 5 weeks,PO,,1081,1473,1
MMRF_1577,,Second Line Therapy (after,Induction,,Other,Selinexor (KPT-330),,,Patient decision,,60,mg,,Oth,q 1 week for 5 weeks,PO,,1333,1473,1
MMRF_1577,,Second Line Therapy (after,Induction,,Other,Selinexor (KPT-330),,,Adverse Event or co-morbidity,,80,mg,,Oth,q 1 week for 5 weeks,PO,,1228,1332,1
MMRF_1577,,Third Line Therapy (followi,Induction,,Pomalidomide,,,Checked,,,4,mg,,QD,,PO,,1572,,1
MMRF_1577,,Third Line Therapy (followi,Induction,,Cyclophosphamide,,,Checked,,,400,mg,,Oth,"Days 1, 8, 15",PO,,1572,,1
MMRF_1577,,Third Line Therapy (followi,Induction,,Daratumumab,,,Checked,,,16,mg/kg,,Q d,,IV,,1572,,1
MMRF_1577,,Third Line Therapy (followi,Induction,,Dexamethasone,,,Checked,,,20,mg,,Q d,,PO,,1572,,1
MMRF_1589,Baseline,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,600,mg,,Oth,(at 263.2mg/m2) twice a day  for 14 days,PO,,1,128,1
MMRF_1589,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,for 1 day,PO,,1,134,1
MMRF_1589,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,3.4,mg,,Oth,(at 1.5mg/m2) daily for 1day for 14 days,IV SubQ,,1,128,1
MMRF_1589,,First line of therapy,Consolidation,,Cyclophosphamide,,,,Completed regimen,,2500,mg/m^,,Oth,Daily for 1 day,IV,,162,162,1
MMRF_1589,,First line of therapy,Consolidation,,Cyclophosphamide,,,,Completed regimen,,2500,mg/m^,,Oth,Daily for 1 day,IV,,167,196,1
MMRF_1589,,First line of therapy,Maintenance,,Lenalidomide,,,,Investigator decision for other reasons,,10,mg,,Oth,daily for 21 days,PO,,273,480,1
MMRF_1589,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,12,mg,,Oth,Daily for 1 day,PO,,162,196,1
MMRF_1589,,First line of therapy,Maintenance,,Lenalidomide,,,,Completed regimen,,10,mg,,Oth,Daily for 21 days.,PO,,610,1211,1
MMRF_1715,Baseline,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,525,mg,,Oth,q 1 week for 4 weeks,PO,,1,126,1
MMRF_1715,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,2.3,mg,,Oth,Daily for 1 day,IV,,64,64,1
MMRF_1715,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,2.6,mg,,Oth,Daily for 1 day weekly,IV,,15,43,1
MMRF_1715,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,"12 mg prior to chemo,4mg for four doses starting on day 1 of each cycle.",PO,,1,126,1
MMRF_1715,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,2.6,mg,,Oth,Daily for 1 day every two weeks,IV,,50,63,1
MMRF_1867,Baseline,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,q 1 week for 4 weeks,PO,,1,91,1
MMRF_1867,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.5,mg/m^,,Oth,once a week for three weeks,IV,,1,71,1
MMRF_1867,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,q 1 week for four weeks,PO,,1,91,1
MMRF_1867,,First line of therapy,Other,Part of bone marrow transplant procedure.,Cyclophosphamide,,,,Completed regimen,,2500,mg/m^,,Oth,For 1 day.,IV,,92,92,1
MMRF_1867,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,10,mg,,Oth,Daily for 21 days.,PO,,233,,1
MMRF_1867,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,12,mg,,Oth,Daily for 1 day,PO,,92,93,1
MMRF_1867,,First line of therapy,Other,Botezomib Pre-treatment for Autologous bone marrow transplant,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,Oth,for 1 day,IV,,121,124,1
MMRF_1873,,First line of therapy,Induction,,Dexamethasone,,,,Investigator decision for other reasons,,20,mg,,Oth,once a week for 4 weeks,PO,,1,127,1
MMRF_1873,Baseline,First line of therapy,Induction,,Cyclophosphamide,,,,Investigator decision for other reasons,,300,mg,,Oth,once a week for 4 weeks,PO,,1,127,1
MMRF_1873,,First line of therapy,Induction,,Bortezomib,,,,Investigator decision for other reasons,,1.3,mg/m^,,Oth,"on days 1, 8, and 16.",IV,,1,127,1
MMRF_1910,Baseline,First line of therapy,Induction,,Prednisone,,,,Investigator decision for other reasons,,5,mg,,Oth,Daily,PO,,1,62,1
MMRF_1910,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,Oral q 1 week for 4 weeks,PO,,52,93,1
MMRF_1910,,First line of therapy,Induction,,Bortezomib,,,,Investigator decision for other reasons,,1.3,mg/m^,,Oth,once a week for 4 weeks,IV,,52,94,1
MMRF_1910,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,once a week for 4 weeks,PO,,52,220,1
MMRF_1910,,Second Line Therapy (after,Induction,,Cyclophosphamide,,,,Completed regimen,,2500,mg/m^,,Oth,Daily for 1 day,IV,,220,220,1
MMRF_1910,,Second Line Therapy (after,Induction,,Lenalidomide,,,,Disease progression/Relapse,,25,mg,,Oth,daily for 21 days,PO,,123,415,1
MMRF_1910,,Second Line Therapy (after,Induction,,Bortezomib,,,,Investigator decision for other reasons,,1.5,mg/m^,,Oth,Daily for 1 day,IV,,95,193,1
MMRF_1910,,Second Line Therapy (after,Induction,,Bortezomib,,,,Disease progression/Relapse,,1.5,mg/m^,,Oth,q 1 week for 3 weeks,IV,,333,415,1
MMRF_1910,,Second Line Therapy (after,Induction,,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,Oth,Once a week,PO,,333,415,1
MMRF_1910,,Third Line Therapy (followi,Induction,,Pomalidomide,,,,Disease progression/Relapse,,4,mg,,Oth,Daily for 21 days.,PO,,417,487,1
MMRF_1910,,Fourth Line Therapy (follow,Induction,,Other,KPT-330,,,Disease progression/Relapse,,40,mg,,Oth,Daily on Monday and Wednesday for 7 days.,PO,,491,507,1
MMRF_1910,,Third Line Therapy (followi,Induction,,Bortezomib,,,,Disease progression/Relapse,,1.5,mg/m^,,Oth,q 1 week for 3 weeks,IV,,417,487,1
MMRF_1910,,Fifth Line Therapy (followi,Induction,,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,Oth,"20mg daily on Tu Th for 7 days, 8mg every 8 hours for 4 weeks.",PO,,512,514,1
MMRF_1910,,Fifth Line Therapy (followi,Induction,,Other,KPT-330,,,Disease progression/Relapse,,60,mg,,Oth,Daily on Tu and Thur for 7 days.,PO,,512,533,1
MMRF_1910,,Fourth Line Therapy (follow,Induction,,Prednisone,,,,Disease progression/Relapse,,5,mg,,QID,,PO,,526,535,1
MMRF_1927,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.5,mg/m^,,Oth,Once a week,IV,,1,274,1
MMRF_1927,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,once a week for 4 weeks,PO,,1,204,1
MMRF_1927,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,8,mg,,Oth,Daily for 12 days,PO,,3,148,1
MMRF_1927,,First line of therapy,Induction,,Cyclophosphamide,,,,Investigator decision for other reasons,,5200,mg,,Oth,Once for One day,IV,,175,175,1
MMRF_1927,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,q 1 week for 4 weeks,PO,,175,204,1
MMRF_1927,,First line of therapy,Maintenance,,Lenalidomide,,,,Investigator decision for other reasons,,10,mg,,Oth,Daily for 21 days.,PO,,389,472,1
MMRF_1927,,First line of therapy,Maintenance,,Lenalidomide,,,,Investigator decision for other reasons,,5,mg,,Oth,Daily for 21 days.,PO,,473,788,1
MMRF_1927,,Second Line Therapy (after,Induction,,Daratumumab,,,,Disease progression/Relapse,,16,mg/kg,,Oth,Q1 week for 4 weeks in each cycle.,IV,,1072,1121,1
MMRF_1927,,Second Line Therapy (after,Induction,,Pomalidomide,,,,Disease progression/Relapse,,4,mg,,Oth,Daily for 14 days.,PO,,1128,1260,1
MMRF_1927,,Second Line Therapy (after,Induction,,Dexamethasone,,,Checked,,,40,mg,,Oth,Q 1 week for 4 weeks,PO,,1072,,1
MMRF_1927,,Fourth Line Therapy (follow,Consolidation,,Carfilzomib,,,,Other,dose change,40,mg,,Oth,daily for 2 days,IV,,1260,1261,1
MMRF_1927,,Fourth Line Therapy (follow,Consolidation,,Carfilzomib,,,Checked,,,54,mg,,Oth,daily for 2 days,IV,,1292,,1
MMRF_1927,,Third Line Therapy (followi,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,1.9,mg,,Oth,"daily M,F for 2 weeks",IV SubQ,,1128,1238,1
MMRF_1927,,Fourth Line Therapy (follow,Consolidation,,Carfilzomib,,,,Other,dose change,113,mg,,Oth,daily for 2 days,IV,,1271,1279,1
MMRF_2265,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,"Days 1to 4, and 17 to 20.",PO,,1,124,1
MMRF_2265,Baseline,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,276.2,mg/m^,,Oth,q 1 week for 4 weeks,PO,,1,124,1
MMRF_2265,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.5,mg/m^,,Oth,Daily for 1 day,IV,,1,124,1
MMRF_2265,,First line of therapy,Consolidation,,Bortezomib,,,,Completed regimen,,1,mg/m^,,Oth,for day 1 and day 3.,IV,,155,158,1
MMRF_2265,,First line of therapy,Consolidation,,Lenalidomide,,,,Other,starting maintenance,10,mg,,Oth,Daily for 21 days.,PO,,260,315,1
MMRF_2265,,First line of therapy,Consolidation,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,Once a week for 4 weeks.,PO,,260,316,1
MMRF_2265,,First line of therapy,Consolidation,,Dexamethasone,,,,Completed regimen,,12,mg,,Oth,for 1 day,PO,,126,127,1
MMRF_2265,,First line of therapy,Consolidation,,Cyclophosphamide,,,,Completed regimen,,2500,mg/m^,,Oth,for 1 day,IV,,126,127,1
MMRF_2265,,First line of therapy,Consolidation,,Bortezomib,,,,Completed regimen,,1,mg/m^,,Oth,for 1 day,IV,,153,153,1
MMRF_2265,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,10,mg,,Oth,days 1-21,PO,,316,,1
MMRF_2563,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.5,mg/m^,,QD,,IV,,1,98,1
MMRF_2563,,First line of therapy,Induction,,Dexamethasone,,,,Investigator decision for other reasons,,40,mg,,Oth,q 1 week for 4 weeks,PO,,1,299,1
MMRF_2563,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,q1 week for 4 weeks,PO,,1,113,1
MMRF_2563,,First line of therapy,Consolidation,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,Oth,For 1 day.,IV,,167,171,1
MMRF_2563,,First line of therapy,Consolidation,,Bortezomib,,,,Completed regimen,,1.5,mg/m^,,Oth,q1 week for 4 weeks,IV,,240,300,1
MMRF_2563,,First line of therapy,Consolidation,,Cyclophosphamide,,,,Completed regimen,,2500,mg/m^,,Oth,For 1 day.,IV,,134,135,1
MMRF_2563,,First line of therapy,Consolidation,,Lenalidomide,,,,Completed regimen,,10,mg,,Oth,"10 mg per day for 21 days, then 7 days off.",PO,,238,293,1
MMRF_2563,,First line of therapy,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,10,mg,,Oth,Daily for 21 days.,PO,,342,707,1
MMRF_2563,,First line of therapy,Maintenance,,Bortezomib,,,,Investigator decision for other reasons,,1.5,mg/m^,,Oth,q 2 weeks for 2 doses.,IV SubQ,,342,650,1
MMRF_2563,,First line of therapy,Maintenance,,Bortezomib,,,Checked,,,1.3,mg/m^,,Oth,q 2 weeks for 4 doses.,IV,,651,,1
MMRF_2563,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,5,mg,,Oth,daily for 21 tro 42 days,PO,,775,,1
MMRF_1597,,First line of therapy,Maintenance,,Dexamethasone,,,,Patient decision,,40,mg,,Oth,one dose,PO,,27,27,1
MMRF_1597,,First line of therapy,Maintenance,,Bortezomib,,,,Completed regimen,,3,mg,,Oth,"Day 1, D7, D14",IV SubQ,,27,100,1
MMRF_1597,,First line of therapy,Induction,,Dexamethasone,,,,Other,maintenance therapy started,40,mg,,Oth,"Day 1, 8, 15",PO,,2,16,1
MMRF_1597,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,2.6,mg,,QD,,IV SubQ,,2,12,1
MMRF_1597,,First line of therapy,Induction,,Dexamethasone,,,,Patient decision,,40,mg,,Oth,single dose,PO,,1,1,1
MMRF_1597,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,600,mg,,Oth,"D1, 8, 15",PO,,2,16,1
MMRF_1597,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,5100,mg,,Q d,,IV,,117,117,1
MMRF_1597,,First line of therapy,Induction,,Other,busulphan,,,Completed regimen,,225,mg,,Oth,"Day -5, -4, -3",IV,,147,149,1
MMRF_1597,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,280,mg,,Oth,single dose,IV,,150,150,1
MMRF_1597,,First line of therapy,Maintenance,,Lenalidomide,,,,Investigator decision for other reasons,,10,mg,,QD,,PO,,251,501,1
MMRF_1597,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,15,mg,,QD,,PO,,502,,1
MMRF_1610,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,3.4,mg,,Oth,"Day 1, 8, 15",IV SubQ,,1,15,1
MMRF_1610,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,"Day 1, 8, 15, 22",PO,,1,22,1
MMRF_1610,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,700,mg,,Oth,"Day 1, 8, 15, 22",PO,,1,22,1
MMRF_1610,,First line of therapy,Induction,,Other,busulphan,,,Completed regimen,,274.6,mg,,Oth,"Day -5, -4, -3",IV,,150,152,1
MMRF_1610,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,330.4,mg,,Oth,single dose,IV,,153,153,1
MMRF_1610,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,10,mg,,Q d,,PO,,260,,1
MMRF_1614,Baseline,First line of therapy,Induction,,Lenalidomide,,,Checked,,,25,mg,,QD,,PO,,1,,1
MMRF_1614,,First line of therapy,Induction,,Dexamethasone,,,,Other,excellant response so discontinued,40,mg,,Q w,,PO,,1,394,1
MMRF_1638,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,500,mg,,Oth,"D1, 8, 15, 22",PO,,1,128,1
MMRF_1638,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,"D1, 8, 15, 22",PO,,1,128,1
MMRF_1638,Baseline,First line of therapy,Induction,,Bortezomib,,,,Other,dose titrated,3.2,mg,,Oth,"D1, 8, 15",IV SubQ,,1,15,1
MMRF_1638,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,3.3,mg,,QWK,,IV SubQ,,29,135,1
MMRF_1638,,First line of therapy,Maintenance,,Lenalidomide,,,,Disease progression/Relapse,,10,mg,,Q d,,PO,,319,683,1
MMRF_1638,,First line of therapy,Other,transplant induction,Melphalan,,,,Completed regimen,,440,Other,mcg,Oth,single dose,IV,,184,184,1
MMRF_1638,,Second Line Therapy (after,Induction,,Pomalidomide,,,,Disease progression/Relapse,,4,mg,,QD,,PO,,683,767,1
MMRF_1638,,Second Line Therapy (after,Induction,,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,QWK,,PO,,683,767,1
MMRF_1655,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,2.5,mg,,Q w,,IV SubQ,,1,162,1
MMRF_1655,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,QWK,,PO,,1,162,1
MMRF_1655,,First line of therapy,Induction,,Cyclophosphamide,,,,Other,titrated,300,mg,,QWK,,PO,,1,77,1
MMRF_1655,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,500,mg,,QWK,,PO,,84,162,1
MMRF_1655,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,10,mg,,Q d,,PO,,318,,1
MMRF_1655,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,350,Other,mcg,Oth,one dose,IV,,225,225,1
MMRF_1856,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,3.1,mg,,Q w,,IV SubQ,,1,138,1
MMRF_1856,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,500,mg,,Q w,,PO,,1,138,1
MMRF_1856,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Q w,,PO,,1,138,1
MMRF_1856,,First line of therapy,Maintenance,,Lenalidomide,,,,Disease progression/Relapse,,10,mg,,Oth,Daily x 28 days /month,PO,,340,432,1
MMRF_1856,,First line of therapy,Consolidation,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,253,335,1
MMRF_1856,,First line of therapy,Consolidation,,Dexamethasone,,,,Completed regimen,,20,mg,,Q w,,PO,,253,335,1
MMRF_2170,,First line of therapy,Induction,,Bortezomib,,,,Investigator decision for other reasons,,1.9,mg,,Q w,,IV SubQ,,15,71,1
MMRF_2170,Baseline,First line of therapy,Induction,,Bortezomib,,,,Other,dose adjusted for weight loss,2.2,mg,,Q w,,IV SubQ,,2,10,1
MMRF_2170,,First line of therapy,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,20,mg,,Oth,"Day 1, 8,15 & 22",PO,,15,429,1
MMRF_2170,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.5,mg,,Q w,,IV SubQ,,72,107,1
MMRF_2170,,First line of therapy,Induction,,Dexamethasone,,,,Investigator decision for other reasons,,40,mg,,Oth,"D1, 8, 15",PO,,1,14,1
MMRF_2170,,First line of therapy,Induction,,Cyclophosphamide,,,,Other,drug sensitivity,441,mg,,Oth,"D1,8,15, 22",PO,,1,65,1
MMRF_2170,,First line of therapy,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,15,mg,,QD,,PO,,86,429,1
MMRF_2279,Baseline,First line of therapy,Induction,,Bortezomib,,,Checked,,,2.8,mg,,Oth,"D1, 8, 15, 22",IV SubQ,,1,,1
MMRF_2279,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,550,mg,,Oth,"D1, 8, 15, 22",PO,,1,101,1
MMRF_2279,,First line of therapy,Induction,,Dexamethasone,,,Checked,,,40,mg,,Oth,"D1, 8, 15, 22",PO,,1,,1
MMRF_2288,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,2.9,mg,,Q w,,IV SubQ,,1,333,1
MMRF_2288,,First line of therapy,Induction,,Cyclophosphamide,,,,Adverse Event or co-morbidity,,500,mg,,Q w,,PO,,1,22,1
MMRF_2288,,First line of therapy,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,40,mg,,Q w,,PO,,1,333,1
MMRF_2288,,First line of therapy,Induction,,Cyclophosphamide,,,,Adverse Event or co-morbidity,,300,mg,,Q w,,PO,,32,332,1
MMRF_2288,,First line of therapy,Maintenance,,Bortezomib,,,,Completed regimen,,2.5,mg,,QD,,IV SubQ,,416,466,1
MMRF_1676,,First line of therapy,Induction,,Dexamethasone,,,,Other,Stem cell mobilizaton and collection,40,mg,,Q w,,PO,,1,112,1
MMRF_1676,Baseline,First line of therapy,Induction,,Bortezomib,,,,Other,Stem cell mobilizaton and collection,1.5,mg/m^,,Q w,,IV SubQ,,1,112,1
MMRF_1676,,First line of therapy,Induction,,Cyclophosphamide,,,,Other,Stem cell mobilizaton and collection,550,mg,,Q w,,PO,,1,112,1
MMRF_1676,,First line of therapy,Other,Stem cell mobilization,Cyclophosphamide,,,,Completed regimen,,4700,mg,,Q d,,IV,,123,123,1
MMRF_1676,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Q w,,PO,,140,175,1
MMRF_1676,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,550,mg,,Q w,,PO,,140,175,1
MMRF_1676,,First line of therapy,Other,ASCT conditioning,Other,Busulfan,,,Completed regimen,,3.2,mg/kg,,Q d,,IV,,176,178,1
MMRF_1676,,First line of therapy,Other,ASCT conditioning,Melphalan,,,,Completed regimen,,140,mg/m^,,Q d,,IV,,179,179,1
MMRF_1676,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.5,mg/m^,,Q w,,IV SubQ,,140,175,1
MMRF_1676,,First line of therapy,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,10,mg,,Q d,,PO,,271,326,1
MMRF_1676,,First line of therapy,Maintenance,,Lenalidomide,,,,Other,Dose increase,5,mg,,Q d,,PO,,327,354,1
MMRF_1676,,First line of therapy,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,10,mg,,Q d,,PO,,355,1426,1
MMRF_1676,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,,Other,alternate between 5 and 10mg daily,Oth,alternate between 5 and 10mg daily,PO,,1426,,1
MMRF_1725,Baseline,First line of therapy,Induction,,Bortezomib,,,,Other,Stem cell mobilization and collection,1.5,mg/m^,,Q w,,IV SubQ,,1,112,1
MMRF_1725,,First line of therapy,Induction,,Cyclophosphamide,,,,Other,Stem cell mobilization and collection,575,mg,,Q w,,PO,,1,112,1
MMRF_1725,,First line of therapy,Induction,,Dexamethasone,,,,Investigator decision for other reasons,,40,mg,,QD,,PO,,1,56,1
MMRF_1725,,First line of therapy,Induction,,Dexamethasone,,,,Other,Stem cell mobilization and collection,40,mg,,Q w,,PO,,57,112,1
MMRF_1725,,First line of therapy,Other,Stem cell mobilization,Cyclophosphamide,,,,Completed regimen,,4750,mg,,Q d,,IV,,119,119,1
MMRF_1725,,First line of therapy,Other,ASCT conditioning,Other,Busulfan,,,Completed regimen,,3.2,mg/kg,,Q d,,IV,,192,194,1
MMRF_1725,,First line of therapy,Other,ASCT conditioning,Melphalan,,,,Completed regimen,,140,mg/m^,,Q d,,IV,,195,195,1
MMRF_1725,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,575,mg,,Q w,,PO,,148,196,1
MMRF_1725,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Q w,,PO,,148,196,1
MMRF_1725,,First line of therapy,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,10,mg,,Q d,,PO,,271,452,1
MMRF_1725,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.5,mg/m^,,Q w,,IV SubQ,,148,196,1
MMRF_1725,,First line of therapy,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,10,mg,,Q d,,PO,,513,627,1
MMRF_1725,,First line of therapy,Maintenance,,Lenalidomide,,,,Other,Antibiotics prophylaxis due to root canal,10,mg,,Q d,,PO,,452,504,1
MMRF_1725,,First line of therapy,Maintenance,,Lenalidomide,,,,Investigator decision for other reasons,,5,mg,,Q d,,PO,,638,932,1
MMRF_1725,,First line of therapy,Maintenance,,Lenalidomide,,,,Other,dose reduce,10,mg,,Q d,,PO,,932,1107,1
MMRF_1725,,First line of therapy,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,10,mg,,QD,,PO,,1107,1380,1
MMRF_1725,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,5,mg,,QD,,PO,,1380,,1
MMRF_1771,,First line of therapy,Induction,,Cyclophosphamide,,,,Adverse Event or co-morbidity,,550,mg,,Q w,,PO,,1,48,1
MMRF_1771,Baseline,First line of therapy,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,1.5,mg/m^,,Q w,,IV SubQ,,1,48,1
MMRF_1771,,First line of therapy,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,40,mg,,Q w,,PO,,1,48,1
MMRF_1771,,First line of therapy,Induction,,Dexamethasone,,,,Other,Stem cell mobilization and collection,40,mg,,Q w,,PO,,56,111,1
MMRF_1771,,First line of therapy,Other,Stem cell mobilization,Cyclophosphamide,,,,Completed regimen,,4550,mg,,Q d,,IV,,118,118,1
MMRF_1771,,First line of therapy,Other,Stem cell transplant conditioning,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,203,203,1
MMRF_1771,,First line of therapy,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,1.5,mg,,Q w,,IV SubQ,,133,160,1
MMRF_1771,,First line of therapy,Induction,,Cyclophosphamide,,,,Adverse Event or co-morbidity,,550,mg,,Q w,,PO,,133,160,1
MMRF_1771,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Q w,,PO,,189,201,1
MMRF_1771,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,550,mg,,Q w,,PO,,189,201,1
MMRF_1771,,First line of therapy,Induction,,Bortezomib,,,,Other,Stem cell mobilization and collection,1.5,mg,,Q w,,IV SubQ,,56,111,1
MMRF_1771,,First line of therapy,Induction,,Cyclophosphamide,,,,Other,Stem cell mobilization and collection,550,mg,,Q w,,PO,,56,111,1
MMRF_1771,,First line of therapy,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,40,mg,,Q w,,PO,,133,160,1
MMRF_1771,,First line of therapy,Maintenance,,Lenalidomide,,,,Other,Dose increase,5,mg,,Oth,"Monday, Wednesday and Friday (3 days per week)",PO,,364,426,1
MMRF_1771,,First line of therapy,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,5,mg,,Q d,,PO,,310,346,1
MMRF_1771,,First line of therapy,Maintenance,,Lenalidomide,,,,Other,elevated liver function tests. Treat held due to suspected viral hepatitis,5,mg,,Oth,Monday to Friday (5 days per week),PO,,427,455,1
MMRF_1771,,Second Line Therapy (after,Other,Treatment of Cerebrospinal fluid involvement,Other,Methotrexate,,,Other,lost to follow-up,12,mg,,Oth,twice weekly,Other,intrathecal,491,507,1
MMRF_1771,,Second Line Therapy (after,Other,Treatment of Cerebrospinal fluid involvement,Other,Cytarabine,,,Other,lost to follow-up,40,mg,,Oth,twice weekly,Other,Intrathecal,491,507,1
MMRF_1771,,Second Line Therapy (after,Other,Treatment of Cerebrospinal fluid involvement,Other,Hydrocortisone,,,Other,lost to follow-up,15,mg,,Oth,twice weekly,Other,Intrathecal,491,507,1
MMRF_1777,Baseline,First line of therapy,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,1.5,mg/m^,,Q w,,IV SubQ,,1,97,1
MMRF_1777,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,525,mg,,Q w,,PO,,1,405,1
MMRF_1777,,First line of therapy,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,40,mg,,QD,,PO,,1,29,1
MMRF_1777,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.5,mg/m^,,Q w,,IV SubQ,,112,405,1
MMRF_1777,,First line of therapy,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,40,mg,,Q w,,PO,,30,92,1
MMRF_1777,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Q w,,PO,,163,405,1
MMRF_1777,,First line of therapy,Maintenance,,Bortezomib,,,Checked,,,1.5,mg/m^,,Oth,once every 2 weeks,IV SubQ,,441,,1
MMRF_1785,,First line of therapy,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,40,mg,,Q w,,PO,,1,11,1
MMRF_1785,Baseline,First line of therapy,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,1.5,mg/m^,,Q w,,IV SubQ,,1,11,1
MMRF_1785,,First line of therapy,Induction,,Cyclophosphamide,,,,Adverse Event or co-morbidity,,550,mg,,Q w,,PO,,1,11,1
MMRF_1785,,First line of therapy,Other,Stem cell mobilization,Cyclophosphamide,,,,Completed regimen,,4550,mg,,Q d,,IV,,223,223,1
MMRF_1785,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.5,mg/m^,,Q w,,IV SubQ,,49,217,1
MMRF_1785,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,550,mg,,Q w,,PO,,49,217,1
MMRF_1785,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Q w,,PO,,49,217,1
MMRF_1785,,First line of therapy,Other,Stem cell transplant conditioning,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,258,258,1
MMRF_1785,,First line of therapy,Other,Stem cell transplant conditioning,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,417,417,1
MMRF_1785,,First line of therapy,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,10,mg,,Oth,day 1 to 21 of a 28 day cycle,PO,,461,553,1
MMRF_1785,,First line of therapy,Maintenance,,Lenalidomide,,,,Other,recurring cough,10,mg,,Oth,day 1 to 21 of a 28 day cycle,PO,,639,687,1
MMRF_1785,,Second Line Therapy (after,Other,relapse,Carfilzomib,,,,Completed regimen,,,Other,unknown,Oth,unknown,IV,,796,1352,1
MMRF_1785,,Second Line Therapy (after,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,40,mg,,Q w,,PO,,796,884,1
MMRF_1785,,Second Line Therapy (after,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,20,mg,,Q w,,PO,,884,888,1
MMRF_1785,,Second Line Therapy (after,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,15,mg,,Oth,QD (D1-21 of 28),PO,,796,1010,1
MMRF_1785,,Second Line Therapy (after,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,8,mg,,Q w,,PO,,888,940,1
MMRF_1785,,Second Line Therapy (after,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,15,mg,,QD,,PO,,1010,1248,1
MMRF_1785,,Second Line Therapy (after,Other,relapse,Lenalidomide,,,,Completed regimen,,5,mg,,QD,,PO,,1248,1366,1
MMRF_1785,,Second Line Therapy (after,Maintenance,,Ixazomib,,,Checked,,,4,mg,,Q w,,Other,unknown,1366,,1
MMRF_1792,Baseline,First line of therapy,Induction,,Bortezomib,,,,Other,Stem cell mobilization and collection,1.5,mg/m^,,Q w,,IV SubQ,,1,113,1
MMRF_1792,,First line of therapy,Induction,,Cyclophosphamide,,,,Other,Stem cell mobilization and collection,550,mg,,Q w,,PO,,1,113,1
MMRF_1792,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,PO,,1,57,1
MMRF_1792,,First line of therapy,Induction,,Dexamethasone,,,,Other,Stem cell mobilization and collection,40,mg,,Q w,,PO,,58,113,1
MMRF_1792,,First line of therapy,Other,Stem cell mobilization,Cyclophosphamide,,,,Completed regimen,,4600,mg,,Q d,,IV,,118,118,1
MMRF_1792,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1,mg/m^,,Q w,,IV SubQ,,163,197,1
MMRF_1792,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,550,mg,,Q w,,PO,,149,197,1
MMRF_1792,,First line of therapy,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,1.5,mg/m^,,Q w,,IV SubQ,,149,162,1
MMRF_1792,,First line of therapy,Other,Stem cell transplant conditioning,Other,Busulfan,,,Completed regimen,,3.2,mg/kg,,Q d,,IV,,203,205,1
MMRF_1792,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Q w,,PO,,149,197,1
MMRF_1792,,First line of therapy,Other,stem cell transplant conditioning,Melphalan,,,,Completed regimen,,140,mg/m^,,Q d,,IV,,206,206,1
MMRF_1792,,First line of therapy,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,10,mg,,Q d,,PO,,301,482,1
MMRF_1792,,First line of therapy,Maintenance,,Lenalidomide,,,,Disease progression/Relapse,,10,mg,,Q d,,PO,,484,1131,1
MMRF_1792,,Fourth Line Therapy (follow,Other,Relapse,Daratumumab,,,Checked,,,,,,,,IV,,1276,,1
MMRF_1792,,Third Line Therapy (followi,Induction,,Bortezomib,,,,Disease progression/Relapse,,2.91,mg,,Q w,,IV SubQ,,1252,1279,1
MMRF_1792,,Second Line Therapy (after,Induction,,Dexamethasone,,,,Investigator decision for other reasons,,40,mg,,Oth,4 days on 4 days off,PO,,1143,1153,1
MMRF_1792,,Third Line Therapy (followi,Induction,,Bortezomib,,,,Disease progression/Relapse,,2.91,mg,,Q w,,IV SubQ,,1229,1244,1
MMRF_1792,,Third Line Therapy (followi,Induction,,Dexamethasone,,,,Disease progression/Relapse,,,,,,,PO,,1229,1274,1
MMRF_1792,,Third Line Therapy (followi,Induction,,Pomalidomide,,,,Disease progression/Relapse,,,,,,,PO,,1229,1274,1
MMRF_1792,,Second Line Therapy (after,Induction,,Bortezomib,,,,Patient decision,,2.91,mg,,Q w,,IV SubQ,,1154,1181,1
MMRF_1792,,Second Line Therapy (after,Induction,,Bortezomib,,,,Disease progression/Relapse,,2.91,mg,,Q w,,IV SubQ,,1189,1229,1
MMRF_1792,,Second Line Therapy (after,Induction,,Dexamethasone,,,,Disease progression/Relapse,,,,,,,PO,,1154,1228,1
MMRF_1792,,Second Line Therapy (after,Induction,,Cyclophosphamide,,,,Disease progression/Relapse,,,,,,,PO,,1154,1228,1
MMRF_1792,,Fourth Line Therapy (follow,Other,Relapse,Dexamethasone,,,Checked,,,40,mg,,QWK,,PO,,1276,,1
MMRF_1792,,Fourth Line Therapy (follow,Other,Relapse,Carfilzomib,,,Checked,,,,,,Oth,twice weekly,,,1284,,1
MMRF_1792,,Fourth Line Therapy (follow,Other,relapse,Pomalidomide,,,Checked,,,4,mg,,QD,,PO,,1406,,1
MMRF_1805,Baseline,First line of therapy,Induction,,Bortezomib,,,,Other,Stem cell mobilization and collection,1.5,mg/m^,,Q w,,IV SubQ,,1,168,1
MMRF_1805,,First line of therapy,Induction,,Cyclophosphamide,,,,Other,Stem cell mobilization and collection,525,mg,,Q w,,PO,,1,175,1
MMRF_1805,,First line of therapy,Induction,,Bortezomib,,,,Other,Stem cell mobilization and collection,1.5,mg/m^,,Oth,"QD (D1, D8, D15, D22) of 35 day cycle",IV SubQ,,190,259,1
MMRF_1805,,First line of therapy,Induction,,Cyclophosphamide,,,,Other,Autologous stem cell transplant,500,mg,,Q w,,PO,,281,313,1
MMRF_1805,,First line of therapy,Induction,,Dexamethasone,,,,Other,Autologous stem cell transplant,40,mg,,Q w,,PO,,281,313,1
MMRF_1805,,First line of therapy,Induction,,Cyclophosphamide,,,,Other,Dose increase,500,mg,,Q w,,PO,,190,224,1
MMRF_1805,,First line of therapy,Induction,,Cyclophosphamide,,,,Other,Stem cell mobilization and collection,550,mg,,Q w,,PO,,225,259,1
MMRF_1805,,First line of therapy,Other,Conditioning for Autologous stem cell transplant,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,314,314,1
MMRF_1805,,First line of therapy,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,10,mg,,Q d,,PO,,415,467,1
MMRF_1805,,First line of therapy,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,10,mg,,Oth,every other day,PO,,467,498,1
MMRF_1805,,First line of therapy,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,5,mg,,Oth,Every other day,PO,,532,589,1
MMRF_1805,,First line of therapy,Maintenance,,Lenalidomide,,,,Investigator decision for other reasons,,5,mg,,Oth,3 times per week,PO,,701,889,1
MMRF_1805,,First line of therapy,Maintenance,,Lenalidomide,,,,Investigator decision for other reasons,,5,mg,,Oth,every other day,PO,,889,973,1
MMRF_1805,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,5,mg,,QD,,PO,,973,,1
MMRF_1846,Baseline,First line of therapy,Induction,,Bortezomib,,,,Other,Stem cell mobilization and collection,1.5,mg/m^,,Q w,,IV SubQ,,1,116,1
MMRF_1846,,First line of therapy,Induction,,Dexamethasone,,,,Other,Stem cell mobilization and collection,40,mg,,Q w,,PO,,1,116,1
MMRF_1846,,First line of therapy,Induction,,Cyclophosphamide,,,,Investigator decision for other reasons,,600,mg,,Q w,,PO,,1,28,1
MMRF_1846,,First line of therapy,Induction,,Cyclophosphamide,,,,Other,Stem cell mobilization and collection,500,mg,,Q w,,PO,,28,116,1
MMRF_1846,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Q w,,PO,,145,186,1
MMRF_1846,,First line of therapy,Induction,,Cyclophosphamide,,,,Adverse Event or co-morbidity,,500,mg,,Q w,,PO,,145,168,1
MMRF_1846,,First line of therapy,Other,ASCT conditioning,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,190,190,1
MMRF_1846,,First line of therapy,Other,Stem cell mobilization,Cyclophosphamide,,,,Completed regimen,,4950,mg,,Q d,,IV,,119,119,1
MMRF_1846,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.5,mg/m^,,Q w,,IV SubQ,,145,186,1
MMRF_1846,,First line of therapy,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,10,mg,,Q d,,PO,,317,561,1
MMRF_1846,,First line of therapy,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,10,mg,,Q d,,PO,,575,833,1
MMRF_1846,,First line of therapy,Maintenance,,Lenalidomide,,,,Investigator decision for other reasons,,10,mg,,Oth,every other day,PO,,834,885,1
MMRF_1846,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,5,mg,,Q d,,PO,,885,,1
MMRF_1845,Baseline,First line of therapy,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,1.5,mg/m^,,Q w,,IV SubQ,,1,56,1
MMRF_1845,,First line of therapy,Induction,,Cyclophosphamide,,,,Adverse Event or co-morbidity,,475,mg,,Q w,,PO,,1,56,1
MMRF_1845,,First line of therapy,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,40,mg,,QD,,PO,,1,56,1
MMRF_1845,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Q w,,PO,,171,198,1
MMRF_1845,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,15,mg,,QD,,PO,,145,198,1
MMRF_1845,,First line of therapy,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,40,mg,,Q w,,PO,,145,170,1
MMRF_1845,,First line of therapy,Other,Stem cell transplant conditioning,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,200,200,1
MMRF_1845,,Second Line Therapy (after,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Q w,,PO,,1167,1278,1
MMRF_1845,,Second Line Therapy (after,Other,stem cell transplant conditioning,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,1297,1297,1
MMRF_1845,,Second Line Therapy (after,Induction,,Carfilzomib,,,,Completed regimen,,40,mg,,QD,,IV,,1147,1278,1
MMRF_1845,,Second Line Therapy (after,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,QD 1-21 of 28 day cycle,PO,,1147,1278,1
MMRF_1845,,Second Line Therapy (after,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,40,mg,,Q w,,PO,,1147,1166,1
MMRF_1845,,Second Line Therapy (after,Consolidation,,Carfilzomib,,,Checked,,,40,mg,,QD,,IV,,1399,,1
MMRF_1845,,Second Line Therapy (after,Consolidation,,Dexamethasone,,,Checked,,,40,mg,,Q w,,PO,,1399,,1
MMRF_1845,,Second Line Therapy (after,Consolidation,,Lenalidomide,,,Checked,,,25,mg,,Oth,days 1 to 21 of 28 day cycle,PO,,1399,,1
MMRF_1928,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.5,mg/m^,,Q w,,IV SubQ,,1,119,1
MMRF_1928,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,500,mg,,Q w,,PO,,1,119,1
MMRF_1928,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Q w,,PO,,1,119,1
MMRF_1928,,First line of therapy,Other,Stem cell mobilization,Cyclophosphamide,,,,Completed regimen,,5150,mg,,Q d,,IV,,123,123,1
MMRF_1928,,First line of therapy,Induction,,Cyclophosphamide,,,,Other,Admitted for ASCT,600,mg,,Q w,,PO,,138,169,1
MMRF_1928,,First line of therapy,Induction,,Dexamethasone,,,,Other,Admitted for ASCT,40,mg,,Q w,,PO,,138,169,1
MMRF_1928,,First line of therapy,Consolidation,,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,170,170,1
MMRF_1928,,First line of therapy,Induction,,Bortezomib,,,,Other,Admitted for ASCT,1.5,mg/m^,,Q w,,IV SubQ,,148,169,1
MMRF_1928,,First line of therapy,Maintenance,,Lenalidomide,,,,Disease progression/Relapse,,10,mg,,Q d,,PO,,276,1140,1
MMRF_1928,,Second Line Therapy (after,Induction,,Pomalidomide,,,Checked,,,4,mg,,QD,,PO,,1162,,1
MMRF_1928,,Second Line Therapy (after,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,40,mg,,Q w,,PO,,1162,1300,1
MMRF_1928,,Second Line Therapy (after,Induction,,Daratumumab,,,Checked,,,16,mg/kg,,Q w,,IV,,1162,,1
MMRF_1928,,Second Line Therapy (after,Other,relapse,Dexamethasone,,,Checked,,,20,mg,,Q w,,PO,,1301,,1
MMRF_1960,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,Oth,"QD (D1, D8, D15, D22) of 35 day cycle",IV SubQ,,1,315,1
MMRF_1960,,First line of therapy,Induction,,Melphalan,,,,Investigator decision for other reasons,,14,mg,,QD,,PO,,1,35,1
MMRF_1960,,First line of therapy,Induction,,Prednisone,,,,Completed regimen,,95,mg,,QD,,PO,,1,315,1
MMRF_1960,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,10,mg,,QD,,PO,,36,315,1
MMRF_1960,,First line of therapy,Other,Suspected amyloid involvement,Lenalidomide,,,,Other,Palliative,5,mg,,Oth,every other day,PO,,525,565,1
MMRF_1960,,First line of therapy,Other,Suspected amyloid involvement,Dexamethasone,,,,Other,Palliative,20,mg,,Q w,,PO,,525,565,1
MMRF_2174,Baseline,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Q d,,PO,,1,4,1
MMRF_2174,,First line of therapy,Induction,,Bortezomib,,,,Investigator decision for other reasons,,1.3,mg/m^,,Oth,"1, 8, 15, 22 of a 35 day cycle",IV SubQ,,6,250,1
MMRF_2174,,First line of therapy,Induction,,Melphalan,,,,Other,Concerns on noncompliance and lack of response,4,mg,,QD,,PO,,6,145,1
MMRF_2174,,First line of therapy,Induction,,Prednisone,,,,Other,Concerns on noncompliance and lack of response,120,mg,,QD,,PO,,6,145,1
MMRF_2174,,Second Line Therapy (after,Induction,,Cyclophosphamide,,,,Investigator decision for other reasons,,400,mg,,Oth,"1, 8, 15, 22 of 35 day cycle",PO,,146,250,1
MMRF_2174,,Second Line Therapy (after,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,20,mg,,Oth,"1, 8, 15, 22 of a 35 day cycle",PO,,146,201,1
MMRF_2174,,First line of therapy,Induction,,Dexamethasone,,,,Investigator decision for other reasons,,10,mg,,Oth,"1, 8, 15, 22 of a 35 day cycle",PO,,202,250,1
MMRF_2251,Baseline,First line of therapy,Induction,,Bortezomib,,,,Disease progression/Relapse,,1.5,mg/m^,,Q w,,IV SubQ,,8,99,1
MMRF_2251,,First line of therapy,Induction,,Cyclophosphamide,,,,Other,Dose increase,400,mg,,Q w,,PO,,8,21,1
MMRF_2251,,First line of therapy,Induction,,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,Oth,"QD (D1-4, D9-12, D17-20)",PO,,8,99,1
MMRF_2251,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Q d,,IV,,1,4,1
MMRF_2251,,First line of therapy,Induction,,Cyclophosphamide,,,,Disease progression/Relapse,,500,mg,,Q w,,PO,,22,99,1
MMRF_2428,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Q w,,PO,,1,147,1
MMRF_2428,Baseline,First line of therapy,Induction,,Bortezomib,,,,Other,Start clinical trial,1.5,mg/m^,,Q w,,IV SubQ,,15,28,1
MMRF_2428,,First line of therapy,Induction,,Cyclophosphamide,,,,Other,Start clinical trial,300,mg/m^,,Q w,,PO,,1,28,1
MMRF_2428,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"QD (D1-2, D8-9, D15-16). First cycle only 20mg/m^2 for D1-2.",IV,,29,147,1
MMRF_2428,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,days 1 to 21 of a 28 day cycle,PO,,29,147,1
MMRF_2428,,First line of therapy,Other,ASCT conditioning,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,261,261,1
MMRF_2428,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Day 1,2,8,9,15 and 16 of a 28 day cycle",IV,,197,224,1
MMRF_2428,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,days 1 to 21 of a 28 day cycle,PO,,197,224,1
MMRF_2428,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Q w,,PO,,197,224,1
MMRF_2428,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,4 days on then 4 days off,PO,,176,191,1
MMRF_2428,,First line of therapy,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,1.5,mg/m^,,Q w,,IV SubQ,,1,8,1
MMRF_2428,,First line of therapy,Consolidation,,Carfilzomib,,,,Adverse Event or co-morbidity,,36,mg/m^,,Oth,"QD (D1-2, D8-9, D15-16) of a 28 day cycle",IV,,351,357,1
MMRF_2428,,First line of therapy,Consolidation,,Dexamethasone,,,,Adverse Event or co-morbidity,,20,mg,,Q w,,PO,,351,385,1
MMRF_2428,,First line of therapy,Consolidation,,Lenalidomide,,,,Other,dose increase,15,mg,,QD,,PO,,351,378,1
MMRF_2428,,First line of therapy,Consolidation,,Carfilzomib,,,,Adverse Event or co-morbidity,,36,mg/m^,,Oth,"QD (D1-2, D8-9, D15-16) of a 28 day cycle",IV,,365,385,1
MMRF_2428,,First line of therapy,Consolidation,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,407,434,1
MMRF_2428,,First line of therapy,Consolidation,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,QD,,IV,,407,434,1
MMRF_2428,,First line of therapy,Consolidation,,Dexamethasone,,,,Completed regimen,,20,mg,,Q w,,PO,,407,434,1
MMRF_2428,,First line of therapy,Maintenance,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"QD (D1-2, D15-16)",IV,,435,715,1
MMRF_2428,,First line of therapy,Maintenance,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,435,715,1
MMRF_2428,,First line of therapy,Maintenance,,Dexamethasone,,,,Completed regimen,,20,mg,,Q w,,PO,,435,715,1
MMRF_2428,,First line of therapy,Consolidation,,Lenalidomide,,,,Adverse Event or co-morbidity,,25,mg,,QD,,PO,,379,385,1
MMRF_2428,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,10,mg,,Q d,,PO,,715,,1
MMRF_1555,,First line of therapy,Induction,,Dexamethasone,,,,Investigator decision for other reasons,,20,mg,,Oth,D1 and d8,PO,,1,79,1
MMRF_1555,,First line of therapy,Induction,,Lenalidomide,,,,Investigator decision for other reasons,,10,mg,,QD,,PO,,47,79,1
MMRF_1555,Baseline,First line of therapy,Induction,,Bortezomib,,,,Investigator decision for other reasons,,1.3,mg/m^,,Oth,Q D1 & D8 q21days,IV SubQ,,1,79,1
MMRF_1555,,First line of therapy,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,15,mg,,QD,,PO,,1,47,1
MMRF_1555,,Second Line Therapy (after,Induction,,Carfilzomib,,,,Disease progression/Relapse,,20,mg,,QD,,IV SubQ,,130,230,1
MMRF_1555,,Second Line Therapy (after,Induction,,Lenalidomide,,,,Disease progression/Relapse,,10,mg,,QD,,PO,,130,230,1
MMRF_1555,,Second Line Therapy (after,Induction,,Dexamethasone,,,,Disease progression/Relapse,,20,mg,,QD,,PO,,130,230,1
MMRF_1555,,Third Line Therapy (followi,Induction,,Pomalidomide,,,,Disease progression/Relapse,,2,mg,,Oth,QD D1-21,PO,,248,340,1
MMRF_1555,,Third Line Therapy (followi,Induction,,Carfilzomib,,,,Disease progression/Relapse,,20,mg/m^,,Oth,twice weekly,IV,,248,340,1
MMRF_1555,,Third Line Therapy (followi,Induction,,Dexamethasone,,,,Disease progression/Relapse,,4,mg,,Oth,twice weekly before Carfilzomib,IV,,248,340,1
MMRF_1564,Baseline,First line of therapy,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,10,mg,,QD,,PO,,1,193,1
MMRF_1564,,First line of therapy,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,20,mg,,Q w,,PO,,1,72,1
MMRF_1564,,First line of therapy,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,12,mg,,Q w,,PO,,72,137,1
MMRF_1564,,First line of therapy,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,4,mg,,Oth,Three times a week,PO,,137,193,1
MMRF_1564,,First line of therapy,Induction,,Dexamethasone,,,,Investigator decision for other reasons,,2,mg,,Q w,,PO,,216,528,1
MMRF_1564,,First line of therapy,Induction,,Dexamethasone,,,,Investigator decision for other reasons,,1,mg,,Oth,"Take 1 mg for 2 days then 1 day off, repeat cycle",PO,,528,603,1
MMRF_1564,,First line of therapy,Induction,,Dexamethasone,,,,Investigator decision for other reasons,,0.5,mg,,Q d,,PO,,603,884,1
MMRF_1564,,First line of therapy,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,4,mg,,Oth,"0900 every other day, days 1-21 of 28 day cycle",PO,,193,216,1
MMRF_1564,,First line of therapy,Induction,,Lenalidomide,,,,Disease progression/Relapse,,5,mg,,QD,,PO,,193,1215,1
MMRF_1564,,First line of therapy,Induction,,Dexamethasone,,,,Disease progression/Relapse,,1,mg,,Oth,QD every Saturday and Sunday,PO,,884,1215,1
MMRF_1564,,Second Line Therapy (after,Unknown,,Lenalidomide,,,,Lack of response,,5,mg,,QD,,PO,,1215,1290,1
MMRF_1564,,Second Line Therapy (after,Unknown,,Bortezomib,,,,Lack of response,,2.75,mg,,Q w,,IV,,1215,1290,1
MMRF_1564,,Second Line Therapy (after,Unknown,,Pomalidomide,,,,Completed regimen,,2,mg,,Oth,Every other day,PO,,1397,1493,1
MMRF_1564,,Second Line Therapy (after,Induction,,Daratumumab,,,,Adverse Event or co-morbidity,,1640,mg,,Oth,"weekly infusions for 8 weeks, then every two weeks for 16 weeks, followed b",IV,,1304,1355,1
MMRF_1564,,Second Line Therapy (after,Unknown,,Dexamethasone,,,,Lack of response,,8,mg,,Oth,8mg prior to Bortezomib  infusion and 1mg Q day for adrenal support,PO,,1215,1290,1
MMRF_1564,,Second Line Therapy (after,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,8,mg,,Oth,prior to Dara infusion and 4mg x2 days following each daratumumab infusion,Other,IV on DARA dosing days PO x2 days following,1304,1355,1
MMRF_1564,,Second Line Therapy (after,Unknown,,Daratumumab,,,,Completed regimen,,1640,mg,,Oth,Every 2 weeks,IV,,1397,1493,1
MMRF_1569,Baseline,First line of therapy,Induction,,Lenalidomide,,,,Disease progression/Relapse,,15,mg,,QD,,PO,,1,1202,1
MMRF_1569,,First line of therapy,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,20,mg,,Q w,,PO,,1,429,1
MMRF_1569,,First line of therapy,Induction,,Dexamethasone,,,,Disease progression/Relapse,,8,mg,,Q w,,PO,,616,1104,1
MMRF_1569,,Third Line Therapy (followi,Unknown,,Dexamethasone,,,,Adverse Event or co-morbidity,,4,mg,,Oth,"Days 1, 8, 15, 22 of cycle",PO,,1407,1557,1
MMRF_1569,,Third Line Therapy (followi,Unknown,,Other,Durvalumab,,,Adverse Event or co-morbidity,,1500,mg,,Oth,Once every 4 weeks,IV,,1407,1557,1
MMRF_1569,,Third Line Therapy (followi,Unknown,,Pomalidomide,,,,Adverse Event or co-morbidity,,4,mg,,Oth,Days 1-21 of cycle,PO,,1407,1557,1
MMRF_1569,,Second Line Therapy (after,Induction,,Ixazomib,,,,Disease progression/Relapse,,4,mg,,Oth,"days 1,8,15",PO,,1222,1361,1
MMRF_1569,,Second Line Therapy (after,Induction,,Dexamethasone,,,,Disease progression/Relapse,,20,mg,,Oth,"days 1,8,15",PO,,1222,1361,1
MMRF_1569,,Second Line Therapy (after,Induction,,Lenalidomide,,,,Disease progression/Relapse,,15,mg,,QD,,PO,,1222,1361,1
MMRF_1569,,Fourth Line Therapy (follow,Unknown,,Bortezomib,,,Checked,,,1.5,mg/m^,,Q w,,IV SubQ,,1556,,1
MMRF_1569,,Fourth Line Therapy (follow,Unknown,,Dexamethasone,,,Checked,,,20,mg,,Q w,,IV,,1556,,1
MMRF_1569,,Fourth Line Therapy (follow,Unknown,,Daratumumab,,,Checked,,,16,mg/kg,,Q w,,IV,,1556,,1
MMRF_1574,Baseline,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,32,1
MMRF_1574,,First line of therapy,Induction,,Dexamethasone,,,,Other,transplant,40,mg,,Q w,,PO,,1,221,1
MMRF_1574,,First line of therapy,Induction,,Lenalidomide,,,,Other,transplant,15,mg,,QD,,PO,,32,221,1
MMRF_1574,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,455,mg,,Oth,Once,IV,,246,246,1
MMRF_1574,,First line of therapy,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,10,mg,,Q d,,PO,,569,723,1
MMRF_1574,,First line of therapy,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,10,mg,,Oth,every other day,PO,,569,1577,1
MMRF_1593,Baseline,First line of therapy,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,1.3,mg/m^,,Oth,twice a week,IV,,1,73,1
MMRF_1593,,First line of therapy,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,20,mg,,Oth,"Twice a week, prior to velcade dose",PO,,1,73,1
MMRF_1593,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,216,216,1
MMRF_1593,,Second Line Therapy (after,Induction,,Carfilzomib,,,,Other,Dose Change,20,mg/m^,,QD,,IVB,,105,133,1
MMRF_1593,,Second Line Therapy (after,Induction,,Carfilzomib,,,,Other,Transplant,27,mg/m^,,QD,,IVB,,133,189,1
MMRF_1593,,Second Line Therapy (after,Induction,,Lenalidomide,,,,Other,transplant,15,mg,,QD,,PO,,105,189,1
MMRF_1593,,Second Line Therapy (after,Induction,,Dexamethasone,,,,Other,Transplant,8,mg,,QD,,IVB,,133,217,1
MMRF_1593,,First line of therapy,Maintenance,,Lenalidomide,,,,Other,Dose change,10,mg,,Oth,"2 weeks on, 1 week off",PO,,343,492,1
MMRF_1593,,First line of therapy,Maintenance,,Lenalidomide,,,,Other,Dose change secondary to diarrhea at daily dosing level s/p 28 days,10,mg,,Q d,,PO,,312,343,1
MMRF_1593,,First line of therapy,Maintenance,,Lenalidomide,,,,Other,Dose change,10,mg,,Q d,,PO,,492,606,1
MMRF_1593,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,10,mg,,QD,,PO,,606,,1
MMRF_1618,Baseline,First line of therapy,Induction,,Bortezomib,,,,Other,transplant,2.44,mg,,Oth,"Twice a week, Mondays and Thursdays",IV SubQ,,1,86,1
MMRF_1618,,First line of therapy,Induction,,Lenalidomide,,,,Other,transplant,25,mg,,QD,,PO,,1,86,1
MMRF_1618,,First line of therapy,Induction,,Dexamethasone,,,,Other,transplant,4,mg,,Oth,"Twice Weekly, Mondays and Thursdays",PO,,1,86,1
MMRF_1618,,First line of therapy,Maintenance,,Lenalidomide,,,,Other,decrease of dose due to neutropenia (not deemed Grade 3),10,mg,,Q d,,PO,,338,1479,1
MMRF_1618,,Second Line Therapy (after,Induction,,Pomalidomide,,,Checked,,,4,mg,,QD,,PO,,1479,,1
MMRF_1618,,Second Line Therapy (after,Induction,,Dexamethasone,,,Checked,,,40,mg,,Q w,,IV,,1479,,1
MMRF_1618,,Second Line Therapy (after,Induction,,Daratumumab,,,Checked,,,16,mg/kg,,Oth,every 2 weeks,IV,,1479,,1
MMRF_1717,Baseline,First line of therapy,Induction,,Lenalidomide,,,,Other,Transplant,15,mg,,QD,,PO,,1,104,1
MMRF_1717,,First line of therapy,Induction,,Dexamethasone,,,,Other,Transplant,20,mg,,Q w,,PO,,1,104,1
MMRF_1717,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,200,mg/m^,,Oth,Once,IV,,160,162,1
MMRF_1717,,First line of therapy,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,5,mg,,Oth,"Revlimid restarted 25-Mar-2015 TIW x 1 week, then QOD x 1 week, then daily.",PO,,334,391,1
MMRF_1717,,First line of therapy,Induction,,Lenalidomide,,,,Other,Dose Modification,5,mg,,Oth,"TIW x 1 week, then QOD x 1 week, then daily",PO,,419,454,1
MMRF_1717,,First line of therapy,Induction,,Lenalidomide,,,,Disease progression/Relapse,,5,mg,,Q d,,PO,,454,1464,1
MMRF_1717,,Second Line Therapy (after,Induction,,Pomalidomide,,,Checked,,,2,mg,,QD,,PO,,1499,,1
MMRF_1717,,Second Line Therapy (after,Induction,,Dexamethasone,,,Checked,,,20,mg,,Oth,"Days 1, 8, and 15 of 28 day cycles",Other,PO or IV depending on chemo days,1499,,1
MMRF_1717,,Second Line Therapy (after,Induction,,Carfilzomib,,,Checked,,,20,mg/m^,,Q w,,IV,,1499,,1
MMRF_1726,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,2.75,mg,,Q w,,Other,subQ,1,99,1
MMRF_1726,,First line of therapy,Induction,,Dexamethasone,,,,Lack of response,,20,mg,,QWK,,PO,,1,119,1
MMRF_1726,,First line of therapy,Induction,,Lenalidomide,,,,Lack of response,,15,mg,,QD,,PO,,99,176,1
MMRF_1726,,Second Line Therapy (after,Induction,,Lenalidomide,,,,Disease progression/Relapse,,10,mg,,QD,,PO,,176,564,1
MMRF_1726,,Second Line Therapy (after,Induction,,Dexamethasone,,,,Disease progression/Relapse,,20,mg,,Q w,,PO,,135,564,1
MMRF_1726,,Third Line Therapy (followi,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,10,mg,,QD,,PO,,564,635,1
MMRF_1726,,Third Line Therapy (followi,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,20,mg,,Q w,,PO,,564,635,1
MMRF_1726,,Third Line Therapy (followi,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,1,mg/m^,,Oth,"Days 1, 8, 15",IV SubQ,,566,635,1
MMRF_1726,,Third Line Therapy (followi,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,10,mg/dL,,QD,,PO,,664,693,1
MMRF_1726,,Third Line Therapy (followi,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,1,mg/m^,,Oth,"Days 1,8,15",IV SubQ,,664,678,1
MMRF_1726,,Third Line Therapy (followi,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,20,mg,,Q w,,PO,,664,678,1
MMRF_1763,Baseline,First line of therapy,Unknown,,Dexamethasone,,,,Other,Transplant,40,mg,,Q w,,PO,,1,133,1
MMRF_1763,,First line of therapy,Unknown,,Lenalidomide,,,,Other,high copay,25,mg,,Q d,,PO,,2,38,1
MMRF_1763,,First line of therapy,Unknown,,Lenalidomide,,,,Other,dose change,21,mg,,Q d,,PO,,1,2,1
MMRF_1763,,First line of therapy,Unknown,,Bortezomib,,,,Other,transplant,1.3,mg/m^,,QD,,IV,,54,106,1
MMRF_1763,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,200,mg/m^,,Oth,Once,IV,,131,131,1
MMRF_1763,,First line of therapy,Maintenance,,Bortezomib,,,,Disease progression/Relapse,,1.3,mg/m^,,Oth,Q 2wks,IV SubQ,,194,764,1
MMRF_1763,,Second Line Therapy (after,Unknown,,Bortezomib,,,,Adverse Event or co-morbidity,,1.32,mg/m^,,Oth,"Days 1, 8, 15",IV,,769,937,1
MMRF_1763,,Second Line Therapy (after,Unknown,,Dexamethasone,,,,Adverse Event or co-morbidity,,20,mg,,Q w,,PO,,769,937,1
MMRF_1763,,Second Line Therapy (after,Unknown,,Lenalidomide,,,,Adverse Event or co-morbidity,,25,mg,,QD,,PO,,769,937,1
MMRF_1763,,Second Line Therapy (after,Unknown,,Dexamethasone,,,,Other,Allogenic SCT 1/17/2017,12,mg,,Oth,weekly,PO,,939,1072,1
MMRF_1763,,Second Line Therapy (after,Unknown,,Lenalidomide,,,,Other,Allogenic SCT 1/17/2017,25,mg,,Oth,Days 1-21,PO,,939,1072,1
MMRF_1763,,Second Line Therapy (after,Maintenance,,Ixazomib,,,,Other,dose increase due to a study protocol,3,mg,,Oth,"days 1, 8, 15",PO,,1192,1275,1
MMRF_1763,,Third Line Therapy (followi,Maintenance,,Ixazomib,,,,Investigator decision for other reasons,,7,mg,,Oth,"days 1, 8, 15",PO,,1276,1400,1
MMRF_1763,,Third Line Therapy (followi,Maintenance,,Ixazomib,,,Checked,,,2.3,mg,,Oth,"days 1, 8, 15",PO,,1405,,1
MMRF_1763,,Third Line Therapy (followi,Maintenance,,Prednisone,,,Checked,,,20,mg,,Q d,,PO,,1496,,1
MMRF_1847,,First line of therapy,Other,in addittion,Lenalidomide,,,,Adverse Event or co-morbidity,,15,mg,,QD,,PO,,20,44,1
MMRF_1847,Baseline,First line of therapy,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,20,mg,,Oth,"day 1,4,8&11",PO,,1,44,1
MMRF_1847,,First line of therapy,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,1.3,mg/m^,,Oth,"Days 1,4,8 &11",IV SubQ,,1,44,1
MMRF_1847,,First line of therapy,Induction,,Lenalidomide,,,,Other,Transplant,10,mg,,QD,,PO,,44,128,1
MMRF_1847,,First line of therapy,Induction,,Bortezomib,,,,Other,Transplant,1.3,mg/m^,,Oth,"Day 1,8",IV SubQ,,44,128,1
MMRF_1847,,First line of therapy,Induction,,Dexamethasone,,,,Other,Transplant,20,mg,,Oth,"Day 1,8",PO,,44,128,1
MMRF_1847,,First line of therapy,Induction,,Lenalidomide,,,,Other,for pt. convenience,10,mg,,QD,,PO,,380,672,1
MMRF_1847,,First line of therapy,Induction,,Bortezomib,,,,Other,for pt. convenience,1.3,mg/m^,,Oth,QD D1 and D15,IV SubQ,,380,672,1
MMRF_1847,,First line of therapy,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,12,mg,,Oth,QD D1 and D15,PO,,380,455,1
MMRF_1847,,First line of therapy,Induction,,Dexamethasone,,,,Other,for pt. convenience,8,mg,,Oth,Take on Days 1 and 15,PO,,455,672,1
MMRF_1847,,First line of therapy,Maintenance,,Ixazomib,,,Checked,,,4,mg,,Oth,"days 1,8,15 of 28 day cycle",PO,,692,,1
MMRF_1847,,First line of therapy,Maintenance,,Dexamethasone,,,Checked,,,8,mg,,Oth,"days 1,8,15 of 28 day cycle",PO,,692,,1
MMRF_1847,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,10,mg,,QD,,PO,,692,,1
MMRF_1888,Baseline,First line of therapy,Induction,,Bortezomib,,,,Lack of response,,1.3,mg/m^,,QWK,,IV SubQ,,1,29,1
MMRF_1888,,First line of therapy,Induction,,Dexamethasone,,,,Lack of response,,20,mg,,QWK,,PO,,1,29,1
MMRF_1888,,First line of therapy,Induction,,Dexamethasone,,,,Other,transplant,20,mg,,Oth,BIW ( Monday and Thursday),PO,,29,85,1
MMRF_1888,,First line of therapy,Induction,,Bortezomib,,,,Other,transplant,1.3,mg/m^,,Oth,"Day 1,8&15",IV SubQ,,29,85,1
MMRF_1888,,First line of therapy,Induction,,Lenalidomide,,,,Other,transplant,15,mg,,QD,,PO,,29,85,1
MMRF_1888,,First line of therapy,Induction,,Lenalidomide,,,Checked,,,10,mg,,Oth,Days 1-21,PO,,388,,1
MMRF_1915,Baseline,First line of therapy,Induction,,Bortezomib,,,,Other,Decreased does d/t prepheral neuropathy,1.3,mg/m^,,Oth,BIW,IV SubQ,,1,53,1
MMRF_1915,,First line of therapy,Induction,,Dexamethasone,,,,Other,Transplant,20,mg,,Q w,,PO,,1,82,1
MMRF_1915,,First line of therapy,Induction,,Bortezomib,,,,Other,Transplant,1,mg/m^,,Oth,BIW,IV SubQ,,53,82,1
MMRF_1915,,First line of therapy,Induction,,Lenalidomide,,,,Other,Transplant,10,mg,,QD,,PO,,25,82,1
MMRF_1915,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,360,mg,,Oth,Once w Auto-HSCT,IV,,113,113,1
MMRF_1915,,First line of therapy,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,10,mg,,Q d,,PO,,358,365,1
MMRF_1915,,First line of therapy,Induction,,Lenalidomide,,,,Investigator decision for other reasons,,10,mg,,Oth,"TIW x 1 week, then every other day x1 week then daily",PO,,358,850,1
MMRF_2041,,First line of therapy,Induction,,Bortezomib,,,,Other,Transplant,1.3,mg/m^,,QD,,IV SubQ,,1,29,1
MMRF_2041,Baseline,First line of therapy,Induction,,Dexamethasone,,,,Other,Transplant,20,mg,,QD,,PO,,1,29,1
MMRF_2041,,First line of therapy,Induction,,Cyclophosphamide,,,,Other,Transplant,400,mg,,Oth,on D1 and 8 every 21days,PO,,1,29,1
MMRF_2041,,First line of therapy,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,10,mg,,Oth,QD Days 1-21 each 28 Day Cycle,PO,,199,497,1
MMRF_2041,,First line of therapy,Induction,,Lenalidomide,,,Checked,,,5,mg,,QD,,PO,,497,,1
MMRF_2064,Baseline,First line of therapy,Induction,,Bortezomib,,,,Other,Transplant,1.3,mg/m^,,QD,,IV SubQ,,1,102,1
MMRF_2064,,First line of therapy,Induction,,Dexamethasone,,,,Other,Transplant,20,mg,,QD,,PO,,1,102,1
MMRF_2064,,Second Line Therapy (after,Induction,,Carfilzomib,,,,Patient decision,,20,mg/m^,,Q w,,IV,,1221,1338,1
MMRF_2064,,Second Line Therapy (after,Induction,,Dexamethasone,,,,Patient decision,,20,mg,,Q w,,IV,,1221,1338,1
MMRF_2064,,Second Line Therapy (after,Induction,,Lenalidomide,,,Checked,,,10,mg,,QD,,PO,,1341,,1
MMRF_2064,,Second Line Therapy (after,Induction,,Dexamethasone,,,Checked,,,12,mg,,Q w,,PO,,1341,,1
MMRF_2409,Baseline,First line of therapy,Induction,,Bortezomib,,,,Other,Transplant,1.3,mg/m^,,Oth,BIW,IV SubQ,,1,135,1
MMRF_2409,,First line of therapy,Induction,,Dexamethasone,,,,Other,Stem Cell Transplant,20,mg,,Oth,Pre Med,PO,,1,135,1
MMRF_2409,,First line of therapy,Induction,,Melphalan,,,,Other,Auto-HSCT,410,mg/dL,,Oth,Once,IV,,176,176,1
MMRF_2409,,First line of therapy,Induction,,Lenalidomide,,,Checked,,,10,mg,,Q d,,PO,,345,,1
MMRF_2585,,First line of therapy,Induction,,Dexamethasone,,,,Other,Transplant Auto HSCT,20,mg,,QWK,,PO,,1,413,1
MMRF_2585,Baseline,First line of therapy,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,15,mg,,QD,,PO,,1,8,1
MMRF_2585,,First line of therapy,Induction,,Lenalidomide,,,,Other,Changed Dose Frequency,15,mg,,Oth,TIW,PO,,19,44,1
MMRF_2585,,First line of therapy,Induction,,Lenalidomide,,,,Other,Changed Drug Frequency,15,mg,,Q d,,PO,,45,59,1
MMRF_2585,,First line of therapy,Induction,,Lenalidomide,,,,Other,Transplant Auto HSCT,15,mg,,QD,,PO,,59,413,1
MMRF_2585,,First line of therapy,Consolidation,,Lenalidomide,,,Checked,,,10,mg,,QD,,PO,,635,,1
MMRF_2585,,First line of therapy,Consolidation,,Dexamethasone,,,Checked,,,8,mg,,Oth,"days 1, 8, 15",PO,,635,,1
MMRF_1750,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,2.6,mg,,Q w,,IV SubQ,,51,79,1
MMRF_1750,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,50,mg,,Q w,,PO,,1,79,1
MMRF_1750,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,4,mg,,Q w,,PO,,1,79,1
MMRF_1750,Baseline,First line of therapy,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,3,mg,,Q w,,IV SubQ,,1,51,1
MMRF_1750,,First line of therapy,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,15,mg,,Q d,,PO,,212,316,1
MMRF_1750,,First line of therapy,Other,Conditioning regimen,Melphalan,,,,Completed regimen,,200,mg/m^,,Oth,Once,IV,,126,126,1
MMRF_1750,,First line of therapy,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,10,mg,,Q d,,PO,,317,961,1
MMRF_1750,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,5,mg,,Q d,,PO,,962,,1
MMRF_2019,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,115,1
MMRF_2019,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Q w,,PO,,1,140,1
MMRF_2019,,First line of therapy,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,10,mg,,Q d,,PO,,251,303,1
MMRF_2019,,First line of therapy,Maintenance,,Bortezomib,,,,Adverse Event or co-morbidity,,1.3,mg/m^,,Oth,Days 1&15 Q 28 Days,IV SubQ,,399,771,1
MMRF_2377,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 4, 5, 8,9,11, and 12",PO,,1,53,1
MMRF_2377,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,53,1
MMRF_2377,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV,,1,53,1
MMRF_2377,,First line of therapy,Other,Mobilization for transplant,Cyclophosphamide,,,,Completed regimen,,3000,mg/m^,,Oth,Once,IV,,85,85,1
MMRF_2377,,First line of therapy,Consolidation,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV,,113,207,1
MMRF_2377,,First line of therapy,Consolidation,,Lenalidomide,,,,Completed regimen,,10,mg,,QD,,PO,,113,207,1
MMRF_2377,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,15,mg,,Q d,,PO,,211,,1
MMRF_2377,,First line of therapy,Consolidation,,Dexamethasone,,,,Completed regimen,,10,mg,,QD,,PO,,113,207,1
MMRF_2380,,First line of therapy,Induction,,Dexamethasone,,,,Investigator decision for other reasons,,20,mg,,Oth,Day of and velcade and day after velcade,PO,,4,177,1
MMRF_2380,Baseline,First line of therapy,Induction,,Bortezomib,,,,Investigator decision for other reasons,,1.3,mg/m^,,QD,,IV,,1,170,1
MMRF_2380,,Second Line Therapy (after,Induction,,Lenalidomide,,,,Completed regimen,,10,mg,,QD,,PO,,547,631,1
MMRF_2380,,Second Line Therapy (after,Other,conditioning regimen for SCT,Melphalan,,,,Completed regimen,,200,mg,,Oth,ONCE,IV,,659,659,1
MMRF_2380,,Second Line Therapy (after,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Q w,,PO,,547,631,1
MMRF_2380,,Second Line Therapy (after,Induction,,Bortezomib,,,,Completed regimen,,1.5,mg/m^,,Q w,,IV,,547,631,1
MMRF_2402,Baseline,First line of therapy,Induction,,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,QWK,,PO,,1,414,1
MMRF_2402,,First line of therapy,Induction,,Lenalidomide,,,,Disease progression/Relapse,,25,mg,,QD,,PO,,1,414,1
MMRF_2402,,Second Line Therapy (after,Induction,,Lenalidomide,,,Checked,,,20,mg,,Oth,QD Days 1-21/28,PO,,414,,1
MMRF_2402,,Second Line Therapy (after,Induction,,Ixazomib,,,Checked,,,4,mg,,Oth,"Days 1, 8, 15 / 28",PO,,414,,1
MMRF_2402,,Second Line Therapy (after,Induction,,Dexamethasone,,,Checked,,,40,mg,,QWK,,PO,,414,,1
MMRF_1930,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,59,1
MMRF_1930,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"D1, D2, D4, D5, D8, D9, D11, D12",PO,,1,59,1
MMRF_1930,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV,,1,59,1
MMRF_1930,,First line of therapy,Consolidation,,Dexamethasone,,,,Completed regimen,,10,mg,,QD,,PO,,224,273,1
MMRF_1930,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,10,mg,,Q d,,PO,,274,,1
MMRF_1930,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,113,113,1
MMRF_1930,,First line of therapy,Consolidation,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV,,224,256,1
MMRF_1930,,First line of therapy,Consolidation,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,224,259,1
MMRF_1930,,First line of therapy,Other,mobilization,Cyclophosphamide,,,,Completed regimen,,3000,mg/m^,,Q d,,IV,,87,87,1
MMRF_2167,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Q d,,IV,,1,4,1
MMRF_2167,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,10,mg,,QWK,,IV,,10,194,1
MMRF_2167,Baseline,First line of therapy,Induction,,Bortezomib,,,,Lack of response,,3.07,mg,,QWK,,IV,,1,185,1
MMRF_2167,,Second Line Therapy (after,Induction,,Dexamethasone,,,,Completed regimen,,10,mg,,QD,,IV,,201,299,1
MMRF_2167,,Second Line Therapy (after,Induction,,Carfilzomib,,,,Completed regimen,,27,mg/m^,,QD,,IV,,201,299,1
MMRF_2167,,Second Line Therapy (after,Induction,,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,333,333,1
MMRF_2167,,Third Line Therapy (followi,Induction,,Lenalidomide,,,,Disease progression/Relapse,,5,mg,,Q d,,PO,,454,531,1
MMRF_2167,,Third Line Therapy (followi,Induction,,Dexamethasone,,,,Other,death,20,mg,,Q w,,IV,,460,839,1
MMRF_2167,,Third Line Therapy (followi,Induction,,Other,Elotuzumab,,,Disease progression/Relapse,,1202,mg,,Q w,,IV,,460,517,1
MMRF_2167,,Fifth Line Therapy (followi,Induction,,Carfilzomib,,,,Disease progression/Relapse,,66,mg,,QD,,IV,,636,824,1
MMRF_2167,,Fifth Line Therapy (followi,Induction,,Cyclophosphamide,,,,Disease progression/Relapse,,660,mg/dL,,QD,,IV,,678,823,1
MMRF_2167,,Sixth Line Therapy (followi,Induction,,Other,Pembrolizumab (Keytruda),,,Other,subject on hospice 1-5-17 and expired same day,200,mg,,Oth,once,IV,,825,825,1
MMRF_2167,,Fourth Line Therapy (follow,Induction,,Pomalidomide,,,,Disease progression/Relapse,,2,mg,,QD,,PO,,517,833,1
MMRF_2167,,Fourth Line Therapy (follow,Induction,,Daratumumab,,,,Disease progression/Relapse,,1886.4,mg,,Oth,"QWK C1-2, C3-6 D 1&15, then D1 every cycle (1 cycle=28 days)",IV,,524,622,1
MMRF_2167,,Second Line Therapy (after,Induction,,Lenalidomide,,,,Disease progression/Relapse,,15,mg,,QD,,PO,,201,307,1
MMRF_1456,Baseline,First line of therapy,,,Bortezomib,,,,Patient decision,,1.3,mg/m^,,QD,,IV SubQ,,1,43,1
MMRF_1456,,First line of therapy,,,Dexamethasone,,,,Patient decision,,40,mg,,Q w,,PO,,1,43,1
MMRF_1456,,First line of therapy,Unknown,,Lenalidomide,,,,Patient decision,,15,mg,,Q d,,PO,,22,43,1
MMRF_1535,Baseline,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Q w,,PO,,1,154,1
MMRF_1535,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,154,1
MMRF_1535,,First line of therapy,Maintenance,,Lenalidomide,,,,Investigator decision for other reasons,,5,mg,,Oth,"Monday, Wednesday, Friday",PO,,366,394,1
MMRF_2112,Baseline,First line of therapy,Induction,,Lenalidomide,,,,Other,Patient deceased,25,mg,,Q d,,PO,,1,201,1
MMRF_2112,,First line of therapy,Induction,,Bortezomib,,,,Other,Patient deceased,2.3,mg,,QD,,IV SubQ,,5,201,1
MMRF_2112,,First line of therapy,Induction,,Dexamethasone,,,,Other,death,4,mg,,TID,,PO,,1,201,1
MMRF_2151,Baseline,First line of therapy,Induction,,Bortezomib,,,,Disease progression/Relapse,,2.5,mg,,QD,,IV,,1,13,1
MMRF_2151,,First line of therapy,Induction,,Lenalidomide,,,,Disease progression/Relapse,,15,mg,,QD,,PO,,9,13,1
MMRF_2151,,First line of therapy,Induction,,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,Q w,,PO,,1,13,1
MMRF_2379,Baseline,First line of therapy,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,10,mg,,QD,,PO,,1,83,1
MMRF_1882,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,3.3,mg,,QWK,,IV SubQ,,1,86,1
MMRF_1882,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,450,mg,,QWK,,PO,,37,268,1
MMRF_1882,,First line of therapy,Induction,,Dexamethasone,,,,Patient decision,,40,mg,,QWK,,PO,,30,562,1
MMRF_1882,,First line of therapy,Maintenance,,Bortezomib,,,,Patient decision,,3.6,mg,,Q w,,Other,subQ,280,562,1
MMRF_1882,,First line of therapy,Maintenance,,Bortezomib,,,,Completed regimen,,3.3,mg,,Q w,,Other,subcutaneously,134,268,1
MMRF_1882,,First line of therapy,Consolidation,,Bortezomib,,,,Completed regimen,,3.5,mg,,Q w,,Other,subcutaneously,93,121,1
MMRF_2015,Baseline,First line of therapy,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,2.8,mg,,QWK,,IV SubQ,,33,138,1
MMRF_2015,,First line of therapy,Induction,,Dexamethasone,,,Checked,,,40,mg,,Q d,,PO,,1,,1
MMRF_2015,,First line of therapy,Induction,,Cyclophosphamide,,,,Investigator decision for other reasons,,50,mg,,QD,,PO,,8,23,1
MMRF_2187,Baseline,First line of therapy,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,3,mg,,QD,,IV SubQ,,1,11,1
MMRF_2187,,First line of therapy,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,40,mg,,Q w,,PO,,1,11,1
MMRF_2187,,First line of therapy,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,10,mg,,Oth,once,PO,,1,11,1
MMRF_2386,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,3.17,mg,,Q w,,Other,sub-Q,1,210,1
MMRF_2386,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,600,mg,,Q w,,PO,,1,179,1
MMRF_2386,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Q w,,PO,,1,179,1
MMRF_2386,,Second Line Therapy (after,Unknown,,Bortezomib,,,,Disease progression/Relapse,,2.9,mg/m^,,Q w,,IV SubQ,,197,316,1
MMRF_2386,,Second Line Therapy (after,Unknown,,Lenalidomide,,,,Disease progression/Relapse,,25,mg,,QD,,PO,,197,316,1
MMRF_2386,,Second Line Therapy (after,Unknown,,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,Q w,,PO,,197,316,1
MMRF_2386,,Third Line Therapy (followi,Unknown,,Carfilzomib,,,,Lack of response,,60,mg,,QD,,IV,,341,867,1
MMRF_2386,,Third Line Therapy (followi,Unknown,,Dexamethasone,,,Checked,,,4,mg,,QD,,PO,,341,,1
MMRF_2386,,Third Line Therapy (followi,Unknown,,Lenalidomide,,,,Lack of response,,25,mg,,QD,,PO,,341,454,1
MMRF_2386,,Third Line Therapy (followi,Unknown,,Pomalidomide,,,Checked,,,4,mg,,QD,,PO,,467,,1
MMRF_2386,,Fourth Line Therapy (follow,Unknown,,Daratumumab,,,Checked,,,1600,mg,,Q w,,IV,,867,,1
MMRF_2078,Baseline,First line of therapy,Induction,,Bortezomib,,,Checked,,,1.8,mg,,QWK,,Other,sub q,1,,1
MMRF_1644,Baseline,First line of therapy,Induction,,Bortezomib,,,Checked,,,2.1,mg,,Q w,,IV SubQ,,1,,1
MMRF_2118,Baseline,First line of therapy,Induction,,Bortezomib,,,,Disease progression/Relapse,,2.4,mg,,QD,,IV,,1,705,1
MMRF_2118,,First line of therapy,Induction,,Dexamethasone,,,Checked,,,40,mg,,Q d,,Other,first IV and then PO,1,,1
MMRF_2118,,Second Line Therapy (after,Maintenance,,Elotuzumab,,,,Disease progression/Relapse,,667,mg,,Q w,,IV,,624,1016,1
MMRF_2118,,Second Line Therapy (after,Maintenance,,Lenalidomide,,,,Disease progression/Relapse,,10,mg,,QD,,PO,,624,1044,1
MMRF_2118,,Third Line Therapy (followi,Maintenance,,Daratumumab,,,Checked,,,1110,mg/kg,,QD,,IV,,1056,,1
MMRF_2118,,Third Line Therapy (followi,Maintenance,,Bortezomib,,,Checked,,,2.4,mg/m^,,QD,,IV,,1056,,1
MMRF_2118,,Third Line Therapy (followi,Consolidation,,Other,methotrexate,,,Completed regimen,,12,mg,,Q w,,Other,intrathecal,1037,1058,1
MMRF_2138,Baseline,First line of therapy,Induction,,Bortezomib,,,,Lack of response,,2.2,mg,,QD,,IV SubQ,,1,119,1
MMRF_2138,,First line of therapy,Induction,,Dexamethasone,,,Checked,,,40,mg,,Q d,,Other,first IV then PO,1,,1
MMRF_2138,,First line of therapy,Maintenance,,Carfilzomib,,,,Disease progression/Relapse,,34,mg,,QD,,IV,,165,567,1
MMRF_2138,,Second Line Therapy (after,Unknown,,Elotuzumab,,,Checked,,,667,mg,,QWK,,IV,,609,,1
MMRF_2138,,Second Line Therapy (after,Unknown,,Lenalidomide,,,Checked,,,25,mg,,QD,,PO,,609,,1
MMRF_1706,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.5,mg/m^,,Q w,,IV SubQ,,1,105,1
MMRF_1706,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Q w,,PO,,1,105,1
MMRF_1706,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,700,mg,,Q w,,PO,,1,105,1
MMRF_1706,,First line of therapy,Other,Stem Cell Mobilization,Cyclophosphamide,,,,Completed regimen,,5650,mg,,Oth,Once (single treatment),IV,,116,116,1
MMRF_1706,,First line of therapy,Other,Stem Cell transplant Conditioning,Melphalan,,,,Completed regimen,,310,mg,,Oth,Once (single treatment),IV,,163,163,1
MMRF_1706,,First line of therapy,Other,Stem Cell transplant Conditioning,Other,Busulfan,,,Completed regimen,,280,mg,,Q d,,IV,,160,162,1
MMRF_1706,,First line of therapy,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,10,mg,,Q d,,PO,,265,475,1
MMRF_1881,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.5,mg/m^,,Q w,,IV SubQ,,1,171,1
MMRF_1881,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Q w,,PO,,1,171,1
MMRF_1881,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Q w,,PO,,1,171,1
MMRF_1881,,First line of therapy,Other,Stem Cell Transplant Conditioning,Melphalan,,,,Completed regimen,,250,mg,,Oth,Once (single administration),IV,,252,252,1
MMRF_1881,,First line of therapy,Other,Stem Cell Mobilization,Cyclophosphamide,,,,Completed regimen,,4400,mg,,Oth,Once (single administration),IV,,196,196,1
MMRF_1881,,First line of therapy,Other,Stem Cell Transplant Conditioning,Other,Busulfan,,,Completed regimen,,216,mg,,Q d,,IV,,249,251,1
MMRF_1881,,First line of therapy,Maintenance,,Lenalidomide,,,,Other,per MCRN-001 protocol (maintenance Rev dose to be increased to 15 mg),10,mg,,Oth,QDay (D1-28 of 28 day cycle),PO,,358,447,1
MMRF_1881,,First line of therapy,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,15,mg,,Oth,Q day (D1-28 of 28 day cycle),PO,,448,751,1
MMRF_1972,Baseline,First line of therapy,Induction,,Bortezomib,,,,Investigator decision for other reasons,,1.5,mg/m^,,Q w,,IV SubQ,,1,88,1
MMRF_1972,,First line of therapy,Induction,,Dexamethasone,,,,Investigator decision for other reasons,,20,mg,,Q w,,PO,,1,88,1
MMRF_1972,,First line of therapy,Induction,,Cyclophosphamide,,,,Investigator decision for other reasons,,300,mg/m^,,Q w,,PO,,1,88,1
MMRF_1972,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.5,mg/m^,,Oth,"day 1, 7, 15 of 28 day cycle (3weeks on, 1 week rest)",IV SubQ,,95,368,1
MMRF_1972,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"day 1, 7, 15 of 28 day cycle (3weeks on, 1 week rest)",PO,,95,368,1
MMRF_1972,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,"day 1, 7, 15 of 28 day cycle (3weeks on, 1 week rest)",PO,,95,368,1
MMRF_1972,,Second Line Therapy (after,Induction,,Lenalidomide,,,Checked,,,10,mg,,QD,,PO,,1236,,1
MMRF_1972,,Second Line Therapy (after,Induction,,Dexamethasone,,,Checked,,,20,mg,,Oth,"D1, D8, D15, D22 of 28 day cycle",PO,,1054,,1
MMRF_1972,,Second Line Therapy (after,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,15,mg,,QD,,PO,,1184,1235,1
MMRF_1972,,Second Line Therapy (after,Induction,,Lenalidomide,,,,Other,physician increased dose to 15 mg,10,mg,,QD,,PO,,1054,1183,1
MMRF_2007,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Q w,,PO,,1,101,1
MMRF_2007,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.5,mg/m^,,Q w,,IV SubQ,,1,101,1
MMRF_2007,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Q w,,PO,,1,101,1
MMRF_2007,,First line of therapy,Other,Melphalan Conditioning for ASCT,Melphalan,,,,Completed regimen,,210,mg,,Oth,qDay for 2 days,IV,,151,152,1
MMRF_2007,,First line of therapy,Other,Stem Cell Mobilization,Cyclophosphamide,,,,Completed regimen,,2500,mg/m^,,Oth,Once,IV,,112,112,1
MMRF_2007,,First line of therapy,Other,Consolidation and maintenance,Lenalidomide,,,Checked,,,10,mg,,Oth,QDay (D1-28 of 28 day cycle),PO,,436,,1
MMRF_1829,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Q w,,PO,,104,245,1
MMRF_1829,Baseline,First line of therapy,Induction,,Bortezomib,,,,Other,Death,2.7,mg,,QD,,IV,,1,27,1
MMRF_1829,,First line of therapy,Consolidation,,Bortezomib,,,,Adverse Event or co-morbidity,,2.6,mg,,Oth,"D1, D4, D8",IV,,94,104,1
MMRF_1829,,First line of therapy,Consolidation,,Dexamethasone,,,,Investigator decision for other reasons,,10,mg,,Oth,"D1, D4, D8",IV,,94,167,1
MMRF_1829,,First line of therapy,Consolidation,,Lenalidomide,,,,Other,UTI,5,mg,,QD,,PO,,49,248,1
MMRF_1829,,Second Line Therapy (after,Induction,,Carfilzomib,,,,Adverse Event or co-morbidity,,20,mg/m^,,QD,,IV,,938,939,1
MMRF_1829,,First line of therapy,Consolidation,,Bortezomib,,,,Adverse Event or co-morbidity,,2.4,mg,,QD,,IV SubQ,,160,216,1
MMRF_1829,,First line of therapy,Consolidation,,Bortezomib,,,,Adverse Event or co-morbidity,,2.5,mg,,QD,,IV,,104,167,1
MMRF_1829,,First line of therapy,Maintenance,,Lenalidomide,,,,Investigator decision for other reasons,,2.5,mg,,QD,,PO,,230,455,1
MMRF_1977,,First line of therapy,Induction,,Dexamethasone,,,Checked,,,40,mg,,Q w,,PO,,1,,1
MMRF_1977,Baseline,First line of therapy,Induction,,Bortezomib,,,Checked,,,2.3,mg,,QD,,IV,,1,,1
MMRF_1977,,First line of therapy,Induction,,Lenalidomide,,,Checked,,,15,mg,,Oth,q 48 hours x 14 days,PO,,1,,1
MMRF_2012,,First line of therapy,Induction,,Dexamethasone,,,,Other,Not sure why study MD changed the decreased the dose,20,mg,,Q w,,PO,,1,39,1
MMRF_2012,Baseline,First line of therapy,Induction,,Lenalidomide,,,,Investigator decision for other reasons,,15,mg,,QD,,PO,,1,325,1
MMRF_2012,,First line of therapy,Induction,,Dexamethasone,,,Checked,,,8,mg,,Q w,,PO,,39,,1
MMRF_2106,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,225,1
MMRF_2106,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"D1-5, 8-9, 11-12",PO,,1,225,1
MMRF_2106,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV,,1,225,1
MMRF_2106,,Second Line Therapy (after,Induction,,Carfilzomib,,,,Investigator decision for other reasons,,20,mg/m^,,QD,,IV,,271,272,1
MMRF_2106,,Second Line Therapy (after,Induction,,Doxorubicin,,,,Completed regimen,,30,mg/m^,,Oth,one dose,IV,,276,276,1
MMRF_2106,,Second Line Therapy (after,Consolidation,,Other,Etoposide,,,Completed regimen,,68,mg,,Q d,,IV,,272,277,1
MMRF_2106,,Second Line Therapy (after,Induction,,Bortezomib,,,,Completed regimen,,1,mg/m^,,Oth,One dose,IV,,276,276,1
MMRF_2106,,Second Line Therapy (after,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,one dose,PO,,337,337,1
MMRF_2106,,Second Line Therapy (after,Consolidation,,Dexamethasone,,,,Investigator decision for other reasons,,2,mg,,Q d,,PO,,271,337,1
MMRF_2106,,Second Line Therapy (after,Induction,,Cyclophosphamide,,,,Completed regimen,,475,mg,,Oth,one dose,PO,,337,337,1
MMRF_2106,,Second Line Therapy (after,Induction,,Carfilzomib,,,,Completed regimen,,20,mg/m^,,Oth,one dose,IV,,337,337,1
MMRF_2125,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV,,1,294,1
MMRF_2125,,First line of therapy,Induction,,Lenalidomide,,,,Disease progression/Relapse,,25,mg,,QD,,PO,,1,442,1
MMRF_2125,,First line of therapy,Induction,,Dexamethasone,,,,Other,Dose adjustment,20,mg,,Oth,"D1, 2, 4, 5, 8-9 and 11-12",PO,,1,116,1
MMRF_2125,,First line of therapy,Consolidation,,Dexamethasone,,,,Completed regimen,,10,mg,,Oth,"D1, D2, D4, D5, D8, D9, D11, D12",PO,,116,294,1
MMRF_2125,,Second Line Therapy (after,Induction,,Dexamethasone,,,,Completed regimen,,28,mg,,Oth,"3-24 hours prior to Elo on D1, D8, D15, D22",PO,,455,512,1
MMRF_2125,,Second Line Therapy (after,Induction,,Elotuzumab,,,,Other,Elotuzumab was approved by the FDA.,10,mg/kg,,Oth,"D1, D8, D15, D22",IV,,455,512,1
MMRF_2125,,Second Line Therapy (after,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,455,512,1
MMRF_2125,,Second Line Therapy (after,Induction,,Dexamethasone,,,,Completed regimen,,8,mg,,Oth,"45-90 minutes prior to Elo infusion on D1, D8, D15, D22",IV,,455,512,1
MMRF_2125,,Second Line Therapy (after,Consolidation,,Elotuzumab,,,,Other,Changed due to stable proteins,10,mg/kg,,Oth,Every two weeks,IV,,518,609,1
MMRF_2125,,Second Line Therapy (after,Consolidation,,Dexamethasone,,,,Other,Stable proteins,8,mg,,Oth,Every two weeks,IV,,518,609,1
MMRF_2125,,Second Line Therapy (after,Consolidation,,Carfilzomib,,,Checked,,,20,mg/m^,,Oth,Every two weeks,IV,,609,,1
MMRF_2125,,Second Line Therapy (after,Consolidation,,Dexamethasone,,,Checked,,,10,mg,,Oth,Every two weeks,IV,,609,,1
MMRF_2256,Baseline,First line of therapy,Induction,,Bortezomib,,,,Disease progression/Relapse,,1.3,mg/m^,,Oth,"D1, D4, D7, D10",IV,,1,309,1
MMRF_2256,,First line of therapy,Induction,,Dexamethasone,,,,Investigator decision for other reasons,,10,mg,,Oth,"D1, D4, D7, D10",PO,,1,196,1
MMRF_2259,,First line of therapy,Induction,,Lenalidomide,,,,Other,Death,25,mg,,Oth,every day x 14 days,PO,,1,123,1
MMRF_2259,Baseline,First line of therapy,Induction,,Bortezomib,,,,Other,Death,1.3,mg/m^,,QD,,IV,,1,123,1
MMRF_2259,,First line of therapy,Induction,,Dexamethasone,,,,Other,Death,20,mg,,Oth,"D1, D2, D4, D5, D8, D9",PO,,1,123,1
MMRF_2525,Baseline,First line of therapy,Induction,,Lenalidomide,,,,Lack of response,,25,mg,,Q d,,PO,,1,148,1
MMRF_2525,,First line of therapy,Induction,,Dexamethasone,,,Checked,,,40,mg,,Q w,,PO,,1,,1
MMRF_1753,Baseline,First line of therapy,Induction,,Bortezomib,,,,Other,Death,1.3,mg/m^,,QD,,IV SubQ,,1,101,1
MMRF_1753,,First line of therapy,Induction,,Cyclophosphamide,,,,Other,Death,300,mg/m^,,QWK,,PO,,1,101,1
MMRF_1753,,First line of therapy,Induction,,Dexamethasone,,,,Other,Death,40,mg,,QWK,,PO,,1,101,1
MMRF_1786,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,QD,,PO,,8,120,1
MMRF_1786,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,109,1
MMRF_1786,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,PO,,8,120,1
MMRF_1786,,First line of therapy,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,15,mg,,Oth,daily 1-21 (28 day cycle),PO,,207,360,1
MMRF_1786,,First line of therapy,Maintenance,,Lenalidomide,,,,Investigator decision for other reasons,,10,mg,,QD,,PO,,360,1290,1
MMRF_1786,,Second Line Therapy (after,Maintenance,,Elotuzumab,,,Checked,,,10,mg/kg,,Oth,Day 1,IV,,1444,,1
MMRF_1786,,Second Line Therapy (after,Maintenance,,Dexamethasone,,,Checked,,,28,mg,,Oth,Day 1,PO,,1444,,1
MMRF_1786,,Second Line Therapy (after,Maintenance,,Carfilzomib,,,Checked,,,20,mg/m^,,Oth,"Days 1, 2",IV,,1444,,1
MMRF_1786,,Second Line Therapy (after,Maintenance,,Dexamethasone,,,Checked,,,8,mg,,Oth,Day 1,IV,,1444,,1
MMRF_1786,,Second Line Therapy (after,Maintenance,,Lenalidomide,,,Checked,,,25,mg,,QD,,PO,,1444,,1
MMRF_1793,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,42,1
MMRF_1793,,First line of therapy,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,40,mg,,QD,,PO,,1,42,1
MMRF_1793,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,105,1
MMRF_1793,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1,mg/m^,,QD,,IV SubQ,,64,105,1
MMRF_1793,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,QD,,PO,,64,105,1
MMRF_1793,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,10,mg,,QD,,PO,,196,,1
MMRF_1816,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,PO,,1,100,1
MMRF_1816,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,2,mg/m^,,QD,,IV SubQ,,1,96,1
MMRF_1816,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,450,mg,,QD,,PO,,1,100,1
MMRF_1816,,First line of therapy,Consolidation,,Melphalan,,,,Completed regimen,,200,mg,,Oth,Once,IV,,140,140,1
MMRF_1816,,First line of therapy,Maintenance,,Pomalidomide,,,Checked,,,2,mg,,QD,,PO,,232,,1
MMRF_1816,,First line of therapy,Maintenance,,Carfilzomib,,,,Investigator decision for other reasons,,56,mg/m^,,QD,,IV,,359,1235,1
MMRF_1816,,First line of therapy,Maintenance,,Carfilzomib,,,,Investigator decision for other reasons,,20,mg/m^,,Q d,,IV,,232,233,1
MMRF_1816,,First line of therapy,Maintenance,,Carfilzomib,,,,Investigator decision for other reasons,,27,mg/m^,,QD,,IV,,239,352,1
MMRF_1816,,First line of therapy,Maintenance,,Dexamethasone,,,,Investigator decision for other reasons,,40,mg,,QD,,PO,,232,562,1
MMRF_1816,,First line of therapy,Maintenance,,Dexamethasone,,,,Investigator decision for other reasons,,20,mg,,QD,,PO,,576,1235,1
MMRF_1842,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,2.7,mg,,QD,,IV SubQ,,1,123,1
MMRF_1842,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,PO,,1,103,1
MMRF_1842,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,106,1
MMRF_1842,,First line of therapy,Consolidation,,Melphalan,,,,Completed regimen,,400,mg,,Oth,once,IV,,159,159,1
MMRF_1842,,First line of therapy,Maintenance,,Lenalidomide,,,,Disease progression/Relapse,,10,mg,,QD,,PO,,227,689,1
MMRF_1842,,Second Line Therapy (after,Maintenance,,Lenalidomide,,,,Other,M-spike and FLC continue to rise,25,mg,,QD,,PO,,732,897,1
MMRF_1842,,Second Line Therapy (after,Unknown,,Dexamethasone,,,,Investigator decision for other reasons,,20,mg,,Oth,"Days 1, 8, 15, 22",PO,,732,1289,1
MMRF_1842,,Second Line Therapy (after,Maintenance,,Elotuzumab,,,,Other,M-spike and FLC continue to rise,10,mg/kg,,Oth,"Days 1, 15",IV,,732,884,1
MMRF_1842,,Third Line Therapy (followi,Maintenance,,Pomalidomide,,,,Investigator decision for other reasons,,2,mg,,QD,,PO,,898,1072,1
MMRF_1842,,Third Line Therapy (followi,Maintenance,,Daratumumab,,,,Investigator decision for other reasons,,16,mg/m^,,Oth,"Days 1, 8, 15, 22",IV,,898,1122,1
MMRF_1842,,Fourth Line Therapy (follow,Maintenance,,Carfilzomib,,,,Completed regimen,,42,mg,,Oth,"Days 1, 2",IV,,1157,1158,1
MMRF_1842,,Fourth Line Therapy (follow,Maintenance,,Carfilzomib,,,,Investigator decision for other reasons,,60,mg,,Oth,"Days 8, 9, 15, 16",IV,,1157,1290,1
MMRF_1842,,Fourth Line Therapy (follow,Maintenance,,Other,Venetoclax,,,Other,Patient did not take C1D1 correctly,200,mg,,Oth,Days 1-7,PO,,1157,1163,1
MMRF_1842,,Fourth Line Therapy (follow,Maintenance,,Other,Venetoclax,,,Other,Patient did not take C1D1 correctly,800,mg,,Oth,Days 15-21,PO,,1171,1177,1
MMRF_1842,,Fourth Line Therapy (follow,Maintenance,,Other,Venetoclax,,,Investigator decision for other reasons,,800,mg,,QD,,PO,,1191,1211,1
MMRF_1842,,Fourth Line Therapy (follow,Maintenance,,Other,Venetoclax,,,Investigator decision for other reasons,,700,mg,,QD,,PO,,1219,1267,1
MMRF_1842,,Fourth Line Therapy (follow,Maintenance,,Other,Venetoclax,,,Investigator decision for other reasons,,200,mg,,QD,,PO,,1275,1295,1
MMRF_1842,,Fourth Line Therapy (follow,Maintenance,,Other,Venetoclax,,,Other,Patient did not take C1D1 correctly,400,mg,,Oth,Days 8-14,PO,,1164,1170,1
MMRF_1842,,Third Line Therapy (followi,Maintenance,,Pomalidomide,,,,Investigator decision for other reasons,,4,mg,,QD,,PO,,1094,1142,1
MMRF_1842,,Sixth Line Therapy (followi,Maintenance,,Panobinostat,,,,Investigator decision for other reasons,,10,mg,,Oth,"Days 1, 3, 5, 15, 17, 18",PO,,1325,1372,1
MMRF_1842,,Sixth Line Therapy (followi,Maintenance,,Dexamethasone,,,Checked,,,40,mg,,Oth,"Days 1, 8, 15, 22",PO,,1325,,1
MMRF_1842,,Fifth Line Therapy (followi,Maintenance,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,"Days 1, 2, 3, 4",PO,,1297,1300,1
MMRF_1842,,Fifth Line Therapy (followi,Maintenance,,Carfilzomib,,,,Completed regimen,,43,mg,,Oth,"Day 1, 2",IV,,1297,1298,1
MMRF_1842,,Fifth Line Therapy (followi,Maintenance,,Other,Cisplatin,,,Completed regimen,,22,mg,,Oth,"Days 1, 2, 3, 4",IV,,1297,1327,1
MMRF_1842,,Fifth Line Therapy (followi,Maintenance,,Other,Etoposide,,,Completed regimen,,64,mg,,Oth,"Days 1, 2, 3, 4",IV,,1297,1327,1
MMRF_1842,,Fifth Line Therapy (followi,Maintenance,,Cyclophosphamide,,,,Completed regimen,,860,mg,,Oth,"Days 1, 2, 3, 4",IV,,1297,1300,1
MMRF_1842,,Fifth Line Therapy (followi,Maintenance,,Doxorubicin,,,,Completed regimen,,16,mg,,Oth,"Days 1, 2, 3, 4",IV,,1297,1300,1
MMRF_1842,,Sixth Line Therapy (followi,Maintenance,,Carfilzomib,,,,Investigator decision for other reasons,,120,mg,,Oth,"Days 1, 8, 15, 22",IV,,1325,1375,1
MMRF_1842,,Seventh Line of Therapy (fo,Maintenance,,Cyclophosphamide,,,Checked,,,500,mg,,Oth,"Days 1, 8, 15, 22",IV,,1409,,1
MMRF_1842,,Seventh Line of Therapy (fo,Maintenance,,Pomalidomide,,,Checked,,,4,mg,,QD,,PO,,1409,,1
MMRF_1858,,First line of therapy,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,40,mg,,QD,,PO,,1,25,1
MMRF_1858,,First line of therapy,Induction,,Cyclophosphamide,,,,Adverse Event or co-morbidity,,500,mg,,QD,,PO,,1,25,1
MMRF_1858,Baseline,First line of therapy,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,2.2,mg,,QD,,IV SubQ,,1,25,1
MMRF_1858,,First line of therapy,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,15,mg,,QD,,PO,,76,327,1
MMRF_1858,,First line of therapy,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,12,mg,,Q w,,PO,,153,327,1
MMRF_1858,,First line of therapy,Induction,,Dexamethasone,,,,Investigator decision for other reasons,,40,mg,,Q w,,PO,,76,153,1
MMRF_1858,,Second Line Therapy (after,Maintenance,,Lenalidomide,,,,Disease progression/Relapse,,15,mg,,QD,,PO,,744,1033,1
MMRF_1858,,Second Line Therapy (after,Maintenance,,Dexamethasone,,,,Completed regimen,,12,mg,,Q w,,PO,,744,909,1
MMRF_1858,,Second Line Therapy (after,Maintenance,,Dexamethasone,,,,Disease progression/Relapse,,8,mg,,Q w,,PO,,910,1033,1
MMRF_1858,,Third Line Therapy (followi,Maintenance,,Dexamethasone,,,,Other,Death,20,mg,,Oth,"Days 1, 8, 15, 22",PO,,1037,1278,1
MMRF_1858,,Third Line Therapy (followi,Maintenance,,Carfilzomib,,,,Other,Death,20,mg/m^,,Oth,Day 1,IV,,1037,1278,1
MMRF_1858,,Third Line Therapy (followi,Maintenance,,Carfilzomib,,,,Other,Death,56,mg/m^,,Oth,"Days 8, 15",IV,,1037,1278,1
MMRF_1858,,Third Line Therapy (followi,Maintenance,,Cyclophosphamide,,,,Other,Death,300,mg/m^,,Oth,"Days 1, 8, 15",IV,,1037,1278,1
MMRF_1886,Baseline,First line of therapy,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,1.3,mg/m^,,QD,,IV SubQ,,1,99,1
MMRF_1886,,First line of therapy,Induction,,Cyclophosphamide,,,,Adverse Event or co-morbidity,,500,mg/m^,,QD,,PO,,1,43,1
MMRF_1886,,First line of therapy,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,40,mg,,QD,,PO,,1,43,1
MMRF_1886,,First line of therapy,Maintenance,,Bortezomib,,,,Adverse Event or co-morbidity,,1,mg/m^,,Oth,Days 1  and Day15,IV SubQ,,155,477,1
MMRF_1886,,First line of therapy,Maintenance,,Dexamethasone,,,,Adverse Event or co-morbidity,,12,mg,,Oth,Days 1 and Day 15,PO,,155,477,1
MMRF_1886,,First line of therapy,Induction,,Cyclophosphamide,,,,Adverse Event or co-morbidity,,300,mg/m^,,QD,,PO,,43,99,1
MMRF_1886,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,200,mg/m^,,QD,,PO,,99,143,1
MMRF_1886,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,QD,,PO,,43,143,1
MMRF_1886,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1,mg/m^,,QD,,IV SubQ,,99,143,1
MMRF_1886,,First line of therapy,Maintenance,,Bortezomib,,,,Adverse Event or co-morbidity,,0.8,mg/m^,,Oth,Days 1 and 15,IV SubQ,,547,561,1
MMRF_2074,Baseline,First line of therapy,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,1.3,mg/m^,,QD,,IV SubQ,,1,67,1
MMRF_2074,,First line of therapy,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,40,mg,,QD,,PO,,1,67,1
MMRF_2074,,First line of therapy,Induction,,Thalidomide,,,,Adverse Event or co-morbidity,,100,mg,,QD,,PO,,1,50,1
MMRF_2074,,First line of therapy,Consolidation,,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,169,169,1
MMRF_2074,,First line of therapy,Induction,,Thalidomide,,,,Completed regimen,,50,mg,,QD,,PO,,57,127,1
MMRF_2074,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,12,mg,,QD,,PO,,85,116,1
MMRF_2074,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1,mg/m^,,QD,,IV SubQ,,85,116,1
MMRF_2074,,First line of therapy,Maintenance,,Bortezomib,,,,Disease progression/Relapse,,1,mg/m^,,Oth,Days 1 and 15,IV SubQ,,302,1198,1
MMRF_2074,,Second Line Therapy (after,Maintenance,,Dexamethasone,,,Checked,,,20,mg,,Oth,"Days 1, 2",IV,,1268,,1
MMRF_2074,,Second Line Therapy (after,Maintenance,,Carfilzomib,,,Checked,,,20,mg/m^,,Oth,"Days 1, 2",IV,,1268,,1
MMRF_2093,,First line of therapy,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,40,mg,,QD,,PO,,1,43,1
MMRF_2093,Baseline,First line of therapy,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,1.3,mg/m^,,QD,,IV SubQ,,1,57,1
MMRF_2093,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,QD,,PO,,1,127,1
MMRF_2093,,First line of therapy,Maintenance,,Lenalidomide,,,,Investigator decision for other reasons,,10,mg,,QD,,PO,,253,531,1
MMRF_2093,,First line of therapy,Consolidation,,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,177,177,1
MMRF_2093,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1,mg/m^,,QD,,IV SubQ,,57,123,1
MMRF_2093,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,QD,,PO,,57,127,1
MMRF_2093,,Second Line Therapy (after,Maintenance,,Dexamethasone,,,,Investigator decision for other reasons,,20,mg,,Oth,"Days 1, 8, 15, 22 (Missed C2 D8, 15, 22)",PO,,827,1158,1
MMRF_2093,,Second Line Therapy (after,Maintenance,,Carfilzomib,,,,Investigator decision for other reasons,,27,mg/m^,,Oth,"Days 8, 9, 15, 16 (Missed C2 D8, 9, 15, 16)",IV,,827,843,1
MMRF_2093,,Second Line Therapy (after,Maintenance,,Carfilzomib,,,,Investigator decision for other reasons,,20,mg/m^,,Oth,"Days 1, 2",IV,,827,829,1
MMRF_2093,,Second Line Therapy (after,Maintenance,,Cyclophosphamide,,,,Investigator decision for other reasons,,300,mg/m^,,Oth,"Days 1, 8, 15 (Missed C2 D8, 15)",IV,,827,1158,1
MMRF_2093,,Third Line Therapy (followi,Maintenance,,Daratumumab,,,Checked,,,16,mg/kg,,Oth,Day 1,IV,,1172,,1
MMRF_2093,,Third Line Therapy (followi,Maintenance,,Pomalidomide,,,Checked,,,2,mg,,QD,,PO,,1172,,1
MMRF_2093,,Third Line Therapy (followi,Maintenance,,Dexamethasone,,,Checked,,,20,mg,,Oth,Day 1,IV,,1172,,1
MMRF_2093,,Second Line Therapy (after,Maintenance,,Carfilzomib,,,,Investigator decision for other reasons,,27,mg/m^,,Oth,"Days 1, 2, 8, 9, 15, 16",IV,,855,1158,1
MMRF_2266,Baseline,First line of therapy,Induction,,Bortezomib,,,,Investigator decision for other reasons,,1.3,mg/m^,,Oth,"day 1, day 7, day 14",IV SubQ,,1,68,1
MMRF_2266,,First line of therapy,Induction,,Cyclophosphamide,,,,Investigator decision for other reasons,,300,mg/m^,,Oth,"day 1, day 7, day 14",IV,,1,68,1
MMRF_2266,,First line of therapy,Induction,,Dexamethasone,,,,Investigator decision for other reasons,,40,mg,,Oth,"day 1, day 7, day 14",IV,,1,68,1
MMRF_2266,,First line of therapy,Induction,,Bortezomib,,,,Investigator decision for other reasons,,1,mg/m^,,Oth,Days 1 and 15 every 28 days,IV SubQ,,68,369,1
MMRF_2266,,First line of therapy,Induction,,Dexamethasone,,,,Investigator decision for other reasons,,8,mg,,Oth,Days 1 and 15 of every 28 days,IV,,68,369,1
MMRF_2306,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.5,mg/m^,,Oth,"Day 1, 7, 14",IV SubQ,,1,14,1
MMRF_2306,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,"Day 1, 7, 14",PO,,1,14,1
MMRF_2306,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,500,mg/m^,,Oth,"Day 1, 7, 14",IV,,1,14,1
MMRF_2306,,First line of therapy,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,1.5,mg/m^,,Oth,"Day 1, 8, 15",IV SubQ,,21,98,1
MMRF_2306,,First line of therapy,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,40,mg,,Oth,"Day 1, 8, 15",PO,,21,119,1
MMRF_2306,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,500,mg/m^,,Oth,"Day 1, 8, 15",IV,,21,168,1
MMRF_2306,,First line of therapy,Induction,,Bortezomib,,,,Disease progression/Relapse,,1,mg,,Oth,"Day 1, 15",IV SubQ,,126,245,1
MMRF_2306,,First line of therapy,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,1,mg/m^,,Oth,"Day 1, 8, 15",IV SubQ,,105,168,1
MMRF_2306,,Second Line Therapy (after,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,40,mg,,Oth,"Days 1, 8, 15, 22",PO,,266,287,1
MMRF_2306,,Second Line Therapy (after,Induction,,Carfilzomib,,,,Completed regimen,,20,mg/m^,,Oth,Days 1 and 2,IV,,266,267,1
MMRF_2306,,Second Line Therapy (after,Induction,,Carfilzomib,,,,Completed regimen,,27,mg/m^,,Oth,"Days 8, 9, 15, and 16",IV,,273,281,1
MMRF_2306,,Second Line Therapy (after,Induction,,Cyclophosphamide,,,,Completed regimen,,500,mg/m^,,Oth,"Days 1, 8, 15",IV,,266,364,1
MMRF_2306,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Day 1, 8, 15",PO,,126,168,1
MMRF_2306,,Second Line Therapy (after,Induction,,Dexamethasone,,,,Completed regimen,,12,mg,,Oth,"Days 1, 8, 15, 22",PO,,294,371,1
MMRF_2306,,Second Line Therapy (after,Induction,,Carfilzomib,,,,Completed regimen,,27,mg/m^,,QD,,IV,,294,365,1
MMRF_2306,,First line of therapy,Consolidation,,Melphalan,,,,Completed regimen,,200,mg/m^,,Oth,Once on Day -2,IV,,425,425,1
MMRF_2306,,Second Line Therapy (after,Maintenance,,Carfilzomib,,,,Investigator decision for other reasons,,27,mg/m^,,Oth,Q 2 weeks,IV,,502,961,1
MMRF_2306,,Second Line Therapy (after,Maintenance,,Dexamethasone,,,,Investigator decision for other reasons,,8,mg,,Oth,"Days 1, 15",IV,,516,852,1
MMRF_2306,,Third Line Therapy (followi,Maintenance,,Carfilzomib,,,Checked,,,27,mg/m^,,QD,,IV,,1006,,1
MMRF_2306,,Third Line Therapy (followi,Maintenance,,Lenalidomide,,,Checked,,,25,mg,,QD,,PO,,1006,,1
MMRF_2306,,Third Line Therapy (followi,Maintenance,,Dexamethasone,,,Checked,,,20,mg,,Oth,"Days 1, 8, 15",PO,,1006,,1
MMRF_2306,,Second Line Therapy (after,Maintenance,,Dexamethasone,,,,Investigator decision for other reasons,,4,mg,,Oth,"Days 1, 15",IV,,866,961,1
MMRF_2486,Baseline,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,800,mg,,Oth,"Days 1, 8, 15, 22",PO,,1,176,1
MMRF_2486,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,"Days 1, 8, 15, 22",PO,,1,176,1
MMRF_2486,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,Oth,"Days 1, 8, 15, 22",IV SubQ,,1,176,1
MMRF_2486,,First line of therapy,Consolidation,,Melphalan,,,,Completed regimen,,200,mg/m^,,Oth,Once on Day -2,IV,,217,217,1
MMRF_2486,,First line of therapy,Maintenance,,Carfilzomib,,,,Completed regimen,,20,mg/m^,,Oth,Day 1 (Patient missed Day 2),IV,,288,288,1
MMRF_2486,,First line of therapy,Maintenance,,Carfilzomib,,,,Completed regimen,,56,mg/m^,,Oth,Days 1 (Missed Day 15),IV,,344,344,1
MMRF_2486,,First line of therapy,Maintenance,,Carfilzomib,,,,Completed regimen,,27,mg/m^,,QD,,IV,,316,331,1
MMRF_2486,,First line of therapy,Maintenance,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,"Days 1, 8, 15, 22",PO,,288,337,1
MMRF_2486,,First line of therapy,Maintenance,,Carfilzomib,,,,Completed regimen,,27,mg/m^,,Oth,"Days 8, 9, 15, 16",IV,,295,303,1
MMRF_2486,,First line of therapy,Maintenance,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,288,552,1
MMRF_2486,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,"Days 1, 8, 15, 22",PO,,383,553,1
MMRF_2486,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,27,mg/m^,,Oth,"Days 1-2,8-9,15-16",IV,,383,547,1
MMRF_2486,,First line of therapy,Consolidation,,Lenalidomide,,,,Investigator decision for other reasons,,15,mg,,QD,,PO,,560,629,1
MMRF_2486,,First line of therapy,Consolidation,,Carfilzomib,,,Checked,,,27,mg/m^,,Oth,"Days 1, 15",IV,,560,,1
MMRF_2486,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,5,mg,,QD,,PO,,714,,1
MMRF_2497,Baseline,First line of therapy,Induction,,Lenalidomide,,,,Other,Decreased to 10mg for cycle 1 for createnine clearence < 60,10,mg,,QD,,PO,,1,22,1
MMRF_2497,,First line of therapy,Induction,,Dexamethasone,,,Checked,,,20,mg,,Oth,"D1, D8, D15, D22",PO,,1,,1
MMRF_2497,,First line of therapy,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,25,mg,,QD,,PO,,30,223,1
MMRF_2497,,First line of therapy,Induction,,Lenalidomide,,,,Investigator decision for other reasons,,15,mg,,QD,,PO,,240,490,1
MMRF_2497,,First line of therapy,Induction,,Lenalidomide,,,Checked,,,10,mg,,QD,,PO,,511,,1
MMRF_2501,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,"D1, D8, D15, D22",PO,,1,113,1
MMRF_2501,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,"D1, D8, D15, D22",PO,,1,113,1
MMRF_2501,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,Oth,"D1, D8, D15, D22",IV SubQ,,1,113,1
MMRF_2501,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,200,mg/m^,,Oth,IV over 20 minutes,IV,,170,170,1
MMRF_2501,,First line of therapy,Maintenance,,Lenalidomide,,,,Disease progression/Relapse,,10,mg,,QD,,PO,,276,984,1
MMRF_2501,,Second Line Therapy (after,Maintenance,,Daratumumab,,,Checked,,,16,mg/kg,,Oth,"Days 1, 8, 15 (Cycle 1: Day 1 only)",IV,,1012,,1
MMRF_2501,,Second Line Therapy (after,Maintenance,,Bortezomib,,,Checked,,,1.3,mg/m^,,Oth,"Days 1, 8, 15 (Cycle 1: Day 1 only)",IV SubQ,,1012,,1
MMRF_2501,,Second Line Therapy (after,Maintenance,,Dexamethasone,,,Checked,,,40,mg,,Oth,"Days 1, 8, 15 (Cycle 2+)",PO,,1029,,1
MMRF_2557,,First line of therapy,Induction,,Dexamethasone,,,,Investigator decision for other reasons,,20,mg,,Oth,"Days 1, 8, and 15",PO,,1,264,1
MMRF_2557,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.01,mg/m^,,Oth,"Days 1, 8, 15",IV SubQ,,5,117,1
MMRF_2557,,First line of therapy,Induction,,Cyclophosphamide,,,,Disease progression/Relapse,,300,mg/m^,,Oth,"Days 1, 8, 15",IV,,131,222,1
MMRF_2557,,Second Line Therapy (after,Induction,,Carfilzomib,,,,Adverse Event or co-morbidity,,20,mg/m^,,Oth,"Days 1, 8, 15",IV,,251,264,1
MMRF_2557,,First line of therapy,Induction,,Dexamethasone,,,,Disease progression/Relapse,,10,mg,,Oth,Over 3 minutes for 1 day,IV,,131,222,1
MMRF_2557,,First line of therapy,Induction,,Bortezomib,,,,Disease progression/Relapse,,1,mg/m^,,Oth,"Days 1, 8, 15",IV SubQ,,131,222,1
MMRF_2557,,Second Line Therapy (after,Induction,,Lenalidomide,,,,Patient decision,,15,mg,,QD,,PO,,232,257,1
MMRF_2087,,First line of therapy,Induction,,Dexamethasone,,,,Other,Increased dosage,20,mg,,QWK,,PO,,1,165,1
MMRF_2087,Baseline,First line of therapy,Induction,,Lenalidomide,,,,Other,Medication is on hold due to patient's nausea,10,mg,,Oth,3 weeks on 1 week off,PO,,1,26,1
MMRF_2087,,First line of therapy,Induction,,Lenalidomide,,,,Other,Held by Physician for Pt developing Shingles; plan restart after recovery,5,mg,,Oth,Every Other Day,PO,,131,198,1
MMRF_2087,,First line of therapy,Induction,,Lenalidomide,,,,Other,Medication Hold/Chemo induced Neutropenia,10,mg,,Q d,,PO,,58,86,1
MMRF_2087,,First line of therapy,Induction,,Lenalidomide,,,,Other,Reduced dose/ 5 mg Every Other Day,5,mg,,Q d,,PO,,103,130,1
MMRF_2087,,First line of therapy,Induction,,Dexamethasone,,,,Other,Held by Physician for Pt developing Shingles; plan restart after recovery,40,mg,,Q w,,PO,,166,198,1
MMRF_2087,,First line of therapy,Induction,,Bortezomib,,,,Other,Held by Physician for Pt developing Shingles; plan restart after recovery,2.34,mg,,Oth,"QD (1, 4, 8, 15)",Other,SubQ,165,198,1
MMRF_2087,,Second Line Therapy (after,Induction,,Dexamethasone,,,,Other,Began Hospice Care strict palliative care only without chemotherapy,20,mg,,Q w,,PO,,230,261,1
MMRF_2087,,Second Line Therapy (after,Induction,,Bortezomib,,,,Lack of response,,2.2,mg,,Q w,,Other,subQ,208,249,1
MMRF_2087,,Second Line Therapy (after,Induction,,Lenalidomide,,,,Other,Covering Doctor held medication,5,mg,,Oth,Every Other Day,PO,,208,229,1
MMRF_2087,,Second Line Therapy (after,Induction,,Dexamethasone,,,,Other,Doctor covering: Reduced dose to 20 mg QWk,40,mg,,Q w,,PO,,208,229,1
MMRF_2087,,Second Line Therapy (after,Induction,,Carfilzomib,,,,Other,Covering Doctor Increased Dosage to 45 mg,35,mg,,Oth,"day 1, day 2 of every week, 3 weeks on, 1 week off",IV,,249,256,1
MMRF_2087,,Second Line Therapy (after,Induction,,Carfilzomib,,,,Other,Began Hospice Care strict palliative care only without chemotherapy,45,mg,,Oth,"day 1, day 2 of every week, 3 weeks on, 1 week off",IV,,256,261,1
MMRF_2141,Baseline,First line of therapy,Induction,,Bortezomib,,,,Other,Hold Velcade: eval for autologous transplant,2.67,mg,,Q w,,Other,SubQ,3,175,1
MMRF_2141,,First line of therapy,Induction,,Dexamethasone,,,,Other,Decrease Dose to 20 mg to minimize side effects,40,mg,,Q w,,PO,,1,175,1
MMRF_2141,,First line of therapy,Induction,,Dexamethasone,,,Checked,,,20,mg,,Q w,,PO,,176,,1
MMRF_2149,Baseline,First line of therapy,Induction,,Bortezomib,,,,Patient decision,,2.27,mg,,Q w,,Other,SubQ,1,163,1
MMRF_2149,,First line of therapy,Induction,,Dexamethasone,,,,Patient decision,,40,mg,,Q w,,PO,,1,163,1
MMRF_2153,,First line of therapy,Induction,,Dexamethasone,,,,Disease progression/Relapse,,20,mg,,Q w,,PO,,1,382,1
MMRF_2153,Baseline,First line of therapy,Induction,,Bortezomib,,,,Disease progression/Relapse,,2,mg,,Q w,,Other,SubQ,3,382,1
MMRF_2153,,Second Line Therapy (after,Maintenance,,Lenalidomide,,,,Other,"Patient lost to follow-up after this cycle, moved to different city",10,mg,,Q d,,PO,,393,584,1
MMRF_2191,Baseline,First line of therapy,Induction,,Bortezomib,,,,Investigator decision for other reasons,,3,mg,,QWK,,Other,SubQ,1,135,1
MMRF_2191,,First line of therapy,Induction,,Dexamethasone,,,,Investigator decision for other reasons,,40,mg,,Q w,,PO,,1,379,1
MMRF_2191,,First line of therapy,Maintenance,,Bortezomib,,,,Disease progression/Relapse,,2.6,mg,,Q w,,Other,SubQ,287,352,1
MMRF_2191,,First line of therapy,Maintenance,,Bortezomib,,,,Investigator decision for other reasons,,2.6,mg,,Q w,,Other,SubQ,141,268,1
MMRF_2191,,Second Line Therapy (after,Maintenance,,Carfilzomib,,,,Investigator decision for other reasons,,96,mg,,QWK,,IV,,581,689,1
MMRF_2191,,Second Line Therapy (after,Maintenance,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,568,694,1
MMRF_2191,,Third Line Therapy (followi,Maintenance,,Daratumumab,,,Checked,,,8,mg/kg,,Oth,D1-2 q28D,IV,,868,,1
MMRF_2191,,Third Line Therapy (followi,Maintenance,,Lenalidomide,,,Checked,,,20,mg,,QD,,PO,,868,,1
MMRF_2191,,Third Line Therapy (followi,Maintenance,,Dexamethasone,,,Checked,,,20,mg,,Oth,"Day 2, q28D cycle",IV,,869,,1
MMRF_2228,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Q w,,PO,,1,392,1
MMRF_2228,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,3.5,mg,,Q w,,Other,SubQ,1,406,1
MMRF_2301,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,2.9,mg,,Q w,,Other,SubQ,1,157,1
MMRF_2301,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,With Bortezomib,PO,,1,157,1
MMRF_2301,,Second Line Therapy (after,Maintenance,,Lenalidomide,,,Checked,,,20,mg,,QD,,PO,,1122,,1
MMRF_2301,,Second Line Therapy (after,Maintenance,,Dexamethasone,,,Checked,,,20,mg,,Q w,,PO,,1122,,1
MMRF_1766,,First line of therapy,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,40,mg,,Q w,,PO,,1,22,1
MMRF_1766,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Q w,,PO,,1,155,1
MMRF_1766,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.5,mg/m^,,Q w,,IV SubQ,,1,155,1
MMRF_1766,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Q w,,PO,,22,155,1
MMRF_1766,,First line of therapy,Other,Priming chemotherapy,Cyclophosphamide,,,,Completed regimen,,8440,mg,,Oth,once,IV,,185,185,1
MMRF_1766,,First line of therapy,Other,Prep Regimen,Melphalan,,,,Completed regimen,,410,mg,,Oth,once,IV,,217,217,1
MMRF_1766,,First line of therapy,Maintenance,,Bortezomib,,,,Disease progression/Relapse,,1.3,mg/m^,,Oth,Q2W,IV SubQ,,339,989,1
MMRF_1766,,Second Line Therapy (after,Induction,,Lenalidomide,,,Checked,,,25,mg,,QD,,PO,,1066,,1
MMRF_1766,,Second Line Therapy (after,Induction,,Dexamethasone,,,Checked,,,20,mg,,Q w,,PO,,1066,,1
MMRF_1766,,Second Line Therapy (after,Induction,,Other,selinexor,,Checked,,,60,mg,,Q w,,PO,,1066,,1
MMRF_1824,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,"QD (D1, D8, D15)",PO,,1,162,1
MMRF_1824,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Q w,,PO,,1,162,1
MMRF_1824,Baseline,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,42,mg,,QD,,IV,,1,163,1
MMRF_1824,,First line of therapy,Other,Prep Regimen,Melphalan,,,,Completed regimen,,255,mg,,Oth,once,IV,,220,220,1
MMRF_1824,,First line of therapy,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,10,mg,,Q d,,PO,,325,430,1
MMRF_1824,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,5,mg,,Q d,,PO,,430,,1
MMRF_1879,Baseline,First line of therapy,Induction,,Bortezomib,,,,Other,Patient inable to comply with treatment,1.3,mg/m^,,Oth,"QD (D1, D8, D15)",IV SubQ,,1,225,1
MMRF_1879,,First line of therapy,Induction,,Dexamethasone,,,,Other,Patient inable to comply with treatment,40,mg,,Oth,"QD (D1, D8, D15)",PO,,1,225,1
MMRF_1879,,First line of therapy,Induction,,Cyclophosphamide,,,,Other,Patient inable to comply with treatment,300,mg/m^,,Oth,"QD (D1, D8, D15)",PO,,1,225,1
MMRF_2006,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Q w,,PO,,1,102,1
MMRF_2006,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,Oth,"QD (D1, D8, D15)",IV SubQ,,7,102,1
MMRF_2006,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,700,mg,,Q w,,PO,,1,102,1
MMRF_2006,,First line of therapy,Maintenance,,Bortezomib,,,Checked,,,1.3,mg/m^,,Oth,every other week,IV SubQ,,232,,1
MMRF_2006,,First line of therapy,Other,Priming chemotherapy,Melphalan,,,,Completed regimen,,440,mg,,Oth,once,IV,,127,127,1
MMRF_2006,,First line of therapy,Other,Priming chemotherapy,Other,plerixafor,,,Completed regimen,,27,mg,,Oth,once,IV SubQ,,121,121,1
MMRF_2006,,First line of therapy,Other,Priming chemotherapy,Other,plerixafor,,,Completed regimen,,24,mg,,Q d,,IV SubQ,,122,123,1
MMRF_2047,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,"QD (D1, D8, D15)",PO,,1,162,1
MMRF_2047,Baseline,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,56,mg/m^,,QD,,IV,,1,162,1
MMRF_2047,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,"QD (D1, D8, D15, D22)",PO,,1,162,1
MMRF_2047,,First line of therapy,Other,conditioning,Melphalan,,,,Completed regimen,,200,mg/m^,,Oth,once,IV,,185,185,1
MMRF_2047,,First line of therapy,Maintenance,,Bortezomib,,,Checked,,,1.3,mg/m^,,Oth,every other week,IV SubQ,,288,,1
MMRF_2116,Baseline,First line of therapy,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,1.3,mg/m^,,QD,,IV SubQ,,1,99,1
MMRF_2116,,First line of therapy,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,40,mg,,Oth,"D1, D8, D15, D21",PO,,1,99,1
MMRF_2116,,First line of therapy,Induction,,Cyclophosphamide,,,,Adverse Event or co-morbidity,,300,mg/m^,,Oth,"D1, D8, D15",PO,,1,99,1
MMRF_2116,,First line of therapy,Induction,,Dexamethasone,,,,Other,went to transplant,40,mg,,Q w,,PO,,107,190,1
MMRF_2116,,First line of therapy,Induction,,Lenalidomide,,,,Other,went to transplant,25,mg,,QD,,PO,,107,190,1
MMRF_2116,,First line of therapy,Other,conditioning,Melphalan,,,,Completed regimen,,420,mg,,Oth,once,IV,,226,226,1
MMRF_2116,,First line of therapy,Maintenance,,Lenalidomide,,,,Patient decision,,10,mg/dL,,Q d,,PO,,303,487,1
MMRF_2116,,First line of therapy,Maintenance,,Bortezomib,,,Checked,,,1.3,mg/m^,,Oth,every other week,IV SubQ,,729,,1
MMRF_2116,,First line of therapy,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,5,mg,,Q d,,PO,,631,639,1
MMRF_2201,,First line of therapy,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,40,mg,,Oth,"QD (D1, D8, D15)",PO,,1,8,1
MMRF_2201,Baseline,First line of therapy,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,1.3,mg/m^,,Oth,"QD (D1, D8, D15)",IV SubQ,,1,8,1
MMRF_2201,,First line of therapy,Induction,,Cyclophosphamide,,,,Adverse Event or co-morbidity,,300,mg/m^,,Oth,"QD (D1, D8, D15)",PO,,1,8,1
MMRF_2232,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1,Other,mg/mL,QD,,IV,,1,50,1
MMRF_2232,Baseline,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,57,1
MMRF_2232,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"QD (D1, D2, D4, D5, D8, D9, D11, D12)",PO,,1,53,1
MMRF_2232,,First line of therapy,Consolidation,,Dexamethasone,,,,Completed regimen,,10,mg,,Oth,"QD (D1, D2, D4, D5, D8, D9, D11, D12)",PO,,176,207,1
MMRF_2232,,First line of therapy,Other,Prep Regimen,Melphalan,,,,Completed regimen,,200,mg/m^,,Oth,once,IV,,99,99,1
MMRF_2232,,First line of therapy,Other,Priming chemotherapy,Cyclophosphamide,,,,Completed regimen,,3000,mg/m^,,Oth,once,IV,,80,80,1
MMRF_2232,,First line of therapy,Consolidation,,Bortezomib,,,,Completed regimen,,1,mg/m^,,QD,,IV,,176,207,1
MMRF_2232,,First line of therapy,Consolidation,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,176,207,1
MMRF_2232,,First line of therapy,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,15,mg,,Q d,,PO,,311,380,1
MMRF_2232,,First line of therapy,Maintenance,,Lenalidomide,,,,Other,per protocol dose increased,10,mg,,Q d,,PO,,227,310,1
MMRF_2232,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,10,mg,,Q d,,PO,,381,,1
MMRF_2425,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.5,mg/m^,,Q w,,IV SubQ,,1,225,1
MMRF_2425,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Q w,,PO,,1,225,1
MMRF_2425,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Q w,,PO,,1,225,1
MMRF_2425,,First line of therapy,Other,conditioning,Melphalan,,,,Completed regimen,,200,mg/m^,,Oth,once,IV,,232,232,1
MMRF_2425,,First line of therapy,Maintenance,,Lenalidomide,,,,Other,increased dose,10,mg,,Q d,,PO,,344,521,1
MMRF_2425,,First line of therapy,Maintenance,,Lenalidomide,,,,Other,pt was on Leanalidomide maintenance up to hospital admit on 5/22,15,mg,,Q d,,PO,,521,812,1
MMRF_2440,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV,,1,84,1
MMRF_2440,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,84,1
MMRF_2440,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"QD (D1, D2, D4, D5, D8, D9, D11, D12)",PO,,1,84,1
MMRF_2440,,First line of therapy,Consolidation,,Dexamethasone,,,,Completed regimen,,10,mg,,QD,,PO,,210,253,1
MMRF_2440,,First line of therapy,Consolidation,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,210,253,1
MMRF_2440,,First line of therapy,Other,Priming chemotherapy,Cyclophosphamide,,,,Completed regimen,,3000,mg/m^,,Oth,once,IV,,88,88,1
MMRF_2440,,First line of therapy,Consolidation,,Bortezomib,,,,Completed regimen,,1,mg/m^,,QD,,IV SubQ,,210,253,1
MMRF_2440,,First line of therapy,Other,conditioning,Melphalan,,,,Completed regimen,,200,mg/m^,,Oth,once,IV,,113,113,1
MMRF_2440,,First line of therapy,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,15,mg,,Q d,,PO,,350,462,1
MMRF_2440,,First line of therapy,Maintenance,,Lenalidomide,,,,Other,increased dose,10,mg,,Q d,,PO,,259,349,1
MMRF_2440,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,10,mg,,Q d,,PO,,463,,1
MMRF_2485,,First line of therapy,Induction,,Cyclophosphamide,,,,Other,went to transplant,300,mg/m^,,Q w,,IV,,1,238,1
MMRF_2485,Baseline,First line of therapy,Induction,,Bortezomib,,,,Other,went to transplant,1.5,mg/m^,,Q w,,IV SubQ,,1,238,1
MMRF_2485,,First line of therapy,Induction,,Dexamethasone,,,,Other,went to transplant,40,mg,,Q w,,IV,,1,238,1
MMRF_2485,,First line of therapy,Other,conditioning,Melphalan,,,,Completed regimen,,200,mg/m^,,Oth,once,IV,,291,291,1
MMRF_2485,,First line of therapy,Maintenance,,Bortezomib,,,Checked,,,1.3,mg/m^,,Oth,every other week,IV SubQ,,434,,1
MMRF_2566,Baseline,First line of therapy,Induction,,Bortezomib,,,,Other,stopped for stem cell collection,1.3,mg/m^,,QD,,IV SubQ,,1,53,1
MMRF_2566,,First line of therapy,Induction,,Lenalidomide,,,,Other,stopped for stem cell collection,25,mg,,QD,,PO,,1,57,1
MMRF_2566,,First line of therapy,Induction,,Dexamethasone,,,,Other,stopped for stem cell collection,20,mg,,Oth,"QD (D1, D2, D4, D5, D8, D9, D11, D12)",PO,,1,74,1
MMRF_2566,,First line of therapy,Other,Priming chemotherapy,Cyclophosphamide,,,,Completed regimen,,3000,mg/m^,,Oth,once,IV,,74,74,1
MMRF_2566,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,10,mg,,Q d,,PO,,241,,1
MMRF_2566,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1,mg/m^,,QD,,IV SubQ,,123,221,1
MMRF_2566,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,10,mg,,Oth,"QD (D1, D2, D4, D5, D8, D9, D11, D12)",PO,,123,221,1
MMRF_2566,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,123,221,1
MMRF_2590,,First line of therapy,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,25,mg,,QD,,PO,,1,8,1
MMRF_2590,Baseline,First line of therapy,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,1.3,mg/m^,,QD,,IV SubQ,,1,8,1
MMRF_2590,,First line of therapy,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,20,mg,,QD,,PO,,1,8,1
MMRF_2590,,First line of therapy,Induction,,Bortezomib,,,,Patient decision,,1.3,mg/m^,,QD,,IV SubQ,,71,113,1
MMRF_2590,,First line of therapy,Induction,,Dexamethasone,,,,Patient decision,,20,mg,,QD,,PO,,71,113,1
MMRF_2590,,First line of therapy,Induction,,Bortezomib,,,,Other,"Tolerated well, increased dose",1,mg/m^,,QD,,IV SubQ,,50,60,1
MMRF_2590,,First line of therapy,Induction,,Prednisone,,,,Adverse Event or co-morbidity,,62.5,mg,,Q w,,Other,Intramuscular,113,127,1
MMRF_2590,,First line of therapy,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,1.3,mg/m^,,Q w,,IV SubQ,,113,127,1
MMRF_2590,,First line of therapy,Induction,,Bortezomib,,,Checked,,,1,mg/m^,,Q w,,IV SubQ,,199,,1
MMRF_2590,,First line of therapy,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,1.3,mg/m^,,Q w,,IV SubQ,,192,199,1
MMRF_2590,,First line of therapy,Induction,,Prednisone,,,,Lack of response,,62.5,mg,,Q w,,Other,Intramuscular,192,253,1
MMRF_2590,,First line of therapy,Induction,,Prednisone,,,,Patient decision,,60,mg,,Q w,,PO,,113,120,1
MMRF_2622,Baseline,First line of therapy,Induction,,Bortezomib,,,,Other,stem cell collection,1.3,mg/m^,,QD,,IV,,1,53,1
MMRF_2622,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"QD (D1, D2, D4, D5, D8, D9, D11, D12)",PO,,1,205,1
MMRF_2622,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,197,1
MMRF_2622,,First line of therapy,Maintenance,,Lenalidomide,,,,Other,dose changed,10,mg/dL,,Q d,,PO,,205,288,1
MMRF_2622,,First line of therapy,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,15,mg,,Q d,,PO,,288,316,1
MMRF_2622,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,10,mg,,Q d,,PO,,337,,1
MMRF_2147,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,45,mg,,Oth,D1 and D2,IV,,1,2,1
MMRF_2147,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,21,1
MMRF_2147,Baseline,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,"Q Week D1, D8 D15, D22",PO,,1,22,1
MMRF_2147,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg,,Oth,"D 8, D9, D15, D16",IV,,12,16,1
MMRF_2147,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,78,mg,,QD,,IV,,29,274,1
MMRF_2147,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,29,280,1
MMRF_2147,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,"D1, D8, D15, D22",PO,,29,281,1
MMRF_2147,,First line of therapy,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,15,mg,,Oth,daily 3 weeks out of 4,PO,,309,392,1
MMRF_2419,,First line of therapy,Induction,,Cyclophosphamide,,,,Other,PBSCT,600,mg,,Oth,"Weekly D1, D8, D15, D21, D28",PO,,1,274,1
MMRF_2419,,First line of therapy,Induction,,Dexamethasone,,,,Other,PBSCT,40,mg,,Oth,"Weekly D1, D8,D15,D21,D28",PO,,1,274,1
MMRF_2419,Baseline,First line of therapy,Induction,,Bortezomib,,,,Lack of response,,3.3,mg,,Oth,"Weekly D1,D8,D15,D21,D28",IV,,1,162,1
MMRF_2419,,Second Line Therapy (after,Induction,,Dexamethasone,,,,Other,PBSCT,40,mg,,QWK,,PO,,162,274,1
MMRF_2419,,First line of therapy,Induction,,Lenalidomide,,,,Other,PBSCT,25,mg,,Q d,,PO,,162,274,1
MMRF_2419,,Second Line Therapy (after,Induction,,Carfilzomib,,,,Other,PBSCT,43.6,mg,,QD,,IV,,162,274,1
MMRF_2419,,Second Line Therapy (after,Maintenance,,Lenalidomide,,,Checked,,,5,mg,,QD,,PO,,519,,1
MMRF_2438,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,500,mg,,Oth,"D1,D8, D15, and D22",PO,,1,106,1
MMRF_2438,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,2.93,mg,,Oth,"D1, D8, D15, and D22",Other,Subcutaneously,1,106,1
MMRF_2438,,First line of therapy,Maintenance,,Bortezomib,,,,Disease progression/Relapse,,2.5,Other,mg/mL,Q w,,IV SubQ,,288,457,1
MMRF_2438,,Second Line Therapy (after,Induction,,Lenalidomide,,,,Disease progression/Relapse,,25,mg,,QD,,PO,,458,465,1
MMRF_2438,,Second Line Therapy (after,Induction,,Dexamethasone,,,,Disease progression/Relapse,,4,mg,,QD,,IV,,458,606,1
MMRF_2438,,Second Line Therapy (after,Induction,,Carfilzomib,,,,Disease progression/Relapse,,52,mg,,QD,,IV,,458,606,1
MMRF_2438,,Third Line Therapy (followi,Induction,,Daratumumab,,,,Disease progression/Relapse,,1300,mg,,Oth,Qweek (W1-8) Q2weeks (W9-24),IV,,739,866,1
MMRF_2438,,Third Line Therapy (followi,Induction,,Pomalidomide,,,,Disease progression/Relapse,,4,mg,,Oth,QD (D1-28),PO,,739,866,1
MMRF_2438,,Third Line Therapy (followi,Induction,,Dexamethasone,,,,Disease progression/Relapse,,4,mg,,Oth,"QAM (D2, D3, following Dara infusion)",PO,,739,866,1
MMRF_2438,,Third Line Therapy (followi,Unknown,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,PO,,684,694,1
MMRF_2438,,Third Line Therapy (followi,Unknown,,Bortezomib,,,,Completed regimen,,1,mg/m^,,QD,,IV,,684,694,1
MMRF_2438,,Third Line Therapy (followi,Unknown,,Other,Cisplatin,,,Completed regimen,,10,mg/m^,,QD,,IV,,684,694,1
MMRF_2438,,Third Line Therapy (followi,Unknown,,Cyclophosphamide,,,,Completed regimen,,400,mg/m^,,QD,,IV,,684,694,1
MMRF_2438,,Third Line Therapy (followi,Unknown,,Doxorubicin,,,,Completed regimen,,10,mg/m^,,QD,,IV,,684,694,1
MMRF_2438,,Third Line Therapy (followi,Unknown,,Dexamethasone,,,,Investigator decision for other reasons,,4,mg,,QD,,IV SubQ,,656,671,1
MMRF_2438,,Third Line Therapy (followi,Unknown,,Other,Etoposide,,,Completed regimen,,40,mg/m^,,QD,,IV,,684,694,1
MMRF_2438,,Fourth Line Therapy (follow,Unknown,,Dexamethasone,,,Checked,,,40,mg,,Q w,,PO,,929,,1
MMRF_2438,,Fourth Line Therapy (follow,Unknown,,Cyclophosphamide,,,Checked,,,300,mg,,Oth,"QD (D1, D8, D15; every 28 day cycle)",PO,,929,,1
MMRF_2438,,Fourth Line Therapy (follow,Unknown,,Pomalidomide,,,Checked,,,2,mg,,QD,,PO,,929,,1
MMRF_2517,Baseline,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,Every 7 days,PO,,1,120,1
MMRF_2517,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,3.2,mg,,Oth,"Q D1, D8, D15, and D22",IV SubQ,,1,106,1
MMRF_2517,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Q d,,PO,,1,120,1
MMRF_2517,,First line of therapy,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,10,mg,,Q d,,PO,,260,673,1
MMRF_2573,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,40,mg,,Oth,QD day 1 and day 2,IV,,1,2,1
MMRF_2573,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,27,mg,,Oth,"QD day 8 , day 9, day 15, and day 16",IV,,8,268,1
MMRF_2573,Baseline,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,10,mg,,QD,,PO,,1,268,1
MMRF_2573,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,4,mg,,Oth,"QD day 2, day 9, and day16",PO,,2,268,1
MMRF_2573,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Q w,,PO,,1,268,1
MMRF_2573,,First line of therapy,Maintenance,,Lenalidomide,,,,Patient decision,,15,mg,,QD,,PO,,284,979,1
MMRF_2573,,First line of therapy,Unknown,,Daratumumab,,,Checked,,,1300,mg,,Q w,,IV,,981,,1
MMRF_2573,,First line of therapy,Unknown,,Dexamethasone,,,Checked,,,8,mg,,Oth,"Q Week (D2, D3; with Dara being infused on D1)",PO,,982,,1
MMRF_2597,Baseline,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,"QD days 1,8,15,and 22",PO,,1,106,1
MMRF_2597,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,2.85,mg,,Oth,"QD days 1,8,15, and 22",IV SubQ,,1,106,1
MMRF_2597,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,600,mg,,Oth,"QD days 1,8, 15, and 22",PO,,1,106,1
MMRF_2597,,First line of therapy,Consolidation,,Dexamethasone,,,,Completed regimen,,40,mg,,Q d,,PO,,261,288,1
MMRF_2597,,First line of therapy,Consolidation,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,261,288,1
MMRF_2597,,First line of therapy,Maintenance,,Lenalidomide,,,,Investigator decision for other reasons,,10,mg,,Q d,,PO,,290,988,1
MMRF_2608,Baseline,First line of therapy,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,2.9,mg,,QD,,IV,,4,105,1
MMRF_2608,,First line of therapy,Induction,,Cyclophosphamide,,,,Other,does reduced,500,mg,,Oth,"QD D1, D4, D8, D11",PO,,4,105,1
MMRF_2608,,First line of therapy,Induction,,Dexamethasone,,,,Investigator decision for other reasons,,40,mg,,Oth,"QD (D1-4, D9-13, D17-21)",PO,,1,33,1
MMRF_2608,,First line of therapy,Induction,,Dexamethasone,,,,Investigator decision for other reasons,,20,mg,,Q w,,PO,,44,326,1
MMRF_2608,,First line of therapy,Induction,,Cyclophosphamide,,,,Other,Concerns worsening Heart failure,400,mg,,Q w,,PO,,168,326,1
MMRF_2608,,Second Line Therapy (after,Unknown,,Dexamethasone,,,Checked,,,8,mg,,Oth,"D1, D8, D15",PO,,986,,1
MMRF_2608,,Second Line Therapy (after,Unknown,,Lenalidomide,,,Checked,,,15,mg,,QD,,PO,,986,,1
MMRF_2223,Baseline,First line of therapy,Induction,,Bortezomib,,,,Investigator decision for other reasons,,1.3,mg/m^,,QD,,IV SubQ,,1,158,1
MMRF_2223,,First line of therapy,Induction,,Dexamethasone,,,Checked,,,10,mg,,QD,,PO,,22,,1
MMRF_2223,,First line of therapy,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,40,mg,,QD,,PO,,1,22,1
MMRF_2223,,First line of therapy,Maintenance,,Bortezomib,,,Checked,,,1.3,mg/m^,,Oth,Day 1 and Day 15,IV,,447,,1
MMRF_2568,Baseline,First line of therapy,Induction,,Lenalidomide,,,Checked,,,25,mg,,QD,,PO,,1,,1
MMRF_2568,,First line of therapy,Induction,,Dexamethasone,,,Checked,,,40,mg,,QWK,,PO,,1,,1
MMRF_2568,,First line of therapy,Unknown,,Melphalan,,,,Completed regimen,,270,mg,,Oth,Once,IVB,,169,169,1
MMRF_1833,Baseline,First line of therapy,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,2.85,mg,,QD,,IV,,8,162,1
MMRF_1833,,Second Line Therapy (after,Consolidation,,Carfilzomib,,,,Completed regimen,,43,mg,,QD,,IV,,176,360,1
MMRF_1833,,First line of therapy,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,25,mg,,QD,,PO,,1,44,1
MMRF_1833,,Third Line Therapy (followi,Consolidation,,Pomalidomide,,,Checked,,,4,mg,,QD,,PO,,1009,,1
MMRF_2196,Baseline,First line of therapy,Induction,,Bortezomib,,,,,,3.08,mg,,Oth,"D1, D8, D15, D22",IV,,1,134,1
MMRF_2196,,First line of therapy,Unknown,,Cyclophosphamide,,,,Investigator decision for other reasons,,50,mg,,Oth,"Day 1, 8, 15, 22",PO,,1,126,1
MMRF_2196,,First line of therapy,Unknown,,Dexamethasone,,,,Completed regimen,,40,mg,,Q w,,PO,,1,126,1
MMRF_2196,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,10,mg,,QD,,PO,,406,,1
MMRF_2196,,First line of therapy,Other,Conditioning,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,PO,,196,198,1
MMRF_2196,,Second Line Therapy (after,Unknown,,Pomalidomide,,,,Investigator decision for other reasons,,4,mg,,Oth,QD for 21 days,PO,,1073,1121,1
MMRF_2196,,Second Line Therapy (after,Unknown,,Daratumumab,,,Checked,,,1500,mg,,Q w,,IV,,1086,,1
MMRF_2196,,Second Line Therapy (after,Unknown,,Pomalidomide,,,,Investigator decision for other reasons,,3,mg,,Oth,QD for 21 days,PO,,1122,1263,1
MMRF_2196,,Second Line Therapy (after,Unknown,,Dexamethasone,,,Checked,,,40,mg,,Oth,PRN,IV,,1086,,1
MMRF_2196,,Second Line Therapy (after,Unknown,,Dexamethasone,,,Checked,,,40,mg,,Q w,,PO,,1086,,1
MMRF_2196,,Second Line Therapy (after,Maintenance,,Pomalidomide,,,,Investigator decision for other reasons,,2,mg,,QD,,PO,,1243,1270,1
MMRF_2196,,Second Line Therapy (after,Maintenance,,Pomalidomide,,,Checked,,,1,mg,,QD,,PO,,1278,,1
MMRF_2054,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,"Days 1,8,15 + 22",PO,,1,576,1
MMRF_2054,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,Oth,"Days # 1,8,15,+ 22",IV SubQ,,1,227,1
MMRF_2054,,First line of therapy,Induction,,Cyclophosphamide,,,,Lack of response,,750,mg/m^,,Oth,Q day #1 only,IVB,,1,85,1
MMRF_2054,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,85,227,1
MMRF_2054,,First line of therapy,Unknown,,Melphalan,,,,Other,mephalan and stem cell reinfusion,380,mg,,Oth,once,IV,,288,288,1
MMRF_2054,,Second Line Therapy (after,Unknown,,Carfilzomib,,,,Completed regimen,,40,mg,,Oth,"d 1, 2, 8 & 15",IV,,401,576,1
MMRF_2054,,Second Line Therapy (after,Other,refractory disease,Pomalidomide,,,,Completed regimen,,4,mg,,QD,,PO,,401,576,1
MMRF_2054,,Second Line Therapy (after,Other,salvage,Ixazomib,,,,Investigator decision for other reasons,,4,mg,,Oth,"Q D1, D8, D15",PO,,730,933,1
MMRF_2054,,Second Line Therapy (after,Other,salvage,Dexamethasone,,,Checked,,,4,mg,,QD,,PO,,730,,1
MMRF_2054,,Second Line Therapy (after,Other,salvage,Lenalidomide,,,,Investigator decision for other reasons,,25,mg,,QD,,PO,,730,933,1
MMRF_2054,,Second Line Therapy (after,Maintenance,,Ixazomib,,,Checked,,,2.3,mg,,Oth,"Q D1, D8, D15 of 28 day cycle",PO,,1059,,1
MMRF_2054,,Second Line Therapy (after,Maintenance,,Lenalidomide,,,Checked,,,15,mg,,QD,,PO,,1059,,1
MMRF_2054,,Second Line Therapy (after,Maintenance,,Lenalidomide,,,,Other,change to 15mg dose,20,mg,,QD,,PO,,934,1059,1
MMRF_2054,,Second Line Therapy (after,Maintenance,,Ixazomib,,,,Other,change dose to 2.3,3,mg,,Oth,"Q D1, D8, D15",PO,,934,1059,1
MMRF_2062,,First line of therapy,Induction,,Dexamethasone,,,,Other,patient did not keep appointments,40,mg,,Oth,"Days 1,8,15, and 22",IV,,1,472,1
MMRF_2062,Baseline,First line of therapy,Induction,,Bortezomib,,,,Other,patient failed to come for appointments,2.9,mg,,Oth,"Days # 1,8,15, + 22",IV SubQ,,1,472,1
MMRF_2171,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.5,mg/m^,,QWK,,Other,subq,1,120,1
MMRF_2171,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,750,mg/m^,,Oth,Day 1 of each cycle,IV,,1,95,1
MMRF_2171,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,QWK,,PO,,1,95,1
MMRF_2171,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,5,mg,,Oth,"daily for 21 days, then none for 1 week",PO,,287,,1
MMRF_2181,Baseline,First line of therapy,Induction,,Bortezomib,,,,Investigator decision for other reasons,,1.3,mg/m^,,QD,,Other,subQ,1,304,1
MMRF_2181,,First line of therapy,Induction,,Dexamethasone,,,,Investigator decision for other reasons,,40,mg,,QD,,IV,,1,304,1
MMRF_2181,,First line of therapy,Induction,,Cyclophosphamide,,,,Investigator decision for other reasons,,500,mg,,QD,,PO,,42,155,1
MMRF_2181,,First line of therapy,Induction,,Lenalidomide,,,Checked,,,5,mg,,QD,,PO,,318,,1
MMRF_2222,Baseline,First line of therapy,Induction,,Cyclophosphamide,,,,Investigator decision for other reasons,,1665,mg,,Oth,one time,IV,,1,1,1
MMRF_2222,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,4,mg,,QD,,IV,,1,106,1
MMRF_2222,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,3.33,mg,,QD,,Other,subcu,1,106,1
MMRF_2222,,First line of therapy,Unknown,,Melphalan,,,,Completed regimen,,400,mg,,Oth,one time,IV,,153,153,1
MMRF_2222,,First line of therapy,Maintenance,,Lenalidomide,,,,Investigator decision for other reasons,,5,mg,,Q d,,PO,,258,915,1
MMRF_2222,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,5,mg,,QD,,PO,,915,,1
MMRF_2286,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,3,mg,,Oth,"Days 1, 8, 15, 22",IV SubQ,,1,110,1
MMRF_2286,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,1507,mg,,Oth,"Days 1, 8, 15, 22",IV,,1,110,1
MMRF_2286,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,"Days 1, 8, 15, 22",PO,,1,110,1
MMRF_2286,,First line of therapy,Other,prior to stem cell transplant,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,342,342,1
MMRF_2286,,First line of therapy,Maintenance,,Lenalidomide,,,,Other,"unknown, occurred during hospital stay",5,mg,,Q d,,PO,,473,920,1
MMRF_2286,,First line of therapy,Maintenance,,Lenalidomide,,,,Other,death,5,mg,,Q d,,PO,,985,1069,1
MMRF_2507,Baseline,First line of therapy,Induction,,Bortezomib,,,,Other,care transferred to another facility,2.2,mg,,Oth,every 3rd day,IV SubQ,,1,162,1
MMRF_2507,,First line of therapy,Induction,,Prednisone,,,,Other,moved treatment to another facility,40,mg,,Oth,every third day,IV,,1,162,1
MMRF_2507,,First line of therapy,Induction,,Cyclophosphamide,,,,Other,pt being followed at another facility,1257,mg,,Oth,every 3 weeks,IV,,28,162,1
MMRF_2507,,First line of therapy,Induction,,Bortezomib,,,Checked,,,2.2,mg/kg,,QD,,IV SubQ,,328,,1
MMRF_2507,,First line of therapy,Induction,,Lenalidomide,,,,Investigator decision for other reasons,,15,mg,,QD,,PO,,171,324,1
MMRF_2507,,First line of therapy,Induction,,Dexamethasone,,,Checked,,,40,mg,,Q w,,PO,,171,,1
MMRF_2126,,First line of therapy,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,25,mg,,QD,,PO,,1,36,1
MMRF_2126,Baseline,First line of therapy,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,3,mg,,QD,,IV SubQ,,1,36,1
MMRF_2126,,First line of therapy,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,20,mg,,QD,,PO,,1,249,1
MMRF_2126,,First line of therapy,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,2.2,mg,,QD,,IV SubQ,,134,246,1
MMRF_2126,,First line of therapy,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,2.8,mg,,QD,,IV SubQ,,92,117,1
MMRF_2126,,Second Line Therapy (after,Maintenance,,Lenalidomide,,,,Disease progression/Relapse,,15,mg,,QD,,PO,,330,551,1
MMRF_2126,,Second Line Therapy (after,Maintenance,,Dexamethasone,,,,Disease progression/Relapse,,20,mg,,Oth,Q week 3 weeks on 1 week off,PO,,330,543,1
MMRF_2339,Baseline,First line of therapy,Induction,,Bortezomib,,,,Other,Change in dose,2.2,mg,,Q w,,IV SubQ,,1,50,1
MMRF_2339,,First line of therapy,Induction,,Lenalidomide,,,Checked,,,25,mg,,QD,,PO,,1,,1
MMRF_2339,,First line of therapy,Induction,,Dexamethasone,,,Checked,,,40,mg,,Q w,,PO,,1,,1
MMRF_2339,,First line of therapy,Induction,,Bortezomib,,,Checked,,,2.3,mg,,Q w,,IV SubQ,,57,,1
MMRF_2114,Baseline,First line of therapy,Induction,,Bortezomib,,,,Other,Tx d'ced because pt is going for stem cell harvest on 1/13 -1/14/15,1.3,mg/m^,,Q w,,IV SubQ,,1,134,1
MMRF_2114,,First line of therapy,Induction,,Dexamethasone,,,,Other,Tx d'ced because pt is going for stem cell harvest on 1/13 -1/14/15,40,mg,,Q w,,PO,,1,134,1
MMRF_2114,,First line of therapy,Induction,,Lenalidomide,,,,Other,Dose reduced due to neutropenia,25,mg,,QD,,PO,,1,36,1
MMRF_2114,,First line of therapy,Induction,,Cyclophosphamide,,,,Other,Cytoxan was replaced with Revlimid while waiting to schedule for transplant,300,mg/m^,,Oth,weekly 3/4 weeks,IV,,109,134,1
MMRF_2114,,First line of therapy,Consolidation,,Melphalan,,,,Completed regimen,,200,mg/m^,,Oth,once,IV,,236,236,1
MMRF_2114,,First line of therapy,Maintenance,,Lenalidomide,,,,Other,MS MD decided to dose reduced due to Diarrhea & increase in Neuropathy,15,mg,,QD,,PO,,351,635,1
MMRF_2114,,First line of therapy,Maintenance,,Dexamethasone,,,,Other,dose reduced with the new regimen,40,mg,,QWK,,PO,,351,383,1
MMRF_2114,,First line of therapy,Induction,,Carfilzomib,,,,Other,Tx was held because pt going for ASCTX on 4/7/15,27,mg/m^,,QD,,IV,,189,218,1
MMRF_2114,,First line of therapy,Unknown,,Lenalidomide,,,,Other,Tx dced in prep for possible transplant,15,mg,,QD,,PO,,37,85,1
MMRF_2114,,First line of therapy,Induction,,Lenalidomide,,,,Other,Treatment was interrupted due to right breast mastitis & due to cytopenias,15,mg,,QD,,PO,,169,179,1
MMRF_2114,,First line of therapy,Maintenance,,Bortezomib,,,,Other,D'ced due to worsening of neuropathy,1.3,mg/m^,,QWK,,IV SubQ,,351,383,1
MMRF_2114,,First line of therapy,Induction,,Dexamethasone,,,,Other,Treatment was interrupted due to right breast mastitis.,20,mg,,QWK,,PO,,169,177,1
MMRF_2114,,First line of therapy,Induction,,Carfilzomib,,,,Other,Treatment was interrupted due to right breast mastitis.,20,mg/m^,,QD,,IV,,169,177,1
MMRF_2114,,First line of therapy,Induction,,Dexamethasone,,,,Other,Tx was held because pt going for ASCTX on 4/7/15,20,mg,,QWK,,PO,,189,211,1
MMRF_2114,,First line of therapy,Induction,,Lenalidomide,,,,Other,Tx was held because pt going for ASCTX on 4/7/15,15,mg,,QD,,PO,,204,224,1
MMRF_2114,,First line of therapy,Maintenance,,Dexamethasone,,,,Other,Dose increased due to addition of more meds,20,mg,,QWK,,PO,,393,1041,1
MMRF_2114,,Second Line Therapy (after,Maintenance,,Dexamethasone,,,,Other,Changed due to URI & right brest mastitis,40,mg,,QWK,,PO,,1054,1222,1
MMRF_2114,,Second Line Therapy (after,Maintenance,,Elotuzumab,,,,Disease progression/Relapse,,10,mg/kg,,Oth,EOW,IV,,1237,1266,1
MMRF_2114,,Third Line Therapy (followi,Maintenance,,Dexamethasone,,,Checked,,,20,mg,,Oth,Only Day after Tx,PO,,1280,,1
MMRF_2114,,Second Line Therapy (after,Maintenance,,Lenalidomide,,,,Other,Dose reduced due to diarrhea,15,mg,,QD,,PO,,1062,1082,1
MMRF_2114,,Second Line Therapy (after,Maintenance,,Elotuzumab,,,,Other,Changed due to URI & right brest mastitis,10,mg/kg,,Oth,EOW,IV,,1111,1222,1
MMRF_2114,,Second Line Therapy (after,Maintenance,,Carfilzomib,,,,Disease progression/Relapse,,27,mg/m^,,QD,,IV,,1237,1266,1
MMRF_2114,,Third Line Therapy (followi,Maintenance,,Daratumumab,,,,Completed regimen,,16,mg/m^,,QWK,,IV,,1279,1328,1
MMRF_2114,,Second Line Therapy (after,Maintenance,,Carfilzomib,,,,Other,Changed due to URI & right brest mastitis,27,mg/m^,,QD,,IV,,908,1222,1
MMRF_2114,,First line of therapy,Maintenance,,Carfilzomib,,,,Other,Dose increased to accomodate patients travel plans,20,mg/m^,,QD,,IV,,393,475,1
MMRF_2114,,First line of therapy,Maintenance,,Carfilzomib,,,,Other,MD changed regimen to 2 consecutive days EOW,27,mg/m^,,QD,,IV,,481,796,1
MMRF_2114,,First line of therapy,Maintenance,,Lenalidomide,,,,Other,Stopped due to chronic Diarrhea,10,mg,,QD,,PO,,642,725,1
MMRF_2114,,First line of therapy,Maintenance,,Carfilzomib,,,,Disease progression/Relapse,,27,mg/m^,,Oth,2 consecutive days EOW for a 28 day cycle,IV,,817,887,1
MMRF_2114,,Second Line Therapy (after,Maintenance,,Elotuzumab,,,,Completed regimen,,10,mg/kg,,QWK,,IV,,1054,1097,1
MMRF_2114,,Second Line Therapy (after,Maintenance,,Lenalidomide,,,,Disease progression/Relapse,,10,mg,,QD,,PO,,1083,1266,1
MMRF_2114,,Second Line Therapy (after,Maintenance,,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,Oth,Weekly for 3 out of 4 weeks,PO,,1237,1266,1
MMRF_2114,,Third Line Therapy (followi,Maintenance,,Daratumumab,,,Checked,,,16,mg/m^,,QWK,,IV,,1335,,1
MMRF_2150,Baseline,First line of therapy,Induction,,Bortezomib,,,,Other,Tx was held in the anticipation of stem cell harvest,1.3,mg/m^,,QWK,,IV SubQ,,1,212,1
MMRF_2150,,First line of therapy,Induction,,Dexamethasone,,,,Other,Tx was held in the anticipation of stem cell harvest,40,mg,,QWK,,PO,,1,212,1
MMRF_2150,,First line of therapy,Unknown,,Cyclophosphamide,,,,Other,Progressive Increase in IgA,300,mg/m^,,QWK,,IV,,225,267,1
MMRF_2150,,First line of therapy,Unknown,,Lenalidomide,,,,Other,Tx was held in the anticipation of Stem Cell Harvest,15,mg,,QD,,PO,,120,212,1
MMRF_2150,,First line of therapy,Unknown,,Lenalidomide,,,,Other,"Progressive decrease in monoclonal protein, therefore, Tx reg was changed.",15,mg,,QD,,PO,,288,470,1
MMRF_2150,,Second Line Therapy (after,Unknown,,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,QWK,,PO,,1143,1213,1
MMRF_2150,,First line of therapy,Induction,,Bortezomib,,,,Other,Switched from 1st line to 2nd line therapy,1.3,mg/m^,,Oth,Every other week,IV SubQ,,491,1129,1
MMRF_2150,,First line of therapy,Maintenance,,Dexamethasone,,,,Other,POD confirmed by increase in monoclonal protein + progressive Anemia,40,mg,,QWK,,PO,,491,1135,1
MMRF_2150,,Third Line Therapy (followi,Unknown,,Daratumumab,,,Checked,,,16,mg/kg,,Oth,Every other week for 16 weeks,IV,,1289,,1
MMRF_2150,,First line of therapy,Unknown,,Bortezomib,,,,Other,Progressive Increase in IgA,1.3,mg/m^,,QWK,,IV SubQ,,225,267,1
MMRF_2150,,First line of therapy,Unknown,,Dexamethasone,,,,Other,Progressive Increase in IgA,40,mg,,QWK,,PO,,225,267,1
MMRF_2150,,First line of therapy,Induction,,Dexamethasone,,,,Other,"Progressive decrease in monoclonal protein, therefore, Tx reg was changed.",40,mg,,QWK,,PO,,288,470,1
MMRF_2150,,First line of therapy,Maintenance,,Lenalidomide,,,,Disease progression/Relapse,,15,mg,,QD,,PO,,491,1135,1
MMRF_2150,,Second Line Therapy (after,Unknown,,Pomalidomide,,,,Other,"Switched lines of therapy, due to POD",2,mg,,QD,,PO,,1143,1219,1
MMRF_2150,,Third Line Therapy (followi,Unknown,,Daratumumab,,,,Completed regimen,,16,mg/kg,,QWK,,IV,,1226,1282,1
MMRF_2150,,Second Line Therapy (after,Unknown,,Bortezomib,,,,Disease progression/Relapse,,1.3,mg/m^,,Oth,Every other week,IV SubQ,,1143,1213,1
MMRF_2150,,Third Line Therapy (followi,Unknown,,Dexamethasone,,,Checked,,,40,mg,,QWK,,PO,,1226,,1
MMRF_2150,,First line of therapy,Induction,,Bortezomib,,,,Other,"Progressive decrease in monoclonal protein, therefore, Tx reg was changed.",1.3,mg/m^,,QWK,,IV SubQ,,288,470,1
MMRF_2150,,Third Line Therapy (followi,Unknown,,Pomalidomide,,,Checked,,,2,mg,,QD,,PO,,1227,,1
MMRF_1642,Baseline,First line of therapy,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,2.2,mg,,QD,,IV SubQ,,1,8,1
MMRF_1642,,First line of therapy,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,10,mg,,Q d,,PO,,1,8,1
MMRF_1661,Baseline,First line of therapy,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,2.5,mg,,QD,,IV SubQ,,1,250,1
MMRF_1661,,First line of therapy,Induction,,Melphalan,,,,Investigator decision for other reasons,,14,mg,,QD,,PO,,18,36,1
MMRF_1661,,First line of therapy,Induction,,Cyclophosphamide,,,,Adverse Event or co-morbidity,,1200,mg,,QD,,IV,,86,250,1
MMRF_1661,,First line of therapy,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,20,mg,,QD,,PO,,18,250,1
MMRF_1682,Baseline,First line of therapy,Induction,,Bortezomib,,,,Disease progression/Relapse,,2.2,mg,,QD,,IV SubQ,,1,295,1
MMRF_1682,,First line of therapy,Induction,,Melphalan,,,,Disease progression/Relapse,,14,mg,,QD,,PO,,1,295,1
MMRF_1682,,First line of therapy,Induction,,Prednisone,,,,Disease progression/Relapse,,100,mg,,QD,,PO,,1,295,1
MMRF_1682,,Second Line Therapy (after,Maintenance,,Bortezomib,,,,Investigator decision for other reasons,,2.2,mg,,QD,,IV SubQ,,338,447,1
MMRF_1682,,Second Line Therapy (after,Maintenance,,Lenalidomide,,,,Investigator decision for other reasons,,25,mg,,QD,,PO,,338,447,1
MMRF_1682,,Second Line Therapy (after,Maintenance,,Dexamethasone,,,,Investigator decision for other reasons,,40,mg,,QD,,PO,,338,447,1
MMRF_1682,,Third Line Therapy (followi,Maintenance,,Dexamethasone,,,,Disease progression/Relapse,,20,mg,,QD,,PO,,448,577,1
MMRF_1682,,Third Line Therapy (followi,Maintenance,,Bortezomib,,,,Disease progression/Relapse,,1.3,mg,,QD,,IV SubQ,,448,577,1
MMRF_1682,,Third Line Therapy (followi,Maintenance,,Lenalidomide,,,,Disease progression/Relapse,,15,mg,,QD,,PO,,448,577,1
MMRF_1682,,Fourth Line Therapy (follow,Maintenance,,Bortezomib,,,,Investigator decision for other reasons,,1.3,mg/m^,,QD,,IV SubQ,,578,617,1
MMRF_1682,,Fourth Line Therapy (follow,Maintenance,,Dexamethasone,,,,Investigator decision for other reasons,,40,mg,,QD,,PO,,578,617,1
MMRF_1682,,Fourth Line Therapy (follow,Maintenance,,Doxorubicin,,,,Investigator decision for other reasons,,36,mg/m^,,Q d,,IV,,612,612,1
MMRF_1682,,Fourth Line Therapy (follow,Maintenance,,Cyclophosphamide,,,,Investigator decision for other reasons,,30,mg/m^,,Q d,,IV,,578,580,1
MMRF_1705,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,2,mg,,QD,,IV SubQ,,1,610,1
MMRF_1705,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,14,mg,,QD,,PO,,1,610,1
MMRF_1705,,First line of therapy,Induction,,Prednisone,,,,Completed regimen,,100,mg,,QD,,PO,,1,610,1
MMRF_1862,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,10,mg,,Q d,,PO,,1,198,1
MMRF_1862,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,2.4,mg,,QD,,IV SubQ,,1,198,1
MMRF_1862,,First line of therapy,Maintenance,,Lenalidomide,,,,Investigator decision for other reasons,,5,mg,,QD,,PO,,728,1059,1
MMRF_1862,,First line of therapy,Maintenance,,Dexamethasone,,,,Investigator decision for other reasons,,20,mg,,QD,,PO,,728,1059,1
MMRF_1969,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,2,mg,,QD,,IV SubQ,,2,279,1
MMRF_1969,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Q d,,IV,,1,279,1
MMRF_1969,,First line of therapy,Maintenance,,Lenalidomide,,,,Other,death,5,mg,,QD,,PO,,600,945,1
MMRF_1969,,First line of therapy,Maintenance,,Dexamethasone,,,,Other,death,20,mg,,QD,,PO,,628,945,1
MMRF_1969,,First line of therapy,Consolidation,,Bortezomib,,,,Completed regimen,,2,mg,,QD,,IV SubQ,,538,600,1
MMRF_1969,,First line of therapy,Consolidation,,Lenalidomide,,,,Completed regimen,,5,mg,,Q d,,PO,,538,600,1
MMRF_1969,,First line of therapy,Consolidation,,Dexamethasone,,,,Completed regimen,,20,mg,,QD,,PO,,538,600,1
MMRF_2024,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,10,mg,,QD,,PO,,1,200,1
MMRF_2024,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,2,mg,,QD,,IV SubQ,,3,200,1
MMRF_2024,,First line of therapy,Consolidation,,Lenalidomide,,,,Other,dose changed,15,mg,,QD,,PO,,88,95,1
MMRF_2024,,First line of therapy,Consolidation,,Lenalidomide,,,,Completed regimen,,5,mg,,Q d,,PO,,96,200,1
MMRF_2024,,First line of therapy,Consolidation,,Bortezomib,,,,Completed regimen,,1.2,mg,,QD,,IV SubQ,,374,420,1
MMRF_2024,,First line of therapy,Consolidation,,Dexamethasone,,,,Completed regimen,,40,mg,,Q d,,PO,,374,420,1
MMRF_2024,,First line of therapy,Consolidation,,Lenalidomide,,,,Completed regimen,,10,mg,,QD,,PO,,374,420,1
MMRF_2024,,First line of therapy,Maintenance,,Lenalidomide,,,,Lack of response,,5,mg,,QD,,PO,,452,732,1
MMRF_2024,,First line of therapy,Induction,,Lenalidomide,,,Checked,,,5,mg,,QD,,PO,,1313,,1
MMRF_2039,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,2,mg,,QD,,IV SubQ,,1,197,1
MMRF_2039,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,IV,,1,197,1
MMRF_2039,,First line of therapy,Induction,,Thalidomide,,,,Disease progression/Relapse,,100,mg,,BID,,PO,,154,280,1
MMRF_2039,,Second Line Therapy (after,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,5,mg,,QD,,PO,,386,473,1
MMRF_2039,,Second Line Therapy (after,Maintenance,,Bortezomib,,,,Adverse Event or co-morbidity,,2,mg,,QD,,IV SubQ,,312,473,1
MMRF_2039,,Second Line Therapy (after,Maintenance,,Dexamethasone,,,,Adverse Event or co-morbidity,,40,mg,,QD,,PO,,312,475,1
MMRF_2515,,First line of therapy,Induction,,Bortezomib,,,Checked,,,1.8,mg,,QD,,IV SubQ,,33,,1
MMRF_2515,Baseline,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,12,mg,,QD,,PO,,1,441,1
MMRF_2515,,First line of therapy,Induction,,Prednisone,,,Checked,,,20,mg,,QD,,PO,,1,,1
MMRF_2543,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,2.4,mg,,QD,,IV SubQ,,1,161,1
MMRF_2543,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,1900,mg,,QD,,IV,,1,161,1
MMRF_2543,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,PO,,1,161,1
MMRF_2543,,Second Line Therapy (after,Consolidation,,Dexamethasone,,,Checked,,,20,mg,,QD,,PO,,800,,1
MMRF_2543,,Second Line Therapy (after,Consolidation,,Lenalidomide,,,Checked,,,25,mg,,QD,,PO,,800,,1
MMRF_2586,,First line of therapy,Induction,,Melphalan,,,,Disease progression/Relapse,,16,mg,,QD,,PO,,1,707,1
MMRF_2586,,First line of therapy,Induction,,Prednisone,,,,Disease progression/Relapse,,100,mg,,QD,,PO,,1,707,1
MMRF_2586,Baseline,First line of therapy,Induction,,Bortezomib,,,,Disease progression/Relapse,,2.3,mg,,QD,,IV SubQ,,1,707,1
MMRF_1908,Baseline,First line of therapy,Induction,,Bortezomib,,,,Investigator decision for other reasons,,1.99,mg,,QD,,IV SubQ,,1,123,1
MMRF_1908,,First line of therapy,Induction,,Thalidomide,,,,Other,Paresthesia,100,mg,,Q d,,PO,,1,179,1
MMRF_1908,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,PO,,1,123,1
MMRF_1908,,First line of therapy,Maintenance,,Thalidomide,,,,Adverse Event or co-morbidity,,100,mg,,Q d,,PO,,387,718,1
MMRF_1908,,First line of therapy,Other,Conditioning regimen for autologous transplant,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,187,188,1
MMRF_1908,,Second Line Therapy (after,Induction,,Bendamustine,,,Checked,,,100,mg,,QD,,IV,,983,,1
MMRF_1908,,Second Line Therapy (after,Induction,,Bortezomib,,,Checked,,,1.3,mg/m^,,QD,,IV SubQ,,983,,1
MMRF_1908,,Second Line Therapy (after,Induction,,Dexamethasone,,,Checked,,,4,mg,,QD,,PO,,983,,1
MMRF_2013,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV,,1,165,1
MMRF_2013,,First line of therapy,Induction,,Lenalidomide,,,Checked,,,25,mg,,Oth,QD DAYS 1-21,PO,,1,,1
MMRF_2013,,First line of therapy,Induction,,Dexamethasone,,,Checked,,,40,mg,,Oth,"QD days 1,2,3,4,9,10,11,12",PO,,1,,1
MMRF_2013,,First line of therapy,Other,BMT conditioning,Melphalan,,,,Completed regimen,,100,mg/m^,,Q d,,IV,,224,225,1
MMRF_2185,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg,,QD,,Other,sc,1,165,1
MMRF_2185,,First line of therapy,Induction,,Thalidomide,,,,Completed regimen,,100,mg,,Q d,,PO,,1,183,1
MMRF_2185,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,QD days 1 to 11,PO,,1,165,1
MMRF_2185,,First line of therapy,Other,BMT conditioning,Melphalan,,,,Completed regimen,,100,mg/m^,,Q d,,IV,,219,220,1
MMRF_2185,,Second Line Therapy (after,Induction,,Carfilzomib,,,,Adverse Event or co-morbidity,,36,mg/m^,,QD,,IV,,774,861,1
MMRF_2185,,First line of therapy,Maintenance,,Lenalidomide,,,,Disease progression/Relapse,,15,mg,,QD,,PO,,533,718,1
MMRF_2185,,Second Line Therapy (after,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,25,mg,,QD,,PO,,774,861,1
MMRF_2185,,Second Line Therapy (after,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,40,mg,,QD,,PO,,774,861,1
MMRF_2185,,Third Line Therapy (followi,Induction,,Daratumumab,,,,Disease progression/Relapse,,1200,mg,,Q w,,IV,,897,946,1
MMRF_2185,,Fourth Line Therapy (follow,Induction,,Dexamethasone,,,,Disease progression/Relapse,,20,mg,,QD,,PO,,949,1002,1
MMRF_2185,,Second Line Therapy (after,Induction,,Daratumumab,,,,Lack of response,,1200,mg,,Q w,,IV,,949,1002,1
MMRF_2185,,Second Line Therapy (after,Induction,,Bortezomib,,,,Disease progression/Relapse,,2.35,mg,,QD,,Other,subcutaneous,949,1002,1
MMRF_1790,,First line of therapy,Induction,,Prednisone,,,,Investigator decision for other reasons,,90,mg,,QD,,PO,,1,123,1
MMRF_1790,Baseline,First line of therapy,Induction,,Bortezomib,,,,Investigator decision for other reasons,,1.88,mg/m^,,QD,,Other,Subcutaneous,1,113,1
MMRF_1790,,First line of therapy,Induction,,Melphalan,,,,Investigator decision for other reasons,,10,mg,,QD,,PO,,1,123,1
MMRF_1790,,Second Line Therapy (after,Unknown,,Bortezomib,,,,Adverse Event or co-morbidity,,1.88,mg,,QD,,Other,Subcutaneous,359,554,1
MMRF_1790,,Second Line Therapy (after,Unknown,,Dexamethasone,,,,Adverse Event or co-morbidity,,40,mg,,QD,,IV,,359,554,1
MMRF_1790,,Second Line Therapy (after,Unknown,,Bendamustine,,,,Adverse Event or co-morbidity,,100,mg,,QD,,IV,,359,547,1
MMRF_1790,,Third Line Therapy (followi,Unknown,,Lenalidomide,,,,Lack of response,,15,mg,,QD,,PO,,614,660,1
MMRF_1790,,Third Line Therapy (followi,Unknown,,Dexamethasone,,,,Lack of response,,20,mg,,QWK,,PO,,614,663,1
MMRF_1790,,Fourth Line Therapy (follow,Unknown,,Other,Cisplatin,,,Lack of response,,20,mg,,QD,,IV,,677,739,1
MMRF_1790,,Fourth Line Therapy (follow,Unknown,,Dexamethasone,,,,Lack of response,,40,mg,,QD,,IV,,677,740,1
MMRF_1790,,Fourth Line Therapy (follow,Unknown,,Cyclophosphamide,,,,Lack of response,,400,mg,,QD,,IV,,677,739,1
MMRF_1790,,Fourth Line Therapy (follow,Unknown,,Other,Etoposide,,,Lack of response,,40,mg,,QD,,IV,,677,739,1
MMRF_1790,,Fourth Line Therapy (follow,Unknown,,Lenalidomide,,,,Disease progression/Relapse,,10,mg,,QD,,PO,,828,897,1
MMRF_1790,,Fourth Line Therapy (follow,Unknown,,Dexamethasone,,,,Disease progression/Relapse,,20,mg,,Q w,,PO,,780,897,1
MMRF_1790,,Fifth Line Therapy (followi,Unknown,,Carfilzomib,,,,Lack of response,,20,mg/m^,,QD,,IV,,926,962,1
MMRF_1790,,Fifth Line Therapy (followi,Unknown,,Dexamethasone,,,,Lack of response,,20,mg,,QD,,PO,,926,962,1
MMRF_1790,,Fourth Line Therapy (follow,Unknown,,Lenalidomide,,,,Investigator decision for other reasons,,15,mg,,QD,,PO,,780,813,1
MMRF_2225,Baseline,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,PO,,1,168,1
MMRF_2225,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,2.11,mg,,QD,,Other,Subcutaneous,2,165,1
MMRF_2225,,First line of therapy,Induction,,Doxorubicin,,,,Completed regimen,,32,mg,,QD,,IV,,2,165,1
MMRF_2225,,First line of therapy,Consolidation,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,Other,Subcutaneous,239,270,1
MMRF_2225,,First line of therapy,Consolidation,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,PO,,239,270,1
MMRF_2225,,First line of therapy,Other,High dose chemotherapy given for BMT,Melphalan,,,,Completed regimen,,160,mg,,Oth,"D1,D2",IV,,180,181,1
MMRF_2225,,First line of therapy,Consolidation,,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,Q w,,PO,,353,527,1
MMRF_2225,,First line of therapy,Consolidation,,Lenalidomide,,,,Disease progression/Relapse,,25,mg,,QD,,PO,,353,527,1
MMRF_2225,,Third Line Therapy (followi,Unknown,,Carfilzomib,,,,Lack of response,,27,mg/m^,,QD,,IV,,598,635,1
MMRF_2225,,Second Line Therapy (after,Unknown,,Dexamethasone,,,,Lack of response,,40,mg,,QD,,IV,,552,555,1
MMRF_2225,,Second Line Therapy (after,Unknown,,Other,Etoposide,,,Lack of response,,60,mg,,QD,,IV,,552,555,1
MMRF_2225,,Second Line Therapy (after,Unknown,,Other,Cisplatin,,,Lack of response,,10,mg,,QD,,IV,,552,555,1
MMRF_2225,,Second Line Therapy (after,Unknown,,Cyclophosphamide,,,,Lack of response,,630,mg,,QD,,IV,,552,555,1
MMRF_2225,,Third Line Therapy (followi,Unknown,,Carfilzomib,,,,Investigator decision for other reasons,,20,mg/m^,,Oth,D1-D2,IV,,591,592,1
MMRF_2225,,Third Line Therapy (followi,Unknown,,Dexamethasone,,,,Lack of response,,40,mg,,Q w,,IV,,591,635,1
MMRF_2225,,Third Line Therapy (followi,Unknown,,Lenalidomide,,,,Lack of response,,25,mg,,QD,,PO,,591,639,1
MMRF_2225,,Fourth Line Therapy (follow,Unknown,,Pomalidomide,,,,Other,Changed dose,4,mg,,QD,,PO,,648,675,1
MMRF_2225,,Fourth Line Therapy (follow,Unknown,,Pomalidomide,,,,Disease progression/Relapse,,3,mg,,QD,,PO,,684,765,1
MMRF_2225,,Fourth Line Therapy (follow,Unknown,,Cyclophosphamide,,,,Disease progression/Relapse,,50,mg,,QD,,PO,,648,765,1
MMRF_2225,,Fourth Line Therapy (follow,Unknown,,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,Oth,D1-D4 every week,PO,,648,765,1
MMRF_2225,,Fourth Line Therapy (follow,Unknown,,Other,Clarithomycin,,,Disease progression/Relapse,,500,mg,,BID,,PO,,648,765,1
MMRF_2307,Baseline,First line of therapy,Induction,,Bortezomib,,,Checked,,,2.26,mg,,Oth,"D1,D2,D3,D4",Other,Subcutaneous,1,,1
MMRF_2307,,First line of therapy,Induction,,Doxorubicin,,,Checked,,,34,mg,,QD,,IV,,1,,1
MMRF_2307,,First line of therapy,Induction,,Prednisone,,,Checked,,,40,mg,,QD,,PO,,1,,1
MMRF_2465,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,-4/-3/-2/-1,IV,,1,145,1
MMRF_2465,,First line of therapy,Induction,,Doxorubicin,,,,Completed regimen,,26,mg,,QD,,IV,,4,138,1
MMRF_2465,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.92,mg,,QD,,IV,,4,145,1
MMRF_2465,,First line of therapy,Consolidation,,Melphalan,,,,Completed regimen,,200,mg/m^,,Q d,,IV,,177,178,1
MMRF_2556,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,Other,SC,1,180,1
MMRF_2556,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,QD 1-4 / 9-12,PO,,1,181,1
MMRF_2556,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,190,1
MMRF_2556,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,180,mg,,Q d,,IV,,207,208,1
MMRF_2556,,First line of therapy,Consolidation,,Bortezomib,,,,Completed regimen,,2.4,mg,,QD,,IV,,310,348,1
MMRF_2556,,First line of therapy,Consolidation,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,310,358,1
MMRF_2556,,First line of therapy,Consolidation,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,QD (D1-D4) (D9-D12),PO,,310,349,1
MMRF_2556,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,15,mg,,QD,,PO,,408,,1
MMRF_2556,,First line of therapy,Maintenance,,Dexamethasone,,,,Other,Dose reduction,20,mg,,Oth,"D1D4, D9-D12",PO,,408,447,1
MMRF_2556,,First line of therapy,Maintenance,,Dexamethasone,,,Checked,,,10,mg,,Oth,D1-D4/D9-D12,PO,,466,,1
MMRF_2567,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,D1-4 / D9-12,PO,,1,180,1
MMRF_2567,Baseline,First line of therapy,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,1.3,mg/m^,,QD,,Other,Subcutaneous,1,105,1
MMRF_2567,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,189,1
MMRF_2567,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,210,mg,,Q d,,IV,,211,212,1
MMRF_2567,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1,mg/m^,,QD,,Other,Subcutaneous,106,179,1
MMRF_2567,,First line of therapy,Consolidation,,Bortezomib,,,,Completed regimen,,0.7,mg/m^,,QD,,Other,SC,295,343,1
MMRF_2567,,First line of therapy,Consolidation,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,D1-4/D9-12,PO,,295,344,1
MMRF_2567,,First line of therapy,Consolidation,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,295,352,1
MMRF_2567,,First line of therapy,Maintenance,,Lenalidomide,,,,Other,Colon cancer,15,mg,,QD,,PO,,407,443,1
MMRF_2567,,First line of therapy,Maintenance,,Dexamethasone,,,,Other,Colon cancer,20,mg,,Oth,QD D1-4/D9-12,PO,,407,438,1
MMRF_1727,,First line of therapy,Induction,,Prednisone,,,,Completed regimen,,60,mg/m^,,QD,,PO,,1,344,1
MMRF_1727,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,4,mg,,Oth,"DAYS: 8,9,22,23,29,30",PO,,9,29,1
MMRF_1727,Baseline,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"DAYS: 1,2,8.9,22,23,29,30",IV,,1,372,1
MMRF_1727,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,9,mg/m^,,QD,,PO,,1,344,1
MMRF_1727,,Second Line Therapy (after,Induction,,Ixazomib,,,Checked,,,4,mg,,QD,,PO,,831,,1
MMRF_1727,,Second Line Therapy (after,Induction,,Lenalidomide,,,Checked,,,15,mg,,QD,,PO,,831,,1
MMRF_1727,,Second Line Therapy (after,Induction,,Dexamethasone,,,Checked,,,20,mg,,QD,,PO,,831,,1
MMRF_1916,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,370,1
MMRF_1916,Baseline,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,9,mg/m^,,QD,,PO,,1,346,1
MMRF_1916,,First line of therapy,Induction,,Prednisone,,,,Completed regimen,,60,mg/m^,,QD,,Other,D1: IV AND D2-4: PO,1,345,1
MMRF_1916,,First line of therapy,Induction,,Daratumumab,,,,Completed regimen,,16,mg/kg,,Oth,"DAYS, 1, 8,15,22",IV,,1,363,1
MMRF_1916,,Second Line Therapy (after,Induction,,Dexamethasone,,,Checked,,,20,mg,,Q w,,PO,,1266,,1
MMRF_1916,,Second Line Therapy (after,Induction,,Lenalidomide,,,Checked,,,25,mg,,QD,,PO,,1266,,1
MMRF_1916,,Second Line Therapy (after,Induction,,Ixazomib,,,Checked,,,4,mg,,Q w,,PO,,1266,,1
MMRF_1971,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,364,1
MMRF_1971,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"DAYS 1,2,4,5,8,9,15,16",PO,,1,357,1
MMRF_1971,,First line of therapy,Induction,,Daratumumab,,,,Completed regimen,,16,mg/kg,,Oth,"days: 1,8,15,22",IV,,1,357,1
MMRF_1971,,Second Line Therapy (after,Induction,,Lenalidomide,,,,Disease progression/Relapse,,25,mg,,QD,,PO,,865,1239,1
MMRF_1971,,Second Line Therapy (after,Induction,,Dexamethasone,,,,Disease progression/Relapse,,20,mg,,QWK,,PO,,865,1239,1
MMRF_1971,,Second Line Therapy (after,Induction,,Ixazomib,,,,Disease progression/Relapse,,4,mg,,QWK,,PO,,865,1239,1
MMRF_1971,,Third Line Therapy (followi,Induction,,Other,FILANESIB,,,Investigator decision for other reasons,,1.4,mg/m^,,Oth,"DAYS 1,2,15,16 EACH 28",IV,,1246,1391,1
MMRF_1971,,Third Line Therapy (followi,Induction,,Pomalidomide,,,,Investigator decision for other reasons,,4,mg,,QD,,PO,,1246,1391,1
MMRF_1971,,Third Line Therapy (followi,Induction,,Dexamethasone,,,,Investigator decision for other reasons,,20,mg,,QD,,PO,,1246,1391,1
MMRF_2017,Baseline,First line of therapy,Induction,,Bortezomib,,,,Disease progression/Relapse,,1.3,mg/m^,,QD,,IV SubQ,,1,188,1
MMRF_2017,,First line of therapy,Induction,,Dexamethasone,,,,Disease progression/Relapse,,20,mg,,Oth,"DAYS 1,2,4,5,8,9,11,12",IV,,1,188,1
MMRF_2017,,First line of therapy,Induction,,Other,Daratumumab,,,Disease progression/Relapse,,16,mg/kg,,Q w,,IV,,1,188,1
MMRF_2017,,Second Line Therapy (after,Unknown,,Lenalidomide,,,,Disease progression/Relapse,,15,mg,,QD,,PO,,258,366,1
MMRF_2017,,Second Line Therapy (after,Unknown,,Dexamethasone,,,,Disease progression/Relapse,,20,mg,,QD,,PO,,258,366,1
MMRF_2017,,Third Line Therapy (followi,Induction,,Pomalidomide,,,,Other,Death,4,mg,,QD,,PO,,372,410,1
MMRF_2017,,Third Line Therapy (followi,Induction,,Dexamethasone,,,,Other,death,20,mg,,Q w,,PO,,366,400,1
MMRF_2068,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,2.1,mg,,QD,,IV SubQ,,1,397,1
MMRF_2068,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"DAYS: 1,2,4,5,8,9,11,12,15,16 (21 DAYS EACH CYCLE)",Other,"DAYS 1,8,15 IV  ..... REST DAYS  PO",1,397,1
MMRF_2068,,First line of therapy,Induction,,Daratumumab,,,,Completed regimen,,16,mg/kg,,Q w,,IV,,1,391,1
MMRF_2089,,First line of therapy,Induction,,Prednisone,,,,Disease progression/Relapse,,60,mg/m^,,Oth,"DAYS 1,2,3,4",PO,,1,253,1
MMRF_2089,Baseline,First line of therapy,Induction,,Bortezomib,,,,Disease progression/Relapse,,1.3,mg/m^,,Oth,"DAYS 1,4,8,11,22,25,29,32",IV SubQ,,1,274,1
MMRF_2089,,First line of therapy,Induction,,Melphalan,,,,Disease progression/Relapse,,9,mg/m^,,Oth,"DAYS 1,2,3,4",PO,,1,253,1
MMRF_2089,,Second Line Therapy (after,Induction,,Dexamethasone,,,,Other,EXITUS,40,mg,,QD,,PO,,295,449,1
MMRF_2089,,Second Line Therapy (after,Induction,,Lenalidomide,,,,Other,EXITUS,25,mg,,QD,,PO,,295,449,1
MMRF_2102,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,9,mg/m^,,Oth,"DAYS 1,2,3,4",PO,,1,379,1
MMRF_2102,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.2,mg/m^,,Oth,"DAYS 1,4,8,11,22,25,29,32",IV SubQ,,1,379,1
MMRF_2102,,First line of therapy,Induction,,Prednisone,,,,Completed regimen,,60,mg/m^,,Oth,"DAYS 1,2,3,4",PO,,1,379,1
MMRF_2102,,Second Line Therapy (after,Induction,,Lenalidomide,,,,Disease progression/Relapse,,10,mg,,Oth,qd(1-21),PO,,711,1166,1
MMRF_2102,,Second Line Therapy (after,Induction,,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,Oth,"qd(d1,d8,d15)",PO,,711,1166,1
MMRF_2102,,Second Line Therapy (after,Induction,,Carfilzomib,,,,Disease progression/Relapse,,36,mg/m^,,Oth,"qd(d1,d2,d8,d9,d15,d16)",IV,,717,1166,1
MMRF_2102,,Third Line Therapy (followi,Induction,,Dexamethasone,,,Checked,,,20,mg,,QD,,PO,,1173,,1
MMRF_2102,,Third Line Therapy (followi,Induction,,Other,FILANESIB,,Checked,,,1.4,mg/m^,,Oth,"DAYS 1,2,15,16 EACH 28",IV,,1173,,1
MMRF_2102,,Third Line Therapy (followi,Induction,,Pomalidomide,,,Checked,,,4,mg,,QD,,PO,,1173,,1
MMRF_2142,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV,,1,274,1
MMRF_2142,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,14,mg,,QD,,IV,,1,274,1
MMRF_2142,,First line of therapy,Induction,,Prednisone,,,,Completed regimen,,100,mg,,QD,,IV,,1,274,1
MMRF_2335,,First line of therapy,Induction,,Lenalidomide,,,,Other,Death,25,mg,,QD,,PO,,1,264,1
MMRF_2335,Baseline,First line of therapy,Induction,,Bortezomib,,,,Other,Death,1.3,mg/m^,,QD,,IV SubQ,,1,264,1
MMRF_2335,,First line of therapy,Induction,,Dexamethasone,,,,Other,Death,40,mg,,Oth,QD (1-4) QD (9-12),PO,,1,264,1
MMRF_2468,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV,,1,358,1
MMRF_2468,,First line of therapy,Induction,,Dexamethasone,,,Checked,,,40,mg,,Oth,QD (D1-D4) Y (D9-12),PO,,1,,1
MMRF_2468,,First line of therapy,Induction,,Lenalidomide,,,Checked,,,25,mg,,QD,,PO,,1,,1
MMRF_2468,,First line of therapy,Other,BONE MARROW TRASPLANT,Melphalan,,,,Completed regimen,,200,mg/m^,,Oth,"DAYS -2, AND -1 RESPECT AT BONE MARROW TRASPLANT",IV,,220,221,1
MMRF_1654,Baseline,First line of therapy,Induction,,Bortezomib,,,,Other,death,2.21,mg,,QD,,IV SubQ,,1,81,1
MMRF_1654,,First line of therapy,Induction,,Dexamethasone,,,,Other,death,40,mg,,QD,,IV,,1,50,1
MMRF_1678,Baseline,First line of therapy,Induction,,Thalidomide,,,,Other,death,100,mg,,BID,,PO,,1,231,1
MMRF_1678,,First line of therapy,Induction,,Prednisone,,,,Adverse Event or co-morbidity,,100,mg,,BID,,PO,,1,212,1
MMRF_1678,,First line of therapy,Induction,,Melphalan,,,,Adverse Event or co-morbidity,,100,mg,,BID,,PO,,1,212,1
MMRF_1738,Baseline,First line of therapy,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,1.3,mg/m^,,QD,,IV SubQ,,1,71,1
MMRF_1738,,First line of therapy,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,40,mg,,Q w,,PO,,1,71,1
MMRF_1738,,Second Line Therapy (after,Maintenance,,Cyclophosphamide,,,,Disease progression/Relapse,,50,mg,,Q d,,PO,,93,526,1
MMRF_1738,,Third Line Therapy (followi,Unknown,,Lenalidomide,,,,Other,death,15,mg,,QD,,PO,,554,689,1
MMRF_1738,,Third Line Therapy (followi,Unknown,,Dexamethasone,,,,Other,death,20,mg,,QD,,PO,,554,689,1
MMRF_2224,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,2.63,mg,,QD,,Other,sc,1,400,1
MMRF_2224,,First line of therapy,Unknown,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,45,1
MMRF_2224,,First line of therapy,Unknown,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,PO,,1,401,1
MMRF_2224,,First line of therapy,Maintenance,,Lenalidomide,,,,Completed regimen,,15,mg,,QD,,PO,,477,1222,1
MMRF_2224,,First line of therapy,Maintenance,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"QD (1-4, 9-12)",PO,,477,1222,1
MMRF_2368,Baseline,First line of therapy,Induction,,Bortezomib,,,,Disease progression/Relapse,,1.3,mg/m^,,QD,,IV SubQ,,1,106,1
MMRF_2368,,First line of therapy,Induction,,Melphalan,,,,Disease progression/Relapse,,13.32,mg,,QD,,IV,,1,106,1
MMRF_2368,,First line of therapy,Induction,,Prednisone,,,,Disease progression/Relapse,,88.8,mg,,QD,,IV,,1,106,1
MMRF_2050,,First line of therapy,Induction,,Melphalan,,,Checked,,,9,mg/m^,,Oth,Every 42 days,PO,,1,,1
MMRF_2050,,First line of therapy,Induction,,Prednisone,,,Checked,,,60,mg/m^,,Oth,Every042 days,IV SubQ,,1,,1
MMRF_2050,Baseline,First line of therapy,Induction,,Bortezomib,,,Checked,,,1.3,mg/m^,,Oth,Every 42 days,IV,,1,,1
MMRF_2197,Baseline,First line of therapy,Induction,,Bortezomib,,,Checked,,,2.4,mg,,Oth,four days per month,Other,Subcutaneous,1,,1
MMRF_2197,,First line of therapy,Induction,,Melphalan,,,Checked,,,16,mg,,Oth,four times per month,PO,,1,,1
MMRF_2197,,First line of therapy,Induction,,Prednisone,,,Checked,,,110,mg,,Oth,four days per month,PO,,1,,1
MMRF_2200,Baseline,First line of therapy,Induction,,Bortezomib,,,,Disease progression/Relapse,,2.6,mg,,QD,,Other,Subcutaneous,1,147,1
MMRF_2200,,First line of therapy,Induction,,Doxorubicin,,,,Disease progression/Relapse,,79.6,mg,,Oth,ONCE A MONTH,IV,,20,147,1
MMRF_2200,,First line of therapy,Induction,,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,QD,,IV,,1,147,1
MMRF_2200,,Second Line Therapy (after,Induction,,Dexamethasone,,,,Other,"Complete response, patient is admitted for autologous Stem cell TCPH",40,mg,,Oth,"once a day, only the first 4days of each cicle",PO,,147,208,1
MMRF_2200,,Second Line Therapy (after,Induction,,Thalidomide,,,,Other,"Complete response, patient is admitted for autologous Stem cell TCPH",200,mg,,Oth,once a day,PO,,147,208,1
MMRF_2200,,Second Line Therapy (after,Induction,,Cyclophosphamide,,,,Other,"Complete response, patient is admitted for autologous Stem cell TCPH",50,mg,,Oth,once a day,PO,,147,208,1
MMRF_2200,,Second Line Therapy (after,Consolidation,,Melphalan,,,,Completed regimen,,260,mg,,Q d,,IV,,209,940,1
MMRF_2273,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,500,mg,,QD,,IV,,1,266,1
MMRF_2273,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,2.2,mg,,QD,,IV SubQ,,1,266,1
MMRF_2273,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,PO,,1,266,1
MMRF_2273,,Second Line Therapy (after,Induction,,Daratumumab,,,Checked,,,16,mg/kg,,Oth,once a week,IV,,1075,,1
MMRF_2273,,Second Line Therapy (after,Induction,,Lenalidomide,,,Checked,,,25,mg,,Q d,,PO,,1076,,1
MMRF_2273,,Second Line Therapy (after,Induction,,Dexamethasone,,,Checked,,,20,mg,,Oth,once a week,PO,,1075,,1
MMRF_2336,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,2.4,mg,,QD,,IV SubQ,,1,132,1
MMRF_2336,,First line of therapy,Induction,,Thalidomide,,,,Completed regimen,,100,mg,,Oth,100mg a day for 21days. total 2100mg,PO,,1,122,1
MMRF_2336,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,PO,,1,125,1
MMRF_2336,,Second Line Therapy (after,Induction,,Lenalidomide,,,Checked,,,25,mg,,QD,,PO,,670,,1
MMRF_2336,,Second Line Therapy (after,Induction,,Dexamethasone,,,Checked,,,40,mg,,Oth,every week,PO,,670,,1
MMRF_2336,,Second Line Therapy (after,Induction,,Carfilzomib,,,Checked,,,27,mg/m^,,QD,,IV,,729,,1
MMRF_2365,Baseline,First line of therapy,Induction,,Bortezomib,,,Checked,,,1.87,mg,,Oth,"D1,D8",IV SubQ,,1,,1
MMRF_2365,,First line of therapy,Induction,,Prednisone,,,Checked,,,80,mg,,QD,,PO,,1,,1
MMRF_2365,,First line of therapy,Induction,,Melphalan,,,Checked,,,12,mg,,QD,,PO,,1,,1
MMRF_2519,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,2.9,mg,,QD,,IV SubQ,,1,156,1
MMRF_2519,,First line of therapy,Induction,,Thalidomide,,,,Completed regimen,,100,mg,,Oth,once a day,PO,,1,876,1
MMRF_2519,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,"once a day on day 1,2,3,4.",PO,,1,148,1
MMRF_2578,,First line of therapy,Induction,,Melphalan,,,,Adverse Event or co-morbidity,,16,mg,,QD,,IV,,1,81,1
MMRF_2578,,First line of therapy,Induction,,Prednisone,,,,Adverse Event or co-morbidity,,100,mg,,QD,,PO,,1,81,1
MMRF_2578,Baseline,First line of therapy,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,2.28,mg,,Oth,"once a day, days 1,4,8,11,22,25,29,32",IV SubQ,,1,109,1
MMRF_2578,,First line of therapy,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,40,mg,,Oth,"D1, D8, D15, D21",PO,,126,760,1
MMRF_2578,,First line of therapy,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,25,mg,,Q d,,PO,,126,760,1
MMRF_2602,Baseline,First line of therapy,Induction,,Bortezomib,,,Checked,,,1.3,mg/m^,,QD,,IV SubQ,,1,,1
MMRF_2602,,First line of therapy,Induction,,Dexamethasone,,,Checked,,,40,mg,,QD,,IV,,1,,1
MMRF_2606,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.98,mg,,QD,,IV SubQ,,1,200,1
MMRF_2606,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,460,mg,,Oth,"once a day on days 1, 8, 15 and 22",IV,,1,211,1
MMRF_2606,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,PO,,1,209,1
MMRF_2606,,First line of therapy,Consolidation,,Melphalan,,,,Completed regimen,,310,mg,,QD,,IV,,220,227,1
MMRF_2606,,Second Line Therapy (after,Induction,,Carfilzomib,,,Checked,,,27,mg/m^,,QD,,IV,,625,,1
MMRF_2606,,Second Line Therapy (after,Induction,,Lenalidomide,,,Checked,,,25,mg,,QD,,PO,,592,,1
MMRF_2606,,Second Line Therapy (after,Induction,,Dexamethasone,,,Checked,,,40,mg,,Q w,,PO,,592,,1
MMRF_1923,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,162,1
MMRF_1923,,First line of therapy,Induction,,Thalidomide,,,,Completed regimen,,10,mg,,Oth,D1-21,PO,,1,152,1
MMRF_1923,,First line of therapy,Induction,,Daratumumab,,,,Completed regimen,,16,mg/kg,,Oth,"D1, D8, D15",IV,,1,152,1
MMRF_1923,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,"D1-2, D8-9",PO,,1,152,1
MMRF_1923,,First line of therapy,Maintenance,,Other,Ixazomib vs Placebo,,Checked,,,2.3,mg,,Oth,"Days 1, 8, 15",PO,,318,,1
MMRF_1923,,First line of therapy,Consolidation,,Melphalan,,,,Completed regimen,,360,mg,,Q d,,IV,,171,171,1
MMRF_1716,Baseline,First line of therapy,Induction,,Bortezomib,,,,Other,DEATH,1.3,mg/m^,,QD,,IV SubQ,,1,76,1
MMRF_1716,,First line of therapy,Induction,,Prednisone,,,,Other,DEATH,60,mg,,QD,,PO,,1,76,1
MMRF_1716,,First line of therapy,Induction,,Melphalan,,,,Other,DEATH,9,mg,,QD,,PO,,1,76,1
MMRF_1931,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,9,mg/m^,,QD,,PO,,1,310,1
MMRF_1931,,First line of therapy,Induction,,Prednisone,,,,Completed regimen,,60,mg/m^,,QD,,PO,,1,310,1
MMRF_1931,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,Oth,"QD(D1,D4,D8,D11,D22,D25,D29,D32",Other,SC,1,310,1
MMRF_1931,,Second Line Therapy (after,Induction,,Lenalidomide,,,Checked,,,25,mg,,QD,,PO,,796,,1
MMRF_1931,,Second Line Therapy (after,Induction,,Dexamethasone,,,,Other,change of dose,40,mg,,Q w,,PO,,796,936,1
MMRF_1931,,Second Line Therapy (after,Maintenance,,Dexamethasone,,,Checked,,,20,mg,,Q w,,PO,,936,,1
MMRF_2194,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,Other,SUBCUTANEOUS,1,289,1
MMRF_2194,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,9,mg/m^,,QD,,PO,,1,289,1
MMRF_2194,,First line of therapy,Induction,,Prednisone,,,,Completed regimen,,60,mg/m^,,QD,,PO,,1,289,1
MMRF_2194,,Second Line Therapy (after,Induction,,Dexamethasone,,,,Lack of response,,40,mg,,Q w,,IV,,449,591,1
MMRF_2194,,Second Line Therapy (after,Induction,,Lenalidomide,,,,Lack of response,,25,mg,,QD,,PO,,449,591,1
MMRF_2194,,Second Line Therapy (after,Induction,,Cyclophosphamide,,,,Lack of response,,50,mg,,Q d,,PO,,542,591,1
MMRF_2194,,Third Line Therapy (followi,Induction,,Vincristine,,,,Lack of response,,0.4,mg,,QD,,IV,,592,648,1
MMRF_2194,,Third Line Therapy (followi,Induction,,Other,Adriamycin,,,Lack of response,,9,mg/m^,,QD,,IV,,592,648,1
MMRF_2194,,Third Line Therapy (followi,Induction,,Dexamethasone,,,,Lack of response,,40,mg,,QD,,IV,,592,648,1
MMRF_2194,,Fourth Line Therapy (follow,Induction,,Carfilzomib,,,,Lack of response,,27,mg/m^,,QD,,IV,,670,787,1
MMRF_2194,,Fourth Line Therapy (follow,Induction,,Lenalidomide,,,,Lack of response,,25,mg,,QD,,PO,,670,787,1
MMRF_2194,,Fourth Line Therapy (follow,Induction,,Dexamethasone,,,,Lack of response,,40,mg,,Oth,"QD (D 1-4, D9-12)",PO,,670,787,1
MMRF_2194,,Fifth Line Therapy (followi,Induction,,Daratumumab,,,,Disease progression/Relapse,,16,mg/kg,,Q w,,IV,,850,1061,1
MMRF_2245,Baseline,First line of therapy,Induction,,Bortezomib,,,Checked,,,1.3,mg/m^,,Q w,,Other,SUBCUTANEOUS,1,,1
MMRF_2245,,First line of therapy,Induction,,Melphalan,,,Checked,,,9,mg/m^,,QD,,PO,,1,,1
MMRF_2245,,First line of therapy,Induction,,Prednisone,,,Checked,,,60,mg/m^,,QD,,PO,,1,,1
MMRF_2257,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,Other,SUBCUTANEOUS,1,103,1
MMRF_2257,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,PO,,1,103,1
MMRF_2257,,Second Line Therapy (after,Induction,,Bortezomib,,,Checked,,,1.3,mg/m^,,Q w,,Other,subcutaneous,1154,,1
MMRF_2257,,Second Line Therapy (after,Induction,,Cyclophosphamide,,,Checked,,,400,mg,,Q w,,PO,,1154,,1
MMRF_2257,,Second Line Therapy (after,Induction,,Dexamethasone,,,Checked,,,20,mg,,Q w,,PO,,1154,,1
MMRF_2526,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,2.3,mg,,QD,,Other,SUBCUTANEOUS,1,260,1
MMRF_2526,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,8,mg,,QD,,PO,,1,260,1
MMRF_2526,,First line of therapy,Induction,,Prednisone,,,,Completed regimen,,90,mg,,QD,,PO,,1,260,1
MMRF_1913,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,9,mg/m^,,QD,,PO,,1,369,1
MMRF_1913,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,369,1
MMRF_1913,,First line of therapy,Induction,,Prednisone,,,,Completed regimen,,60,mg/m^,,QD,,PO,,1,369,1
MMRF_1913,,Second Line Therapy (after,Induction,,Lenalidomide,,,,Investigator decision for other reasons,,15,mg,,Oth,Alternate days,PO,,651,676,1
MMRF_1913,,Second Line Therapy (after,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,15,mg,,Q d,,PO,,677,733,1
MMRF_1913,,Second Line Therapy (after,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,40,mg,,Oth,"QD (D1-4, 9-12)",PO,,651,662,1
MMRF_1913,,Second Line Therapy (after,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,4,mg,,Q w,,PO,,684,704,1
MMRF_1913,,Second Line Therapy (after,Induction,,Prednisone,,,,Adverse Event or co-morbidity,,50,mg,,Q w,,PO,,705,733,1
MMRF_1913,,Second Line Therapy (after,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,20,mg,,Q w,,PO,,677,683,1
MMRF_1913,,Third Line Therapy (followi,Induction,,Carfilzomib,,,,Adverse Event or co-morbidity,,70,mg/m^,,Oth,"QD (D1, D8, D15)",IV,,804,936,1
MMRF_1913,,Third Line Therapy (followi,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,40,mg,,Q w,,PO,,804,936,1
MMRF_1913,,Fourth Line Therapy (follow,Induction,,Daratumumab,,,,Disease progression/Relapse,,1800,mg,,Oth,"C1-2: D1, 8, 15, 22; C3-6: D1, 15; from C7: D1.",Other,subcutaneous,1104,1265,1
MMRF_1978,Baseline,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,18,mg,,QD,,PO,,1,263,1
MMRF_1978,,First line of therapy,Induction,,Prednisone,,,,Completed regimen,,120,mg,,QD,,PO,,1,263,1
MMRF_1978,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,2.5,mg,,QD,,IV,,1,281,1
MMRF_1978,,Second Line Therapy (after,Unknown,,Lenalidomide,,,Checked,,,15,mg,,QD,,PO,,646,,1
MMRF_1978,,Second Line Therapy (after,Unknown,,Dexamethasone,,,Checked,,,40,mg,,Q w,,PO,,646,,1
MMRF_1989,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,2.7,mg,,QD,,IV,,1,190,1
MMRF_1989,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,1,200,1
MMRF_1989,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,"QD (D1-4, D9-12)",PO,,1,191,1
MMRF_1989,,First line of therapy,Maintenance,,Bortezomib,,,,Completed regimen,,2.7,mg,,QD,,IV,,333,1205,1
MMRF_1989,,First line of therapy,Maintenance,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,333,1205,1
MMRF_1989,,First line of therapy,Maintenance,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,"QD (D1-4, D9-12)",PO,,333,1205,1
MMRF_1989,,First line of therapy,Other,conditioning treatment pretrasplant,Melphalan,,,,Completed regimen,,100,mg/m^,,Q d,,IV,,232,233,1
MMRF_2049,Baseline,First line of therapy,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,25,mg,,Q d,,PO,,1,157,1
MMRF_2049,,First line of therapy,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,1.3,mg/m^,,QD,,IV,,1,147,1
MMRF_2049,,First line of therapy,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,40,mg,,Oth,"QD (D 1-4, D9-12)",PO,,1,147,1
MMRF_2384,Baseline,First line of therapy,Induction,,Bortezomib,,,Checked,,,1.9,mg,,QD,,IV,,1,,1
MMRF_2384,,First line of therapy,Induction,,Lenalidomide,,,Checked,,,25,mg,,QD,,PO,,1,,1
MMRF_2384,,First line of therapy,Induction,,Dexamethasone,,,Checked,,,40,mg,,Oth,"QD (D1-4, D9-12)",PO,,1,,1
MMRF_2385,,First line of therapy,Induction,,Other,methylprednisolone,,,Completed regimen,,125,mg,,Oth,monthly,IV,,1,77,1
MMRF_2385,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV,,1,77,1
MMRF_2385,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,1600,mg,,Oth,monthly,IV,,1,77,1
MMRF_2385,,Second Line Therapy (after,Other,rescue,Dexamethasone,,,,Completed regimen,,40,mg,,QWK,,PO,,619,701,1
MMRF_2385,,Second Line Therapy (after,Other,rescue,Bortezomib,,,,Completed regimen,,2.8,mg,,QWK,,IV SubQ,,619,701,1
MMRF_2385,,Second Line Therapy (after,Other,rescue,Cyclophosphamide,,,,Completed regimen,,1080,mg,,Oth,monthly,IV,,619,701,1
MMRF_2385,,Second Line Therapy (after,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,25,mg,,QD,,PO,,738,1027,1
MMRF_2385,,Second Line Therapy (after,Maintenance,,Dexamethasone,,,,Adverse Event or co-morbidity,,40,mg,,Q w,,PO,,738,1027,1
MMRF_2385,,Third Line Therapy (followi,Unknown,,Daratumumab,,,Checked,,,1550,mg,,Q w,,IV,,1137,,1
MMRF_2385,,Third Line Therapy (followi,Unknown,,Bortezomib,,,Checked,,,2.8,mg,,QD,,IV SubQ,,1137,,1
MMRF_2385,,Third Line Therapy (followi,Unknown,,Dexamethasone,,,Checked,,,20,mg,,Q w,,IV,,1137,,1
MMRF_2413,Baseline,First line of therapy,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,2.9,mg,,QD,,IV,,1,11,1
MMRF_2413,,First line of therapy,Induction,,Melphalan,,,,Adverse Event or co-morbidity,,16,mg,,QD,,PO,,1,4,1
MMRF_2413,,First line of therapy,Induction,,Prednisone,,,,Adverse Event or co-morbidity,,125,mg,,QD,,PO,,1,4,1
MMRF_2413,,First line of therapy,Induction,,Prednisone,,,,Completed regimen,,15,mg,,Q d,,PO,,48,400,1
MMRF_2413,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,1200,mg,,Oth,each 4 weeks,IV,,48,400,1
MMRF_2413,,Second Line Therapy (after,Unknown,,Lenalidomide,,,Checked,,,15,mg,,QD,,PO,,935,,1
MMRF_2413,,Second Line Therapy (after,Unknown,,Dexamethasone,,,Checked,,,20,mg,,Q w,,PO,,935,,1
MMRF_2413,,Second Line Therapy (after,Unknown,,Cyclophosphamide,,,,Lack of response,,1200,mg,,Q w,,IV,,851,935,1
MMRF_2413,,Second Line Therapy (after,Unknown,,Prednisone,,,,Disease progression/Relapse,,15,mg,,Q d,,PO,,857,913,1
MMRF_2580,,First line of therapy,Induction,,Melphalan,,,Checked,,,14,mg,,QD,,PO,,1,,1
MMRF_2580,Baseline,First line of therapy,Induction,,Bortezomib,,,Checked,,,2.1,mg,,QD,,IV,,1,,1
MMRF_2580,,First line of therapy,Induction,,Prednisone,,,Checked,,,96,mg,,QD,,PO,,1,,1
MMRF_1861,Baseline,First line of therapy,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,1.3,mg/m^,,Oth,"D1, D4, D8, D11, D22, D25, D29, D32 (Cycle 1) and Q week starting cycle 2",Other,subcutaneous,1,123,1
MMRF_1861,,First line of therapy,Induction,,Melphalan,,,,Adverse Event or co-morbidity,,12,mg,,QD,,PO,,1,77,1
MMRF_1861,,First line of therapy,Induction,,Prednisone,,,,Completed regimen,,90,mg,,QD,,PO,,1,252,1
MMRF_1861,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,10,mg,,QD,,PO,,102,252,1
MMRF_1861,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1,mg/m^,,Q w,,Other,subcutaneos,130,270,1
MMRF_1861,,Second Line Therapy (after,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,25,mg,,QD,,PO,,1040,1067,1
MMRF_1861,,Second Line Therapy (after,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,40,mg,,QD,,PO,,1040,1067,1
MMRF_1861,,Second Line Therapy (after,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,15,mg,,QD,,PO,,1068,1305,1
MMRF_1861,,Second Line Therapy (after,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,20,mg,,QD,,PO,,1068,1305,1
MMRF_1861,,Second Line Therapy (after,Induction,,Ixazomib,,,,Adverse Event or co-morbidity,,4,mg,,Q w,,PO,,1237,1255,1
MMRF_1933,Baseline,First line of therapy,Induction,,Bortezomib,,,,Investigator decision for other reasons,,1.3,mg/m^,,QD,,Other,subcutaneous,1,29,1
MMRF_1933,,First line of therapy,Induction,,Melphalan,,,,Other,BY MISSUNDERSTANDING OF THE PROPER ADMINISTRATION,2,mg,,Q d,,PO,,1,38,1
MMRF_1933,,First line of therapy,Induction,,Prednisone,,,,Completed regimen,,120,mg,,QD,,PO,,1,242,1
MMRF_1933,,First line of therapy,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,1.3,mg/m^,,Q w,,Other,subcutaneous,39,95,1
MMRF_1933,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,Q w,,Other,sUBCUTANEOS,109,260,1
MMRF_1933,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,12,mg,,QD,,PO,,151,242,1
MMRF_1933,,First line of therapy,Induction,,Melphalan,,,,Adverse Event or co-morbidity,,16,mg,,QD,,PO,,39,126,1
MMRF_1933,,Second Line Therapy (after,Induction,,Melphalan,,,Checked,,,12,mg,,QD,,PO,,944,,1
MMRF_1933,,Second Line Therapy (after,Induction,,Prednisone,,,Checked,,,120,mg,,QD,,PO,,944,,1
MMRF_1995,Baseline,First line of therapy,Induction,,Bortezomib,,,,Other,we decided only one cycle of velcade+dexa and then another treatment,1.3,mg/m^,,QD,,IV,,1,22,1
MMRF_1995,,First line of therapy,Induction,,Dexamethasone,,,,Other,we decided only one cycle of velcade+dexa and then another treatment,40,mg,,QD,,PO,,1,22,1
MMRF_1995,,First line of therapy,Induction,,Bortezomib,,,,Other,change of frecuency,1.3,mg/m^,,Oth,"day 1,4,8,11,22,25,29,32 (cycles of 42 days)",IV,,41,75,1
MMRF_1995,,First line of therapy,Induction,,Prednisone,,,,Completed regimen,,120,mg,,QD,,PO,,41,275,1
MMRF_1995,,First line of therapy,Induction,,Melphalan,,,,Other,change of dose,18,mg,,QD,,PO,,41,145,1
MMRF_1995,,First line of therapy,Induction,,Bortezomib,,,,Other,change of dose,1.3,mg/m^,,Q w,,IV,,76,208,1
MMRF_1995,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,14,mg,,QD,,PO,,146,275,1
MMRF_1995,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,0.7,mg/m^,,Q w,,IV,,209,293,1
MMRF_1995,,Second Line Therapy (after,Induction,,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,QD,,PO,,460,1159,1
MMRF_1995,,Second Line Therapy (after,Induction,,Lenalidomide,,,,Investigator decision for other reasons,,10,mg,,QD,,PO,,460,980,1
MMRF_1995,,Third Line Therapy (followi,Induction,,Daratumumab,,,,Disease progression/Relapse,,1184,mg,,Q w,,IV,,1198,1218,1
MMRF_1995,,Third Line Therapy (followi,Induction,,Bortezomib,,,,Disease progression/Relapse,,1.3,mg/m^,,QD,,Other,subQ,1198,1218,1
MMRF_1995,,Third Line Therapy (followi,Induction,,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,Q w,,IV,,1198,1218,1
MMRF_1995,,Fourth Line Therapy (follow,Induction,,Carfilzomib,,,,Other,"days 1,2 different dose",37,mg,,Q d,,IV,,1232,1233,1
MMRF_1995,,Fourth Line Therapy (follow,Induction,,Carfilzomib,,,,Disease progression/Relapse,,128,mg,,Oth,"days 1,8,15",IV,,1234,1362,1
MMRF_1995,,Fourth Line Therapy (follow,Induction,,Cyclophosphamide,,,,Disease progression/Relapse,,550,mg,,Oth,"days1,8,15",IV,,1232,1362,1
MMRF_1995,,Second Line Therapy (after,Induction,,Lenalidomide,,,,Disease progression/Relapse,,15,mg,,QD,,PO,,981,1147,1
MMRF_1995,,Fourth Line Therapy (follow,Induction,,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,QD,,PO,,1232,1363,1
MMRF_1995,,Fifth Line Therapy (followi,Induction,,Pomalidomide,,,Checked,,,4,mg,,QD,,PO,,1367,,1
MMRF_1995,,Fifth Line Therapy (followi,Induction,,Dexamethasone,,,Checked,,,40,mg,,Q w,,PO,,1367,,1
MMRF_2008,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,6,426,1
MMRF_2008,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,1-4 and 9-12 days,PO,,1,12,1
MMRF_2008,,First line of therapy,Induction,,Melphalan,,,,Other,increase of dose,12,mg,,QD,,PO,,62,208,1
MMRF_2008,,First line of therapy,Induction,,Melphalan,,,,Other,dosis reduced due to renal insuficence,9,mg/m^,,QD,,PO,,34,61,1
MMRF_2008,,First line of therapy,Induction,,Prednisone,,,,Other,dosis reduced due to adverse event,60,mg/m^,,QD,,PO,,34,61,1
MMRF_2008,,First line of therapy,Induction,,Prednisone,,,,Completed regimen,,90,mg,,QD,,PO,,62,426,1
MMRF_2008,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,18,mg,,QD,,PO,,237,426,1
MMRF_2008,,First line of therapy,Induction,,Melphalan,,,,Other,increase of dose due to creatinine is better,14,mg,,QD,,PO,,209,236,1
MMRF_2008,,First line of therapy,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,25,mg,,QD,,PO,,427,568,1
MMRF_2008,,First line of therapy,Induction,,Dexamethasone,,,,Lack of response,,20,mg,,Q w,,PO,,427,925,1
MMRF_2008,,First line of therapy,Induction,,Lenalidomide,,,,Disease progression/Relapse,,15,mg,,QD,,PO,,569,1063,1
MMRF_2008,,First line of therapy,Induction,,Dexamethasone,,,,Disease progression/Relapse,,30,mg,,Oth,2 days per week,PO,,926,1065,1
MMRF_2008,,Second Line Therapy (after,Induction,,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,Q w,,PO,,1101,1210,1
MMRF_2008,,Second Line Therapy (after,Induction,,Pomalidomide,,,,Disease progression/Relapse,,4,mg,,QD,,PO,,1101,1210,1
MMRF_2008,,Third Line Therapy (followi,Induction,,Daratumumab,,,,Disease progression/Relapse,,1600,mg,,Q w,,IV,,1263,1324,1
MMRF_2008,,Third Line Therapy (followi,Induction,,Dexamethasone,,,,Disease progression/Relapse,,20,mg,,Q w,,IV,,1263,1324,1
MMRF_2008,,Fourth Line Therapy (follow,Induction,,Cyclophosphamide,,,Checked,,,650,mg,,Oth,"days 1,8,15",IV,,1325,,1
MMRF_2008,,Fourth Line Therapy (follow,Induction,,Dexamethasone,,,Checked,,,40,mg,,Oth,"days 1,8,15,22",PO,,1325,,1
MMRF_2008,,Fourth Line Therapy (follow,Induction,,Carfilzomib,,,Checked,,,70,mg/m^,,Oth,"day 1,8,15",IV,,1325,,1
MMRF_2011,Baseline,First line of therapy,Induction,,Bortezomib,,,,Investigator decision for other reasons,,1.3,mg/m^,,Oth,"D1, D8, D22 and D29",Other,SC,1,42,1
MMRF_2011,,First line of therapy,Induction,,Dexamethasone,,,,Investigator decision for other reasons,,40,mg,,Q d,,PO,,1,4,1
MMRF_2011,,First line of therapy,Induction,,Melphalan,,,,Adverse Event or co-morbidity,,10,mg,,QD,,PO,,1,98,1
MMRF_2011,,First line of therapy,Induction,,Prednisone,,,,Adverse Event or co-morbidity,,60,mg,,QD,,PO,,5,98,1
MMRF_2011,,First line of therapy,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,1.3,mg/m^,,Q w,,Other,SC,43,98,1
MMRF_2011,,First line of therapy,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,1.3,mg/m^,,Oth,"D1, D4, D8, D11, D22, D25, D29, D32",Other,SC,113,133,1
MMRF_2011,,First line of therapy,Induction,,Melphalan,,,,Disease progression/Relapse,,20,mg,,QD,,PO,,113,315,1
MMRF_2011,,First line of therapy,Induction,,Prednisone,,,,Disease progression/Relapse,,60,mg,,QD,,PO,,113,315,1
MMRF_2011,,Second Line Therapy (after,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,15,mg,,Oth,Every 48 hours D1-D21,PO,,400,429,1
MMRF_2011,,Second Line Therapy (after,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,10,mg,,QD,,PO,,316,399,1
MMRF_2011,,Second Line Therapy (after,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,20,mg,,Oth,"D1-2, D8-9, D15-16, D22-23",PO,,316,429,1
MMRF_2011,,First line of therapy,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,1,mg/m^,,QD,,Other,SC,239,259,1
MMRF_2011,,First line of therapy,Induction,,Bortezomib,,,,Investigator decision for other reasons,,1,mg/m^,,QD,,Other,SC,267,280,1
MMRF_2011,,First line of therapy,Induction,,Bortezomib,,,,Other,Adverse event + Disease progresion,1.3,mg/m^,,QD,,Other,SC,281,302,1
MMRF_2011,,Second Line Therapy (after,Induction,,Lenalidomide,,,,Disease progression/Relapse,,15,mg,,Oth,Every 48 hours D1-D21,PO,,444,464,1
MMRF_2011,,Second Line Therapy (after,Induction,,Dexamethasone,,,,Disease progression/Relapse,,20,mg,,Oth,"QD (D1-2, D8-9, D14-15, D21-22)",PO,,444,466,1
MMRF_2011,,First line of therapy,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,1,mg/m^,,QD,,Other,SC,137,227,1
MMRF_2011,,Third Line Therapy (followi,Induction,,Carfilzomib,,,,Completed regimen,,20,mg/m^,,QD,,IV,,661,688,1
MMRF_2011,,Third Line Therapy (followi,Induction,,Dexamethasone,,,,Investigator decision for other reasons,,40,mg,,QWK,,PO,,661,1207,1
MMRF_2011,,Third Line Therapy (followi,Induction,,Carfilzomib,,,,Adverse Event or co-morbidity,,120,mg,,QWK,,IV,,689,1193,1
MMRF_2011,,Fourth Line Therapy (follow,Induction,,Pomalidomide,,,Checked,,,4,mg,,Q d,,PO,,1348,,1
MMRF_2011,,Fourth Line Therapy (follow,Induction,,Dexamethasone,,,Checked,,,20,mg,,Q w,,PO,,1348,,1
MMRF_2085,Baseline,First line of therapy,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,1.3,mg/m^,,Oth,"day 1,4,8,11,22,25,29,32 (cycles of 42 days)",Other,sc,1,9,1
MMRF_2085,,First line of therapy,Induction,,Melphalan,,,,Adverse Event or co-morbidity,,20,mg,,QD,,PO,,1,4,1
MMRF_2085,,First line of therapy,Induction,,Prednisone,,,,Adverse Event or co-morbidity,,120,mg,,QD,,PO,,1,4,1
MMRF_2085,,Second Line Therapy (after,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,IV,,96,99,1
MMRF_2085,,Second Line Therapy (after,Induction,,Cyclophosphamide,,,,Completed regimen,,1000,mg,,Oth,only 1 day,IV,,96,96,1
MMRF_2085,,Second Line Therapy (after,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,25,mg,,QD,,PO,,122,141,1
MMRF_2085,,Second Line Therapy (after,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,20,mg,,QD,,PO,,122,141,1
MMRF_2085,,Second Line Therapy (after,Induction,,Melphalan,,,,Disease progression/Relapse,,20,mg,,QD,,PO,,234,417,1
MMRF_2085,,Second Line Therapy (after,Induction,,Prednisone,,,,Disease progression/Relapse,,120,mg,,QD,,PO,,234,417,1
MMRF_2085,,Third Line Therapy (followi,Induction,,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,Q w,,PO,,418,435,1
MMRF_2229,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,Q w,,IV SubQ,,1,239,1
MMRF_2229,,First line of therapy,Induction,,Prednisone,,,,Completed regimen,,100,mg,,Oth,"3 times per week (monday, wednesday and friday)",PO,,1,250,1
MMRF_2229,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,1000,mg,,Oth,day 1 of each cycle,IV,,29,225,1
MMRF_2229,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,250,mg,,Oth,"days 2,9,16",PO,,1,28,1
MMRF_2229,,First line of therapy,Maintenance,,Bortezomib,,,,Other,TOXICITY,1.3,mg/m^,,Oth,day 1 and 8 of cycles of 28 days,IV SubQ,,337,966,1
MMRF_2229,,First line of therapy,Induction,,Dexamethasone,,,,Disease progression/Relapse,,20,mg,,Q w,,PO,,533,1002,1
MMRF_2229,,First line of therapy,Maintenance,,Bortezomib,,,,Disease progression/Relapse,,1,mg/m^,,Oth,day 1 and 8 of cycles of 28 days,IV SubQ,,967,1002,1
MMRF_2328,Baseline,First line of therapy,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,1.3,mg/m^,,Oth,"D1, D4, D8, D11, D21, D24, D28, D31",IV SubQ,,5,35,1
MMRF_2328,,First line of therapy,Induction,,Cyclophosphamide,,,,Other,Interrupted due to mobilization previous TPH,1000,mg,,Oth,"D1, D21",IV,,5,272,1
MMRF_2328,,First line of therapy,Induction,,Dexamethasone,,,,Investigator decision for other reasons,,40,mg,,Oth,"D1-4, D25-28",PO,,1,28,1
MMRF_2328,,First line of therapy,Induction,,Dexamethasone,,,,Investigator decision for other reasons,,40,mg,,Oth,"D1-4, D25-28",PO,,179,357,1
MMRF_2328,,First line of therapy,Induction,,Bortezomib,,,,Investigator decision for other reasons,,0.7,mg/m^,,QD,,Other,Subcutaneos,137,165,1
MMRF_2328,,First line of therapy,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,1,mg/m^,,Oth,"D1, D4, D8, D11, D21, D24, D28, D31",Other,Subcutaneos,63,77,1
MMRF_2328,,First line of therapy,Induction,,Dexamethasone,,,,Investigator decision for other reasons,,40,mg,,Oth,D25-28,PO,,74,161,1
MMRF_2328,,First line of therapy,Other,Mobilization of peripheral blood hematopoietic progenitors,Cyclophosphamide,,,,Completed regimen,,2870,mg,,Q d,,IV,,273,273,1
MMRF_2328,,First line of therapy,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,1,mg/m^,,Oth,"D1, D4, D8, D11, D21, D24, D28, D31",Other,Subcutaneos,53,56,1
MMRF_2328,,First line of therapy,Induction,,Bortezomib,,,,Investigator decision for other reasons,,1,mg/m^,,QD,,Other,Subcutaneos,179,207,1
MMRF_2328,,First line of therapy,Induction,,Bortezomib,,,,Other,Interrupted due to mobilization previous TPH,1.3,mg/m^,,QD,,Other,Subcutaneos,221,272,1
MMRF_2328,,First line of therapy,Induction,,Bortezomib,,,,Investigator decision for other reasons,,1.3,mg/m^,,QD,,Other,subcutaneous,312,354,1
MMRF_2328,,First line of therapy,Other,"in order to obtain a better response previous to TPH, there was no relapse/progression",Lenalidomide,,,,Adverse Event or co-morbidity,,25,mg,,QD,,PO,,426,572,1
MMRF_2328,,First line of therapy,Other,"in oder to obtain a better response previous to TPH, there was no relapse/progression",Dexamethasone,,,,Adverse Event or co-morbidity,,40,mg,,Oth,"D1-4, D9-12, D17-20",PO,,426,572,1
MMRF_2328,,First line of therapy,Other,Mobilization of peripheral blood hematopoietic progenitors,Cyclophosphamide,,,,Completed regimen,,2870,mg,,Q d,,IV,,385,385,1
MMRF_2328,,Second Line Therapy (after,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,20,mg,,QD,,PO,,690,774,1
MMRF_2328,,Second Line Therapy (after,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,25,mg,,QD,,PO,,690,774,1
MMRF_2328,,Third Line Therapy (followi,Induction,,Carfilzomib,,,,Disease progression/Relapse,,66,mg,,QID,,IV,,866,867,1
MMRF_2328,,Third Line Therapy (followi,Maintenance,,Dexamethasone,,,,Completed regimen,,40,mg,,Q d,,PO,,880,883,1
MMRF_2328,,Third Line Therapy (followi,Induction,,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,Q w,,Other,IV+PO,824,879,1
MMRF_2328,,Fourth Line Therapy (follow,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,10,mg,,QD,,PO,,908,919,1
MMRF_2328,,Fourth Line Therapy (follow,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,40,mg,,Q w,,IV,,908,919,1
MMRF_2328,,Fourth Line Therapy (follow,Induction,,Pomalidomide,,,,Adverse Event or co-morbidity,,4,mg,,Q d,,PO,,939,941,1
MMRF_2328,,Fourth Line Therapy (follow,Induction,,Other,Claritromicine,,,Adverse Event or co-morbidity,,500,mg,,BID,,PO,,939,941,1
MMRF_2328,,Fourth Line Therapy (follow,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,40,mg,,QD,,PO,,939,941,1
MMRF_2328,,Fourth Line Therapy (follow,Induction,,Daratumumab,,,,Disease progression/Relapse,,1100,mg,,Q w,,IV,,945,970,1
MMRF_2328,,Fourth Line Therapy (follow,Induction,,Bortezomib,,,,Disease progression/Relapse,,2.3,mg,,Oth,"D1, D7",Other,SC,945,970,1
MMRF_2328,,Fourth Line Therapy (follow,Induction,,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,Q w,,IV,,945,970,1
MMRF_2328,,Second Line Therapy (after,Maintenance,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,"D 1-4, D8-11",PO,,813,823,1
MMRF_2328,,Fourth Line Therapy (follow,Induction,,Daratumumab,,,,Adverse Event or co-morbidity,,1176,mg,,Q w,,IV,,908,919,1
MMRF_2328,,Third Line Therapy (followi,Induction,,Carfilzomib,,,,Adverse Event or co-morbidity,,36,mg,,QD,,IV,,824,858,1
MMRF_2328,,Third Line Therapy (followi,Induction,,Cyclophosphamide,,,,Disease progression/Relapse,,545,mg,,Q w,,IV,,824,879,1
MMRF_2401,Baseline,First line of therapy,Induction,,Bortezomib,,,,Disease progression/Relapse,,1.3,mg/m^,,QD,,Other,Subcutaneos,1,99,1
MMRF_2401,,First line of therapy,Induction,,Thalidomide,,,,Investigator decision for other reasons,,50,mg,,Q d,,PO,,1,14,1
MMRF_2401,,First line of therapy,Induction,,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,Oth,"day 1-4, day 8-11",Other,IV and PO,1,98,1
MMRF_2401,,Second Line Therapy (after,Induction,,Bortezomib,,,,Other,evolution to plasma cell leukemia,1.3,mg/m^,,Oth,"QD (D1, 5, 8, 12,22, 26, 29, 33)",Other,Subcutaneos,123,249,1
MMRF_2401,,Second Line Therapy (after,Induction,,Dexamethasone,,,,Other,evolution to plasma cell leukemia,40,mg,,Oth,"QD (D1-4, D22-25)",Other,IV + PO,123,249,1
MMRF_2401,,Second Line Therapy (after,Induction,,Cyclophosphamide,,,,Other,evolution to plasma cell leukemia,1000,mg/m^,,Oth,"QD (D1, D22)",IV,,123,249,1
MMRF_2401,,First line of therapy,Induction,,Thalidomide,,,,Disease progression/Relapse,,100,mg,,Q d,,PO,,15,115,1
MMRF_2401,,Third Line Therapy (followi,Unknown,,Doxorubicin,,,,Disease progression/Relapse,,10,mg/m^,,QD,,IV,,251,270,1
MMRF_2401,,Third Line Therapy (followi,Unknown,,Melphalan,,,,Disease progression/Relapse,,16,mg,,QD,,IV,,251,270,1
MMRF_2401,,Third Line Therapy (followi,Other,conditioning for auto-trasplant,Melphalan,,,,Disease progression/Relapse,,167,mg,,Q d,,IV,,271,272,1
MMRF_2401,,Third Line Therapy (followi,Maintenance,,Dexamethasone,,,,Adverse Event or co-morbidity,,20,mg,,Oth,every 2 days /week,PO,,305,364,1
MMRF_2401,,Third Line Therapy (followi,Maintenance,,Bortezomib,,,,Adverse Event or co-morbidity,,1,mg/m^,,Q w,,Other,Subcutaneos,305,364,1
MMRF_2401,,Third Line Therapy (followi,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,10,mg,,QD,,PO,,305,350,1
MMRF_2401,,Third Line Therapy (followi,Unknown,,Dexamethasone,,,,Disease progression/Relapse,,40,mg,,QD,,PO,,251,270,1
MMRF_2401,,Third Line Therapy (followi,Unknown,,Other,cisplatine,,,Disease progression/Relapse,,10,mg/m^,,QD,,IV,,251,270,1
MMRF_2401,,Third Line Therapy (followi,Unknown,,Other,etoposide (VP16),,,Disease progression/Relapse,,40,mg/m^,,QD,,IV,,251,270,1
MMRF_2401,,Second Line Therapy (after,Maintenance,,Dexamethasone,,,,Completed regimen,,20,mg,,QD,,PO,,295,298,1
MMRF_2401,,Third Line Therapy (followi,Unknown,,Other,Clarithromycin,,,Disease progression/Relapse,,500,mg,,Oth,12 hours,PO,,251,270,1
MMRF_2427,Baseline,First line of therapy,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,1.3,mg/m^,,QD,,IV SubQ,,1,235,1
MMRF_2427,,First line of therapy,Induction,,Dexamethasone,,,,Investigator decision for other reasons,,40,mg,,Oth,1-4 and 9-12 days,PO,,1,306,1
MMRF_2427,,First line of therapy,Induction,,Thalidomide,,,,Adverse Event or co-morbidity,,100,mg,,Q d,,PO,,1,246,1
MMRF_2427,,First line of therapy,Induction,,Other,claritromicina,,,Adverse Event or co-morbidity,,500,mg,,BID,,PO,,180,250,1
MMRF_2427,,First line of therapy,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,25,mg,,QD,,PO,,344,370,1
MMRF_2427,,First line of therapy,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,1,mg/m^,,QD,,IV SubQ,,246,250,1
MMRF_2427,,First line of therapy,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,15,mg,,QD,,PO,,371,398,1
MMRF_2427,,First line of therapy,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,40,mg,,QD,,PO,,344,398,1
MMRF_2427,,Second Line Therapy (after,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,,10,mg,,Oth,day1-21,PO,,446,554,1
MMRF_2427,,Second Line Therapy (after,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,40,mg,,QD,,PO,,446,554,1
MMRF_2435,,First line of therapy,Induction,,Melphalan,,,,Adverse Event or co-morbidity,,14,mg,,QD,,PO,,1,102,1
MMRF_2435,,First line of therapy,Induction,,Prednisone,,,,Completed regimen,,105,mg,,QD,,PO,,1,221,1
MMRF_2435,Baseline,First line of therapy,Induction,,Bortezomib,,,,Investigator decision for other reasons,,1.3,mg/m^,,Oth,"D 1, 4, 8, 11, 22, 25, 29, 32",Other,Subcutaneos,1,32,1
MMRF_2435,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,Q w,,Other,Subcutaneos,43,218,1
MMRF_2435,,First line of therapy,Induction,,Melphalan,,,,Adverse Event or co-morbidity,,12,mg,,QD,,PO,,127,130,1
MMRF_2435,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,12,mg,,Q d,,PO,,218,221,1
MMRF_2435,,First line of therapy,Maintenance,,Dexamethasone,,,,Adverse Event or co-morbidity,,20,mg,,Q w,,PO,,260,705,1
MMRF_2488,,First line of therapy,Induction,,Dexamethasone,,,,Other,extraction progenitors for Auto-TPH,40,mg,,Oth,"D1-4, D9-12",PO,,1,90,1
MMRF_2488,Baseline,First line of therapy,Induction,,Bortezomib,,,,Other,extraction progenitors for Auto-TPH,1.3,mg/m^,,QD,,Other,Subcutaneos,1,90,1
MMRF_2488,,First line of therapy,Induction,,Lenalidomide,,,,Other,extraction progenitors for Auto-TPH,25,mg,,QD,,PO,,1,90,1
MMRF_2488,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,Other,sUBCUTANEOS,105,188,1
MMRF_2488,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,"D1-4, D8-11",PO,,105,188,1
MMRF_2488,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,105,188,1
MMRF_2488,,First line of therapy,Other,conditioning for auto-TPH,Other,Busulfan,,,Completed regimen,,3.2,mg/kg,,Q d,,IV,,243,245,1
MMRF_2488,,First line of therapy,Other,conditioning for auto-TPH,Melphalan,,,,Completed regimen,,140,mg/m^,,Q d,,IV,,246,246,1
MMRF_2488,,First line of therapy,Consolidation,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,Other,Subcutaneos,346,402,1
MMRF_2488,,First line of therapy,Consolidation,,Lenalidomide,,,,Completed regimen,,25,mg,,QD,,PO,,346,402,1
MMRF_2488,,First line of therapy,Consolidation,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,"D1-4, D8-11",PO,,346,402,1
MMRF_2488,,First line of therapy,Maintenance,,Lenalidomide,,,,Adverse Event or co-morbidity,,15,mg,,QD,,PO,,430,609,1
MMRF_2488,,First line of therapy,Maintenance,,Dexamethasone,,,,Adverse Event or co-morbidity,,20,mg,,Oth,days 1-4 and 9-12,PO,,430,609,1
MMRF_2488,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,15,mg,,QD,,PO,,700,,1
MMRF_2488,,First line of therapy,Maintenance,,Dexamethasone,,,Checked,,,20,mg,,Oth,"D1-4, 8-11",PO,,700,,1
MMRF_2490,Baseline,First line of therapy,Induction,,Bortezomib,,,,Other,dose changed,1.3,mg/m^,,QD,,IV SubQ,,1,53,1
MMRF_2490,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,days 1-4 and 8-11,PO,,1,53,1
MMRF_2490,,First line of therapy,Induction,,Bortezomib,,,,Disease progression/Relapse,,1,mg/m^,,Q w,,IV SubQ,,54,82,1
MMRF_2490,,First line of therapy,Induction,,Melphalan,,,,Disease progression/Relapse,,8,mg,,QD,,PO,,54,82,1
MMRF_2490,,Second Line Therapy (after,Induction,,Dexamethasone,,,,Disease progression/Relapse,,20,mg,,Q w,,PO,,91,146,1
MMRF_2490,,First line of therapy,Induction,,Prednisone,,,,Disease progression/Relapse,,60,mg/m^,,Q w,,PO,,54,82,1
MMRF_2490,,Second Line Therapy (after,Induction,,Lenalidomide,,,,Disease progression/Relapse,,10,mg,,QD,,PO,,91,146,1
MMRF_2490,,Second Line Therapy (after,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,40,mg,,Q w,,PO,,161,343,1
MMRF_2490,,Second Line Therapy (after,Induction,,Cyclophosphamide,,,,Adverse Event or co-morbidity,,1000,mg,,Oth,day 1 of each cycle,IV,,161,343,1
MMRF_2490,,Second Line Therapy (after,Induction,,Other,claritromicina,,,Adverse Event or co-morbidity,,500,mg,,Oth,BID during 21 days,PO,,161,343,1
MMRF_2490,,Second Line Therapy (after,Induction,,Thalidomide,,,,Adverse Event or co-morbidity,,50,mg,,Q d,,PO,,161,223,1
MMRF_2518,,First line of therapy,Induction,,Bortezomib,,,,Adverse Event or co-morbidity,,1.3,mg/m^,,Q w,,IV SubQ,,43,125,1
MMRF_2518,,First line of therapy,Induction,,Daratumumab,,,,Patient decision,,16,mg/kg,,QD,,IV,,43,188,1
MMRF_2518,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,42,1
MMRF_2518,,First line of therapy,Induction,,Melphalan,,,,Patient decision,,16,mg,,QD,,PO,,1,171,1
MMRF_2518,,First line of therapy,Induction,,Prednisone,,,,Patient decision,,105,mg,,QD,,PO,,1,171,1
MMRF_2518,,First line of therapy,Induction,,Daratumumab,,,,Completed regimen,,1168,mg,,QWK,,IV,,1,42,1
MMRF_2518,,First line of therapy,Induction,,Bortezomib,,,,Patient decision,,1,mg/m^,,Q w,,IV SubQ,,126,237,1
MMRF_2293,Baseline,First line of therapy,Induction,,Bortezomib,,,Checked,,,1.3,mg/m^,,QD,,IV SubQ,,1,,1
MMRF_2293,,First line of therapy,Induction,,Thalidomide,,,,Completed regimen,,200,mg,,Q d,,PO,,1,399,1
MMRF_2293,,First line of therapy,Induction,,Dexamethasone,,,Checked,,,40,mg,,Oth,"QD (D1-4, D 9-13)",PO,,1,,1
MMRF_2300,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,QD,,IV,,1,14,1
MMRF_2300,,First line of therapy,Induction,,Prednisone,,,,Other,EXITUS,100,mg,,QD,,PO,,24,66,1
MMRF_2300,Baseline,First line of therapy,Induction,,Bortezomib,,,,Other,EXITUS,1.3,mg/m^,,QD,,IV SubQ,,3,66,1
MMRF_2300,,First line of therapy,Induction,,Cyclophosphamide,,,,Other,EXITUS,1000,mg,,Oth,Q 3WK,IV,,42,66,1
MMRF_2313,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,"QD (D1-4, D 9-13)",PO,,1,340,1
MMRF_2313,,First line of therapy,Induction,,Thalidomide,,,,Completed regimen,,200,mg,,Q d,,PO,,8,358,1
MMRF_2313,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,340,1
MMRF_2313,,Second Line Therapy (after,Other,treatment at relapse while waiting for a definitive regimen,Bortezomib,,,,Completed regimen,,2.6,mg,,QD,,IV SubQ,,749,759,1
MMRF_2313,,Second Line Therapy (after,Other,treatment at relapse while waiting for a definitive regimen,Cyclophosphamide,,,,Completed regimen,,500,mg,,Oth,single dose,IV,,743,743,1
MMRF_2313,,Second Line Therapy (after,Other,treatment at relapse while waiting for a definitive regimen,Dexamethasone,,,,Completed regimen,,40,mg,,Q d,,IV,,743,746,1
MMRF_2313,,Second Line Therapy (after,Other,treatment at relapse,Carfilzomib,,,Checked,,,60,mg,,QD,,IV,,773,,1
MMRF_2313,,Second Line Therapy (after,Other,treatment at relapse,Lenalidomide,,,Checked,,,25,mg,,QD,,PO,,773,,1
MMRF_2313,,Second Line Therapy (after,Other,treatment at relapse,Dexamethasone,,,Checked,,,40,mg,,Oth,"D1, D8, CD15, D22",PO,,773,,1
MMRF_2314,Baseline,First line of therapy,Induction,,Bortezomib,,,,Other,EXITUS,1.3,mg/m^,,QD,,IV SubQ,,2,90,1
MMRF_2314,,First line of therapy,Induction,,Dexamethasone,,,,Other,EXITUS,40,mg,,QD,,IV,,1,90,1
MMRF_2314,,First line of therapy,Induction,,Thalidomide,,,,Other,EXITUS,50,mg,,Q d,,PO,,5,90,1
MMRF_2327,,First line of therapy,Induction,,Prednisone,,,,Lack of response,,100,mg,,QD,,PO,,2,204,1
MMRF_2327,Baseline,First line of therapy,Induction,,Bortezomib,,,,Lack of response,,1.3,mg/m^,,Oth,"QD (D1, D4, D8, D11, D22, D25, D29, D32)",IV SubQ,,1,204,1
MMRF_2327,,First line of therapy,Induction,,Melphalan,,,,Lack of response,,16,mg,,QD,,PO,,2,204,1
MMRF_2327,,First line of therapy,Unknown,,Cyclophosphamide,,,,Investigator decision for other reasons,,1000,mg,,Q d,,IV,,225,225,1
MMRF_2327,,First line of therapy,Unknown,,Dexamethasone,,,,Adverse Event or co-morbidity,,40,mg,,QD,,PO,,263,1108,1
MMRF_2327,,First line of therapy,Unknown,,Lenalidomide,,,,Adverse Event or co-morbidity,,25,mg,,QD,,PO,,263,1108,1
MMRF_2327,,First line of therapy,Unknown,,Lenalidomide,,,,Lack of response,,10,mg,,QD,,PO,,1140,1196,1
MMRF_2327,,First line of therapy,Unknown,,Dexamethasone,,,Checked,,,20,mg,,Q w,,PO,,1140,,1
MMRF_2327,,First line of therapy,Unknown,,Lenalidomide,,,Checked,,,25,mg,,QD,,PO,,1196,,1
MMRF_2364,,First line of therapy,Induction,,Dexamethasone,,,,Other,EXITUS,40,mg,,QD,,PO,,1,156,1
MMRF_2364,,First line of therapy,Induction,,Thalidomide,,,,Other,EXITUS,200,mg,,Q d,,PO,,1,156,1
MMRF_2364,Baseline,First line of therapy,Induction,,Bortezomib,,,,Other,EXITUS,2.6,mg,,QD,,IV SubQ,,1,156,1
MMRF_2452,Baseline,First line of therapy,Induction,,Bortezomib,,,Checked,,,2.3,mg,,QD,,IV SubQ,,1,,1
MMRF_2452,,First line of therapy,Induction,,Thalidomide,,,,Adverse Event or co-morbidity,,200,mg,,Q d,,PO,,1,294,1
MMRF_2452,,First line of therapy,Induction,,Dexamethasone,,,Checked,,,40,mg,,Oth,"QD (D1-4, D9-13)",PO,,1,,1
MMRF_2535,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,2,mg,,QD,,IV SubQ,,3,200,1
MMRF_2535,,First line of therapy,Induction,,Thalidomide,,,,Completed regimen,,200,mg,,Q d,,PO,,17,200,1
MMRF_2535,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,"D 1-4, D 5-9 Q 28D",PO,,1,200,1
MMRF_2535,,Second Line Therapy (after,Other,Second line therapy after first relapse,Vincristine,,,,Completed regimen,,2,mg,,Oth,Q10week,IV,,342,358,1
MMRF_2535,,Second Line Therapy (after,Other,Second line therapy after first relapse,Other,Carmustine,,,Completed regimen,,37,mg,,Oth,Q10 semanas,IV,,342,358,1
MMRF_2535,,Second Line Therapy (after,Other,Second line therapy after first relapse,Prednisone,,,,Completed regimen,,75,mg,,QD,,PO,,341,358,1
MMRF_2535,,Second Line Therapy (after,Other,Second line therapy after first relapse,Cyclophosphamide,,,,Completed regimen,,749,mg,,Oth,Q10week,IV,,342,358,1
MMRF_2535,,Second Line Therapy (after,Other,Second line therapy after first relapse,Melphalan,,,,Completed regimen,,20,mg,,QD,,PO,,341,358,1
MMRF_2535,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,200,mg/m^,,Oth,Single dose,IV,,212,212,1
MMRF_2572,,First line of therapy,Induction,,Prednisone,,,,Completed regimen,,100,mg,,QD,,PO,,1,376,1
MMRF_2572,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,2.3,mg,,Oth,"QD (D1, D4, D8, D11, D22, D25, D29, D32)",IV SubQ,,1,376,1
MMRF_2572,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,16,mg,,QD,,PO,,1,376,1
MMRF_2572,,Second Line Therapy (after,Other,second line after first progression,Cyclophosphamide,,,,Lack of response,,750,mg,,Oth,every 2 months,IV,,813,876,1
MMRF_2572,,Second Line Therapy (after,Other,second line after first progresssion,Bortezomib,,,,Lack of response,,2,mg,,Oth,Days 1 and 8,IV SubQ,,652,729,1
MMRF_2572,,Second Line Therapy (after,Other,second line after first progression,Cyclophosphamide,,,,Lack of response,,50,mg,,Q d,,PO,,652,715,1
MMRF_2572,,Third Line Therapy (followi,Other,second line after first progression,Lenalidomide,,,Checked,,,10,mg,,QD,,PO,,887,,1
MMRF_2572,,Third Line Therapy (followi,Other,second line after first progression,Dexamethasone,,,Checked,,,16,mg,,QWK,,PO,,887,,1
MMRF_2601,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,16,mg,,QD,,PO,,1,341,1
MMRF_2601,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,2.47,mg,,QD,,IV SubQ,,1,366,1
MMRF_2601,,First line of therapy,Induction,,Prednisone,,,,Completed regimen,,100,mg,,QD,,PO,,1,341,1
MMRF_2601,,Second Line Therapy (after,Other,treatmene at first relapse,Lenalidomide,,,Checked,,,25,mg,,QD,,PO,,575,,1
MMRF_2601,,Second Line Therapy (after,Other,treatmene at first relapse,Dexamethasone,,,Checked,,,40,mg,,Oth,"D1, D8, D15, D22",PO,,575,,1
MMRF_2613,,First line of therapy,Induction,,Melphalan,,,,Other,death,14,mg,,QD,,PO,,4,621,1
MMRF_2613,,First line of therapy,Induction,,Prednisone,,,,Completed regimen,,100,mg,,QD,,PO,,4,326,1
MMRF_2613,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,2.3,mg,,QD,,IV SubQ,,1,326,1
MMRF_2613,,Second Line Therapy (after,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,,40,mg,,QD,,PO,,344,348,1
MMRF_2613,,Second Line Therapy (after,Induction,,Lenalidomide,,,,Lack of response,,25,mg,,QD,,PO,,344,534,1
MMRF_2613,,Third Line Therapy (followi,Other,treatment at relapse,Carfilzomib,,,,Other,death,44,mg,,QD,,IV,,582,621,1
MMRF_2613,,Third Line Therapy (followi,Other,treatment at relapse,Lenalidomide,,,,Other,death,25,mg,,QD,,PO,,582,621,1
MMRF_2613,,Third Line Therapy (followi,Other,treatment at relapse,Dexamethasone,,,,Other,death,20,mg,,QD,,PO,,582,621,1
MMRF_2613,,Third Line Therapy (followi,Other,treatmene at second relapse,Cyclophosphamide,,,,Lack of response,,1000,mg,,Oth,D1 every 28 days,IV,,536,575,1
MMRF_2016,,First line of therapy,Unknown,,Melphalan,,,,Adverse Event or co-morbidity,,9,mg/m^,,QD,,PO,,1,107,1
MMRF_2016,,First line of therapy,Unknown,,Prednisone,,,,Adverse Event or co-morbidity,,120,mg,,QD,,PO,,1,107,1
MMRF_2016,Baseline,First line of therapy,Unknown,,Bortezomib,,,,Adverse Event or co-morbidity,,1.3,mg/m^,,QD,,Other,SC,1,107,1
MMRF_2016,,First line of therapy,Induction,,Prednisone,,,Checked,,,10,mg,,Q d,,PO,,124,,1
MMRF_2016,,First line of therapy,Induction,,Lenalidomide,,,Checked,,,25,mg,,QD,,PO,,124,,1
MMRF_2268,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,85,1
MMRF_2268,,First line of therapy,Induction,,Prednisone,,,,Completed regimen,,60,mg/m^,,QD,,PO,,1,405,1
MMRF_2268,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,9,mg/m^,,QD,,PO,,1,405,1
MMRF_2268,,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,92,405,1
MMRF_2268,,Second Line Therapy (after,Induction,,Lenalidomide,,,Checked,,,25,mg,,Q d,,PO,,907,,1
MMRF_2268,,Second Line Therapy (after,Induction,,Dexamethasone,,,Checked,,,20,mg,,QWK,,PO,,907,,1
MMRF_2268,,Second Line Therapy (after,Induction,,Carfilzomib,,,,Adverse Event or co-morbidity,,27,mg/m^,,Oth,"days 1,2, 8,9, 15,16",IV,,907,1184,1
MMRF_2305,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,131,1
MMRF_2305,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,900,mg/m^,,Oth,every three weeks,IV,,1,131,1
MMRF_2305,,First line of therapy,Induction,,Prednisone,,,,Lack of response,,15,mg,,Q d,,PO,,1,131,1
MMRF_2305,,Second Line Therapy (after,Induction,,Lenalidomide,,,Checked,,,25,mg,,QD,,PO,,862,,1
MMRF_2305,,Second Line Therapy (after,Induction,,Dexamethasone,,,Checked,,,40,mg,,Q w,,PO,,862,,1
MMRF_2305,,Second Line Therapy (after,Induction,,Carfilzomib,,,,Adverse Event or co-morbidity,,27,mg/m^,,QD,,IV,,873,889,1
MMRF_2421,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.3,mg/m^,,QD,,IV SubQ,,1,98,1
MMRF_2421,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,40,mg,,Oth,"QD1,2,4,5,8,9,11,12",PO,,1,98,1
MMRF_2421,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,900,mg/m^,,Oth,EVERY 3 WEEKS,IV,,1,98,1
MMRF_2444,Baseline,First line of therapy,Induction,,Bortezomib,,,,Other,Paient died 23.05.15 at 00:05H,1.3,mg/m^,,QD,,IV SubQ,,1,75,1
MMRF_2444,,First line of therapy,Induction,,Melphalan,,,,Adverse Event or co-morbidity,,9,mg/m^,,QD,,PO,,1,75,1
MMRF_2444,,First line of therapy,Induction,,Prednisone,,,,Adverse Event or co-morbidity,,60,mg/m^,,QD,,PO,,1,75,1
MMRF_2558,Baseline,First line of therapy,Induction,,Bortezomib,,,,Patient decision,,1.3,mg/m^,,QD,,IV SubQ,,1,113,1
MMRF_2558,,First line of therapy,Induction,,Melphalan,,,,Patient decision,,9,mg/m^,,Oth,"D1,D9",PO,,1,113,1
MMRF_2558,,First line of therapy,Induction,,Prednisone,,,,Patient decision,,60,mg/m^,,Oth,"D1, D9",PO,,1,113,1
MMRF_2195,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,2.4,mg,,QD,,Other,Subcutaneous,1,405,1
MMRF_2195,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,16,mg,,QD,,PO,,1,380,1
MMRF_2195,,First line of therapy,Induction,,Prednisone,,,,Completed regimen,,75,mg,,QD,,PO,,1,380,1
MMRF_2195,,Second Line Therapy (after,Induction,,Lenalidomide,,,Checked,,,25,mg,,QD,,PO,,741,,1
MMRF_2195,,Second Line Therapy (after,Induction,,Dexamethasone,,,Checked,,,40,mg,,Q w,,PO,,741,,1
MMRF_2317,,First line of therapy,Induction,,Prednisone,,,,Completed regimen,,75,mg,,QD,,PO,,1,319,1
MMRF_2317,Baseline,First line of therapy,Induction,,Bortezomib,,,,Completed regimen,,1.8,mg,,QD,,Other,SUBCUTANEOUS,1,338,1
MMRF_2317,,First line of therapy,Induction,,Melphalan,,,,Completed regimen,,16,mg,,QD,,PO,,1,288,1
MMRF_2317,,Second Line Therapy (after,Induction,,Dexamethasone,,,Checked,,,20,mg,,Q w,,PO,,610,,1
MMRF_2317,,Second Line Therapy (after,Induction,,Lenalidomide,,,Checked,,,15,mg,,QD,,PO,,610,,1
MMRF_2426,,First line of therapy,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,Fatigue,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,64,1
MMRF_2426,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,125,1
MMRF_2426,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,1,125,1
MMRF_2426,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,10,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,64,125,1
MMRF_2426,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,125,135,1
MMRF_2426,,First line of therapy,Other,In preparation for stem cell infusion,Melphalan,,,,Completed regimen,,344,mg/m^,,Oth,prior to stem cell infusion,IV,,169,169,1
MMRF_2426,,First line of therapy,Consolidation,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,262,443,1
MMRF_2426,,First line of therapy,Consolidation,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,262,443,1
MMRF_2426,,First line of therapy,Consolidation,,Dexamethasone,,,,Completed regimen,,10,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,262,443,1
MMRF_2426,,First line of therapy,Maintenance,,Lenalidomide,,,,Completed regimen,,10,mg,,Oth,Days 1-21 per cycle,PO,,443,583,1
MMRF_2583,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,116,1
MMRF_2583,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,1,116,1
MMRF_2583,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,116,1
MMRF_2583,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,116,128,1
MMRF_2583,,First line of therapy,Other,In preparation for stem cell infusion,Melphalan,,,,Completed regimen,,292,mg/m^,,Oth,prior to stem cell infusion,IV,,157,157,1
MMRF_2583,,First line of therapy,Consolidation,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,267,414,1
MMRF_2583,,First line of therapy,Consolidation,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,267,414,1
MMRF_2583,,First line of therapy,Consolidation,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,267,414,1
MMRF_2583,,First line of therapy,Maintenance,,Lenalidomide,,,,Completed regimen,,10,mg,,Oth,Days 1-21 per cycle,PO,,414,526,1
MMRF_2584,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,118,1
MMRF_2584,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,"Days 1, 8, 15 per cycle",PO,,1,118,1
MMRF_2584,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,118,1
MMRF_2584,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,118,129,1
MMRF_2584,,First line of therapy,Other,In preparation for stem cell infusion,Melphalan,,,,Completed regimen,,284,mg/m^,,Oth,prior to stem cell infusion,IV,,153,153,1
MMRF_2584,,First line of therapy,Consolidation,,Dexamethasone,,,,Adverse Event or co-morbidity,Respiratory tox,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,267,267,1
MMRF_2584,,First line of therapy,Consolidation,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,267,422,1
MMRF_2584,,First line of therapy,Consolidation,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,"Days 1, 8, 15 per cycle",PO,,267,422,1
MMRF_2584,,First line of therapy,Consolidation,,Dexamethasone,,,,Completed regimen,,10,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,267,422,1
MMRF_2584,,First line of therapy,Maintenance,,Lenalidomide,,,,Completed regimen,,10,mg,,Oth,Days 1-21 per cycle,PO,,422,534,1
MMRF_2604,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,133,1
MMRF_2604,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,"Days 1, 8, 15 per cycle",PO,,1,133,1
MMRF_2604,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,133,1
MMRF_2604,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,133,143,1
MMRF_2604,,First line of therapy,Other,In preparation for stem cell infusion,Melphalan,,,,Completed regimen,,390,mg/m^,,Oth,prior to stem cell infusion,IV,,203,203,1
MMRF_2604,,First line of therapy,Consolidation,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,311,437,1
MMRF_2604,,First line of therapy,Consolidation,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,"Days 1, 8, 15 per cycle",PO,,311,437,1
MMRF_2604,,First line of therapy,Consolidation,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,311,437,1
MMRF_2604,,First line of therapy,Maintenance,,Carfilzomib,,,Checked,,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,437,,1
MMRF_2604,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,10,mg,,Oth,Days 1-21 per cycle,PO,,437,,1
MMRF_2609,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,114,1
MMRF_2609,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,1,114,1
MMRF_2609,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,114,1
MMRF_2609,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,114,125,1
MMRF_2609,,First line of therapy,Consolidation,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,169,407,1
MMRF_2609,,First line of therapy,Consolidation,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,169,407,1
MMRF_2609,,First line of therapy,Consolidation,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,169,407,1
MMRF_2609,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,10,mg,,Oth,Days 1-21 per cycle,PO,,407,,1
MMRF_2624,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,114,1
MMRF_2624,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,"Days 1, 8, 15 per cycle",PO,,1,114,1
MMRF_2624,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,114,1
MMRF_2624,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,114,125,1
MMRF_2624,,First line of therapy,Other,In preparation for stem cell infusion,Melphalan,,,,Completed regimen,,320,mg/m^,,Oth,prior to stem cell infusion,IV,,161,161,1
MMRF_2624,,First line of therapy,Consolidation,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,274,405,1
MMRF_2624,,First line of therapy,Consolidation,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,"Days 1, 8, 15 per cycle",PO,,274,405,1
MMRF_2624,,First line of therapy,Consolidation,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,274,405,1
MMRF_2624,,First line of therapy,Maintenance,,Carfilzomib,,,Checked,,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,405,,1
MMRF_2624,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,10,mg,,Oth,Days 1-21 per cycle,PO,,405,,1
MMRF_2626,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,130,1
MMRF_2626,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,1,130,1
MMRF_2626,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,130,1
MMRF_2626,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,130,142,1
MMRF_2626,,First line of therapy,Consolidation,,Carfilzomib,,,Checked,,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,218,,1
MMRF_2626,,First line of therapy,Consolidation,,Lenalidomide,,,Checked,,,25,mg,,Oth,Days 1-21 per cycle,PO,,218,,1
MMRF_2626,,First line of therapy,Consolidation,,Dexamethasone,,,Checked,,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,218,,1
MMRF_2628,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,114,1
MMRF_2628,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,1,114,1
MMRF_2628,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,114,1
MMRF_2628,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,114,127,1
MMRF_2628,,First line of therapy,Other,In preparation for stem cell infusion,Melphalan,,,,Completed regimen,,390,mg/m^,,Oth,prior to stem cell infusion,IV,,157,157,1
MMRF_2628,,First line of therapy,Consolidation,,Carfilzomib,,,Checked,,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,253,,1
MMRF_2628,,First line of therapy,Consolidation,,Lenalidomide,,,Checked,,,25,mg,,Oth,Days 1-21 per cycle,PO,,253,,1
MMRF_2628,,First line of therapy,Consolidation,,Dexamethasone,,,Checked,,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,253,,1
MMRF_2630,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,139,1
MMRF_2630,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,1,139,1
MMRF_2630,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,139,1
MMRF_2630,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,139,151,1
MMRF_2630,,First line of therapy,Other,In preparation for stem cell infusion,Melphalan,,,,Completed regimen,,380,mg/m^,,Oth,prior to stem cell infusion,IV,,198,198,1
MMRF_2630,,First line of therapy,Consolidation,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,296,429,1
MMRF_2630,,First line of therapy,Consolidation,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,296,429,1
MMRF_2630,,First line of therapy,Consolidation,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,296,429,1
MMRF_2630,,First line of therapy,Maintenance,,Carfilzomib,,,Checked,,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,429,,1
MMRF_2630,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,10,mg,,Oth,Days 1-21 per cycle,PO,,429,,1
MMRF_2631,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,121,1
MMRF_2631,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,"Days 1, 8, 15 per cycle",PO,,1,121,1
MMRF_2631,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,121,1
MMRF_2631,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,121,132,1
MMRF_2631,,First line of therapy,Other,In preparation for stem cell infusion,Melphalan,,,,Completed regimen,,390,mg/m^,,Oth,prior to stem cell infusion,IV,,157,157,1
MMRF_2631,,First line of therapy,Consolidation,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,274,393,1
MMRF_2631,,First line of therapy,Consolidation,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,"Days 1, 8, 15 per cycle",PO,,274,393,1
MMRF_2631,,First line of therapy,Consolidation,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,274,393,1
MMRF_2631,,First line of therapy,Maintenance,,Carfilzomib,,,Checked,,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,393,,1
MMRF_2631,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,10,mg,,Oth,Days 1-21 per cycle,PO,,393,,1
MMRF_2634,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,117,1
MMRF_2634,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,1,117,1
MMRF_2634,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,117,1
MMRF_2634,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,117,129,1
MMRF_2634,,First line of therapy,Other,In preparation for stem cell infusion,Melphalan,,,,Completed regimen,,386,mg/m^,,Oth,prior to stem cell infusion,IV,,170,170,1
MMRF_2634,,First line of therapy,Consolidation,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,263,382,1
MMRF_2634,,First line of therapy,Consolidation,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,263,382,1
MMRF_2634,,First line of therapy,Consolidation,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,263,382,1
MMRF_2634,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,10,mg,,Oth,Days 1-21 per cycle,PO,,382,,1
MMRF_2635,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,123,1
MMRF_2635,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,1,123,1
MMRF_2635,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,123,1
MMRF_2635,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,123,134,1
MMRF_2635,,First line of therapy,Other,In preparation for stem cell infusion,Melphalan,,,,Completed regimen,,366,mg/m^,,Oth,prior to stem cell infusion,IV,,163,163,1
MMRF_2635,,First line of therapy,Consolidation,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,275,385,1
MMRF_2635,,First line of therapy,Consolidation,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,275,385,1
MMRF_2635,,First line of therapy,Consolidation,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,275,385,1
MMRF_2635,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,10,mg,,Oth,Days 1-21 per cycle,PO,,385,,1
MMRF_2636,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,113,1
MMRF_2636,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,"Days 1, 8, 15 per cycle",PO,,1,113,1
MMRF_2636,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,113,1
MMRF_2636,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,113,125,1
MMRF_2636,,First line of therapy,Other,In preparation for stem cell infusion,Melphalan,,,,Completed regimen,,400,mg/m^,,Oth,prior to stem cell infusion,IV,,158,158,1
MMRF_2636,,First line of therapy,Consolidation,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,259,371,1
MMRF_2636,,First line of therapy,Consolidation,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,"Days 1, 8, 15 per cycle",PO,,259,371,1
MMRF_2636,,First line of therapy,Consolidation,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,259,371,1
MMRF_2637,,First line of therapy,Induction,,Carfilzomib,,,,Adverse Event or co-morbidity,Hepatic tox,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,30,1
MMRF_2637,,First line of therapy,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,Hepatic tox,25,mg,,Oth,Days 1-21 per cycle,PO,,1,30,1
MMRF_2637,,First line of therapy,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,Hepatic tox,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,30,1
MMRF_2637,,First line of therapy,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,Hepatic tox,15,mg,,Oth,Days 1-21 per cycle,PO,,30,71,1
MMRF_2637,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,20,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,30,144,1
MMRF_2637,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,4,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,30,144,1
MMRF_2637,,First line of therapy,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,Hepatic tox,10,mg,,Oth,Days 1-21 per cycle,PO,,71,106,1
MMRF_2637,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,5,mg,,Oth,Days 1-21 per cycle,PO,,106,144,1
MMRF_2637,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,144,154,1
MMRF_2637,,First line of therapy,Other,In preparation for stem cell infusion,Melphalan,,,,Completed regimen,,334,mg/m^,,Oth,prior to stem cell infusion,IV,,185,185,1
MMRF_2637,,First line of therapy,Consolidation,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,281,393,1
MMRF_2637,,First line of therapy,Consolidation,,Lenalidomide,,,,Completed regimen,,5,mg,,Oth,Days 1-21 per cycle,PO,,281,393,1
MMRF_2637,,First line of therapy,Consolidation,,Dexamethasone,,,,Completed regimen,,4,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,281,393,1
MMRF_2638,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,120,1
MMRF_2638,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,"Days 1, 8, 15 per cycle",PO,,1,120,1
MMRF_2638,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,120,1
MMRF_2638,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,120,132,1
MMRF_2638,,First line of therapy,Other,In preparation for stem cell infusion,Melphalan,,,,Completed regimen,,300,mg/m^,,Oth,prior to stem cell infusion,IV,,163,163,1
MMRF_2638,,First line of therapy,Consolidation,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,260,386,1
MMRF_2638,,First line of therapy,Consolidation,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,"Days 1, 8, 15 per cycle",PO,,260,386,1
MMRF_2638,,First line of therapy,Consolidation,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,260,386,1
MMRF_2638,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,10,mg,,Oth,Days 1-21 per cycle,PO,,386,,1
MMRF_2639,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,146,1
MMRF_2639,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,1,146,1
MMRF_2639,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,146,1
MMRF_2639,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,146,155,1
MMRF_2639,,First line of therapy,Consolidation,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,203,441,1
MMRF_2639,,First line of therapy,Consolidation,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,203,441,1
MMRF_2639,,First line of therapy,Consolidation,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,203,441,1
MMRF_2640,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,157,1
MMRF_2640,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,"Days 1, 8, 15 per cycle",PO,,1,157,1
MMRF_2640,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,157,1
MMRF_2640,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,157,170,1
MMRF_2640,,First line of therapy,Other,In preparation for stem cell infusion,Melphalan,,,,Completed regimen,,370,mg/m^,,Oth,prior to stem cell infusion,IV,,201,201,1
MMRF_2640,,First line of therapy,Consolidation,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,302,421,1
MMRF_2640,,First line of therapy,Consolidation,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,"Days 1, 8, 15 per cycle",PO,,302,421,1
MMRF_2640,,First line of therapy,Consolidation,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,302,421,1
MMRF_2640,,First line of therapy,Maintenance,,Carfilzomib,,,Checked,,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,421,,1
MMRF_2640,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,10,mg,,Oth,Days 1-21 per cycle,PO,,421,,1
MMRF_2641,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,128,1
MMRF_2641,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,1,128,1
MMRF_2641,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,128,1
MMRF_2641,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,128,140,1
MMRF_2641,,First line of therapy,Consolidation,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,232,428,1
MMRF_2641,,First line of therapy,Consolidation,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,232,428,1
MMRF_2641,,First line of therapy,Consolidation,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,232,428,1
MMRF_2642,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,122,1
MMRF_2642,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,1,122,1
MMRF_2642,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,122,1
MMRF_2642,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,122,171,1
MMRF_2642,,First line of therapy,Consolidation,,Carfilzomib,,,,Adverse Event or co-morbidity,asthenia,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,196,315,1
MMRF_2642,,First line of therapy,Consolidation,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,196,427,1
MMRF_2642,,First line of therapy,Consolidation,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,196,427,1
MMRF_2642,,First line of therapy,Consolidation,,Carfilzomib,,,,Completed regimen,,27,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,315,427,1
MMRF_2643,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,117,1
MMRF_2643,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,"Days 1, 8, 15 per cycle",PO,,1,117,1
MMRF_2643,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,117,1
MMRF_2643,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,117,128,1
MMRF_2643,,First line of therapy,Other,In preparation for stem cell infusion,Melphalan,,,,Completed regimen,,380,mg/m^,,Oth,prior to stem cell infusion,IV,,156,156,1
MMRF_2643,,First line of therapy,Consolidation,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,253,365,1
MMRF_2643,,First line of therapy,Consolidation,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,"Days 1, 8, 15 per cycle",PO,,253,365,1
MMRF_2643,,First line of therapy,Consolidation,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,253,365,1
MMRF_2647,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,138,1
MMRF_2647,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,1,138,1
MMRF_2647,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,138,1
MMRF_2647,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,138,150,1
MMRF_2647,,First line of therapy,Other,In preparation for stem cell infusion,Melphalan,,,,Completed regimen,,370,mg/m^,,Oth,prior to stem cell infusion,IV,,198,198,1
MMRF_2647,,First line of therapy,Consolidation,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,309,421,1
MMRF_2647,,First line of therapy,Consolidation,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,309,421,1
MMRF_2647,,First line of therapy,Consolidation,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,309,421,1
MMRF_2644,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,130,1
MMRF_2644,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,"Days 1, 8, 15 per cycle",PO,,1,130,1
MMRF_2644,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,130,1
MMRF_2644,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,130,140,1
MMRF_2644,,First line of therapy,Other,In preparation for stem cell infusion,Melphalan,,,,Completed regimen,,350,mg/m^,,Oth,prior to stem cell infusion,IV,,162,162,1
MMRF_2644,,First line of therapy,Consolidation,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,260,384,1
MMRF_2644,,First line of therapy,Consolidation,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,"Days 1, 8, 15 per cycle",PO,,260,384,1
MMRF_2644,,First line of therapy,Consolidation,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,260,384,1
MMRF_2644,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,10,mg,,Oth,Days 1-21 per cycle,PO,,384,,1
MMRF_2646,,First line of therapy,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,Hyperglicemia,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,42,1
MMRF_2646,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,127,1
MMRF_2646,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,1,127,1
MMRF_2646,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,15,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,42,127,1
MMRF_2646,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,127,138,1
MMRF_2646,,First line of therapy,Consolidation,,Carfilzomib,,,Checked,,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,154,,1
MMRF_2646,,First line of therapy,Consolidation,,Lenalidomide,,,Checked,,,25,mg,,Oth,Days 1-21 per cycle,PO,,154,,1
MMRF_2646,,First line of therapy,Consolidation,,Dexamethasone,,,Checked,,,10,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,154,,1
MMRF_2646,,First line of therapy,Consolidation,,Dexamethasone,,,,Adverse Event or co-morbidity,Investigations and metabolism disorders,15,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,154,154,1
MMRF_2648,,First line of therapy,Induction,,Carfilzomib,,,,Adverse Event or co-morbidity,GGT increased,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,50,1
MMRF_2648,,First line of therapy,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,GGT increased,25,mg,,Oth,Days 1-21 per cycle,PO,,1,78,1
MMRF_2648,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,144,1
MMRF_2648,,First line of therapy,Induction,,Carfilzomib,,,,Adverse Event or co-morbidity,GGT increased,27,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,50,78,1
MMRF_2648,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,20,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,78,144,1
MMRF_2648,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,15,mg,,Oth,Days 1-21 per cycle,PO,,78,144,1
MMRF_2648,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,144,155,1
MMRF_2648,,First line of therapy,Consolidation,,Carfilzomib,,,,Completed regimen,,20,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,183,423,1
MMRF_2648,,First line of therapy,Consolidation,,Lenalidomide,,,,Completed regimen,,15,mg,,Oth,Days 1-21 per cycle,PO,,183,423,1
MMRF_2648,,First line of therapy,Consolidation,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,183,423,1
MMRF_2648,,First line of therapy,Maintenance,,Carfilzomib,,,Checked,,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,423,,1
MMRF_2648,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,10,mg,,Oth,Days 1-21 per cycle,PO,,423,,1
MMRF_2650,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,149,1
MMRF_2650,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,1,149,1
MMRF_2650,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,149,1
MMRF_2650,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,149,163,1
MMRF_2650,,First line of therapy,Other,In preparation for stem cell infusion,Melphalan,,,,Completed regimen,,340,mg/m^,,Oth,prior to stem cell infusion,IV,,188,188,1
MMRF_2651,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,123,1
MMRF_2651,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,"Days 1, 8, 15 per cycle",PO,,1,123,1
MMRF_2651,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,123,1
MMRF_2651,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,123,136,1
MMRF_2651,,First line of therapy,Other,In preparation for stem cell infusion,Melphalan,,,,Completed regimen,,368,mg/m^,,Oth,prior to stem cell infusion,IV,,169,169,1
MMRF_2651,,First line of therapy,Consolidation,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,267,414,1
MMRF_2651,,First line of therapy,Consolidation,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,"Days 1, 8, 15 per cycle",PO,,267,414,1
MMRF_2651,,First line of therapy,Consolidation,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,267,414,1
MMRF_2651,,First line of therapy,Maintenance,,Carfilzomib,,,Checked,,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,414,,1
MMRF_2651,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,10,mg,,Oth,Days 1-21 per cycle,PO,,414,,1
MMRF_2652,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,117,1
MMRF_2652,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,1,117,1
MMRF_2652,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,117,1
MMRF_2652,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,117,150,1
MMRF_2652,,First line of therapy,Consolidation,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,157,415,1
MMRF_2652,,First line of therapy,Consolidation,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,157,415,1
MMRF_2652,,First line of therapy,Consolidation,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,157,415,1
MMRF_2652,,First line of therapy,Maintenance,,Carfilzomib,,,Checked,,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,415,,1
MMRF_2652,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,10,mg,,Oth,Days 1-21 per cycle,PO,,415,,1
MMRF_2653,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,130,1
MMRF_2653,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,1,130,1
MMRF_2653,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,130,1
MMRF_2653,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,130,141,1
MMRF_2653,,First line of therapy,Consolidation,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,183,456,1
MMRF_2653,,First line of therapy,Consolidation,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,183,456,1
MMRF_2653,,First line of therapy,Consolidation,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,183,456,1
MMRF_2654,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,116,1
MMRF_2654,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,"Days 1, 8, 15 per cycle",PO,,1,116,1
MMRF_2654,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,116,1
MMRF_2654,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,116,126,1
MMRF_2654,,First line of therapy,Other,In preparation for stem cell infusion,Melphalan,,,,Completed regimen,,320,mg/m^,,Oth,prior to stem cell infusion,IV,,175,175,1
MMRF_2655,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,150,1
MMRF_2655,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,"Days 1, 8, 15 per cycle",PO,,1,150,1
MMRF_2655,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,150,1
MMRF_2655,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,150,162,1
MMRF_2655,,First line of therapy,Other,In preparation for stem cell infusion,Melphalan,,,,Completed regimen,,315,mg/m^,,Oth,prior to stem cell infusion,IV,,183,183,1
MMRF_2655,,First line of therapy,Consolidation,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,300,447,1
MMRF_2655,,First line of therapy,Consolidation,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,"Days 1, 8, 15 per cycle",PO,,300,447,1
MMRF_2655,,First line of therapy,Consolidation,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,300,447,1
MMRF_2659,,First line of therapy,Induction,,Carfilzomib,,,Checked,,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,,1
MMRF_2659,,First line of therapy,Induction,,Lenalidomide,,,Checked,,,25,mg,,Oth,Days 1-21 per cycle,PO,,1,,1
MMRF_2659,,First line of therapy,Induction,,Dexamethasone,,,Checked,,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,,1
MMRF_2660,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,123,1
MMRF_2660,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,1,123,1
MMRF_2660,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,123,1
MMRF_2660,,First line of therapy,Consolidation,,Carfilzomib,,,Checked,,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,30,,1
MMRF_2660,,First line of therapy,Consolidation,,Lenalidomide,,,Checked,,,25,mg,,Oth,Days 1-21 per cycle,PO,,30,,1
MMRF_2660,,First line of therapy,Consolidation,,Dexamethasone,,,Checked,,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,30,,1
MMRF_2660,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,123,134,1
MMRF_2660,,First line of therapy,Other,In preparation for stem cell infusion,Melphalan,,,,Completed regimen,,400,mg/m^,,Oth,prior to stem cell infusion,IV,,162,162,1
MMRF_2664,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,138,1
MMRF_2664,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,1,138,1
MMRF_2664,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,138,1
MMRF_2664,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,138,152,1
MMRF_2664,,First line of therapy,Other,In preparation for stem cell infusion,Melphalan,,,,Completed regimen,,360,mg/m^,,Oth,prior to stem cell infusion,IV,,183,183,1
MMRF_2664,,First line of therapy,Consolidation,,Carfilzomib,,,Checked,,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,276,,1
MMRF_2664,,First line of therapy,Consolidation,,Lenalidomide,,,Checked,,,25,mg,,Oth,Days 1-21 per cycle,PO,,276,,1
MMRF_2664,,First line of therapy,Consolidation,,Dexamethasone,,,Checked,,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,276,,1
MMRF_2665,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,115,1
MMRF_2665,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,"Days 1, 8, 15 per cycle",PO,,1,115,1
MMRF_2665,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,115,1
MMRF_2665,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,115,126,1
MMRF_2665,,First line of therapy,Other,In preparation for stem cell infusion,Melphalan,,,,Completed regimen,,400,mg/m^,,Oth,prior to stem cell infusion,IV,,168,168,1
MMRF_2665,,First line of therapy,Consolidation,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,223,344,1
MMRF_2665,,First line of therapy,Consolidation,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,"Days 1, 8, 15 per cycle",PO,,223,344,1
MMRF_2665,,First line of therapy,Consolidation,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,223,344,1
MMRF_2665,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,10,mg,,Oth,Days 1-21 per cycle,PO,,344,,1
MMRF_2667,,First line of therapy,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,Costitutional Symptoms (Insomnia - Medical History,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,1,1
MMRF_2667,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,122,1
MMRF_2667,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,1,122,1
MMRF_2667,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,10,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,122,1
MMRF_2667,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,122,131,1
MMRF_2667,,First line of therapy,Other,In preparation for stem cell infusion,Melphalan,,,,Completed regimen,,320,mg/m^,,Oth,prior to stem cell infusion,IV,,162,162,1
MMRF_2667,,First line of therapy,Consolidation,,Dexamethasone,,,,Adverse Event or co-morbidity,Gastrintestinal tox,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,247,275,1
MMRF_2667,,First line of therapy,Consolidation,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,247,366,1
MMRF_2667,,First line of therapy,Consolidation,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,247,366,1
MMRF_2667,,First line of therapy,Consolidation,,Dexamethasone,,,,Completed regimen,,10,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,275,366,1
MMRF_2667,,First line of therapy,Maintenance,,Lenalidomide,,,Checked,,,10,mg,,Oth,Days 1-21 per cycle,PO,,366,,1
MMRF_2666,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,117,1
MMRF_2666,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,"Days 1, 8, 15 per cycle",PO,,1,117,1
MMRF_2666,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,117,1
MMRF_2666,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,117,128,1
MMRF_2666,,First line of therapy,Other,In preparation for stem cell infusion,Melphalan,,,,Completed regimen,,388,mg/m^,,Oth,prior to stem cell infusion,IV,,156,156,1
MMRF_2669,,First line of therapy,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,Rash maculo-papular,25,mg,,Oth,Days 1-21 per cycle,PO,,1,62,1
MMRF_2669,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,128,1
MMRF_2669,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,128,1
MMRF_2669,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,15,mg,,Oth,Days 1-21 per cycle,PO,,62,128,1
MMRF_2669,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,128,140,1
MMRF_2669,,First line of therapy,Consolidation,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,230,342,1
MMRF_2669,,First line of therapy,Consolidation,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,230,342,1
MMRF_2669,,First line of therapy,Consolidation,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,230,342,1
MMRF_2670,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,124,1
MMRF_2670,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,1,124,1
MMRF_2670,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,124,1
MMRF_2670,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,124,134,1
MMRF_2670,,First line of therapy,Consolidation,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,169,386,1
MMRF_2670,,First line of therapy,Consolidation,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,169,386,1
MMRF_2670,,First line of therapy,Consolidation,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,169,386,1
MMRF_2671,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,160,1
MMRF_2671,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,1,160,1
MMRF_2671,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,160,1
MMRF_2671,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,160,173,1
MMRF_2671,,First line of therapy,Other,In preparation for stem cell infusion,Melphalan,,,,Completed regimen,,200,mg/m^,,Oth,prior to stem cell infusion,IV,,197,197,1
MMRF_2671,,First line of therapy,Consolidation,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,310,436,1
MMRF_2671,,First line of therapy,Consolidation,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,310,436,1
MMRF_2671,,First line of therapy,Consolidation,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,310,436,1
MMRF_2675,,First line of therapy,Induction,,Carfilzomib,,,Checked,,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,,1
MMRF_2675,,First line of therapy,Induction,,Dexamethasone,,,Checked,,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,,1
MMRF_2675,,First line of therapy,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,Atrial fibrillation,25,mg,,Oth,Days 1-21 per cycle,PO,,1,29,1
MMRF_2675,,First line of therapy,Induction,,Lenalidomide,,,Checked,,,15,mg,,Oth,Days 1-21 per cycle,PO,,29,,1
MMRF_2676,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,131,1
MMRF_2676,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,"Days 1, 8, 15 per cycle",PO,,1,131,1
MMRF_2676,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,131,1
MMRF_2676,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,131,142,1
MMRF_2676,,First line of therapy,Other,In preparation for stem cell infusion,Melphalan,,,,Completed regimen,,360,mg/m^,,Oth,prior to stem cell infusion,IV,,178,178,1
MMRF_2676,,First line of therapy,Consolidation,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,269,451,1
MMRF_2676,,First line of therapy,Consolidation,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,"Days 1, 8, 15 per cycle",PO,,269,451,1
MMRF_2676,,First line of therapy,Consolidation,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,269,451,1
MMRF_2677,,First line of therapy,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,Creatinine increase,25,mg,,Oth,Days 1-21 per cycle,PO,,1,34,1
MMRF_2677,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,123,1
MMRF_2677,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,123,1
MMRF_2677,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,10,mg,,Oth,Days 1-21 per cycle,PO,,34,123,1
MMRF_2677,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,123,135,1
MMRF_2677,,First line of therapy,Consolidation,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,170,447,1
MMRF_2677,,First line of therapy,Consolidation,,Lenalidomide,,,,Completed regimen,,10,mg,,Oth,Days 1-21 per cycle,PO,,170,447,1
MMRF_2677,,First line of therapy,Consolidation,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,170,447,1
MMRF_2678,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,117,1
MMRF_2678,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,"Days 1, 8, 15 per cycle",PO,,1,117,1
MMRF_2678,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,117,1
MMRF_2678,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,117,127,1
MMRF_2678,,First line of therapy,Other,In preparation for stem cell infusion,Melphalan,,,,Completed regimen,,292,mg/m^,,Oth,prior to stem cell infusion,IV,,151,151,1
MMRF_2678,,First line of therapy,Consolidation,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,262,381,1
MMRF_2678,,First line of therapy,Consolidation,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,"Days 1, 8, 15 per cycle",PO,,262,381,1
MMRF_2678,,First line of therapy,Consolidation,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,262,381,1
MMRF_2679,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,116,1
MMRF_2679,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,1,116,1
MMRF_2679,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,116,1
MMRF_2679,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,116,127,1
MMRF_2679,,First line of therapy,Other,In preparation for stem cell infusion,Melphalan,,,,Completed regimen,,350,mg/m^,,Oth,prior to stem cell infusion,IV,,149,149,1
MMRF_2679,,First line of therapy,Consolidation,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,246,372,1
MMRF_2679,,First line of therapy,Consolidation,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,246,372,1
MMRF_2679,,First line of therapy,Consolidation,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,246,372,1
MMRF_2680,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,144,1
MMRF_2680,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,1,144,1
MMRF_2680,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,144,1
MMRF_2680,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,144,154,1
MMRF_2680,,First line of therapy,Consolidation,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,184,429,1
MMRF_2680,,First line of therapy,Consolidation,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,184,429,1
MMRF_2680,,First line of therapy,Consolidation,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,184,429,1
MMRF_2681,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,121,1
MMRF_2681,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,"Days 1, 8, 15 per cycle",PO,,1,121,1
MMRF_2681,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,121,1
MMRF_2681,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,121,133,1
MMRF_2681,,First line of therapy,Other,In preparation for stem cell infusion,Melphalan,,,,Completed regimen,,400,mg/m^,,Oth,prior to stem cell infusion,IV,,160,160,1
MMRF_2681,,First line of therapy,Consolidation,,Dexamethasone,,,,Adverse Event or co-morbidity,Gastrintestinal tox,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,253,288,1
MMRF_2681,,First line of therapy,Consolidation,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,253,377,1
MMRF_2681,,First line of therapy,Consolidation,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,"Days 1, 8, 15 per cycle",PO,,253,377,1
MMRF_2681,,First line of therapy,Consolidation,,Dexamethasone,,,,Completed regimen,,10,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,288,377,1
MMRF_2682,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,139,1
MMRF_2682,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,1,139,1
MMRF_2682,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,139,1
MMRF_2682,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,139,152,1
MMRF_2682,,First line of therapy,Other,In preparation for stem cell infusion,Melphalan,,,,Completed regimen,,372,mg/m^,,Oth,prior to stem cell infusion,IV,,196,196,1
MMRF_2682,,First line of therapy,Consolidation,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,295,427,1
MMRF_2682,,First line of therapy,Consolidation,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,295,427,1
MMRF_2682,,First line of therapy,Consolidation,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,295,427,1
MMRF_2683,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,130,1
MMRF_2683,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,1,130,1
MMRF_2683,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,130,1
MMRF_2683,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,130,142,1
MMRF_2683,,First line of therapy,Other,In preparation for stem cell infusion,Melphalan,,,,Completed regimen,,320,mg/m^,,Oth,prior to stem cell infusion,IV,,222,222,1
MMRF_2685,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,145,1
MMRF_2685,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,1,145,1
MMRF_2685,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,145,1
MMRF_2685,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,145,157,1
MMRF_2685,,First line of therapy,Consolidation,,Carfilzomib,,,Checked,,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,268,,1
MMRF_2685,,First line of therapy,Consolidation,,Lenalidomide,,,Checked,,,25,mg,,Oth,Days 1-21 per cycle,PO,,268,,1
MMRF_2685,,First line of therapy,Consolidation,,Dexamethasone,,,Checked,,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,268,,1
MMRF_2688,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,123,1
MMRF_2688,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,"Days 1, 8, 15 per cycle",PO,,1,123,1
MMRF_2688,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,123,1
MMRF_2688,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,123,137,1
MMRF_2688,,First line of therapy,Other,In preparation for stem cell infusion,Melphalan,,,,Completed regimen,,340,mg/m^,,Oth,prior to stem cell infusion,IV,,155,155,1
MMRF_2690,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,117,1
MMRF_2690,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,1,117,1
MMRF_2690,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,117,1
MMRF_2690,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,117,128,1
MMRF_2690,,First line of therapy,Consolidation,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,183,411,1
MMRF_2690,,First line of therapy,Consolidation,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,183,411,1
MMRF_2690,,First line of therapy,Consolidation,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,183,411,1
MMRF_2689,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,141,1
MMRF_2689,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,1,141,1
MMRF_2689,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,141,1
MMRF_2689,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,141,152,1
MMRF_2689,,First line of therapy,Consolidation,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,170,403,1
MMRF_2689,,First line of therapy,Consolidation,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,170,403,1
MMRF_2689,,First line of therapy,Consolidation,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,170,403,1
MMRF_2691,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,113,1
MMRF_2691,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,1,113,1
MMRF_2691,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,113,1
MMRF_2691,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,113,124,1
MMRF_2691,,First line of therapy,Other,In preparation for stem cell infusion,Melphalan,,,,Completed regimen,,350,mg/m^,,Oth,prior to stem cell infusion,IV,,152,152,1
MMRF_2691,,First line of therapy,Consolidation,,Carfilzomib,,,Checked,,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,251,,1
MMRF_2691,,First line of therapy,Consolidation,,Lenalidomide,,,Checked,,,25,mg,,Oth,Days 1-21 per cycle,PO,,251,,1
MMRF_2691,,First line of therapy,Consolidation,,Dexamethasone,,,Checked,,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,251,,1
MMRF_2692,,First line of therapy,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,Creatinine increase,25,mg,,Oth,Days 1-21 per cycle,PO,,1,29,1
MMRF_2692,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,125,1
MMRF_2692,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,125,1
MMRF_2692,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,10,mg,,Oth,Days 1-21 per cycle,PO,,29,125,1
MMRF_2692,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,125,136,1
MMRF_2694,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,125,1
MMRF_2694,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,"Days 1, 8, 15 per cycle",PO,,1,125,1
MMRF_2694,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,125,1
MMRF_2694,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,125,136,1
MMRF_2694,,First line of therapy,Other,In preparation for stem cell infusion,Melphalan,,,,Completed regimen,,350,mg/m^,,Oth,prior to stem cell infusion,IV,,171,171,1
MMRF_2694,,First line of therapy,Consolidation,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,263,410,1
MMRF_2694,,First line of therapy,Consolidation,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,"Days 1, 8, 15 per cycle",PO,,263,410,1
MMRF_2694,,First line of therapy,Consolidation,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,263,410,1
MMRF_2695,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,145,1
MMRF_2695,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,"Days 1, 8, 15 per cycle",PO,,1,145,1
MMRF_2695,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,145,1
MMRF_2695,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,145,156,1
MMRF_2695,,First line of therapy,Other,In preparation for stem cell infusion,Melphalan,,,,Completed regimen,,200,mg/m^,,Oth,prior to stem cell infusion,IV,,191,191,1
MMRF_2695,,First line of therapy,Consolidation,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,268,450,1
MMRF_2695,,First line of therapy,Consolidation,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,"Days 1, 8, 15 per cycle",PO,,268,450,1
MMRF_2695,,First line of therapy,Consolidation,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,268,450,1
MMRF_2696,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,111,1
MMRF_2696,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,"Days 1, 8, 15 per cycle",PO,,1,111,1
MMRF_2696,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,111,1
MMRF_2696,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,111,133,1
MMRF_2696,,First line of therapy,Other,In preparation for stem cell infusion,Melphalan,,,,Completed regimen,,200,mg/m^,,Oth,prior to stem cell infusion,IV,,162,162,1
MMRF_2696,,First line of therapy,Consolidation,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,274,386,1
MMRF_2696,,First line of therapy,Consolidation,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,"Days 1, 8, 15 per cycle",PO,,274,386,1
MMRF_2696,,First line of therapy,Consolidation,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,274,386,1
MMRF_2697,,First line of therapy,Induction,,Carfilzomib,,,,Adverse Event or co-morbidity,Hepatic tox,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,71,1
MMRF_2697,,First line of therapy,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,Hepatic tox,25,mg,,Oth,Days 1-21 per cycle,PO,,1,71,1
MMRF_2697,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,113,1
MMRF_2697,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,27,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,71,183,1
MMRF_2697,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,15,mg,,Oth,Days 1-21 per cycle,PO,,71,183,1
MMRF_2698,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,121,1
MMRF_2698,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,1,121,1
MMRF_2698,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,121,1
MMRF_2698,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,121,131,1
MMRF_2698,,First line of therapy,Consolidation,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,196,420,1
MMRF_2698,,First line of therapy,Consolidation,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,196,420,1
MMRF_2698,,First line of therapy,Consolidation,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,196,420,1
MMRF_2702,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,124,1
MMRF_2702,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,1,124,1
MMRF_2702,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,124,1
MMRF_2702,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,124,135,1
MMRF_2702,,First line of therapy,Consolidation,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,183,428,1
MMRF_2702,,First line of therapy,Consolidation,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,183,428,1
MMRF_2702,,First line of therapy,Consolidation,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,183,428,1
MMRF_2699,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,135,1
MMRF_2699,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,1,135,1
MMRF_2699,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,135,1
MMRF_2699,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,135,146,1
MMRF_2699,,First line of therapy,Consolidation,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,181,456,1
MMRF_2699,,First line of therapy,Consolidation,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,181,456,1
MMRF_2699,,First line of therapy,Consolidation,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,181,456,1
MMRF_2700,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,150,1
MMRF_2700,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,1,150,1
MMRF_2700,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,150,1
MMRF_2700,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,150,162,1
MMRF_2700,,First line of therapy,Consolidation,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,191,428,1
MMRF_2700,,First line of therapy,Consolidation,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,191,428,1
MMRF_2700,,First line of therapy,Consolidation,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,191,428,1
MMRF_2701,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,153,1
MMRF_2701,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,1,153,1
MMRF_2701,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,153,1
MMRF_2701,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,153,165,1
MMRF_2701,,First line of therapy,Other,In preparation for stem cell infusion,Melphalan,,,,Completed regimen,,140,mg/m^,,Oth,prior to stem cell infusion,IV,,195,195,1
MMRF_2703,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,165,1
MMRF_2703,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,1,165,1
MMRF_2703,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,165,1
MMRF_2703,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,165,178,1
MMRF_2703,,First line of therapy,Consolidation,,Carfilzomib,,,Checked,,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,206,,1
MMRF_2703,,First line of therapy,Consolidation,,Lenalidomide,,,Checked,,,25,mg,,Oth,Days 1-21 per cycle,PO,,206,,1
MMRF_2703,,First line of therapy,Consolidation,,Dexamethasone,,,Checked,,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,206,,1
MMRF_2704,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,123,1
MMRF_2704,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,1,123,1
MMRF_2704,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,123,1
MMRF_2704,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,123,137,1
MMRF_2704,,First line of therapy,Consolidation,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,155,295,1
MMRF_2704,,First line of therapy,Consolidation,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,155,295,1
MMRF_2704,,First line of therapy,Consolidation,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,155,295,1
MMRF_2705,,First line of therapy,Induction,,Carfilzomib,,,,Adverse Event or co-morbidity,Hepatic tox,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,37,1
MMRF_2705,,First line of therapy,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,Hepatic tox,25,mg,,Oth,Days 1-21 per cycle,PO,,1,37,1
MMRF_2705,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,124,1
MMRF_2705,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,27,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,37,124,1
MMRF_2705,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,15,mg,,Oth,Days 1-21 per cycle,PO,,37,124,1
MMRF_2705,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,124,164,1
MMRF_2705,,First line of therapy,Other,In preparation for stem cell infusion,Melphalan,,,,Completed regimen,,320,mg/m^,,Oth,prior to stem cell infusion,IV,,194,194,1
MMRF_2706,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,116,1
MMRF_2706,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,"Days 1, 8, 15 per cycle",PO,,1,116,1
MMRF_2706,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,116,1
MMRF_2706,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,116,128,1
MMRF_2706,,First line of therapy,Other,In preparation for stem cell infusion,Melphalan,,,,Completed regimen,,320,mg/m^,,Oth,prior to stem cell infusion,IV,,156,156,1
MMRF_2707,,First line of therapy,Induction,,Carfilzomib,,,Checked,,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,,1
MMRF_2707,,First line of therapy,Induction,,Lenalidomide,,,Checked,,,25,mg,,Oth,Days 1-21 per cycle,PO,,1,,1
MMRF_2707,,First line of therapy,Induction,,Dexamethasone,,,Checked,,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,,1
MMRF_2708,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,131,1
MMRF_2708,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,"Days 1, 8, 15 per cycle",PO,,1,131,1
MMRF_2708,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,131,1
MMRF_2708,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,131,142,1
MMRF_2709,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,120,1
MMRF_2709,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,1,120,1
MMRF_2709,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,120,1
MMRF_2709,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,120,132,1
MMRF_2709,,First line of therapy,Other,In preparation for stem cell infusion,Melphalan,,,,Completed regimen,,300,mg/m^,,Oth,prior to stem cell infusion,IV,,166,166,1
MMRF_2716,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,118,1
MMRF_2716,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,"Days 1, 8, 15 per cycle",PO,,1,118,1
MMRF_2716,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,118,1
MMRF_2716,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,118,128,1
MMRF_2716,,First line of therapy,Other,In preparation for stem cell infusion,Melphalan,,,,Completed regimen,,328,mg/m^,,Oth,prior to stem cell infusion,IV,,162,162,1
MMRF_2716,,First line of therapy,Consolidation,,Carfilzomib,,,Checked,,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,260,,1
MMRF_2716,,First line of therapy,Consolidation,,Cyclophosphamide,,,Checked,,,300,mg/m^,,Oth,"Days 1, 8, 15 per cycle",PO,,260,,1
MMRF_2716,,First line of therapy,Consolidation,,Dexamethasone,,,Checked,,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,260,,1
MMRF_2711,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,137,1
MMRF_2711,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,1,137,1
MMRF_2711,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,137,1
MMRF_2711,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,137,151,1
MMRF_2711,,First line of therapy,Other,In preparation for stem cell infusion,Melphalan,,,,Completed regimen,,332,mg/m^,,Oth,prior to stem cell infusion,IV,,200,200,1
MMRF_2715,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,124,1
MMRF_2715,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,"Days 1, 8, 15 per cycle",PO,,1,124,1
MMRF_2715,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,124,1
MMRF_2715,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,124,135,1
MMRF_2715,,First line of therapy,Other,In preparation for stem cell infusion,Melphalan,,,,Completed regimen,,400,mg/m^,,Oth,prior to stem cell infusion,IV,,159,159,1
MMRF_2717,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,117,1
MMRF_2717,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,1,117,1
MMRF_2717,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,117,1
MMRF_2717,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,117,131,1
MMRF_2717,,First line of therapy,Consolidation,,Carfilzomib,,,Checked,,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,158,,1
MMRF_2717,,First line of therapy,Consolidation,,Lenalidomide,,,Checked,,,25,mg,,Oth,Days 1-21 per cycle,PO,,158,,1
MMRF_2717,,First line of therapy,Consolidation,,Dexamethasone,,,Checked,,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,158,,1
MMRF_2714,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,139,1
MMRF_2714,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,1,139,1
MMRF_2714,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,139,1
MMRF_2714,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,139,150,1
MMRF_2714,,First line of therapy,Other,In preparation for stem cell infusion,Melphalan,,,,Completed regimen,,388.4,mg/m^,,Oth,prior to stem cell infusion,IV,,177,177,1
MMRF_2714,,First line of therapy,Consolidation,,Carfilzomib,,,Checked,,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,274,,1
MMRF_2714,,First line of therapy,Consolidation,,Lenalidomide,,,Checked,,,25,mg,,Oth,Days 1-21 per cycle,PO,,274,,1
MMRF_2714,,First line of therapy,Consolidation,,Dexamethasone,,,Checked,,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,274,,1
MMRF_2718,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,109,1
MMRF_2718,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,1,109,1
MMRF_2718,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,109,1
MMRF_2718,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,109,119,1
MMRF_2718,,First line of therapy,Consolidation,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,148,260,1
MMRF_2718,,First line of therapy,Consolidation,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,148,260,1
MMRF_2718,,First line of therapy,Consolidation,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,148,260,1
MMRF_2719,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,152,1
MMRF_2719,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,1,152,1
MMRF_2719,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,152,1
MMRF_2719,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,152,205,1
MMRF_2719,,First line of therapy,Other,In preparation for stem cell infusion,Melphalan,,,,Completed regimen,,380,mg/m^,,Oth,prior to stem cell infusion,IV,,231,231,1
MMRF_2720,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,115,1
MMRF_2720,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,"Days 1, 8, 15 per cycle",PO,,1,115,1
MMRF_2720,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,115,1
MMRF_2720,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,115,129,1
MMRF_2721,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,125,1
MMRF_2721,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,"Days 1, 8, 15 per cycle",PO,,1,125,1
MMRF_2721,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,125,1
MMRF_2721,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,125,135,1
MMRF_2727,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,145,1
MMRF_2727,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,1,145,1
MMRF_2727,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,145,1
MMRF_2727,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,145,156,1
MMRF_2722,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,130,1
MMRF_2722,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,"Days 1, 8, 15 per cycle",PO,,1,130,1
MMRF_2722,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,130,1
MMRF_2722,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,130,141,1
MMRF_2723,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,125,1
MMRF_2723,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,"Days 1, 8, 15 per cycle",PO,,1,125,1
MMRF_2723,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,125,1
MMRF_2723,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,125,134,1
MMRF_2723,,First line of therapy,Other,In preparation for stem cell infusion,Melphalan,,,,Completed regimen,,404,mg/m^,,Oth,prior to stem cell infusion,IV,,158,158,1
MMRF_2728,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,118,1
MMRF_2728,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,1,118,1
MMRF_2728,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,118,1
MMRF_2728,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,118,129,1
MMRF_2728,,First line of therapy,Consolidation,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,154,266,1
MMRF_2728,,First line of therapy,Consolidation,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,154,266,1
MMRF_2728,,First line of therapy,Consolidation,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,154,266,1
MMRF_2729,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,115,1
MMRF_2729,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,1,115,1
MMRF_2729,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,115,1
MMRF_2729,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,115,126,1
MMRF_2729,,First line of therapy,Other,In preparation for stem cell infusion,Melphalan,,,,Completed regimen,,200,mg/m^,,Oth,prior to stem cell infusion,IV,,154,154,1
MMRF_2730,,First line of therapy,Induction,,Carfilzomib,,,Checked,,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,,1
MMRF_2730,,First line of therapy,Induction,,Lenalidomide,,,Checked,,,25,mg,,Oth,Days 1-21 per cycle,PO,,1,,1
MMRF_2730,,First line of therapy,Induction,,Dexamethasone,,,Checked,,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,,1
MMRF_2731,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,120,1
MMRF_2731,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,"Days 1, 8, 15 per cycle",PO,,1,120,1
MMRF_2731,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,120,1
MMRF_2731,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,120,129,1
MMRF_2731,,First line of therapy,Other,In preparation for stem cell infusion,Melphalan,,,,Completed regimen,,408,mg/m^,,Oth,prior to stem cell infusion,IV,,165,165,1
MMRF_2732,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,131,1
MMRF_2732,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,1,131,1
MMRF_2732,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,131,1
MMRF_2732,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,131,142,1
MMRF_2732,,First line of therapy,Other,In preparation for stem cell infusion,Melphalan,,,,Completed regimen,,394,mg/m^,,Oth,prior to stem cell infusion,IV,,184,184,1
MMRF_2733,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,160,1
MMRF_2733,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,1,160,1
MMRF_2733,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,160,1
MMRF_2733,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,160,171,1
MMRF_2733,,First line of therapy,Other,In preparation for stem cell infusion,Melphalan,,,,Completed regimen,,360,mg/m^,,Oth,prior to stem cell infusion,IV,,223,223,1
MMRF_2734,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,113,1
MMRF_2734,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,"Days 1, 8, 15 per cycle",PO,,1,113,1
MMRF_2734,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,113,1
MMRF_2734,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,113,125,1
MMRF_2734,,First line of therapy,Other,In preparation for stem cell infusion,Melphalan,,,,Completed regimen,,350,mg/m^,,Oth,prior to stem cell infusion,IV,,154,154,1
MMRF_2736,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,120,1
MMRF_2736,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,"Days 1, 8, 15 per cycle",PO,,1,120,1
MMRF_2736,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,120,1
MMRF_2736,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,120,131,1
MMRF_2736,,First line of therapy,Other,In preparation for stem cell infusion,Melphalan,,,,Completed regimen,,310,mg/m^,,Oth,prior to stem cell infusion,IV,,150,150,1
MMRF_2737,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,116,1
MMRF_2737,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,"Days 1, 8, 15 per cycle",PO,,1,116,1
MMRF_2737,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,116,1
MMRF_2737,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,116,125,1
MMRF_2737,,First line of therapy,Other,In preparation for stem cell infusion,Melphalan,,,,Completed regimen,,320,mg/m^,,Oth,prior to stem cell infusion,IV,,160,160,1
MMRF_2738,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,124,1
MMRF_2738,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,1,124,1
MMRF_2738,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,124,1
MMRF_2738,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,124,137,1
MMRF_2738,,First line of therapy,Consolidation,,Carfilzomib,,,Checked,,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,172,,1
MMRF_2738,,First line of therapy,Consolidation,,Lenalidomide,,,Checked,,,25,mg,,Oth,Days 1-21 per cycle,PO,,172,,1
MMRF_2738,,First line of therapy,Consolidation,,Dexamethasone,,,Checked,,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,172,,1
MMRF_2739,,First line of therapy,Induction,,Carfilzomib,,,Checked,,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,,1
MMRF_2739,,First line of therapy,Induction,,Cyclophosphamide,,,Checked,,,300,mg/m^,,Oth,"Days 1, 8, 15 per cycle",PO,,1,,1
MMRF_2739,,First line of therapy,Induction,,Dexamethasone,,,Checked,,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,,1
MMRF_2742,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,121,1
MMRF_2742,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,1,121,1
MMRF_2742,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,121,1
MMRF_2742,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,121,134,1
MMRF_2740,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,122,1
MMRF_2740,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,1,122,1
MMRF_2740,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,122,1
MMRF_2740,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,122,133,1
MMRF_2740,,First line of therapy,Consolidation,,Carfilzomib,,,Checked,,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,162,,1
MMRF_2740,,First line of therapy,Consolidation,,Lenalidomide,,,Checked,,,25,mg,,Oth,Days 1-21 per cycle,PO,,162,,1
MMRF_2740,,First line of therapy,Consolidation,,Dexamethasone,,,Checked,,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,162,,1
MMRF_2743,,First line of therapy,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,Rash maculo-papular,25,mg,,Oth,Days 1-21 per cycle,PO,,1,29,1
MMRF_2743,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,122,1
MMRF_2743,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,122,1
MMRF_2743,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,15,mg,,Oth,Days 1-21 per cycle,PO,,29,122,1
MMRF_2743,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,122,132,1
MMRF_2743,,First line of therapy,Other,In preparation for stem cell infusion,Melphalan,,,,Completed regimen,,330,mg/m^,,Oth,prior to stem cell infusion,IV,,164,164,1
MMRF_2745,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,119,1
MMRF_2745,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,1,119,1
MMRF_2745,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,119,1
MMRF_2745,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,119,133,1
MMRF_2745,,First line of therapy,Consolidation,,Carfilzomib,,,Checked,,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,162,,1
MMRF_2745,,First line of therapy,Consolidation,,Lenalidomide,,,Checked,,,25,mg,,Oth,Days 1-21 per cycle,PO,,162,,1
MMRF_2745,,First line of therapy,Consolidation,,Dexamethasone,,,Checked,,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,162,,1
MMRF_2746,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,136,1
MMRF_2746,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,"Days 1, 8, 15 per cycle",PO,,1,136,1
MMRF_2746,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,136,1
MMRF_2746,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,136,146,1
MMRF_2746,,First line of therapy,Other,In preparation for stem cell infusion,Melphalan,,,,Completed regimen,,200,mg/m^,,Oth,prior to stem cell infusion,IV,,171,171,1
MMRF_2749,,First line of therapy,Induction,,Carfilzomib,,,,Adverse Event or co-morbidity,Hepatic tox,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,32,1
MMRF_2749,,First line of therapy,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,Hepatic tox,25,mg,,Oth,Days 1-21 per cycle,PO,,1,88,1
MMRF_2749,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,124,1
MMRF_2749,,First line of therapy,Induction,,Carfilzomib,,,,Adverse Event or co-morbidity,Hepatic tox,27,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,32,88,1
MMRF_2749,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,20,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,88,124,1
MMRF_2749,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,15,mg,,Oth,Days 1-21 per cycle,PO,,88,124,1
MMRF_2749,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,124,136,1
MMRF_2749,,First line of therapy,Consolidation,,Carfilzomib,,,Checked,,,20,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,190,,1
MMRF_2749,,First line of therapy,Consolidation,,Lenalidomide,,,Checked,,,15,mg,,Oth,Days 1-21 per cycle,PO,,190,,1
MMRF_2749,,First line of therapy,Consolidation,,Dexamethasone,,,Checked,,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,190,,1
MMRF_2750,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,123,1
MMRF_2750,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,1,123,1
MMRF_2750,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,123,1
MMRF_2750,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,123,133,1
MMRF_2750,,First line of therapy,Consolidation,,Carfilzomib,,,Checked,,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,183,,1
MMRF_2750,,First line of therapy,Consolidation,,Lenalidomide,,,Checked,,,25,mg,,Oth,Days 1-21 per cycle,PO,,183,,1
MMRF_2750,,First line of therapy,Consolidation,,Dexamethasone,,,Checked,,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,183,,1
MMRF_2751,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,128,1
MMRF_2751,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,1,128,1
MMRF_2751,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,128,1
MMRF_2751,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,128,142,1
MMRF_2752,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,140,1
MMRF_2752,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,1,140,1
MMRF_2752,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,140,1
MMRF_2752,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,140,151,1
MMRF_2754,,First line of therapy,Induction,,Carfilzomib,,,Checked,,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,,1
MMRF_2754,,First line of therapy,Induction,,Lenalidomide,,,Checked,,,25,mg,,Oth,Days 1-21 per cycle,PO,,1,,1
MMRF_2754,,First line of therapy,Induction,,Dexamethasone,,,Checked,,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,,1
MMRF_2753,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,136,1
MMRF_2753,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,"Days 1, 8, 15 per cycle",PO,,1,136,1
MMRF_2753,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,136,1
MMRF_2753,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,136,148,1
MMRF_2753,,First line of therapy,Other,In preparation for stem cell infusion,Melphalan,,,,Completed regimen,,400,mg/m^,,Oth,prior to stem cell infusion,IV,,174,174,1
MMRF_2755,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,117,1
MMRF_2755,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,"Days 1, 8, 15 per cycle",PO,,1,117,1
MMRF_2755,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,117,1
MMRF_2755,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,117,128,1
MMRF_2755,,First line of therapy,Other,In preparation for stem cell infusion,Melphalan,,,,Completed regimen,,370,mg/m^,,Oth,prior to stem cell infusion,IV,,152,152,1
MMRF_2756,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,143,1
MMRF_2756,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,1,143,1
MMRF_2756,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,143,1
MMRF_2756,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,143,154,1
MMRF_2757,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,131,1
MMRF_2757,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,1,131,1
MMRF_2757,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,131,1
MMRF_2757,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,131,142,1
MMRF_2757,,First line of therapy,Consolidation,,Carfilzomib,,,Checked,,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,191,,1
MMRF_2757,,First line of therapy,Consolidation,,Lenalidomide,,,Checked,,,25,mg,,Oth,Days 1-21 per cycle,PO,,191,,1
MMRF_2757,,First line of therapy,Consolidation,,Dexamethasone,,,Checked,,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,191,,1
MMRF_2758,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,135,1
MMRF_2758,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,"Days 1, 8, 15 per cycle",PO,,1,135,1
MMRF_2758,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,135,1
MMRF_2758,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,135,146,1
MMRF_2758,,First line of therapy,Other,In preparation for stem cell infusion,Melphalan,,,,Completed regimen,,400,mg/m^,,Oth,prior to stem cell infusion,IV,,197,197,1
MMRF_2760,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,117,1
MMRF_2760,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,"Days 1, 8, 15 per cycle",PO,,1,117,1
MMRF_2760,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,117,1
MMRF_2760,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,117,129,1
MMRF_2760,,First line of therapy,Other,In preparation for stem cell infusion,Melphalan,,,,Completed regimen,,286,mg/m^,,Oth,prior to stem cell infusion,IV,,161,161,1
MMRF_2761,,First line of therapy,Induction,,Carfilzomib,,,Checked,,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,,1
MMRF_2761,,First line of therapy,Induction,,Lenalidomide,,,Checked,,,25,mg,,Oth,Days 1-21 per cycle,PO,,1,,1
MMRF_2761,,First line of therapy,Induction,,Dexamethasone,,,Checked,,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,,1
MMRF_2762,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,126,1
MMRF_2762,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,1,126,1
MMRF_2762,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,126,1
MMRF_2762,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,126,135,1
MMRF_2762,,First line of therapy,Consolidation,,Carfilzomib,,,Checked,,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,155,,1
MMRF_2762,,First line of therapy,Consolidation,,Lenalidomide,,,Checked,,,25,mg,,Oth,Days 1-21 per cycle,PO,,155,,1
MMRF_2762,,First line of therapy,Consolidation,,Dexamethasone,,,Checked,,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,155,,1
MMRF_2763,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,127,1
MMRF_2763,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,1,127,1
MMRF_2763,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,127,1
MMRF_2763,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,127,137,1
MMRF_2763,,First line of therapy,Other,In preparation for stem cell infusion,Melphalan,,,,Completed regimen,,300,mg/m^,,Oth,prior to stem cell infusion,IV,,160,160,1
MMRF_2764,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,130,1
MMRF_2764,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,1,130,1
MMRF_2764,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,130,1
MMRF_2764,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,130,150,1
MMRF_2764,,First line of therapy,Other,In preparation for stem cell infusion,Melphalan,,,,Completed regimen,,400,mg/m^,,Oth,prior to stem cell infusion,IV,,214,214,1
MMRF_2765,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,138,1
MMRF_2765,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,"Days 1, 8, 15 per cycle",PO,,1,138,1
MMRF_2765,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,138,1
MMRF_2765,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,138,149,1
MMRF_2767,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,143,1
MMRF_2767,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,1,143,1
MMRF_2767,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,143,1
MMRF_2767,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,143,155,1
MMRF_2767,,First line of therapy,Other,In preparation for stem cell infusion,Melphalan,,,,Completed regimen,,280,mg/m^,,Oth,prior to stem cell infusion,IV,,179,179,1
MMRF_2768,,First line of therapy,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,Erythroderma,25,mg,,Oth,Days 1-21 per cycle,PO,,1,94,1
MMRF_2768,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,154,1
MMRF_2768,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,154,1
MMRF_2768,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,15,mg,,Oth,Days 1-21 per cycle,PO,,94,154,1
MMRF_2768,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,154,165,1
MMRF_2769,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,122,1
MMRF_2769,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,1,122,1
MMRF_2769,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,122,1
MMRF_2769,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,122,133,1
MMRF_2769,,First line of therapy,Other,In preparation for stem cell infusion,Melphalan,,,,Completed regimen,,400,mg/m^,,Oth,prior to stem cell infusion,IV,,156,156,1
MMRF_2770,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,123,1
MMRF_2770,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,"Days 1, 8, 15 per cycle",PO,,1,123,1
MMRF_2770,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,123,1
MMRF_2770,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,123,133,1
MMRF_2770,,First line of therapy,Other,In preparation for stem cell infusion,Melphalan,,,,Completed regimen,,200,mg/m^,,Oth,prior to stem cell infusion,IV,,160,160,1
MMRF_2772,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,147,1
MMRF_2772,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,1,147,1
MMRF_2772,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,147,1
MMRF_2772,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,147,158,1
MMRF_2774,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,122,1
MMRF_2774,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,"Days 1, 8, 15 per cycle",PO,,1,122,1
MMRF_2774,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,122,1
MMRF_2774,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,122,134,1
MMRF_2774,,First line of therapy,Other,In preparation for stem cell infusion,Melphalan,,,,Completed regimen,,303,mg/m^,,Oth,prior to stem cell infusion,IV,,174,174,1
MMRF_2775,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,132,1
MMRF_2775,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,1,132,1
MMRF_2775,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,132,1
MMRF_2775,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,132,178,1
MMRF_2775,,First line of therapy,Other,In preparation for stem cell infusion,Melphalan,,,,Completed regimen,,300,mg/m^,,Oth,prior to stem cell infusion,IV,,198,198,1
MMRF_2776,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,133,1
MMRF_2776,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,"Days 1, 8, 15 per cycle",PO,,1,133,1
MMRF_2776,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,133,1
MMRF_2776,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,133,145,1
MMRF_2776,,First line of therapy,Other,In preparation for stem cell infusion,Melphalan,,,,Completed regimen,,180,mg/m^,,Oth,prior to stem cell infusion,IV,,203,203,1
MMRF_2778,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,113,1
MMRF_2778,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,1,113,1
MMRF_2778,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,113,1
MMRF_2778,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,113,124,1
MMRF_2778,,First line of therapy,Other,In preparation for stem cell infusion,Melphalan,,,,Completed regimen,,335,mg/m^,,Oth,prior to stem cell infusion,IV,,151,151,1
MMRF_2779,,First line of therapy,Induction,,Carfilzomib,,,,Adverse Event or co-morbidity,Rash maculo-papular,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,44,1
MMRF_2779,,First line of therapy,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,Rash maculo-papular,25,mg,,Oth,Days 1-21 per cycle,PO,,1,44,1
MMRF_2779,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,133,1
MMRF_2779,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,20,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,44,133,1
MMRF_2779,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,15,mg,,Oth,Days 1-21 per cycle,PO,,44,133,1
MMRF_2779,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,133,143,1
MMRF_2781,,First line of therapy,Induction,,Carfilzomib,,,Checked,,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,,1
MMRF_2781,,First line of therapy,Induction,,Cyclophosphamide,,,Checked,,,300,mg/m^,,Oth,"Days 1, 8, 15 per cycle",PO,,1,,1
MMRF_2781,,First line of therapy,Induction,,Dexamethasone,,,Checked,,,10,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,,1
MMRF_2781,,First line of therapy,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,Hyperglycemia,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,1,1
MMRF_2782,,First line of therapy,Induction,,Dexamethasone,,,,Adverse Event or co-morbidity,Hyperglycemia,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,92,1
MMRF_2782,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,127,1
MMRF_2782,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,"Days 1, 8, 15 per cycle",PO,,1,127,1
MMRF_2782,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,15,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,92,127,1
MMRF_2782,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,127,139,1
MMRF_2782,,First line of therapy,Other,In preparation for stem cell infusion,Melphalan,,,,Completed regimen,,358,mg/m^,,Oth,prior to stem cell infusion,IV,,213,213,1
MMRF_2787,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,123,1
MMRF_2787,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,1,123,1
MMRF_2787,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,123,1
MMRF_2787,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,123,132,1
MMRF_2788,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,138,1
MMRF_2788,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,"Days 1, 8, 15 per cycle",PO,,1,138,1
MMRF_2788,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,138,1
MMRF_2788,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,138,148,1
MMRF_2788,,First line of therapy,Other,In preparation for stem cell infusion,Melphalan,,,,Completed regimen,,400,mg/m^,,Oth,prior to stem cell infusion,IV,,198,198,1
MMRF_2789,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,117,1
MMRF_2789,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,1,117,1
MMRF_2789,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,117,1
MMRF_2789,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,117,128,1
MMRF_2792,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,134,1
MMRF_2792,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,1,134,1
MMRF_2792,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,134,1
MMRF_2792,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,134,148,1
MMRF_2793,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,137,1
MMRF_2793,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,"Days 1, 8, 15 per cycle",PO,,1,137,1
MMRF_2793,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,137,1
MMRF_2793,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,137,148,1
MMRF_2793,,First line of therapy,Other,In preparation for stem cell infusion,Melphalan,,,,Completed regimen,,300,mg/m^,,Oth,prior to stem cell infusion,IV,,179,179,1
MMRF_2794,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,131,1
MMRF_2794,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,1,131,1
MMRF_2794,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,131,1
MMRF_2794,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,131,143,1
MMRF_2795,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,119,1
MMRF_2795,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,1,119,1
MMRF_2795,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,119,1
MMRF_2795,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,119,130,1
MMRF_2795,,First line of therapy,Other,In preparation for stem cell infusion,Melphalan,,,,Completed regimen,,346,mg/m^,,Oth,prior to stem cell infusion,IV,,162,162,1
MMRF_2801,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,127,1
MMRF_2801,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,1,127,1
MMRF_2801,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,127,1
MMRF_2801,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,127,165,1
MMRF_2801,,First line of therapy,Other,In preparation for stem cell infusion,Melphalan,,,,Completed regimen,,294,mg/m^,,Oth,prior to stem cell infusion,IV,,203,203,1
MMRF_2796,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,121,1
MMRF_2796,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,1,121,1
MMRF_2796,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,121,1
MMRF_2796,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,121,132,1
MMRF_2796,,First line of therapy,Other,In preparation for stem cell infusion,Melphalan,,,,Completed regimen,,330,mg/m^,,Oth,prior to stem cell infusion,IV,,159,159,1
MMRF_2799,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,128,1
MMRF_2799,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,"Days 1, 8, 15 per cycle",PO,,1,128,1
MMRF_2799,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,128,1
MMRF_2799,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,128,138,1
MMRF_2805,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,118,1
MMRF_2805,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,1,118,1
MMRF_2805,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,118,1
MMRF_2805,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,118,128,1
MMRF_2805,,First line of therapy,Other,In preparation for stem cell infusion,Melphalan,,,,Completed regimen,,200,mg/m^,,Oth,prior to stem cell infusion,IV,,163,163,1
MMRF_2807,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,124,1
MMRF_2807,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,"Days 1, 8, 15 per cycle",PO,,1,124,1
MMRF_2807,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,124,1
MMRF_2807,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,124,137,1
MMRF_2807,,First line of therapy,Other,In preparation for stem cell infusion,Melphalan,,,,Completed regimen,,400,mg/m^,,Oth,prior to stem cell infusion,IV,,194,194,1
MMRF_2808,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,131,1
MMRF_2808,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,1,131,1
MMRF_2808,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,131,1
MMRF_2808,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,131,177,1
MMRF_2809,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,127,1
MMRF_2809,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,1,127,1
MMRF_2809,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,127,1
MMRF_2809,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,127,138,1
MMRF_2809,,First line of therapy,Other,In preparation for stem cell infusion,Melphalan,,,,Completed regimen,,370,mg/m^,,Oth,prior to stem cell infusion,IV,,223,223,1
MMRF_2810,,First line of therapy,Induction,,Carfilzomib,,,,Adverse Event or co-morbidity,ischemic heart disease,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,29,1
MMRF_2810,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,"Days 1, 8, 15 per cycle",PO,,1,130,1
MMRF_2810,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,130,1
MMRF_2810,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,27,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,29,130,1
MMRF_2810,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,130,140,1
MMRF_2810,,First line of therapy,Other,In preparation for stem cell infusion,Melphalan,,,,Completed regimen,,200,mg/m^,,Oth,prior to stem cell infusion,IV,,175,175,1
MMRF_2813,,First line of therapy,Induction,,Carfilzomib,,,,Adverse Event or co-morbidity,Infusion-related reaction (acute episode of intens,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,30,1
MMRF_2813,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,1,116,1
MMRF_2813,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,116,1
MMRF_2813,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,27,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,30,116,1
MMRF_2813,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,116,128,1
MMRF_2814,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,128,1
MMRF_2814,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,1,128,1
MMRF_2814,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,128,1
MMRF_2814,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,128,140,1
MMRF_2814,,First line of therapy,Other,In preparation for stem cell infusion,Melphalan,,,,Completed regimen,,400,mg/m^,,Oth,prior to stem cell infusion,IV,,198,198,1
MMRF_2815,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,141,1
MMRF_2815,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,1,141,1
MMRF_2815,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,141,1
MMRF_2815,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,141,150,1
MMRF_2816,,First line of therapy,Induction,,Cyclophosphamide,,,,Adverse Event or co-morbidity,Hematological tox,300,mg/m^,,Oth,"Days 1, 8, 15 per cycle",PO,,1,65,1
MMRF_2816,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,130,1
MMRF_2816,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,130,1
MMRF_2816,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,200,mg/m^,,Oth,"Days 1, 8, 15 per cycle",PO,,65,130,1
MMRF_2816,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,130,141,1
MMRF_2816,,First line of therapy,Other,In preparation for stem cell infusion,Melphalan,,,,Completed regimen,,366,mg/m^,,Oth,prior to stem cell infusion,IV,,169,169,1
MMRF_2817,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,118,1
MMRF_2817,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,"Days 1, 8, 15 per cycle",PO,,1,118,1
MMRF_2817,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,118,1
MMRF_2817,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,118,160,1
MMRF_2818,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,140,1
MMRF_2818,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,1,140,1
MMRF_2818,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,140,1
MMRF_2818,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,140,152,1
MMRF_2819,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,127,1
MMRF_2819,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,1,127,1
MMRF_2819,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,127,1
MMRF_2819,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,127,139,1
MMRF_2819,,First line of therapy,Other,In preparation for stem cell infusion,Melphalan,,,,Completed regimen,,271.6,mg/m^,,Oth,prior to stem cell infusion,IV,,245,245,1
MMRF_2820,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,129,1
MMRF_2820,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,"Days 1, 8, 15 per cycle",PO,,1,129,1
MMRF_2820,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,129,1
MMRF_2820,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,129,139,1
MMRF_2820,,First line of therapy,Other,In preparation for stem cell infusion,Melphalan,,,,Completed regimen,,330,mg/m^,,Oth,prior to stem cell infusion,IV,,175,175,1
MMRF_2821,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,124,1
MMRF_2821,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,1,124,1
MMRF_2821,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,124,1
MMRF_2821,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,124,135,1
MMRF_2822,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,123,1
MMRF_2822,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,1,123,1
MMRF_2822,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,123,1
MMRF_2822,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,123,134,1
MMRF_2822,,First line of therapy,Other,In preparation for stem cell infusion,Melphalan,,,,Completed regimen,,280,mg/m^,,Oth,prior to stem cell infusion,IV,,173,173,1
MMRF_2823,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,183,1
MMRF_2823,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,"Days 1, 8, 15 per cycle",PO,,1,183,1
MMRF_2823,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,183,1
MMRF_2823,,First line of therapy,Other,In preparation for stem cell infusion,Melphalan,,,,Completed regimen,,340,mg/m^,,Oth,prior to stem cell infusion,IV,,223,223,1
MMRF_2826,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,119,1
MMRF_2826,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,1,119,1
MMRF_2826,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,119,1
MMRF_2826,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,119,130,1
MMRF_2827,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,133,1
MMRF_2827,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,15,mg,,Oth,Days 1-21 per cycle,PO,,1,133,1
MMRF_2827,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,133,1
MMRF_2827,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,133,143,1
MMRF_2827,,First line of therapy,Other,In preparation for stem cell infusion,Melphalan,,,,Completed regimen,,360,mg/m^,,Oth,prior to stem cell infusion,IV,,189,189,1
MMRF_2828,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,145,1
MMRF_2828,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,1,145,1
MMRF_2828,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,145,1
MMRF_2828,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,145,157,1
MMRF_2829,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,144,1
MMRF_2829,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,1,144,1
MMRF_2829,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,144,1
MMRF_2829,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,144,155,1
MMRF_2830,,First line of therapy,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,Rash maculo-papular,25,mg,,Oth,Days 1-21 per cycle,PO,,1,58,1
MMRF_2830,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,113,1
MMRF_2830,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,113,1
MMRF_2830,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,15,mg,,Oth,Days 1-21 per cycle,PO,,58,113,1
MMRF_2830,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,113,124,1
MMRF_2831,,First line of therapy,Induction,,Carfilzomib,,,,Adverse Event or co-morbidity,Cardiac ischemia,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,85,1
MMRF_2831,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,1,166,1
MMRF_2831,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,166,1
MMRF_2831,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,27,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,85,166,1
MMRF_2831,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,166,177,1
MMRF_2831,,First line of therapy,Other,In preparation for stem cell infusion,Melphalan,,,,Completed regimen,,374,mg/m^,,Oth,prior to stem cell infusion,IV,,203,203,1
MMRF_2832,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,124,1
MMRF_2832,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,"Days 1, 8, 15 per cycle",PO,,1,124,1
MMRF_2832,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,124,1
MMRF_2832,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,124,134,1
MMRF_2832,,First line of therapy,Other,In preparation for stem cell infusion,Melphalan,,,,Completed regimen,,360,mg/m^,,Oth,prior to stem cell infusion,IV,,173,173,1
MMRF_2833,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,113,1
MMRF_2833,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,1,113,1
MMRF_2833,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,113,1
MMRF_2834,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,126,1
MMRF_2834,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,"Days 1, 8, 15 per cycle",PO,,1,126,1
MMRF_2834,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,126,1
MMRF_2834,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,126,140,1
MMRF_2835,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,136,1
MMRF_2835,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,1,136,1
MMRF_2835,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,136,1
MMRF_2835,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,136,147,1
MMRF_2835,,First line of therapy,Other,In preparation for stem cell infusion,Melphalan,,,,Completed regimen,,400,mg/m^,,Oth,prior to stem cell infusion,IV,,167,167,1
MMRF_2836,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,126,1
MMRF_2836,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,1,126,1
MMRF_2836,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,126,1
MMRF_2836,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,126,135,1
MMRF_2836,,First line of therapy,Other,In preparation for stem cell infusion,Melphalan,,,,Completed regimen,,340,mg/m^,,Oth,prior to stem cell infusion,IV,,161,161,1
MMRF_2838,,First line of therapy,Induction,,Lenalidomide,,,,Adverse Event or co-morbidity,Rash maculo-papular,25,mg,,Oth,Days 1-21 per cycle,PO,,1,65,1
MMRF_2838,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,145,1
MMRF_2838,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,145,1
MMRF_2838,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,15,mg,,Oth,Days 1-21 per cycle,PO,,65,145,1
MMRF_2838,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,145,159,1
MMRF_2839,,First line of therapy,Induction,,Carfilzomib,,,Checked,,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,,1
MMRF_2839,,First line of therapy,Induction,,Cyclophosphamide,,,Checked,,,300,mg/m^,,Oth,"Days 1, 8, 15 per cycle",PO,,1,,1
MMRF_2839,,First line of therapy,Induction,,Dexamethasone,,,Checked,,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,,1
MMRF_2840,,First line of therapy,Induction,,Carfilzomib,,,Checked,,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,,1
MMRF_2840,,First line of therapy,Induction,,Cyclophosphamide,,,Checked,,,300,mg/m^,,Oth,"Days 1, 8, 15 per cycle",PO,,1,,1
MMRF_2840,,First line of therapy,Induction,,Dexamethasone,,,Checked,,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,,1
MMRF_2843,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,177,1
MMRF_2843,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,1,177,1
MMRF_2843,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,177,1
MMRF_2843,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,177,190,1
MMRF_2846,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,121,1
MMRF_2846,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,"Days 1, 8, 15 per cycle",PO,,1,121,1
MMRF_2846,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,121,1
MMRF_2846,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,121,131,1
MMRF_2846,,First line of therapy,Other,In preparation for stem cell infusion,Melphalan,,,,Completed regimen,,200,mg/m^,,Oth,prior to stem cell infusion,IV,,199,199,1
MMRF_2847,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,131,1
MMRF_2847,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,1,131,1
MMRF_2847,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,131,1
MMRF_2847,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,131,144,1
MMRF_2848,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,154,1
MMRF_2848,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,1,154,1
MMRF_2848,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,154,1
MMRF_2848,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,154,166,1
MMRF_2848,,First line of therapy,Other,In preparation for stem cell infusion,Melphalan,,,,Completed regimen,,340,mg/m^,,Oth,prior to stem cell infusion,IV,,198,198,1
MMRF_2851,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,122,1
MMRF_2851,,First line of therapy,Induction,,Cyclophosphamide,,,,Completed regimen,,300,mg/m^,,Oth,"Days 1, 8, 15 per cycle",PO,,1,122,1
MMRF_2851,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,122,1
MMRF_2851,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,122,133,1
MMRF_2851,,First line of therapy,Other,In preparation for stem cell infusion,Melphalan,,,,Completed regimen,,360,mg/m^,,Oth,prior to stem cell infusion,IV,,189,189,1
MMRF_2853,,First line of therapy,Induction,,Carfilzomib,,,,Completed regimen,,36,mg/m^,,Oth,"Days 1-2, 8-9, 15-16 per cycle",IV,,1,129,1
MMRF_2853,,First line of therapy,Induction,,Lenalidomide,,,,Completed regimen,,25,mg,,Oth,Days 1-21 per cycle,PO,,1,129,1
MMRF_2853,,First line of therapy,Induction,,Dexamethasone,,,,Completed regimen,,20,mg,,Oth,"Days 1, 2, 8, 9, 15, 16, 22, 23 per cycle",PO,,1,129,1
MMRF_2853,,First line of therapy,Other,Mobilization - CD34+ cells generation for stem cell collection,Cyclophosphamide,,,,Completed regimen,,2,g/m^2,,Oth,"9-14 days, dependent on CD34+ cell generation",IV,,129,139,1
MMRF_2853,,First line of therapy,Other,In preparation for stem cell infusion,Melphalan,,,,Completed regimen,,200,mg/m^,,Oth,prior to stem cell infusion,IV,,170,170,1
